coronaviruses circulated among humans animals many years several strains highly transmissible pathogenic humans <NUMBER> severe acute respiratory syndrome sars emerged <NUMBER> <NUMBER> middle east respiratory syndrome coronavirus merscov emerged <NUMBER> years later <NUMBER> december <NUMBER> novel coronavirus emerged wuhan china <NUMBER> subsequently called severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> sarscov<NUMBER> causes coronavirus disease coronaviruses predominantly cause respiratory tract infections humans <NUMBER> specifically main symptoms covid<NUMBER> reported fever cough shortness breath <NUMBER> less abrupt onset symptoms compared sars <NUMBER> <NUMBER> data still emerging regarding epidemiology covid<NUMBER> though initial reports estimate transmission rate basic reproduction number r<NUMBER> <NUMBER> <NUMBER> case fatality rate increases among older adults <NUMBER> given current pandemic urgent need identify effective safe treatments covid<NUMBER> two proposed treatments chloroquine hydroxychloroquine wellestablished medications predominantly used treat malaria lupus rheumatoid arthritis vitro studies shown chloroquine hydroxychloroquine effective inhibiting sarscov<NUMBER> infection latter appearing potent antiviral activity <NUMBER> <NUMBER> thus repositioning drugs antiviral therapies covid<NUMBER> global interest however clinical data limited inconclusive currently multiple ongoing clinical trials use treatments covid<NUMBER> us food drug administration fda issued emergency use authorization eua oral formulations chloroquine phosphate hydroxychloroquine sulfate patients hospitalised covid <NUMBER> <NUMBER> date whilst many publications described main effectiveness safety concerns treatments systematic benefitrisk assessment use chloroquine hydroxychloroquine covid<NUMBER> treatment using structured descriptive framework systematic benefitrisk assessment strengthens ongoing monitoring benefitrisk balance chloroquine hydroxychloroquine covid<NUMBER> treatment assessment benefitrisk action team brat framework highly applicable allows identification key benefits risks product defined disease context within structured descriptive framework quantitative assessments applied conducted according availability relevant data time <NUMBER> brat framework also specifically designed assist communication regulatory authorities <NUMBER> decision ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint making process transparent due framework design assumptions explored sensitivity analysis quantitative component <NUMBER> given public health urgency covid<NUMBER> pandemic benefitrisk assessment conducted based publicly available information date datalock april <NUMBER> th <NUMBER> however acknowledged extremely limited data available ongoing clinical trials timepoint inform debate expeditiously benefitrisk assessment designed implemented regardless quantity data available intention framework subsequently readily available repeat assessment data arise eg results new clinical trials allowing rapid decisionmaking examine benefitrisk profile chloroquine hydroxychloroquine covid<NUMBER> patients compared standard care placebo treatments overall benefitrisk use chloroquine hydroxychloroquine treatment covid<NUMBER> compared standard care placebo treatments assessed using brat framework brat uses six step iterative process support decision communication benefitrisk assessment define decision context identify outcomes identify data sources customise framework assess outcome importance display interpret key benefitrisk metrics <NUMBER> <NUMBER> three settings interest identified use treatments covid<NUMBER> treatment severe disease treatment milder disease community prevention health care professionals exposed virus purposes benefit risk assessment focused use chloroquine hydroxychloroquine treatment severe covid<NUMBER> disease population interest patients severe covid<NUMBER> exposure interest hydroxychloroquine chloroquine comparators interest standard care placebo treatments covid<NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint initially potential benefits risks related hydroxychloroquine chloroquine regardless importance identified key benefits risks associated hydroxychloroquine chloroquine use selected clinician judgement key benefits risks considered drive benefitrisk balance drug value tree constructed using key benefits risks ranked order considered importance searched pubmed google scholar identify suitable data inclusion databases searched papers chloroquine sars chloroquine covid chloroquine coronavirus chloroquine <NUMBER>ncov hydroxychloroquine sars hydroxychloroquine covid hydroxychloroquine coronavirus hydroxychloroquine <NUMBER>ncov papers included reported quantitative data effectiveness andor safety chloroquine hydroxychloroquine patients severe covid<NUMBER> case reports excluded results restricted english language abstracts english language acceptable sufficient data provided peerreviewed publications since <NUMBER> <NUMBER> th april <NUMBER> data extracted benefit risk hydroxychloroquine chloroquine comparator standard care placebo treatments available eudravigilance <NUMBER> th april <NUMBER> faers spontaneous reporting data <NUMBER> st december <NUMBER> hydroxycholoroquine chloroquine also examined summary benefitrisk table created allow visualisation magnitude benefit risk risk differences corresponding <NUMBER> confidence intervals ci calculated outcome numerator number events denominator number patients risk available treatment group hydroxychloroquine chloroquine comparator group appropriate comparator groups identified eudraviligance hydroxychloroquine chloroquine established treatments covid<NUMBER> time consequently spontaneous reports included benefitrisk table presented text ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint due lack data fully quantitative assessment undertaken however outcomes identified value tree ranked swing weighting applied future assessments weighted net clinical benefit wncb subsequently calculated using weights <NUMBER> <NUMBER> <NUMBER> would propose using sutton et al method benefits positive contribution wncb risks negative contribution <NUMBER> overall wncb would considered positive benefit outweighs risk wncb <NUMBER> sensitivity analysis also used examine robustness assigned weights whether significant changes would alter benefitrisk profile <NUMBER> value tree reflecting key benefits risks related hydroxychloroquine chloroquine treatment covid<NUMBER> displayed fig <NUMBER> data outcomes presented data extraction table key benefitrisk summary table tables <NUMBER> <NUMBER> respectively literature searching identified <NUMBER> papers pubmed <NUMBER> results google scholar chloroquine also identified <NUMBER> papers pubmed <NUMBER> results google scholar hydroxychloroquine initial review removal duplicates <NUMBER> papers reviewed determine met inclusion criteria <NUMBER> papers included final benefitrisk assessment reduction risk death covid<NUMBER> considered key benefit treatment chloroquine hydroxychloroquine compared standard care placebo treatments found comparative data available key benefit reduction risk icu admission identified key benefit though comparative data found existing literature another key benefit identified reduction risk noninvasive ventilation data comparing hydroxychloroquine chloroquine standard care placebo treatments identified ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint secondary clinical outcomes also considered key benefits refer anticipated clinical endpoints result chloroquine hydroxychloroquine treatment reflect potential reductions disease progression development pneumonia acute respiratory distress syndrome ards comparative data found existing literature outcomes key benefit identified reduction number patients requiring supplementalhigh flow oxygen comparative data identified viral load parameters considered surrogate endpoint benefit risk assessment context outcomes virological clearance reflecting benefit recovery covid<NUMBER> study gautret et al <NUMBER> authors examined virological clearance ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> comparative data identified cardiac toxicity eudravigilance <NUMBER> reports qt prolongation one report ventricular arrythmia one report atrioventricular av block one fatal cardiac arrest one nonfatal cardiac arrest patients using hydroxychloroquine coronavirus infection addition <NUMBER> reports qt prolongation one report tachyarrhythmia one report ventricular tachycardia patients using chloroquine coronavirus infection comparative data identified immune reactions among patients using hydroxychloroquine chloroquine covid<NUMBER> treatment comparative data ocular events among patients using hydroxychloroquine chloroquine covid<NUMBER> treatment identified comparative data identified serious skin reactions among patients using hydroxychloroquine chloroquine covid<NUMBER> treatment study chen j et al <NUMBER> abnormal liver function reported four patients hydroxychloroquine group risk<NUMBER> three patients comparator group risk<NUMBER> significant difference risk two groups rd<NUMBER> <NUMBER> ci <NUMBER> <NUMBER> eudravigilance two reports liver injury one report hepatocellular injury patients using hydroxychloroquine coronavirus infection addition one report hepatocellular injury patient using chloroquine coronavirus infection comparative data identified severe hypoglycaemia among patients using hydroxychloroquine chloroquine covid<NUMBER> treatment ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint comparative data identified adverse haematological events eudravigilance two reports neutropenia patients using hydroxychloroquine coronavirus infection comparative data identified drug interactions chloroquine hydroxychloroquine eudravigilance one potentiating drug interaction reported patient using chloroquine coronavirus infection patient experienced qt prolongation also taking lithium carbonate quetiapine fumarate several potential key benefits identified use hydroxychloroquine chloroquine covid<NUMBER> treatment reduction risk death reduction icu admission reduction noninvasive ventilation reduction secondary clinical outcomes reduction use oxygen improved viral load parameters eg virological clearance key benefits outcomes highlighted currently ongoing clinical trials addition several potential key risks also identified cardiac events immune reactions ocular events skin events liver events severe hypoglycaemia blood events drug interactions cardiac toxicity particular importance covid<NUMBER> patients potentially disease anticipated treatment strategies chloroquine hydroxychloroquine pose significant risk cardiac arrhythmias <NUMBER> short term use expected treatment covid<NUMBER> likely pose lower risk cardiac toxicity nevertheless risk cannot overlooked patients expected higher doses possibly concomitantly taking qt prolonging agents addition potentially elevated risk due disease one serious toxic effects hydroxychloroquine chloroquine ocular side effects notably retinopathy <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> although risk hydroxychloroquine considered lower <NUMBER> duration use weightbased dosing dose per kg important parameters risk developing retinopathy <NUMBER> risk retinal damage short time period may negligible even high doses <NUMBER> however given seriousness outcome identified key risk benefitrisk framework addition whilst robust evidence safety concerns associated chloroquine hydroxychloroquine longer term use although rare case reports ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint weeks opposed longer duration use respect adverse hepatic haematological effects hypoglycaemia <NUMBER> <NUMBER> <NUMBER> studies identified compared benefits risks using hydroxychloroquine chloroquine receiving standard care placebo treatments data identified one benefit viral load parameters one risk liver events benefit virological clearance three studies small sample sizes identified studies examined virological clearance different time points primary outcome meaning results studies could pooled one study revealed significant risk difference hydroxychloroquine comparator group standard care though given small sample size biases study design interpreted caution risk abnormal lfts one studied identified small sample size significant risk difference hydroxychloroquine comparator group standard care whilst paucity comparative data literature search stage identified number reports eudravigilance following data obtained eudravigilance patients taking chloroquine hydroxychloroquine qt prolongation n<NUMBER> ventricular arrythmia n<NUMBER> atrioventricular av block n<NUMBER> nonfatal cardiac arrest n<NUMBER> fatal cardiac arrest n<NUMBER> tachyarrhythmia n<NUMBER> ventricular tachycardia n<NUMBER> liver injury n<NUMBER> hepatocellular injury n<NUMBER> neutropenia n<NUMBER> drug interaction n<NUMBER> data used future benefitrisk assessments appropriate treatment comparator identified established treatment covid<NUMBER> given paucity available data benefits risks hydroxychloroquine chloroquine compared standard care placebo treatments chose undertake fully quantitative assessment benefitrisk balance time instead available comparative data key benefits risks presented summary table data clinical trials observational studies required order determine whether benefitrisk profile hydroxychloroquine chloroquine treating covid<NUMBER> favourable important point discussion regardless benefits risks hydroxychloroquine chloroquine covid<NUMBER> treatment availability medicines inadequate ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> supply shortages already reported <NUMBER> meaning availability guaranteed using treatments licensed indications covid<NUMBER> must taken consideration addition benefitrisk assessment since benefit medication unobtainable sample sizes outcome limited available original studies may adequate power detect differences risk groups especially outcomes examined primary outcome interest benefitrisk assessment limited availability data published literature however assessment subsequently updated data clinical trials available addition given public health urgency covid<NUMBER> pandemic important provide systematic assessment benefits risks hydroxychloroquine chloroquine treatments evidence available date create framework used rapidly update assessment data available data quality reflected benefitrisk assessment though data included extracted peerreviewed manuscripts note statement issued international society antimicrobial chemotherapy <NUMBER> regarding gautret et al paper published international journal antimicrobial agents <NUMBER> paper considered meet societys expected standards though peerreviewed editorinchief involved process <NUMBER> confirmation causality requirement inclusion data brat assessment patients may concomitant medications medical conditions time hydroxychloroquine chloroquine treatment finally considered hospitalisation patients reflect severe covid<NUMBER> acknowledge severity disease may vary regardless hospitalisation overall conclusion made benefitrisk profile hydroxychloroquine chloroquine treatment covid<NUMBER> compared standard care placebo treatments time whilst availability comparative data limited current framework summarises key anticipated benefits risks data clinical trials real world use benefits risks becomes available incorporated framework ongoing benefitrisk assessment ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> data results clinical trial comparing hydroxychloroquine without azithromycin standard care treatment covid<NUMBER> published international journal antimicrobial agents philippe gautret et al <NUMBER> study provides outstanding results combination hydroxychloroquine azithromycin standard care publication considered interesting several health authorities including ministers health evidence deemed insufficiently robust warrant public health decision widen use hydroxychloroquine treatment covid<NUMBER> <NUMBER> world health organization initially issue opinion study recommendation use hydroxychloroquine commonly used wellestablished product treatment malaria endemic malaria regions also used treat diseases instead later world health organization warned using untested medicines without right supporting evidence could raise false hope referring obviously hydroxychloroquine <NUMBER> poland however appears outlier updated summary product characteristics chloroquine introduce mention efficacy coronavirus <NUMBER> dr krzysztof simon reported successful use chloroquine wroclaw hospital clinical practice <NUMBER> poland followed jordan <NUMBER> tunisian health agency ineas recommended use hydroxychloroquine first guidelines <NUMBER> high concentrations cytokines identified critically ill patients coronavirus <NUMBER> infection <NUMBER> hydroxychloroquine widely used autoimmune diseases lupus contribute reduce production cytokine proinflammatory factors vitro trials shown efficacy hydroxychloroquine coronaviruses <NUMBER> recently vitro trials showed hydroxychloroquine chloroquine potent inhibiting coronavirus <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> years experience chloroquine wellestablished safety profile wellknown serious adverse events preventable appropriate pretreatment ontreatment monitoring urgency public health crisis dramatic increase number fatalities europe high risk emerging countries weak hospital intensive care unit infrastructure contrast lack recommendation combination hydroxychloroquine azithromycin lay media several criticized quality study questioned reliability results <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however scientific critical review study published aim paper provide objective scientific critical review gautret et al publication put results context current knowledge provide evaluation validity results methodologic perspective discuss public health implications prospective openlabel nonrandomized controlled trial conducted across five study centers one center institut hospitalouniversitaire mediterranée ihu administered hydroxychloroquine four centers region recruited control patients unclear whether control patients part study protocol reported sample size power calculation applies comparative <NUMBER>arm study however abstract refers singlearm study according protocol submitted eu clinical trials register clinicaltrialsregistereu id number <NUMBER>fr study originally designed noncontrolled study thus appears control arm later amendment study intervention hydroxychloroquine alone combined azithromycin used addition standard care treatment coronavirus <NUMBER> comparator standard care yet standardizedthis may introduce bias patients receiving active treatment enrolled specialized unit benefiting highlevel experts uptodate infrastructure comparison control patients recruited hospitals briançon remote hospital french alps would receive fair good quality care specialized ihu raises question whether differences management patients centers therefore arms might influenced outcomes viral clearance management patients intensive help survive maintaining vital functions preventing complications eg infections heart kidney failure however differences patient management may necessarily impact coronavirus carriage clearance addition open study always raises issue observer bias ie investigators knowledge patients treatment may influence study outcome assessment considering subjective outcomes represents important source bias however case outcome measure automated biological measure unlikely outcome measure might influenced open design development study product doubleblind trial would required several months provide appropriate formulation relevant stability data required good manufacturing practices good clinical practices feasible option context ongoing crisis important methodologic biases represent clear conceptual methodologic limitations several could avoided unlikely avoiding would reversed trend seen trial study included hospitalized patients aged <NUMBER> years polymerase chain reaction pcrdocumented coronavirus <NUMBER> carriage nasopharyngeal sample admission whatever clinical status patients refused receive hydroxychloroquine used control patients noneligible patients obviously makes comparability participants control active treatment arms highly questionable comparing two treatment arms important comparable populations alternatively statistical methods used control differences patient characteristics arms obvious selection bias patients randomly assigned patients ihu different centers channeled based unknown drivers expected analysis baseline characteristics showed clear differences treatment arms hydroxychloroquinetreated patients older <NUMBER> years vs <NUMBER> years less likely asymptomatic <NUMBER> vs <NUMBER> likely present pneumonia <NUMBER> vs <NUMBER> differences considerable even nonstatistically significant probably bias hydroxychloroquine intervention suggests study provided conservative results considering population differences indeed older severely ill patients likely weaker immune defense response virus bacterial infection although may serious impact patient prognosis survival may limited impact efficacy hydroxychloroquine virus clearance unclear publication whether participants active control arm gave informed consent however control patients treated according normal practice primary outcome assessment interfering normal care may considered external standardofcare control arm may part study although point requires clarification unlikely affect results carriage coronavirus <NUMBER> based nasal oropharynx sampling assessed wellestablished technique detect coronavirus <NUMBER> rna using realtime reverse transcriptasepcr reliable technique raise significant objections however appears endpoint changed study although article unclear planned assessment time points days <NUMBER> <NUMBER> <NUMBER> <NUMBER> reported sample size calculation refers reduction viral load day <NUMBER> contradicts outcome section article primary outcome stated viral clearance day <NUMBER> results reported days <NUMBER> <NUMBER> <NUMBER> <NUMBER> may <NUMBER> days initially intended main assessment endpoint authors decided report findings <NUMBER> days clear results observed considering urgency situation however contradictions within article well article protocol raise questions credibility article important note endpoint surrogate endpoint would preclude clinical survival benefit however lack approved drugs fight coronavirus <NUMBER> infection fatal patients information high importance dosing hydroxychloroquine well reported methods section <NUMBER> mg three times day <NUMBER> days however administration schedule azithromycin reported description methods rather results section may also noted mention azithromycin summary protocol eu clinical trials register according abstract patients receiving azithromycin selected based clinical profile specific profile reported clarity point review baseline results allow identification clear criteria age lower respiratory tract infection onset disease plasma concentration hydroxychloroquine combination therapy arm different monotherapy treatment arm male patients likely receive azithromycin male patients comprised <NUMBER> control arm <NUMBER> hydroxychloroquine arm <NUMBER> combined hydroxychloroquineazithromycin arm obvious imbalance however unclear sex may confounding factor may impacted high rate clearance covid<NUMBER> subgroup population still must clarified although constitutes poor practice study reporting unlikely introduce significant bias reported results use fisher exact test appropriate statistical methods interim analyses early interruption clinical trials used <NUMBER> appears daily interim statistical analyses performed trial interrupted early without using methods control probability incorrectly rejecting null hypothesis treatment differences however magnitude difference appears large hypothesis difference arms would rejected even appropriate methods interim statistical used important point concerns population used assess primary endpoint authors used perprotocol population whereas intentiontotreat analysis normally employed clinical trials aiming establish superiority clinical treatment <NUMBER> particularly important point study patients dropped belonged hydroxychloroquine arm imbalance requires careful reanalysis results among patients dropped three patients transferred intensive care unit two pcr positive one pcr negative time transfer one died pcr negative one withdrew consent pcr negative one stopped adverse event nausea pcr positive thus patients dropped <NUMBER> negative time dropout <NUMBER> positive performing statistical analysis using lastobservationcarriedforward imputation method account missing data conservative methodology widely used regulatory authorities <NUMBER> could assess proportion patients negative <NUMBER> hydroxychloroquine arm compared <NUMBER> control arm still statistically significant p <NUMBER> clinically relevant employ conservative method assumes dropouts pcr positive day <NUMBER> proportion patients pcr negative would become <NUMBER> hydroxychloroquine arm compared <NUMBER> control arm still statistically significant p <NUMBER> clinically relevant finally informative also consider separately subgroup patients treated hydroxychloroquine alone among proportion viral clearance <NUMBER> compared <NUMBER> control arm difference significant statistical p <NUMBER> clinical perspectives although may uncertainty effect size ranging <NUMBER> <NUMBER> intervention shown large effect size could undermined statistical considerations poor quality medical writing also issue identified dozen inaccuracies imprecisions mistakes abstract alone reported table <NUMBER> may related time pressure release first nonchinese clinical results coronavirus <NUMBER>infected patients however level medical writing may compromise perceived quality evidence reported may lead readers doubt quality investigational procedures used trial well important corrected final version uploaded journal study poorly reported trial design introduces several biases biases could avoided time protocol development thoughtful consideration quality medical writing poor suggests quickly written manuscript support skilled methodologist priority obviously given fast communication results may dramatic impact situation severe pandemic authors could significantly improved quality manuscript public health impact discussing transparent way limitations study invested additional effort medical writing however none observations nature reverse results results appear acceptable light effect size data may influenced several biases identified study manuscript extent make intervention ineffective clearly works even cannot accurately specify actual effect size china <NUMBER> studies covid<NUMBER> registered national clinical trial registry <NUMBER> studied intervention chloroquine hydroxychloroquine monotherapy part combination therapy represented <NUMBER> trials results yet published evidence accumulated effectiveness chloroquine hydroxychloroquine recent review <NUMBER> patients aggregated several trials published reports benefit chloroquine clearing coronavirus <NUMBER> infected patients <NUMBER> however provide details patient disposition outcomes aims signal community evidence supports use chloroquine details follow trials yet finalized us centers disease control prevention provides information use hydroxychloroquine chloroquine usa treat coronavirus <NUMBER>infected patients describe multiplicity different hydroxychloroquine regimens currently used usa also used prophylactic treatment healthcare professionals <NUMBER> beyond chinese trials chloroquine hydroxychloroquine several randomized trials table <NUMBER> inaccuracies inconsistencies mistakes abstract <NUMBER> efficient instead effectiveness reported twice <NUMBER> patients included instead enrolled <NUMBER> role hydroxychloroquine efficacy safety <NUMBER> respiratory viral load nasopharyngeal viral load <NUMBER> single arm later abstract comparative negative control <NUMBER> patients included protocol instead study <NUMBER> negative control instead standard care control <NUMBER> early march march <NUMBER>th precise study approved <NUMBER>th march clear started <NUMBER> viral load tested instead measured <NUMBER> hydroxychoroquine specified top standard care <NUMBER> azithromycin appears new intervention described methodology protocol <NUMBER> untreated patients another center <NUMBER> centers <NUMBER> presence virus day <NUMBER> primary end point supposed day <NUMBER> protocol protocol specify objective measure time clearance virus load <NUMBER> study measure time virus clearance concluded reduction carrying duration <NUMBER> survey instead study conducted efficacy safety hydroxychloroquine usa south korea norway australia coronavirus <NUMBER>infected patients clinicaltrialsgov id nct<NUMBER> nct<NUMBER> nct<NUMBER> addition two studies ongoing assessing prophylactic effect healthcare professionals exposed exposed patients infected coronavirus <NUMBER> clinicaltrialsgov id nct<NUMBER> nct<NUMBER> <NUMBER> treatment guidelines endorsed national health commission china including chinese expert consensus report recommended using chloroquine <NUMBER> mg twice daily <NUMBER> days maximum table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however one guideline recommended using conjunction azithromycin avoid risk cardiac arrhythmia table <NUMBER> korean guidelines recommend use chloroquine <NUMBER> mg twice daily hydroxychloroquine <NUMBER> mg per day <NUMBER> gautret et al study consistent results recent chinese studies fully reported consistent current scientific knowledge wellfounded biological assumption support validity tested hypothesis realworld largescale clinical practice china korea supports experimental finding even though exact contribution chloroquine control outbreak cannot accurately quantified time either country current evidence robust doubleblind randomized clinical trial points effectiveness hydroxychloroquine patients coronavirus <NUMBER> infection evidencebased medicine teaches us consider evidence including case reports expert opinions decisionmaking specific case available evidence hydroxychloroquine used coronavirus <NUMBER> infection recommendation would receive evidence level <NUMBER>b <NUMBER> c <NUMBER> <NUMBER> <NUMBER> evidence grading supports recommendation use hydroxychloroquine covid<NUMBER> infection especially crisis situation overall knowledge around hydroxychloroquine translate policy decisionmaking control covid<NUMBER> pandemic especially alternative option currently exists readily accessible quantities numerous public questions hydroxychloroquine recommended early table <NUMBER> inclusion chloroquine phosphate guidelines publishing organization key information <NUMBER> novel coronavirus pneumonia diagnosis treatment plan provisional <NUMBER>th ed <NUMBER> national health commission eligibility general treatments covid<NUMBER> cases regardless disease severity dosage <NUMBER> mg twice per day use longer <NUMBER> days <NUMBER> expert consensus chloroquine phosphate treatment novel coronavirus pneumonia <NUMBER> health commission guangdong province chloroquine covid<NUMBER> treatment recommended chloroquine phosphate tablet <NUMBER> mg twice per day <NUMBER> days patients diagnosed mild moderate severe cases novel coronavirus pneumonia without contraindications chloroquine contraindicated use combined macrolide antibiotics including azithromycin <NUMBER> close monitoring adverse effects chloroquine phosphate treatment novel coronavirus pneumonia <NUMBER> health commission hubei province chloroquine phosphate cause acute death lethal dose adults <NUMBER> g <NUMBER> notifications adjustment dosage chloroquine phosphate treatment novel coronavirus pneumonia <NUMBER> national health commission chloroquine phosphate <NUMBER> mg bid <NUMBER> days adults aged <NUMBER> years body weight <NUMBER> kg <NUMBER> mg bid days <NUMBER> <NUMBER> <NUMBER> mg qd days <NUMBER> adults body weight <NUMBER> kg contraindicated use combined macrolide antibiotics including azithromycin <NUMBER> shanghai expert consensus integrated treatment novel coronavirus pneumonia <NUMBER> shanghai expert panel clinical treatments covid<NUMBER> hydroxychloroquine sulphate chloroquine phosphate recommended novel coronavirus pneumonia diagnosis treatment plan provisional <NUMBER>th edition <NUMBER> national health commission chloroquine phosphate <NUMBER> mg bid <NUMBER> days adults aged <NUMBER> years body weight <NUMBER> kg <NUMBER> mg bid days <NUMBER> <NUMBER> <NUMBER> mg qd days <NUMBER> adults body weight <NUMBER> kg <NUMBER> guangdong expert consensus chinese integrative medicines prevention treatment covid<NUMBER> <NUMBER> guangdong association integrative medicine chloroquine phosphate <NUMBER> mg bid <NUMBER> days adults aged <NUMBER> years body weight <NUMBER> kg <NUMBER> mg bid days <NUMBER> <NUMBER> <NUMBER> mg qd days <NUMBER> adults body weight <NUMBER> kg <NUMBER> shandong expert consensus diagnosis treatment novel coronavirus pneumonia <NUMBER> shandong expert panel clinical treatments covid<NUMBER> hydroxychloroquine sulphate <NUMBER> mg <NUMBER> times per day treatment france one authors study raoult also member expert council advising president government covid<NUMBER> crisis therefore council certainly well informed study raises question study leading recommendation generalized use hydroxychloroquine defeat covid<NUMBER> outbreak france methodology tends supersede evidence methodology perfect evidence ignored well illustrated debate two major experts field jean luc harousseau jean françois bergman highly respected experts extensive experience policy decisionmaking several governmental agencies <NUMBER> context poor reporting multiplicity biases study prevent french methodologist considering study careful assessment would shown limited impact poor reporting biases results french methodologists tend disqualify studies assess learning points despite biases put context current knowledge possible second scientific obstacle may competition scientists always high competition among scientists first scientists succeeded establishing gautret et al study hypothesisgeneration study hypothesistesting study several experts convinced biases poor reporting invalidated study results addition large european study discovery launched next week enroll <NUMBER> patients <NUMBER> arms including placebo remdesivir combination lopinavir ritonavir without interferon beta hydroxychloroquine apparently without azithromycin <NUMBER> six hundred fifty patients per arm seems large information available time writing concerning sample size estimated depending population included results may negative little reported time submit manuscript launching similar global study called solidarity test interventions placebo <NUMBER> thus decision recommendation hydroxychloroquine may delayed several hypothesistesting studies reported lot knowledge available chinese south korean experience low risk associated hydroxychloroquine recommendation specific population versus potential high benefit would argue favor use hydroxychloroquine evidence brings definite results rather waiting new evidence difficult politicians make right decision crisis decisions scrutinized criticized hydroxychloroquine presented unsafe therapy study widely criticized media primacy precautionary principle primare non nocere extensive transmission hiv via blood transfusion france left profound effects <NUMBER> <NUMBER> decisionmakers driven safety first making decisions recently massive ordering h<NUMBER>n<NUMBER> vaccines stockpiling antivirals france provoked considerable public controversy <NUMBER> european public health decisionmakers appear riskaverse clear comparing us food drug administration european medicines agency regulatory approval decisions important question likely raise future controversy evidence accumulated start recommendation hydroxychloroquine prescription earlier risk serious adverse events shortterm administration hydroxychloroquine well case fatality rate estimates europe <NUMBER> hydroxychloroquine may offer potential quickly control covid<NUMBER> outbreak associated social economic psychiatric consequences well consequences healthcare professionals adverse events manageable current confinement strategy probably worse direct consequences health eg severe psychiatric consequences <NUMBER> also indirect consequences health economic losses entailed strategy impact future funding health systems therapeutic option available limited evidence one carefully weigh benefit risk option versus alternative options hydroxychloroquine treatment massive testing limited confinement successfully worked south korea control outbreak impressively low rate fatalities <NUMBER> gautret et al conducted quick dirty study methodologists would legitimately say poor quality reporting several biases however critical review study suggests brings useful knowledge top already existing one could prompted quicker policy decisionmaking temporary conditional approval known france recommandation temporaire dutilisation could granted hydroxychloroquine potentially saved lives assuming ongoing studies return negative results everyone consider good decision recommend hydroxychloroquine results positive highly probable furious discussion taken earlier case learn risk delaying decisions uncertain environment evidencebased medicine would likely allow intermediate grade recommending use hydroxychloroquine treatment specific cases covid<NUMBER> far european decisionmakers shown little ability learn china <NUMBER> south korea <NUMBER> two countries able control outbreak cultural differences language barriers arrogance old europe may certainly explain best practice knowledge sharing failed situation without therapeutic vaccine specific antiviral drugs desperate attempt find cure novel corona virus disease <NUMBER> covid<NUMBER> <NUMBER> limelight shifted hydoxychloroquine derivative chloroquine antimalarial antiinflammatory immunosuppressive antiautophagy activities <NUMBER> <NUMBER> upon tweet us president mr donald j trump <NUMBER>st march <NUMBER> tweeted hydroxychloroquine azithromycin taken together real chance one biggest game changers history medicine httpstwittercomrealdonaldtrumpstatus <NUMBER>langen however easier said done initial studies covid<NUMBER> patients treated hydoxychloroquine without azithromycin shown mixed results scrutiny raised lack proper design studies without clinical trials robust methodologically correct scientific studies skepticism benefits efficacy hydoxychloroquine covid<NUMBER> till writing article per information available ncbi currently worldwide <NUMBER> clinical trials going httpsclinicaltrialsgovct<NUMBER>resultscond <NUMBER>wuhancoronavirus<NUMBER> <NUMBER> different compounds tested covid<NUMBER> httpspubchemncbi nlmnihgovtabcompoundquerycovid<NUMBER> <NUMBER>clinicaltrials though exact mechanisms still unclear however established scientific literature molecular level hydroxychloroquine affects activity lysosomes turn autophagy disrupts lysosomal membrane stability also alters transcriptional activity signaling pathways cellular level also precise mode action hydroxychloroquine yet amit pal anil pawar cofirst authors amit pal anil pawar contributed equally work electronic supplementary material online version article httpsdoiorg<NUMBER>s<NUMBER>x contains supplementary material available authorized users delineated based upon current understanding hydroxychloroquine shown inhibit immune system activation suppression immune system activation hydroxychloroquine achieved reducing cytokine production tolllike receptor tlr signaling pathways <NUMBER> <NUMBER> main aim review discuss mode action hydroxychloroquine cellular molecular levels potentially support clinical efficacy adverse side effects observed covid<NUMBER> patients treated hydroxychloroquine may help improving clinical outcomes modifying altering drug restricted use certain individuals enforcing strict inclusion exclusion criteria readers referred holistic review clinical use hydroxychloroquine diseases like rheumatoid arthritis systemic lupus erythematosus antiphospholipid syndrome primary sjögren syndrome <NUMBER> <NUMBER> towards end year <NUMBER> december <NUMBER> chinese province wuhan reported emergence covid<NUMBER> humans characterized atypical pneumonia fever dry cough progressive dyspnea <NUMBER> novel coronavirus <NUMBER> ncov<NUMBER> officially known severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> demonstrated cause covid<NUMBER> <NUMBER> within span around <NUMBER> months covid<NUMBER> spread worldwide forcing world health organization declare pandemic <NUMBER>th march <NUMBER> per whocovid<NUMBER> dashboard available httpscovid<NUMBER>whoint <NUMBER>st may <NUMBER> <NUMBER> confirmed cases covid<NUMBER> including <NUMBER> deaths worldwide well established respiratory transmission direct contact transmission main routes covid<NUMBER> transmission previously coronaviruses covs also responsible severe acute respiratory syndrome sars middle east respiratory syndrome mers outbreaks <NUMBER> <NUMBER> according centers disease control prevention cdc usa available httpswwwcdcgovcor onavirus<NUMBER>ncovsymptomstestingsymptomshtml recent literature covid<NUMBER> infected people demonstrate wide range symptomsranging mild symptoms severe illness common symptoms confirmed positive covid<NUMBER> patients fever cough shortness breath myalgia fatigue sore throat whereas headache chills new loss taste smell sputum production diarrhea vomiting like symptoms may also occur <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> elderly people people severe underlying medical conditions seem higher risk developing serious complications covid<NUMBER> compared young healthy adults <NUMBER> <NUMBER> <NUMBER> <NUMBER> deaths due covid<NUMBER> due severe respiratory failure pneumonia multiple organ failure <NUMBER> initially combination computed tomography ct imaging electron microscopy whole genome sequencing used screen identify sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> confirmatory diagnosis covid<NUMBER> relies realtime reverse transcriptasepolymerase chain reaction rtpcr method rnadependent rna polymerase rdrp gene orf<NUMBER>ab sequence e gene n gene gene sarscov<NUMBER> genome basis rtpcr tests diagnosis sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> among laboratory parameters moderate covid<NUMBER> patients exhibited leucopenia lymphopenia high level creactive protein crp erythrocyte sedimentation rate <NUMBER> <NUMBER> however severe covid<NUMBER> patients showed frequent lymphopenia increased levels lactate dehydrogenase crp ferritin alanine aminotransferase ddimer along grossly higher levels interleukins ils il<NUMBER>r il<NUMBER> il<NUMBER> tumor necrosis factora <NUMBER> <NUMBER> <NUMBER> <NUMBER> acute respiratory distress syndrome ards multipleorgan failure covid<NUMBER> thought result cytokine storm also known cytokine release syndrome cytokine storm excessive immune response external stimulus cytokine storm severe covid<NUMBER> cases left untreated longer time results increased risk vascular hyperpermeability multiorgan failure eventually death <NUMBER> <NUMBER> due observance cytokine storm severe covid<NUMBER> cases authors suggested theoretical treatment strategies like use il<NUMBER> il<NUMBER> family antagonists tnf blockers corticosteroid therapy among strategies <NUMBER> <NUMBER> hydroxychloroquine pubchem cid <NUMBER> httpspub chemncbinlmnihgovcompound<NUMBER> molecular formula c <NUMBER> h <NUMBER> cln <NUMBER> also known plaquenil oxichloroquine oxychlorochin derivative chloroquine exhibiting immunosuppressive antiinflammatory antiautophagy antimalarial activities due properties hydroxychloroquine often used antirheumatologic agent systemic lupus erythematosis rheumatoid arthritis reason ind j clin biochem hydroxychloroquine chloroquine classified diseasemodifying antirheumatic drugs dmards hydroxychloroquine derived chloroquine differ presence hydroxyl group hydroxychloroquine chloroquine weak bases halflife around <NUMBER> days hydroxychloroquine chloroquine belong <NUMBER>aminoquinolines drugs class reviewed <NUMBER> chloroquine hydroxychloroquine almost similar structure mode action drugs used sarscov<NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> compared chloroquine hydroxychloroquine better therapeutic agent terms safety index various modes action postulated explain therapeutic uses hydroxychloroquine based vitro studies reviewed <NUMBER> hydroxychloroquine administered hydroxychloroquine sulfate lag time <NUMBER> h <NUMBER> mg salt time oral absorption measurement blood usually absorbed upper intestinal region <NUMBER> overall bioavailability <NUMBER> concentration hydroxychloroquine vary plasma blood serum individual patient also among different patients <NUMBER> intriguing note hydroxychloroquine halflife period approximately <NUMBER> months mean residence time nearly <NUMBER> h <NUMBER> precise mechanism action hydroxychloroquine known till date lots research going existing knowledge gap using diverse advanced scientific tools like <NUMBER> computational biology <NUMBER> immunology <NUMBER> <NUMBER> structural biology <NUMBER> <NUMBER> modern molecular medicine <NUMBER> <NUMBER> synthetic biology <NUMBER> <NUMBER> big datadriven public health science <NUMBER> <NUMBER> hydroxychloroquine may suppress immune function interfering processing presentation antigens production cytokines acidic vesicles endosomeslysosomes essential membrane fusion act major locations action chloroquine hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> chloroquine accumulates lysosomes lysosomotropism increasing ph interferes glycosylation cellular receptor sarscov<NUMBER> thereby inhibits infection virus <NUMBER> <NUMBER> important feature hydroxychloroquine capability inhibit innate well acquired immunity <NUMBER> hydroxychloroquine may also affect signaling tlr receptors changing endosomal ph <NUMBER> well inhibiting tlrligand interactions research required know exact mechanism drug affects tlr activation additionally hydroxychloroquine interfering lysosomal activity autophagy inhibits antigen processing presentation along mhcii molecules subsequently immune system activation reduced activation cd<NUMBER> cells leads decreased production proinflammatory markers cytokines <NUMBER> <NUMBER> suggested autophagy involved autoantigen presentation mediated mhc class ii molecules activation thelper cells <NUMBER> immunomodulatory antiinflammatory properties hydroxychloroquine prove better remedy sarscov<NUMBER> patients cytokine storm emerged potentially fatal condition <NUMBER> <NUMBER> antiinflammatory agent hydroxychloroquine also used treat various autoimmune disorders rheumatoid arthritis systemic lupus erythematosus sjogrens syndrome <NUMBER> <NUMBER> hydroxychloroquine also exhibits antibacterial property particularly intracellular bacteria coxiella burnetii <NUMBER> however due strong affinity hydroxychloroquine melanin deposit tissues skin eyes hydroxychloroquine retinopathy <NUMBER> hydroxychloroquine thought prevent thrombotic complications behaving like anticoagulant agents hence prove beneficial cases secondary coagulopathy owing systemic inflammation <NUMBER> done probably inhibiting platelet aggregation <NUMBER> <NUMBER> inhibition binding antiphospholipid antibody autoinflammatory diseases <NUMBER> hydroxychloroquine found safe use pregnancy various studies shown checks initiation congenital heart blockage <NUMBER> <NUMBER> possibly reducing expression type interferon ifn signature <NUMBER> combination therapy hydroxychloroquine may interfere functioning drugs vice versa metabolized enzyme cytochrome p<NUMBER> cyp responsible metabolism many drugs <NUMBER> <NUMBER> <NUMBER> <NUMBER> hydroxychloroquine increases bioavailability metoprolol blood plasma reducing metabolism although similar effect observed drugs dextromethorphan <NUMBER> methotrexate <NUMBER> hand bioavailability hydroxychloroquine may affected medicines increase ph gastric juice <NUMBER> hydroxychloroquine also interfere drugs affect qt interval hence possibility cardiac arrhythmia checked patients <NUMBER> <NUMBER> combination therapy breast cancer using tamoxifen hydroxychloroquine may cause eye toxicity due synergistic inhibition enzymes lysosomes retinal epithelial cells <NUMBER> thus duration therapy monitored carefully adverse outcomes hydroxychloroquine usage gastrointestinal effects including nausea vomiting diarrhea abdominal discomfort <NUMBER> moreover hydroxychloroquineassociated cardiotoxic effects including rhythm disorders cardiomyopathy rheumatic patients also reported <NUMBER> <NUMBER> hydroxychloroquine attracted attention past decades potential antiviral agent currently possible treatment covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> however whether hydroxychloroquine works vivo covid<NUMBER> remains seen conclusively word caution randomized controlled trials number viruses including influenza hydroxychloroquine havent work hydroxychloroquine known decrease acidity endosomes turn might avert endosome releasing virus cytoplasm biggest limitation lack preclinical data hydroxychloroquine covid<NUMBER> repeated failure viral diseases vivo conditions <NUMBER> another issue hydroxychloroquine adverse outcomes certain patients comorbid conditions medications <NUMBER> <NUMBER> <NUMBER> reported hydroxychloroquine also interfere drugs affect qt interval <NUMBER> one concern covid<NUMBER> patients receiving hydroxychloroquinechloroquine ± azithromycin prolongation qt interval may possibly increase risk torsade de pointes tdp <NUMBER> sudden cardiac death prospective observational study large cohort covid<NUMBER> patients treated chloroquinehydroxychloroquine ± azithromycin demonstrated instances tdp arrhythmogenic death even though shown use medications resulted qt prolongation <NUMBER> due cellular molecular effects discussed previous sections quite clinical trials studying effectiveness safety hydroxychloroquine also chloroquine covid<NUMBER> httpsclinicaltrialsgovct<NUMBER> resultscond<NUMBER>wuhancoronavirus<NUMBER> upon searching interventional studies among clinical trials covid<NUMBER> till writing article authors found <NUMBER> interventional studies using various drugs among <NUMBER> studies <NUMBER> studies found using hydroxychloroquine alone table <NUMBER> <NUMBER> studies using hydroxychloroquine combination antiviralnutritional supplementsprobiotics etc supplementary material <NUMBER> studies hydroxychloroquine covid<NUMBER> focussing safety efficacy well use prophylaxis measure covid<NUMBER> table <NUMBER> clinical trials also evaluating optimal hydroxychloroquine dose use moderate severe covid<NUMBER> cases pregnant covid<NUMBER> positive women table <NUMBER> seven clinical trial registries also found chinese clinical trial registry httpwwwchictrorgcn using hydoxychloroquine treat covid<NUMBER> <NUMBER> recent significant development may <NUMBER>nd <NUMBER> observational study published lancet journal reported hydroxychloroquine chloroquine used alone macrolide inhospital outcomes covid<NUMBER> associated decreased inhospital survival along increased frequency ventricular arrhythmias <NUMBER> acting swiftly report may <NUMBER>th <NUMBER> executive group implemented temporary pause hydroxychloroquine arm within solidarity trial safety data reviewed data safety monitoring board httpswwwwhointemergen ciesdiseasesnovelcoronavirus<NUMBER>globalresearchonnovelcoronavirus<NUMBER>ncovsolidarityclinicaltrialforcovid<NUMBER>treatments expressing shock move various eminent scientists <NUMBER> scientists written open letter editor lancet journal authors study concerns data integrity plenty loopholes erroneous conclusions study among host concerns httpswwwtropi calmedicineoxacuknewsanopenlettertorichardhor toneditorofthelancetregardingmehraetal however indian council medical research icmr new delhi india maintained earlier guidelines use hydroxychloroquine prophylaxis sarscov<NUMBER> infection httpswwwmohfwgovinpdfadvisor yontheuseofhydroxychloroquina sprophylaxisforsarscov<NUMBER>infectionpdf revised guidelines httpswwwicmrgovinpdfcovidtechdoc v<NUMBER>revisedadvisoryontheuseofhcqsars cov<NUMBER>infectionpdf revised guidelines published <NUMBER>nd may <NUMBER> icmr expanded include following personnel use hydroxychloroquine prophylaxis sarscov<NUMBER> infection <NUMBER> asymptomatic healthcare workers working covid hospitalnoncovid hospitals noncovid areas covid hospitalsblocks <NUMBER> asymptomatic frontline workersparamilitarypolice personnel working covid<NUMBER> containment zones <NUMBER> covid<NUMBER> caused sarscov<NUMBER> become pandemic public health concern considering health economy related challenges combat contain disease due sudden emergence covid<NUMBER> healthcare system caught unaware without effective safe treatment infectious disease chloroquine hydroxychloroquine weak bases tend accumulate acidic compartments lysosomes inflamed acidic tissues raising intralysosomal ph hydroxychloroquine impairs autophagic protein degradation <NUMBER> studies required understand concentration distribution effects hydroxychloroquine various tissues well interrelationship given dose response generated identification exact molecular targets hydroxychloroquine within cell well different microbes need hour importantly efficacy antimalarial compounds chloroquine hydroxychloroquine monitored sarscov including sarscov<NUMBER> newer compounds closely mimicking hydroxychloroquine like hydroxyferrochloroquine synthesized past shown exert antiviral effects selectivity toward sarscov infection <NUMBER> approach exploited andor reinforced make newer compound less toxicity greater selectivity towards sarscov<NUMBER> reports high risk thrombosis patients severe sarscov<NUMBER> infection <NUMBER> procoagulant pattern patients covid<NUMBER> ards justify clinical reports thromboembolic complications pulmonary embolism course covid<NUMBER> <NUMBER> interestingly hydroxychloroquine associated reduced risk thrombosis several vitro animal studies potential mechanisms hydroxychloroquine chloroquine reduce procoagulatory state autoinflammatory diseases include inhibition antiphospholipid antibody binding <NUMBER> inhibition platelet aggregation <NUMBER> <NUMBER> <NUMBER> notably mouse model antiphospholipid syndrome hydroxychloroquine treatment associated improvement endothelial function <NUMBER> <NUMBER> exact molecular mechanisms dmard hydroxychloroquine drug mediate antithrombotic effects remain largely unknown lay platform future prospective studies chloroquine <NUMBER>aminoquinoline known since <NUMBER> apart wellknown antimalarial effects drug interesting biochemical properties might applied viral infections chloroquine exerts direct antiviral effects inhibiting phdependent steps replication several viruses including members flaviviruses retroviruses coronaviruses beststudied effects hiv replication tested clinical trials moreover chloroquine immunomodulatory effects suppressing productionrelease tumour necrosis factor ␣ interleukin <NUMBER> mediate inflammatory complications several viral diseases review available information effects chloroquine viral infections raising question whether old drug may experience revival clinical management viral diseases aids severe acute respiratory syndrome afflict mankind era globalisation chloroquine <NUMBER>aminoquinoline known since <NUMBER> specifically synthesised used antimalarial agent chloroquine subsequently shown immunomodulatory properties encouraged application treatment autoimmune diseases rheumatoid arthritis specific pathology chloroquine hydroxyanalogue hydroxychloroquine represented valid contribution available pharmacological tools since proved able slow progress disease showing limited toxicity <NUMBER> unfortunately chloroquine gradually dismissed antimalarial therapy prophylaxis due continuous emergence chloroquineresistant plasmodium falciparum strains however tolerability low cost immunomodulatory properties chloroquinehydroxychloroquine associated biochemical effects suggest potential use viral infections whose symptoms may result inflammatory response <NUMBER> <NUMBER> raise question whether old drug whose parent compound quinine isolated late <NUMBER>th century bark tropical cinchona tree may experience revival clinical management viral diseases era globalisation chloroquine hydroxychloroquine weak bases known affect acid vesicles leading dysfunction several enzymes extracellularly chloroquinehydroxychloroquine present mostly protonated form due positive charge incapable crossing plasma membrane however nonprotonated portion enter intracellular compartment turn becomes protonated manner inversely proportional ph according hendersonhasselbach law thus surprising chloroquinehydroxychloroquine concentrated within acidic organelles endosome golgi vesicles lysosomes ph low chloroquinehydroxychloroquine molecules positively charged <NUMBER> andor action multidrug resistance protein mrp<NUMBER> cell surface drug transporter belonging atpbinding cassette family also includes thoroughly studied pglycoprotein <NUMBER> <NUMBER> <NUMBER> well established weak bases increasing ph lysosomal transgolgi network tgn vesicles disrupt several enzymes including acid hydrolases inhibit posttranslational modification newly synthesised proteins chloroquinemediated rise endosomal ph modulates iron metabolism within human cells impairing endosomal release iron ferrated transferrin thus decreasing intracellular concentration iron decrease turn affects function several cellular enzymes involved pathways leading replication cellular dna expression different genes <NUMBER> <NUMBER> general mechanisms viral inhibition chloroquine chloroquinehydroxychloroquine impair replication several viruses interacting endosomemediated viral entry late stages replication enveloped viruses figure <NUMBER> viruses enter target cells endocytosis process targets virus lysosomal compartment low ph along action enzymes disrupts viral particle thus liberating infectious nucleic acid several cases enzymes necessary viral replication chloroquine shown inhibit different viruses requiring phdependent step entry borna disease virus <NUMBER> minute virus mice mvmp <NUMBER> avian leucosis virus <NUMBER> particular interest human pathology report chloroquine inhibits uncoating hepatitis virus thus blocking entire replication cycle <NUMBER> enveloped viruses posttranslational modification envelope glycoproteins occurs within endoplasmic tgn vesicles process involves proteases glycosyltransferases require low ph line phdependence events chloroquine seen inhibit budding mayaro virus particles <NUMBER> induce accumulation noninfectious herpes simplex virus <NUMBER> particles tgn <NUMBER> chloroquine also inhibits replication members flaviviridae family affecting normal proteolytic processing flavivirus prm protein <NUMBER> result viral infectivity impaired finally chloroquine induces production noninfectious retrovirus particles shown avian reticuloendotheliosis virus reva hiv<NUMBER> <NUMBER> mechanism inhibition seems inhibition glycosylation envelope glycoproteins discussed accumulation chloroquinehydroxychloroquine lymphocytes macrophages results antiinflammatory properties led clinical use conditions rheumatoid arthritis lupus erythematosus sarcoidosis last characterised overproduction tumour necrosis factor ␣ tnf␣ alveolar macrophages <NUMBER> chloroquinehydroxychloroquine reduces secretion proinflammatory cytokines particular tnf␣ shown murine macrophage cell line <NUMBER> mouse peritoneal macrophages <NUMBER> human peripheral blood mononuclear cells <NUMBER> human whole blood <NUMBER> several mechanisms evoked explain chloroquinehydroxychloroquineinduced inhibition tnf␣ production monocytemacrophages disruption cellular iron homeostasis <NUMBER> inhibition tnf␣ mrna expression <NUMBER> inhibition pretranslational stage nonlysosomotropic mechanism <NUMBER> posttranslational stage blocking conversion cellassociated protnf␣ soluble mature form <NUMBER> apart inhibiting tnf␣ production stimulated monocytemacrophages chloroquine also decreases surface expression tnf␣ receptors human monocytic cell lines hence receptormediated tnf␣ signalling <NUMBER> results impairment tnf␣mediated signalling shown figure <NUMBER> studies reviewed show chloroquine hydroxychloroquine invitro antiviral effects antiinflammatory properties may interest viral infections associated inflammation andor immune activation analysing potential effects drug disease safety criteria met estimate riskbenefit ratio chloroquinehydroxychloroquine wellstudied toxicity profile halfcenturylong use drug therapy malaria demonstrates safety acute administration chloroquine human beings use chloroquinehydroxychloroquine rheumatic diseases antimalarial prophylaxis showed low incidence adverse events chronic administration drug periods years cases serious toxic effect macular retinopathy depends cumulative dose rather daily dose permanent damage may prevented regular visual monitoring treatment <NUMBER> <NUMBER> <NUMBER> recent study <NUMBER> provided encouraging results safety high dosage drug <NUMBER> mg chloroquine base per day even pregnancy conclude chloroquinehydroxychloroquine administration presents limited wellpreventable toxicity may thus result low riskbenefit balance least used lifethreatening conditions henceforth discuss potential usefulness old drug treatment two infectious diseases posing serious threat public health era globalisationie aids severe acute respiratory syndrome sars diseases caused enveloped rna viruses share clinical manifestations likely mediated immune reactions host testing conditions intended mimic best possible clinical situations chloroquinehydroxychloroquine capable inhibiting hiv vitro ability shown either overloading cells high concentrations chloroquinehydroxychloroquine infection <NUMBER> mimic drug buildup taking place tissues patients subject chronic treatment keeping hivinfected cells constant incubation concentrations chloroquine detected whole blood individuals chronically treated drug <NUMBER> <NUMBER> antihiv activity chloroquine shown cell line models also peripheral blood lymphocytes monocytes <NUMBER> ie cell culture models cellular uptake chloroquine closer conditions occurring vivo conditions possible obtain levels inhibition viral replication <NUMBER> hydroxychloroquine antiviral activity vivo reported two phase ii clinical trials <NUMBER> <NUMBER> first trial small randomised doubleblind placebocontrolled pilot study <NUMBER> patients <NUMBER> patients per arm <NUMBER> antiretroviral treatmentnaive hydroxychloroquine administration <NUMBER> weeks resulted mean <NUMBER>·<NUMBER> log reduction plasma hiv<NUMBER> rna copy numbers p<NUMBER>·<NUMBER> well decrease interleukin <NUMBER> concentrations whereas placebo effects hiv<NUMBER> rna interleukin <NUMBER> <NUMBER> second trial also small randomised doubleblinded trial comparing effectiveness hydroxychloroquine zidovudine monotherapy <NUMBER> <NUMBER> mean log reduction <NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> since eight <NUMBER> people zidovudine group none <NUMBER> individuals hydroxychloroquine group showed increase hiv<NUMBER> rna levels cultured virus levels therapy data consistent hypothesis resistance hydroxychloroquine may easily develop opposed wellknown development resistance monotherapy antiretrovirals zidovudine <NUMBER> results larger clinical trials necessary accurate analysis possible discrepancies effects chloroquine vitro hivinfected individuals us recently shown chloroquine nontoxic clinically achievable concentrations invitro activity primary isolates belonging different hiv<NUMBER> hiv<NUMBER> clades <NUMBER> mechanism antihiv effects chloroquinehydroxychloroquine reduction infectivity newly produced virions reviewed savarino et al <NUMBER> antiviral effects chloroquine associated reduced production heavily glycosylated epitope <NUMBER>g<NUMBER> located gp<NUMBER> envelope glycoprotein surface fundamental virus infectivity <NUMBER> effects likely attributed increased ph tgn impairs function glycosyltransferases involved posttranslational processing hiv glycoproteins <NUMBER> <NUMBER> <NUMBER> hiv glycosylation may therefore represent new target antiretroviral therapy viral envelope glycosylation mediated cellular enzymes inhibition may explain broad spectrum invitro antihiv activity chloroquine major subtypes hiv<NUMBER> hiv<NUMBER> <NUMBER> effect chloroquinehydroxychloroquine cellular rather viral enzymes may also result low propensity resistance development chloroquinehydroxychloroquine probably inhibits viral replication mechanism different currently used antiretroviral drugs application studied combination antiretroviral drugs use chloroquine combination antiretrovirals theoretically supported observation chloroquine also shows antihiv activity vitro towards isolates patients therapeutic failure multidrugresistant profile <NUMBER> first hydroxychloroquine additive vitro antihiv effect zidovudine <NUMBER> second chloroquine exerts vitro additive antihiv<NUMBER> effect combinations hydroxyurea plus didanosine hydroxyurea plus zidovudine tcell lines monocytes primary tcells <NUMBER> <NUMBER> <NUMBER> didanosinehydroxyureahydroxychloroquine combination especially attractive developing countries due low cost tested clinically singapore open study initial <NUMBER> patients started study six withdrawn due noncompliance remaining <NUMBER> patients hiv<NUMBER> rna plasma levels decreased mean <NUMBER>·<NUMBER> log week <NUMBER> <NUMBER> <NUMBER> smaller study didanosine hydroxyureachloroquine hiv<NUMBER> rna remained lowered mean <NUMBER>·<NUMBER> log <NUMBER> weeks <NUMBER> open pilot studies yet allow determination contribution chloroquinehydroxychloroquine viral load drop however concluded addition chloroquinehydroxychloroquine hydroxyurea didanosine potentially safe thus encouraging design larger studies multiple arms possible hypothesise chloroquine may find potential application prevention mothertochild transmission mtct hiv breastfeeding problem still far solved resourcepoor countries <NUMBER> one us reported <NUMBER>fold accumulation chloroquine colostrum cells burkinabè mothers taking <NUMBER> mg chloroquine daily hypothesised high degree chloroquine accumulation mammary cells actively replicating hiv<NUMBER> may allow decrease milk viral load andor infectivity milk hence may lower risk breastfeedingrelated transmission <NUMBER> accounts onethird onehalf hiv<NUMBER> mtcts <NUMBER> therefore charge chloroquine administration reduce hiv<NUMBER> genome exposure study set placebocontrolled pilot study breastfeeding mothers received together infant peripartum nevirapine assess whether daily chloroquine administration compared placebo administration mother early months breastfeeding may result decreased hiv<NUMBER> rna milk levels andor decreased ex vivo infectivity virions isolated milk chloroquinehydroxychloroquineinduced suppression synthesis proinflammatory cytokines tnf␣ may beneficial decreasing inappropriate immune activation characteristic hiv infection may particularly useful people hivaids developing world probably due concomitant infections present higher levels tnf␣ production immune activation developed world <NUMBER> <NUMBER> <NUMBER> chloroquine hydroxychloroquine studied particularly areas high prevalence hiv<NUMBER>c southern africa indeed tnf␣ used invitro stimulation rate transcriptional activation hiv<NUMBER> higher hiv<NUMBER>c hiv<NUMBER>b hiv<NUMBER> crf<NUMBER>ae enhanced capacity respond tnf␣ may related extra nfkappab binding sites present long terminal repeat hiv<NUMBER>c genome <NUMBER> based effects chloroquinehydroxychloroquine several enveloped viruses immune activation raise hypothesis drug might use clinical management sars present attempt treat disease known antiviral drugsnamely ribavirin oseltamivirhas inconclusive <NUMBER> corticosteroids may benefit controlling inflammatory response lung level <NUMBER> may also cause uncontrolled immunodepression resulting pulmonary superinfection causative agent sars recently described new coronavirus <NUMBER> <NUMBER> recent studies support idea coronaviridae infect target cells endocytic pathway chloroquine might inhibit replication <NUMBER> <NUMBER> hypothesise chloroquine black arrow inhibiting tnf␣ interleukin <NUMBER> il<NUMBER> production might block subsequent cascade events leads ards hcov<NUMBER>e treated nocodazole microtubuledepolymerising agent blocks transport early late endosomes produced decreased amounts hcov<NUMBER>e antigens <NUMBER> result indicates endosomal transport needed hcov<NUMBER>e infection cells treated chloroquine expressed decreased amounts hcov<NUMBER>e antigens <NUMBER> preliminary data obtained group confirm reports show chloroquine potently inhibits replication canine coronavirus therapeutically reachable concentrations c buonavoglia et al university bari italy unpublished although sars coronavirus distinct unique characteristics tempting ask whether chloroquine might affect sars coronavirus replication well antiinflammatory properties chloroquine hydroxychloroquine also considered clinical worsening individuals sars week <NUMBER> apparently unrelated uncontrolled sars coronavirus replication may related immunopathological damage <NUMBER> model taking account role proinflammatory cytokines could help interpret event figure <NUMBER> view derived effects porcine respiratory coronavirus prcv shares sars coronavirus ability cause disease similar histopathological features symptomatology <NUMBER> prcv induces severe lung damage immunemediated mechanismsie probably increase concentrations proinflammatory cytokines tnf␣ interleukin <NUMBER> whose role inducing lung damage proved using adenoviral vectors animal models <NUMBER> grounds think associations tnf␣ interleukin <NUMBER> concentrations disease severity also tested stored samples human patients sars confirmatory results obtained would reasonable consider chloroquinehydroxychloroquine suppress tnf␣ interleukin <NUMBER> production purpose efforts develop animal model sars would welcome model would help clarify immunemediated component symptoms disease well testing chloroquine immunomodulatory drugs studies could also lay groundwork suggestion chloroquine considered treatment viral infections involve immunopathology present difficult answer question whether old chloroquine able live second youth due main effectie raising endosomal phthe drug exceptionally broad spectrum antimicrobial activity could exploited many infections results obtained prophylaxis q fever indicate chloroquinehydroxychloroquine successfully used clinical management infections malaria <NUMBER> regards viral diseases clear drug antiviral immunomodulatory effects warrant particular consideration effects hiv infection best studied among antiviral effects chloroquinehydroxychloroquine tested clinical trials antihiv effect chloroquinehydroxychloroquine modest least vitro additive synergistic combined selected antiretrovirals invitro results warrant invivo confirmation hivpositive individuals comparing longterm antiviral effect highly active antiretroviral therapy regimens without chloroquine hydroxychloroquine studies provide encouraging results may lead strategy whereby coadministration chloroquinehydroxychloroquine allows lower doses antiretrovirals lessening cost possibly toxicity costlessening would course particularly welcome developing countries moreover potential ability chloroquine inhibit replication drugresistant viral isolates could important treatment drugexperienced hivpositive patients developed multiple resistance antiretroviral drugs thus limited therapeutic options developing countries malaria endemic concomitant administration chloroquinehydroxychloroquine highly active antiretroviral therapy regimen may result least p falciparum still susceptible chloroquine decreased incidence malaria episodes adverse effects hivinfected people especially pregnancy <NUMBER> moreover antiinflammatory properties chloroquine may temper noxious immune hyperactivation characteristic hivaids <NUMBER> due broad spectrum antiviral activity well suppressive effects productionrelease tnf␣ interleukin <NUMBER> chloroquinehydroxychloroquine may also find place treatment viral infections characterised symptoms associated inflammatory processes andor immunehyperactivation believe study devoted inhibitory effects chloroquine infectivity flaviviruses one members family hepatitis c virus great importance human pathology often coinfects individuals hiv<NUMBER> flaviviridae also include several arthropodborne viruses yellow fever virus west nile virus recently caused epidemic north america finally want share scientific community speculative hypothesis chloroquinehydroxychloroquine due antiviral antiinflammatory literature reviews using relevant medline search terms various combinationschloroquine virus retrovirus tnf␣ cytokines endothelium macrophages hiv sars nfkappa b coronavirus proinflammatory cytokines ardsscreened articles relevance reviewed references space restrictions <NUMBER> cited review articles place original manuscripts possible <NUMBER> excluded articles whose content line bulk published information without giving convincing explanations <NUMBER> ranked articles basis relevance date publication journal impact factor also searched internet relevant web pages discarded edited peopleinstitutions directly involved research reviewed references references intended provide comprehensive listing chosen best highlight critical issues properties may effect sars emphasise need testing cell cultures infected sars coronavirus effects chloroquine well substances possessing invitro activity members coronaviridae family remember possibility new outbreaks sars cannot excluded absence effective inhibitors sars coronavirus possibility inhibition least vitro replication virus would represent breakthrough knowledge sars covid<NUMBER> pandemic streaked around plant pursuit therapeutic options developed fast pace coronaviruses new past two decades virus responsible previous outbreaks severe acute respiratory syndrome sars middle east respiratory syndrome mers yet despite experience clear treatment pathway agreed countries therefore current pandemic variant novel virus taken world surprise option delivering empirical treatment early stages vaccine available search find effective treatments covid<NUMBER> chloroquine cq hydroxychloroquine entered spotlight <NUMBER> current evidence comes poorly controlled clinical trials demonstrating antiviral activity severeacute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> systematic reviews variable quality started appear focusing current patients without looking past evidence viruses family <NUMBER> date systematic reviews published examining clinical effectiveness chloroquine hydroxychloroquine context current pandemic past treatment patients severe coronavirus respiratory infections past outbreaks coronaviruses documented useful treatments including chloroquine hydroxychloroquine compounds used treat malaria systemic lupus erythematosus rheumatic diseases chloroquine increases endosomal ph required viruscell fusion interferes glycosylation cellular receptors sarscov <NUMBER> authors wang et al <NUMBER> reported chloroquine ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint functions entry postentry stages <NUMBER>ncov addition antiviral activity immunemodulating effect <NUMBER> <NUMBER> effective concentration ec<NUMBER> value chloroquine <NUMBER>ncov vitro demonstrated clinically achievable plasma rheumatoid arthritis patients received <NUMBER> mg <NUMBER> metabolism chloroquine oral administration occurs mostly liver excretion slow maintains plasma halflife <NUMBER> <NUMBER> days furthermore individuals impaired compromised liver function baseline eg ventilated patients itu multiple fatsoluble infusions running likely experience accumulation invivo require close monitoring liver function test risk liver failure adult acute lethal dose chloroquine two four grams ages <NUMBER> <NUMBER> according wuhan institute virology <NUMBER> study stop medication appropriate also requires knowing better start treatment sars know clinical worsening individuals week <NUMBER> apparently related immunopathological damage uncontrolled coronavirus replication <NUMBER> keyaerts et al <NUMBER> observed chloroquine displayed significant antisarscov activity <NUMBER> inhibitory capability sharply declined administered within fivehour post infection <NUMBER> yet advantages chloroquine low cost wellestablished safety could allow use prophylaxis individuals high risk healthcare workers <NUMBER> aim research report existent clinical evidence chloroquine hydroxychloroquine effectiveness either alone combination recovery human patients infected coronavirus respiratory infections addition difference dosages treatment initiation times analysed literature searches medical electronic databases conducted studies published <NUMBER> onwards ovid medline embase global health hmic please refer s<NUMBER> file example search strategy studies use chloroquine hydroxychloroquine treatment coronavirus respiratory symptoms human patients children adults diagnosed sars mers covid<NUMBER> studies needed include least one following outcomes elimination active infection detected blood swabs recovery understood active infection reduction symptoms acceptable level discharge extubation ventilators studies full text available english included studies conducted solely healthy subjects common cold excluded rapid reviews narrative reviews comments opinion pieces methodological reports editorials letters conference abstracts nonhuman studies mice invitro cultures also excluded search included mesh terms ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> study selection conducted two reviewers independently title abstract screening followed full texts performed using covidence software eligibility criteria deduplication reviewer summarised results compared disagreement resolved discussion discrepancies resolved consensus systematic review conducted according preferred reporting items systematic reviews metaanalysis prisma guidelines please see s<NUMBER> file table <NUMBER> selected studies exported stored tracked computer software reference manager zotero data relevant study question extracted included studies summarized information author study design associated treatment coronavirus using chloroquine hydroxychloroquine collected quality primary studies assessed three reviewers scored using national heart lung blood institute nhlbi quality assessment tools controlled intervention studies observational studies systematic reviews <NUMBER> quality assessment case reports case series murad et al <NUMBER> tool used studies excluded based quality assessment studies critically appraised risk bias ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> outcomes extubation ventilators patient recovery latter defined active infection either blood swabs reduction symptoms acceptable level patient discharge hospital due methodological heterogeneity varying clinical outcome measures reported across studies metaanalysis results performed narrative synthesis finding conducted search identified <NUMBER> papers six studies met eligibility criteria please see s<NUMBER> file figure <NUMBER> two systematic reviews <NUMBER> <NUMBER> one randomised control trial <NUMBER> one nonrandomised clinical trial <NUMBER> one observational cohort study <NUMBER> one case report <NUMBER> study characteristics summarised table <NUMBER> six selected studies scored using national heart lung blood institute nhlbi maryland usa murad et al quality assessment tools two scored poor <NUMBER> <NUMBER> two good <NUMBER> <NUMBER> two fair <NUMBER> table <NUMBER> clinical study huang et al <NUMBER> demonstrated patients treated chloroquine <NUMBER> mg orally twice daily <NUMBER> days appear show better patient recovery compared patients treated lopinavirritonavir result patients treated chloroquine discharged hospital earlier table <NUMBER> summarises results eligible studies effectiveness drugs treating infected coronavirus patients ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> study gautret et al <NUMBER> <NUMBER> patients treated <NUMBER> mg hydroxychloroquine <NUMBER> mg three times per day <NUMBER> days virologically cured day six post inclusion compared <NUMBER> patients control group p<NUMBER> another group <NUMBER> patients treated hydroxychloroquine azithromycin virologically cured day <NUMBER> post inclusion compared <NUMBER> patients treated hydroxychloroquine alone <NUMBER> control group p<NUMBER> gautret et al <NUMBER> carried cohort study looked outcomes patients treated combination hydroxychloroquine sulfate <NUMBER> mg three times per day <NUMBER> days four days antibiotic azithromycin <NUMBER> mg day <NUMBER> followed <NUMBER> mg per day next four days reporting positive results study broadspectrum antibiotic ceftriaxone added developed pneumonia case report study spezzani et al <NUMBER> reported patients treated darunavircobicistat hydroxychloroquine <NUMBER> mg twice daily combination triple antibiotic therapy levofloxacin piperacillin plus tazobactam better outcome compared darunavircobicistat hydroxychloroquine combined double therapy ceftriaxone azithromycin italian patients started treatment admission seven days initial symptoms despite couple achieved remission different weeks course disease differed due individual risk factors patient one metastatic breast cancer recent exposure antineoplastic chemotherapy produced leukopenia immunosuppression admission whereas hint significant immunosuppression patient two however patient one rapid recovery compared prolonged severe course compared patient two relatively low risk profile except hypertension ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> systematic review singh et al <NUMBER> looked effects hydroxychloroquine impact covid<NUMBER> patients type <NUMBER> diabetes resource constrained settings reference india provide current dosage guidelines chloroquine hydroxychloroquine use china south korea united states netherlands canada belgium treatment covid<NUMBER> using chloroquine hydroxychloroquine <NUMBER> dosage recommendations adults sources vary depending severity cases based results study authors conclude limited side effects availability costeffectiveness drugs worthy fast track clinical trials treatment covid<NUMBER> however another systematic review sarma et al <NUMBER> found compared conventional treatment difference observed virological cure death clinical worsening disease safety main benefit treatment hydroxychloroquine alone resulted lower number cases showing radiological progression lung disease additional benefits included less days temperature normalisation lowered total cough days compared conventional treatment authors recommended data acquired making definitive conclusion safety effectiveness drugs results systematic review indicate positive trend favouring use chloroquine singularly combination hydroxychloroquine antibiotic therapy regardless added bacterial infection beginning treatment evidence insufficient favour treatment start week one versus week two vice ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> versa symptoms appearing however spezzani et al <NUMBER> showed immunosuppression may actually enhance treatment effectiveness use combination hydroxychloroquine antibiotic therapy darunavircobicistat patients started treatment seven days initial symptoms findings implications clinical practice policy current pandemic despite potential therapeutic effect chloroquine hydroxychloroquine fears exist excess demand may lead shortage people diseases currently taking drugs <NUMBER> chloroquine hydroxychloroquine usually safe well tolerated normal dosage extremely toxic overdose potential adverse effects considered prescribing include prolongation qt interval especially preexisting cardiac disease combined azithromycin hypoglycemia neuropsychiatric effects drugdrug interactions idiosyncratic hypersensitivity reactions <NUMBER> moreover chloroquine widely available hydroxychloroquine countries associated greater adverse effects interaction lopinavirritonavir resulting prolongation qt interval <NUMBER> knowledge systematic review first attempt gather evidence fully published studies focus treatment date coronavirus outbreaks human subjects contrasting previous research explores suitability either chloroquine hydroxychloroquine treating coronavirus relying findings animal studies dosage recommendations unpublished trials search identified six eligible studies two scored highly methodological quality assessment may due small sample size unclear absent ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> two studies <NUMBER> <NUMBER> outline key information sociodemographic clinical characteristics used comparison groups test effectiveness drugs patients tested hospital admission prior administered specific dosage chloroquine hydroxychloroquine studies patients monitored given treatment <NUMBER> days reported outcomes focused viral clearance lung improvement review also included casereport <NUMBER> identifying two patients household discharged hospital following combination therapy antibiotics hydroxychloroquine <NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint <NUMBER> systematic reviews casereport met inclusion criteria <NUMBER> <NUMBER> <NUMBER> summary past ongoing trials found across included studies consulted table <NUMBER> recent public media attention many countries use chloroquine hydroxychloroquine increased focus repurposing drugs combat covid<NUMBER> pandemic prompted world health organisation reconsider leaving drugs large trial study effectiveness safety promising medications suitable treating covid<NUMBER> patients <NUMBER> institutions also began launching fast track trials understand whether help recovery time outcomes types studies come issues design bias unlikely provide important data true effects drugs without essential data provide key information suitability compounds ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint different populations difficult provide need future research adhere rigorous standard guidelines randomised control observational cohort studies best possible valuable unbiased information provided medications current evidence exists real human patients weak despite effectiveness shown invitro cultures past coronavirus outbreaks covid<NUMBER> variant unclear effect effectiveness depending early late stage administration nevertheless recent clinical trials suggest positive outcome patients treated chloroquine singularly hydroxychloroquine combinations offlabel use drugs covid<NUMBER> could raise demand would require counterbalance production otherwise may lead negative impact treated malaria lupus rheumatic diseases randomised trials needed urgently ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> none declared ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> virological clearance day<NUMBER> postinclusion primary outcome hcq vs control <NUMBER> versus <NUMBER> respectively p <NUMBER> note small sample size dropout six patients limited followup apart nonrandomized openlabel nature trial coronavirus disease pandemic caused severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> gorbalenya et al <NUMBER> rapidly spreading disease globally far claimed thousands lives around world caused enormous damage society economy cebm <NUMBER> world health organization declared covid<NUMBER> pandemic public health emergency international concern wee et al <NUMBER> novel coronavirus sarscov<NUMBER> four transmission stages line infectious diseases generally categorized asymptomatic moderate extreme critical sarscov<NUMBER> exhibits different symptoms depending severity disease including fever dry cough dyspnea pneumonia hypoxemia encephalopathy heart failure acute kidney injury currently defined antiviral drug therapy available covid<NUMBER> treatment mostly disease managed symptomatically yuki et al <NUMBER> several medications tested clinical trials covid<NUMBER> including antiviral antiinflammatory antimalarial pharmacologically active drugs rabby <NUMBER> however recently chloroquine derivative hydroxychloroquine positioned possible treatment covid<NUMBER> presently multicentric global clinical trials underway evaluate therapeutic potential chloroquine hydroxychloroquine treatment novel coronavirus infection food drug administration fda usa however approved chloroquine hydroxychloroquine covid<NUMBER> control treatment emergency purposes scholz derwand <NUMBER> order address virus infection replication critical understand proteins involved process functionally sarscov<NUMBER> consists two different types proteins include structural proteins nonstructural proteins nsps structural proteins involved formation spherical shape virus including spike protein trimeric membrane protein envelope protein nucleocapsid protein sixteen nonstructural proteins nsps formed proteolytic cleavage two polyproteins pp<NUMBER>a pp<NUMBER>b nsps essential metabolic molecular events include transcription translation prajapat et al <NUMBER> context key regulatory proteins enzymes associated pathogenesis sarscov<NUMBER> selected drug targets chloroquine derivatives chloroquine hydroxychloroquine antimalarial drugs also used treatment rheumatoid arthritis lupus erythematosus touret de lamballerie <NUMBER> drugs believed relatively safe administered within clinically advised limits mild side effects furthermore chloroquine derivatives tested pneumocystis pneumonia pcp therapeutic activity repurposing antimalarial drugs pneumonia gomes et al <NUMBER> yeo et al <NUMBER> pneumonia lifethreatening symptom advanced stage coronavirus infected patients clinicians using chloroquine derivative hydroxychloroquine treat disease currently two drugs reused treatment covid<NUMBER> since infection involves pneumonia devaux et al <NUMBER> recently treatment combination hydroxychloroquine azithromycin shown significant improvement within covid<NUMBER> patients gautret et al <NUMBER> similarly patients treated chloroquine hydroxychloroquine also shown significant recovery covid<NUMBER> singh et al <NUMBER> chloroquine hydroxychloroquine cost effective drug long therapy choice malaria prophylaxis due excellent results good safety tolerability recently world chloroquine derivative analog hydroxychloroquine garnered enormous attention possible treatment sarscov<NUMBER> infection although context exact mechanism action chloroquine hydroxychloroquine still known time reports cautioned use chloroquine due known doserelated toxicity chloroquine derivative several adverse events mainly involving retinal psychiatric symptoms observed chloroquine however symptoms dosedependent observed dosage levels exceed prescribed pharmacological dosage limits understanding sarscov<NUMBER> disease biology indicates important target viral replication order effectively control infection also perceived chloroquine derivative prevent disease onset covid negative healthy subjects treat sarscov<NUMBER> infection healthy asymptomatic carriers effectively accomplished understanding detailed mechanism action chloroquine hydroxychloroquine preventing coronavirus infection mechanism action two drugs well known demonstrated vitro drugs inhibit sarscov<NUMBER> elevating endosomal ph alter ace<NUMBER> terminal glycosylation leading interruption virus receptor binding vincent et al <NUMBER> however chloroquine derivative hydroxychloroquine acts exclusively elevating endosomal ph chloroquine act broadspectrum antiviral agent since modulation endosomal ph common strategy utilized viruses internalization appears doubtful since chloroquine effective viral diseases like dengue tricou et al <NUMBER> chickenguniya lamballerie et al <NUMBER> hiv savarino shytaj <NUMBER> however chloroquine derivative hydroxychloroquine shown use countering sars virus vincent et al <NUMBER> wellestablished fact sars virus sarscov sarscov<NUMBER> share almost <NUMBER> sequence similarity postulated chloroquine might actively binding one sarscov<NUMBER> proteins inhibit viral replication study multiple chloroquine derivatives reported earlier screened binding potential various sarsc<NUMBER>v<NUMBER> virus proteins important binding internalization replication budding host cell using molecular docking studies work demonstrated capability chloroquine derivatives reported antipcp potential earlier gomes et al <NUMBER> selective binding different viral proteins work aims increasing information antiviral mechanism chloroquine hydroxychloroquine sarscov<NUMBER> virus research support new antiviral drug discovery sarscov<NUMBER> virus time support drug repurposing efforts around chloroquine also results used basis modifying clinical dosage chloroquine thereby rendering effective coronavirus infection post approval hydroxychloroquine food drug administration fda usa used potential drug treatment management emerging disease covid<NUMBER> using insilico molecular docking studies binding potential chloroquine derivatives different sarscov<NUMBER> proteins involved viral replication evaluated <NUMBER>dstructures chloroquine derivatives viz hydroxychloroquine chloroquine sulfate chloroquine mustard chloroquine pyrolidinyl taken pubchem httpspubchemncbinlmnihgov database <NUMBER>dstructures chemically synthesized chloroquine derivatives gomes et al <NUMBER> drawn using chemsketch software named cqn<NUMBER>a cqn<NUMBER>b cqn<NUMBER>c cqn<NUMBER>d cqn<NUMBER>e cqn<NUMBER>f cqn<NUMBER>g cqn<NUMBER>h cqn<NUMBER>i cqn<NUMBER>j cqn<NUMBER>a cqn<NUMBER>b cqn<NUMBER>a cqn<NUMBER>b table <NUMBER> structures chloroquine derivatives organized compound library following energy minimization using open babel module pyrx software compounds study also assessed drug likeliness based lipinskis rule five using swissadme server key regulatory proteins enzymes associated pathogenesis severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> selected potential targets chloroquine analogues specifically proteins table <NUMBER> threedimensional structures drug targets retrieved rcsb protein data bank wwwrcsborg docking pdb structures observed sequence break ligand association using pymol molecular visualization system delano <NUMBER> proteins <NUMBER>m<NUMBER> <NUMBER>svb sequence break subjected homology modeling using swissmodel server daina et al <NUMBER> subsequently used studies liganded form protein <NUMBER>lu<NUMBER> identified retrieved employed validation docking nimgampalle et al <NUMBER> nonliganded forms proteins <NUMBER>m<NUMBER> <NUMBER>vsb <NUMBER>vw<NUMBER> <NUMBER>vxs <NUMBER>w<NUMBER>b subjected active site prediction using castp server tian et al <NUMBER> study molecular docking performed known active site ligand form proteins <NUMBER>lu<NUMBER> whereas blind docking predicted active site docking sitespecific docking performed remaining nonliganded form proteins <NUMBER>m<NUMBER> <NUMBER>vsb <NUMBER>vw<NUMBER>e <NUMBER>vxs <NUMBER>w<NUMBER> <NUMBER>w<NUMBER>b examine binding affinities chloroquine derivatives drug target sarscov<NUMBER> docking performed using pyrx <NUMBER> software consist autodock <NUMBER> morris et al <NUMBER> structures chloroquine derivatives organized compound library subjecting energy minimization using open babel module virtual screening software pyrx later protein structures refined heteroatoms water molecules demarcate active sites proteins gasteiger charges hydrogen atoms added drug target maintain coordination various interactions using ucsf chimera<NUMBER> software huang et al <NUMBER> drug target saved pdb format chloroquine derivative compounds examination also uploaded saved ligandpdbqt format grid set around active site drug target sitespecific docking whereas grid maximized surround entire protein surface blind docking generate possible binding conformation chloroquine derivatives empirical free energy force fields applied lamarckian genetic algorithm lga default parameters lga <NUMBER> energy evaluations bommu et al <NUMBER> grid spacing generated around active site residues drug target grid parameters drug target given table <NUMBER> <NUMBER> supplementary file completion docking dock results saved observation binding affinities binding interactions ligandtarget analyzed ligplot software wallace et al <NUMBER> prior molecular docking studies synthetic derivatives chloroquine tested druglikeliness properties based lipinskis rule five shown table <NUMBER> compounds used present study follow lipinskis rule five molecular weight <NUMBER> hydrogen acceptor <NUMBER> hydrogen donor <NUMBER> logp <NUMBER> without exception results demonstrate chloroquine derivatives studied study capable eliciting pharmacological response absorption distribution metabolism excretion details druglikeness relevant molecular properties compounds listed table <NUMBER> important chemical compound demonstrate druglikeness properties since would render order completely understand binding potential chloroquine derivatives different sarscov<NUMBER> proteins important identify natural active sites active sites proteins predicted ascertaining geometric topological properties protein structures castp server used predicted active sites nonliganded form proteins <NUMBER>w<NUMBER> <NUMBER>m<NUMBER> <NUMBER>vsb <NUMBER>vw<NUMBER> <NUMBER>vxs <NUMBER>w<NUMBER>b amino acids form active site viral protein exact position polypeptide chain listed table <NUMBER> presumed chloroquine derivatives bind active site viral proteins thereby inhibiting natural function active site protein identified procedure used molecular docking studies study nineteen compounds including chloroquine derivatives chloroquine hydroxychloroquine chloroquine sulfate chloroquine mustard chloroquine pyrolidinyl chemically synthesized chloroquine derivatives cqn<NUMBER>a cqn<NUMBER>b cqn<NUMBER>c cqn<NUMBER>d cqn<NUMBER>e cqn<NUMBER>f cqn<NUMBER>g cqn<NUMBER>h cqn<NUMBER>i cqn<NUMBER>j cqn<NUMBER>a cqn<NUMBER>b cqn<NUMBER>a cqn<NUMBER>b studied evaluate binding potential various viral proteins enzymes <NUMBER>w<NUMBER> <NUMBER>lu<NUMBER> <NUMBER>m<NUMBER> <NUMBER>vsb <NUMBER>vw<NUMBER>e <NUMBER>vxs <NUMBER>w<NUMBER>b molecular docking approaches results clearly demonstrate ability hydroxychloroquine chloroquine bind different viral proteins albeit different efficiencies contrary chemically synthesized chloroquine derivatives exhibit higher binding affinities tested viral proteins hydroxychloroquine table <NUMBER> results point fact potential inhibitors viral target proteins derived modifying chloroquine structures results blind docked ligandprotein complexes illustrated figures amino acid residues involved sitespecific docking listed table <NUMBER> predicted active sites nonliganded form viral proteins results demonstrate hydroxychloroquine bind nsp<NUMBER> binding affinity à<NUMBER> kcalmol à<NUMBER> kcalmol blind sitespecific docking respectively table <NUMBER> parallel even stronger binding nsp<NUMBER> compared hydroxychloroquine demonstrated chemically synthesized chloroquine derivative cqn<NUMBER>h showing maximum binding affinity à<NUMBER> kcal mol à<NUMBER> kcalmol blind sitespecific docking tables <NUMBER> <NUMBER> <NUMBER> supplementary hydroxychloroquine shows hydrogen bonding residues gly<NUMBER> leu<NUMBER> whereas cqn<NUMBER>h forms hydrogen bonds aminoacid residues asn<NUMBER> gly<NUMBER> gly<NUMBER> figure <NUMBER> overall chloroquine derivatives demonstrated higher binding affinity nsp<NUMBER> viral protein compared proteins included study thereby signifying potential inhibitors nsp<NUMBER> function main protease moderately inhibited hydroxychloroquine binding affinity à<NUMBER> kcalmol tables <NUMBER> <NUMBER> supplementary amino acid residues main protease involved formation five hydrogen bonds hydroxychloroquine leu<NUMBER> thr<NUMBER> thr<NUMBER> thr<NUMBER> thr<NUMBER> figure <NUMBER> however compared hydroxychloroquine cqn<NUMBER>h cqn<NUMBER>b show considerable higher binding affinity à<NUMBER> kcalmol main protease tables <NUMBER> <NUMBER> <NUMBER> supplementary compound cqn<NUMBER>h shows hydrogen interactions residues thr<NUMBER> ser<NUMBER> figure <NUMBER> results indicate derivatives chloroquine derivatives capable binding main viral protease results obtained blind docking sitespecific docking demonstrate hydroxychloroquine effectively bind rna polymerase binding affinities à<NUMBER> à<NUMBER> kcalmol respectively table <NUMBER> amino acid residues asn<NUMBER> asn<NUMBER> rna polymerase involved formation hydrogen bond hydroxychloroquine figure <NUMBER> interestingly compound cqn<NUMBER>h demonstrate strong binding rna polymerase highest binding affinity blind docking à<NUMBER> kcalmol sitespecific docking à<NUMBER> kcalmol tables <NUMBER> <NUMBER> supplementary cqn<NUMBER>h shows ability form hydrogen interactions rna polymerase residues thr<NUMBER> thr<NUMBER> figure <NUMBER> high binding affinity cqn<NUMBER>h indicates towards potential inhibitor viral rna polymerase hydroxychloroquine exhibits considerable binding efficiency spike glycoprotein blind docking sitespecific docking binding affinities à<NUMBER> à<NUMBER> kcalmole respectively table <NUMBER> additionally compounds cqn<NUMBER>b cqn<NUMBER>h demonstrated even stronger binding spike glycoprotein binding affinities à<NUMBER> kcal mol à<NUMBER> kcalmol blind docking predicted active site binding respectively table <NUMBER> interestingly single amino acid ile<NUMBER> viral spike protein involved formation hydrogen bond hydroxychloroquine whereas cqn<NUMBER>b shows hydrogen bonds formation rather forms van dar waal interactions various amino acid residues figure <NUMBER> obtained results demonstrate compounds cqn<NUMBER>b cqn<NUMBER>h may act potential inhibitor viral spike glycoprotein function studies demonstrate hydroxychloroquine also bind receptorbinding domain moderate binding affinity à<NUMBER> à<NUMBER> kcalmol blind docking sitespecific docking table <NUMBER> amino acid residues receptorbinding domain involved hydrogen bonding asp<NUMBER> met<NUMBER> phe<NUMBER> glu<NUMBER> figures <NUMBER> <NUMBER> supplementary contrary chloroquine derivatives like cqn<NUMBER>a cqn<NUMBER>b show strong binding affinity à<NUMBER> kcalmol receptor binding domain viral spike protein blind docking sitespecific docking studies table <NUMBER> high binding affinities exhibited compounds represent potential inhibitors receptorbinding domain cqn<NUMBER>a shows hydrogen interaction residues ile<NUMBER> asn<NUMBER> figure <NUMBER> molecular docking studies chloroquine derivatives adpribose<NUMBER> monophosphatase demonstrated ability hydroxychloroquine bind mentioned viral protein binding affinity à<NUMBER> kcalmol blind docking sitespecific docking studies table <NUMBER> detailed analysis dock showed hydroxychloroquine able form hydrogen bonds leu<NUMBER> ala<NUMBER> ala<NUMBER> residues figure <NUMBER> two compounds cqn<NUMBER>e cqn<NUMBER>i also show effective binding adpribose<NUMBER> monophosphatase binding affinity à<NUMBER> kcalmol blind docking table <NUMBER> amino acid residues involved formation hydrogen bonding cqn<NUMBER>i val<NUMBER> ala<NUMBER> figure <NUMBER> compound cqn<NUMBER>c also demonstrated strong binding adpribose<NUMBER> monophosphatase binding affinity à<NUMBER> kcalmol sitespecific docking studies hydroxychloroquine shows moderate minimal binding replicase protein binding affinities à<NUMBER> à<NUMBER> kcalmol blind docking sitespecific docking respectively table <NUMBER> residues replicase protein val<NUMBER> pro<NUMBER> involved formation hydrogen bonds hydroxychloroquine figure <NUMBER> however another derivative chloroquine compound cqn<NUMBER>h potentially inhibits replicase protein blind docking sitespecific docking binding affinities à<NUMBER> à<NUMBER> kcalmol respectively table <NUMBER> forms hydrogen bonds arg<NUMBER> pro<NUMBER> thr<NUMBER> residues replicase protein figure <NUMBER> present work use molecular docking techniques molecular interactions chloroquine derivatives selective sarscov<NUMBER> viral proteins studied since viral proteins potential drug targets study aims understanding potential role chloroquine potent derivative hydroxychloroquine inhibition sarscov<NUMBER> viral infection replication assessing binding efficiency chloroquine derivatives various viral proteins results obtained study also extrapolated evaluate therapeutic efficiency chloroquine hydroxychloroquine controlling sarscov<NUMBER> infection also study attempted screen derivatives chloroquine bind sarscov<NUMBER> viral drug targets efficiently chloroquine hope open case chloroquine remodeling better inhibition sarscov<NUMBER> multiplication based recent reports essential regulatory proteins enzymes associated pathogenesis sarscov<NUMBER> selected drug targets spike glycoprotein enables virus internalization rna dependent rna polymerase supports replication viral genetic material chimeric rbd receptor binding domain interacts ace <NUMBER> main protease responsible cleaving viral polypeptide nonstructural protein<NUMBER> nonstructural protein <NUMBER> nonstructural protein <NUMBER> replicase table <NUMBER> druglikeness properties chloroquine derivatives predicted swissadme web tool protein adpribose<NUMBER> monophosphatase order detailed understanding interaction chloroquine allied compounds sarscov<NUMBER> viral proteins potential active site proteins amino acid residues involved formation active sites identified molecular docking studies hydrogen bonds van der waals interactions formed result binding drugs sarscov<NUMBER> viral proteins identified table <NUMBER> <NUMBER> supplementary normal function sarscov<NUMBER> proteins inhibited result binding drugs active site sarscov<NUMBER> proteins results clearly demonstrate chloroquine derivatives bind sarscov<NUMBER> proteins thereby disrupt normal functioning proteins also found chemically synthesized derivatives chloroquine efficient binding viral proteins compared chloroquine hydroxychloroquine however derivatives elicit toxicity therefore better modeling chloroquine lead identification effective inhibitor sarscov<NUMBER> virus supplementary table <NUMBER> <NUMBER> write report extensive research ongoing around globe discover specific effective drugs drug combination halt spread covid<NUMBER> pandemic help computational methods drug discovery repurposing several natural compounds antiviral compounds antimalarial drugs antibiotics pharmacologically active compounds screened investigated ability inhibit sarscov<NUMBER> protein function elfiky <NUMBER> fantini et al <NUMBER> wu et al <NUMBER> however best knowledge much research performed probe effect chloroquine hydroxychloroquine derivatives various drug targets sarscov<NUMBER> virus post internalization virus host cell nonstructural protein <NUMBER> <NUMBER> involved formation multidomain protease plays key role replication process stobart et al <NUMBER> context binding potential chloroquine derivatives assessed binding nonstructural protein <NUMBER> interaction disrupt sarscov<NUMBER> multiplication within host cell results indicate chloroquine derivatives effectively bind nsp <NUMBER> moreover found chloroquine derivatives cqn<NUMBER>b à<NUMBER> kcalmol cqn<NUMBER>a à<NUMBER> kcal mol cqn<NUMBER>h à<NUMBER> kcalmol bind even strongly nsp <NUMBER> binding affinity hydroxychloroquine à<NUMBER> kcal mol nsp<NUMBER> main protease also critical enzyme life cycle sarscov<NUMBER> virus involved cleavage polyprotein pp cterminal end leads formation nonstructural proteins lindner et al <NUMBER> targeting main protease one ways prevent replication sarscov<NUMBER> obtained results clearly demonstrate chloroquine derivatives cqn<NUMBER>h cqn<NUMBER>b bind main protease thereby potentially inhibit activity nonstructural protein <NUMBER> acts rna dependent rna polymerase rdrp vital enzyme replication rna viruses therefore studied various viruses table <NUMBER> predicted active sites nonliganded form proteins using castp server active site predicted castp <NUMBER>w<NUMBER> ala<NUMBER> asp<NUMBER> ile<NUMBER> ala<NUMBER> ala<NUMBER> asn<NUMBER> lys<NUMBER> his<NUMBER> gly<NUMBER> gly<NUMBER> gly<NUMBER> val<NUMBER> ala<NUMBER> ala<NUMBER> gly<NUMBER> ly<NUMBER> pro<NUMBER> leu<NUMBER> leu<NUMBER> ser<NUMBER> ala<NUMBER> gly<NUMBER> ile<NUMBER> phe<NUMBER> ala<NUMBER> val<NUMBER> phe<NUMBER> asp<NUMBER> leu<NUMBER> <NUMBER>m<NUMBER> val<NUMBER> glu<NUMBER> his<NUMBER> phe<NUMBER> asp<NUMBER> tyr<NUMBER> tyr<NUMBER> ile<NUMBER> asn<NUMBER> asn<NUMBER> leu<NUMBER> asp<NUMBER> ser<NUMBER> lys<NUMBER> arg<NUMBER> thr<NUMBER> met<NUMBER> asn<NUMBER> leu<NUMBER> lys<NUMBER> tyr<NUMBER> ala<NUMBER> ile<NUMBER> ser<NUMBER> ala<NUMBER> lys<NUMBER> arg<NUMBER> ala<NUMBER> arg<NUMBER> arg<NUMBER> thr<NUMBER> thr<NUMBER> val<NUMBER> ala<NUMBER> gly<NUMBER> his<NUMBER> leu<NUMBER> lys<NUMBER> ala<NUMBER> val<NUMBER> ile<NUMBER> gly<NUMBER> thr<NUMBER> thr<NUMBER> ser<NUMBER> lys<NUMBER> phe<NUMBER> tyr<NUMBER> trp<NUMBER> gly<NUMBER> trp<NUMBER> asp<NUMBER> tyr<NUMBER> pro<NUMBER> lys<NUMBER> cys<NUMBER> asp<NUMBER> arg<NUMBER> glu<NUMBER> val<NUMBER> lys<NUMBER> ser<NUMBER> ser<NUMBER> gly<NUMBER> ala<NUMBER> thr<NUMBER> thr<NUMBER> ala<NUMBER> asn<NUMBER> leu<NUMBER> ser<NUMBER> asp<NUMBER> asp<NUMBER> phe<NUMBER> ser<NUMBER> trp<NUMBER> trp<NUMBER> glu<NUMBER> phe<NUMBER> cys<NUMBER> ser<NUMBER> gln<NUMBER> pro<NUMBER> arg<NUMBER> ile<NUMBER> ala<NUMBER> val<NUMBER> asp<NUMBER> ile<NUMBER> val<NUMBER> thr<NUMBER> leu<NUMBER> arg<NUMBER> val<NUMBER> leu<NUMBER> ile<NUMBER> tyr<NUMBER> ser<NUMBER> asn<NUMBER> arg<NUMBER> tyr<NUMBER> <NUMBER>vsb ala<NUMBER> tyr<NUMBER> thr<NUMBER> asn<NUMBER> phe<NUMBER> thr<NUMBER> tyr<NUMBER> pro<NUMBER> asp<NUMBER> lys<NUMBER> val<NUMBER> phe<NUMBER> arg<NUMBER> ser<NUMBER> ser<NUMBER> val<NUMBER> leu<NUMBER> his<NUMBER> ser<NUMBER> thr<NUMBER> gln<NUMBER> asp<NUMBER> leu<NUMBER> leu<NUMBER> pro<NUMBER> phe<NUMBER> phe<NUMBER> ser<NUMBER> asn<NUMBER> val<NUMBER> thr<NUMBER> trp<NUMBER> phe<NUMBER> pro<NUMBER> val<NUMBER> leu<NUMBER> pro<NUMBER> phe<NUMBER> asn<NUMBER> asp<NUMBER> gly<NUMBER> lys<NUMBER> asn<NUMBER> ile<NUMBER> asp<NUMBER> gly<NUMBER> tyr<NUMBER> lys<NUMBER> ile<NUMBER> tyr<NUMBER> leu<NUMBER> gln<NUMBER> gly<NUMBER> phe<NUMBER> pro<NUMBER> leu<NUMBER> val<NUMBER> asp<NUMBER> ile<NUMBER> asn<NUMBER> ile<NUMBER> thr<NUMBER> arg<NUMBER> arg<NUMBER> ser<NUMBER> tyr<NUMBER> leu<NUMBER> thr<NUMBER> pro<NUMBER> asp<NUMBER> val<NUMBER> val<NUMBER> gly<NUMBER> tyr<NUMBER> tyr<NUMBER> leu<NUMBER> gln<NUMBER> pro<NUMBER> arg<NUMBER> thr<NUMBER> asp<NUMBER> including hepatitis c virus zika virus elfiky <NUMBER> ganesan barakat <NUMBER> recently fda approved antirdrp drugs ribavirin remdesivir sofosbuvir galidesivir tenofovir shown potential inhibitory activity rdrp sarscov<NUMBER> elfiky <NUMBER> study chloroquine derivative cqn<NUMBER>h demonstrated strong binding affinity rdrp à<NUMBER> kcalmol even stronger hydroxychloroquine rdrp protein results valuable repurposing redesigning cqn<NUMBER>h potential inhibitor rdrp function spike glycoprotein plays essential role attachment coronavirus ace<NUMBER> host cell surface hence protein considered important drug target drug discovery prajapat et al <NUMBER> results demonstrate hydroxychloroquine effectively bind spike glycoprotein chimeric receptor binding domain along compounds cqn<NUMBER>b cqn<NUMBER>h effectively inhibit spike glycoprotein besides compounds cqn<NUMBER>a cqn<NUMBER>b also potentially inhibit receptor binding domain results point fact chloroquine chloroquine sulfatechebi<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> <NUMBER> chloroquine pyrolidylinzinc<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> <NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> <NUMBER> chloroquine mustardzinc<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> chemically synthesized chloroquine derivatives <NUMBER> cqn<NUMBER>a derivatives bind spike glycoprotein potentially lead disruption spike protein interaction ace<NUMBER> host cell surface however another recent study demonstrated chloroquine hydroxychloroquine prevent interaction spike protein sialic acids gangliosides present host cell surface fantini et al <NUMBER> matrosovich et al <NUMBER> nonstructural protein <NUMBER> nsp<NUMBER> acts replicase protein rnabinding protein dimerization essential viral propagation prajapat et al <NUMBER> therefore targeting dimerization nsp<NUMBER> effective strategy control virus multiplication egloff et al <NUMBER> hu et al <NUMBER> results show chloroquine derivative cqn<NUMBER>h bind replicase protein higher efficiency hydroxychloroquine derivatives chloroquine cqn<NUMBER>e cqn<NUMBER>i cqn<NUMBER>c also effectively inhibit adpribose<NUMBER> monophosphatase hydroxychloroquine results apparent chloroquine derivatives possess therapeutic activity sarscov<NUMBER> virus studies clearly demonstrate binding chloroquine hydroxychloroquine derivatives various sarscov<NUMBER> proteins however results need substantiated binding experiments ascertain drugprotein interaction parameters time specificity studies ascertained fact one derivatives chloroquine cqn<NUMBER>f show binding viral protein included study although chloroquine hydroxychloroquine losing popularity due possible mutagenic activity literature survey points fact chloroquine hydroxychloroquine well established toxicokinetic properties might elicit dosage dependent toxicity also chloroquine hydroxychloroquine represent economical option prevent spread covid<NUMBER> pandemic believe study informed approach taken understand drugprotein interaction modify drug structure minimal toxic burden maximal inhibitory potential sarscov<NUMBER> viral proteins results also enhance basic knowledge interaction chloroquine derivatives various drug targets sarscov<NUMBER> point possible novel mechanism action century old drug results infered hydroxychloroquine considerably inhibits drug targets sarscov<NUMBER> found hydroxychloroquine might enhance endosomal ph could also interact various proteins sarscov<NUMBER> chemically synthesized chloroquine derivatives reveal effective inhibitory activity drug targets sarscov<NUMBER> hydroxychloroquine among various derivatives chloroquine cqn<NUMBER>h cqn<NUMBER>b show potential inhibition drug targets results could also used constructive research chemically synthesized chloroquine derivatives identify successful drugs treatment covid<NUMBER> conflict interest current project insilico work require additional financial support purely working arising work situation otherwise authors thankful financial support respective institutes httporcidorg<NUMBER>x ambrish saxena httporcidorg<NUMBER> coronavirus disease <NUMBER> covid<NUMBER> novel viral respiratory disease caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> first report took place china <NUMBER> subsequently spread across globe rapidly <NUMBER> april <NUMBER> total <NUMBER> confirmed infections reported <NUMBER> deaths <NUMBER> upon emerging covid<NUMBER> known approved specific effective antiviral treatment treat fatal disease <NUMBER> therefore utmost urgency identify potential therapies sarscov<NUMBER> infected patients <NUMBER> covid<NUMBER> resemble severe acute respiratory syndrome sars middle eastern respiratory syndrome mers phylogenetically symptomatically variety agents tried according clinical experience sars mers <NUMBER> <NUMBER> broadspectrum antiviral agent ribavirin <NUMBER> protease inhibitor lopinavir ritonavir <NUMBER> <NUMBER> immune upregulator interferon <NUMBER> <NUMBER> commonly used addition vitro vivo studies suggested chloroquine hydroxychloroquine <NUMBER> <NUMBER> remdesivir <NUMBER> arbidol <NUMBER> effective inhibiting viral replication sarsassociated coronavirus cov merscov sarscov<NUMBER> infections <NUMBER> however efficacy safety treatments covid<NUMBER> remains unclear <NUMBER> systematic reviews previously summarized clinical trials potential therapeutic agents sars mers covid<NUMBER> resulting inconclusive outcomes <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> herein conduct review identify efficacy safety current option therapies sars mers besides covid<NUMBER> attempt identify promising therapy sarscov<NUMBER> infected patients present study conducted according preferred reporting items systematic reviews metaanalyses prisma guidelines previously published protocol prospero crd<NUMBER> comprehensive searching pubmed embase cochrane library china national knowledge infrastructure cnki china science technology journal database vip wanfang data performed inception april <NUMBER>th <NUMBER> without language restriction unpublished trials also identified clinical trial registry platforms httpclinicaltrialsgov httpwwwchictrorgcn preprint articles also retrieved websites medrxiv httpswwwmedrxivorg biorxiv httpswwwbiorxivorg manual search conducted screening reference lists inclusive studies search strategy consisting patient relevant terms covid<NUMBER> middle east respiratory syndrome severe acute respiratory syndrome etc intervention relevant terms lopinavir ritonavir chloroquine hydroxychloroquine interferon ribavirin remdesivir arbidol etc applied medical subject headings mesh free text comprehensive search syntax available supplemental table <NUMBER> two authors z z hz independently screened titles abstracts fulltext retrieved articles identify eligibility figure <NUMBER> studies considered inclusion randomized controlled trials rcts prospective cohort retrospective cohort studies performed among adult patients covid<NUMBER> mers sars evaluated efficacy safety anticoronavirus agents furthermore studies considered excluded lacked control group target quantitative outcomes vitro vivo studies disagreements resolved discussions corresponding author z g primary outcomes study included mortality virological eradication clinical improvement secondary outcomes included improvement symptoms time j u r n l p r e p r f become afebrile improvement chest radiography results utilization mechanical ventilation intensive care unit admission adverse events aes data extraction independently conducted two authors h z z z using standardized data collection form included study characteristics author year publication region study design sample size population characteristics age gender indication intervention characteristics anticoronavirus agents dosage duration concomitant therapy outcomes mortality viral eradication clinical outcomes aes risk bias inclusive rcts assessed accordance cochrane collaboration risk bias tool <NUMBER> methodological quality assessment prospective cohort retrospective cohort studies performed using newcastle ottawa scale nos <NUMBER> risk bias individual study rated low moderate high quality evidence assessed gradepro software graded high moderate low low <NUMBER> dichotomous data shown relative risks rr <NUMBER> confidence intervals cis continuous variables calculated weight mean difference wmd associated <NUMBER> cis using randomeffects model <NUMBER> <NUMBER> representing notable heterogeneity <NUMBER> subgroup analysis treatments including hydroxychloroquine lopinavirritonavir alone combination ribavirin alone combination arbidol interferon performed detect robustness results sensitivity analysis conducted sequential elimination study pool potential publication bias assessed using visual inspection funnel plots number included studies ten statistics performed using stata software version<NUMBER> statacorp college station texas usa p<NUMBER> indicating statistically significant difference present searches totally identified <NUMBER> citations excluded <NUMBER> publications cautious screening titles abstracts <NUMBER> potential studies fulltext assessed eligibility <NUMBER> excluded reviews contain eligible comparators report outcomes interest case series others figure <NUMBER> finally <NUMBER> articles <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients met inclusion criteria retrieved quantitative synthesis table <NUMBER> <NUMBER> rcts <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> prospective studies <NUMBER> <NUMBER> whilst remaining <NUMBER> trials retrospective studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> thirteen studies conducted china <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> canada <NUMBER> <NUMBER> <NUMBER> <NUMBER> saudi arabia <NUMBER> <NUMBER> <NUMBER> france <NUMBER> <NUMBER> studies involving patients covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies involving patients sars <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies involving patients mers <NUMBER> <NUMBER> interventions included arbidol <NUMBER> study <NUMBER> arbidol lopinavirritonavir <NUMBER> study <NUMBER> hydroxychloroquine <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> interferon corticosteroid <NUMBER> studies <NUMBER> <NUMBER> lopinavirritonavir <NUMBER> studies <NUMBER> <NUMBER> lopinavirritonavir plus ribavirin corticosteroids <NUMBER> studies <NUMBER> <NUMBER> ribavirin <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> ribavirin interferon <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> ribavirin corticosteroids <NUMBER> study <NUMBER> table <NUMBER> primary outcomes mortality reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> virological clearance reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> clinical improvement reported <NUMBER> study <NUMBER> patients <NUMBER> secondary outcomes radiographical improvement reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> acute respiratory disease syndrome ards reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> intubation reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> adverse events aes reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> leukopenia reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> anemia reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> thrombocytopenia reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> transaminitis reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> j u r n l p r e p r f elevated total bilirubin reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> elevated creatinine reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> bradycardia reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> diarrhea reported <NUMBER> studies <NUMBER> patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> considering rcts information randomization unclear <NUMBER> studies <NUMBER> <NUMBER> concealing allocation absent unclear <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> moreover blinding participants outcome assessors absent unclear <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> supplementary table s<NUMBER> therefore decided identify <NUMBER> studies risk bias terms observational studies nos scores <NUMBER> indicating studies low risk bias supplementary table s<NUMBER> performed metaanalysis <NUMBER> studies <NUMBER> patients demonstrating data mortality indication considered <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> compared comparators interventions could notably reduce mortality seven studies <NUMBER> patients documented data virological eradication indication taken consideration <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> pooled result j u r n l p r e p r f showed virological eradication ability interventions equal comparator group rr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> subgroup analysis combination lopinavirritonavir arbidol combination lopinavirritonavir ribavirin corticosteroids appeared show superior ability virological eradication generating rr <NUMBER> <NUMBER> ci <NUMBER> rr <NUMBER> <NUMBER> ci <NUMBER> respectively additionally value p interaction less <NUMBER> indicating significant difference across treatments <NUMBER> studies <NUMBER> patients demonstrated time become afebrile present data diversity showing mean±sd medium range thus could generate metaanalysis outcome addition results controversial one hand one study reported hydroxychloroquine treatment significantly shortened fever recovery time control group <NUMBER>±<NUMBER> vs <NUMBER>±<NUMBER> <NUMBER> hand chen et al showed hydroxychloroquine treatment observed difference time course become afebrile <NUMBER> vs <NUMBER> <NUMBER> another <NUMBER> studies also documented lopinavirritonavir arbidol combination interferon corticosteroids therapies effects time course defervescence compared control therapy <NUMBER> <NUMBER> radiographical improvement metaanalysis <NUMBER> studies generated rr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> indicating superior ability interventions radiographical improvement subgroup analysis combination lopinavirritonavir arbidol hydroxychloroquine showed notable inadequate inclusive studies perform sensitivity analysis assess influence included study generate funnel plot evaluate publication bias either reason quality evidence outlined table <NUMBER> quality findings relevant mortality virological clearance radiographical improvement prevalence ards intubation mechanical ventilation low addition total aes leukopenia anemia thrombocytopenia diarrhea transaminitis increased total bilirubin low quality evidence well however outcome quality clinical improvement increased creatinine low bradycardia moderate quality evidence upon emergency sarscov<NUMBER> conducted systematic review metaanalysis identify potential therapeutic options covid<NUMBER> based previous studies therapies sars mers present review included <NUMBER> articles involving <NUMBER> patients compared control treatment anticoronavirus interventions significantly reduced mortality notably augmented clinical improvement radiographical improvement without significant effect symptoms alleviation time become afebrile virologic eradication incidence ards intubation aes hydroxychloroquine earned reputation potential promising role covid<NUMBER> <NUMBER> increasing number studies conducted published <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently chloroquine hydroxychloroquine demonstrated inhibit sarscov<NUMBER> vitro ec<NUMBER>µm ec<NUMBER>µm respectively <NUMBER> <NUMBER> underlying mechanisms inferred follows <NUMBER> weakly alkaline chloroquine could increase endosomal ph therefore block virus infection <NUMBER> <NUMBER> <NUMBER> spike protein angiotensinconverting enzyme <NUMBER> ace<NUMBER> blocker chloroquine hydroxychloroquine interfered glycosylation cellular sarscov receptor thus inhibit virus attacking <NUMBER> <NUMBER> immunomodulant chloroquine hydroxychloroquine could counteract proinflammatory cytokine storm critically ill patients covid<NUMBER> <NUMBER> <NUMBER> unfortunately outcomes hydroxychloroquine <NUMBER> <NUMBER> additionally hydroxychloroquine therapy improved radiographical benefit <NUMBER> despite accompanied aes especially diarrhea <NUMBER> date could recommend hydroxychloroquine superior standard care sarscov<NUMBER> infection need wait larger randomized trials target population sensitive endpoints valid value hydroxychloroquine covid<NUMBER> inhibitor human immunodeficiency virus hiv protease lopinavirritonavir major focus recommended patients mers <NUMBER> covid<NUMBER> <NUMBER> reported lopinavir could inhibit sarscov merscov replication vitro ec<NUMBER> <NUMBER> μm <NUMBER> μm respectively <NUMBER> lopinavir also found demonstrated antiviral effect sarscov<NUMBER> vero e<NUMBER> cells ec<NUMBER> <NUMBER> μm <NUMBER> ritonavir effect coronavirus prolonged bioavailability j u r n l p r e p r f lopinavir inhibiting hosts cytochrome p<NUMBER> <NUMBER>a<NUMBER> enzyme <NUMBER> five studies reported effectiveness safety lopinavirritonavir alone combination therapy lopinavirritonavir alone combination ribavirin corticosteroids show mortality benefit however lopinavirritonavirbased treatments observed inconsistent results virological clearance rr <NUMBER> lopinavirritonavir alone revealed ineffective lowering virus load sarscov<NUMBER> <NUMBER> <NUMBER> lopinavirritonavir accompanying arbidol ribavirin augmented eradication sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> speculated lopinavirritonavir <NUMBER> mg<NUMBER> mg twice daily may reach minimal lopinavir serum concentration <NUMBER> μm <NUMBER> μm inadequate inhibition sarscov<NUMBER> <NUMBER> nevertheless lopinavirritonavir accompanied agents showing effects sarscov<NUMBER> might decrease inhibitory concentration lopinavir produce synergy <NUMBER> furthermore lopinavirritonavirbased therapies documented notably better clinical radiographical improvement reduced incidence ards intubation take adverse reactions consideration aes rate comparable groups conversely lopinavirritonavir alone showed tendency diarrhea events combination lopinavirritonavir ribavirin corticosteroids reduced incidence diarrhea significantly suspected lopinavirritonavir alone show demonstrably beneficial effects covid<NUMBER> lopinavirritonavir combinations might play roles eradication sarscov<NUMBER> <NUMBER> extensively used therapies ribavirin ribavirinbased combinations ribavirin reported tightly bind sarscov<NUMBER> rna dependent rna polymerase rdrp binding energy <NUMBER> kcalmol thus may used covid<NUMBER> <NUMBER> <NUMBER> studies reporting sars mers patients treated ribavirin combinations ribavirin metaanalysis yielded inconsistent results mortality rr <NUMBER> <NUMBER> combination ribavirin corticosteroids showed remarkable lower mortality j u r n l p r e p r f compared control group addition patients treated ribavirinbased therapies showed comparable rates intubation mechanical ventilation control group note major problem ribavirin significantly higher incidence adverse events especially bradycardia anemia transaminitis compared control group intriguingly combination ribavirin interferon observe problems summarily inconsistent benefit considerable safety concerns low quality evidence hard make clear recommendation use ribavirin ribavirinbased combinations covid<NUMBER> revealed arbidol vitro antiviral activity early replication stage sarscov <NUMBER> however arbidol alone generated equivalent outcome patients covid<NUMBER> compared control group addition lopinavirritonavir showed better efficacy <NUMBER> furthermore interferon widely used sars mers epidemic <NUMBER> <NUMBER> studies reported combinations interferon unfortunately difference noted treatment control group terms mortality intubation rate adverse reactions recommendation treatments uncertain small sample size study risk low quality <NUMBER> <NUMBER> <NUMBER> firstly best knowledge first systematic review metaanalysis capability anticoronavirus agents conversely ribavirin might cause safety concern especially bradycardia currently growing trials related anticoronavirus agents ongoing including lopinavirritonavir initial therapy associated lower mortality compared matched cohorts lopinavirritonavir rescue therapy observed difference mortality compared matched cohorts lopinavirritonavir initial therapy associated lower rate incubation use corticosteroids reduced dose compared matched cohorts lopinavirritonavir rescue therapy observed difference rates intubation oxygen desaturation compared matched cohorts oral hydroxychloroquine treatment superior supportive therapy change baseline day <NUMBER> day <NUMBER> day <NUMBER> clinical symptoms criteria improvement clinical symptoms body temperature returned normal sao<NUMBER> returned normal respiratory symptoms reduced <NUMBER> baseline oral hydroxychloroquine treatment superior supportive therapy change baseline day <NUMBER> day <NUMBER> day <NUMBER> laboratory indicators crp decreased <NUMBER> baseline erythrocyte sedimentation decreased <NUMBER> absolute peripheral lymphocyte count returned normal oral hydroxychloroquine treatment superior supportive therapy change baseline day <NUMBER> improving rate imaging chest ct lesion absorption day <NUMBER> treatment <NUMBER> current study openlabel randomized trial evaluation efficacy safety hcq sulphate treatment <NUMBER>ncov respiratory infection hcq sulphate approved clinical application antiinflammation antimicroorganisms good reported efficacy safety profiles therefore anticipate administration hcq bring additional major risks potential benefits： <NUMBER> participants could benefit treatment group tested drug planned investigation study thought offer potential benefits individual subjects based upon previous preclinical several retrospective caseseries investigations regard control group patients treated according latest guideline therefore receive best treatment current stage <NUMBER> participant either assigned treatment control group expenses examination treatment covered sponsors confidential record personal information kept private without publication according legislation laws results study identity may shared local medical providers government health organizations international health workers help better understand <NUMBER>ncov infection since disease course prognosis largely improved effective inhibition virus replication whereas drug yet approved treat human cov <NUMBER> one best solutions problem use approved drugs potential antiviral effects good safety profiles among hydroxychloroquine hcq promising candidate hcq commonly used antimalarial drug together chloroquine cq belong class drugs known <NUMBER>aminoquinolines first successful chemical synthesis cq <NUMBER> hcq generated replacing ethyl hydroxyethyl basic side chine cq comparing cq hcq absorbed faster intestinal tract wider distribution human body clinical applications hcq first reported antimalarial treatment expands systemic lupus erythematosus <NUMBER> rheumatoid arthritis <NUMBER> immune modulatory effects safety treatment efficacy hcq widely acknowledged <NUMBER> although hcq cq similar treatment efficacy hcq preferred due reduced toxicity <NUMBER> clinical applications expanded rheumatic diseases dermatology malignancies fields multifaceted effects immune modulation antiinflammation inhibiting malignant cell growth viability enhancing clearance lipid antithrombosis reducing diabetes risk <NUMBER> <NUMBER> addition cq significantly reduces inflammatory response sars possibly inhibition tnfα il<NUMBER> <NUMBER> similarly cq able prevent overexuberant inflammatory response patients human immunodeficiency virus hiv infection inhibiting hiv activated tlr<NUMBER> signaling pathway <NUMBER> treatment hcq <NUMBER> mgday <NUMBER> weeks found significantly reduce immune response especially patients high viral load <NUMBER> <NUMBER> importantly high dose hcq treatment demonstrates antiviral effects studies investigating sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> proposed use hcq prophylaxis treatment sarscov infection <NUMBER> animal studies demonstrate survival rate <NUMBER> using cq treatment mice infected merscov <NUMBER> main antiviral mechanisms hcq include <NUMBER> impairing maturation lysosomes autophagosomes increasing ph endosomal compartments <NUMBER> interfering cellular ferritin metabolism <NUMBER> inhibiting posttranslational modification virus protein increasing ph golgi apparatus moreover cq able inhibit p<NUMBER> mapk signaling pathway hcov<NUMBER>e infected cell <NUMBER> <NUMBER> <NUMBER> cq also reported interfere terminal glycosylation cellular receptor angiotensin converting enzyme <NUMBER> sarscov negatively influence virusreceptor binding abrogate infection <NUMBER> finally animal studies demonstrated good safety tissue distribution hcq <NUMBER> <NUMBER> 。 aim current study evaluate efficacy safety high dose hcq treatment patients <NUMBER>ncov respiratory infection stratified mild moderate severe group prospective multicenter randomized clinical trial performed evaluate effects hcq negative conversion rate virus rna improvement clinical symptom laboratory parameters prevention disease progression hypothesized hcq could effective drug treatment <NUMBER>ncov respiratory infection primary objective study evaluate efficacy safety high dose hcq sulfate patients <NUMBER>ncov respiratory infection comparisons hcq plus standardofcare soc group soc group evaluate efficacy safety high dose hcq sulfate patients <NUMBER>ncov respiratory infection trial prospective multicenter openlabel randomized trial patients <NUMBER>ncov trial enrolled <NUMBER> patients <NUMBER> randomization ratio stratified disease severity mildmoderatesevere receive either hcq plus soc soc alone  dose adjustment treatment dose adjusted adverse events related investigated drug judged investigators case investigator perform evaluation carefully based clinical experience treatment temporarily stopped adjusted lower level dose switch <NUMBER>mg <NUMBER>mg investigator considers continued treatment predefined dose increase toxicity based individual safety tolerance treatment restarted original dose lower level patients recovered <NUMBER> adverse events investigators also evaluate clinical benefits decide whether continues treatment day<NUMBER> cases disease progression standard drugs recommended guideline used soc except drugs belongs <NUMBER>aminoquinolines eg cq phosphate patients received cq enrolled <NUMBER>h withdrawal medications diseases <NUMBER>ncov respiratory infection used study period trail terminated early following circumstance occurs ① treatment needs changed due disease progression study period comprehensive assessment investigators ② serious adverse events lead disease progression ③ patient longer willing treated investigated drug primary endpoint negative conversion rate virus nucleic acid within <NUMBER>day severe disease subgroup considering virology conversion clinical improvement  definition clinical improvement：decline two categories enrollment status sixcategory ordinal scale clinical status ranging <NUMBER> discharged <NUMBER> death <NUMBER> improvement rate clinical symptoms within <NUMBER>day  definition clinical symptoms improvement resolving fever axillary temperature ≤<NUMBER>℃，or oral temperature ≤<NUMBER>℃ rectalear temperature ≤<NUMBER>℃ normalization spo<NUMBER> spo<NUMBER> <NUMBER> room air disappearance respiratory symptom <NUMBER> improvement rate laboratory parameters within <NUMBER>day  definition laboratory parameters improvement <NUMBER> decline creactive protein erythrocyte sedimentation rate il<NUMBER> tnfα level baseline normalization absolute blood lymphocyte count <NUMBER> improvement rate chest radiology within <NUMBER>day  definition radiology improvement resolved <NUMBER> baseline chest ct given hcq sulphate widely used antimalarial rheumatoid arthritis treatment sideeffects hcq fully established listed table <NUMBER> <NUMBER> among sideeffects gastrointestinal upset particularly diarrhea retinopathy relative common regular dose usually resolve treatment stopped ② dropout rate applied control familywise typei error <NUMBER> twosided study first interim analysis occur <NUMBER> subjects around <NUMBER> subjects treated <NUMBER> days discontinued goal evaluate efficacy need sample size reestimation pvalue boundary efficacy significance <NUMBER> twosided final analysis conducted <NUMBER> events observed pvalue boundary <NUMBER> twosided actual α spent pvalue boundaries analysis calculated based exact observed number events extended followup <NUMBER> visit <NUMBER>lead electrocardiogram × <NUMBER> × × × crp esr × <NUMBER> × × × × × × tnfα，il<NUMBER> × <NUMBER> × × × × × × cbc differential <NUMBER> × <NUMBER> × × × × × × urinalysis <NUMBER> × <NUMBER> × × × blood chemistry <NUMBER> hepatic kidney panel myocardial enzyme × <NUMBER> × × × × × × coagulation panel <NUMBER> × <NUMBER> × × × × × × <NUMBER>ncov rtpcr <NUMBER> × <NUMBER> <NUMBER> epidemiological information includes recent travel history exposure epidemic area infected patients medical history includes present illness past medical history including comorbidity medications <NUMBER> physical examination includes height weight general outlook head eye ear nose throat neck thyroid skin cardiovascular system anterior chest lung abdomen neuro system skeletal muscle system lymphatic system <NUMBER> vital signs body temperature respiratory rate pulse blood pressure record maximum temperature visiting day use measurement criteria throughout study period <NUMBER> cbc differential includes haptoglobin absolute count red blood cell platelet total white blood cell neutrophil lymphocyte monocyte eosinophil basophil <NUMBER> urinalysis urinary ph urinary red blood cell urinary white blood cell urinary protein glucose ketone <NUMBER> blood chemistry includes alanine aminotransferase aspartate aminotransferase total bilirubin albumin γglutamyl transpeptidase lactate dehydrogenase creatine kinase creatine kinase isoenzymemb blood urea nitrogen creatinine <NUMBER> coagulation panel includes prothrombin time activated partial thrombin time thrombin time fibrinogen international normalized ratio <NUMBER> rtpcr results upon unplanned visit also recorded crf <NUMBER> record daily administration tested drug including use use <NUMBER> examinations exempted investigators participants provide qualified examination results within <NUMBER>day prior initiation study <NUMBER> rtpcr results <NUMBER>ncov within <NUMBER>day prior initiation study used screening <NUMBER> patients discharge alive medications ae information collected via telephone contact extended followup <NUMBER> <NUMBER>lead electrocardiogram × <NUMBER> × × crp esr × <NUMBER> × × × × × × tnfα，il<NUMBER> × <NUMBER> × × × × × × cbc differential <NUMBER> × <NUMBER> × × × × × × urinalysis <NUMBER> × <NUMBER> × × blood chemistry <NUMBER> hepatic kidney panel myocardial enzyme × <NUMBER> × × × × × × coagulation panel <NUMBER> × <NUMBER> × × × × × × <NUMBER>ncov rtpcr <NUMBER> × <NUMBER> × × × × × × pulse oximetryon room air × × × × × × × arterial blood gas analysis × <NUMBER> optional per clinical needs urine hcg × <NUMBER> × chest ct × <NUMBER> <NUMBER> epidemiological information includes recent travel history exposure epidemic area infected patients medical history includes present illness past medical history including comorbidity medications <NUMBER> physical examination includes height weight general outlook head eye ear nose throat neck thyroid skin cardiovascular system anterior chest lung abdomen neuro system skeletal muscle system lymphatic system <NUMBER> vital signs body temperature respiratory rate pulse blood pressure record maximum temperature visiting day use measurement criteria throughout study period <NUMBER> cbc differential includes haptoglobin absolute count red blood cell platelet total white blood cell neutrophil lymphocyte monocyte eosinophil basophil <NUMBER> urinalysis urinary ph urinary red blood cell urinary white blood cell urinary protein glucose ketone <NUMBER> blood chemistry includes alanine aminotransferase aspartate aminotransferase total bilirubin albumin γglutamyl transpeptidase lactate dehydrogenase creatine kinase creatine kinase isoenzymemb blood urea nitrogen creatinine <NUMBER> coagulation panel includes prothrombin time activated partial thrombin time thrombin time fibrinogen international normalized ratio <NUMBER> rtpcr results upon unplanned visit also recorded crf <NUMBER> record daily administration tested drug including use use <NUMBER> examinations exempted investigators participants provide qualified examination results within <NUMBER>day prior initiation study <NUMBER> rtpcr results <NUMBER>ncov within <NUMBER>day prior initiation study used screening patients discharge alive medications ae information collected via telephone contact current study openlabel randomized trial evaluation efficacy safety hcq sulphate treatment <NUMBER>ncov respiratory infection hcq sulphate approved clinical application antiinflammation antimicroorganisms good reported efficacy safety profiles therefore anticipate administration hcq bring additional major risks participants could benefit treatment group tested drug planned investigation study thought offer potential benefits individual subjects based upon previous preclinical several retrospective caseseries investigations regard control group patients treated according latest guideline therefore receive best treatment current stage participant either assigned treatment control group expenses examination treatment covered sponsors confidential record personal information kept private without publication according legislation laws results study identity may shared local medical providers government health organizations international health workers help better understand <NUMBER>ncov infection 肝功能、肾功能、心肌酶 × <NUMBER> × × × × × × 凝血功能 <NUMBER> × <NUMBER> × × × × × × 新型冠状病毒核酸检测 <NUMBER> × <NUMBER> 凝血功能 <NUMBER> × <NUMBER> × × × × × × 新型冠状病毒核酸检测 <NUMBER> × <NUMBER> translated version final protocol originally written chinese <NUMBER> introduction modified based updating knowledge <NUMBER>ncov hydroxychloroquine <NUMBER> sample size <NUMBER> cases original version replaced <NUMBER> cases newest version based alternative hypothesis <NUMBER> reduction time virus nucleic acid negativity exponential distribution benefit translates reduction median time virology negativity <NUMBER> days <NUMBER> days total <NUMBER> events would provide power <NUMBER> detect <NUMBER> reduction hazard ratio control vs treatment <NUMBER> logrank test assuming twosided significance level <NUMBER> <NUMBER>day accrual period additional <NUMBER>day followup assumed sample size calculation also taken consideration annual dropout rate <NUMBER> <NUMBER> original version protocol patients severe pneumonia excluded however considering antiinflammatory property hcq favoring disease regression decided change exclusion criteria order include patients severe type pneumonia stratified random sampling applied stratify eligible patients according disease severity mildtomoderate severe followed random assignment <NUMBER> ratio stratum ensure balanced distribution disease severity treatment hcq plus soc control soc groups <NUMBER> original version protocol age patients restricted <NUMBER> higher however given data available covid<NUMBER> adolescents decided focus adult patients without risking younger patients lifted threshold age limitation <NUMBER> years <NUMBER> patients severe liver disease renal diseases excluded due safety concerns using hydroxychloroquine population <NUMBER> <NUMBER>th version onset illness <NUMBER> days added focus earlier stage covid<NUMBER> possible however hospitalized patients criterion would rule many patients could previously participate therefore remove criterion last version <NUMBER> original version study drug orally administrated <NUMBER> tabletstime hydroxychloroquine <NUMBER>mg tablet twice day day<NUMBER>day<NUMBER> followed <NUMBER> tablettime hydroxychloroquine <NUMBER>mg tablet twice day day<NUMBER>day<NUMBER> newest version study drug changed orally administrated hydroxychloroquine sulfate tablets <NUMBER>mg tablet <NUMBER> tablets time three times day day <NUMBER> day <NUMBER> followed hydroxychloroquine sulfate <NUMBER>mg tablet <NUMBER> tabletstime twice day day <NUMBER> day <NUMBER> mildtomoderate patients day <NUMBER> day <NUMBER>for severe patients <NUMBER> concomitant antiviral treatments forbidden randomization original version however considering fact drugs recommended standardofcare national guideline decided remove restriction later version moreover usage chloroquine prohibited randomization subject already used chloroquine medication prior randomization participate clinical study <NUMBER> hours chloroquine medication <NUMBER> newest version addition secondary efficacy endpoint time negative novel coronavirus nucleic acid detection day rate negative percentage novel coronavirus detection treatment day <NUMBER> day <NUMBER> day <NUMBER> day <NUMBER> <NUMBER> original version clinical symptom improvement one secondary study endpoints described respiratory symptom reduction ≥<NUMBER> newest version described respiratory symptom disappearance add sixlevel classification scale evaluation clinical severity subjects severe type <NUMBER>ncov pneumonia level specific description follows score <NUMBER> death score <NUMBER> icu administration andor requiring extracorporeal membrane pulmonary oxygenation ecmo andor invasive mechanical ventilation imv score <NUMBER> icu hospitalization requiring noninvasive mechanical ventilation nivhighflow nasal catheter oxygen therapy hfnc score <NUMBER> hospitalization requiring oxygen therapy nonniv hfnc score <NUMBER> hospitalization need oxygen therapy score<NUMBER>discharge hospital <NUMBER> add details safety end point newest version gastrointestinal reactions especially diarrhea retinopathy relatively common clinically prescribed doses reversed withdrawal longterm high doses may cause irreversible retinal damage risk visual impairment <NUMBER> add secondary endpoint subject severe type <NUMBER>ncov pneumonia allcause mortality <NUMBER> add secondary endpoint subject severe type <NUMBER>ncov pneumonia clinical status days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> add secondary endpoint subject severe type <NUMBER>ncov pneumonia duration mechanical ventilation imv niv days extracorporeal membrane oxygenation days oxygen therapy nasal catheter mask oxygen days hospitalization days version date <NUMBER> february <NUMBER> amendment statistical analysis plan study completion eligible patients randomly assigned one treatment arms ratio <NUMBER> randomization number generated computer implemented random envelops stratification factor includes severity disease mildmoderate severe extended followup <NUMBER> visit × <NUMBER> × × × × × × urinalysis <NUMBER> × <NUMBER> × × × blood chemistry <NUMBER> hepatic kidney panel myocardial enzyme × <NUMBER> × × × × × × coagulation panel <NUMBER> × <NUMBER> × × × × × × <NUMBER>ncov rtpcr <NUMBER> × <NUMBER> <NUMBER> epidemiological information includes recent travel history exposure epidemic area infected patients medical history includes present illness past medical history including comorbidity medications <NUMBER> physical examination includes height weight general outlook head eye ear nose throat neck thyroid skin cardiovascular system anterior chest lung abdomen neuro system skeletal muscle system lymphatic system <NUMBER> vital signs body temperature respiratory rate pulse blood pressure record maximum temperature visiting day use measurement criteria throughout study period <NUMBER> cbc differential includes haptoglobin absolute count red blood cell platelet total white blood cell neutrophil lymphocyte monocyte eosinophil basophil <NUMBER> urinalysis urinary ph urinary red blood cell urinary white blood cell urinary protein glucose ketone <NUMBER> blood chemistry includes alanine aminotransferase aspartate aminotransferase total bilirubin albumin γglutamyl transpeptidase lactate dehydrogenase creatine kinase creatine kinase isoenzymemb blood urea nitrogen creatinine <NUMBER> coagulation panel includes prothrombin time activated partial thrombin time thrombin time fibrinogen international normalized ratio <NUMBER> rtpcr results upon unplanned visit also recorded crf <NUMBER> record daily administration tested drug including use use <NUMBER> examinations exempted investigators participants provide qualified examination results within <NUMBER>day prior initiation study <NUMBER> rtpcr results <NUMBER>ncov within <NUMBER>day prior initiation study used screening <NUMBER> patients discharge alive medications ae information collected via telephone contact <NUMBER> × × electrocardiogram crp esr × <NUMBER> × × × × × × tnfα，il<NUMBER> × <NUMBER> × × × × × × cbc differential <NUMBER> × <NUMBER> × × × × × × × <NUMBER> × × blood chemistry <NUMBER> hepatic kidney panel myocardial enzyme × <NUMBER> × × × × × × coagulation panel <NUMBER> × <NUMBER> × × × × × × <NUMBER>ncov rtpcr <NUMBER> × <NUMBER> arterial blood gas analysis × <NUMBER> optional per clinical needs pregnancy test serum urine hcg × <NUMBER> × chest ct × <NUMBER> demographics include birth date gender ethnicity <NUMBER> epidemiological information includes recent travel history exposure epidemic area infected patients medical history includes present illness past medical history including comorbidity medications <NUMBER> physical examination includes height weight general outlook head eye ear nose throat neck thyroid skin cardiovascular system anterior chest lung abdomen neuro system skeletal muscle system lymphatic system <NUMBER> vital signs body temperature respiratory rate pulse blood pressure record maximum temperature visiting day use measurement criteria throughout study period <NUMBER> cbc differential includes haptoglobin absolute count red blood cell platelet total white blood cell neutrophil lymphocyte monocyte eosinophil basophil <NUMBER> urinalysis urinary ph urinary red blood cell urinary white blood cell urinary protein glucose ketone <NUMBER> blood chemistry includes alanine aminotransferase aspartate aminotransferase total bilirubin albumin γglutamyl transpeptidase lactate dehydrogenase creatine kinase creatine kinase isoenzymemb blood urea nitrogen creatinine <NUMBER> coagulation panel includes prothrombin time activated partial thrombin time thrombin time fibrinogen international normalized ratio <NUMBER> rtpcr results upon unplanned visit also recorded crf <NUMBER> record daily administration tested drug including use use <NUMBER> examinations exempted investigators participants provide qualified examination results within <NUMBER>day prior initiation study <NUMBER> rtpcr results <NUMBER>ncov within <NUMBER>day prior initiation study used screening patients discharge alive medications ae information collected via telephone contact <NUMBER> negative conversion rate virus nucleic acid within <NUMBER>day <NUMBER> severe disease subgroup considering virology conversion clinical improvement • definition clinical improvement：decline two categories enrollment status sixcategory ordinal scale clinical status ranging <NUMBER> discharged <NUMBER> death adverse events，laboratory values ecg vital signs physical examination findings monitored recorded approximately <NUMBER> subjects <NUMBER> per group randomized study sample size study based alternative hypothesis <NUMBER> reduction risk virus nucleic acid negativity exponential distribution benefit translates reduction median virology negativity <NUMBER> days <NUMBER> days total <NUMBER> events would provide power <NUMBER> detect reduction <NUMBER> hazard ratio control vs treatment <NUMBER> logrank test assuming twosided significance level <NUMBER> <NUMBER>day accrual period additional <NUMBER>day followup assumed sample size calculation also taken consideration annual dropout rate <NUMBER> meanwhile coprimary endpoint subgroup defined severe disease <NUMBER>day clinical improvement assume <NUMBER> patients clinical improvement day <NUMBER> control group <NUMBER> patients detect <NUMBER> improvement treatment group power<NUMBER> intenttotreat itt defined subjects randomly assigned treatment group placebo group analyses efficacy based population itt analyses grouping based treatment planned per protocol set pps： subset itt，defined subjects randomly assigned study received least <NUMBER>day treatmentmildmoderate disease <NUMBER>day treatmentsevere disease，and major pd significantly impact primary endpoint analyses grouping according treatment planned safety setss defined subjects received least <NUMBER> administration study treatment partial complete population used safety analyses safety analyses grouping according treatment actually received patients control arm included ss randomization date used substitute treatment date analyses conducted sas <NUMBER>or higher version general continuous variables summarized using descriptive statistics mean standard deviation sd median range categorical variables summarized using frequency percentage timetoevent variables kaplanmeier method used descriptive summaries listing list results testsevaluation actually happened unless otherwise specified listing follows order treatment patient id visit parameters study monthnumber days<NUMBER>。 unless otherwise specified display mean median one digit original data standard deviation <NUMBER> digit mean numerical display show <NUMBER> digits percentage <NUMBER> digit percentage display frequency <NUMBER> general denominator percentage number patients corresponding header primary efficacy analysis itt supportive efficacy analysis pps safety analysis ss <NUMBER> lab value recorded ＜normal value，≤normal value，＞normal value ≥normal value value treated normal value summary tables listed asis listings <NUMBER>missingpartial date birth end date adverse event missing completely partially following imputation rules used ➢ month year present day month missing last day month imputed ➢ year present <NUMBER>st december used ➢ imputed date later date death available date death used imputed date instead <NUMBER> relevance ae study drug missing evaluable ae counted relevant unless otherwise specified，baseline values defined values visit v<NUMBER> change baseline defined valuesbaseline value overview subject disposition treatment group provided overview includes summary total number subjects randomized treatment group number percentage subjects randomized treated number percentage subjects treated number percentage subjects discontinued study treatment including reason discontinuation indicated investigators summarized similar summaries presented randomized subjects discontinued study participation listing subjects discontinued study treatment including reasons discontinuation provided similar listing provided subjects discontinued study participation major protocol deviations summarized itt population following types deviation treatment group entered satisfy inclusionexclusion criteria developed withdrawal criteria withdrawn received excluded concomitant treatment protocol noncompliance list subjects major protocol deviations including subject id type deviation reasons deviation provided unless specified otherwise demographic baseline characteristics variables summarized itt population statistical comparisons <NUMBER> treatment groups planned parameters relevant study disease summarized itt treatment group including time first positive test randomization time first onset symptoms randomization exposure history spo<NUMBER> onset fever onset respiratory symptom medication allergy history etc preexisting conditions medical history coded meddra version <NUMBER> higher summarized soc pt listing subjects preexisting conditions medical history provided historical medications concomitant medications coded based ddthe lastest version historical medication defined medication ending date randomization date concomitant medication defined medication ending date randomization date missing historicalconcomitant medication collected crf page study summarized therapeutic class pharmacologic class drug name treatment group similar analytic approach historicalconcomitant treatmentmedications efficacy analysis done itt pps results itt primary frequency proportion virology negativity day <NUMBER>、<NUMBER>、<NUMBER>、<NUMBER>、<NUMBER> reported group proportion defined cumulative patients negativity given daynumber itt group conversion virology negativity defined two consecutive testing results showing negativity least one day interval two tests result positive end studyor early dropout planned test done result pending impute result positive unscheduled testing used confirm negativity kaplanmeier method used estimate distribution time negativity treatment group median time negativity <NUMBER> ci provided addition number percentage subjects event censored reported kaplanmeier curve also plotted treatment group compared stratified logrank test stratification factor factor considered randomization primary treatment comparison distribution overall negativity based stratified logrank test pvalue stratified logrank test reported hazard ratio <NUMBER> confidence interval estimated based stratified coxs regression model treatment sole explanatory variable stratification factors used analyses include severity disease addition <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> day negativity rate <NUMBER> ci estimated kaplanmeier method reported treatment group determination dates event dates censoring summarized table <NUMBER> • severe disease subgroup ， report clinical state change time point summarize duration days mechanical ventilation extracorporeal membrane oxygenation supplemental oxygenation hospital stay • mildmoderate subgroup report progression rate time point。 safety analysis conducted among ss set compliance defined actual doseplanned dose<NUMBER> summarize compliance treatment duration treatment duration study drug defined last day drug usethe first day drug use treatment duration control group defined last day studyrandomization date general rule ae analyzed ➢ adverse events coded using latest version medical dictionary regulatory activities meddra coding dictionary recorded standard medical terminology graded according national cancer institute common terminology criteria adverse events ncictcae ➢ ae summarized actual treatment received ➢ patient ae multiple times table summarizing prevalence patientlevel highest grade ae summarized table summarizing prevalence incidencelevel ae patient date highest grade summarized ➢ summary ae events come alone percentage ➢ summarizing subgroup ae prevalence greater given percentage search ae within socpt incidence prevalence aes summarized overall treatment group meddra system organ class soc preferred term toxicity grade relationship study treatment administration specifically following ae summaries presented meaningful postbaseline value provided ecg summarized visit treatment group shift table baseline value normal vs abnormal clinical meaningful vs abnormal clinical meaningful postbaseline value may provided vital signs systolic diastolic blood pressure heart rate temperature values change baseline summarized visit treatment group shift table baseline value normal vs abnormal clinical meaningful vs abnormal clinical meaningful postbaseline value may provided physical examination findings summarized visit treatment group shift table baseline value normal vs abnormal clinical meaningful vs abnormal clinical meaningful worst postbaseline value may provided independent data monitoring committee idmc established review data <NUMBER> interim analyses prior primary endpoint analysis following cumulative αspending function obrienfleming type landemets algorimth landemets，<NUMBER>will applied control familywise typei error <NUMBER> where， cumulative information time kth analysis，φ standard normal distribution，φ −<NUMBER> quantile function cumulative alpha spending function α function cumulative information therefore significance level pvalue boundary function cumulative information ie observed number events first interim analysis occur <NUMBER> subjects around <NUMBER> subjects treated least <NUMBER> days discontinued goal evaluate efficacy need sample size reestimation pvalue boundary efficacy significance <NUMBER>twosided final analysis conducted <NUMBER> events observed pvalue boundary <NUMBER>twosided actual alpha spent pvalue boundaries analysis calculated based exact number events tfl shells provided separate file mild common type confidential information contained relates trade secrets business information business information terms confidential content proprietary information except required regulations shall disclosed person individual access document shall aware proprietary confidential nature shall disclose document without authorization restrictions confidentiality documents apply information provided future marked proprietary confidential <NUMBER> case report form shall recorded authorized person page crf shall carefully checked signed <NUMBER> trial physicians familiar trial protocol master gcp principles <NUMBER> please write clearly legibly sign pen blue black ink preferably capital letters english example：case report form <NUMBER> filling numbers open squares fill one number box；if number digits less corresponding number squares please fill zero spaces allowed example：<NUMBER>kg，fill blanks follows <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> kg <NUMBER> date international iso<NUMBER> date format：yyyymmdd example december <NUMBER> <NUMBER> written <NUMBER> <NUMBER> <NUMBER> <NUMBER> year <NUMBER> <NUMBER> month <NUMBER> <NUMBER> day。 <NUMBER> items □in form please type ×in corresponding box fill relevant numbers done data available please fill ndnot done nknot known corresponding space na applicable item must filled accurately arbitrarily alter use correction fluid ways cover original data find errors please cross wrong record single <NUMBER> change format case report form find place form fill information recorder wishes record please contact responsible cra <NUMBER> upon completion case report form principal investigator shall examine page case report form sign investigators statement adverse events occurred since signing informed consent please fill form adverse events medication combination please fill form previouscombined medication combined nondrug therapy please fill previouscombined nondrug therapy form outofplan inspection please fill outofplan inspection form imvniv ecmo hfnc oxygen therapy please fill imvniv ecmo hfnc oxygen therapy form protocol number：ky<NUMBER> adverse events occurred since last visit please fill adverse events form medication combination please fill previouscombined medication form combined nondrug therapy please fill comined nondrug therapy form outofplan inspection please fill outofplan inspection form subject discharged hospital following contents may carried please leave blank subject discharged please conduct following examinations □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> glutamicoxalacetic transamineaseast □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> total bilirubintbil □<NUMBER> μmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> albuminalb □<NUMBER> gl □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γglutamyl transpeptidas ggt □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> lactic dehydrogenase ldh □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> creatine kinaseck □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> creatine kinase isoenzymeckmb □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> blood urea nitrogen bun □<NUMBER> mmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> ureaurea □<NUMBER> mmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> serum creatininecr □<NUMBER> μmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> urine subject discharged hospital following contents may carried please leave blank subject discharged please conduct following examinations severe type confidential information contained relates trade secrets business information business information terms confidential content proprietary information except required regulations shall disclosed person individual access document shall aware proprietary confidential nature shall disclose document without authorization restrictions confidentiality documents apply information provided future marked proprietary confidential <NUMBER> change format case report form find place form fill information recorder wishes record please contact responsible cra <NUMBER> upon completion case report form principal investigator shall examine page case report form sign investigators statement lactic dehydrogenase adverse events occurred since signing informed consent please fill form adverse events medication combination please fill form previouscombined medication combined nondrug therapy please fill previouscombined nondrug therapy form outofplan inspection please fill outofplan inspection form imvniv ecmo hfnc oxygen therapy please fill imvniv ecmo hfnc oxygen therapy form adverse events occurred since last visit please fill adverse events form medication combination please fill previouscombined medication form combined nondrug therapy please fill combined nondrug therapy form outofplan inspection please fill outofplan inspection form adverse events occurred since last visit please fill adverse events form medication combination please fill previouscombined medication form combined nondrug therapy please fill combined nondrug therapy form outofplan inspection please fill outofplan inspection form protocol number：ky<NUMBER> protocol number：ky<NUMBER> adverse events occurred since last visit please fill adverse events form medication combination please fill previouscombined medication form combined nondrug therapy please fill combined nondrug therapy form outofplan inspection please fill outofplan inspection form imvniv、ecmo、hfnc、oxygen therapy please fill imvniv、ecmo、hfnc、oxygen therapy form protocol number：ky<NUMBER> subject discharged hospital following contents may carried please leave blank subject discharged please conduct following examinations date yearmonthday date：yearmonthday protocol number：ky<NUMBER> extend followup adverse events occurred since last visit please fill adverse events form medication combination please fill previouscombined medication form combined nondrug therapy please fill combined nondrug therapy form outofplan inspection please fill outofplan inspection form imvniv、ecmo、hfnc、oxygen therapy please fill imvniv、ecmo、hfnc、 oxygen therapy form name treatment please describe professional medical terms <NUMBER> please describe professional medical terms <NUMBER> 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 自上次访视以来，受试者如有不良事件发生，请填写不良事件表；如有合并药物治疗，请填 写既往合并药物治疗表；如有合并非药物治疗，请填写既往合并非药物治疗表；如有计划 外检查，请填写计划外检查表。如有 imvniv、ecmo、hfnc、氧疗，请填写在imvniv、 □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> glutamicoxalacetic transamineaseast □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> total bilirubintbil □<NUMBER> μmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> albuminalb □<NUMBER> gl □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γglutamyl transpeptidas ggt □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> lactic dehydrogenase ldh □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> creatine kinaseck □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> creatine kinase isoenzymeckmb □<NUMBER> ul □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> blood urea nitrogen bun □<NUMBER> mmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> ureaurea □<NUMBER> mmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> serum creatininecr □<NUMBER> μmoll □<NUMBER>other： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> protocol确认入选排除标准 受试者是否满足所有入选标准且不满足所有排除标准？ □<NUMBER> 是 □<NUMBER> 否，请填写。 □<NUMBER> 不满足入选标准，入选标准编号可多选 □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ 其他，请描述： □<NUMBER> 满足排除标准，排除标准编号可多选 □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ <NUMBER> □ 其他，请描述： 人口学资料 性 别 □<NUMBER> 男 □<NUMBER> 女 出 生 日 期 年月日 如不能获得，请填写年龄： 岁 民 族 □<NUMBER> 汉 □<NUMBER>白蛋白alb □<NUMBER> gl □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γ谷氨酰转肽酶ggt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 乳酸脱氢酶ldh □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶ck □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶同工酶ckmb □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血尿素氮bun □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 尿素urea □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血肌酐cr □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER>白蛋白alb □<NUMBER> gl □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γ谷氨酰转肽酶ggt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 乳酸脱氢酶ldh □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶ck □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶同工酶ckmb □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血尿素氮bun □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 尿素urea □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血肌酐cr □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER>白蛋白alb □<NUMBER> gl □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γ谷氨酰转肽酶ggt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 乳酸脱氢酶ldh □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶ck □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶同工酶ckmb □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血尿素氮bun □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 尿素urea □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血肌酐cr □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER>谷丙转氨酶alt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 谷草转氨酶ast □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 总胆红素tbil □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 白蛋白alb □<NUMBER> gl □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γ谷氨酰转肽酶ggt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 乳酸脱氢酶ldh □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶ck □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶同工酶ckmb □<NUMBER> ul□<NUMBER>谷丙转氨酶alt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 谷草转氨酶ast □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 总胆红素tbil □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 白蛋白alb □<NUMBER> gl □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> γ谷氨酰转肽酶ggt □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 乳酸脱氢酶ldh □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶ck □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 肌酸激酶同工酶ckmb □<NUMBER> ul □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血尿素氮bun □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 尿素urea □<NUMBER> mmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> □<NUMBER> 血肌酐cr □<NUMBER> μmoll □<NUMBER> 其他： □<NUMBER> □<NUMBER> □<NUMBER> dear sir madame invite participate randomized controlled open multicenter study hydroxychloroquine sulfate treatment covid<NUMBER> infection clinical research agree participate study please read following message carefully may also discuss relatives ask doctor researcher questions wish know get satisfied answer agree participate study please sign informed consent keep copy informed consent signed parties since study carried <NUMBER> centers across country participate study follow observe condition <NUMBER> days including <NUMBER> days <NUMBER>days according disease severity treatment <NUMBER> days treatment receive standard care according chinese guideline covid<NUMBER> pneumonia edition <NUMBER> standard care hydroxychloroquine sulfate orally routine consultation physical examination chest hrct vital signs monitoring relevant blood examination viral nucleic acid sampling done according protocol participate study doctor treat disease according current covid <NUMBER> pneumonia chinese guideline give fully active treatment followup randomly without use hydroxychloroquine sulfate orally <NUMBER> days according disease severity investigators collect demographic information evaluate clinical condition treatment <NUMBER> days <NUMBER> days <NUMBER> days <NUMBER> days <NUMBER> days severe pneumonia treatment laboratory examination safety treatment followed along treatment <NUMBER> days treatment participation study may contribute recovery covid <NUMBER> infection additional risk enrolled routine medical program examinations diseases required examination treatment study completed according routine diagnosis treatment additional cost participate study study related diseases public health emergencies corresponding financial compensation time treatment received participating study carried accordance standard management diseases additional hydroxychloroquine sulfate tablets received commonly used routine clinical medication individual patients may still individual adverse drug reactions however since drug market many years investigators familiar type severity adverse reactions take corresponding treatment according condition happens corresponding measures include stopping use drug according severity adverse reactions participation make important contribution treatment covid<NUMBER> infection provide help future treatment similar patients appreciate participation much clinical observation study willing participate study according routine management disease affect clinical treatment medical records including research medical records physical laboratory examination reports kept hospital required addition investigators ethics committees supervision auditing pharmaceutical administration departments relevant personnel allowed access medical records personnel related study access medical records without permission public reports results study disclose personal identity everything protect privacy personal medical information despite reports vitro activity hydroxychloroquine severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> controversies preventive efficacy coronavirus disease<NUMBER> covid<NUMBER> although anecdotal report successful use hydroxychloroquine postexposure prophylaxis <NUMBER> covid<NUMBER> cases hydroxychloroquine use reported <NUMBER> recently randomized controlled trial failed show postexposure prophylactic efficacy hydroxychloroquine covid<NUMBER> <NUMBER> describe additional breakthrough case covid<NUMBER> prolonged use hydroxychloroquine due underlying disease addition measured serum saliva concentrations hydroxychloroquine discuss prophylactic effect april <NUMBER> <NUMBER> returned korea april <NUMBER> <NUMBER> quarantined airport inspection body temperature <NUMBER>°c next day april <NUMBER> <NUMBER> ie <NUMBER>rd day illness laboratoryconfirmed positive covid<NUMBER> transferred seoul metropolitan governmentseoul national university boramae medical center seoul time admission blood pressure pulse rate respiratory rate body temperature <NUMBER> mmhg <NUMBER>min <NUMBER>min <NUMBER>°c respectively <NUMBER> cm high body weight <NUMBER> kg although persistent constitutional symptoms denied respiratory symptoms laboratory tests showed mild leukopenia whereas blood chemistry tests including creactive protein within normal limits initial chest radiography showed apparent infiltration however persistent fever <NUMBER>°c suspicion progression infiltration left lower lung field hydroxychloroquine dosage increased <NUMBER> mg daily azithromycin <NUMBER> mg daily administered april <NUMBER> <NUMBER> <NUMBER> fig <NUMBER> transferred seoul national university hospital participate randomized controlled trial involving remdesivir april <NUMBER> <NUMBER>th day illness <NUMBER> chest computed tomography revealed patchy ground glass opacities lower lobes fig <NUMBER> clinical trial daily dose hydroxychloroquine returned <NUMBER> mg azithromycin discontinued defervesced days treatment deisolated april <NUMBER> <NUMBER>th day illness confirming negative polymerase chain reaction tests twice serum saliva taken examining hydroxychloroquine concentrations samples day transfer fig <NUMBER> liquid chromatographytandem mass spectrometry using <NUMBER> triple quadrupole system agilent technologies santa clara ca usa waters symmetry c<NUMBER> <NUMBER> × <NUMBER> mm column packed <NUMBER> µm material waters corporation milford usa calibration standards hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> µgl prepared spiking blank serum using chloroquine internal standard test sample preparation <NUMBER> dithiothreitol volume specimen mixed saliva sputum liquefaction methanol added serum saliva volume ratio <NUMBER> protein precipitation <NUMBER> supernatant used test centrifugation <NUMBER> g <NUMBER> minutes serum saliva hydroxychloroquine concentrations <NUMBER> µgl <NUMBER> µmoll <NUMBER> µgl <NUMBER> µmoll respectively institutional review board irb seoul national university hospital approved report irb <NUMBER> written informed consent obtained patient described case breakthrough covid<NUMBER> patient taking hydroxychloroquine six months control underlying disease although reported half maximal effective concentration ec <NUMBER> values hydroxychloroquine sarscov<NUMBER> largely varied multiplicity infection <NUMBER> ranging <NUMBER> <NUMBER> µmoll <NUMBER> levels hydroxychloroquine serum saliva patient tended higher ec <NUMBER> values despite reports covid<NUMBER> cases occurred hydroxychloroquine use <NUMBER> first one examined concentrations hydroxychloroquine serum saliva antiviral agents saliva potential barrier respiratory virus <NUMBER> breakthrough covid<NUMBER> case patient effective concentrations hydroxychloroquine worth noting mounting evidences limited prophylactic effect hydroxychloroquine <NUMBER> accordant studies reported negative results hydroxychloroquine treatment covid<NUMBER> previously described limited vitro activity hydroxychloroquine sarscov<NUMBER> concentrations could achieved usual dosages <NUMBER> observational study small randomized controlled trial could show better clinical outcomes hydroxychloroquinetreated group <NUMBER> several points considered interpreting present report ec <NUMBER> could different different inoculum size present report prudently interpreted single case uncertain intensity exposure also possibility maintenance hydroxychloroquine attributed mild course covid<NUMBER> patient could ruled concentrations hydroxychloroquine possibly affected increased dose three days measurement however effect might substantial considering delayed pharmacokinetics hydroxychloroquine <NUMBER> present case raise concerns role hydroxychloroquine prophylactic agent covid<NUMBER> taken together results recent randomized clinical trial <NUMBER> prophylactic use hydroxychloroquine limited rapid spread covid<NUMBER> caused severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> posed enormous challenge public healthcare across globe <NUMBER> <NUMBER> <NUMBER> world health organization declared outbreak covid<NUMBER> pandemic march <NUMBER> <NUMBER> <NUMBER> april <NUMBER> affected <NUMBER> million individuals sarscov<NUMBER> newly identified pathogen targetspecific antiviral drugs vaccines currently available adoption crisis intervention approach required additionally scientific merit repurposing existing drugs mechanistic potential may provide quick yet costeffective treatment paradigm chloroquine hydroxychloroquine gained broad attention possible treatment options covid<NUMBER> based three main rationales first chloroquine demonstrated broadspectrum antiviral activity viruses human immunodeficiency virus zika virus dengue virus coronavirus oc<NUMBER> <NUMBER> outbreak covid<NUMBER> wuhan china wang et al screened existing antiviral drugs potential treatments covid <NUMBER> results showed chloroquine phosphate potent antiviral activity sarscov<NUMBER> vitro <NUMBER> drug also high selection index si low concentrations <NUMBER> <NUMBER> secondly concentrations chloroquine lungs may hundreds times higher plasma <NUMBER> unique distribution pattern conducive treatment covid<NUMBER> analyzed reported ec <NUMBER> chloroquine phosphate sarscov<NUMBER> vero e<NUMBER> cells reported wang et al <NUMBER> hypothesized reported ec <NUMBER> potentially achievable humans licensed dose chloroquine phosphate administered third chloroquine hydroxychloroquine immune modulators affect multiaspects immune response <NUMBER> compounds block production inflammatory cytokines interferon tumor necrosis factor interleukins bcell activation factor <NUMBER> <NUMBER> additionally chloroquine hydroxychloroquine inhibit interaction tolllike receptors <NUMBER> nucleic acid ligands thus blocking activation innate immunity <NUMBER> effects may also suppress formation cytokine storms covid<NUMBER> pathogenesis <NUMBER> <NUMBER> finally chloroquine may downregulate expression coinhibitory molecules expressed plasmacytoid dendritic cells ido pdl<NUMBER> suppress tcell activation <NUMBER> chloroquine thus positively regulates certain aspects immune function addition broad immunosuppressive effects based rationales investigated therapeutic utility chloroquine treating covid<NUMBER> hydroxychloroquine derivative chloroquine improved safety profile designed randomized openlabel <NUMBER>arm prospective study compare effects chloroquine hydroxychloroquine standard care treating covid<NUMBER> study conducted hospital wuhan study period china national health commission published <NUMBER> th <NUMBER> th editions diagnosis treatment protocol novel coronavirus pneumonia recommend use chloroquine <NUMBER> <NUMBER> singlecenter prospective study evaluate effects chloroquine phosphate hydroxychloroquine sulfate treating covid<NUMBER> original study design planned recruit <NUMBER> subjects confirmed mildmoderate types covid<NUMBER> however city wuhan rapidly controlled epidemic complete study march <NUMBER> <NUMBER> enrolling <NUMBER> subjects mildmoderate covid<NUMBER> report data <NUMBER> patients moderate type covid<NUMBER> provide evidence patients treated either chloroquine hydroxychloroquine showed positive trend toward faster clinical recovery rapid return viral rna negativity shorter hospitalization molecules manageable safety profiles dosage regimens similar used treat extraintestinal amebiasis rheumatoid arthritis hope data provided serve reference justification investigation use hydroxychloroquine healthcare professionals across globe fighting covid<NUMBER> certified peer review authorfunder granted medrxiv license display preprint perpetuity trial designed assess efficacy safetytolerability chloroquine hydroxychloroquine compared standard care study openlabel study eligible patients randomized <NUMBER> ratio one three treatment groups using computergenerated randomization number patient received one following treatment options oral chloroquine phosphatestandard treatment hydroxychloroquine sulphatestandard treatment standard treatment randomization patients received standard treatment according chinese diagnosis treatment protocol novel coronavirus pneumonia <NUMBER> th edition <NUMBER> chloroquine group patients received standard treatment chloroquine phosphate guangdong zhongsheng pharmaceutical co ltd guangzhou china orally <NUMBER> mg qd first day <NUMBER> mg qd additional <NUMBER> days hydroxychloroquine group patients received standard treatment plus oral hydroxychloroquine sulphate shanghai pharmaceutical co ltd shanghai china <NUMBER> mg bid <NUMBER> days study period <NUMBER> days prior hospital discharge patients assessed following robust synopsis available online vital signs parameters reflecting clinical recovery eg body temperature respiratory rate sao<NUMBER> cough safety evaluation performed daily laboratory exams eg complete blood count blood chemistry creactive protein crp procalcitonin performed patients also tested cardiac enzyme panel troponin myoglobin creatine kinasemb ckmb time screening day <NUMBER> patients abnormal levels cardiac enzymes baseline one additional test done day <NUMBER> <NUMBER> patients received quick bedside cardiac monitoring day <NUMBER> <NUMBER> abnormality observed patient would receive comprehensive electrocardiography ecg test sarscov<NUMBER> rtpcr chest ct performed study andor prior discharge additionally exploratory biomarkers measured cytokines il<NUMBER>β il<NUMBER>r il<NUMBER> il<NUMBER> il<NUMBER> tnfα sarcov<NUMBER>specific iggigm antibody primary outcome measurement study time clinical recovery ttcr defined number days randomization clinical recovery maximum ttcr <NUMBER> days patients considered achieved clinical recovery met following criteria least <NUMBER> hours <NUMBER> results laboratory testing used semiquantitative scoring system similar method reported pan et al estimate pulmonary manifestations ct scan <NUMBER> five lobes rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint lungs assigned total score <NUMBER> points based volume tissue affected score given based overall affected areas side lung every <NUMBER> affected areas lung recorded <NUMBER> point changes cytokine levels covid<NUMBER>specific iggigm levels measured first week hospitalization measurement data tested normality normally distributed measurement data described mean ± standard deviation nonnormally distributed measurement data shown median interquartile range statistical analysis primary endpoint conducted using kaplanmeier curve logrank testing primary comparisons included chloroquine vs control hydroxychloroquine vs control taking overall alpha<NUMBER> test standard deemed difference p<NUMBER> statistically significant statistical analyses considered exploratory spss v<NUMBER> software used statistical analysis feb <NUMBER> <NUMBER> mar <NUMBER> <NUMBER> evaluated <NUMBER> hospitalized patients mildmoderate covid<NUMBER> sixtyseven patients enrolled study included chloroquine group n<NUMBER> hydroxychloroquine group n<NUMBER> control group n<NUMBER> patients randomly assigned treatment groups ratio <NUMBER> figure <NUMBER> seven patients chloroquine arm <NUMBER> patients hydroxychloroquine arm <NUMBER> patients control arm excluded analysis covid<NUMBER> manifested mild symptoms additional <NUMBER> patients hydroxychloroquine arm misdiagnosed covid<NUMBER> therefore excluded thus reported <NUMBER> cases moderate covid<NUMBER> <NUMBER> chloroquine arm <NUMBER> asymptomatic <NUMBER> hydroxychloroquine arm <NUMBER> asymptomatic <NUMBER> control arm figure <NUMBER> chloroquine arm average age <NUMBER> ± <NUMBER> years including <NUMBER> males <NUMBER> hydroxychloroquine arm average age <NUMBER>±<NUMBER> years included <NUMBER> males <NUMBER> control arm average age <NUMBER> ± <NUMBER> years <NUMBER> males <NUMBER> three treatment groups balanced terms age gender body mass index bmi preexisting conditions table <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity baseline groups similar terms frequency pyrexia peripheral sao <NUMBER> requirement oxygen therapy admission pulmonary ct score supplementary table <NUMBER> additionally significant differences among groups results baseline laboratory tests including levels cytokines il<NUMBER> il<NUMBER>r il<NUMBER> il<NUMBER> il<NUMBER> tnfα livercardiac enzymes sarscov<NUMBER>specific iggigm supplementary table <NUMBER> none patients included study progressed moderate covid<NUMBER> severe critical forms disease death chloroquine hydroxychloroquine generally safe well tolerated adverse events including abnormal laboratory results mild except one instance grade <NUMBER> alt elevation ctcae grading mild adverse events common chloroquine group <NUMBER> hydroxychloroquine group <NUMBER> control group <NUMBER> table <NUMBER> incidence diarrhea higher chloroquine group hydroxychloroquine group <NUMBER> <NUMBER> respectively control group <NUMBER> two patients altast elevation study ecg results obtained time screening used exclude patients prior history cardiac diseases originally planned include comprehensive ecg evaluation part study however due open setting ward desire minimize repetitive contact hospital staff members patients able perform full ecg assessment every patient originally planned nevertheless cardiac monitoring patient conducted day <NUMBER> <NUMBER> patient apparent cardiac abnormality patients rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity table <NUMBER> used ttcr primary endpoint kaplanmeier ttcr curves generated compare chloroquine vs control hydroxychloroquine vs control figure <NUMBER>a also analyzed days hospitalizationrandomization discharge figure <NUMBER>c modest trend toward decrease duration hospitalization rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> chloroquine hydroxychloroquine groups consistent directional changes ttcr time reach rna negativity figure <NUMBER>c evaluated chest ct score day <NUMBER> compared baseline number days randomization termination oxygen therapy table <NUMBER> chest ct scores chloroquine hydroxychloroquine groups showed trend toward improvement latter show improvement analyses cytokines sarscov<NUMBER>specific iggigm changes day <NUMBER> day <NUMBER> reveal significant differences supplementary table <NUMBER> conducted clinical trial study team area ongoing covid<NUMBER> epidemic study demonstrated compared control treatment chloroquine phosphate treatment significantly improved ttcr moderate form covid<NUMBER> p<NUMBER> additionally chloroquine phosphate treatment accelerated time viral rna negativity shortened hospital stay improved chest ct scan scores observed similar trends hydroxychloroquine treatment group dosage regimen chose albeit lesser degree although comparisons among groups terms time discharge reveal significant difference p<NUMBER> median numbers days hospital lower chloroquine hydroxychloroquine groups control group prospective randomized controlled trial consistent criteria enrollment three arms balanced terms age gender underlying disease baseline characteristics study thus largely avoided issues common nonrandomized trials inspired conduct study results vitro research sarscov<NUMBER> <NUMBER> robust antiviral activity chloroquine phosphate sarscov<NUMBER> vitro unique pattern distribution enriched lung tissue distribution <NUMBER> times greater plasma concentration <NUMBER> make potentially rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint useful treatment covid<NUMBER> <NUMBER> <NUMBER> study generated positive evidence supportive using hydroxychloroquine treat moderate forms covid<NUMBER> however data must interpreted caution couple limitations study first due unexpected onset epidemic availability active drugs able conduct placebocontrolled doubleblinded study would objective largely excluded possible impact openlabel use given physicians assessment second chinese government implemented robust intervention approach effectively controlled epidemic study terminated full enrollment n<NUMBER> chloroquine hydroxychloroquine groups n<NUMBER> control group thus demonstrated positive results study per se underpowered used onemonth study period sample size <NUMBER> n<NUMBER> hydroxychloroquine vs n<NUMBER> control conduct posthoc power analysis alpha level singlesided set <NUMBER> would expect <NUMBER> chloroquine vs control <NUMBER> hydroxychloroquine vs control power respectively detection real difference median numbers ttcr days <NUMBER> days <NUMBER> days <NUMBER> days chloroquine hydroxychloroquine control treatment respectively study dosage regimen chloroquine phosphate administration based desire maximize efficacy minimizing safety concerns according prescription label chloroquine phosphate china drug licensed treatment malaria extraintestinal amebiasis rheumatoid arthritis treating acute infectious diseases covid<NUMBER> key achieve therapeutic efficacy may finding path ensure blood levels chloroquine rapidly reach steady state treatment chloroquine may lead cardiotoxicity excluded patients prior history cardiac disorders prohibited use medications eg quinolones may lead qt elongation ventricular arrhythmia therefore study cautiously used dosing regimen similar rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint used extraintestinal amebiasis <NUMBER> mg qd loading dose chloroquine phosphate day <NUMBER> followed <NUMBER> mg qd dose <NUMBER> days <NUMBER> noticeably daily total amounts chloroquine given study less potent presumably safer recommended dosing regimens chinese diagnosis treatment protocol novel coronavirus pneumonia <NUMBER> th <NUMBER> th editions <NUMBER> mg bid <NUMBER> days time preparing manuscript vitro data clinical data inhibitory effect hydroxychloroquine regard sarscov<NUMBER> however hydroxychloroquine chloroquine highly similar terms molecular structure mechanism action hydroxychloroquine better safety profile prescribed commonly therefore designed study included hydroxychloroquine exploratory purposes without solid understanding optimal dosing regimen safety concerns used <NUMBER> recently published study hydroxychloroquine treatment moderate covid<NUMBER> <NUMBER> mg bid <NUMBER>day treatment hydroxychloroquine showed significantly improved ttcr compared control treatment <NUMBER> nevertheless study hydroxychloroquine treatment appear superior chloroquine treatment effect hydroxychloroquine compared control treatment shortening ttcr reach predefined criteria statistical significance may implicated following three factors first sample size small second used kaplanmeier ttcr curveslogrank testing point estimation efficacy rather rigorous statistical assessment third regimen used dosing hydroxychloroquine may require optimization study used dose recommended treatment rheumatoid arthritis dosing regimen good safety profile may require time achieve rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> additional studies necessary optimize patient selection dosing mode action underlying effects remains unclear empirical experience vitro studies shown chloroquine may inhibit production inflammatory mediators cytokines however results support mechanism observed significant difference levels inflammatory cytokines vs treatment patients enrolled study moderate covid<NUMBER> limited inflammation observe changes patterns lymphocyte infiltration sarscov<NUMBER>specific iggigm production cellular humoral immunity respectively chloroquine hydroxychloroquine well tolerated considered safe adverse effects generally mild comparable chloroquine hydroxychloroquine groups serious adverse event occurred modest rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> increases gastrointestinal symptoms diarrhea nausea treatment groups relieved symptomatic treatment without affecting subsequent dosing one patient discontinued chloroquine phosphate fifth day treatment elevated altast levels patients liver enzyme abnormalities mild ctcae grading associated elevated levels bilirubin one patient hydroxychloroquine group increased baseline levels altast baseline altast levels increased dosing alt increase reaching grade <NUMBER> ctcae grading finishing treatment hydroxychloroquine levels altast declined patients anticovid<NUMBER> treatments effective study demonstrated therefore feasible treat covid<NUMBER> chloroquine according dosage regimen approved indications long patients safety monitored eg altast measurement cardiac monitoring chinese diagnosis treatment protocol novel coronavirus pneumonia evolved throughout study period early days study patients pulmonary manifestations positive sarscov<NUMBER>specific antibody negative viral rna included later stage clinical trial fewer patients admitted ward patient enrollment study discontinued study provides evidence clinical utility chloroquine results need verified larger trials designed determine optimal dosing regimen evaluated effectiveness hydroxylchloroquine treating patients moderate covid<NUMBER> data suggest chloroquine likely effective treating certain types disease dosage used hydroxychloroquine exerted effects similar chloroquine however magnitude hydroxychloroquines effects limited current knowledge topic vitro studies demonstrated hydroxylchloroquine inhibit sarscov<NUMBER> concentrations used approved indications however translatability drugs vitro activity efficacy safety patients variable manifestations covid<NUMBER> need carefully assessed prospective randomized controlled trials certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint chloroquine nivaquine® hydroxylated derivative hydroxychloroquine plaquenil ® old drugs antimalarial properties use become progressively reduced appearance chloroquineresistant strains plasmodium falciparum also antiinflammatory immunomodulatory activity regulating production tumor necrosis factor tnfα interferon certain cytokines <NUMBER> <NUMBER> <NUMBER> properties justify use hydroxychloroquine certain autoimmune diseases lupus rheumatoid arthritis addition since several decades drugs shown inhibitory activity replication many viruses <NUMBER> although mechanisms antiviral properties fully understood chloroquine hydroxychloroquine weak bases accumulate lysosomes modify ph interfere certain enzymes thus capacity inhibit phdependent entry certain viruses host cells even block replication enveloped viruses inhibiting glycosylation envelope proteins <NUMBER> vitro antiviral effects raised lot hope openingup consideration repositioning old inexpensive drugs management many viral infections effective treatments drugs exist widely available especially countries limited resources <NUMBER> demonstration antiviral activity vitro obviously synonymous efficacy clinically relevant parameters several studies demonstrated effect chloroquine hydroxychloroquine replication hiv vitro <NUMBER> however doubleblind randomized controlled trial comparing hydroxychloroquine <NUMBER> mgday placebo <NUMBER> hiv positive patients treated antiretrovirals cd<NUMBER> level <NUMBER>µl showed <NUMBER> weeks treatment greater decrease cd<NUMBER> increased viral load group treated hydroxychloroquine compared controls <NUMBER> paradoxical effect also observed doubleblind randomized controlled trial comparing efficacy <NUMBER> days chloroquine placebo patients infected chikungunya besides lack effect chloroquine viremia patients chloroquine group significantly arthralgia placebo group <NUMBER> despite inhibitory effect chloroquine replication virus vitro <NUMBER> case chikungunya clinical versus laboratory discrepancy might explained immunomodulatory effects drugs modify cellular humoral immune response infection <NUMBER> indications treatment dengue fever prevention influenza chloroquine proved ineffective despite vitro activity <NUMBER> <NUMBER> <NUMBER> <NUMBER> finally activity hepatitis c virus hcv described <NUMBER> pilot clinical trial conducted dozen patients hcv genotype <NUMBER> respond combination pegylated interferon alpha ribavirin showed reduction viral load alt effect ceased stopping chloroquine table <NUMBER> <NUMBER> thus date despite many promising vitro leads chloroquine hydroxychloroquine never shown real clinical efficacy treatment prevention viral infections <NUMBER> several reasons may explain discrepancy vitro clinical results validity experimental model pharmacokinetic issues ie reaching sufficient inhibitory concentration site infection <NUMBER> coronavirus responsible severe acute respiratory syndrome sarscov quickly affected many countries since hypothesis chloroquine therapeutic option emerged based antiviral properties also immunomodulatory effect <NUMBER> hypothesis confirmed vitro chloroquine inhibiting replication sarscov virus concentrations close used patients treated malaria <NUMBER> subsequent work still vitro confirmed results also suggested possible prophylactic effect <NUMBER> <NUMBER> chloroquine described vitro activity middle east respiratory syndrome coronavirus merscov <NUMBER> however results followed clinical trials demonstrating clinical efficacy context current sarscov<NUMBER> pandemic responsible novel coronavirus disease chloroquine question resurfaced vitro studies shown chloroquine <NUMBER> also hydroxychloroquine exhibits antiviral activity sarscov<NUMBER> lower ec<NUMBER> hydroxychloroquine <NUMBER> µm vs <NUMBER> µm <NUMBER> h suggesting potent activity <NUMBER> article authors developed pbpk model two drugs order simulate diffusion pulmonary tissue several dosage regimens taking account safety profile based simulations propose hydroxychloroquine loading dose <NUMBER> mg twice day <NUMBER> followed maintenance dose <NUMBER> mg twice day next four days dosages simulations show apparently low plasma concentrations order <NUMBER> μgml could allow significant pulmonary exposure high tissuefree inhibitor quotients <NUMBER> day <NUMBER> start treatment <NUMBER> <NUMBER> yet reports shown <NUMBER>fold higher ec<NUMBER> higher potency chloroquine hydroxychloroquine highlighting substantial variability vitro models <NUMBER> <NUMBER> stresses difficulty extrapolate appropriate drug concentration site infection reached safe doses chloroquine hydroxychloroquine based experimental data around twenty clinical trials evaluating efficacy chloroquine hydroxychloroquine covid<NUMBER> started china midmarch <NUMBER> <NUMBER> almost <NUMBER> trials registered worldwide end april frenetic activity originates positive preliminary results obtained one hundred patients announced without formal interim analysis detailed report results published <NUMBER> followed different studies various methodological quality singlearm noncontrolled studies cohorts propensity scorematched controls randomized controlled trials france pilot study published weeks later evaluated effect hydroxychloroquine patients covid<NUMBER> nonrandomized openlabel study primary endpoint presence nasopharyngeal virus <NUMBER> days inclusion main result higher proportion patients virus longer detected hydroxychloroquine group <NUMBER> mgd <NUMBER> days control group <NUMBER> vs <NUMBER> p <NUMBER> addition six patients received hydroxychloroquineazithromycin combination negative samples day <NUMBER> d<NUMBER> <NUMBER> open interesting perspectives results work must considered greatest caution due major methodological weaknesses first nonrandomized study imbalances groups expose major bias case use geographic controls protect possible selection bias addition <NUMBER> patients received hydroxychloroquine six left trial prematurely among three transferred intensive care fourth died intentiontotreat analysis exclude patients consider cases failures treatment hydroxychloroquine control group result primary endpoint pcr day <NUMBER> d<NUMBER> available <NUMBER> <NUMBER> subjects nearly <NUMBER> authors considered positive ie carrying virus another point concerns pcr results reported way <NUMBER> patients control group compared <NUMBER> controls <NUMBER> patients group treated hydroxychloroquine results pcrs also seem variable two patients control group negative d<NUMBER> positive d<NUMBER> counted main endpoint however arm treated hydroxychloroquine patient found negative d<NUMBER> data missing d<NUMBER> presumed negative reanalyzing data actually available d<NUMBER> difference groups longer significant suggesting possible risk phacking consists multiplying comparisons obtaining pvalue significance threshold obviously increases risk false positive article also concludes azithromycin effective results relate series <NUMBER> patients without randomization results supplemented prepublication team cohort <NUMBER> patients receiving combination hydroxychloroquineazithromycin early first symptoms followedup nine days longer results show rate poor clinical outcome prolonged hospitalisation transfer intensive care death <NUMBER> <NUMBER> mortality <NUMBER> ie close observed among infected people france <NUMBER> however absence control group possible conclude efficacy association several studies based data collected routine care compared outcomes patients confirmed sarscov<NUMBER> infection treated hydroxychloroquine untreated used propensity scorebased methods account betweengroup differences inherent nonrandomized studies first study conducted four hospitals france compared <NUMBER> patients pneumonia requiring oxygen received hydroxychloroquine <NUMBER> controls results show difference two groups regarding risk transfer intensive care death <NUMBER> second study reports data department veterans affairs usa among <NUMBER> patients <NUMBER> received hydroxychloroquine alone <NUMBER> hydroxychloroquine azithromycin <NUMBER> unexposed hydroxychloroquine results suggest higher risk death patients treated hydroxychloroquine alone without difference three groups regarding risk ventilation <NUMBER> two studies later completed two larger cohorts patients admitted hospital new york usa first one n <NUMBER> show significant association hydroxychloroquine use primary end point respiratory failure hr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> note almost <NUMBER> patients receiving hydroxychloroquine cohort also received azithromycin proportion <NUMBER> propensitymatched patients receiving hydroxychloroquine second large cohort n <NUMBER> hydroxychloroquine used associated decrease inhospital hospital mortality whether associated azithromycin used alone <NUMBER> however nonrandomized nature studies exposes bias prevents drawing clear conclusions randomized clinical trials conducted properly reported far summary small randomized trial conducted china nct<NUMBER> <NUMBER> patients published end march <NUMBER> results show difference group treated hydroxychloroquine <NUMBER> days <NUMBER> mgd control group neither virologically based clinical criteria <NUMBER> another chinese study chictr<NUMBER> concluded superiority hydroxychloroquine <NUMBER> days <NUMBER> mgday standard treatment treating fever cough associated pneumonia <NUMBER> yet cannot exclude significant reporting bias since outcomes number patients dose regimens reported study differed initially declared registry largest randomized trial openlabel multicenter study including <NUMBER> patients treated hydroxychloroquine compared <NUMBER> patients receiving standard care dose higher previous trials loading dose <NUMBER> mgday three days followed <NUMBER> mgday <NUMBER> <NUMBER> weeks according severity disease results show difference viral clearance day <NUMBER> primary outcome symptoms also comparable two groups <NUMBER> differences observed posthoc subgroup analyses altogether available evidence limited studies biased date results live metaanalysis suggest efficacy hydroxychloroquine patients covid<NUMBER> <NUMBER> nonetheless media societal excitement generated early announcements based vitro data uncontrolled case studies origin huge demand significant use drug absence evidence efficacy first risk unnecessarily expose patients adverse effects <NUMBER> relatively safe doses used prevent malaria <NUMBER> mgday chloroquine wellknown dosedependent adverse drug reactions adrs common abdominal pain diarrhea described almost <NUMBER> users well pruritus rashes headache ringing ears dizziness tinnitus also possible signs cinchonism described quinine psychiatric adrs also reported ranging anxiety disorders insomnia psychotic decompensations psychotic effects hallucinations delusions seem frequent thymic disorders depression regarding hydroxychloroquine serious psychiatric effects relatively rare within framework usual prescription however current context anxietyprovoking nature epidemic confinement population adrs potentially likely appear chloroquine hydroxychloroquine also wellknown cardiac adrs linked inhibitory effect herg potassium channels repolarize action potentials cardiomyocytes potassium efflux phase <NUMBER> action potential ikr potassium current property increases risk prolonging corrected qt interval qtc electrocardiogram ecg <NUMBER> although adr dosedependent therefore frequent event overdose serious arrhythmias reported therapeutic doses among risk factors qt prolongation facilitate precipitate arrhythmias slow heart rate <NUMBER> bpm female <NUMBER> especially hypokalemia combination qtcprolonging drugs macrolides <NUMBER> <NUMBER> besides effect ikr current hydroxychloroquine may reduce heart rate inhibiting ifcurrent phase <NUMBER> action potential <NUMBER> among patients receiving hydroxychloroquine covid<NUMBER> <NUMBER> discontinue due ecg modifications <NUMBER> largest randomized trial adverse events observed <NUMBER> patients received hydroxychlorquine vs <NUMBER> patients <NUMBER> qtc <NUMBER> ms observed <NUMBER> <NUMBER> patients receiving combination hydroxychloroquine azithromycin <NUMBER> <NUMBER> proportion reached <NUMBER> highest dose hydroxychloroquine <NUMBER> mgday <NUMBER> days doubleblinded randomized trial comparing two dose regimens combination azithromycin <NUMBER> among <NUMBER> patients severe infection admitted intensive care units received either hydroxychloroquine hydroxychloroquine azithromycin increase qtc <NUMBER> <NUMBER> patients <NUMBER> drug administration qtc prolongation defined δqtc <NUMBER> ms qtc ≥<NUMBER> ms observed <NUMBER> patients <NUMBER> <NUMBER> risk significantly lower yet significant hydroxychloroquine used alone <NUMBER> <NUMBER> consistent observational data collected patients rheumatoid arthritis combination hydroxychloroquine azithromycin associated increased risk <NUMBER>day cardiac mortality hydroxychloroquine alone <NUMBER> details cardiac effects hydroxychloroquine drugs used covid<NUMBER> reviewed recently <NUMBER> light known cardiac adrs hydroxychloroquine pandemic results suggest increased cardiac risk patients covid<NUMBER> could explained frequent hypokalemia patients possibly due particular tropism sarscov<NUMBER> towards ace<NUMBER> angiotensinconverting enzyme <NUMBER> also diarrhea vomiting associated infection therefore essential monitor potassium level correct hypokalemia administering hydroxychloroquine cause diarrhea similarly combination azithromycin hydroxychloroquine justifies reinforced monitoring ecg possible start treatment within <NUMBER> h first administration twice week duration treatment event symptoms suggestive heart rhythm disorder another doselimiting adr hydroxychloroquine risk retinopathy could affect <NUMBER> treated patients especially dose high <NUMBER> mgkg treatment prolonged <NUMBER> years <NUMBER> finally since hydroxychloroquine metabolized several isoforms cytochrome p<NUMBER> cyp particular <NUMBER>a<NUMBER> <NUMBER>d<NUMBER> <NUMBER>c<NUMBER> increased risk adrs drugs inhibit cyp context covid<NUMBER> special care must taken antiinfectives combination lopinavirritonavir latter powerful inhibitor cyp<NUMBER>a addition clinical surveillance mentioned hydroxychloroquine use justifies therapeutic drug monitoring tdm also recommended context autoimmune diseases <NUMBER> framework prescription management sarscov<NUMBER> infection high variability concentrations tested expected view populations treated elderly resuscitation dialysis patients <NUMBER> possibilities therapeutic ineffectiveness adrs addition given proposed short duration treatment state equilibrium unlikely reached increases pharmacokinetic variability pharmacology group ac<NUMBER> national agency research aids viral hepatitis therapeutic drug monitoring group french society pharmacology therapeutics proposed end march <NUMBER> tdm evaluation performed <NUMBER> hours start treatment check early attainment adequate residual concentration based data currently available minimum threshold reached estimated <NUMBER> µgml plasma assay <NUMBER> µgml whole blood assay tdm assays could proposed throughout course treatment ensure threshold concentration considered toxic <NUMBER> µgml plasma <NUMBER> µgml whole blood exceeded recommendations therapeutic drug monitoring lopinavirr hydroxychloroquine patients treated sarscov<NUMBER> covid<NUMBER> infection available website <NUMBER> available efficacy safety results mentioned high risk bias leaves degree uncertainty regarding relevance hydroxychloroquine use covid<NUMBER> addition pandemic emergency justified early publication results preprints since reports peerreviewed cannot considered validated information thus guide clinical practice <NUMBER> parallel recorded growing request reliable information efficacy safety hydroxychloroquine population <NUMBER> march <NUMBER> <NUMBER> context public pressure french high council public health hcsp recommended use hydroxychloroquine except severe hospitalized cases collegial decision physicians strict medical supervision hcsp insists prescription hydroxychloroquine general population nonsevere forms excluded advice followed days later decree restricting use hydroxychloroquine covid<NUMBER> health facilities nonetheless majority french population favored large use hydroxychloroquine sometimes encouraged healthcare professionals likely impacted rigorous clinical research penalizing recruitment randomized controlled trials indeed taking hydroxychloroquine drug antiviral properties days weeks preceding randomization usually criterion noninclusion trials addition patients refused participate randomized trials fearing receive placebo instead hydroxychloroquine would perceived given best possible treatment <NUMBER> interestingly alternative designs proposed openlabel randomized trials nested cohort randomization derived zelens method <NUMBER> although approach prevents abovementioned issue raises several concerns <NUMBER> able quickly conclude efficacy treatments extremely detrimental terms public health context epidemic indeed difficult correctly carry complete randomized controlled trials example therapeutic trial type conducted ebola virus epidemic <NUMBER> west africa could completed leaving unanswered question potential efficacy humanized monoclonal antibodies zmapp ® <NUMBER> chloroquine hydroxychloroquine shown activity sarscov<NUMBER> coronavirus vitro possibly superior effect hydroxychloroquine currently center attention however midmay <NUMBER> available clinical data support efficacy drugs patients covid<NUMBER> good quality randomized controlled trials still underway essential able include patients trials rapidly order reliable data whether drugs truly effective covid<NUMBER> yet chloroquine hype fueled lowquality studies media announcements yielded implementation hundred studies risk wasting resources delaying rigorous trials pending results lack evidence possible benefit must weighed known adrs hydroxychloroquine may magnified covid<NUMBER> patients although relatively safe therapeutic dose short period time drug narrow therapeutic index requires regular cardiac therapeutic drug monitoring serious adverse reactions hydroxychloroquine already reported patients covid<NUMBER> especially combined azithromycin authors competing interest declare efficacy hydroxychloroquine postexposure prophylaxis pep prevent severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> infection among adults exposed coronavirus disease covid<NUMBER> blinded randomized study hydroxychloroquine covid<NUMBER> pep postexposure prophylaxis pep defined taking antimicrobial medication exposed potentially exposed infectious agent prevent becoming infected pep routinely used prevention variety viral bacterial parasitic infections including influenza human immunodeficiency virus based experience pep infections therapy started soon possible recent possible exposure hydroxychloroquine hcq currently approved suppressive treatment treatment acute attacks malaria due several plasmodium strains also indicated treatment discoid systemic lupus erythematosus rheumatoid arthritis first food drug administration approval <NUMBER> safety tolerability hcq well described vitro hcq displays antiviral activity coronaviruses including severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> pharmacologic modeling based observed drug concentrations vitro drug testing suggest prophylaxis approved doses could prevent sarscov<NUMBER> infection andor ameliorate viral shedding clinical trials hcq treatment coronavirus disease covid <NUMBER> pneumonia underway china separate protocols • test efficacy hcq <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily additional <NUMBER> days complete <NUMBER> days prevent incident sarscov<NUMBER> infection compared ascorbic acid among contacts persons sarscov<NUMBER> infection randomized multicenter placeboequivalent ascorbic acid controlled blinded study hcq pep prevention sarscov<NUMBER> infection adults exposed virus study enroll <NUMBER> asymptomatic men women <NUMBER> <NUMBER> years age inclusive baseline close contacts persons polymerase chain reaction pcrconfirmed sarscov<NUMBER> clinically suspected covid<NUMBER> pending sarscov<NUMBER> pcr test eligible participants enrolled randomized <NUMBER> hcq ascorbic acid level household eligible participants <NUMBER> household receive intervention participants counseled preliminary vitro data hcq activity sarscov<NUMBER> equipoise regarding efficacy humans participants may participate substudy asked provide dried blood spot sample therapy concentration pharmacokinetics pk hcq well sarscov<NUMBER> antibody testing possible index cases invited participate index case substudy independent data safety monitoring board dsmb convened study expertise covid<NUMBER> respiratory viruses pep emerging epidemics dsmb include biostatistician purpose dsmb monitor study operational futility social harms efficacy additional data emerge alternative effective agents sarscov<NUMBER> prophylaxis andor data hcq pep protocol could modified amendment evaluate alternative therapy pep alternatively platform study could modified adaptive design test efficacy new potential agents covid<NUMBER> pep <NUMBER> eligible participants randomly assigned level household <NUMBER> study treatment hcq ascorbic acid <NUMBER> index cases enrolled protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> duration study participation approximately <NUMBER> days households randomized <NUMBER> level household close contact participants receiving one following therapies • hcq <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily additional <NUMBER> days • ascorbic acid <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily <NUMBER> days <NUMBER> days treatment completed participants asked participate study additional <NUMBER> ±<NUMBER> days eligible index cases asked provide midnasal swab baseline determine viral load complete questionnaire baseline day <NUMBER> report clinical course note denotes either <NUMBER> mg dose hcq <NUMBER> mg dose ascorbic acid depending group assignment denotes either <NUMBER> mg dose hcq <NUMBER> mg dose ascorbic acid depending group assignment screening day <NUMBER> evaluations conducted webbased screening tool hipaacompliant video conference telehealth telephone text messaging screening day <NUMBER> evaluations may occur day b evaluations conducted telephone text messaging telehealth c index case substudy participants randomized multicenter placeboequivalent ascorbic acid controlled blinded study efficacy hydroxychloroquine hcq postexposure prophylaxis pep prevention severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> infection adults exposed virus evaluations include safety tolerability sarscov<NUMBER> viral shedding coronavirus disease covid<NUMBER> diagnosis two study groups one active one receiving ascorbic acid vitamin c serve placeboequivalent comparator enrolled assess daily dosing regimen administered <NUMBER> days appears approximate incubation period sarscov<NUMBER> infection <NUMBER> eligible participants <NUMBER> <NUMBER> years age randomized level household <NUMBER> receive one following therapies • hcq <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily additional <NUMBER> days • ascorbic acid <NUMBER> orally daily <NUMBER> days <NUMBER> mg orally daily <NUMBER> days hcq ascorbic acid appear similar taste partially masked hcq bitter ascorbic acid sour study participants perform following • collect midnasal swabs viral detection primary trial endpoint • complete surveys include questions symptoms drug regimen virus infection review concomitant medications pertinent topics note participants report respiratory febrile illness referred assessment primary care provider first <NUMBER> study days participants take medication complete surveys collect midnasal swab assess symptoms virus exposure day <NUMBER> final swab collected survey completed duration study participation approximately <NUMBER> days <NUMBER> eligible index cases covid<NUMBER> pep study invited participate asked provide baseline midnasal swab sarscov<NUMBER> testing complete questionnaire baseline day <NUMBER> report clinical course illness sarscov<NUMBER> coronavirus novel human population discovered december <NUMBER> currently cause global pandemic <NUMBER> <NUMBER> <NUMBER> world health organization named novel coronavirus sarscov<NUMBER> disease caused sarscov<NUMBER> covid<NUMBER> <NUMBER> march <NUMBER> persontoperson transmission occurred china across temperate asia europe north america sporadic cases africa southern hemisphere accurate reporting limited availability diagnostic testing declared covid<NUMBER> pandemic public health emergency international concern <NUMBER> january <NUMBER> <NUMBER> united states declared national emergency <NUMBER> march <NUMBER> <NUMBER> protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> deaths severe pneumonitis occurred elderly persons underlying pulmonary cardiac comorbidities diabetes healthy adults including pregnant women cause febrile selflimited pneumonia infection appears less symptomatic children younger adults <NUMBER> nevertheless burden pandemic global health economic systems expected substantial acquired immunity novel viral infection appears exist human population globally effective treatment preventative agent licensed time many infectious epidemics household contacts first responders caregivers medical personnel attending persons covid<NUMBER> high risk infection incubation time requires <NUMBER> days quarantine exposed individuals wearing personal protective equipment <NUMBER> <NUMBER> march <NUMBER> declared global shortage personal protective equipment leaving doctors nurses frontline workers dangerously illequipped care covid<NUMBER> patients <NUMBER> extensive absences care network health system degrade ability care covid<NUMBER> also routine healthcare issues well pep defined taking antimicrobial medication potential exposure infectious agent prevent becoming infected pep started soon possible recent possible exposure infectious agent <NUMBER> time known effective prophylaxis covid<NUMBER> thus equipoise testing nonactive comparator eg ascorbic acid potentially active drug sarscov<NUMBER> novel betacoronavirus zoonotic origin similar coronaviruses severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus mers based current evidence case fatality rate sarscov<NUMBER> <NUMBER> significantly lower sarscov <NUMBER> merscov <NUMBER> <NUMBER> however sarscov<NUMBER> potentially higher transmissibility r<NUMBER> <NUMBER> sarscov r<NUMBER> <NUMBER> merscov r<NUMBER> <NUMBER> <NUMBER> understanding viral pathogenesis sarscov<NUMBER> remains limited however appears virus cell entry depends binding viral spike proteins cellular receptors protein priming host cell proteases sarscov<NUMBER> like sarscov uses receptor angiotensin converting enzyme <NUMBER> ace<NUMBER> pulmonary epithelial cells entry transmembrane serine protease <NUMBER> protein priming <NUMBER> receptor binding domain lineage b betacoronaviruses single continuous domain contains structural information necessary interact host receptor fusion mediated cell membrane delivering viral nucleocapsid inside cell subsequent replication ace<NUMBER> expression found lung epithelial cells vascular endothelium renal tubular epithelium epithelia small intestine viral shedding localized primarily respiratory droplets fecal samples <NUMBER> medications treat andor prevent sarscov<NUMBER> need inhibit aspects viral life cycle ultimately blocking replication alreadyapproved available medications ideal confidential protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> immediate evaluation sarscov<NUMBER> infection treatment prevention two potential targets antisarscov<NUMBER> medications viral polymerases proteases <NUMBER> pilot clinical studies already ongoing sarscov<NUMBER> using various repurposed antiviral medicines httpswwwwhointemergenciesdiseasesnovelcoronavirus<NUMBER>globalresearchonnovelcoronavirus<NUMBER>ncov similarities sarscov<NUMBER> sarscov mers suggest antivirals vitro efficacy sarscov mers may promising agents sarscov<NUMBER> pep <NUMBER> <NUMBER> chloroquine cq discovered <NUMBER> bayer used <NUMBER> antimalarial become one prescribed drugs globally prior emergence widespread drug resistance plasmodium falciparum <NUMBER> cq found effective rheumatoid tenosynovitis <NUMBER> <NUMBER> hcq licensed united states <NUMBER> antimalarial drug rheumatoid arthritis widely marketed latter due favorable safety profile chronic use <NUMBER> mechanisms action hcq treatment rheumatoid arthritis autoimmune diseases still fully understood despite widespread use past <NUMBER> years <NUMBER> cq hcq proposed potential agents treatment prevention infectious agents beyond malaria <NUMBER> <NUMBER> mechanism action differs according pathogen intracellular bacteria fungi alkalinizing vacuoles containing microorganisms restoring activity antibiotics viral replication alkalization acidic organelles namely endosomes lysosomes golgi vesicles cq effective vitro sarscov coronavirus vero e<NUMBER> cells ec<NUMBER> <NUMBER> µm <NUMBER> shown evidence prevention activity vivo <NUMBER> hence repurposed drugs obvious hits testing sarscov<NUMBER> vitro inhibition vero e<NUMBER> cells novel coronavirus sarscov<NUMBER> published recent weeks wang et al <NUMBER> showed ec<NUMBER> ec<NUMBER> cq vero e<NUMBER> cells <NUMBER> µm <NUMBER> µm respectively <NUMBER> yao et al <NUMBER> showed ec<NUMBER> cq treatment infected cells <NUMBER> hours <NUMBER> µm whereas hcq appeared slightly potent ec<NUMBER> <NUMBER> µm <NUMBER> hours <NUMBER> levels appear within range exposures could achieved standard hcq treatment likely prophylaxis due concentrations drug achieved lung tissue <NUMBER> vitro data lung epithelial cells available animal model data multiple observational small investigatorinitiated covid<NUMBER> pneumonia treatment trials using cq hcq variety medications ongoing china httpswwwwhointemergenciesdiseasesnovelcoronavirus<NUMBER>globalresearchonnovelcoronavirus<NUMBER>ncov gao et al reported anecdotal efficacy cq treatment covid<NUMBER>associated pneumonia <NUMBER> trial test daily regimen hcq <NUMBER> days exposure sarscov<NUMBER> package insert appendix <NUMBER> daily dosing highest likelihood achieve sustained required drug levels viral inhibition shown physiologically based pk pbpk modeling appendix <NUMBER> hcq commonly used daily doses <NUMBER> mg hcq sulfate <NUMBER> mg base per day rheumatoid arthritis systemic lupus erythematosus initially usual maintenance dose <NUMBER> mg <NUMBER> mg base maintenance therapy hcq cq commonly used weekly dosing schedule malaria chemoprophylaxis hcq associated better safety profile daily chronic use cq including <NUMBER> decades experience use dose ranges adults elderly essential medicines list use rheumatic disorders widely prescribed antiinflammatory rheumatoid arthritis systemic lupus erythematosus autoimmune syndromes based limited vitro data available hcq appears slightly potent cq sarscov<NUMBER> <NUMBER> covid<NUMBER> epidemic remains fluid new data emerging observational clinical trials daily protocol written allow adaptation incorporate additional medications beyond hcq tested pep hqc longacting drug terminal halflife approximately <NUMBER> days well absorbed moderately protein bound accumulate tissues including lung heart liver kidneys typically given loading dose approximately <NUMBER>fold standard dose accelerate achieving steady state drug concentrations <NUMBER> since drug used recent highrisk exposure sarscov<NUMBER> desirable achieve adequate drug levels quickly pbpk model built simcyp simulator v<NUMBER> using physical chemical parameters hcq obtained literature <NUMBER> pk parameters liver intrinsic clearance fa ka determined clinical data <NUMBER> pbpk model used simulate hcq concentrations plasma lung fluid following <NUMBER> proposed dosing regimens order select optimal regimen peking university third hospitals ongoing trial hcq china combination vitro antiviral concentrationeffect predicted drug concentrations study used propose loading dose <NUMBER> mg hcq twice day day <NUMBER> followed hcq <NUMBER> mg twice day day <NUMBER> day <NUMBER> second study bysydctccppohcqpbpkar undertaken simulate hcq concentrationtime profiles plasma whole blood lung chinese healthy populations since elderly patients reduced glomerular filtration rate gfr simulations conducted using healthy caucasian healthy population renal injury gfr <NUMBER> <NUMBER> mlmin compared population normal renal function support study design prophylactic use hcq analysis <NUMBER> dosing regimens simulated modeling suggests loading dose <NUMBER> mg <NUMBER> days followed <NUMBER> mg daily <NUMBER> weeks result shorter time pk steadystate appendix <NUMBER> <NUMBER>week treatment duration represents coverage duration viral incubation time protocol investigate single dosage hcq participants receive loading dose <NUMBER> mg <NUMBER> days followed <NUMBER> mg daily <NUMBER> days subsequent investigations encouraged undertake rigorous exposureresponse assessment define optimal dosing including exploration lowest possible effective dose possible alternate dosing schedules ie weekly instead daily healthy adults covid<NUMBER> infection likely express febrile disease cough fatigue variability symptomatology include oligosymptomatic infection possibility <NUMBER> study participants already exposed sarscov<NUMBER> likely quarantine result randomization unlikely affect future risk behavior respect sarscov<NUMBER> symptom reporting may vary based participants perception whether taking hcq ascorbic acid <NUMBER> primary study endpoints infection viral shedding affected therefore use control acceptable ethical participants health safety well ensuring rigorous trial design evaluate pep sarscov<NUMBER> participants blinded allocation extent possible comparator ascorbic acid used provide similar taste hcq specifically tablets labeled either hcq ascorbic acid ascorbic acid tablet comparable size shape hcq used participants household assigned regimen comparisons cannot made medications minimize crossover drug sharing household members dose ascorbic acid <NUMBER> mg <NUMBER> days <NUMBER> mg daily <NUMBER> days safe participants regardless assigned group able take additional ascorbic acid eg counter vitamins food choose known maximum daily safe dose ascorbic acid clinical trial evidence demonstrated ascorbic acid alone combination micronutrients substantially reduce risk upper respiratory infections severe consequences infectious processes <NUMBER> <NUMBER> thus ascorbic acid expected prevention effect sarscov<NUMBER> considered placeboequivalent product study <NUMBER> quantity virus shed individual frequently predicts transmissibility thus may relate likelihood sarscov<NUMBER> transmission index cases enrolled nasal swab collected sarscov<NUMBER> testing ascertain whether index case shedding virus level viral shedding genotype virus shed investigated subset participants evaluation paired samples index case contact provide evidence whether level shedding associated sarscov<NUMBER> transmission whether subsequent infections among contacts acquired within households genetic markers may plausibly associated sarscov<NUMBER> acquisition recent studies indicate ace<NUMBER> could host receptor sarscov<NUMBER> number ace<NUMBER> variants could reduce association ace<NUMBER> sarscov<NUMBER> therefore expression human ace<NUMBER> might important susceptibility symptoms outcome sarscov<NUMBER> infection <NUMBER> association plausible genetic markers sarscov<NUMBER> infection disease assessed study unpredictable severity <NUMBER> mortality rate observed among clinical pneumonia cases elderly <NUMBER> years medical comorbidities highest risk poor outcomes <NUMBER> <NUMBER> <NUMBER> moreover transmission younger persons amplifies infection communities putting susceptible persons risk proven preventive drug transmission avoidance barrier droplet precautions likely exposed quarantine <NUMBER> days beyond viral incubation period currently recommended hcq excellent safety record proposed doses <NUMBER> years potent viral suppression vitro equipoise whether vitro efficacy hcq drug translate preventive efficacy disease even reduction viral shedding thus potential benefittorisk ratio testing hcq pep favorable population overarching goal study assess effectiveness hcq pep incidence sarscov<NUMBER> detection polymerase chain reaction pcr inform public health control strategies randomized multicenter placeboequivalent ascorbic acid controlled blinded study efficacy hcq pep prevention sarscov<NUMBER> infection adults exposed virus study enroll <NUMBER> asymptomatic men women <NUMBER> <NUMBER> years age inclusive baseline close contacts persons pcrconfirmed sarscov<NUMBER> clinically suspected covid<NUMBER> pending sarscov<NUMBER> pcr test eligible participants enrolled randomized <NUMBER> hcq ascorbic acid level household eligible participants <NUMBER> household receive intervention participants counseled preliminary vitro data hcq activity sarscov<NUMBER> equipoise regarding efficacy humans index cases invited participate substudy asked provide midnasal swab baseline complete questionnaires baseline day <NUMBER> assess extent sarscov<NUMBER> transmission occurs within household contacts whether dependent quantity virus shed independent data safety monitoring board dsmb convened study expertise covid<NUMBER> respiratory viruses pep emerging epidemics dsmb include biostatistician purpose dsmb monitor study operational futility social harms efficacy multicenter study conducted high covid<NUMBER> incidence areas united states time writing document sites expected western washington snohomish king pierce counties new york ny <NUMBER> march <NUMBER> <NUMBER> cases <NUMBER> deaths king county seattle <NUMBER> march <NUMBER> <NUMBER> cases new york city setting urban areas seattle population <NUMBER> million new york <NUMBER> million additional data emerge alternative effective agents sarscov<NUMBER> prophylaxis andor data hcq pep protocol could modified amendment alter sample size evaluate alternative therapy pep alternatively platform study could modified adaptive design test efficacy new potential agents covid<NUMBER> pep <NUMBER> participants randomly assigned study treatment <NUMBER> index cases enrolled participant considered completed study heshe completed phases study including last scheduled procedure shown schedule activities soa study considered completed sufficient number participants complete study enable appropriate evaluation primary endpoint prospective approval protocol deviations recruitment enrollment criteria also known protocol waivers exemptions permitted <NUMBER> participants eligible included study following criteria apply <NUMBER> men women <NUMBER> <NUMBER> years age inclusive time signing informed consent <NUMBER> willing able provide informed consent <NUMBER> close contact person index known pcrconfirmed sarscov<NUMBER> infection index currently assessed covid<NUMBER> close contact defined household contact ie residing index case <NUMBER> days prior index diagnosis prolonged exposure within residencevehicleenclosed space without maintaining social distance b medical staff first responders care persons cared index case without personal protection mask gloves <NUMBER> less <NUMBER> days since last exposure close contact person sarscov<NUMBER> infection index case <NUMBER> access device internet telehealth visits <NUMBER> planning take hcq addition study medication participants excluded study following criteria apply screen failures defined participants consent participate clinical study subsequently randomly assigned study treatment minimal set screen failure information required ensure transparent reporting screen failure participants meet consolidated standards reporting trials publishing requirements respond queries regulatory authorities minimal information includes demography screen failure details eligibility criteria serious adverse event sae individuals meet criteria participation study screen failure rescreened change eligibility site establish local recruitment screening methods operationalize protocolspecified requirements eligibility determination manner tailored efficient local study setting target study population site use variety recruitment approaches including direct recruitment clinics referrals providers sarscov<NUMBER> testing sites laboratories use online social networking websites apps recruitment materials educate participants covid<NUMBER> transmission within households epidemiology community vitro data hcq limiting sarscov<NUMBER> cell entry initially study enroll <NUMBER> clinical sites western washington new york established track records high quality clinical research integrated clinical care settings annual retention rates clinical trials conducted sites exceed <NUMBER> <NUMBER> sites large covid<NUMBER> epidemics regulation limiting contact reduce infectious spread close contact participants may coenrolled research studies provided observational studies exception requires approval coprincipal confidential protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> investigators study team consulted coenrollment studies meet guidance questions eligibility coenrollment coenrolled study combined blood draws exceed current red cross phlebotomy guidance index case participants may enroll point another study study treatment defined investigational treatments marketed products placebo medical devices intended administered study participant according study protocol hydroxychloroquine sulfate ascorbic acid take <NUMBER> tablets first <NUMBER> days <NUMBER> tablet subsequent <NUMBER> days total <NUMBER> days treatment take approximately time day meal glass milk dose missed taken soon possible less <NUMBER> hours next dose dose skipped medication home delivery dispensed unmarked container study label container labeled unique identifier container packed standard box used mail delivery medications needed determined determined risks associated pep reflect adverse events aes related hcq administration tens millions doses administrated malaria autoimmune diseases side effect profile hcq well described drug generally well tolerated shortterm administration opposed chronicyearlong use rheumatologic disease management major aes gastrointestinal nausea vomiting dyspepsia abdominal cramps diarrhea transient skin rashes gastrointestinal symptoms may vary specific generic manufacturer hcq <NUMBER> best managed taking drug food glass milk appendix <NUMBER> transient rash commonly morbilliform psoriasiform develop <NUMBER> participants often sustained loading dose often managed lowering dose avoid potential side effect protocol using short loading dose sustained one uncommonly idiosyncratic leukopeniathrombocytopenia occur drug confidential protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> given underlying bone marrow disorders lastly hypoglycemia occur taking insulin glucoselowering drugs risk blood glucose monitored minor blurry vision may occur acute hcq use reversible doserelated generally severe may also associated mild headaches caused deposition hcq cornea ocular muscle weakness predictor longterm toxicity participants experiencing minor blurry vision may adjust counselling reassurance reversible progressive severe rashes including drugrelated eosinophilia systemic symptoms stevensjohnson syndrome occur rarely longterm manifestations hcq including retinitis renal hepatic disease cardiomyopathy appendix <NUMBER> likely <NUMBER>week pep exposure enrollment protocol impact public health departments advice selfquarantine said quarantine known stressful especially healthcare workers enrollment may improve morale public health quarantine since clinical equipoise regarding hcq efficacy viral shedding participants counseled follow recommendations selfquarantine recommended dose hcq chronic use lupus erythematosus <NUMBER> mg <NUMBER> mg dailya dose safely taken years including among elderly patients ≥<NUMBER> years selection <NUMBER> mg <NUMBER> days <NUMBER> mg daily <NUMBER> days likely safe transient aes gastrointestinal symptoms rashes selfremitting limit transmission sarscov<NUMBER> participants receive visits via secure telehealth order limit movement persons potential sarscov<NUMBER> leave clinical space free patients seeking care also limit exposure waiting rooms pharmacies clinical specimens selfcollected medications delivered homes study therapy dose missed taken soon possible less <NUMBER> hours next dose dose skipped modification toxicities discussed toxicities related study medications provided study considered toxicity management section participants rescomdocsdefaultsourcesafetydivisionofaidsdaidstableforgradingtheseverityofadultandpediatricadverseeventscorrectedv<NUMBER>pdf considered related study medication may continue study treatment discretion site investigator close followup participant chooses discontinue study treatment site notify study protocol team within <NUMBER> days participants remain study study treatment evaluations performed • participants develop grade <NUMBER> symptomatic toxicity thought site investigator related study drug hcq pep withheld site consult core protocol team participant reevaluated every <NUMBER> days ae returns grade ≤<NUMBER> time study drug may reintroduced discretion site investigator consultation protocol team • participants experiencing grade <NUMBER> toxicity requiring permanent discontinuation study medication followed weekly resolution toxicity participants premature study treatment discontinuation evaluations performed participants remain study study treatment evaluations performed per soa • participants develop grade <NUMBER> symptomatic toxicity study medication permanently discontinued site notify study team within <NUMBER> hours • participants experiencing grade <NUMBER> toxicity requiring permanent discontinuation hcq pep followed weekly resolution ae return baseline participants remain study study treatment evaluations performed per soa gastrointestinal disturbance gastrointestinal disturbance nausea vomiting diarrhea common known possible side effect hcq dividing doses <NUMBER> hours taking food milk may improve tolerability hcq discontinued permanently serious allergic reaction suspected participants remain study study treatment evaluations performed per standard operating procedures participants randomized <NUMBER> ratio hcq ascorbic acid level household eligible participants <NUMBER> household receive intervention randomization plan written study statistician randomization code resulting allocation list generated maintained study statistician list blocked stratified site contact type household versus healthcare worker blinded study eligible participants receive one following therapies • hcq <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily additional <NUMBER> days • ascorbic acid <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily <NUMBER> days hcq ascorbic acid appear similar taste partially masked hcq bitter ascorbic acid sour participants blinded randomization group assigned within <NUMBER> <NUMBER> hours enrollment unblinded study pharmacist use randomization code revealed point randomization provide participant group assignment dispense allocated study medication bottle marked study label medication medication information midnasal swabs sufficient complete study procedures dbs sampling kit within substudy study instructions delivered participant drugs stored room temperature per package insert records must maintained document receipt release dosing disposal return sponsor participant contacted ensure received box study supplies able collect first midnasal swab store appropriately took first day medication participants asked complete survey includes information regarding treatment administration substudy hcq concentration via dbs also evaluated consultation via telehealth text messaging telephone available provide support participant complete study procedures participants asked concomitant medications screeningbaseline evaluation visit study participants asked complete surveys daily survey exit contact survey include information regarding medication vaccine including overthecounter prescription medicines vitamins andor herbal supplements participant receives study contact investigator designee question participant medication taken prohibited medications include digoxin cyclosporin cimetidine amiodarone tamoxifen antimalarial medications including chloroquine artemether lumefantrine mefloquine use medications classified precautionary study prohibitory discussed study clinician participant medications include androgens antidiabetic agents phenothiazines betablockers cardiac glycosides citalopram dapsone escitalopram haloperidol herbs maitake monoamine oxidase inhibitors pegvisomant prothionamide quinolones salicylates selective serotonin reuptake inhibitors additional treatment provided end study study treatment discontinued following reasons • requirement prohibited concomitant medications contraindication hcq • occurrence ae requiring discontinuation study medication • request participant terminate study treatment • clinical reasons believed lifethreatening physician even addressed section <NUMBER> participants stop study treatment continue study participation study medication continued evaluations per soa reason study medication discontinuation recorded participants identified sarscov<NUMBER> positive pcr baseline continue study therapy study participation participants clinical diagnosis covid<NUMBER> continue study therapy unless started covid<NUMBER> treatment outside study • participant may withdraw study time hisher request may withdrawn time following reasons request primary care provider heshe thinks study longer best interest participant participant judged investigator significant risk failing comply provisions protocol cause harm self seriously interfere validity study results discretion institutional review boardethics committee government agencies part duties investigator industry supporter • participant withdraws consent disclosure future information sponsor may retain continue use data collected withdrawal consent • participant withdraws study heshe may request destruction samples taken tested investigator must document site study records • see soa data collected time study discontinuation followup evaluations need completed participant considered lost followup heshe unable contacted study site following actions must taken participant fails comply required study procedures • site must attempt contact participant soon possible counsel participant importance maintaining assigned procedure schedule ascertain whether participant wishes andor continue study • participant deemed lost followup investigator designee must make every effort regain contact participant possible <NUMBER> telephone calls necessary certified letter participants last known mailing address local equivalent methods contact attempts documented participants medical record • participant continue unreachable heshe considered withdrawn study primary reason lost followup current covid<NUMBER> pandemic placed significant burden healthcare system study specimen data collection conducted minimize impact nonill participants within healthcare system participant assessed eligible contact study participants study personnel occur via health insurance portability accountability act hipaacompliant video conference telehealth although inperson visits either participants home research center permitted protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> participants instructed seek clinical care manifest signs symptoms covid<NUMBER> <NUMBER> participants assessed study eligibility screening conducted webbased screening tool hipaacompliant video conference telehealth telephone text messaging day <NUMBER> evaluations follows • informed consent • collection demographic information • collection past current medical conditions including known pregnancy andor lactation status • collection concomitant medication information • collection information regarding exposure index case • check inclusion exclusion criteria eligible participants randomized members household assigned arm participants receive swab kit either via courier mail includes quick start instruction card swabs plastic tubes swab collection return box affixed category b un<NUMBER> label required international air transport association iata guidelines <NUMBER> participant following day <NUMBER> • collect midnasal swab pcr • take study therapy hcq ascorbic acid assigned • complete daily survey online telehealth telephone text messaging survey include confirmation adherence study therapy dosing daily swab collection concomitant medication review symptoms review instructions skin puncture dbs sample preparation provided appendix <NUMBER> study team member available via telehealth telephone text messaging provide support completion study procedure screeningday <NUMBER> day <NUMBER> procedures may occur day index case sarscov<NUMBER> positive test results confirmed selfreport contact participant index case substudy shedding sarscov<NUMBER> assessed pcr midnasal swab section <NUMBER> protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> participant following every day day <NUMBER> day <NUMBER> inclusive • collect midnasal swab pcr • take study therapy hcq ascorbic acid assigned • complete daily survey online telephone text messaging survey include confirmation adherence study therapy dosing daily swab collection concomitant medication review symptoms review • dbs substudy collect dbs samples analysis hcq concentration time period <NUMBER> <NUMBER> times study drug dosing commenced <NUMBER> sample per day collected study team member available via telehealth text messaging telephone provide support completion study procedures courier collect swabs minimum within <NUMBER> <NUMBER> days day <NUMBER> day <NUMBER> potentially frequently daily participant following day <NUMBER> • collect midnasal swab pcr • take study therapy hcq ascorbic acid assigned • complete daily survey online telephone text messaging survey include confirmation adherence study therapy dosing daily swab collection concomitant medication review symptoms review study team member available via telehealth text messaging telephone provide support completion study procedures participants instructed place selfcollected nasal swabs directly plastic tube prelabeled unique barcode next participants instructed place plastic tube containing selfcollected nasal swab specimen bag prepackaged absorbent sheet place specimen bag provided return shipping box category b un<NUMBER> stickers affixed outside return box previous testing demonstrated respiratory viral ribonucleic acid rna stable room temperature <NUMBER> week courier collect swabs minimum within <NUMBER> <NUMBER> days day <NUMBER> exit contact conducted telehealth online telephone text messaging exit contact evaluations follows • collect midnasal swab pcr • review aes • complete exit contact survey online telehealth telephone text messaging survey include concomitant medication review symptoms review • exit contact survey include evaluation sarscov<NUMBER> infection andor covid<NUMBER> associated testing medical care clinical outcomes confirmed electronic health record possible final swab collected courier returned via postal service participants develop symptoms concerning covid<NUMBER> instructed contact provider clinical care testing study results available participants study completion tested realtime clinical diagnosis participants develop sarscov<NUMBER> infection may sent home pulse oximeter measure oxygen saturation provide direct information clinical assessment participants clinical diagnosis covid<NUMBER> continue study therapy unless started covid<NUMBER> treatment outside study study procedures continue early exit possible document covid<NUMBER> diagnosis participants assessed study eligibility screening conducted webbased screening tool telehealth telephone text messaging • informed consent • collection demographic information • check inclusion exclusion criteria eligible participants receive swab kit either via courier mail includes quick start instruction card swab plastic tube swab collection return container affixed category b un<NUMBER> label required international air transport association iata guidelines <NUMBER> • collect midnasal swab pcr • complete survey online telehealth telephone text messaging survey include assessment risk covid<NUMBER> acquisition engagement testing treatment symptom review protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> exit contact conducted telehealth online telephone text messaging exit contact evaluations follows • complete exit contact survey online telehealth telephone text messaging survey include assessment risk covid<NUMBER> acquisition engagement testing treatment symptom review clinical outcomes confirmed electronic health record possible participants reimbursed day <NUMBER> day <NUMBER> index cases enrolled index case substudy receive reimbursement day <NUMBER> reimbursement provided index cases referral close contacts reimbursement provided unscheduled telehealth visits requested participants support study procedures • study procedures timing summarized soa • protocol waivers exemptions allowed • immediate safety concerns discussed sponsor immediately upon occurrence awareness determine participant continue discontinue study treatment • adherence study design requirements including specified soa essential required study conduct • baseline evaluations must completed reviewed confirm potential participants meet eligibility criteria investigator maintain screening log record details participants screened confirm eligibility record reasons screening failure applicable • procedures conducted part participants routine clinical management obtained signing informed consent form may utilized screening baseline purposes provided procedures met protocolspecified criteria performed within time frame defined soa • blood samples collected part substudy maximum amount blood collected participant duration study including extra assessments may required exceed <NUMBER> ml participants collect daily midnasal swabs initial <NUMBER> days exit contact viral detection protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> participants receive swab kit either via courier mail includes quick start instruction card swabs plastic tubes swab collection return box affixed category b un<NUMBER> label required iata guidelines <NUMBER> participants collect store nasal swabs box return used swabs collected courier returned via postal service swabs subjected rna amplification tested sarscov<NUMBER> applicable participants asked complete surveys daily survey exit contact survey include questions symptoms drug regimen virus infection review concomitant medications pertinent topics include information symptoms may associated covid<NUMBER> ae information collected close contact participants information regarding aes index case participants see section <NUMBER> participants asked complete surveys daily survey exit contact survey include information symptoms experiencing addition ae review staff member via telephone telehealth text messaging performed aes must recorded electronic case report forms ecrfs following criteria met • aes meeting sae definition • aes judged participant clinician associated study medication sae defined untoward medical occurrence • results death • lifethreatening • requires inpatient hospitalization prolongation existing hospitalization • results persistent significant disabilityincapacity • important medical event may immediately lifethreatening result death hospitalization may jeopardize patient may require intervention prevent one outcomes listed definition aes recorded severity graded grade aes sites refer daids ae grading table corrected version <NUMBER> july <NUMBER> found daids regulatory support center website httpsrsctechrescomdocsdefaultsourcesafetydivisionofaidsdaidstableforgradingtheseverityofadultandpediatricadverseeventscorrectedv<NUMBER>pdf aes saes attribution recorded related related study medication judgment site investigator • medication exposure pregnancy reported sponsor within <NUMBER> weeks participants exit contact • misuse abuse medication outside protocol reported sponsor within <NUMBER> weeks participants exit contact overdose hcq managed according labeling information see appendix <NUMBER> ascorbic acid exhibits low toxicity risks overdose expected minimal overdose study medication reported sponsor within <NUMBER> hours aes among index case participants index case substudy collected reported index cases receiving study medication interventions safety assessed via participant surveys shown soa participants asked complete surveys daily survey exit contact survey include questions health healthcare seeking symptoms illness within household contact mobility qualifying events recorded ecrf reported aes described section <NUMBER> social harms assessed throughout study reported using social harms form reported sponsor within <NUMBER> hours <NUMBER> participants enrolled dbs substudy dbs requested required participants study sites wishing participate dbs substudy considered protocol deviation aim dbs substudy evaluate hcq drug concentrations adherence measure pk hcq serological assays sarscov<NUMBER> available dbs may tested sarscov<NUMBER> antibodies exposureresponse relationship hcq pep participants exposed sarscov<NUMBER> established population pk analyses used inform dose selection populations support concentrationresponse investigations efficacy safety outcomes genetic testing dried blood spot midnasal swab samples collected study could used potentially genetic studies consent process participants opt genetic testing used study genes related diseases sarscov<NUMBER> respiratory viruses genomewide screening snp screening planned transmission sarscov<NUMBER> respiratory droplet pathogens occur contact respiratory droplets contaminated surfaces precautions employed personnel handling specimens study currently recommended centers disease control prevention national institutes health dangerous goods materials including diagnostic specimens infectious substances must transported using packaging mandated code federal regulations <NUMBER> part <NUMBER> please refer instructions detailed iata dangerous goods regulations individuals exposed covid<NUMBER> become infected early estimates place family members <NUMBER> <NUMBER> risk infection likely exposure <NUMBER> <NUMBER> sample size required show <NUMBER> protective efficacy pep entirely dependent attack rate sample size calculations used estimated <NUMBER> attack rate sample size chosen group hcq ascorbic acid achieve <NUMBER> power <NUMBER> twosided type <NUMBER> error endpoint laboratorydetected incident sarscov<NUMBER> exclusion participants positive sarscov<NUMBER> baseline attack rate <NUMBER> <NUMBER> efficacy hcq reducing sarscov<NUMBER> incidence randomizing first household member enrolled subsequent household members intervention assumptions cohort <NUMBER> households <NUMBER> control <NUMBER> intervention cohort provide least <NUMBER> power detect decrease sarscov<NUMBER> incidence <NUMBER> <NUMBER> household size increases power increase household members randomized unit analyzed individuals table estimates power assuming households randomized either <NUMBER> households randomized <NUMBER> individuals randomized row shows distribution numbers individuals within household randomized individual risk assumed independent power may lower depending correlation risk within households table <NUMBER> power calculations indicate final power depend heavily population enrolled mitigate potential loss power lack information cluster size final target sample size estimated midway study based observed distribution number household contacts procedure redetermining sample size described interim monitoring plan approved dsmb analysis purposes following populations defined intention treat enrolled participants contacts modified intention treat mitt contacts sarscov<NUMBER> negative pcr baseline visit whose corresponding index case sarscov<NUMBER> positive report pcr pk evaluable participants dbs substudy least <NUMBER> interpretable pk sample dbs dried blood spot pk pharmacokinetic pcr polymerase chain reaction sarscov<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> note pcr negative household contacts included mitt analyses statistical analysis plan developed finalized database lock describe participant populations included analyses procedures accounting missing unused spurious data section summary planned statistical analyses primary secondary endpoints listed section <NUMBER> protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> demographic characteristics age sex race study group tabulated mean age plus range standard deviation sex enrolled participants whole per group calculated primary analysis performed using modified intentiontotreat population participant sarscov<NUMBER> positive laboratory test infection time censored last negative swab test date day <NUMBER> swab logistic model stratified site accounting withinhousehold correlation used assess efficacy hcq group compared control aid understanding results logistic model cumulative incidence kaplanmeier curves time infection presented site treatment arm subgroup analyses prespecified statistical analysis plan subgroups considered ad hoc due design study retention activities expect able categorize infections either incident prevalent baseline however unlikely event missing test result missing data imputed additional analyses described statistical analysis plan finalized database lock safety analyses performed intentiontotreat population aes social harms compared study group sparse pk dbs analyzed using standard population pk analysis methodologies using standard software nonmem® v<NUMBER> phoenix nlme v<NUMBER> pkevaluable participants posthoc individual concentration profiles exposure estimates determined exploratory exposureresponse analyses primary secondary efficacy safety endpoints exploratory pkpharmacodynamic analyses performed data allow index case substudy assess risk sarscov<NUMBER> transmission association semiquantitative pcr results also risk transmission close contacts assessed determining whether viruses genetic match among household members sarscov<NUMBER> sequencing protocol hydroxychloroquine covid<NUMBER> pep version <NUMBER> protocol published model protocol institutions consider undertake studying pep sarscov<NUMBER> infection hoped individual patient data similar studies pooled combined study analysis deidentified data present study made available purposes accordance funders open access policy httpswwwgatesfoundationorghowweworkgeneralinformationopenaccesspolicy study team monitor conduct study monthly summary reports arms accrual baseline characteristics quarterly reports data pooled treatment arms data completeness specimen collection adverse events aes study review individual participantlevel safety data frequently assess relation reported aes study treatment weekly basis study team review byarm summaries premature study discontinuations premature study treatment discontinuations reasons aes study conduct monitored independent monitor monitors visit participating clinical research sites review individual participant records including consent forms electronic case report forms supporting data laboratory specimen records endpoints laboratory medical records physicians progress notes nurses notes individuals hospital charts ensure protection study participants compliance protocol accuracy completeness records monitors also inspect sites regulatory files ensure regulatory requirements followed sites pharmacies review product storage management independent data safety monitoring board dsmb convened study expertise coronavirus disease respiratory viruses postexposure prophylaxis pep emerging epidemics biostatistician purpose dsmb monitor study operational futility social harms efficacy dsmb evaluate progress project including periodic assessments accrual retention safety performance variation project sites factors affect project implementation target number households index cases contacts enrolled study reassessed according distribution cluster householdinstitution sizes seen study dsmb review approve modifications overall enrollment target dsmb review study half twothirds followup time prespecified stopping rules efficacy futility terms efficacy hydroxychloroquine hcq pep reducing incidence sarscov<NUMBER> infection overall ability study meet objectives dsmb review severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> endpoints dsmb consider factors external project relevant information becomes available policy changes scientific developments may impact project implementation safety integration covid<NUMBER> pep communitybased disease prevention dsmb conduct interim reviews adequate data accrued convene teleconference open reports containing accrual retention rates participant characteristics serious adverse events sent protocol team dsmb members week prior dsmb meeting dsmb members unblinded biostatistician receive passwordprotected closed reports sarscov<NUMBER> endpoints randomization arm study conducted according good clinical practice belmont report declaration helsinki study protocol sitespecific informed consent forms icfs participant education recruitment materials requested documentsincluding subsequent modificationswill reviewed approved western institutional review board wirb single irb record responsible oversight research conducted study sites subsequent initial review approval wirb review study least annually principles informed consent current edition declaration helsinki implemented clinical study protocolspecified procedures interventions carried consent form describe purpose study procedures followed risks benefits participation copy consent form given participant fact documented participants record participant rescreened required sign another icf eligibility study must rechecked prior enrollment study site establish standard operating procedure confidentiality protection site ensure study records including administrative documentation regulatory documentation well documentation related participant enrolled study including icfs locator forms case report forms notations contacts participant source documents stored secure manner participants study information released without written permission except necessary oversight protocol coprincipal investigators designees study funders wirb new york university irb university washington irb laboratory specimens evaluation forms reports records leave site identified coded number maintain participant confidentiality exceptions sarscov<NUMBER> testing results subject local state reporting namesbased local public health may contact participants diagnosed sarscov<NUMBER> purpose surveillance contact notification participants informed prior sarscov<NUMBER> testing results reportable may lead contact local public health results positive infection records kept locked computer entry networking programs done coded numbers clinical information released without written permission participant except necessary monitoring irb office human research protections local united states international regulatory entities part duties industry supporters designees local sitespecific information <NUMBER> identify key study personnel include name title address point contact information <NUMBER> description key study personnel roles responsibilities <NUMBER> describe local recruiting procedures strategies provide copy sitespecific recruitment material identification personnel responsible completing tasks <NUMBER> describe local consenting process provide copy sitespecific consent forms ombudsman named study site provide name title point contact information <NUMBER> identify local study collaborations site pharmacy laboratories institutional departments <NUMBER> describe local specimensampling procedures place include acquisition disposition storage unique coding samples kept future use describe procedures security measures shortterm longterm management provide name repository <NUMBER> describe plan onsite management study records data participant study records explain procedures security measures place shortterm longterm management declare access data <NUMBER> describe local measures place promote privacy confidentiality <NUMBER> describe local procedures place provision care participant regarding researchrelated injuries <NUMBER> identify participant contact locally participant questions regarding research identify participant contact participant questions regarding rights study participant include points contact information name title telephone number <NUMBER> describe procedures place address health insurance portability accountability act requirements separate authorization form used following chronic oral administration hydroxychloroquine significant levels three metabolites desethylhydroxychloroquine dhcq desethylchloroquine dcq bidesethylhydroxychloroquine bdcq found plasma blood dhcq major metabolite absorption halflife approximately <NUMBER> <NUMBER> hours terminal halflife ranged <NUMBER> <NUMBER> days long halflife attributed extensive tissue uptake rather decreased excretion peak plasma levels hydroxychloroquine seen <NUMBER> <NUMBER> hours renal clearance rheumatoid arthritis ra patients taking hydroxychloroquine sulfate least six months seemed similar single dose studies volunteers suggesting change occurs chronic dosing range renal clearance unchanged drug approximately <NUMBER> <NUMBER> correlate creatinine clearance therefore dosage adjustment required patients renal impairment ra patients large variability fraction dose absorbed ie <NUMBER> <NUMBER> mean hydroxychloroquine levels significantly higher patients less disease activity cellular levels patients daily hydroxychloroquine shown higher mononuclear cells polymorphonuclear leucocytes precise mechanism hydroxychloroquine exhibits activity plasmodium known hydroxychloroquine like chloroquine weak base may exert effect concentrating acid vesicles parasite inhibiting polymerization heme also inhibit certain enzymes interaction dna chloroquine resistance occurs • hydroxychloroquine sulfate prevent relapses p vivax p ovale active hypnozoite forms parasites radical cure p vivax p ovale infections concomitant therapy <NUMBER>aminoquinoline compound necessary see clinical pharmacology microbiology prior prescribing hydroxychloroquine sulfate treatment prophylaxis malaria consult centers disease control prevention cdc malaria website httpwwwcdcgovmalaria hydroxychloroquine sulfate indicated treatment chronic discoid lupus erythematosus systemic lupus erythematosus adults hydroxychloroquine sulfate indicated treatment acute chronic rheumatoid arthritis adults use hydroxychloroquine sulfate contraindicated patients known hypersensitivity <NUMBER>aminoquinoline compounds hydroxychloroquine sulfate effective chloroquineresistant strains p falciparum see clinical pharmacology microbiology irreversible retinal damage observed patients received hydroxychloroquine sulfate significant risk factors retinal damage include daily doses hydroxychloroquine sulfate <NUMBER> mgkg <NUMBER> mgkg base actual body weight durations use <NUMBER> years subnormal glomerular filtration use concomitant drug products tamoxifen citrate concurrent macular disease baseline ocular examination recommended within first year starting hydroxychloroquine sulfate baseline exam include best corrected distance visual acuity bcva automated threshold visual field vf central <NUMBER> degrees retesting abnormality noted spectral domain ocular coherence tomography sdoct individuals significant risk factors daily dose hydroxychloroquine sulfate <NUMBER> mgkg base actual body weight subnormal glomerular filtration use tamoxifen citrate concurrent macular disease monitoring include annual examinations include bcva vf sdoct individuals without significant risk factors annual exams usually deferred five years treatment individuals asian descent retinal toxicity may first noticed outside macula patients asian descent recommended visual field testing performed central <NUMBER> degrees instead central <NUMBER> degrees recommended hydroxychloroquine discontinued ocular toxicity suspected patient closely observed given retinal changes visual disturbances may progress even cessation therapy use hydroxychloroquine sulfate patients psoriasis may precipitate severe attack psoriasis used patients porphyria condition may exacerbated preparation used conditions unless judgment physician benefit patient outweighs possible hazard skeletal muscle myopathy neuropathy leading progressive weakness atrophy proximal muscle groups depressed tendon reflexes abnormal nerve conduction reported muscle nerve biopsies associated curvilinear bodies muscle fiber atrophy vacuolar changes assess muscle strength deep tendon reflexes periodically patients longterm therapy hydroxychloroquine sulfate suicidal behavior rarely reported patients treated hydroxychloroquine sulfate hydroxychloroquine sulfate shown cause severe hypoglycemia including loss consciousness could life threatening patients treated without antidiabetic medications see drug interactions adverse reactions patients treated hydroxychloroquine sulfate warned risk hypoglycemia associated clinical signs symptoms patients presenting clinical symptoms suggestive hypoglycemia treatment hydroxychloroquine sulfate blood glucose checked treatment reviewed necessary us e caution patients gas trointes tinal neurological blood dis orders thos e ens itivity quinine antimalarial compounds used caution patients hepatic disease alcoholism conjunction known hepatotoxic drugs reduction dosage may necessary patients hepatic renal disease well taking medicines known affect organs antimalarial compounds used caution patients hepatic disease alcoholism conjunction known hepatotoxic drugs periodic blood cell counts performed patients given prolonged therapy severe blood disorder aplastic anemia agranulocytosis leukopenia thrombocytopenia appears attributable disease treatment consider discontinuation hydroxychloroquine sulfate hydroxychloroquine sulfate administered caution patients glucose<NUMBER>phosphate dehydrogenase g<NUMBER>pd deficiency dermatologic reactions hydroxychloroquine sulfate may occur therefore proper care exercised administered patient receiving drug significant tendency produce dermatitis concomitant hydroxychloroquine sulfate digoxin therapy may result increased serum digoxin levels serum digoxin levels closely monitored patients receiving combined therapy hydroxychloroquine sulfate may enhance effects hypoglycemic treatment decrease doses insulin antidiabetic drugs may required hydroxychloroquine sulfate prolongs qt interval administered drugs potential induce cardiac arrhythmias also may increased risk inducing ventricular arrhythmias hydroxychloroquine sulfate used concomitantly arrhythmogenic drugs hydroxychloroquine sulfate lower convulsive threshold coadministration hydroxychloroquine sulfate antimalarials known lower convulsion threshold eg mefloquine may increase risk convulsions activity antiepileptic drugs might impaired coadministered hydroxychloroquine sulfate combined use methotrexate hydroxychloroquine sulfate studied may increase incidence adverse effects increased plasma cyclosporin level reported cyclosporin hydroxychloroquine sulfate coadministered chloroquine reported reduce bioavailability praziquantel antacids kaolin reduce absorption chloroquine interval least <NUMBER> hours intake agents chloroquine observed cimetidine inhibit metabolism chloroquine increasing plasma level concomitant use cimetidine avoided study healthy volunteers chloroquine significantly reduced bioavailability ampicillin patients informed early signs symptoms toxicity rash visual changes patients must see physicians promptly case appearance unusual effects periodic laboratory tests may recommended patients patients fully informed potential risks use hydroxychloroquine sulfate especially pregnancy children longterm studies animals conducted evaluate carcinogenic potential hydroxychloroquine sulfate mutagenic potential hydroxychloroquine evaluated however chloroquine shown catalytic inhibitor dna repair enzymes topoisomerase ii produce weak genotoxic effects mode action human pregnancies resulting live births reported literature increase rate birth defects demonstrated embryonic deaths malformations anophthalmia microphthalmia offspring reported pregnant rats received large doses chloroquine caution exercised administering hydroxychloroquine sulfate nursing women demonstrated hydroxychloroquine administered nursing women excreted human milk known infants extremely sensitive toxic effects <NUMBER>aminoquinolines safety efficacy established chronic use hydroxychloroquine sulfate systemic lupus erythematosus juvenile idiopathic arthritis children children especially sensitive <NUMBER>aminoquinoline compounds reported fatalities followed accidental ingestion chloroquine sometimes small doses <NUMBER> g <NUMBER> g one <NUMBER>yearold child patients strongly warned keep drugs reach children see overdosage clinical studies hydroxychloroquine sulfate include sufficient numbers subjects aged <NUMBER> determine whether respond differently younger subjects however drug known substantially excreted kidney risk toxic reactions drug may greater patients impaired renal function elderly patients likely decreased renal function care taken dose selection may useful monitor renal function following adverse reactions identified postapproval use hydroxychloroquine sulfate <NUMBER>aminoqunoline compounds reactions reported voluntarily population uncertain size always possible reliably estimate frequency establish causal relationship drug exposure bone marrow failure anemia aplastic anemia agranulocytosis leukopenia thrombocytopenia hemolysis reported individuals glucose<NUMBER>phosphate dehydrogenase g<NUMBER>pd deficiency cardiomyopathy may result cardiac failure cases fatal outcome see warnings overdosage hydroxychloroquine sulfate prolongs qt interval ventricular arrhythmias torsades de pointes reported patients taking hydroxychloroquine sulfate see overdosage drug interactions vertigo tinnitus nystagmus nerve deafness deafness irreversible retinopathy retinal pigmentation changes bulls eye appearance visual field defects paracentral scotomas visual disturbances visual acuity maculopathies macular degeneration decreased dark adaptation color vision abnormalities corneal changes edema opacities including corneal deposition drug without accompanying symptoms halo around lights photophobia blurred vision nausea vomiting diarrhea abdominal pain fatigue liver function tests abnormal hepatic failure acute urticaria angioedema bronchospasm decreased appetite hypoglycemia porphyria weight decreased sensorimotor disorder skeletal muscle myopathy neuromyopathy leading progressive weakness atrophy proximal muscle groups depression tendon reflexes abnormal nerve conduction headache dizziness seizure ataxia extrapyramidal disorders dystonia dyskinesia tremor reported class drugs affectemotional lability nervousness irritability nightmares psychosis suicidal behavior rash pruritus pigmentation disorders skin mucous membranes hair color changes alopecia dermatitis bullous eruptions including erythema multiforme stevensjohnson syndrome toxic epidermal necrolysis drug reaction eosinophilia systemic symptoms dress syndrome photosensitivity dermatitis exfoliative acute generalized exanthematous pustulosis agep agep distinguished psoriasis although hydroxychloroquine sulfate may precipitate attacks psoriasis may associated pyrexia hyperleukocytosis report suspected adverse reactions contact sandoz inc <NUMBER> fda <NUMBER>fda<NUMBER> wwwfdagovmedwatch <NUMBER>aminoquinoline compounds rapidly completely absorbed ingestion accidental overdosage rarely lower doses hypersensitive patients toxic symptoms may occur within <NUMBER> minutes symptoms overdosage may include headache drowsiness visual disturbances cardiovascular collapse convulsions hypokalemia rhythm conduction disorders including qt prolongation torsades de pointes ventricular tachycardia ventricular fibrillation followed sudden potentially fatal respiratory cardiac arrest treatment symptomatic must prompt immediate gastric lavage stomach completely emptied indicated lavage activated charcoal introduced stomach tube within <NUMBER> minutes ingestion drug may inhibit intestinal absorption effective dose activated charcoal least five times estimated dose hydroxychloroquine ingested consideration given administering diazepam parenterally since studies suggest may beneficial reversing chloroquine hydroxychloroquine cardiotoxicity respiratory support shock management instituted necessary exchange transfusions used reduce level <NUMBER>aminoquinoline drug blood patient survives acute phase asymptomatic closely observed least six hours fluids may forced sufficient ammonium chloride <NUMBER> g daily divided doses adults may administered days acidify urine promote urinary excretion cases overdosage sensitivity however caution must exercised patients impaired renal function andor metabolic acidosis one tablet <NUMBER> mg hydroxychloroquine sulfate equivalent <NUMBER> mg base take hydroxychloroquine sulfate meal glass milk adults <NUMBER> mg <NUMBER> mg base weekly day week starting <NUMBER> weeks prior exposure continued <NUMBER> weeks leaving endemic area <NUMBER> mgkg <NUMBER> mgkg base exceed <NUMBER> mg <NUMBER> mg base weekly day week starting <NUMBER> weeks prior exposure continued <NUMBER> weeks leaving endemic area adults <NUMBER> mg <NUMBER> mg base followed <NUMBER> mg <NUMBER> mg base <NUMBER> hours <NUMBER> hours <NUMBER> hours initial dose total <NUMBER> mg hydroxychloroquine sulfate <NUMBER> mg base <NUMBER> mgkg <NUMBER> mgkg base exceed <NUMBER> mg <NUMBER> mg base followed <NUMBER> mgkg <NUMBER> mgkg base exceed <NUMBER> mg <NUMBER> mg base <NUMBER> hours <NUMBER> hours <NUMBER> hours initial dose hydroxychloroquine sulfate filmcoated tablets cannot divided therefore used treat patients weigh less <NUMBER> kg radical cure p vivax p malariae infections concomitant therapy <NUMBER>aminoquinoline compound necessary recommended adult dosage <NUMBER> <NUMBER> mg <NUMBER> <NUMBER> mg base daily administered single daily dose two divided doses doses <NUMBER> mg day recommended incidence retinopathy reported higher maintenance dose exceeded action hydroxychloroquine cumulative may require weeks months achieve maximum therapeutic effect see clinical pharmacology <NUMBER> mg <NUMBER> mg <NUMBER> <NUMBER> mg base daily administered single daily dose two divided doses small percentage patients side effects may require temporary reduction initial dosage good response obtained dosage may reduced <NUMBER> percent continued maintenance level <NUMBER> mg <NUMBER> mg <NUMBER> <NUMBER> mg base daily administered single daily dose two divided doses exceed <NUMBER> mg <NUMBER> mgkg <NUMBER> mgkg base per day whichever lower incidence retinopathy reported higher maintenance dose exceeded corticosteroids salicylates may used conjunction hydroxychloroquine sulfate generally decreased gradually dosage eliminated maintenance dose hydroxychloroquine sulfate achieved hydroxychloroquine sulfate tablets usp oral administration available simulate hydroxychloroquine hcq concentrationtime profiles plasma whole blood lung chinese healthy populations caucasian healthy populations caucasian renal injury gfr <NUMBER> mlmin support study design prophylactic use hcq since hydroxychloroquine parameters obtained published articles published human pharmacokinetics data hydroxychloroquine collected literatures total <NUMBER> articles related human pharmacokinetics hydroxychloroquine collected according retrieval method included research included three parts developed hydroxychloroquine pbpk model version <NUMBER> published previous study <NUMBER> simcyp simulator trial design set match population demographics including ethnicity age sex well drug administration blood collection time points collected clinical studies population simulation generated including <NUMBER> trials <NUMBER> subjects trial predicted auc cmax compared clinical observations assess predictive performance pbpk model evaluation criteria <NUMBER> observed value within <NUMBER> confidence interval predicted value <NUMBER> ratio auc cmax predicted value versus observed value within <NUMBER>fold <NUMBER>≤ratio≤<NUMBER> validation results published previous study <NUMBER> default population library simhealthy volunteers simchinese healthy volunteer simrenalgfr<NUMBER> simcyp ® version <NUMBER> certara sheffield uk used simulation population simulation generated page <NUMBER> <NUMBER> pharmacometrics analysis report bysydctccppocqhcqpbpkar<NUMBER> including <NUMBER> trials <NUMBER> subjects trial simulation scenarios hydroxychloroquine shown table <NUMBER> caucasians healthy caucasians renal injury gfr <NUMBER> mlmin chinese healthy population simulated respectively developed hydroxychloroquine pbpk model version <NUMBER> published previous study <NUMBER> mean pk profiles hcq plasma blood lung three conditions chinese healthy population shown figures <NUMBER> <NUMBER> <NUMBER> mean pk profiles hcq plasma blood lung three conditions trial design randomized multicenter placeboequivalent ascorbic acid controlled blinded study hcq pep prevention sarscov<NUMBER> infection adults exposed virus participants study enroll <NUMBER> asymptomatic adults <NUMBER> <NUMBER> years age inclusive baseline close contacts persons polymerase chain reaction pcrconfirmed sarscov<NUMBER> clinically suspected covid<NUMBER> pending sarscov<NUMBER> pcr test multisite trial conducted seven sites seattle uw los angeles ucla new orleans tulane baltimore umb new york city nyu syracuse sunyupstate boston bmc participants eligible included study following criteria apply <NUMBER> men women <NUMBER> <NUMBER> years age inclusive time signing informed consent <NUMBER> willing able provide informed consent <NUMBER> close contact person index known pcrconfirmed sarscov<NUMBER> infection index currently assessed covid<NUMBER> close contact defined household contact ie residing index case <NUMBER> days prior index diagnosis prolonged exposure within residencevehicleenclosed space without maintaining social distance b medical staff first responders care persons cared index case without personal protection mask gloves <NUMBER> less <NUMBER> days since last exposure close contact person sarscov<NUMBER> infection index case <NUMBER> access device internet telehealth visits <NUMBER> planning take hcq addition study medication participants excluded study following criteria apply <NUMBER> known hypersensitivity hcq <NUMBER>aminoquinoline compounds <NUMBER> currently hospitalized <NUMBER> symptomatic subjective fever cough shortness breath <NUMBER> current medications exclude concomitant use hcq <NUMBER> concomitant use antimalarial treatment chemoprophylaxis including chloroquine mefloquine artemether lumefantrine <NUMBER> history retinopathy etiology <NUMBER> psoriasis <NUMBER> porphyria <NUMBER> known bone marrow disorders significant neutropenia polymorphonuclear leukocytes <NUMBER> thrombocytopenia <NUMBER> k <NUMBER> concomitant use digoxin cyclosporin cimetidine amiodarone tamoxifen <NUMBER> known moderate severe liver disease <NUMBER> known long qt syndrome <NUMBER> severe renal impairment <NUMBER> use investigational nonregistered drug vaccine within <NUMBER> days preceding first dose study drugs planned use study period continued next page intervention comparator households randomized <NUMBER> level household close contact participants receiving one following therapies •hcq <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily additional <NUMBER> days •placebolike control ascorbic acid <NUMBER> mg orally daily <NUMBER> days <NUMBER> mg orally daily <NUMBER> days main outcomes primary outcome study incidence sarscov<NUMBER> infection day <NUMBER> among participants sarscov<NUMBER> negative baseline randomization group randomisation participants randomized <NUMBER> ratio hcq ascorbic acid level household eligible participants <NUMBER> household receive intervention randomization code resulting allocation list generated maintained study statistician list blocked stratified site contact type household versus healthcare worker blinding masking blinded study hcq ascorbic acid appear similar taste partially masked hcq bitter ascorbic acid sour participants blinded randomization group assigned study team members apart study pharmacist unblinded statistical staff blinded laboratory staff blinded group allocation numbers randomised sample size sample size study n<NUMBER> <NUMBER> participants randomized <NUMBER> either hcz n<NUMBER> <NUMBER> ascorbic acid n<NUMBER> <NUMBER> full protocol full protocol attached additional file accessible trials website additional file <NUMBER> interest expediting dissemination material familiar formatting eliminated letter serves summary key elements full protocol keywords covid<NUMBER> randomised controlled trial protocol hydroxychloroquine postexposure prophylaxis household contact health care worker supplementary information accompanies paper httpsdoiorg<NUMBER> <NUMBER>s<NUMBER> additional file <NUMBER> full study protocol authors contributions rvb wrote first draft letter authors contributed critically design protocol reviewing approving finalized copy study funded bill melinda gates foundation inv<NUMBER> funding agency staff member rsm coauthor manuscript sandoz donated study drug funders separate role beyond authors study design writing letter decision submit publication corresponding author full access study protocol final responsibility decision submit publication data study available study oversight committee request rbarnabauwedu final dataset available open access name ethics committee western institutional review board file numberreference number <NUMBER> date approval <NUMBER> march <NUMBER> certify trial received ethical approval appropriate ethical committee described study conducted according good clinical practice belmont report declaration helsinki principles informed consent current edition declaration helsinki implemented clinical study protocolspecified procedures interventions carried consent form describe purpose study procedures followed risks benefits participation copy consent form given participant fact documented participants record competing interests ab reports personal fees gates ventures cc reports personal fees gilead sciences merck outside submitted work jmb reports personal fees gilead sciences merck janssen outside submitted work hc reports grants sanofipasteur ellume cepheid genentech personal fees gsk merck outside submitted work authors declare competing interests severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> novel coronavirus causes coronavirus disease <NUMBER> covid <NUMBER> infection characterized flulike symptoms progressing cases acute respiratory distress syndrome ards <NUMBER> <NUMBER> myocarditis <NUMBER> <NUMBER> <NUMBER> <NUMBER> covid<NUMBER> classified pandemic world health organization march <NUMBER> <NUMBER> disease reached nearly every country april <NUMBER> <NUMBER> <NUMBER> confirmed cases worldwide <NUMBER> deaths <NUMBER> death disability covid<NUMBER> combined lack approved treatments created unmet need efficacious therapies researchers pharmaceutical companies race develop vaccines antivirals turned remedies little supporting evidence least <NUMBER> iranians died <NUMBER> sustained blindness brain damage methanol poisoning mistaken belief alcohol could prevent coronavirus infection <NUMBER> social media propagated misinformation snorting cocaine bleach prevent infection <NUMBER> <NUMBER> <NUMBER> desperation acts speaks urgent unmet need effective therapeutics sarscov <NUMBER> intend review familiarize readers toxicities potential therapeutics covid<NUMBER> possible treatments toxicities review draws multiple sources combining news articles social media posts peerreviewed research identified substances included review based discussion media experience practicing physicians scientists pharmacists rely industry news reports source information available discussion presents knowledge novel therapeutics publicly known early april <NUMBER> supervising editor mark b mycyk md article discuss therapeutic options sarcov<NUMBER> using lifecycle sarscov<NUMBER> understand mechanism toxicity agent discuss <NUMBER> viral cell entry inhibitory eg chloroquine hydroxychloroquine apn<NUMBER> <NUMBER> viral replication inhibitors eg protease inhibitors nucleotide analogs <NUMBER> nucleic acid vaccines <NUMBER> miscellaneous medications azithromycin ace inhibitors ibuprofen sarscov<NUMBER> enveloped nonsegmented positivesense rna virus belongs coronaviridae family date seven coronaviruses known infect humans <NUMBER>e nl<NUMBER> oc<NUMBER> hku<NUMBER> merscov sarscov<NUMBER> three sarscov<NUMBER> merscov sarscov<NUMBER> causing severe disease humans <NUMBER> genetic sequence sarscov<NUMBER> closely resembles sarscov<NUMBER> betacoronavirus caused severe acute respiratory syndrome sars epidemic <NUMBER> much current understanding sarscov<NUMBER> based vitro vivo experiments conducted investigate pathogenesis sarscov<NUMBER> coronavirus spreads humans respiratory droplets sarscov<NUMBER> sarscov<NUMBER> gain entry spike protein surface viral capsid binds angiotensinconverting enzyme ii ace<NUMBER> type ii alveolar cells leading fusion viral host cell membranes injection viral rna host cytoplasm <NUMBER> inside cell virus replicates genetic material releases newly created virus particles virions steps opportunity treatments disrupt normal coronavirus life cycle researchers currently investigating treatments covid<NUMBER> developing vaccines novel drugs well testing existing medications vaccine sarscov<NUMBER> may clinically available <NUMBER> months <NUMBER> medications approved food drug administration fda purposess chloroquine repositioned treat covid<NUMBER> therapeutic repurposing ie repositioning expedited drugdevelopment strategy reuse currently fdaapproved therapeutics new medical indications march <NUMBER> fda granted emergency authorization use chloroquine phosphate hydroxychloroquine sulfate treat covid<NUMBER> <NUMBER> european medicines agency recommended restricting use pending outcome clinical trials <NUMBER> american academy clinical toxicology aact american association poison control centers aapcc american college medical toxicology acmt recommended joint press release use chloroquine hydroxychloroquine occur direction medical provider fdaapproved indication part trial treatment covid<NUMBER> part approved hospital protocol <NUMBER> discussion cover drugs intended exhaustive absence direct evidence expect drugs similar class similar toxicity chloroquine <NUMBER>aminoquinoline primarily used treat malaria infectious disease caused several plasmodia species chloroquine concentrates acidic environments digestive vacuole plasmodia spp golgi apparatus human cells chloroquine prevents plasmodia crystallizing heme hemozoin <NUMBER> leading buildup heme becomes toxic parasite golgi apparatus collection vesicles posttranslational modifications glycosylation occur chloroquine freely diffuses vacuoles acidic environment vacuole favors protonated charged form cannot freely diffuse away ion trapping leading buildup chloroquine vacuoles chloroquine alters glycosylation ace<NUMBER> decreases affinity ace<NUMBER> coronavirus spike protein reducing sarscov<NUMBER> entry vitro <NUMBER> additionally chloroquine hydroxychloroquine inhibit tolllike receptor tlr pathway tlr pathway involved proinflammatory cytokine signaling <NUMBER> chloroquine found inhibit sarscov<NUMBER> infection sequence structure homologies sarscov<NUMBER> sarscov<NUMBER> suggest chloroquine could reduce sarscov<NUMBER> infectivity <NUMBER> indeed one vitro study demonstrated chloroquine inhibits sarscov<NUMBER> entry <NUMBER> guangdong province recommended <NUMBER> mg chloroquine twice day <NUMBER> days person diagnosed covid<NUMBER> without contraindications chloroquine <NUMBER> one abstract commentary suggests efficacy cites audio transcript press conference guangdong china supporting data available <NUMBER> doses greater <NUMBER> grams chloroquine associated mortality due ventricular dysrhythmias hypokalemia <NUMBER> cardiovascular collapse profound hypotension occur within <NUMBER> hours overdose sodium channel blockade results qrs widening ecg <NUMBER> <NUMBER> <NUMBER> neurologic effects include seizures cns depression <NUMBER> oxidative stress lead hemolysis particularly patients g<NUMBER>pd deficiency potassium channel blockade result prolonged qtc interval torsades de pointes clinicians avoid using qt prolonging agents chloroquine toxicity present current pandemic man arizona died ingesting chloroquine phosphate form chloroquine used treating aquariums using selfmedicate <NUMBER> cases chloroquine poisoning reported nigeria <NUMBER> important store chloroquine safely avoid secondary harm little <NUMBER> mgkg chloroquine children could <NUMBER> pills requires medical evaluation <NUMBER> mgkg lowest fatal dose toddlers <NUMBER> hydroxychloroquine derivative chloroquine considered less toxic difference mechanisms action chloroquine hydroxychloroquine fully understood chloroquine hydroxychloroquine dealkylated desethylchloroquine cyp<NUMBER>a<NUMBER> <NUMBER>c<NUMBER> <NUMBER> hydroxychloroquine also dealkylated desethylhydroxychloroquine <NUMBER>d<NUMBER> <NUMBER> chloroquine hydroxychloroquine inhibit <NUMBER>d<NUMBER> increase serum concentrations metoprolol propranolol opiates antidysrhythmics antidepressants antipsychotics <NUMBER> minimum fatal dose hydroxychloroquine well defined minimum dose reported elicit severe symptoms hypotension hypokalemia ventricular dysrhythmias <NUMBER> g <NUMBER> one case report <NUMBER> full text available describes <NUMBER> year old died reportedly ingesting <NUMBER> g hydroxychloroquine <NUMBER> <NUMBER>yearold girl ingested <NUMBER> g hydroxychloroquine developed hypokalemia hypotension ventricular tachycardia survived intubation epinephrine infusion highdose diazepam potassium repletion <NUMBER> see treatment chloroquine hydroxychloroquine toxicity section three case reports describe total five severely symptomatic patients survived overdoses <NUMBER> g hydroxychloroquine aggressive interventions including epinephrine highdose diazepam <NUMBER> <NUMBER> <NUMBER> <NUMBER> data regarding efficacy hydroxychloroquine treating covid<NUMBER> limited one clinical trial peer reviewed suggests patients clinical diagnosis covid<NUMBER> <NUMBER> <NUMBER> received hydroxychloroquine clinically improved <NUMBER> days compared <NUMBER> <NUMBER> control group <NUMBER> study one patient received hydroxychloroquine developed rash without mucosal involvement another developed headache resolved without intervention <NUMBER> riou et al published prospective study <NUMBER> patients anticipated likely lethal ingestion chloroquine greater <NUMBER> g chloroquine compared <NUMBER> historical controls individuals treated epinephrine infusion initial <NUMBER> μgkgmin titrated sbp <NUMBER> mmhg <NUMBER> mgkg diazepam <NUMBER> min intubation nasogastric aspiration diazepam continued <NUMBER> mgkg per day <NUMBER> days ten <NUMBER> patients survived hospital discharge compared <NUMBER> <NUMBER> patients control group <NUMBER> diazepam perhaps intuitively incorporated combination therapy due animal <NUMBER> human evidence may beneficial combined overdoses study largely shaped recommended treatment epinephrine high dose diazepam though without controversy regarding generalizability hypokalemia common finding chloroquine hydroxychloroquine overdose likely due intracellular shift potassium retrospective study <NUMBER> patients chloroquine toxicity serum potassium lower <NUMBER> mmoll correlated mortality serum potassium decreased serum chloroquine levels increased <NUMBER> linear relationship serum potassium chloroquine concentrations suggests hypokalemia reflects effect chloroquine although severely ill patients also received epinephrine infusions betaadrenergic agonists cause intracellular potassium shifts total body potassium stores expected depleted setting chloroquine toxicity raising concern rebound hyperkalemia toxicity resolves clinicians recommend less aggressive potassium repletion supplementing normal daily potassium <NUMBER> meq per <NUMBER> h <NUMBER> though severe hypokalemia present would reasonable replete observing rebound hyperkalemia treatment acute toxicity hydroxychloroquine thought acute toxicity chloroquine qrs prolongation xenobioticinduced sodium channel blockade often treated sodium bicarbonate boluses infusions administration sodium bicarbonate may treat cardiac sodium channel blockade worsen hypokalemia patientspecific characteristics must considered weighing use therapy lipid emulsion therapy lead return spontaneous circulation given cardiac arrest either hydroxychloroquine ingestion combined ingestion hydroxychloroquine chloroquine <NUMBER> two case reports suggest lipid emulsion reverse hypotension averting cardiac arrest <NUMBER> <NUMBER> second case report one patient received lipid emulsion therapy develop significant cardiotoxicity beyond prolonged qtc interval although patient ingested smaller dose hydroxychloroquine <NUMBER> g <NUMBER> extracorporeal circulatory support could considered severe overdoses refractory treatments <NUMBER> chloroquine hydroxychloroquine lead retinopathy rare toxicity develop <NUMBER> years therapy <NUMBER> expected shortterm use <NUMBER> patients rheumatoid arthritis ever used hydroxychloroquine <NUMBER> discontinued eye complaints although probable definite retinal toxicity documented less <NUMBER> risk retinal toxicity increased fivefold lifetime exposure reached <NUMBER> kg <NUMBER> longterm use hydroxychloroquine also associated cardiomyopathy <NUMBER> <NUMBER> clinicians also mindful secondary effects increase demand chloroquine hydroxychloroquine treat covid<NUMBER> hydroxychloroquine used treat systemic lupus erythematosus sle patients sle unable fill prescriptions due shortages <NUMBER> state pharmaceutical boards noted surges prescriptions hydroxychloroquine chloroquine azithromycin written physicians either family members practice american medical association promptly denounced <NUMBER> apn<NUMBER> apeiron biologics recombinant human ace<NUMBER> protein first developed treat sars <NUMBER> may treat covid<NUMBER> preventing sarscov<NUMBER> entry reducing acute lung injury acting soluble molecular decoy sarscov<NUMBER> preventing virus binding cellular ace<NUMBER> dosedependent fashion <NUMBER> ace<NUMBER> vitro essential receptor sarscov<NUMBER> entry <NUMBER> also serves maintain normal lung physiology virion binds cell surface ace<NUMBER> lung protective signalingis lost preventing ace<NUMBER>mediated sarscov<NUMBER> interaction therefore restoring physiologic ace<NUMBER> signaling apn<NUMBER> may reduce acute lung injury <NUMBER> randomized unblinded clinical trial underway china investigate efficacy apn<NUMBER> reduce viral load duration covid<NUMBER> symptoms <NUMBER> phase trial apn<NUMBER> <NUMBER> haschke colleagues welltolerated cardiovascular side effects <NUMBER> healthy subjects toxicity recombinant proteins general arises inadvertent activation immune system unintentional immunogenicity binding recombinant proteins cell surface receptors triggering cellular signal transduction cascades consciously targeted offtarget binding unintentional immunogenicity lead formation antidrug antibodies deposit tissues immune complexes example immune complexes deposit kidney impairing kidneys ability filter toxins recover electrolytes immune system treats recombinant protein antigen treatment may precipitate serum sickness offtarget binding apn<NUMBER> could modulate reninangiotensin signaling altering blood pressure organ perfusion one abstract provides evidence <NUMBER> mgkg per day caused immunogenicity cardiovascular toxicity three healthy human volunteers <NUMBER> leronlimab cytodyn investigational humanized igg<NUMBER> monoclonal antibody ccr<NUMBER> receptors found lymphocytes chemokine receptor <NUMBER> ccr<NUMBER> first characterized role coreceptor human immunodeficiency virus hiv viral entry white blood cells <NUMBER> recognize pathogens dengue <NUMBER> staphylococcus aureus <NUMBER> also use ccr<NUMBER> signaling pathway entry virulence factor leronlimab repurposed investigated treatment option patients covid<NUMBER> experience respiratory complications result covid<NUMBER> singlearm openlabel multicenter clinical study set take place investigate clinical improvement total symptom score ie fever myalgia dyspnea cough currently leronlimab fasttrack designation fda hiv metastatic triplenegative breast cancer <NUMBER> serious side effects adverse events reported far leronlimab successfully completed nine phase <NUMBER> <NUMBER> <NUMBER> clinical trials <NUMBER> patients indications achieved primary efficacy endpoints <NUMBER> reasoning analogy approved therapeutics oncology acute toxicity humanized antibodies include <NUMBER> immunosuppression predisposing opportunistic infections viralinduced neoplasias <NUMBER> immunostimulation including dramatic cytokine storm fevers chills myalgias acute lung injury similar severe presentation covid<NUMBER> <NUMBER> hypersensitivity reactions <NUMBER> specificity antibodies likely give rise idiosyncratic side effect profiles antibodies cause degree immunosuppression immune cell activation expect humanized antibodies less likely cause serum sickness antibodies raised horse ie anavip raised sheep ie crofab anavip rare disease therapeutics inc crofab protherics inc antibody therapies used treat envenomation north american crotalids humanized antibody antibody raised nonhuman species modified increase similarity naturally occurring human antibodies provoke less humoral immune response humans example antibodies raised mice fc region replaced human sequences decrease immunogenicity <NUMBER> rna virus must coopt host machinery translating rna protein discussed biology coronavirus section genomes coronaviruses sequences nucleotides human cells treat effectively mrna produce virions virus must make copy rna genome using viral rnadependent polymerase synthesize proteins needed form virion including capsid spike proteins overall goal nucleotide analogs halt production new viral rna making impossible infected host cells become manufacturing sites new virions nucleotide analogs incorporating base replicating strand viral rna polymerase cannot elongate remdesivir gilead prodrug metabolized adenosine nucleotide analog demonstrated vitro efficacy sarscov<NUMBER> <NUMBER> favipiravir toyama chemical mimics adenosine guanine leading rnadependent rna polymerase make errorridden nonfunctional viral genome progeny <NUMBER> absence data remdesivir favipiravir toxicity one extrapolate toxicity reported nucleoside analogs metabolic acidosis occur therapeutic use usually month treatment <NUMBER> though also observed acute overdose severe metabolic acidosis elevated lactate toxicity nucleoside analogs high mortality peripheral neuropathy doserelated subacute phenomenon seen stavudine <NUMBER>′<NUMBER>′didehydro<NUMBER>′<NUMBER>′dideoxythymidine d<NUMBER>t didanosine ddi zalcitabine ddc <NUMBER> bone marrow suppression seen <NUMBER> patient starting <NUMBER>′ azido<NUMBER>′ <NUMBER>′dideoxythymidine azt treatment <NUMBER> pancreatitis myopathy observed several medications class <NUMBER> toxicities thought reflect mitochondrial dysfunction addition inhibiting viral polymerase nucleoside analogs also inhibit mitochondrial dna polymerasegamma leading decreased mitochondrial dna synthesis mitochondrial proteins <NUMBER> severe toxicity occurs offending agent stopped specific antidote though suggest treatment mitochondrial cofactors thiamine riboflavin lcarnitine vitamin c may help patients recover <NUMBER> additional idiosyncratic toxicities may also occur example tenofovir inducing crystalluria <NUMBER> protease inhibitors prevent infected cells forming competent new virions binding inactivating viral proteases halt viral replication viral proteases process initial products translation make final versions viral proteins viral proteases unique virus crystal structure sarscov<NUMBER> main protease recently identified <NUMBER> drugs effective one virus expected effective another virus unless viruses proteases sufficiently similar protease inhibitors target hiv protease example target hepatitis c protease even though rna viruses crystal structure sarscov<NUMBER> main protease identified closely resembles sarscov<NUMBER> known human proteases <NUMBER> screening hiv protease inhibitors sarscov<NUMBER> found nelfinavir ritonavir inhibited viral replication vitro <NUMBER> although study described efficacy nelfinavir determine nelfinavirs effects specifically due sarscov<NUMBER> protease inhibition another screening study identified lopinavir nelfinavir inhibiting sarscov<NUMBER> demonstrated treatment lopinavirritonavir abbvie ribavirin reduced mortality ards compared treatment ribavirin alone <NUMBER> ritonavir added lopinavir pharmacokinetic booster <NUMBER> ritonavir potent inhibitor cytochrome cyp <NUMBER>a<NUMBER> enzyme inactivates lopinavir regimen lopinavirritonavir ribavirin used postexposure prophylaxis healthcare workers treating patients severe middle east respiratory syndrome mers also caused coronavirus showed <NUMBER> decreased risk infection severe adverse effects reported <NUMBER> early experience treatment sarscov<NUMBER> suggests patients treated lopinavirritonavir commonly experience nausea vomiting well mild transaminase elevations <NUMBER> lopinavirritonavir seemed hasten recovery case series <NUMBER> hospitalized patients <NUMBER> larger randomized trial <NUMBER> test subjects <NUMBER> controls showed difference time clinical improvement <NUMBER> three studies many patients receiving combination left study due nausea vomiting diarrhea acute overdose protease inhibitors uncommon large overdose <NUMBER> g lopinavirritonavir generally well tolerated managed supportively <NUMBER> ritonavir potent inhibitor cyp<NUMBER>a<NUMBER> ki <NUMBER> ± <NUMBER>μm may slow metabolism drugs substrates cyp<NUMBER>a<NUMBER> leading potential dangerous drugdrug interactions <NUMBER> lopinavirritonavir associated increases transaminases <NUMBER> individuals treated hiv though clinically significant liver injury appears rare resolves drug removal <NUMBER> cholestatic pattern injury sometimes observed may explained lopinavir reducing expression bile salt export pump bsep human hepatocytes <NUMBER> latency period <NUMBER> month longer common may make less relevant feature treatment sarscov<NUMBER> genetic variations polymorphisms across patients lossoffunction cyp<NUMBER>a<NUMBER> <NUMBER> make patients susceptible metabolic toxicities <NUMBER> screening susceptibilities practical setting short duration treatment sarscov<NUMBER> arthralgias may occur <NUMBER> patients <NUMBER> achilles tendinopathy reported individuals taking lopinavirritonavir even shortterm use postexposure prophylaxis <NUMBER> protease inhibitors cause lipodystrophy characterized central adiposity dorsocervical fat deposition buffalohump extremity wasting used treat hiv multiple mechanisms may explain metabolic derangements including inhibition srebp<NUMBER> master regulator lipogenesis adipocyte differentiation direct inhibition glucose transporter<NUMBER> <NUMBER> goal vaccine develop longstanding immunity without exposure full brunt disease vivo phase trials new vaccine candidates currently underway evaluate safety immune response strimer refers vaccine made resemble spike protein protein capsid surface binds ace<NUMBER> alveolar cells initiate viral entry spike protein attractive target elicits immune response mutations spike protein may explain virulence sarscov<NUMBER> sarscov<NUMBER> spike protein binds ten times tightly ace<NUMBER> sarscov<NUMBER> spike protein <NUMBER> mutations also create need new therapeutics paper noted three monoclonal antibodies raised sarscov<NUMBER> spike protein strongly bind sarscov<NUMBER> spike protein strimer vaccine candidate expected tested preclinical studies shortly generation antibodies spike proteins sars mers <NUMBER> challenging spike proteins coronaviruses heavily glycosylated dna vaccines work inserting dna plasmids encode antigens host cells generates cellular humoral antigenspecific immunity allowing patient mount immune response target disease <NUMBER> <NUMBER> studies ongoing regarding effectiveness longevity vaccine immunogenicity several infections including hiv mers ebola zika gls<NUMBER> inovio pharmaceuticals inc geneone life science inc dna vaccine merscov entering phase <NUMBER> trials merscov coronavirus causes middle east respiratory syndrome gls<NUMBER> encodes merscov spike glycoprotein demonstrated immunogenic response nonhuman primates phase <NUMBER> studies gls<NUMBER> demonstrated local injection site symptoms patients along headaches malaise myalgia patients developed mild creatinine phosphokinase elevations renal injury myopathy developed <NUMBER> ino<NUMBER> inovio pharmaceuticals inc dna vaccine encodes sarscov<NUMBER> spike protein delivered intradermally <NUMBER> phase <NUMBER> clinical trial ino<NUMBER> started early april enhance uptake dna vaccines administered via electroporation device cellectra <NUMBER> safety tolerability studies cellectra identify severe adverse events though injection site pain mild elevations creatinine phosphokinase paresthesias described <NUMBER> animals received vaccine produced antibodies cells virus <NUMBER> phase <NUMBER> clinical trial ino<NUMBER> started beyond local tissue reactions dna vaccines raise concern adverse events plasmid integration host dna disrupting usual transcription vitro studies thus far suggest rate insertional mutagenesis lower rate spontaneous mutations mammalian cells generally dna vaccines appear safe without apparent offtarget effects idiosyncratic toxicities <NUMBER> messenger rna mrna vaccines direct production antigens unlike dna vaccines cannot integrate host genome lowering risk mutations <NUMBER> cytosol mrna vaccines direct antigen production rapidly degrade moderna therapeutics collaboration national institute allergy infectious disease announced launched phase trial mrna<NUMBER> mrna<NUMBER> vaccine novel lipid nanoparticle encapsulated mrnabased vaccine encodes prefusion stabilized form spike protein <NUMBER> prefusion form refers spatial conformation spike protein binds ace<NUMBER> antibody prefusion form could prevent viral entry well mitigate spread virions azithromycin macrolide antibiotic used ability inhibit bacterial protein synthesis binding <NUMBER>s subunit bacterial ribosome also used treat exacerbations copd reactive airway disease second use may reflect azithromycins modulatory effect immune cells reduces respiratory syncytial virus rsv release decreasing interferon signaling vivo inhibits proinflammatory cytokine release airway smooth muscle epithelial cells <NUMBER> prospective trial france <NUMBER> patients noted combination <NUMBER> mg hydroxychloroquine azithromycin <NUMBER> mg first day <NUMBER> mg day next <NUMBER> days reduced viral load effectively hydroxychloroquine alone <NUMBER> trial broke randomization declined treatment analyzed controls main toxicity azithromycin qtc prolongation leading cardiac dysrhythmias owing herg inward rectifying potassium channel blockade <NUMBER> one cohort study <NUMBER>day course azithromycin led nearly threefold increase cardiovascular death compared antibiotics <NUMBER> although followup cohort study similar size <NUMBER> prescriptions <NUMBER> metaanalysis prospective randomized controlled trials identified increased risk mortality <NUMBER> expect combination azithromycin chloroquine hydroxychloroquine likely precipitate cardiac dysrhythmias either alone azithromycin weakly blocks herg conducting potassium ions across cardiac membrane chloroquine hydroxychloroquine decrease number ions available transit concern media angiotensinconverting enzyme ace inhibitors may increase susceptibility sarscov<NUMBER> <NUMBER> ace inhibitors increase ace<NUMBER> expression human tissue <NUMBER> potentially creating binding sites sarscov<NUMBER> receptorbinding domain rbd sarscov<NUMBER> high affinity ace<NUMBER> however ace inhibitors shown reduce viral entry competitive inhibition spike protein binding ace<NUMBER> vitro <NUMBER> lastly alveolar cells infected coronavirus express less ace<NUMBER> cell surface normal cells vitro knocking expression ace<NUMBER> uninfected mice creates acute lung injury histologically similar seen sars suggesting intact ace<NUMBER> function serves lungprotective role <NUMBER> one could interpret findings suggest patients taking ace inhibitors may benefit stopping taking may benefit starting time however direct clinical evidence impact ace inhibitors clinical trajectory covid<NUMBER> retrospective study wuhan china identified hypertension diabetes cerebrovascular disease poor prognostic factors isolate relative risk attributable taking ace inhibitor <NUMBER> worse outcome study patients ace inhibitors may reflect generally poor outcomes patients multiple comorbidities patient abruptly discontinue ace inhibitor except direction physician blood pressure rapidly rises first <NUMBER> hours ace inhibitor discontinuation <NUMBER> could precipitate hypertensive emergencies subsequent acute pulmonary edema study stated ibuprofen increases ace<NUMBER> receptor expression provided supporting evidence neither <NUMBER> fda <NUMBER> recommends withholding ibuprofen symptomatic treatment covid<NUMBER> convalescent plasma refers pooled plasma immunoglobulins patients infected recovered disease ten patients seropositive sarscov<NUMBER> hypoxic intubated one dose <NUMBER> ml convalescent plasma led nearly immediately undetectable viral load improved oxygenation <NUMBER> days <NUMBER> five patients intubated radiographic evidence acute lung injury transfusion <NUMBER> ml convalescent plasma days <NUMBER> <NUMBER> admission reduced hypoxia five three able weaned mechanical ventilation <NUMBER> risks commonly associated plasma transfusion include <NUMBER> transfusionassociated acute lung injury trali <NUMBER> transfusionassociated circulatory overload taco <NUMBER> allergicanaphylactic reactions less common risks include <NUMBER> transmission infections <NUMBER> febrile nonhemolytic transfusion reactions <NUMBER> rbc alloimmunization <NUMBER> hemolytic transfusion reactions <NUMBER> metaanalysis studies used convalescent plasma treat sars influenza h<NUMBER>n<NUMBER> reported adverse effects beyond minor infusion reactions chills fevers <NUMBER> four critically ill patients sarscov<NUMBER> significant adverse events treated convalescent plasma supportive care <NUMBER> unmet need effective treatments covid<NUMBER> spurred pharmaceutical companies develop repurpose therapeutics sarscov<NUMBER> frontline providers may unfamiliar usage older therapeutics chloroquine medicines typically used subspecialists like dna vaccines protease inhibitors convalescent plasma therapy conjunction effective infection control policies combination measured reasoned repurposing existing therapies development vetting novel drugs guidance medical toxicologists may reduce morbidity mortality covid<NUMBER> avoid cases cure worse disease coronavirus disease <NUMBER> covid<NUMBER> emerging infectious disease caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> first reported end december <NUMBER> cause clusters pneumonia cases wuhan city china rapid spread condition declared pandemic march <NUMBER> <NUMBER> world health organization apart mortality morbidity associated covid<NUMBER> massive social financial havoc inflicted pandemic left entire world pondering medical science innovate curtail ongoing damage due sarscov<NUMBER> recent findings openlabel study investigated use hydroxychloroquine azithromycin covid<NUMBER> patients marseille france garnered optimism scientific quarters general public alike terms finding treatment regimen control rampant rise covid<NUMBER> discuss potential offlabel therapy studies pertains covid<NUMBER> searching effective therapy coronavirus pandemic see light end tunnel coronaviruses long known pathogens humans animals apart causing communityacquired coronaviruses novel forms coronavirus implicated outbreak severe acute respiratory syndrome sars outbreak <NUMBER> middle east respiratory syndrome mers <NUMBER> <NUMBER> <NUMBER> towards end december <NUMBER> novel type coronavirus identified causative agent cluster pneumonia cases wuhan city china rapid spread within china caused epidemic believed peaked late january early february <NUMBER> initially referred <NUMBER>ncov causative agent known severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> recommended coronavirus study group international committee taxonomy viruses <NUMBER> officially designated coronavirus disease <NUMBER> covid<NUMBER> world health organization novel coronavirus became pandemic march <NUMBER> <NUMBER> <NUMBER> total case counts around world increasing every day latest case counts found official website sarscov<NUMBER> falls betacoronavirus subgenus similar sars coronavirus <NUMBER> uses angiotensinconverting enzyme <NUMBER> receptor cellular entry closest rna sequencing found similar bat coronaviruses unknown transmission humans intermediate host bats could primary host <NUMBER> wake pandemic preventive measures break chain transmission adopted medical community around world also working hard find effective preventive curative therapy already suffering illness though difficult started see exciting results attempt seek therapy covid<NUMBER> disease revisiting medications sars mers epidemics resurfaced context covid<NUMBER> analysis full genomic sequence coronavirus causes covid<NUMBER> shown resemble sars coronavirus <NUMBER> closely middle eastern respiratory syndrome mers coronavirus <NUMBER> <NUMBER> <NUMBER> sars coronavirus outbreak <NUMBER> multiple attempts find effective treatment virus apart meticulous supportive care experts could recommend specific treatment <NUMBER> epidemic <NUMBER> vast majority patients treated glucocorticoids received ribavirin drugs found immediate longterm beneficial effects <NUMBER> glucocorticoids associated increased risk mortality decelerated process viral clearance mers coronavirus infection mortality benefit rather convincing evidence harm short term long run sars coronavirus <NUMBER> staying lieu pieces evidence centers disease control prevention cdc recommended use glucocorticoids patients covid<NUMBER> unless coexisting compelling indications use exacerbation chronic obstructive lung disease asthma <NUMBER> ribavirin nucleoside analog broad antiviral activity also used along glucocorticoids high dose via intravenous oral routes combat sars <NUMBER> systematic reviews published <NUMBER> <NUMBER> failed establish beneficial effects ribavirin <NUMBER> <NUMBER> prospective observational study included patients received ribavirin <NUMBER> days along glucocorticoids initial improvement fever symptoms pneumonia resurgence fever <NUMBER> patients within mean <NUMBER> days <NUMBER> worsening respiratory symptoms <NUMBER> days fortyfive percent <NUMBER> patients newer lesions radiographs diarrhea seen <NUMBER> patients <NUMBER> days medication use <NUMBER> despite findings study going repurpose utility sofosbuvir ribonucleic acid rnadependent rna polymerase inhibitor used treatment hepatitis c along ribavirin covid<NUMBER> patients data sequence analyzing modeling molecular docking study shown ability sofosbuvir ribavirin tightly bind sars cov<NUMBER> rnadependent rna polymerase indicating potential use treatment covid<NUMBER> patients <NUMBER> data need emerge study considered clinical use lopinavir ritonavir protease inhibitors used along ribavirin glucocorticoids openlabel trial sars outbreak <NUMBER> treatment group given lopinavirritonavir along ribavirin corticosteroids n<NUMBER> compared control arm patients treated ribavirin glucocorticoids n<NUMBER> patients included trial acute respiratory distress syndrome due sars coronavirus <NUMBER> severe hypoxemia death <NUMBER>st day composite primary outcome treatment group <NUMBER> patients severe hypoxemia deaths comparison <NUMBER> hypoxemia control group <NUMBER> deaths <NUMBER> due absence definite treatment guidelines covid<NUMBER> china international exchange promotive association medical health care cpam issued guideline february <NUMBER> recommended using lopinavirritonavir along interferonalpha nebulizer form antiviral action sarscov<NUMBER> recommendations based weaker evidence <NUMBER> <NUMBER> trial lopinavirritonavir conducted adult patients hospitalized severe covid<NUMBER> failed show benefit beyond standard care available <NUMBER> study <NUMBER> patients treated lopinavirritonavir <NUMBER> patients received standard medical care difference time clinical improvement hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> mortality <NUMBER> days <NUMBER> vs <NUMBER> <NUMBER> difference <NUMBER> confidence interval <NUMBER> <NUMBER> decrease detectable viral load two arms notably gastrointestinal adverse effects common lopinavirritonavir group led <NUMBER> patients stopping medication <NUMBER> buoyed activity ebola virus remdesivir also tested reportedly found activity sars mers coronaviruses <NUMBER> remdesivir nucleoside analog investigational agent available commercially manufacturer gilead sciences inc foster city california provided compassionate use programs request treating physician requiring institutions involved randomized trial though clinical trial determine efficacy remdesivir patients sarscov<NUMBER> infection ongoing results may expected april <NUMBER> preclinical trials shown significant activity coronavirus invitro study revealed potent antiviral activity remdesivir sarscov<NUMBER> <NUMBER> <NUMBER> chloroquine hydroxychloroquine analog chloroquine traditionally used antimalarial agents diseasemodifying antirheumatic drugs dmards conditions like lupus rheumatoid arthritis hydroxychloroquine believed disrupt vesicle function parasite increasing ph also arrests various erythrocytes stages plasmodium exert antimalarial effect also inhibits acute phase reactants rheumatoid factor various enzymes immunosuppressive effect <NUMBER> state council china news briefing february <NUMBER> <NUMBER> released first positive experience regarding use chloroquine phosphate patients covid<NUMBER>associated pneumonia <NUMBER> multicenter clinical trial conducted <NUMBER> different hospitals china per news briefing state council china letter published gao j et al february <NUMBER> <NUMBER> <NUMBER> patients found lesser exacerbation pneumonia due covid<NUMBER> improved radiological findings better virusnegative conversion shorter course disease chloroquine phosphate treatment arm comparison control group <NUMBER> per authors chloroquine recommended included next edition official guidelines released national health commission peoples republic china management pneumonia caused covid<NUMBER> <NUMBER> chinese expert panel recommended chloroquine <NUMBER> mg twicedaily dosing <NUMBER> days <NUMBER> besides china several countries based upon benefits shown limited invitro studies anecdotal experiences currently using chloroquine hydroxychloroquine patients covid<NUMBER> pneumonia march <NUMBER> <NUMBER> findings released openlabel study investigated use hydroxychloroquine azithromycin hospitalized patients covid<NUMBER> study conducted mediterranee infection university hospital institute marseille france <NUMBER> patients age <NUMBER> years included polymerase chain reaction pcr technique used detect sarscov<NUMBER> nasopharyngeal samples patients admission study enrolled <NUMBER> <NUMBER> patients meeting inclusion criteria twentysix patients received hydroxychloroquine <NUMBER> patients control reported six patients lost followup due early cessation treatment study included asymptomatic patients <NUMBER> patients upper respiratory tract symptoms urti <NUMBER> lower respiratory tract symptoms lrti <NUMBER> authors confirmed cases lrti pneumonia confirmed radiological findings computed tomography ct chest demographic factors treatment control arms wellmatched except average age hydroxychloroquinereceiving patients <NUMBER> years versus <NUMBER> years control group <NUMBER> patients treatment arm administered <NUMBER> mg oral hydroxychloroquine three times day <NUMBER> days control arm six patients also received azithromycin dose <NUMBER> mg first day followed <NUMBER> mg daily four days prevent secondary bacterial infection primary endpoint virological clearance sixth day initiation treatment results study revealed <NUMBER> hydroxychloroquinetreated patients free virus compared <NUMBER> patients control group interestingly six patients <NUMBER> treated hydroxychloroquine azithromycin cured one patient received hydroxychloroquine remained pcrpositive sixth day able get rid virus ninth day addition azithromycin eighth day <NUMBER> also personally opine results study promising especially current context pandemic entire world struggling find definitive treatment apart cure existing patients study opens avenues studies geared towards finding prophylactic regimen also stop emergence new cases limit burden pandemic however acknowledge study limited due smaller sample size restricted ethnic geographic population shortterm followup also raises queries concerns regarding six patients dropped study results look promising patients received combination hydroxychloroquine azithromycin whether combination two medications leads potential cardiacelated adverse events ventricular arrhythmias mainly due risk qt prolongation something needs addressed future studies another question study raises possibility existence certain resistant strains sarscov<NUMBER> respond hydroxychloroquine treatment united states well clinical trials involving hydroxychloroquine planned treatment mild moderate severe covid<NUMBER> also pre postexposure prophylaxis <NUMBER> currently vaccine approved preexposure postexposure prophylaxis various clinical trials conducted united states countries postexposure prophylaxis <NUMBER> united states first vaccine evaluated prevention covid<NUMBER> using technique would promote expression viral protein potentially induce response immune apparatus host <NUMBER> entire world looking forward breakthrough terms vaccines wait patiently wake pandemic caused covid<NUMBER> medical scientific community around world racing time find cure sarscov<NUMBER> sudden onset unprecedented surge virus instilled urgency seek preventive therapeutic options covid<NUMBER> recent outpouring data rather smaller studies anecdotal experiences cannot considered major breakthrough may looked silver lining bigger studies needed started immediately consolidate data obtained smaller studies must make careful choice designing larger studies based preliminary data smaller studies might risk treating patients therapy may ultimately prove effective may also miss opportunity pursue better options n december <NUMBER> reports unknown pneumonia responsive traditional treatments emerged wuhan china pathogen came identified severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> novel coronavirus known responsible coronavirus disease <NUMBER> covid <NUMBER> illness since virus spread internationally infecting ≈<NUMBER> million individuals resulting <NUMBER> <NUMBER> deaths covid<NUMBER> declared public health emergency international concern january <NUMBER> <NUMBER> <NUMBER> although strong data supporting specific therapy lacking several pharmacological intervention strategies proposed management covid<NUMBER> hopes decreasing morbidity mortality related illness one therapy currently study humans use chloroquine hydroxychloroquine chloroquine medication commonly used treat malaria shown inhibit viral infection changing endosomal ph required viralcell fusion well interfering glycosylation cellular receptors sarscov <NUMBER> compared chloroquine hydroxychloroquine shown vitro higher inhibition sarscov<NUMBER> <NUMBER> limited studies resulted surge use chloroquine hydroxychloroquine without azithromycin patients requiring inpatient care covid<NUMBER> although many hopeful inexpensive readily available medications may key decreasing mortality pandemic writing article data exists notable concern association qt prolongation torsade de pointes tdp medications individually prescribed increased risk administered together especially patients hepatic disease renal failure evaluate arrhythmic safety chloroquinehydroxychloroquine±azithromycin conducted prospective evaluation adult patients hospitalized covid<NUMBER> minimize possibility unintentionally sharing information used reidentify private information subset data generated analytical methods used study available corresponding author researchers upon reasonable request study approved institutional review board northwell health waived requirement individual informed consent start outbreak april <NUMBER> <NUMBER> <NUMBER> patients received combination hydroxychloroquine azithromycin <NUMBER> patients received hydroxychloroquine alone treatment covid<NUMBER> <NUMBER> hospitals new york state northwell health system present study indepth prospective observational study <NUMBER> hospitals hospitalized patients <NUMBER> years age polymerase chain reaction confirmed covid<NUMBER> illness treated chloroquinehydroxychloroquine±azithromycin identified march <NUMBER> march <NUMBER> decision treat chloroquine hydroxychloroquine±azithromycin based clinical decision admitting physician predescribed healthcare system guidelines healthcare system criteria use chloroquinehydroxychloroquine±azithromycin therapy placed march <NUMBER> follows confirmed covid<NUMBER> polymerase chain reaction testing high suspicion covid<NUMBER> test pending acute respiratory distress syndrome severe illness characterized systemic inflammatory response syndrome criteria clinicians judgment patient likely progress acute respiratory distress syndrome severe illness next <NUMBER> hours patients meeting criteria therapy excluded study patients chronically hydroxychloroquine autoimmune diseases lupus documented hypersensitivity agents patient refused therapies excluded study demographics inpatient medication lists values baseline ecgs including qrs duration qrs morphology qt interval duration collected patients initiation therapy inpatient medication orders reviewed daily concomitant qtprolonging agent usage identified twice daily ecgs except patients received mobile cardiac outpatient telemetry mcot patch biotelemetry malvern pa obtained assess corrected qt interval qtc given large number covid<NUMBER> patients admitted throughout health system limited amount telemetry beds available mcot patches used monitor qt prolongation arrhythmias patients nontelemetry units mcot study adds • hospitalized covid<NUMBER> patients use chloroquinehydroxychloroquine azithromycin resulted significantly greater increase corrected qt interval compared monotherapy either chloroquine hydroxychloroquine • although patients experienced corrected qt interval prolongation especially combination therapy used risk arrhythmic death torsade de pointes increased • though efficacy chloroquine hydroxychloroquine±azithromycin patients coronavirus disease <NUMBER> covid<NUMBER> unproven arrhythmic risk appears low may warrant monitoring hospitalized patients patches preprogrammed transmit twice daily telemetry strips qt interval measurements telemetry mcot patch urgent alerts reviewed patients cardiac arrhythmias documented premature discontinuation medications due qt prolongation also noted qt intervals obtained ecg mcot patch manually measured physician research team lead ii utilized measurement qt interval ecg twave could easily measured lead ii leads v<NUMBER> alternatively used end twave defined tangent drawn steepest last limb twave intersection baseline baseline bbb present jt interval measured <NUMBER> ms added obtain qt interval duration bazett formula used calculate corrected qt interval baseline qt interval measurements obtained mcot patch compared baseline ecg utilizing lead mcot patch provides lead strip ensure accuracy serial ecgs obtained mcot patients decrease staff exposure given observational nature study members research team measuring qt interval blinded patient information course telemetry ecg mcot patch monitoring findings qt interval measurements adjudicated senior boardcertified cardiac electrophysiologist cardiac electrophysiology fellow boardcertified cardiovascular disease primary clinical outcome study qt prolongation resulting tdp secondary outcomes included qt prolongation qt prolongation resulted need prematurely terminate chloroquine hydroxychloroquine azithromycin well arrhythmogenic death prospective observational study without specific control population basic statistical analysis utilized continuous variables reported mean±sd categorical variables reported numerical values percentages welch test used compare ecg changes treatment patients baseline ecgs multivariable linear regression analysis performed test impact monotherapy versus combination therapy gender along interaction <NUMBER> outcome change qtc fisher exact test used compare number patients qtc <NUMBER> ms monotherapy versus combination groups sas version <NUMBER> cary nc statistical software used analysis march <NUMBER>st march <NUMBER> <NUMBER> patients treated covid<NUMBER> either chloroquine hydroxychloroquine <NUMBER> hospitals northwell health system minority patients <NUMBER> <NUMBER> received chloroquine <NUMBER> patients either chloroquine hydroxychloroquine <NUMBER> <NUMBER> also received azithromycin treatment regimens medications follows chloroquine <NUMBER> mg mouth twice daily <NUMBER> day followed <NUMBER> mg mouth daily <NUMBER> days hydroxychloroquine <NUMBER> mg mouth twice daily <NUMBER> day followed <NUMBER> mg mouth twice daily <NUMBER> days azithromycin <NUMBER> mg mouth intravenous daily <NUMBER> days average age cohort <NUMBER>±<NUMBER> <NUMBER> <NUMBER> male patients complete demographics displayed table <NUMBER> details regarding inpatient medication usage outlined table <NUMBER> baseline ecg performed initiating therapy covid<NUMBER> patients majority patients sinus rhythm <NUMBER> <NUMBER> baseline heart rate <NUMBER>±<NUMBER> beats per minute mean qrs duration population baseline <NUMBER>±<NUMBER> ms <NUMBER> patients <NUMBER> intraventricular conduction delay incomplete complete right bundle branch block left bundle branch block ventricular paced rhythm serial ecgs used monitor qtc intervals <NUMBER> patients <NUMBER> patients <NUMBER> monitored mcot patch baseline qtc entire cohort <NUMBER>±<NUMBER> ms <NUMBER> patients <NUMBER> baseline qtc <NUMBER> ms average maximum qtc treatment entire cohort <NUMBER>±<NUMBER> ms posttreatment qtc <NUMBER>±<NUMBER> ms average increase qtc <NUMBER>day course treatment <NUMBER>±<NUMBER> ms table <NUMBER> baseline qtc intervals monotherapy group <NUMBER>±<NUMBER> ms combination therapy group <NUMBER>±<NUMBER> ms p<NUMBER> maximum qtc treatment significantly shorter patients table <NUMBER> additionally statistically significant effects gender p<NUMBER> interaction effects gender medications difference maximum qtc baseline qtc p<NUMBER> overall trajectory qtc change represented figure <NUMBER> number patients peak qtc <NUMBER> ms <NUMBER> <NUMBER> monotherapy group versus <NUMBER> <NUMBER> combination therapy group p<NUMBER> figure <NUMBER> details regarding patients found table <NUMBER> addition qt prolongation <NUMBER> instances newonset atrial fibrillation discovered either telemetry mcot patch seven patients monomorphic nonsustained ventricular tachycardia <NUMBER> patient sustained hemodynamically stable monomorphic ventricular tachycardia setting likely viral myocarditis table <NUMBER> primary outcome qt prolongation leading tdp observed entire population arrhythmogenic death also observed entire cohort secondary outcome involving need discontinue hydroxychloroquine due qt prolongation occurred <NUMBER> <NUMBER> patients average qtc <NUMBER>±<NUMBER> ms details regarding patients found tables <NUMBER> <NUMBER> trajectory qtc change represented figure <NUMBER> complete list arrhythmic events interventions listed table <NUMBER> following development implementation northwell flow chart minimize tdp covid<NUMBER> inpatients hydroxychloroquineazithromycin lidocaine used facilitate continuation hydroxychloroquine <NUMBER> patients <NUMBER> first patients qtc increased baseline <NUMBER> <NUMBER> ms receiving hydroxychloroquine <NUMBER> mg <NUMBER> doses followed <NUMBER> mg <NUMBER> doses <NUMBER> doses intravenous azithromycin <NUMBER> mg patient given single dose intravenous lidocaine <NUMBER> mg improved qtc <NUMBER> ms azithromycin discontinued time hydroxychloroquine <NUMBER> mg twice daily continued full <NUMBER>day course note patient given dose intravenous amiodarone <NUMBER> mg <NUMBER> days reaching peak qtc rapid june <NUMBER> <NUMBER> response atrial fibrillation acute hypoxic respiratory failure required intubation two days finishing course hydroxychloroquine qtc prolonged <NUMBER> ms note patient receiving intravenous furosemide pantoprazole may contributed qtc prolongation patient appropriately responded another dose intravenous lidocaine subsequent qtc improved <NUMBER> mg normalized <NUMBER> ms subsequent ecgs second patients qtc increased <NUMBER> ms <NUMBER> ms receiving <NUMBER> dose hydroxychloroquine given dose intravenous lidocaine <NUMBER> mg improved qtc <NUMBER> ms patient went complete <NUMBER>day course hydroxychloroquine prolongation qtc main findings study <NUMBER> use chloroquinehydroxychloroquine azithromycin led significantly greater increase corrected qt interval compared monotherapy either chloroquine hydroxychloroquine <NUMBER> prolongation qtc led premature discontinuation medications <NUMBER> patients <NUMBER> instances primary end point tdp entire cohort sarscov<NUMBER> virus enveloped β coronavirus thought transmitted humans via zoonotic transfer <NUMBER> <NUMBER> virus binding cell entry facilitated type membrane spike glycoprotein surface sarscov<NUMBER> virus binds ace angiotensinconverting enzyme<NUMBER> receptors found upper lower human respiratory tract <NUMBER> <NUMBER> sarscov<NUMBER> virus emerged china december <NUMBER> subsequently resulted explosion proposed therapies treating virus among therapies chloroquinehydroxychloroquine without azithromycin commonly used following studies showed viruscell fusion inhibition <NUMBER> <NUMBER> date little actionable clinical data efficacy using medications humans infected sarscov<NUMBER> virus <NUMBER> cohort <NUMBER> hospitalized patients sarscov et al <NUMBER> reported direct correlation viral load increasing age suggesting increased expression ace<NUMBER> receptors age may result higher viral loads relationship viral load disease severity however addressed viral load noted peak first week illness steadily declined following week <NUMBER> subsequently <NUMBER>patient study mildly symptomatic patients showed benefit chloroquine regards clearance viral load time temperature normalization disease progression <NUMBER> major trials evaluating clinical efficacy combination therapy currently underway globally major concern use therapy risk qt prolongation tdp tdp form polymorphic ventricular tachycardia occurs setting qt prolongation characterized gradual twisting amplitude change qrs complexes around isoelectric line either spontaneously terminates degenerates ventricular fibrillation <NUMBER> cases <NUMBER> <NUMBER> traditionally qtprolonging agents avoided individuals qtc <NUMBER> ms due <NUMBER>fold <NUMBER>fold increase risk tdp intervals <NUMBER> <NUMBER> <NUMBER> drugs cause qt prolongation blocking human etheràgogo related gene herg potassium channel voltagegated ion channel mediates rapid component delayed rectifier potassium current kr resulting lengthening ventricular repolarizations duration ventricular action potential <NUMBER> similar fashion result reactivation calcium influx causing triggered early afterdepolarization activity welltimed early afterdepolarization trigger presence prolonged qt interval result tdp <NUMBER> risk factors tdp include drug interactions affecting drug serum levels concomitant use qtprolonging agents female sex structural heart disease genetic polymorphisms electrolyte disturbances bradycardia hepatic disease risk factors result repolarization reserve reduction <NUMBER> <NUMBER> although qtc sensitive predicting tdp specific relationship qt prolongation tdp linear drugs prolong qt consistently associated cardiac arrhythmias incidences sudden cardiac death occurring absence qt prolongation surface ecg also reported qt prolonging drugs antiarrhythmics highest risk tdp incidence <NUMBER> <NUMBER> whereas risk noncardiovascular drugs much lower <NUMBER> <NUMBER> four hundred million courses antimalarial drugs annually used around world <NUMBER> antimalarial drugs well known potential cardiac toxicity qt prolongation effects drugs used quinidine halofantrine likely cause qt prolongation tdp <NUMBER> <NUMBER> <NUMBER> chloroquines reported risk sudden cardiac death limited cases hypotension due vasodilation negative inotropy resulting rapid parenteral administration medication situations selfinflicted overdose <NUMBER> risk qt prolongation tdp hydroxychloroquine limited series case reports patients either chronic use overdose <NUMBER> <NUMBER> <NUMBER> reported effects chloroquine hydroxychloroquine qt interval may also significantly affected course acute malaria increased sympathetic tone due fevers anxiety anorexia onset illness results qt interval shortening patients recover medical therapy qt interval normalizes qt interval normalization day <NUMBER> therapy coincides peak drug level may mistakenly attributed drugs <NUMBER> furthermore bazett formula used malaria studies overestimates number patients qt prolongation could contributed reported qt prolonging effects chloroquine hydroxychloroquine <NUMBER> azithromycin widely utilized macrolide antibiotic reported increase qt interval incidence tdp <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> retrospective observational study <NUMBER> days therapy azithromycin found small statistically significant increase cardiovascular death driven sudden cardiac death effect persist treatment stopped <NUMBER> proarrhythmic mechanism azithromycin thought due drugs ability increase cardiac sodium current promote intracellular sodium loading <NUMBER> however data lacking show increased risk death azithromycin result qt prolongation tdt moreover azithromycin chloroquine combination therapy used protection malaria sexually transmitted infections pregnant women reports syncope sudden cardiac death <NUMBER> study revealed entire cohort treated chloroquinehydroxychloroquine azithromycin increase qtc peak max qtc posttreatment qtc final qtc statistically significant p<NUMBER> table <NUMBER> broken <NUMBER> treatment cohorts shown table <NUMBER> group treated combination therapy longer max final qtc intervals compared monotherapy group p<NUMBER> p<NUMBER> respectively however important highlight patient qtc prolongation resulted tdp seven patients <NUMBER> needed discontinue medications due qtc prolongation two additional patients treated intravenous lidocaine shortened qtc allowing continuation hydroxychloroquine decision discontinue therapy variable based provider personal threshold comfort explains patients similarly prolonged qtc intervals continued therapy volume hospitalized covid<NUMBER> patients increased throughout health system ability monitor every patient receiving combination therapy became limited due finite amount telemetry beds available use mcot patch monitors allowed us expand remote monitoring cardiac arrhythmias qt prolongation patients traditional telemetry mcot monitor food drug administrationapproved measurement analysis reporting qt intervals use monitor resulted reduction exposures personal protective equipment use healthcare workers need serial ecgs monitor qt interval eliminated subset patients investigation combination therapy needed especially given lack randomized controlled trials showing efficacy based experience although patients experience qtc prolongation especially combination therapy used risk arrhythmic death tdt increased furthermore date total <NUMBER> patients received combination hydroxychloroquine azithromycin <NUMBER> patients received hydroxychloroquine alone treatment covid<NUMBER> healthcare system continues reports tdt patients short use combination therapy period <NUMBER> days may warrant monitoring cardiac arrhythmias patients infection disease team longer recommending addition azithromycin coupled findings study simplified approach monitoring patients therapy baseline qtc ≤<NUMBER> ms <NUMBER> bundle branch block qrs duration <NUMBER> ms monitoring serial ecgs required baseline qtc <NUMBER> ms <NUMBER> bundle branch block qrs duration <NUMBER> ms telemetry mcots serial ecgs utilized arrhythmia qtc monitoring performing prospective analysis approach main limitation study absence control cohort patients covid<NUMBER> infections treated medications although would provided stronger analysis nearly every hospitalized patient covid<NUMBER> received ≥<NUMBER> medications course admission study period number patients underlying cardiac disease study small potentially limiting generalizability population study subject limitations observational studies although baseline qt interval readings mcot correlated baseline ecgs subsequent qt intervals mcot subset obtained therapy fact difference filtering mcot patches versus traditional <NUMBER>lead ecg limitation <NUMBER> patients across <NUMBER> hospitals northwell health system received one therapies april <NUMBER> <NUMBER> reported instances tdt statistic although encouraging may subject reporting bias lastly cohort <NUMBER> patients initial phases pandemic represents small fraction total patients treated work needed confirm findings even larger group patients largest reported cohort date patients covid<NUMBER> treated chloroquinehydroxychloroquine without azithromycin observed marked increase qt intervals patients treatment pronounced patients treated combination therapy despite increase patients medications discontinued prematurely due qt prolongation importantly cases torsade de pointes arrhythmic death entire population study need qt interval monitoring needed final recommendations made received april <NUMBER> <NUMBER> accepted april <NUMBER> <NUMBER> <NUMBER> trajectory corrected qt interval qtc changes patients whose hydroxychloroquine hcq±azithromycin azm discontinued due qt prolongation n<NUMBER> majority patients hcq±azm therapy discontinued reached max qtc <NUMBER> ms decision discontinue therapy based clinician preference hydroxychloroquine vitro activity severe acute respiratory syndrome coronavirus sarscov severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> coronaviruses currently investigation clinical trials preexposure postexposure prophylaxis sarscov<NUMBER> infection treatment patients mild moderate severe coronavirus disease <NUMBER> covid <NUMBER> <NUMBER> currently available data randomized clinical trials inform clinical guidance use dosing interactions duration hydroxychloroquine prophylaxis treatment covid<NUMBER> infection recently gautret cols reported hydroxychloroquine treatment significantly associated viral load reductiondisappearance covid<NUMBER> patients effect reinforced azithromycin drug interaction <NUMBER> preliminary results confirmed viral positivity respiratory secretions significantly decreased day <NUMBER> hydroxychloroquine treated covid<NUMBER> patients versus supportive care supporting current choice hydroxychloroquine firstline treatment <NUMBER> <NUMBER> despite limited studies nowadays hydroxychloroquine recommended hospitalized patients confirmed covid<NUMBER> patients mildto moderate disease age <NUMBER> years andor underlying end organ dysfunction lung heart liver etc diabetes coronaropathy chronic obstructive pulmonary disease arterial hypertension severe disease general guiding principles based considerations however therapeutic window quite narrow cardiotoxicityarrhythmia requiring caution use higher cumulative dosages taking also account therapy required mostly older patients andor case severe disease addition slow elimination variable pharmacokinetics hydroxychloroquine frequently lead delayed actions variable clinical response possible variability arises partly drugdrug interactions ddis genetic differences capacity metabolize hydroxychloroquine shown many drugs <NUMBER> contradictory results inhibitory effect hcq cytochromep<NUMBER> isoenzyme <NUMBER>d<NUMBER> cyp<NUMBER>d<NUMBER> activity vivo published humans generally drugs metabolized cyp<NUMBER>d<NUMBER> may inhibit others metabolism great variety drugs metabolized cyp<NUMBER>d<NUMBER> antiarrhythmics antihypertensives ␤ adrenoceptor antagonists monoamine oxidase inhibitors morphine derivatives antipsychotics antidepressants characterization potential interacting drugs affecting activity enzyme clinically important improve safety drug treatment <NUMBER> hand pglycoprotein pgp transport system efflux transporter found notably gut luminal bloodbrain barrier endothelial cells hydroxychloroquine inhibitor transporterpump presenting also possible interaction <NUMBER> keeping mind hydroxychloroquine use recommended elderly patients number ddis monitored polypharmacy prevalence elderly people <NUMBER> associated increased risk ddis impact patient health effectiveness drugs including hydroxychloroquine <NUMBER> addition combinations hydroxychloroquine qtprolonging medications increase risk developing toxic arrhythmia ventricular fibrillation <NUMBER> <NUMBER> <NUMBER> <NUMBER> developed retrospective analytical study common medical prescription older adults potential drug interactions hydroxychloroquine analyzed chronic medication data <NUMBER> older adults recruited october <NUMBER> may <NUMBER> north spain soria previous studies <NUMBER> potential drug interactions hydroxychloroquine identified classified according information published liverpool drug interactions group <NUMBER> drugbank database data analyzed using relative percentage frequencies classes variable characterize sample studied checked fortyseven drugs elaborated table common drugs aforementioned population monitored patients treated hydroxychloroquine total included information twelve ddis see table <NUMBER> following recommendations five drugs coadministered hydroxychloroquine seven may require close monitoring rifampicin phenobarbital phenytoin carbamazepin could reduce exposure hydroxychloroquine anticonvulsans carbamazepine phenytoin phenobarbital induce many cytochromep<NUMBER> glucuronyl transferase enzymes reduce drastically serum concentration associated drugs substrates enzymes attendant risk related adverse effects <NUMBER> <NUMBER> found one study hydroxychloroquine rifampicin interactions case report women due drug interaction suffered toxicoderma causing systemic autoimmune disease due drug interaction <NUMBER> hand amiodarone coadministered hydroxychloroquine could increase effect antiarrhythmic medication among adverse effects pulmonary toxicity causing interstitial pneumonitis dangerous without causal treatment option <NUMBER> moreover mirandaaquino reported long qt syndrome present amiodarone hydroxychloroquine interacted <NUMBER> httpsdoiorg<NUMBER>jarbres<NUMBER> <NUMBER>© <NUMBER> separ published elsevier españa slu rights reserved abbreviations atc anatomical therapeutic chemical code ↑potencial increased exposure comedication seven consumed drugs older adults could cause potential interactions hydroxychloroquine may require close monitoring alteration drug dosage timing administration hydroxychloroquine coadministered digoxin dabigatran nortryptiline apixaban could increase effect comedication similar overdose dabigatran apixaban direct oral anticoagulants substrates pgp inhibitors enzyme may increase bleeding risk dose oral anticoagulants could reduced compensate potential interaction <NUMBER> ido leden cols observed digoxin concentration plasma reduced spite increased administration hydroxychloroquine coadministered <NUMBER> addition citalopram hydroxyzine nortriptyline salmeterol may require close monitoring alteration drug dosage timing administration due relationship qt prolongation associated ddis older adults <NUMBER> <NUMBER> despite limitations selection criteria used classify drugs aimed useful screening process potential ddis prescribing hydroxychloroquine older adults numerous hydroxychloroquine drug interactions currently known potential use agents drug therapy requires consideration patient safety elderly patients considered increased risk frequent severe covid<NUMBER> clinical course clinicians especially cognizant potential ddis conclusion concomitant administration hydroxychloroquine increases bioavailability several drugs older adults could getting worse situation medication errors known compromise patient safety clinical significance interaction hydroxychloroquine several drugs well potential interactions hydroxychloroquine substrates cyp<NUMBER>d<NUMBER> would need evaluated azithromycin <NUMBER> shown therapeutic effects novel coronavirus infection however reported drug better efficacy comparison combination give life saving results therefore present report able provide comprehensive view combining knowledge drugs altogether context current health emergency around world first category drug chloroquine safer derivative hydroxychloroquine may act therapeutic agent covid<NUMBER> infection earlier used widely treatment rheumatoid arthritis systemic lupus erythematosus chloroquine initially used treatment malaria plasmodium falciparum substantially developed resistance subsequent development new antimalarials drug used prophylaxis malaria <NUMBER> introduction hydroxyl group chloroquine derivative produced known hydroxychloroquine found less acute poisoning former one <NUMBER> drugs otherwise share similar mechanism action structure drugs tend increase ph within intracellular vacuoles act weak base addition known alter processes protein degradation acidic hydrolases lysosome assembly macromolecules endosomes post translation modification proteins golgi apparatus <NUMBER> past decades drug received wider attention potential antiviral drug chang colleagues <NUMBER> revealed hydroxychloroquine activates host antiviral innate immunity <NUMBER> drug accumulates cellular organelles creating acidic environment another study revealed ivermectin broad spectrum antiparasitic drug demonstrated efficacy covid<NUMBER> comes second line drug <NUMBER> ivermectin fda approved drug known widespectrum antiviral activity number viruses vitro conditions <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> causative agent covid<NUMBER> single stranded rna virus positive sense closely related sars conditions revealed inhibit viral replication single treatment drug able reduce virus <NUMBER>fold culture within <NUMBER>h however reduction reported increase time period ie <NUMBER>h moreover toxicity seen drug point time <NUMBER> mechanism ivermectin responded cov<NUMBER> virus known believed working similarly acted viruses known inhibit nuclear import viral host proteins integrase protein viruses importin imp αβ<NUMBER> heterodimer responsible nuclear import increases infection figure <NUMBER> rna viruses dependent upon impαβ<NUMBER> infection ivermectin acts inhibits import increase antiviral response <NUMBER> <NUMBER> third category therapeutic drug azithromycin class antibiotics known macrolide used treat infections like bronchitis pneumonia mac mycobacterium avium complex infection spread sarscov<NUMBER> viral pneumonia started wuhan china many countries world started developing countermeasures order decrease spread disease researchers found apart hydroxychloroquine another fda approved drug known azithromycin shown therapeutic effects covid<NUMBER> study done research group new mexico university researchers able prove azithromycin acted acidotropic lipophilic weak base modulate ph endosomes transgolgi network figure <NUMBER> led vitro effects intracellular organelles similar one conferred hydroxychloroquine <NUMBER> indicates antimicrobial drug immense therapeutic value far treatment covid<NUMBER> patients concerned clinical trials need carried drug act prophylaxis declining infection rate drugs shown potential broadspectrum antiviral response vitro many viruses including coronaviruses however hydroxychloroquine found associated dangerous sideeffects past dosage carefully controlled many cases chloroquine poisoning reported nigeria usa well due sudden rapid increase demand broadspectrum drugs may lead significant shortage patients rely drugs treat disorders like malaria rheumatoid arthritis among others therefore adequate buffer stocks maintained drugs overcome potential scarcity abovementioned drugs three categories drugs seem act novel coronavirus infection however research using large cohort samples randomized controlled clinical trials urgently required drug alone incombination order find concrete solution covid<NUMBER> infection world health organization declared pandemic coronavirus disease <NUMBER> covid<NUMBER> due severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> resulting fatal pneumonia treatments urgently needed prevent hypoxaemic respiratory failure death<NUMBER> hydroxychloroquine received worldwide attention vitro study reported potential activity sarscov<NUMBER> small studies released promising results however effectiveness hydroxychloroquine treating covid<NUMBER> subject serious debate<NUMBER> one uncontrolled french study included <NUMBER> hospital inpatients positive sarscov<NUMBER> pcr polymerase chain reaction nasopharyngeal swab study suggested <NUMBER> mgday hydroxychloroquine associated decrease sarscov<NUMBER> shedding combined azithromycin efficacious<NUMBER> however another uncontrolled french study found evidence antiviral clearance hydroxychloroquine azithromycin <NUMBER> patients admitted hospital<NUMBER> recent study randomised <NUMBER> patients two parallel groups control group group receiving hydroxychloroquine <NUMBER> mgday five days study reported shorter time clinical recovery hydroxychloroquine group<NUMBER> however patients severely ill clinical endpoints clearly defined stratification comorbidities known associated poor outcome<NUMBER> based results studies negligible cost known safety profile hydroxychloroquine treating rheumatic conditions drug considered potentially useful treating patients covid<NUMBER> hydroxychloroquine attracted attention social mass media also received us food drug administration approval patients severe covid<NUMBER> however fears increased shortage essential treatment patients rheumatic diseases including systemic lupus erythematus<NUMBER> questions raised safety patients covid<NUMBER> lack unbiased data urgency determining clinical efficacy hydroxychloroquine treat covid<NUMBER> used observational data collected real world setting patients admitted hospital covid<NUMBER> required oxygen evaluated clinical effectiveness oral hydroxychloroquine daily dose <NUMBER> mg admissions intensive care unit death cause secondary outcomes included effectiveness hydroxychloroquine preventing acute respiratory distress syndrome reducing duration oxygen requirement used data collected routine care assess effectiveness hydroxychloroquine patients admitted hospital covid<NUMBER> required oxygen<NUMBER> physicians screened electronic health records patients covid<NUMBER> pneumonia admitted four french tertiary hospitals <NUMBER> march <NUMBER> march <NUMBER> patients eligible study aged <NUMBER> years pcr confirmed sarscov<NUMBER> infection supplementary data <NUMBER> required oxygen mask nasal prongs corresponding progression score <NUMBER> exclusion criteria presence contraindication hydroxychloroquine <NUMBER> mgday including patients receiving dialysis hydroxychloroquine treatment started admission hospital treatment another experimental drug covid<NUMBER> tocilizumab lopinavirritonavir remdesivir within <NUMBER> hours admission organ failure required immediate admission intensive care unit continuous care unit acute respiratory distress syndrome admission defined need noninvasive ventilation provision continuous positive airway pressure invasive mechanical ventilation<NUMBER> discharge intensive care unit standard care decision limit stop active treatments prescribed admission opposition data collection patients legal representative study performed accordance declaration helsinki amended received approval appropriate irb included amendment extension followup <NUMBER> hôpitaux universitaires henrimondor aphp compared two treatment strategies starting hydroxychloroquine dose <NUMBER> mgday treatment group hydroxychloroquine treatment control group dose chosen publication first study hydroxychloroquine treating covid<NUMBER> patients treatment group could start treatment within grace period <NUMBER> hours admission decision whether treat patients hydroxychloroquine based local medical consensus clinicians’ opinion effectiveness decision made patients admitted hospital characteristics played part supplementary data <NUMBER> provides additional information number patients group hospital start followup baseline time zero patient time admission hospital patients followed baseline death loss followup end followup <NUMBER> april <NUMBER> whichever occurred first primary outcome survival without transfer intensive care unit day <NUMBER> secondary outcomes overall survival survival without acute respiratory distress syndrome weaning oxygen discharge hospital home rehabilitation day <NUMBER> patients received hydroxychloroquine qt prolongation assessed <NUMBER> lead electrocardiogram corrected heart rate bazett’s fredericia’s formula start treatment three five days inverse probability treatment weighting approach used balance differences baseline variables treatment groups<NUMBER> <NUMBER> nonparsimonious multivariable logistic regression model constructed estimate patient’s probability receiving hydroxychloroquine given baseline covariates propensity score variables propensity score model planned prespecified outcome analyses several variables included age sex comorbidities presence chronic respiratory insufficiency oxygen treatment asthma cystic fibrosis chronic respiratory disease likely result decompensation viral infection heart failure new york heart association class iii iv chronic kidney disease liver cirrhosis childpugh class b personal history cardiovascular disease hypertension stroke coronary artery disease cardiac surgery insulin dependent diabetes mellitus diabetic microangiopathy macroangiopathy treatment immunosuppressive drugs including anticancer chemotherapy uncontrolled hiv infection hiv infection cd<NUMBER> cell counts <NUMBER>µl haematological malignancy body mass index ≥<NUMBER> third trimester pregnancy treatment angiotensin converting enzyme inhibitors angiotensin receptor blockers<NUMBER> time since symptom onset severity condition admission percentage lung affected ≥<NUMBER> presence confusion respiratory frequency oxygen saturation without oxygen oxygen flow systolic blood pressure c reactive protein level variables included propensity score model reflected knowledge available baseline standardised differences examined assess balance threshold <NUMBER> designated indicate clinically meaningful imbalance<NUMBER> crude survival rates computed using kaplanmeier method cox proportional hazards models used compute inverse probability treatment weighting hazard ratios inverse probability treatment weighting estimates relative risk computed binary outcomes outcomes presented total population subgroup patients better prognosis admission estimated quick sepsis related organ failure assessment score less <NUMBER> <NUMBER> causal contrast interest per protocol effect compared participants received hydroxychloroquine within <NUMBER> hours admission receive drug patients subsequently received hydroxychloroquine <NUMBER> hours specified two additional comparisons firstly mimicking intentiontotreat analysis patients eligible study analysed received hydroxychloroquine <NUMBER> hours analysed control group secondly mimicking astreated analysis patients received hydroxychloroquine <NUMBER> hours analysed treatment group performed sensitivity analyses assess robustness findings firstly conducted trimmed analysis truncated region common support defined overlap range propensity scores treatment group control group patients propensity scores outside region common support excluded analysis secondly account time dependent bias performed analysis patients control group reached primary outcome transfer intensive care unit death grace period randomly assigned one two groups given observational data compatible groups time event<NUMBER> missing baseline variables handled multiple imputation chained equations using variables available statistical analyses performed r statistical package version <NUMBER> later r foundation statistical computing httpswwwrprojectorg neither patients public involved conception conduct study propensity scores ranged <NUMBER> <NUMBER> treatment group <NUMBER> <NUMBER> control group <NUMBER> region common support propensity scores <NUMBER> supplementary data <NUMBER> inverse probability treatment weighting applied <NUMBER> <NUMBER> covariates planned propensity score weighted standardised differences <NUMBER> four covariates confusion admission chronic kidney disease chronic heart failure new york heart association class iii iv liver cirrhosis childpugh class b exceeded threshold supplementary data <NUMBER> results owing absence confusion admission treatment group compared six patients confusion control group one patient chronic kidney disease treatment group compared eight control group one patient chronic heart failure treatment group compared five control group one patient liver cirrhosis treatment group compared patients control group four variables therefore included final propensity score model supplementary data <NUMBER> median followup surviving patients <NUMBER> days three patients one treatment group two control group <NUMBER> lost followup discharged good health without oxygen two patients followup <NUMBER> days day <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients died nine treatment group eight control group nonweighted analyses among <NUMBER> patients two treatment groups rate survival without transfer intensive care <NUMBER> days <NUMBER> treatment group compared <NUMBER> control group hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> fig <NUMBER> overall survival rate <NUMBER> days <NUMBER> treatment group <NUMBER> control group <NUMBER> <NUMBER> <NUMBER> rate survival without acute respiratory distress syndrome <NUMBER> treatment group <NUMBER> control group <NUMBER> <NUMBER> <NUMBER> table <NUMBER> supplementary data <NUMBER> <NUMBER> day <NUMBER> <NUMBER> patients treatment group weaned oxygen compared <NUMBER> control group relative risk <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> furthermore <NUMBER> patients groups discharged home rehabilitation <NUMBER> <NUMBER> <NUMBER> table <NUMBER> none <NUMBER> patients received combination hydroxychloroquine azithromycin transferred intensive care none died additionally patients fewer severe signs admission compared patients received hydroxychloroquine without azithromycin oxygen flow <NUMBER> lmin interquartile range <NUMBER> v <NUMBER> lmin <NUMBER> respiratory frequency <NUMBER> per min interquartile range <NUMBER> v <NUMBER> per min <NUMBER> percentage lung affected <NUMBER> <NUMBER> v <NUMBER> finally <NUMBER> patients received azithromycin without hydroxychloroquine among patients six admitted intensive care unit five died inverse probability treatment weighting analyses took imbalance baseline account among <NUMBER> patients two groups survival rate without transfer intensive care unit day <NUMBER> <NUMBER> treatment group <NUMBER> control group weighted hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> fig <NUMBER> overall survival rate day <NUMBER> <NUMBER> treatment group <NUMBER> control group <NUMBER> <NUMBER> <NUMBER> rate survival without acute respiratory distress syndrome day <NUMBER> <NUMBER> treatment group compared <NUMBER> control group <NUMBER> <NUMBER> <NUMBER> table <NUMBER> supplementary data <NUMBER> <NUMBER> day <NUMBER> <NUMBER> patients treatment group weaned oxygen compared <NUMBER> control group weighted relative risk <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> furthermore <NUMBER> patients treatment group discharged home rehabilitation compared <NUMBER> control group <NUMBER> <NUMBER> <NUMBER> table <NUMBER> sensitivity analyses consistent principal analysis found hydroxychloroquine effect outcome supplementary data <NUMBER> results also suggested patients fewer symptoms better prognosis admission respond hydroxychloroquine quick sepsis related organ failure assessment score less <NUMBER> n<NUMBER> treatment group n<NUMBER> control group weighted hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> survival without transfer intensive care unit weighted hazard ratio <NUMBER> <NUMBER> <NUMBER> overall survival weighted hazard ratio <NUMBER> <NUMBER> <NUMBER> survival without acute respiratory distress syndrome weighted relative risk <NUMBER> <NUMBER> <NUMBER> oxygen weaning weighted relative risk <NUMBER> <NUMBER> <NUMBER> discharge home rehabilitation finally adding eight patients received hydroxychloroquine treatment <NUMBER> hours admission population <NUMBER> including treatment group mimicking astreated analysis control group mimicking intentiontotreat analysis change results weighted hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> primary outcome respectively supplementary data <NUMBER> <NUMBER> <NUMBER> patients received hydroxychloroquine within first <NUMBER> hours eight <NUMBER> experienced electrocardiographic modifications required discontinuation hydroxychloroquine median <NUMBER> days interquartile range <NUMBER> days began accordance french national guidelines among patients seven corrected qt interval prolongation <NUMBER> ms including one patient corrected qt interval prolongation <NUMBER> ms one patient received drugs might interfered cardiac conduction presented first degree atrioventricular block two days hydroxychloroquine treatment one patient hydroxychloroquine started five days admission control group transferred intensive care two days later patient prescribed lopinavir ritonavir developed left bundle branch block day <NUMBER> none patients concomitantly treated azithromycin study several limitations firstly although used robust methods statistical techniques draw causal inferences observational data treatment randomly assigned potential unmeasured confounders could bias results secondly four potentially important prognostic variables could balanced propensity score model none one patient treatment group presented variables accordingly caution required interpreting results especially overall mortality events observed nevertheless limitation favour hydroxychloroquine group absence difference treated untreated patients strengthens conclusions thirdly take centre effect account propensity score model number patients treated hydroxychloroquine centres unbalanced centres treated patients whereas others nevertheless decision treat treat patients hydroxychloroquine based local medical consensus rather characteristics reduce bias fourthly sample limited number eligible patients available time analysis cannot rule possibility findings owing lack power fifthly included patients admitted hospital cannot reach conclusion possible efficacy hydroxychloroquine preventing covid<NUMBER> preventing severe forms disease finally study designed assess efficacy association hydroxychloroquine azithromycin conclusion efficacy reached research ongoing patients admitted hospital covid<NUMBER> pneumonia require oxygen hydroxychloroquine treatment seemed effect reducing admissions intensive care deaths day <NUMBER> hospital admission additionally hydroxychloroquine treatment effect survival without acute respiratory distress syndrome day <NUMBER> hospital admission results support use hydroxychloroquine patients rapidly progressing coronavirus disease <NUMBER> covid<NUMBER> pandemic led overwhelming interest treatment prevention therapeutics approved therapy covid<NUMBER> number trials initiated including hydroxychloroquine losartan remdesivir tocilizumab intravenous immunoglobulin convalescent plasma <NUMBER> <NUMBER> recruiting yet recruiting treatment studies listed clinicaltrialsgov march <NUMBER> <NUMBER> although reports surfaced regarding use chloroquine hydroxychloroquine drugs used malaria efficacy covid<NUMBER> remains uncertain hydroxychloroquine known vitro activity severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> virus however half maximal effective concentration ec <NUMBER> sarscov<NUMBER> virus different malaria <NUMBER>fold higher vitro ec <NUMBER> hydroxychloroquine sarscov<NUMBER> vs malaria ec <NUMBER> values sarscov<NUMBER> virus literature ranged <NUMBER> μm higher ec <NUMBER> values generally associated higher multiplicity infections indicative potential need greater systemic exposure higher viral loads <NUMBER> <NUMBER> hydroxychloroquine also proposed prophylactic agent high risk healthcare workers immunocompromised household contacts infected individuals oral hydroxychloroquine authorized emergency use us food drug administration fda march <NUMBER> <NUMBER> treat adult adolescent patients weigh <NUMBER> kg hospitalized  findings intended guide research community optimizing dose selection covid<NUMBER> prevention early treatment trials covid<NUMBER> clinical trial available participation feasible httpswwwfdagovmedia <NUMBER> <NUMBER>download approved sarscov<NUMBER> prevention scientifically established doses sarscov<NUMBER> although pharmacometric modeling simulation used several groups propose potential regimens <NUMBER> targeted hospitalized patients advanced disease models specifically evaluated regimens context prophylaxis known pharmacokinetics hydroxychloroquine comes use indications outside covid<NUMBER> malaria rheumatoid arthritis systemic lupus erythematosus hydroxychloroquine linear kinetics high volume distribution readily distributes number tissues <NUMBER> <NUMBER> elimination halflife long pharmacokinetic studies indicating ranges <NUMBER> days <NUMBER> long halflife hydroxychloroquine concentrations sustained days completion treatment course team recently launched nationwide clinical trial examining efficacy shortcourse hydroxychloroquine postexposure prophylaxis early preemptive treatment covid<NUMBER> nct<NUMBER> also process launching protocols preexposure prophylaxis healthcare workers organ transplant recipients choosing correct dose clinical trial needs consider risk toxicities also ensure best chance successful achievement therapeutic targets hydroxychloroquine doses used malaria largely adopted covid<NUMBER> treatment prophylaxis however team sought reevaluate doses evaluate new doses generate rational approach dose selection using simulation models proposed efficacy targets simulated potential dosing regimens preprophylaxis postexposure prophylaxis scenarios using hydroxychloroquine population pharmacokinetic parameter estimates derived hydroxychloroquine plasma concentrations <NUMBER> individuals <NUMBER> healthy volunteers <NUMBER> patients malaria <NUMBER> r package mrgsolve used build population pharmacokinetic simulation rstudio version <NUMBER> rstudio boston median <NUMBER>th percentile hydroxychloroquine simulated concentrations n <NUMBER> subjects time calculated percent subjects troughs sarscov<NUMBER> target concentration ec <NUMBER> <NUMBER> μm <NUMBER> median time target reported preexposure simulations weekly troughs reported whereas postexposure simulations daily troughs reported prophylaxis would given high viral loads achieved targeted lower range ec <NUMBER> <NUMBER> μm <NUMBER> aimed keep least <NUMBER> subjects target postexposure preemptive treatment settings simulated exposures <NUMBER> days represent typical incubation time sarscov<NUMBER> <NUMBER> simulated current fda approved dosing malaria treatment <NUMBER> mg followed <NUMBER> mg <NUMBER> <NUMBER> <NUMBER> hours initial dose total <NUMBER> days prophylaxis <NUMBER> mg weekly regimens tested recent covid<NUMBER> trials ie <NUMBER> mgday <NUMBER> days <NUMBER> mg <NUMBER> times daily <NUMBER> days <NUMBER> <NUMBER> also tested recommended regimens ec <NUMBER> target <NUMBER> μm account potential differences vitro plasma protein binding <NUMBER> simulated concentrationtime data tested regimens shown figure <NUMBER> figures s<NUMBER>s<NUMBER> table <NUMBER> shows percent simulated subjects hydroxychloroquine trough concentrations targeted ec <NUMBER> <NUMBER> cumulative time ec <NUMBER> simulated drug treatment period figures s<NUMBER>s<NUMBER> first examined current prophylaxis preexposure treatment postexposure doses malaria simulations onceweekly dosing predicted <NUMBER> subjects would troughs target per week steadystate reached table <NUMBER> fda recommended treatment dose malaria <NUMBER> mg loading dose followed <NUMBER> mg daily total <NUMBER> days simulations predicted <NUMBER> subjects would troughs target day <NUMBER> however number dropped <NUMBER> day <NUMBER> postexposure start prophylaxis table <NUMBER> next simulated modified dosing scenarios found preexposure prophylaxis <NUMBER> mg loading dose followed <NUMBER> mg dose given <NUMBER> <NUMBER> times weekly maintains weekly troughs ec <NUMBER> <NUMBER> subjects table <NUMBER> figure <NUMBER>a c reaching steadystate postexposure setting simulations indicated <NUMBER> mg loading dose followed <NUMBER> hours <NUMBER> mg daily least <NUMBER> days maintains daily troughs ec <NUMBER> <NUMBER> subjects least <NUMBER> weeks presumed viral incubation time table <NUMBER> also examined treatment regimens tested recently published reports <NUMBER> mgday <NUMBER> days vs <NUMBER> mg <NUMBER> times day <NUMBER> days found latter regimen maintained daily troughs target <NUMBER> subjects table <NUMBER> ec <NUMBER> <NUMBER> μm targeted prophylactic setting twice <NUMBER> times weekly dosing underperformed higher frequent dosing may required table s<NUMBER> postexposure regimens <NUMBER> days <NUMBER> mg daily dosing <NUMBER> patients target <NUMBER> days daily dosing <NUMBER> days would required maintain prophylaxis almost <NUMBER> days absence validated therapeutic concentration targets covid<NUMBER> prevention treatment simulations meant guide researchers doseselection covid<NUMBER> studies aim optimize exposures vitro generated ec <NUMBER> <NUMBER> important note vitro vivo extrapolations could either underestimate overestimate actual drug requirements however reasonable starting point absence data notably therapeutic effect may maintained even longer preclinical models demonstrated <NUMBER>fold accumulation hydroxychloroquine lung tissue <NUMBER> similar proposed treatment groups <NUMBER> simulations suggest higher treatment prophylactic doses covid<NUMBER> may needed recommended malaria consistent <NUMBER>fold lower vitro ec <NUMBER> malaria compared sarscov<NUMBER> <NUMBER> unlike malaria dosing recommended start <NUMBER> weeks travel endemic area prevention covid<NUMBER> requires rapid attainment therapeutic concentrations thus supporting rationale loading dose preexposure prophylaxis setting although general hydroxychloroquine welltolerated drug increasing dose may come untoward effects table <NUMBER> percentage simulated subjects troughs targeted ec <NUMBER> median cumulative time targeted ec <NUMBER> <NUMBER> μm end prophylactic durations preexposure postexposure prophylaxis preexposure prophylaxis <NUMBER>week simulation duration week carefully monitored hydroxychloroquine systemic severe adverse effects include retinaltoxicity cardiotoxicity however toxicities mostly associated daily andor longterm use chose simulate total plasma concentrations vitro generated ec <NUMBER> proteinadjusted yet performed presence protein <NUMBER> previous studies shown vitro protein binding occur presence added protein may equal plasma proteinbinding may observed clinically humans <NUMBER> therefore also evaluated regimens <NUMBER> μm ec <NUMBER> would assume vitro protein binding ie extreme scenario found higher dosing would likely required preexposure setting whereas postexposure regimen performed reasonably although target concentrations maintained long higher ec <NUMBER> targets required dosing may exceed therapeutic index although largely unknown hydroxychloroquine context covid<NUMBER> notably many infections eg malaria influenza pneumocystis pneumonia dosing prophylaxis substantially lower used treatment yet highly effective march <NUMBER> <NUMBER> two peerreviewed studies available examined efficacy hydroxychloroquine treatment covid<NUMBER> testing different dose reaching different conclusions <NUMBER> first clinical study france tested <NUMBER> mg <NUMBER> times daily hydroxychloroquine <NUMBER> days reported promising antiviral effect polymerase chain reactionnegative nasopharyngeal swabs <NUMBER> <NUMBER> patients day <NUMBER> compared <NUMBER> <NUMBER> controls <NUMBER> however authors noted additional six subjects hydroxychloroquine removed analysis complete therapy five still polymerase chain reactionpositive time dropout modest success consistent model simulations contrast study performed china tested <NUMBER> days <NUMBER> mgday observed difference treatment control groups <NUMBER> <NUMBER> vs <NUMBER> <NUMBER> achieving viral negative swabs day <NUMBER> <NUMBER> simulations shown <NUMBER> days <NUMBER> mg without loading dose sufficient maintain daily troughs ec <NUMBER> <NUMBER> subjects <NUMBER> days furthermore patients active covid<NUMBER> disease may require different efficacy target due higher viral loads simulations used pharmacokinetic data obtained healthy volunteers patients malaria caution taken extrapolating populations especially may organ dysfunction critically ill patients covid<NUMBER> recent transplant recipients data need validated pharmacokinetic clinical trials objective assess efficacy safety hydroxychloroquine plus standard care compared standard care alone adults coronavirus disease <NUMBER> covid<NUMBER> design multicentre open label randomised controlled trial setting <NUMBER> government designated covid<NUMBER> treatment centres china <NUMBER> <NUMBER> february <NUMBER> participants <NUMBER> patients admitted hospital laboratory confirmed covid<NUMBER> included intention treat analysis <NUMBER> patients assigned hydroxychloroquine plus standard care <NUMBER> standard care alone interventions hydroxychloroquine administrated loading dose <NUMBER> mg daily three days followed maintenance dose <NUMBER> mg daily total treatment duration two three weeks patients mild moderate severe disease respectively main outcome measure negative conversion severe acute respiratory syndrome coronavirus <NUMBER> <NUMBER> days analysed according intention treat principle adverse events analysed safety population hydroxychloroquine recipients participants received least one dose hydroxychloroquine hydroxychloroquine nonrecipients managed standard care alone results <NUMBER> patients <NUMBER> mild moderate disease two severe disease mean duration symptom onset randomisation <NUMBER> sd <NUMBER> range <NUMBER> days total <NUMBER> <NUMBER> patients <NUMBER> standard care <NUMBER> standard care plus hydroxychloroquine negative conversion well <NUMBER> days remaining <NUMBER> <NUMBER> patients <NUMBER> standard care <NUMBER> standard care plus hydroxychloroquine censored reach negative conversion virus probability negative conversion <NUMBER> days standard care plus hydroxychloroquine group <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> similar standard care group <NUMBER> <NUMBER> <NUMBER> difference groups <NUMBER> <NUMBER> confidence interval <NUMBER> <NUMBER> safety population adverse events recorded <NUMBER> <NUMBER> hydroxychloroquine nonrecipients <NUMBER> <NUMBER> hydroxychloroquine recipients common adverse event hydroxychloroquine recipients diarrhoea reported <NUMBER> <NUMBER> patients two hydroxychloroquine recipients reported serious adverse events conclusions administration hydroxychloroquine result significantly higher probability negative conversion standard care alone patients admitted hospital mainly persistent mild moderate covid<NUMBER> adverse events higher hydroxychloroquine recipients nonrecipients trial registration chictr<NUMBER> hydroxychloroquine patients mainly mild moderate coronavirus disease <NUMBER> open label randomised controlled trial email juanmaciassanchezgmailcom rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity incidence severity covid<NUMBER> among patients autoimmune rheumatic diseases without hydroxychloroquine significantly different hydroxychloroquine seem appropriate therapy postexposure prophylaxis covid<NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint coronavirus disease <NUMBER> covid<NUMBER> pandemic currently health emergency caused around <NUMBER> deaths worldwide four months finding effective therapy prophylactic strategies become maximum priority <NUMBER> hydroxychloroquine hcq shown active severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> vitro inhibiting several steps viral replication cycle including earliest ones fusion cell membrane <NUMBER> reason despite vivo effectivity hcq still matter controversy <NUMBER> <NUMBER> using drug proposed rational strategy postexposure prophylaxis sarscov<NUMBER> infection <NUMBER> indeed least nine clinical trials aimed test hypothesis currently ongoing <NUMBER> hcq commonly used part therapy several autoimmune inflammatory diseases rheumatoid arthritis ra systemic lupus erythematous sle hcq effective postexposure prophylaxis sarscov<NUMBER> reduced incidence covid<NUMBER> could expected patients receiving treatment drug data issue may provide us worthy information potential hcq therapy prophylactic strategy may help better design clinical trials study aimed compare incidence covid<NUMBER> spanish patients autoimmune rheumatic diseases treated hcq without hcq therapy seven weeks pandemic rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> study approved ethic committee valme university hospital rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint seven hundred twentytwo subjects studied two hundred ninety <NUMBER> receiving hcq main features study population including hcq therapy shown table <NUMBER> sevenweek study period five <NUMBER> <NUMBER> ci <NUMBER> cases covid<NUMBER> registered among patients treated hcq five <NUMBER> <NUMBER> p<NUMBER> group subjects receiving drug cases among groups patients met criteria possible covid<NUMBER> four vs two cases respectively confirmed covid<NUMBER> diagnosed one <NUMBER> <NUMBER> ci <NUMBER> subject treated hcq two <NUMBER> <NUMBER> ci <NUMBER> without drug p<NUMBER> table <NUMBER> one patient hcq two subjects without hcq admitted hospital none required transferred intensive care unit icu patient died episode rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint <NUMBER> according results hcq treatment seem appropriate therapy postexposure prophylaxis sarscov<NUMBER> fact incidence covid<NUMBER> among patients autoimmune rheumatic diseases hcq treatment significantly different observed subjects receiving hcq addition severity covid<NUMBER> measured rate admission icu requirement similar groups patients immunemediated inflammatory diseases population particular features includes frequent use biologic agents immunomodulatory drugs fact could increase incidence worsen outcome covid<NUMBER> however preliminary data caseseries new york city suggested use drugs associated different clinical profile covid<NUMBER> <NUMBER> addition study period province seville area <NUMBER> inhabitants <NUMBER> confirmed covid<NUMBER> cases reported <NUMBER> yields overall incidence <NUMBER> <NUMBER> ci <NUMBER> cases figure inside <NUMBER> ci confirmed covid<NUMBER> found herein subjects taking hcq therapy study limitations first cases possible likely covid<NUMBER> cases shortage diagnostic kits health care system collapse spain countries led fact many cases covid<NUMBER> able confirmed addition data come hospital registers mild cases could seen primary care likewise asymptomatic cases would rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint <NUMBER> gone unnoticed however even omitted patients data show incidence covid<NUMBER> subjects treated hcq would far zero therefore hcq would ideal therapy postexposure prophylaxis sarscov<NUMBER> infection summary although definitive information effectiveness hcq postexposure prophylaxis sarscov<NUMBER> infection eventually come controlled clinical trials according results strategies designed tested since hcq monotherapy best protect significant number infections coronavirus rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity n c n l e v g l n c e p e l ó g c n f r e b r e l u c ó n e c v <NUMBER> e n e p ñ pathogen causing covid<NUMBER> identified novel coronavirus sequencing lower respiratory tract samples affected patients novel coronavirus shares <NUMBER>·<NUMBER> sequence identity severe acute respiratory syn drome coronavirus sarscov <NUMBER> named severe acute respiratory syndrome corona virus <NUMBER> sarscov<NUMBER> since detection december <NUMBER> virus spread rapidly <NUMBER> countries territories around world declared pandemic march <NUMBER> <NUMBER> currently specific treatment available covid <NUMBER> although comorbidities diabetes cardiac disease identified risk factors severe covid<NUMBER> <NUMBER> whether patients autoimmune rheumatic disease increased vulnerability infection remains unknown autoimmune rheumatic diseases characterised irregular functioning immune system immunemediated inflammation target tissues patients autoimmune rheumatic diseases rely immunosuppressive diseasemodifying antirheumatic drugs dmards control symptoms disease pro gression therefore immunocompromised susceptible infections general population <NUMBER> however several dmards including hydroxychloroquine baricitinib investigated antiviral effects covid<NUMBER> might affect susceptibility patients rheumatic diseases sarscov<NUMBER> infection <NUMBER> <NUMBER> immune system important role defence viruses virusassociated tissue damage patients sarscov<NUMBER> infection completely recover result effective immune responses thevarajan colleagues <NUMBER> noted circu lating concentrations antibodysecreting cells acti vated follicular helper cells two important immune cell popu lations responsible antiviral immunity increased symptomatic recovery patient covid<NUMBER> concurrent clearance sarscov<NUMBER> recent studies also shown antibodies sarscov<NUMBER> could generated efficiently recovery covid<NUMBER> might provide protection covid<NUMBER> convalescent plasma transfusion <NUMBER> <NUMBER> results suggest anti viral immune response crucial viral clearance however hyperactivation immune response covid<NUMBER> might also cause tissue damage lungs organs <NUMBER> <NUMBER> therefore several immunomodulating drugs including corticosteroids hydroxychloro quine anticytokine agents used treatment severe cases covid<NUMBER> <NUMBER> ongoing covid<NUMBER> pandemic urgent need timely research assess susceptibility patients rheumatic disease sarscov<NUMBER> infection potential risks benefits using antirheumatic drugs covid<NUMBER> treatment analyses comorbidities patients covid<NUMBER> suggest diabetes respiratory disease cardiovascular disease might risk factors covid<NUMBER> <NUMBER> however susceptibility covid<NUMBER> among patients lowprevalence disorders rheumatic diseases difficult assess general population aimed investigate susceptibility covid<NUMBER> patients autoimmune rheumatic diseases hubei province china multicentre retrospective observational study patients rheumatic disease hubei province epicentre covid<NUMBER> outbreak china study protocol approved institutional review board tongji hospital tongji medical college huazhong university science technology registered chictrorg chictr<NUMBER> telephonebased survey patients rheumatic disease investigate susceptibility covid<NUMBER> inclusion criteria follows confirmed diagnosis rheumatic disease including rheumatoid arthritis systemic lupus erythematosus sle sjögrens syndrome polymyositis dermatomyo sitis igg<NUMBER>related disease undifferentiated connective tissue disease disease duration least <NUMBER> months following patients excluded study patients diagnosed rheumatic diseases require immunosuppressive therapy gout osteoarthritis ankylosing spondylitis china patients ankylosing spondylitis treated nonsteroidal antiinflammatory drugs relatively small proportion <NUMBER> study used immunosuppressive agents tumour necrosis factor tnf inhibitors patients invalid contact information answer telephone three consecutive calls interval <NUMBER> per day patients declined participation discontinued completion survey patient demographic information including age sex telephone number medical history data current medi ca tion use retrieved smart system disease management ssdm information covid<NUMBER> exposure diagnosis patients families collected automated telephone survey answers converted text spreadsheet automatic speech recognition programme azure microsoft following information acquired subsequent telephone call carried medical professionals total number family members residing address outbreak infection status covid<NUMBER> date covid<NUMBER> diagnosis severity lab oratory tests sarscov<NUMBER> rna hospital evidence study searched pubmed sciencedirect google scholar march <NUMBER> <NUMBER> studies reporting susceptibility covid<NUMBER> patients rheumatic disease using search terms covid<NUMBER> susceptibility coronavirus disease susceptibility novel coronavirus susceptibility rheumatic disease rheumatic condition identified published research articles reporting susceptibility covid<NUMBER> patients rheumatic disease also searched studies assessing effects antirheumatic medications covid<NUMBER> patients rheumatic disease using search terms covid<NUMBER> coronavirus disease novel coronavirus rheumatic disease rheumatic condition antirheumatic medication identify research articles assessing potential effect antirheumatic medications covid<NUMBER> patients best knowledge first study based primary dataset cases close contacts analyse susceptibility patients autoimmune rheumatic disease covid<NUMBER> patients autoimmune rheumatic disease higher rate covid<NUMBER> family members living household outbreak <NUMBER> vs <NUMBER> finding provides insight risk covid<NUMBER> patients autoimmune rheumatic diseases results indicate patients rheumatic disease might susceptible covid<NUMBER> general population findings valuable strategic planning management patients rheumatic disease ongoing covid<NUMBER> pandemic admission status admitted hospital selfquarantined outpatient diagnosis past medical history age sex infected individuals use current antirheumatic medications also confirmed patients survey ensure records medical system accurate covid<NUMBER> cases among patients rheumatic disease household members identified selfreporting inpatient diagnosis outpatient diagnosis local designated hospitals telephone surveys families least one household member diagnosed covid<NUMBER> dec <NUMBER> <NUMBER> march <NUMBER> <NUMBER> identified members household considered direct covid<NUMBER> exposure history patients rheumatic disease family members without rheumatic disease residing physical address outbreak considered close contacts tested sarscov<NUMBER> rna designated local hospitals confirmed case family individuals diagnosed covid<NUMBER> either selfisolated admitted hospital diagnosis diagnosis covid<NUMBER> determined according guidance coronavirus disease <NUMBER> <NUMBER>th edition released national health commission china either confirmed positive sarscov<NUMBER> rna test clinical diagnosis close contact history plus covid<NUMBER> symptoms plus typical highresolution ct imaging features covid<NUMBER> realtime pcr tests sarscov<NUMBER> rna done designated local hospitals covid<NUMBER> patients family members incidence covid<NUMBER> calculated total number infected individuals divided number individuals covid<NUMBER> exposure history statistical analyses done graphpad prism version <NUMBER> graphpad software spss version <NUMBER> ibm spss statistics descriptive frequency statistics mean sd percentages used describe baseline demographic information clinical information age sex smoking history comorbidities previously reported associated covid<NUMBER> mortality <NUMBER> selected <NUMBER> excluded <NUMBER> invalid contact number respond <NUMBER> declined participation discontinued survey completion covariates clinical relevance logistic regres sion models missing data age sex family members imputed fully conditional specification method ten imputations missing data value binary logistic regression analyses done spss version <NUMBER> analyse effect rheumatic disease demographic factors antirheumatic medications covid<NUMBER> infection individuals exposure history conditional logistic regression used adjust multiple potential confounders including cluster effect family assessing potential effect rheumatic disease covid<NUMBER> infection study patients rheumatic disease family members clustered family level comparison continuous variables two groups done students test tests twotailed p values less <NUMBER>·<NUMBER> considered significant funders study role study design data collection data analysis data interpreta tion writing report corresponding author full access data study final responsibility decision submit publication march <NUMBER> march <NUMBER> <NUMBER> identified <NUMBER> <NUMBER> patients confirmed diagnosis rheumatic disease hubei province china ssdm medical record system exclusion <NUMBER> patients receiving immunosuppressive therapy <NUMBER> <NUMBER> patients autoimmune rheumatic diseases contacted telephone figure among <NUMBER> <NUMBER> patients <NUMBER> invalid telephone number answer telephone resulting pickup rate <NUMBER>·<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients declined participation discontinued study completion survey also excluded therefore analysed data <NUMBER> patients autoimmune rheumatic diseases characteristics included excluded patients summarised appendix p <NUMBER> mean age patients <NUMBER>·<NUMBER> sd <NUMBER>·<NUMBER> years female male patients figure <NUMBER> families patients autoimmune rheumatic disease covid<NUMBER> <NUMBER> families patients autoimmune rheumatic disease family members without rheumatic disease covid<NUMBER> <NUMBER> families family members without autoimmune rheumatic disease covid<NUMBER> appendix p <NUMBER> five families patients rheumatic disease developed symp toms first three families house hold members rheumatic disease developed symptoms first three families household members developed symptoms around time compare infection rates patients rheumatic disease versus without analysed infection rates <NUMBER> families confirmed covid<NUMBER> exposure history significant difference age observed patients rheumatic disease data n n dmardsdiseasemodifying antirheumatic drugs data dmard use provided <NUMBER> patients percentages reported subpopulation patients taking two dmards analyse whether antirheumatic drugs associated susceptibility covid<NUMBER> patients rheumatic disease compared characteristics patients covid<NUMBER> without covid<NUMBER> table <NUMBER> mean age patients covid<NUMBER> <NUMBER>·<NUMBER> sd <NUMBER>·<NUMBER> years noncovid<NUMBER> patients <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> years p<NUMBER>·<NUMBER> <NUMBER> <NUMBER> <NUMBER> patients rheumatic disease history exposure covid<NUMBER> hydroxychloroquine medication significant differences age sex comorbidities prescrip tions immunosuppressive drugs patients taking hydroxychloroquine take hydroxychloroquine appendix p <NUMBER> however patients sle tended prescribed hydroxychloroquine often patients rheumatic diseases therefore sle included confounder assessing potential effects antirheumatic medications covid<NUMBER> nine <NUMBER> <NUMBER> patients without covid<NUMBER> autoimmune rheu matic disease taking hydroxychloroquine whereas seven <NUMBER> <NUMBER> patients rheumatic disease covid<NUMBER> hydroxychloroquine treatment adjustment age sex smoking infection family members comorbidities sle patients rheumatic disease taking hydroxychloroquine lower risk covid<NUMBER> taking dmards <NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> contrast rate corticosteroid use patients covid<NUMBER> similar without covid<NUMBER> <NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> p<NUMBER>·<NUMBER> patients taking lowdose mediumdose corticosteroids ranging <NUMBER> mg per day <NUMBER> mg per day converted dose prednisone appendix p <NUMBER> observed significant differences age sex smoking history comorbidities use dmards risk covid<NUMBER> patients rheumatic disease remains unclear <NUMBER> although patients rheumatic disease certain medications immunocompromised vulnerable infection several antirheumatic medications proposed antiviral effect nevertheless data epidemiological characteristics covid<NUMBER> patients rheumatic disease scarce study provides insight covid<NUMBER> susceptibility patients autoimmune rheumatic diseases patients autoimmune rheumatic diseases rely dmards control autoimmune processes disease progression dysregulated immune function immunosuppressive effect dmards patients medications increased vulnerability infections autoimmune rheumatic diseases frequently complicated primary immunodeficiency <NUMBER> therefore autoimmune disease result immunosuppression increased risk infection additionally use dmards associated increased risk infection <NUMBER> recent analysis clinical features covid<NUMBER> <NUMBER> patients rheumatic diseases showed patients rheumatic diseases might increased risk developing respiratory failure develop covid<NUMBER> <NUMBER> dmards hydroxychloroquine baricitinib proposed antiviral effects patients sarscov<NUMBER> infection biological dmards interleukin il<NUMBER> il<NUMBER> inhibitors also suggested treatment covid<NUMBER> subset patients hyperinflammation <NUMBER> study italy reported four cases confirmed covid<NUMBER> four highly suggestive cases covid<NUMBER> eight patients taking biological targeted synthetic dmards rheumatoid arthritis spondyloarthritis <NUMBER> none patients developed severe respiratory complications authors suggested treatments might suppress aberrant inflammatory cytokine response responsible sex male vs female <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> <NUMBER>·<NUMBER> orodds ratio expressed estimated increase odds infection per year increase age p values multivariable logistic model severe respiratory complications covid<NUMBER> <NUMBER> anakinra biological dmard blocks il<NUMBER> signalling also shown beneficial effects reducing covid<NUMBER> mortality invasive mechanical ventilation rates patients hyperinflammation although clinical trials required confirm efficacy <NUMBER> <NUMBER> analysis data covid<NUMBER> global rheumatology alliance physicianreported registry use tnf inhibitors patients rheumatic diseases associated reduced risk hospital admission covid<NUMBER> <NUMBER> therefore overall effect dmards covid<NUMBER> infection might complex study evaluated overall susceptibility covid<NUMBER> patients rheumatic disease potential effects dmards covid<NUMBER> identified <NUMBER> patients covid<NUMBER> <NUMBER> patients autoimmune rheu matic diseases overall covid<NUMBER> infection rate <NUMBER>·<NUMBER> patients autoimmune rheumatic diseases hubei province higher calculated infection rate <NUMBER>·<NUMBER> hubei province march <NUMBER> <NUMBER> <NUMBER> <NUMBER> covid<NUMBER> cases hubeis popu lation <NUMBER> <NUMBER> <NUMBER> <NUMBER> identified another <NUMBER> fami lies household members without rheu matic diseases covid<NUMBER> together <NUMBER> families <NUMBER> patients rheumatic diseases <NUMBER> family household members without least one household member covid<NUMBER> assess suscepti bility covid<NUMBER> patients rheumatic diseases compared infection rates patients auto immune rheumatic disease infection rates house hold members without rheumatic disease consistent previous analysis analysis families covid<NUMBER> exposure history indicated rate infection higher patients rheumatic diseases family members results indicate patients rheumatic disease might vulnerable covid<NUMBER> general population large pro portion potentially high <NUMBER>·<NUMBER> covid<NUMBER> cases worldwide reported asymptomatic might identified without extensive contact tracing testing <NUMBER> incubation periods covid<NUMBER> cases china less <NUMBER> days <NUMBER> although family members within household confirmed case tested sarscov<NUMBER> rna study identification first case family might largely depended manifestation covid<NUMBER> symptoms especially early stages outbreak therefore overall infection rate calculated study might underestimate considering number unidentifiable asymptomatic cases future populationwide epidemiological studies serology tests needed address issue also found risk sarscov<NUMBER> infection increases age consistent recent publications <NUMBER> based findings patients rheumatic diseases take necessary precautions protect covid<NUMBER> reduce risk sarscov<NUMBER> infection chloroquine hydroxychloroquine originally used oral antimalarial medicines widely used treat rheumatic disease mild immunosuppressive effects recent studies shown chloroquine hydroxychloroquine could suppress sarscov<NUMBER> replication vitro concentration clinically achievable <NUMBER> <NUMBER> current investigations role hydroxychloroquine covid<NUMBER> inconclusive although reports suggest improvement symptoms <NUMBER> <NUMBER> use chloroquine hydroxychloroquine studies reported benefits <NUMBER> <NUMBER> <NUMBER> even hazardous toxic effects <NUMBER> therefore randomised controlled trials required assess efficacy safety hydroxychloroquine patients covid<NUMBER> contrast trials done assess therapeutic effect hydroxychloroquine general popu lation <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> small number reports evaluated preventive effects chronically administered hydroxychloroquine covid<NUMBER> patients rheumatic diseases inconclusive outcomes <NUMBER> present study retrospectively analysed association use hydroxychloroquine covid<NUMBER> patients rheumatic disease found rate symptomatic covid<NUMBER> lower patients taking hydroxy chloroquine patients taking dmards notably however benefits hydroxychloroquine observed comparison immunosuppressive medications patients rheumatic diseases findings generalisable patients require immunosuppression reported study patients rheumatic diseases increased risk developing covid<NUMBER> might partially caused immunosuppressants therefore overall effects hydroxychloroquine general population require investigation due hyperactive status immune activation severe cases viral infection corticosteroids used many patients coronavirus infections including severe acute respiratory syndrome middle east respiratory syndrome mers covid<NUMBER> control immunemediated damage lung tissue <NUMBER> <NUMBER> <NUMBER> however use corticosteroids cases controversial rapid immunosuppressive effects might affect antiviral activity immune system arabi colleagues <NUMBER> retrospectively analysed <NUMBER> critically ill patients mers concluded corticosteroid therapy improve <NUMBER>day mortality instead delayed clearance viral rna study observe significant effect corticosteroids covid<NUMBER> study limitations first small number patients rheumatic disease medication able identify whether vulnerability covid<NUMBER> associated rheumatic dis ease antirheumatic medications second number patients exposure hydroxychloroquine small lower covid<NUMBER> incidence observed comparison patients taking immunosuppressive medications interpreted caution third since retrospective obser vational study potential biases inevitable example patients rheumatic disease covid<NUMBER> might unable answer telephone might already died covid<NUMBER> health conditions might limited ability participate study additionally higher proportion patients included study dmard treatment excluded <NUMBER> vs <NUMBER> lower proportion patients included study rheu matoid arthritis <NUMBER> vs <NUMBER> appendix p <NUMBER> future randomised controlled trials might provide better insight differences fourth limitation rela tion sarscov<NUMBER> rna tests many factors specimen collection limit detection sarscov<NUMBER> rna pcr tests cause falsenegative results thus might potentially affect overall infection rates last sample size patients rheumatic disease covid<NUMBER> relatively small apply pro pensity score weighting approaches small sample size future investigations larger studies needed gather evidence summary data suggest patients rheu matic disease might susceptible covid<NUMBER> general population jz lingli dong conceived idea designed study gs hy ah qh ls az tz ss hl xh wz bw xc ac cy li dong collected data jz xr analysed data wrote manuscript jz zb lingli dong edited manuscript declare competing interests access deidentified data related documents requested submission proposal valuable research question necessary data protection plan ethical approvals contract signed data requests addressed corresponding author corticosteroid doses <NUMBER> patients autoimmune rheumatic disease uninfected n<NUMBER> <NUMBER> mgday <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mgday <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mgday <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mgday <NUMBER> <NUMBER> <NUMBER> <NUMBER> chloroquine widely used antimalarial immunomodulatory effects <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> recent vitro study chloroquine found inhibit growth sarscov<NUMBER> vitro <NUMBER> finding supported clinical studies conducted approximately onehundred sarscov<NUMBER> infected patients <NUMBER> <NUMBER> hydroxychloroquine analog chloroquine fewer concerns drugdrug interactions previous sars outbreak hydroxychloroquine reported antisarscov activity vitro <NUMBER> suggests hydroxychloroquine may potential pharmacological agent treatment covid<NUMBER> infection however date clinical evidence support use hydroxychloroquine treatment sarscov<NUMBER> infection molecular mechanism action chloroquine hydroxychloroquine fully elucidated findings previous studies suggested chloroquine hydroxychloroquine may inhibit coronavirus series steps firstly drugs change ph surface cell membrane thus inhibit fusion virus cell membrane also inhibit nucleic acid replication <NUMBER> <NUMBER> glycosylation viral proteins virus assembly new virus particle transport virus release processes achieve antiviral effects <NUMBER> reliable estimation hydroxychloroquine chloroquine concentrations lung target tissue may used guiding dose recommendations physiologicallybased pharmacokinetic pbpk models mathematical modelling technique predict drug concentrations human tissues silico integrating physiological drug disposition parameters pbpk models widely used drug development help identify whether clinical trial warranted well help guide use drugs based predictions wellvalidated models <NUMBER> <NUMBER> study aimed investigate antiviral prophylactic activity hydroxychloroquine chloroquine vitro ii build pbpk model hydroxychloroquine chloroquine using data literature iii predict drug concentrations different dosing regimens using developed pbpk models chloroquine phosphate hydroxychloroquine sulfate purchased beijing innochem science technology co ltd lyophilized powder diluted double distilled water <NUMBER> mm hydroxychloroquine sulfate readily soluble water chloroquine phosphate dissolved shaking solution room temperature <NUMBER> hours chloroquine hydroxychloroquine solutions <NUMBER> <NUMBER> filtered <NUMBER> μm membrane stored −<NUMBER>°c clinically isolated sarscov<NUMBER> virus strain ctanncov wuhan strain <NUMBER> propagated vero cells vero cells derived african green monkey kidney grown dulbeccos modified eagle medium dmem sigma aldrich boston usa supplemented <NUMBER> fetal bovine serum logan ut usa cells maintained humidified atmosphere <NUMBER> co<NUMBER> <NUMBER>°c culture medium replaced day antisarscov<NUMBER> activity chloroquine hydroxychloroquine investigated vitro cells seeded <NUMBER>well plates density <NUMBER>×<NUMBER> <NUMBER> cellswell grown <NUMBER> hours vitro experiment divided two sections named treatment study ii prophylactic study drug pretreatment study vero cells pretreated chloroquine hydroxychloroquine <NUMBER> hours removed drugcontaining <NUMBER> <NUMBER> medium viruscontaining medium added infected vero cells described treatment study <NUMBER> hours following viruscontaining medium removed replaced fresh medium contain drugs viruses supernatant collected rna extracted analyzed relative quantification using rtpcr methods described previously published study <NUMBER> <NUMBER> experiments conducted triplicates relative expression estimated using <NUMBER> △△ ct method sigmoidal concentrationresponse function ybottom topbottom <NUMBER>logec<NUMBER>xhillslope fit data using nonlinear regression <NUMBER> <NUMBER> ec<NUMBER> values calculated using prism graphpad software san diego ca usa pbpk models chloroquine hydroxychloroquine developed using simcyp simulator version <NUMBER> chloroquine compound file provided simcyp limited certara company blades enterprise centre sheffield uk hydroxychloroquine compound file selfbuilt physical chemical parameters obtained literature <NUMBER> pharmacokinetic parameters liver intrinsic clearance fa ka determined clinical data <NUMBER> data summarized supplement <NUMBER> lung blood concentration ratio chloroquine hydroxychloroquine obtained animal studies used predict drug concentration lungs <NUMBER> <NUMBER> published chloroquine hydroxychloroquine clinical trial data used validate developed pbpk models details summarized supplement <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> data obtained literature graphical form extracted using plot digitizer version <NUMBER> getdata pharmacokinetic parameters could sourced literature estimated using extracted data phoenix version <NUMBER> certara company concentrationtime profiles simulated different published clinical trial <NUMBER> <NUMBER> protocols using developed pbpk models hydroxychloroquine chloroquine <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> simcyp healthy volunteer chinese healthy volunteer pediatric virtual populations used simulations clinical trials conducted caucasian chinese children populations respectively simulated exposure data compared observed data criterion determine model accuracy based whether observed data fell within <NUMBER> confidence interval predicted values ratio predicted pharmacokinetic pk parameters eg cmax auc observed values used evaluate model performance predicted values considered reasonable ratio predicted observed data within <NUMBER>fold range <NUMBER>≤ratio≤<NUMBER> exposure chloroquine hydroxychloroquine lungs plasma blood simulated different dosing regimens shown table <NUMBER> using validated pbpk models correction factor chloroquine base hydroxychloroquine base input model simulations chloroquine phosphate <NUMBER> mg equivalent <NUMBER> mg chloroquine base <NUMBER> mg hydroxychloroquine sulfate equivalent <NUMBER> mg hydroxychloroquine base chinese healthy volunteers virtual population provided simcyp used simulations simulations performed <NUMBER> trials <NUMBER> subjects per trial virtual subjects aged <NUMBER> <NUMBER> years age <NUMBER> subjects male <NUMBER> female pbpk models used predict lung tissue concentrations chloroquine hydroxychloroquine different dosing regimens table <NUMBER> lung trough concentration days <NUMBER> <NUMBER> <NUMBER> <NUMBER> adjusted plasma unbound fraction fuplasma obtain free lung trough concentration ratio free lung trough concentration vitro ec<NUMBER> values rltec calculated results tabulated recent clinical trial <NUMBER> mg chloroquine phosphate given twice daily shown effective study day <NUMBER> rltec day<NUMBER> dosing regimen chloroquine used target dose optimization hydroxychloroquine ie rltec hydroxychloroquine lower rltec day<NUMBER> chloroquine time results vitro study showed chloroquine hydroxychloroquine good antiviral activity chloroquine hydroxychloroquine found decrease viral replication concentrationdependent manner ec<NUMBER> values chloroquine <NUMBER> <NUMBER> μm <NUMBER> <NUMBER> hours respectively figure <NUMBER>a ec<NUMBER> values hydroxychloroquine <NUMBER> <NUMBER> μm <NUMBER> <NUMBER> hours respectively figure <NUMBER>b hydroxychloroquine exhibited superior vitro antiviral effect comparison <NUMBER> <NUMBER> chloroquine drug added prior viral challenge ec<NUMBER> values chloroquine <NUMBER> <NUMBER> μm <NUMBER> <NUMBER> hours respectively ec<NUMBER> values hydroxychloroquine <NUMBER> <NUMBER> μm <NUMBER> <NUMBER> hours respectively noted longer incubation times ec<NUMBER> values chloroquine hydroxychloroquine tended decrease inhibitory effect chloroquine poor particularly evident <NUMBER> hours whereby even highest concentration chloroquine used study inhibition rate exceed <NUMBER> figure <NUMBER>c <NUMBER>d predicted observed plasmablood concentration time profiles chloroquine hydroxychloroquine shown figure <NUMBER> intravenous data used understand distribution elimination phase two drugs oral administration data used understand intracorporal absorption process observed data fell within <NUMBER> prediction interval ratio predicted observed pk parameters cmax auc within range <NUMBER> <NUMBER> details summarized supplement <NUMBER> indicating prediction accuracy developed pbpk models acceptable could used simulate different dosing scenarios simulated lung blood plasma concentration time profiles chloroquine <NUMBER> <NUMBER> hydroxychloroquine different dosing regimens shown figure <NUMBER> seen lung blood plasma concentrations chloroquine increased slowly first dose given yet reach steady state day <NUMBER> simulated chloroquine concentration lung tissue much higher plasma lung plasma ratio increased time reached ratio approximately <NUMBER> projected lung blood plasma concentrations hydroxychloroquine rapidly increased reached steady state following initial loading dose subsequent maintenance doses figure <NUMBER>b <NUMBER>f free lung trough concentrations also projected simulations ratio free lung trough concentration ec<NUMBER> rltec different dosing regimens shown table <NUMBER> rltec values hydroxychloroquine found higher rltec values chloroquine days <NUMBER> <NUMBER> <NUMBER> <NUMBER> suggests hydroxychloroquine may achieve ideal clinical efficacy simulated dosing regimens rltec day <NUMBER> notably higher hydroxychloroquine chloroquine likely due loading dose hydroxychloroquine given thus enabling faster clinical effect significant difference twice daily maintenance dosing regimens regimen c respectively <NUMBER> <NUMBER> used day <NUMBER> day <NUMBER> hence daily dosing regimen may preferred improve patient compliance despite regimen f <NUMBER> day treatment regimen lung trough concentrations still target concentration day <NUMBER> however treatment duration regimen f extended <NUMBER> days ie regimen e resulted higher drug concentration day <NUMBER> overall regimen f may best regimen whilst considering efficacy safety patient compliance study hydroxychloroquine exhibited better vitro antisarscov<NUMBER> activity chloroquine demonstrated ec<NUMBER> values hydroxychloroquine always smaller ec<NUMBER> values chloroquine indicating hydroxychloroquine potent antiviral activity shown figure <NUMBER> study wang et al <NUMBER> chloroquine shown inhibitory effect sarscov<NUMBER> ec<NUMBER> value <NUMBER> μm <NUMBER> hour incubation time findings comparable vitro chloroquine results ec<NUMBER> value <NUMBER> μm addition unpublished clinical trial demonstrated therapeutic effect chloroquine sarscov<NUMBER> infected patients basis hydroxychloroquines superior antiviral prophylactic activity well tolerable safety profile comparison chloroquine believe hydroxychloroquine may promising drug treatment sarscov<NUMBER> infection <NUMBER> study noted ec<NUMBER> values hydroxychloroquine chloroquine decreased longer incubation times suggests incubation time may influence drugs antiviral activity hydroxychloroquine chloroquine reported accumulate cells <NUMBER> possible longer incubation time may provide time drug accumulate higher intracellular concentrations ultimately exhibit better antiviral effect <NUMBER> another possible explanation druginduced cytotoxicity may take time develop hence drug effect may increase time <NUMBER> pbpk model hydroxychloroquine chloroquine validated vivo pk data humans rats mice model able reasonably predict drug concentrations human lung tissue permeability rate limiting model implemented pbpk model mimic characteristics drugs addition high lung plasma partition coefficient ratio kp ratio used imitate drugs high accumulation lung tissue kp ratio humans assumed ratio rats human data available assumption may reasonable transportation drugs completely via passive diffusion ie transporters involved patients reported immune response sarscov<NUMBER> virus results increase cytokines il<NUMBER> il<NUMBER> <NUMBER> <NUMBER> may progress cytokine storm followed multiorgan failure potentially death hydroxychloroquine chloroquine immunomodulatory effects <NUMBER> <NUMBER> suppress increase immune factors <NUMBER> <NUMBER> bearing mind possible early treatment either drugs may help prevent progression disease critical lifethreatening state critically ill sarscov<NUMBER> infected patients use corticosteroids may harmful <NUMBER> whilst use immunosuppressants eg tocilizumab ideal either suppress immune system lead increased risk infection <NUMBER> setting hydroxychloroquine may ideal drug treat sarscov<NUMBER> infection inhibit virus via antiviral effects help mediate cytokine storm via immunomodulatory effects based work conducted lab recommend concomitant use low dose hydroxychloroquine antiinflammatory drug help mitigate cytokine storm critically ill sarscov<NUMBER> patients several clinical trials currently investigating use hydroxychloroquine treat sarscov<NUMBER> infection however worth noting dosing regimens used trials mainly based previous clinical experience raising concern adverse effects may occur study participants supplement <NUMBER> study optimized dosing regimen designed hydroxychloroquine high loading dose low maintenance dose based unique pharmacokinetics ie high accumulation cells long elimination halflife using pbpk modelling simulation techniques optimal dosing regimen hydroxychloroquine evaluated silico simulation results demonstrated regimen f able achieve treatment efficacy well good safety profile even considering <NUMBER> <NUMBER> possible underestimation drug efficacy extent however future clinical trials evaluating regimen required readily used clinic combination vitro antiviral activity data predicted drug concentrations study used support design dosing regimens used future clinical trial figure <NUMBER> antiviral activities chloroquine hydroxychloroquine treatment prophylactic treatment sarscov<NUMBER> vitro antiviral activities chloroquine hydroxychloroquine therapeutic prophylactic use tested vero cells infected sarscov<NUMBER> clinically isolate strain b treatment group chloroquine hydroxychloroquine added medium vero cells infected cells incubated medium contained drugs <NUMBER> <NUMBER> hours c prophylactic treatment group vero cells pretreated chloroquine hydroxychloroquine <NUMBER> hours viruses added medium infect cells medium removed replaced fresh medium without drugs viruses cells incubated <NUMBER> <NUMBER> hours viral yield cell supernatant quantified rtpcr middecember <NUMBER> city wuhan central china epidemic coronavirus declared caused new type coronavirus first named <NUMBER>ncov renamed sarscov<NUMBER> never observed appearance metropolis <NUMBER> million inhabitants chinese health officials officially announced discovery <NUMBER>th january <NUMBER> <NUMBER>th january world health organization declared public health emergency international concern february <NUMBER> gave name disease caused new coronavirus covid<NUMBER> <NUMBER>th march upgraded epidemic pandemic first triggered coronavirus <NUMBER> <NUMBER> subject worries whole world several questions arise coronavirus world epidemiological situation effectiveness using chloroquine hydroxychloroquine treatment answers questions found throughout review therefore called countries act contain coronavirus killed <NUMBER> <NUMBER> people <NUMBER> <NUMBER> cases infection worldwide according data reported authorities <NUMBER> april <NUMBER> <NUMBER> regional director europe said number cases expected increase urged countries continue implementing containment strategy accelerating efforts fight disease essential act quickly every day make difference <NUMBER> indeed <NUMBER>st march <NUMBER> italy became top world ranking deaths due covid<NUMBER> followed spain behind united states terms cases tested positive virus according newspaper world africa subsaharan countries remain <NUMBER>th march still little affected covid<NUMBER> comparison europe even number cases increases rapidly indeed african countries multiply measures much precociously europe <NUMBER> maghreb states take early measures going simple prudence closing borders confinement <NUMBER> indeed situation scale reported <NUMBER> april <NUMBER> shown table <NUMBER> drugs prevent cure covid<NUMBER> center disease control cdc public document website published <NUMBER>st march <NUMBER> informed us food drug administration fdaapproved drugs specifically treatment patients covid<NUMBER> present clinical management includes infection prevention control measures supportive care including supplementary oxygen mechanical ventilator support indicated array drugs approved indications well several investigational drugs studied several hundred clinical trials underway across globe <NUMBER> recent studies tested shown effectiveness use two drugs chloroquine hydroxychloroquine treatment covid<NUMBER> disease according us centers disease control prevention hydroxychloroquine chloroquine oral prescription drugs used treatment malaria certain inflammatory conditions chloroquine used malaria treatment chemoprophylaxis hydroxychloroquine used treatment rheumatoid arthritis systemic lupus erythematosus porphyria cutanea tarda includes list essential medicines meaning kept affordable accessible times drugs invitro activity sarscov sarscov<NUMBER> coronaviruses hydroxychloroquine relatively higher potency sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> studies revealed potential broadspectrum antiviral activities increasing endosomal ph required viruscell fusion well interfering glycosylation cellular receptors sarscov <NUMBER> <NUMBER> according colson et al <NUMBER> activity hydroxychloroquine viruses probably chloroquine since mechanism action two molecules identical hydroxychloroquine prescribed long periods would therefore first choice treatment sarscov<NUMBER> optimal treatment may necessary administer loading dose followed maintenance dose <NUMBER> systematic review appeared line march <NUMBER> <NUMBER> reported study published online <NUMBER>th february <NUMBER> carried chinese group effect chloroquine vitro using vero e<NUMBER> cells infected sarscov<NUMBER> multiplicity infection moi <NUMBER> study demonstrated chloroquine effective reducing viral replication effective concentration ec <NUMBER> <NUMBER> μm easily achievable standard dosage thanks favorable penetration tissues including lungs <NUMBER> authors described chloroquine known block viral infection increasing endosomal ph interfering glycosylation sarscov cellular receptor authors also speculated possibility known immunomodulating effect drug could improve antiviral effect vivo <NUMBER> article published online <NUMBER>th february draws results clinical trial conducted ten chinese hospitals wuhan epicenter epidemic beijing shanghai particular measure effectiveness chloroquine treatment pneumonia associated covid<NUMBER> <NUMBER> study confirmed antiviral antiinflammatory activities chloroquine may account potent efficacy treating patients covid<NUMBER> pneumonia according chinese researchers treatment <NUMBER> mg chloroquine per day ten days would sufficient according chinese researchers treatment <NUMBER> mg chloroquine per day ten days would sufficient chinese researchers point results obtained far <NUMBER> patients shown chloroquine phosphate effective treatment received comparative group contain development pneumonia improve condition lungs make patient negative virus shorten duration illness <NUMBER> however brief study quantify difference effectiveness based results chinese clinical study director mediterranean infection institute <NUMBER>eille <NUMBER>eille center expertise infectious diseases assured tuesday <NUMBER>th february <NUMBER> francepress agency fpa ordinary treatment chloroquine drug commonly used malaria shown signs efficacy coronavirus considers use chloroquine preferred route according rather search vaccine could available anyway long months opinions diverge critics effectiveness treatment chloroquine treat patients coronavirus second study published online <NUMBER>th march <NUMBER> team researchers <NUMBER>eille <NUMBER> patients aged <NUMBER> <NUMBER> suffering coronavirus <NUMBER> objective study defend chloroquine prove effectiveness protocol adopted relevance combination hydroxychloroquine azithromycin according study <NUMBER> one person <NUMBER> years old received treatment died another still serious condition remaining <NUMBER> patients experienced clinical improvement medical condition left intensive care five days majority <NUMBER> <NUMBER> patients favorable results discharged <NUMBER> required oxygen therapy <NUMBER> according newspaper capital critics study however formulated scientists main critic study include control group order make comparison <NUMBER> mediterranean infection institute <NUMBER>eille published day <NUMBER>th march <NUMBER> new article demonstrated combination hydroxychloroquine azithromycin synergistic effect vitro sarscov<NUMBER> concentrations compatible obtained human lung <NUMBER> tested china partially france united states chloroquine antimalarial substance carefully administered switzerland treatment covid<NUMBER> pandemic clinical effect encouraging since severity disease decreased sample patients subjected pilot experiment treatment administered patients suffer severe forms covid<NUMBER> used less severe forms warns public health france france long procrastinated use chloroquine authorized use tuesday <NUMBER>th march <NUMBER> restricted conditions united states also approved use chloroquine shown encouraging preliminary results <NUMBER> morocco technical scientific committee ministry health decided prescribe chloroquine patients severe cases treatment dosage monitoring control procedures carried <NUMBER>rd march <NUMBER> <NUMBER> despite efforts clinical trials assess efficacy drugs previously used diseases treatment covid<NUMBER> however given current serious global epidemiological situation given urgent therapeutic need interesting research find specific vaccine drug epidemic order manage health crisis effectively limit rapid spread save humanity saqrane el mhammedi declare conflict interest middecember <NUMBER> city wuhan central china epidemic coronavirus declared caused new type coronavirus first named <NUMBER>ncov renamed sarscov<NUMBER> never observed appearance metropolis <NUMBER> million inhabitants chinese health officials officially announced discovery <NUMBER>th january <NUMBER> <NUMBER>th january world health organization declared public health emergency international concern february <NUMBER> gave name disease caused new coronavirus covid<NUMBER> <NUMBER>th march upgraded epidemic pandemic first triggered coronavirus <NUMBER> <NUMBER> subject worries whole world several questions arise coronavirus world epidemiological situation effectiveness using chloroquine hydroxychloroquine treatment answers questions found throughout review therefore called countries act contain coronavirus killed <NUMBER> <NUMBER> people <NUMBER> <NUMBER> cases infection worldwide according data reported authorities <NUMBER> april <NUMBER> <NUMBER> regional director europe said number cases expected increase urged countries continue implementing containment strategy accelerating efforts fight disease essential act quickly every day make difference <NUMBER> indeed <NUMBER>st march <NUMBER> italy became top world ranking deaths due covid<NUMBER> followed spain behind united states terms cases tested positive virus according newspaper world africa subsaharan countries remain <NUMBER>th march still little affected covid<NUMBER> comparison europe even number cases increases rapidly indeed african countries multiply measures much precociously europe <NUMBER> maghreb states take early measures going simple prudence closing borders confinement <NUMBER> indeed situation scale reported <NUMBER> april <NUMBER> shown table <NUMBER> drugs prevent cure covid<NUMBER> center disease control cdc public document website published <NUMBER>st march <NUMBER> informed us food drug administration fdaapproved drugs specifically treatment patients covid<NUMBER> present clinical management includes infection prevention control measures supportive care including supplementary oxygen mechanical ventilator support indicated array drugs approved indications well several investigational drugs studied several hundred clinical trials underway across globe <NUMBER> recent studies tested shown effectiveness use two drugs chloroquine hydroxychloroquine treatment covid<NUMBER> disease according us centers disease control prevention hydroxychloroquine chloroquine oral prescription drugs used treatment malaria certain inflammatory conditions chloroquine used malaria treatment chemoprophylaxis hydroxychloroquine used treatment rheumatoid arthritis systemic lupus erythematosus porphyria cutanea tarda includes list essential medicines meaning kept affordable accessible times drugs invitro activity sarscov sarscov<NUMBER> coronaviruses hydroxychloroquine relatively higher potency sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> studies revealed potential broadspectrum antiviral activities increasing endosomal ph required viruscell fusion well interfering glycosylation cellular receptors sarscov <NUMBER> <NUMBER> according colson et al <NUMBER> activity hydroxychloroquine viruses probably chloroquine since mechanism action two molecules identical hydroxychloroquine prescribed long periods would therefore first choice treatment sarscov<NUMBER> optimal treatment may necessary administer loading dose followed maintenance dose <NUMBER> systematic review appeared line march <NUMBER> <NUMBER> reported study published online <NUMBER>th february <NUMBER> carried chinese group effect chloroquine vitro using vero e<NUMBER> cells infected sarscov<NUMBER> multiplicity infection moi <NUMBER> study demonstrated chloroquine effective reducing viral replication effective concentration ec <NUMBER> <NUMBER> μm easily achievable standard dosage thanks favorable penetration tissues including lungs <NUMBER> authors described chloroquine known block viral infection increasing endosomal ph interfering glycosylation sarscov cellular receptor authors also speculated possibility known immunomodulating effect drug could improve antiviral effect vivo <NUMBER> article published online <NUMBER>th february draws results clinical trial conducted ten chinese hospitals wuhan epicenter epidemic beijing shanghai particular measure effectiveness chloroquine treatment pneumonia associated covid<NUMBER> <NUMBER> study confirmed antiviral antiinflammatory activities chloroquine may account potent efficacy treating patients covid<NUMBER> pneumonia according chinese researchers treatment <NUMBER> mg chloroquine per day ten days would sufficient according chinese researchers treatment <NUMBER> mg chloroquine per day ten days would sufficient chinese researchers point results obtained far <NUMBER> patients shown chloroquine phosphate effective treatment received comparative group contain development pneumonia improve condition lungs make patient negative virus shorten duration illness <NUMBER> however brief study quantify difference effectiveness based results chinese clinical study director mediterranean infection institute <NUMBER>eille <NUMBER>eille center expertise infectious diseases assured tuesday <NUMBER>th february <NUMBER> francepress agency fpa ordinary treatment chloroquine drug commonly used malaria shown signs efficacy coronavirus considers use chloroquine preferred route according rather search vaccine could available anyway long months opinions diverge critics effectiveness treatment chloroquine treat patients coronavirus second study published online <NUMBER>th march <NUMBER> team researchers <NUMBER>eille <NUMBER> patients aged <NUMBER> <NUMBER> suffering coronavirus <NUMBER> objective study defend chloroquine prove effectiveness protocol adopted relevance combination hydroxychloroquine azithromycin according study <NUMBER> one person <NUMBER> years old received treatment died another still serious condition remaining <NUMBER> patients experienced clinical improvement medical condition left intensive care five days majority <NUMBER> <NUMBER> patients favorable results discharged <NUMBER> required oxygen therapy <NUMBER> according newspaper capital critics study however formulated scientists main critic study include control group order make comparison <NUMBER> mediterranean infection institute <NUMBER>eille published day <NUMBER>th march <NUMBER> new article demonstrated combination hydroxychloroquine azithromycin synergistic effect vitro sarscov<NUMBER> concentrations compatible obtained human lung <NUMBER> tested china partially france united states chloroquine antimalarial substance carefully administered switzerland treatment covid<NUMBER> pandemic clinical effect encouraging since severity disease decreased sample patients subjected pilot experiment treatment administered patients suffer severe forms covid<NUMBER> used less severe forms warns public health france france long procrastinated use chloroquine authorized use tuesday <NUMBER>th march <NUMBER> restricted conditions united states also approved use chloroquine shown encouraging preliminary results <NUMBER> morocco technical scientific committee ministry health decided prescribe chloroquine patients severe cases treatment dosage monitoring control procedures carried <NUMBER>rd march <NUMBER> <NUMBER> despite efforts clinical trials assess efficacy drugs previously used diseases treatment covid<NUMBER> however given current serious global epidemiological situation given urgent therapeutic need interesting research find specific vaccine drug epidemic order manage health crisis effectively limit rapid spread save humanity saqrane el mhammedi declare conflict interest j u r n l p r e p r f chronic treatment drugs gets accumulated tissues <NUMBER> selected antimalarial drugs used last <NUMBER> years economic proven safety profile categorized essential medicines world health organization <NUMBER> aminoquinolines effectively reduced viral replication zika virus chikungunya virus sarsassociated coronavirus cov merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> chloroquine hydroxychloroquine shown inhibition sarscov<NUMBER> replication <NUMBER> clinical trials demonstrated effective role chloroquine phosphate dose <NUMBER> mgday covid<NUMBER> <NUMBER> nhydroxyethyl substituted derivative chloroquine hydroxychloroquine less toxic soluble similar activity towards covid<NUMBER> inhibition continuous requirement explore molecular mechanism towards underlying antiviral action clinical benefits aminoquinolines toxicity profile detailed outcomes help design randomized clinical trials <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> present manuscript provides systematic review mechanism action efficacy safety chloroquine hydroxychloroquine treatment covid<NUMBER> viral replication stable acidic ph endosomes lysososmes golgi complex host required bioaccumulation properties selected aimnoquinolines explain antiviral mechanism action <NUMBER> chloroquine increases ph intracellular vacuoles lysosomes alters catalysis protein degradation pathways acidic hydrolases also alters endosomal macromolecule synthesis golgi apparatus affects posttranslational modifications antirheumatic response produced interfering j u r n l p r e p r f compared pharmacological profile chloroquine hydroxychloroquine possess equivalent antimalarial activity later preferred due lower ocular toxicity <NUMBER> theoretically antiviral activity chloroqunie hydroxychloroquine similar reported clinical details chloroquine number <NUMBER> use chloroquine less due associated adverse effects lack availability countries patients covid<NUMBER> infection hydroxychloroquine preferred chloroquine used combination lopinavir ritonavir shows prolongation qt interval antiviral therapeutics interfere hydroxychloroquine oseltamivir lopinavirritonavir robavirin interferons immunoglobulins intravenous <NUMBER> toxicological properties reported use chloroquine hydroxychloroquine retinopathy neuromyopathy cardiomyopathy drugs possess affinity melanin affect macular cones phagocytic activity lysosomes declined photoreceptors migrate towards central peripheral regions well induces epithelial atrophy irreversible alterations photoreceptors <NUMBER> lysosomes hydroxychloroquine protonated accumulated due basic nature inhibits activity lysosomal phospholipases causing vacuolization cardiac skeletal muscle cells <NUMBER> prolong use hydroxychloroquine producesi toxicity retina tissue may lead irreversible retinopathy <NUMBER> <NUMBER> ii cardiotoxicity cns toxicity neuromyopathy symptoms alterations gastrointestinal tract <NUMBER> toxicity liver cells genetic material <NUMBER> genotoxicity <NUMBER> <NUMBER> studies shown substantial increase retinal toxicity chronic treatment based hypothesis bioaccumulation <NUMBER> investigators report <NUMBER> incidences retinopathy common asian patients <NUMBER> <NUMBER> studies failed report cardiac complications neuromyopathy may rare longterm treatment <NUMBER> <NUMBER> monitoring side effects need continued even discontinuation treatment due prolong halflife chloroquine hydroxychloroquine side effects keratopathy maculopathy may delayed current anticovid<NUMBER> therapeutic regimen suggests longer duration treatment chloroquine antimalarial drug thus close monitoring adverse reactions pharmacological effects poisoning toxicological mechanisms provide help worldwide clinical work <NUMBER> table <NUMBER> ease access medical fraternity therapeutic use aminoquinolines chloroquine hydroxychoroquine important aspects arei administered millions infected patients covid<NUMBER> ii administered medical workers preventive measure iii acute approach covid<NUMBER> higher dose administered compared use treatment chronic rheumatic diseases <NUMBER> following points concluded considered use ix toxicity associated dose calculated real weight therefore dose suitable patients potential high risk adverse effects cumulative dose <NUMBER> mgkg body weightday high risk category <NUMBER> absence sufficient clinical data detailed information safety adverse effects dose aminoquinolines chloroquine hydroxychloroquine etc made available among health professionals dissipate among patients successful application available resources needs grounded practices minimize risk rigorous screening dose calculation coronavirus disease <NUMBER> covid<NUMBER> caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> continues spread rapidly across china <NUMBER> march <NUMBER> infection reported <NUMBER> countries globally date <NUMBER> <NUMBER> patients confirmed covid<NUMBER> <NUMBER> died <NUMBER> recently many trials designed determine effective therapeutic regimen covid<NUMBER> target regimens chloroquine therapy considered <NUMBER> several clinical trials china shown chloroquine phosphate aminoquinoline used malaria treatment effective covid<NUMBER> dose <NUMBER> mgday <NUMBER> chloroquine phosphate also played promising role management zika virus sarscov outbreaks chloroquine acts increasing ph intracellular vacuoles altering protein degradation pathways acidic hydrolases lysosomes macromolecule synthesis endosomes posttranslational protein modification golgi apparatus macrophages antigenpresenting cells chloroquine interferes antigen processing thereby achieving antirheumatic response <NUMBER> studies demonstrated chloroquine also confers considerable broadspectrum antiviral corresponding author effects via interfering fusion process viruses decreasing ph addition chloroquine alters glycosylation cellular receptors coronaviruses <NUMBER> hydroxychloroquine fig <NUMBER> less toxic aminoquinoline n hydroxyethyl side chain place n diethyl group chloroquine modification makes hydroxychloroquine soluble chloroquine similar chloroquine hydroxychloroquine increases ph confers antiviral effects addition hydroxychloroquine modulating effect activated immune cells downregulates expression tolllike receptors tlrs tlrmediated signal transduction decreases production interleukin<NUMBER> <NUMBER> although antimalarial activity hydroxychloroquine equivalent chloroquine hydroxychloroquine preferred chloroquine owing lower ocular toxicity <NUMBER> retinopathy doselimiting adverse effect hydroxychloroquine safe daily dose appears correspond <NUMBER> mgkg ideal body weight <NUMBER> mgkg actual body weight <NUMBER> although clinical data anticoronaviral activity chloroquine hydroxychloroquine agents theoretically similar antiviral activity <NUMBER> moreover chloroquine widely available hydroxychloroquine countries addition chloroquine associated greater adverse effects hydroxychloroquine example patients covid<NUMBER> chloroquine interact lopinavirritonavir resulting prolongation qt interval hence necessary consider hydroxychloroquine instead chloroquine latter available treating patients covid<NUMBER> example iran serious shortage chloroquine hydroxychloroquine recommended instead therapeutic agents covid<NUMBER> antiviral agents oseltamivir lopinavirritonavir ribavirin etc interferons intravenous immunoglobulins interfere hydroxychloroquine currently investigation funding none ince emergence wuhan province china late <NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> virus responsible coronavirus disease <NUMBER> covid<NUMBER> respiratory illness already claimed lives <NUMBER> individuals worldwide <NUMBER> <NUMBER> number covid<NUMBER> cases deaths increasing passing day perhaps pressing need medicine identify safe efficacious therapies prevent sarscov<NUMBER> infections well attenuate severity resulting covid<NUMBER> respiratory illness <NUMBER> although us food drug administration fdaeapproved drugs prevent treat covid<NUMBER> number promising novel ie remdesivir repurposed ie hydroxychloroquine potentially together azithromycin pharmacological agents reported inhibit growth sarscov<NUMBER> vitro <NUMBER> <NUMBER> evaluated randomized clinical trials q<NUMBER> advance definitive evidence clinicians front lines pandemic begun use medications offlabel compassionateuse circumstances anecdotal success <NUMBER> <NUMBER> light <NUMBER> need practice continue absence viable evidencebased therapies <NUMBER> proclivity many promising covid<NUMBER> pharmacotherapiesdspecifically antimalarial agents hydroxychloroquinedto prolong qtc thereby increasing risk druginduced torsades de pointes ditdp drug inducedsudden cardiac death discd document assembled help health care professionals safely use medications minimize concomitant risks chloroquine analogue hydroxychloroquine used nearly <NUMBER> years prophylactic pharmacotherapies malaria although still used antimalarial agents parts world chloroquinesensitive plasmodium falciparum protozoa hydroxychloroquine found new life diseasemodifying antirheumatic drug management conditions systemic lupus erythematosus rheumatoid arthritis cellular level antimalarial drugs accumulate intracellular vesicles endosomes lysosomes protonated leading increased vesicular ph <NUMBER> process turn inhibits activity phdependent proteases involved intracellular processing secretory proteins number immunologic nonimmunologic effects including tumor necrosis factor interleukin <NUMBER> <NUMBER> collectively reduction secretory proteins believed result <NUMBER> accumulation cytotoxic heme poisons p falciparum protozoa <NUMBER> modulation immune cell behavior manner attenuates inflammatory processes <NUMBER> addition chloroquine hydroxychloroquine possess antiviral properties vitro <NUMBER> <NUMBER> <NUMBER> <NUMBER> chloroquine hydroxychloroquine believed act entry postentry stages severe acute respiratory syndrome coronavirus sarscov<NUMBER> infection likely via effects endosomal ph resulting underglycosylation angiotensinconverting enzyme <NUMBER> receptors required viral entry <NUMBER> <NUMBER> <NUMBER> based vitro data hypothesized hydroxychloroquine chloroquine may therapeutic efficacy covid<NUMBER> pandemic <NUMBER> preventing sarscov<NUMBER> infection inhibiting angiotensinconverting enzyme <NUMBER>emediated viral entry ie preinfection prophylaxis <NUMBER> attenuating postviral cytokine storm observed severe covid<NUMBER> cases via multitude immunomodulatory mechanisms ie treatment active infectionpostviral sequelae promising vitro data <NUMBER> <NUMBER> well anecdotal vivo evidence therapeutic benefit <NUMBER> led many institutions including mayo clinic consider use hydroxychloroquine firstline covid<NUMBER> pharmacotherapy time spurred array clinical trials designed assess efficacy repurposed hydroxychloroquine prevention treatment covid<NUMBER> although collective safety profiles chloroquine hydroxychloroquine relatively favorable drugs block kcnh<NUMBER>encoded hergk v <NUMBER> potassium channel potentially prolong qtc atrisk individuals socalled herg blockers precipitate ditdp worse discd especially longterm use table <NUMBER> result number discds attributable hydroxychloroquine particular trivial table <NUMBER> theoretical possibility substantial proportion world population could receive hydroxychloroquine firstline prophylaxis treatment including estimated <NUMBER> million individuals congenital long qt syndrome lqts number hydroxychloroquinemediated discds could increase precipitously unless appropriate qtc monitoring algorithms instituted risk discd could amplified multiple medications qtcprolonging torsadogenic potential ie chloroquine hydroxychloroquine plus azithromycin lopinavirritonavir used combination table <NUMBER> although might argue discds setting widespread chloroquine hydroxychloroquine use represents acceptable friendly fire war sarscov<NUMBER>covid<NUMBER> believe institution simple safe precautions risk ditdp discd mitigated ultimately comes identifying small subset individuals either secondary underlying genetic predisposition congenital lqts present <NUMBER> <NUMBER> people andor virtue presence multiple modifiable nonmodifiable qtc risk factors table <NUMBER> <NUMBER> excessive baseline qtc prolongation qtc <NUMBER> ms andor inherent tendency development exaggerated qtc response ie dqtc <NUMBER> ms following exposure medications adverse effect potential qtc prolongation figure <NUMBER> although percentage individuals risk small given pandemic nature covid<NUMBER> absolute terms number individuals potentially risk lethal adverse drug effects large least <NUMBER> individuals <NUMBER> covid<NUMBER>epositive patients worldwide expected increased risk ditdp discd treated medications issue would especially true medications adopted postexposure prophylaxis traditionally qtc calculated either lead ii v <NUMBER> <NUMBER>lead electrocardiogram ecg corrected heart rate using bazett fridericia formula intraindividual interindividual qtc comparisons made unfortunately context covid<NUMBER> pandemic acquisition patients qtc <NUMBER>lead ecg requires additional personnel exposure ie ecg technician necessity serial ecgs requires exposure complex equipment multiple ecg wires could strain already limited supply personal protective equipment ppe many countries alternatively fdaapproved consumer mobile ecg devices capable generating accurate qtc measurements <NUMBER> end alivecor inc received emergency clearance fda use kardiamobile <NUMBER>l device fdaapproved atrial fibrillation detection qtc monitoring patients covid<NUMBER> treated qtprolonging medications chloroquinehydroxychloroquine march <NUMBER> <NUMBER> <NUMBER> pm cst similarly many telemetry systems equipped realtime qtc monitoring features could used hospitalized patients patients covid<NUMBER> treated medications increased potential ditdpdiscd figure <NUMBER> baseline qtc status obtained either traditional <NUMBER>lead ecg perhaps preferably use smartphoneenabled mobile qtc meter using simple infection control measures outlined figure <NUMBER> limit personnel exposures conserve critical ppe average <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> qtc values otherwise healthy postpubertal males females around <NUMBER> ms <NUMBER> ms respectively contrast qtc value exceeds <NUMBER>th percentile value otherwise healthy individuals ie <NUMBER> ms sexes puberty <NUMBER> ms postpubertal males <NUMBER> ms postpubertal females absence exogenous qtcaggravating factors may signal individual increased risk qtrelated ventricular arrhythmias <NUMBER> <NUMBER> contrast frame reference average qtc value <NUMBER> ms <NUMBER> patients congenital lqts cared mayo clinics windland smith rice genetic heart rhythm clinic furthermore exceptions amiodarone one patients resting qtc <NUMBER> ms whether secondary congenital lqts acquired qtcprolonging drugs qtcprolonging electrolyte abnormalities hypokalemia qtcprolonging disease states detailed table <NUMBER> considerably greater risk ditdp discd <NUMBER> <NUMBER> <NUMBER> accordingly baseline qtc value used roughly approximate patients risk ditdpdiscd following initiation medication qtcprolonging potential patients qtc values less <NUMBER>th percentile agesex ie <NUMBER> ms prepubertal malesfemales <NUMBER> ms postpubertal males <NUMBER> ms postpubertal females figure <NUMBER> green light status risk ditdpdilqts low chloroquinehydroxychloroquine qtcprolonging covid<NUMBER> pharmacotherapies initiated without delay outlined qtc monitoring algorithm remember whether <NUMBER>lead ecg telemetry smartphoneenabled acquisition ecg noted qt interval less onehalf preceding rr interval calculated qtc always less <NUMBER> ms patient green light go covid<NUMBER> treatments may qtcprolonging potential contrast patients baseline qtc <NUMBER> ms greater increased risk ditdpdiscd figure <NUMBER> red light status every effort made <NUMBER> assess correct contributing electrolyte abnormalities hypocalcemia <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> yes yes yes • correct electrolyte abnormalities k <NUMBER> mg <NUMBER> <NUMBER> • discontinue unnecessary q tcprolonging medications • strict isolation x <NUMBER> days • symptomatic management • follow insitutionalpublic health protocol regarding checkinfollowup timing • age t<NUMBER> • immunosuppressed state transplant malignancy uncontrolled hiv active chemotherapyimmunotherapy • highrisk comorbid conditions ckd copd chf cystic fibrosis pulmonary fibrosis • obtain pretreatment q tc using standard <NUMBER>lead ecg telemetry mobile ecg device see figure <NUMBER> details • obtain baseline expanded electrolytes ca <NUMBER> mg <NUMBER> k • determine home qtcprolonging medications discontinued wwwqtdrugsorg • document highrisk cv comorbid conditions see table <NUMBER> qtc t<NUMBER> ms prepuberty t<NUMBER> ms postpubertal males t<NUMBER> ms postpubertal females <NUMBER> ms • repeat qtc using standard <NUMBER>lead ecg telemetry mobile ecg device see figure <NUMBER> details • obtain baseline expanded electrolytes ca <NUMBER> mg <NUMBER> k consider alternative nonqtcprolonging therapies vitro activity sarscov<NUMBER> ¥ therapy print web <NUMBER>cfpo figure <NUMBER> approach mitigating risk druginduced torsades de pointes tdpdruginduced sudden cardiac death patients coronavirus disease <NUMBER> covid<NUMBER> treated following hypothetical treatment algorithm offlabel hydroxychloroquine alone combination azithromycin medications known herg blockers qtcprolonging torsadogenic potential estimated <NUMBER>th percentile qtc values derived otherwise healthy individuals places patient green light category less <NUMBER> ms puberty less <NUMBER> ms men less <NUMBER> ms women estimate baseline qtc assessment place <NUMBER> patients green light <NUMBER> yellow light <NUMBER> red light status severe covid<NUMBER> cases defined respiratory rate greater <NUMBER> breathsmin adults <NUMBER> breathsmin children q<NUMBER> oxygen saturation <NUMBER> less pao <NUMBER> fraction inspired oxygen ratio less <NUMBER> lung infiltrates involving <NUMBER> lung field <NUMBER> <NUMBER> hours hydroxychloroquine inhibits severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> vitro reduced viral burden small french study q<NUMBER> randomized controlled trial data available support clinical efficacy hydroxychloroquine use covid<NUMBER> use remains label presently u repurposed antiviral alternatives lopinavirritonavir also qtcprolonging effects bid ¼ twice daily chf ¼ congestive heart failure ckd ¼ chronic kidney disease copd ¼ chronic obstructive pulmonary disease cv ¼ cardiovascular ecg ¼ electrocardiography icu ¼ intensive care unit iv ¼ intravenous niaid ¼ national institute allergy infectious diseases po ¼ mouth mayo clin proc n xxx <NUMBER>nnn<NUMBER> n httpsdoiorg<NUMBER>jmayocp<NUMBER> wwwmayoclinicproceedingsorg hypokalemia andor hypomagnesemia <NUMBER> review discontinue unnecessary qtcprolonging medications present transition alternatives less qtc liability andor <NUMBER> proceed closer monitoring telemetry even consideration advanced countermeasures equipping patient wearable defibrillator eg lifevest zoll medical corporation decision made commence therapy setting qtc value <NUMBER> ms greater navigating circumventing qtc liability depends greatly riskbenefit calculus decision rests treating clinician patient example younger patients covid<NUMBER> ie <NUMBER> years mild symptoms qtc <NUMBER> ms greater may reasonable avoid treatment altogether arrhythmia risk may outweigh risk development covid<NUMBER>erelated acute respiratory distress syndrome however patients qtc <NUMBER> ms greater presenting progressively worsening respiratory symptoms greater risk ie <NUMBER> years age immunosuppressed andor highrisk comorbid conditions respiratory complications potential benefit qtcprolonging covid<NUMBER> pharmacotherapies may exceed arrhythmia risk therefore ultimate goal qtc surveillance covid<NUMBER> pandemic identify cannot receive medications identify compromised reduced repolarization reserve increased qtc countermeasures taken mitigate risk drugrelated death ditdpdiscd <NUMBER> ultimately much riskbenefit calculus awaits determination therapeutic efficacy hydroxychloroquine without concomitant azithromycin information available decision figure <NUMBER> protocols possible inpatient outpatient use smartphoneenabled mobile electrocardiogram ecg assess monitor qtc values patients coronavirus disease <NUMBER> inpatient protocol using dedicated institutional smartphone tablet mobile ecg device whenever possible strongly recommend use dedicated institutional bluetoothenabled smartphone tablet device used personal use ie phone calls activities limit spread severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> b inpatient outpatient protocol using personal institutionally loaned smartphonetablet mobile ecg device currently smartphoneenabled mobile ecg us food drug administration approval qtc monitoring alivecor kardiamobile <NUMBER>l device ppe ¼ personal protective equipment <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> made treat patient red light designation figure <NUMBER> based baseline qtc <NUMBER> ms greater seems prudent start hydroxychloroquine alone rather combination drug therapy azithromycin addition combination drug therapy hydroxychloroquine azithromycin initiated patient initial green lightyellow light qtc status individual transitions red light status selfidentification qtc reactor dqtc <NUMBER> ms greater consideration given discontinuing azithromycin optimizing electrolyte status intensifying countermeasures placing telemetry continuous rhythm assessment ideally following baseline qtc assessment therapy may initiated either qtc reassurance low risk vast majority <NUMBER> patients varying qtc countermeasures place flagged increased risk timing ontherapy qtc surveillance dictated pharmacokinetics covid<NUMBER> therapies used also practical logistics institutions method qtc monitoring <NUMBER>lead ecg approach qtc surveillance deemed important one machine designated acquisition data limited number ecg technicianspersonnel used minimize ppe utilization personnel exposure also number ontherapy qtc assessments constrained minimize personnel exposure risk ppe consumption scenario placed red light status baseline qtc <NUMBER> ms greater initial ontherapy qtc obtained around <NUMBER> <NUMBER> hours first dose <NUMBER> hours <NUMBER> hours following treatment initiation patients receiving either green light yellow light status probably forego early qtc assessment wait <NUMBER> hours <NUMBER> hours ondrug qtc determination ontherapy qtc <NUMBER> ms greater patient selfidentified qtc reactor dqtc <NUMBER> ms greater qtc countermeasures need reexamined medications stopped effort neutralize increased potential ditdp discd figure <NUMBER> contrast medical centers able implement fda emergencyapproved smartphoneenabled approach figure <NUMBER> determine qtc telemetry strips ecg technician exposure risk consumption ppe individuals would eliminated patients qtc could obtained health care team already present example qtc obtained per shift another vital sign <NUMBER> increased qtc surveillance would enable discovery qtc reactor implementation countermeasures sooner hopefully would thereby circumvent potentially preventable tragedy discd figure <NUMBER> finally patients wide qrs complex either ventricular pacing rightleft bundle branch block wide qrs complex qtc adjustment need made otherwise patients receive red light signal inappropriately resulting therapy delay discontinuation avoidance altogether setting simplest approach maintain previously indicated qtc green yellow red light thresholds apply simple formula account wide qrs complex wide qrs complexeadjusted qtc ¼ qtc e qrs à <NUMBER> ms example patients left bundle branch block yielded qrs complex <NUMBER> ms qtc <NUMBER> ms scenario would appear activate red light pathway figure <NUMBER> however wide qrs complexeadjusted qtc would <NUMBER> ms e <NUMBER> à <NUMBER> ms ¼ <NUMBER> à <NUMBER> ¼ <NUMBER> ms red light status rather green light go status much qtc reassurance patient low risk discd coronavirus pandemic continues spread wreak havoc economic loss importantly tragic deaths thousands throughout world must part war covid<NUMBER> washing hands physical distancing core components containment efforts flatten curve development coronavirus vaccine progressing unprecedented speed still least <NUMBER> <NUMBER> months away meantime hope longago discovered antimalarial drug hydroxychloroquine may lifesaving therapeutic efficacy covid<NUMBER> hope simple qtc surveillance strategy enabled innovation fdas emergency approval help prevent altogether least substantially reduce number druginduced ventricular arrhythmias sudden cardiac deaths particularly widespread adoption utilization medications covid<NUMBER> first report novel coronavirus sarscov<NUMBER> causing coronavirus disease <NUMBER> covid<NUMBER> originated wuhan china early december <NUMBER> since virus spread across national borders affecting <NUMBER> countries territories <NUMBER> million confirmed cases <NUMBER> <NUMBER> confirmed deaths april <NUMBER>th <NUMBER> <NUMBER> accounts limited personal protective equipment lack critical care resources ventilators healthcare worker shortages become unfortunate daily realities researchers scramble identify strategies interrupt transmission treat disease date <NUMBER> ongoing clinical research trials investigating potential therapeutic options prevention andor treatment covid<NUMBER> <NUMBER> hydroxychloroquine chloroquine labeled potential gamechangers popular press covid<NUMBER> <NUMBER> rapid review provide overview medications pharmacology possible mechanisms action sarscov<NUMBER> appraise body evidence vitro clinical studies published date discuss strengths limitations call additional large scale randomized clinical trials adequately powered show demonstrable impact meaningful clinical outcomes national international guidelines endorse widespread use hydroxychloroquinechloroquine covid<NUMBER> chloroquine first synthesized <NUMBER> prescribed extensively prevention treatment malaria well treatment autoimmune conditions rheumatoid arthritis systemic lupus erythematosus <NUMBER> <NUMBER> hydroxychloroquine later introduced <NUMBER> quickly became favored due superior safety profile <NUMBER> mechanism action drugs plasmodium parasites believed partly related interaction dna inhibition polymerization heme <NUMBER> <NUMBER> immunomodulatory activity hydroxychloroquine related broad spectrum immunoregulation networks discussed extensively work <NUMBER> <NUMBER> <NUMBER> addition activity rheumatic diseases two antimalarial agents also shown therapeutic activity immune modulatory effects wide range diseases including antiphospholipid syndrome amebiasis hivaids cancers <NUMBER> <NUMBER> <NUMBER> <NUMBER> medicines manufactured tablet form oral administration chloroquine phosphate <NUMBER> mg equivalent <NUMBER> mg chloroquine base hydroxychloroquine sulfate <NUMBER> mg equivalent <NUMBER> mg hydroxychloroquine base active drug per tablet respectively dosage varies treatment indication table <NUMBER> supplemental table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> doses high <NUMBER> mg hydroxychloroquine chloroquine used acute treatment malaria hydroxychloroquine chloroquine notable long terminal elimination halflives <NUMBER> <NUMBER> days respectively <NUMBER> <NUMBER> urine hydroxychloroquine detectable three months time last dose <NUMBER> hydroxychloroquine shown reach peak plasma concentration within threefour hours <NUMBER> whereas chloroquine reach peak plasma concentration half hour <NUMBER> common adverse events hydroxychloroquine chloroquine gastrointestinal upset along nausea vomiting diarrhea <NUMBER> <NUMBER> <NUMBER> study evaluating use chloroquine nearly <NUMBER> patients reported nauseaabdominal cramps <NUMBER> diarrhea side effects <NUMBER> <NUMBER> patients receiving hydroxychloroquine report gastrointestinal effect appears dosedependent often occurs loading doses <NUMBER> mg higher <NUMBER> retinopathy one frequently observed severe irreversible side effect associated highdose <NUMBER> mgkg longterm use <NUMBER> years <NUMBER> chloroquine higher risk retinopathy hydroxychloroquine <NUMBER> however concern short term dosing <NUMBER> severe lifethreatening complications use hydroxychloroquine chloroquine include qtc prolongation resultant risk ventricular arrhythmias <NUMBER> incidence qtc prolongation setting chloroquine hydroxychloroquine use largely unknown highly dependent baseline ekg findings risk exacerbated use concomitant qtcprolonging medications study healthy participants <NUMBER> mg chloroquine associated average qtc increase <NUMBER>ms <NUMBER> ci <NUMBER>ms <NUMBER> mg chloroquine associated <NUMBER>ms increase <NUMBER> ci <NUMBER>ms significant qtc prolongation four hours second dose <NUMBER> studies related hydroxychloroquine qtc prolongation largely limited case reports chronic use <NUMBER> <NUMBER> ekg monitoring part standard practice malaria treatment rheumatology use used monotherapy significant drug interactions chloroquine hydroxychloroquine avoided require additional monitoring include digoxin antiepileptics antacids cyclosporine amiodarone azithromycin moxifloxacin insulin antidiabetic agents tamoxifen praziquantel <NUMBER> <NUMBER> combination azithromycin hydroxychloroquine frequently prolongs qtc interval clinically significant manner increasing time <NUMBER> patient consecutive cohort <NUMBER> patients qtc increased <NUMBER> ms <NUMBER> increased <NUMBER> ms <NUMBER> overall qtc <NUMBER> ms <NUMBER> adverse effects acute use hydroxychloroquine chloroquine include limited hypoglycemia diabetic patients neurotoxicity form tinnitus headaches changes mood hemolytic anemia g<NUMBER>pd deficiency <NUMBER> <NUMBER> mechanism action hydroxychloroquinechloroquine sarscov<NUMBER> yet fully elucidated chloroquine first studied sarscov <NUMBER> responsible <NUMBER> sars coronavirus epidemic sarscov shares <NUMBER> genetic sequence similarity sarscov<NUMBER> thought result severe infection case fatality rate <NUMBER> vs <NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> based studies initially performed sarscov believed sarscov<NUMBER> enters cells binding angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor chloroquine may prevent virus binding receptor inhibiting terminal glycosylation <NUMBER> new research proposed hydroxychloroquine may additionally prevent sarscov<NUMBER> binding gangliosides turn may inhibit virion contact ace<NUMBER> receptor <NUMBER> hydroxychloroquine chloroquine additionally incorporate endosomes lysosomes resulting increased ph intracellular compartments organelles normally require acidic environment homeostasis ultimately increase ph results dysfunction leading defective protein degradation endocytosis exocytosis needed viral infection replication propagation <NUMBER> prior work also demonstrated coronaviruses use proteins surface endosomes endolysosomes viral entry host cells <NUMBER> entry endolysosome may necessary viral genome released cytoplasm infected host cells <NUMBER> however remains unclear changes endosomal environment particularly changes ph may affect integrity sarscov<NUMBER> viral genome overall hydroxychloroquinechloroquine capable affecting several cellular pathways therefore may several mechanisms action sarscov<NUMBER> table <NUMBER> clinically available form indications <NUMBER> dosage <NUMBER> clinical side effects warnings fdaapproved drug label plaquenil® <NUMBER> hydroxychloroquine sulfate <NUMBER> mgtablet oral administration treatment prophylaxis uncomplicated malaria hcqcqnonresistant strains plasmodium species prophylaxisonce weekly day week starting <NUMBER> weeks exposure continued <NUMBER> weeks leaving endemic area gastrointestinal upset nausea vomiting diarrhea <NUMBER> <NUMBER> <NUMBER> retinopathy highdose <NUMBER> mgkg base longterm <NUMBER> years use risk factors related retinopathy <NUMBER> rare severe atrioventricular block cardiomyopathy longterm treatment <NUMBER> good response obtained dosage may reduced <NUMBER> percent continued maintenance level <NUMBER> mg <NUMBER> mg daily single dose two divided doses exceed <NUMBER> mg <NUMBER> mgkg per day whichever lower incidence retinopathy reported higher maintenance dose exceeded hcq hydroxychloroquine cq chloroquine dose ed <NUMBER> chloroquine determined <NUMBER> ± <NUMBER>µm <NUMBER> another study demonstrated chloroquine concentration <NUMBER> ± <NUMBER>µm could inhibit viral replication <NUMBER> though exact infectious viral dose used study unclear <NUMBER> <NUMBER> biot et al demonstrated chloroquine potent hydroxychloroquine vitro inhibiting sarscov replication vero cell model ec<NUMBER> <NUMBER> ± <NUMBER>µm vs <NUMBER> ± <NUMBER>µm respectively <NUMBER> since current <NUMBER> outbreak researchers built upon knowledge assess whether chloroquine may inhibit sarscov<NUMBER> earlier march yao et al published results antiviral assay using sarscov<NUMBER> infected vero cell lines contrast findings sarscov hydroxychloroquine found potent sarscov<NUMBER> <NUMBER> experiment demonstrated hydroxychloroquine effective impairing viral replication compared chloroquine given postinfection <NUMBER>hour ec <NUMBER> <NUMBER>µm <NUMBER>µm hydroxychloroquine chloroquine respectively <NUMBER> moreover hydroxychloroquine effective chloroquine impairing sarscov<NUMBER> viral replication given prophylactically <NUMBER>hour ec <NUMBER> hydroxychloroquine chloroquine <NUMBER>µm <NUMBER>µm respectively <NUMBER> additional work focused solely chloroquine denoted similar vitro antiviral findings <NUMBER> <NUMBER> identify potential drug regimen use humans physiologically based pharmacokinetic modeling employed yao et al consider drug administration route physiological parameters ie intestinal absorption lung tissue penetration drug biochemical properties publication reported simulated lung fluid concentrations provide details used model <NUMBER> promising regimen treatment covid<NUMBER> based modeling initial dose <NUMBER> mg hydroxychloroquine twice daily maintenance dose <NUMBER> mg twice daily four days <NUMBER> <NUMBER> confidence interval estimate ec <NUMBER> provided thus dosing regimen interpreted caution may inaccurate estimate using similar antiviral assay four different multiplicities infection previously described liu et al demonstrated chloroquine potent hydroxychloroquine impairing viral replication multiplicities infection tested however effect statistically significant multiplicities infection <NUMBER> <NUMBER> <NUMBER> assess sarscov<NUMBER> specific virion entry endosome lysosome degradation pathway liu et al used colocalization immunofluorescence assay determined cells treated hydroxychloroquine chloroquine significantly virion localized early endosomes fewer localized endolysosomes compared untreated viral infected cells <NUMBER> together findings suggest hydroxychloroquine chloroquine effective impairing sarscov<NUMBER> replication vitro april <NUMBER> <NUMBER> published evidence effectiveness hydroxychloroquine chloroquine prevention treatment covid<NUMBER> humans limited five small studies one subjective report table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> early march chen et al published results first hydroxychloroquine study patients covid<NUMBER> <NUMBER> small <NUMBER>person inpatient randomized controlled trial comparing hydroxychloroquine standard care researchers found statistically significant differences time viral clearance day seven received hydroxychloroquine <NUMBER> clearance versus <NUMBER> p <NUMBER> also identify difference clinical outcomes ie duration fever changes lung imaging comment severity illness enrolled hydroxychloroquine control arms symptoms approximately seven six days respectively two weeks patients negative viral nucleic acid tests march <NUMBER> <NUMBER> gao et al extracted data <NUMBER> patients confirmed covid<NUMBER> ongoing inpatient studies china reported patient improvement use chloroquine <NUMBER> authors claimed chloroquine superior standard care treatment helping reduce time clinical recovery improving lung imaging findings however data supporting findings published clinical information including severity illness outcomes statistical analyses presented brief report <NUMBER> march <NUMBER> <NUMBER> gautret et al reported results nonrandomized openlabel study france absent blinding assessing hydroxychloroquine compared standard care treatment garnering much attention <NUMBER> twentysix hospitalized patients treated hydroxychloroquine <NUMBER> mg ten days six received azithromycin <NUMBER> mg followed <NUMBER> mg total five days sixteen patients meet study inclusion criteria served study controls time enrollment nearly <NUMBER> patients asymptomatic <NUMBER> upper respiratory symptoms <NUMBER> pneumonia bronchitislike symptoms unadjusted analyses authors found significantly reduced viral titers received hydroxychloroquine day six compared <NUMBER> vs <NUMBER> p <NUMBER> however six participants hydroxychloroquine treatment arm <NUMBER> excluded analysis required intensive care admission died withdrew study lost followup given small sample size overall study exclusion six participants absence intention treat analysis table <NUMBER> gao j et al <NUMBER> cq stated superior standard care treatment preventing exacerbation pneu results significantly biased definitive conclusion drawn long term outcome data study available reported outcome viral clearance may good surrogate important patientcentered outcomes need mechanical ventilation mortality six patients received azithromycin addition hydroxychloroquine patients negative sarscov<NUMBER> pcr test day <NUMBER> without comparison adequate controls gautret et al also recently released results another openlabel unblinded study assessing combination hydroxychloroquine azithromycin <NUMBER> hospitalized patients using dosing regimen previously described <NUMBER> <NUMBER> six patients included analysis included original study nearly <NUMBER> patients least one underlying chronic health condition four patients asymptomatic baseline whereas <NUMBER> upper respiratory tract symptoms <NUMBER> pneumonia bronchitislike symptoms approximately <NUMBER> patients low national early warning score indicating overall severity illness population mild reported <NUMBER> patients undetectable nasopharyngeal viral loads day seven however comparison group thus results nearly impossible interpret study <NUMBER> <NUMBER> patients survived hospital discharge whereas three patients required intensive care one died eleven still hospitalized march <NUMBER> <NUMBER> chen et al published results randomized parallelgroup trial <NUMBER> hospitalized participants randomized receive either <NUMBER>mg hydroxychloroquine five days addition standard care standard care alone <NUMBER> placebo utilized study standard care defined oxygen antiviral agents antibacterial agents immunoglobulin without corticosteroids patients chest ct confirmed pneumonia mild illness sao<NUMBER>spo<NUMBER> <NUMBER> pao<NUMBER>fio<NUMBER> <NUMBER> mmhg allowed enroll researchers found substantial proportion receiving hydroxychloroquine clinical improvement pneumonia <NUMBER> vs <NUMBER> p <NUMBER> determined day zero day six chest ct methodology described outcomes likely based subjective individual clinician opinion may blinded treatment allocation decreased duration cough <NUMBER> vs <NUMBER> days p <NUMBER> shortened time clinical recovery also reported receiving hydroxychloroquine compared controls however <NUMBER> <NUMBER> randomized hydroxychloroquine <NUMBER> <NUMBER> controls cough baseline unknown duration four patients control group said progressed severe illness though severe illness defined underlying patient comorbidities examined may overall confounding variable additionally specific antiviral antibacterial medications utilized part standard care treatment unspecified may affected results overall similar prior studies serious limitations exist results nonpeer reviewed study interpreted appropriate caution april <NUMBER>rd molina et al reported outcomes prospective cohort <NUMBER> hospitalized patients response gautret et al work <NUMBER> patients received dose duration hydroxychloroquine azithromycin gautret study eight patients enrolled significant comorbidities time enrollment <NUMBER> receiving oxygen supplementation found <NUMBER> <NUMBER> ci <NUMBER> patients alive days fivesix still sarscov<NUMBER> rna positive nasopharyngeal swabs contrast findings suggested reduced viral titers small cohort two patients transferred intensive care one patient died one medications stopped due qtc prolongation unlike gautret study sicker patients included analysis importantly six studies several important limitations preclude incorporation clinical guidelines studies small sample sizes <NUMBER> participants underpowered demonstrate clinical statistical difference outcomes two studies randomized controlled trials two nonrandomized nonblinded openlabel study one prospective cohort one included combination patients ongoing clinical trials without statistical assessment available four five hydroxychloroquine studies shared dosing regimen <NUMBER> mg hydroxychloroquine five days based vitro data doses high <NUMBER> mg higher followed <NUMBER> mg several days may required effective viral clearance humans <NUMBER> one six studies officially peerreviewed though concerns raised article <NUMBER> studies therefore interpreted solely hypothesisgenerating serve supporting evidence widespread inclusion hydroxychloroquine chloroquine clinical guidelines given studies reported differences disease severity overall patient populations may comparable moving forward researchers report severity covid<NUMBER> illness based symptom duration well using systematic severity scale despite dearth evidence efficacy light pressure covid<NUMBER> posed national health systems several official guidelines already incorporated hydroxychloroquine chloroquine suggested treatment patients covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> subsequent surge prescriptions caused widespread shortages hydroxychloroquine threatened supply medication patients autoimmune diseases like systemic lupus erythematosus rheumatoid arthritis incorporation medications national treatment guidelines several consequences hydroxychloroquine chloroquine seemingly safe medications benign important side effects although side effects common medicines rare adverse effects medication prescribed commonly without rigorous evidence base dangerous population level bluntly stated significant side effect justifiable drug effective given potentially deleterious consequences widespread use drugs absence robust data european medicines agency refused approve chloroquine covid<NUMBER> restricted use solely clinical trials national emergency use programs <NUMBER> date studies hydroxychloroquine treatment covid<NUMBER> adequately powered demonstrate efficacy absence harm presently <NUMBER> million cases covid<NUMBER> identified patients received hydroxychloroquine chloroquine even example qtc prolongation arrhythmia seen less <NUMBER> population would equate <NUMBER> adverse events arguably acceptable medication effective note gautret molina examined treatment covid<NUMBER> combination hydroxychloroquine azithromycin many clinicians started prescribe together without evidence outpatient setting studies combination utilized inpatient environment presumably degree cardiac monitoring azithromycin hydroxychloroquine alone especially combination increase risk qtc prolongation lead malignant arrhythmias <NUMBER> <NUMBER> retrospective population study <NUMBER> <NUMBER> patients receiving hydroxychloroquine rheumatic disease researchers found increased risk cardiovascular mortality hydroxychloroquine used combination azithromycin <NUMBER> deaths compared hydroxychloroquine amoxicillin <NUMBER> deaths hazard ratio <NUMBER> <NUMBER> ci <NUMBER> however allcause mortality hazard ratio <NUMBER> <NUMBER> risk significantly increased considering commonly prescribed medications potential qtc prolongation like selective serotonin reuptake inhibitors tricyclic antidepressants antipsychotics various antimicrobials small studies demonstrate insufficient evidence therefore support routine use hydroxychloroquine azithromycin outside clinical trial adequate cardiac monitoring final consideration lopinavirritonavir protease inhibitor broadly available treating hiv infection vitro activity sarscov infection recommended chinese authorities treat covid <NUMBER> recent openlabel randomized trial <NUMBER> days lopinavirritonavir therapy among severely ill patients hospitalized covid<NUMBER> showed clinical improvement reduction sarscov<NUMBER> viral load beyond standard care <NUMBER> despite negative results lopinavirritonavir still commonly used treat covid settings often concomitantly hydroxychloroquine chloroquine importantly lopinavirritonavir potentially increase chloroquine plasma levels inhibition cytochrome p<NUMBER> cyp<NUMBER>d<NUMBER> enzyme metabolism therefore increasing risk malignant arrhythmias moreover factors myocarditis myocardial ischemia reported context covid<NUMBER> <NUMBER> hypoxia electrolyte abnormalities often seen acute phase severe covid<NUMBER> contribute development acute arrhythmias <NUMBER> thus calls prudent wellinformed use lopinavirritonavir qtcprolonging medications like hydroxychloroquine azithromycin treat covid<NUMBER> additional studies examining hydroxychloroquine chloroquine preventing treating covid<NUMBER> desperately needed given weak evidence available larger controlled trials needed thoroughly assess hydroxychloroquinechloroquine clinical benefit covid<NUMBER> several ongoing randomized clinical trials actively recruiting participants better address question randomized trials powered show reduction meaningful clinical outcomes development covid<NUMBER> prevention trials need hospitalization critical care death treatment trials results trials instrumental determining whether two antimalarial medications efficacious dose duration safely recommended guidelines supplementary materials available open forum infectious diseases online consisting data provided authors benefit reader posted materials copyedited sole responsibility authors questions comments addressed corresponding author severe acute respiratory syndrome caused coronavirus <NUMBER> sarscov<NUMBER> cause global pandemic began <NUMBER> significant mortality patients worldwide <NUMBER> coronavirus disease <NUMBER> abbreviated covid<NUMBER> world health organization relatively high mortality transmissibility viral disease <NUMBER> official fatality rates <NUMBER> united states us per centers disease control prevention cdc <NUMBER> per chinese data probably overestimated given number asymptomatic carriers doubt covid<NUMBER> overwhelmed healthcare systems globally <NUMBER> march <NUMBER> definitive vaccine antiviral treatment despite ongoing efforts develop sarscov<NUMBER> causes acute respiratory distress syndrome ards elderly <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> significant cardiopulmonary comorbidities <NUMBER> recent published small clinical trial france shown combination pharmacological treatment hydroxychloroquine old antimalarial drug azithromycin antibiotic led decreased viral load average carrying duration covid<NUMBER> patients <NUMBER> french study inspired smaller chinese study showing similar improvements <NUMBER> studies led many healthcare providers globally utilize hydroxychloroquineazithromycin combinations treat covid<NUMBER> patients critical care settings <NUMBER> state university new york suny downstate medical center brooklyn new york designated covidonly patient hospital per new york governor cuomos order march <NUMBER> <NUMBER> covid<NUMBER> patients suny downstate receive combination hydroxychloroquine azithromycin case report examines clinical course one first patients receive treatment elderly african american male ards secondary covid<NUMBER> despite significant comorbidities patient steadily improved throughout intensive care unit icu stay extubated fifth day admission transferred medical floor continued treatment communityacquired pneumonia cap case anecdotal supports efficacy hydroxychloroquine azithromycin safe effective treatment covid<NUMBER> patient <NUMBER>yearold male living nursing home new york known focus covid<NUMBER> outbreak past medical history significant squamous cell carcinoma lung invasion esophagus statuspost resection chemoradiation seven years earlier cerebrovascular accident right residual weakness diabetes mellitus hypertension peripheral vascular disease pvd brought suny downstate medical center septic shock altered mental status fever tachycardia hypotension patients renal function preserved baseline creatinine <NUMBER> mgdl presentation acute respiratory failure desaturation <NUMBER> <NUMBER> litersminute nasal oxygen required intubation mechanical ventilation upon transfer icu patient underwent organ systembased management sepsis ards secondary covid<NUMBER> viral pneumonia complicated secondary bacterial infection maintained mechanical ventilation volume control mode sedated dexmedetomidine drip first two days admission required vasopressor support norepinephrine third day norepinephrine titrated remained hemodynamically stable without vasopressor support episode acute kidney injury aki resolved initiation free water flush <NUMBER> ml every six hours <NUMBER> ml per hour intravenous iv normal saline later stopped chest xray admission showed bilateral lung opacities focal right lower lobe consolidation consistent viral pneumonia complicated bacterial superinfection covid<NUMBER> test patients sputum performed new york department health positive blood cultures grew methicillinsensitive staphylococcus aureus mssa per recommendations infectious disease id team patient one first suny downstate receive pharmacological treatment covid<NUMBER> consisting hydroxychloroquine <NUMBER> milligrams mg twice day one day followed <NUMBER> mg twice day four days addition azithromycin <NUMBER> mg first day <NUMBER> mg four days based recently published study france demonstrated combination treatment hydroxychloroquine azithromycin led improved outcomes covid<NUMBER> patients measured decreased viral count taken nasal swabs <NUMBER> patient also started iv vancomycin blood cultures came back positive mssa infection despite poor prognosis admission patient steadily improved daily chest xrays showed gradual resolution bilateral patchy infiltrates right lower lobe consolidation figures <NUMBER> patient remained hemodynamically stable adequate urine output without use vasopressors patients mental status improved day <NUMBER> responded voice command bedside serial arterial blood gases showed improvement oxygenation even ventilator settings gradually decreased decreasing fraction inspired oxygen fio <NUMBER> positive expiratory end pressure peep respiratory rate patient passed continuous positive pressure cpap spontaneous breathing trial day <NUMBER> admission rapid shallow breathing index rsbi <NUMBER> successfully extubated downgraded covidonly medical floor appropriate droplet contact isolation precautions pending discharge case report documents hospital course critically ill covid<NUMBER> patient improved critical care icu fiveday regimen hydroxychloroquine azithromycin provides demonstration highly positive outcome patient high risk mortality given advanced age numerous comorbidities mortality rate patients age group <NUMBER> given patients numerous comorbidities risk likely higher <NUMBER> <NUMBER> patients relatively transient need mechanical ventilation totaling five days rapid improvement mental status rapid resolution septic shock resolution infection radiological imaging support potential efficacy hydroxychloroquine azithromycin combination treatment covid<NUMBER> case report substitute randomized clinical trial determine efficacy hydroxychloroquineazithromycin patients hospital course representative case series least <NUMBER> patients suny downstate received hydroxychloroquine azithromycin recorded positive outcome either downgrade icu discharge hospital though mechanism wellunderstood hypothesized hydroxychloroquine azithromycin may work several ways first hydroxychloroquine chloroquine reduce glycosylation angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors sarscov<NUMBER> use enter host cells figure <NUMBER> <NUMBER> second hypothesized hydroxychloroquine decreases production proinflammatory cytokines whose expression lead ards pathway <NUMBER> finally large amounts virus known enter host cells endocytosis chloroquine accumulates endosomes decreasing space available viruses like sarscov<NUMBER> also raises endosomal ph interfering entry exit viruses host cells <NUMBER> although potential mechanism azithromycin welldefined noted oftcited french study showing decreased covid viral loads <NUMBER> patients group received hydroxychloroquine alone showed viral load day <NUMBER> <NUMBER> patients group received hydroxychloroquineazithromycin showed viral load day <NUMBER> versus <NUMBER> patients received treatment pointing synergistic effect hydroxychloroquine <NUMBER> covid<NUMBER> novel viral respiratory illness caused large pandemic significant mortality <NUMBER> <NUMBER> march <NUMBER> curative treatment covid<NUMBER> first antiviral agents vaccines anticipated appear fall <NUMBER> date management critically ill covid<NUMBER> patients highly provider institutiondependent many hospitals including suny downstate case documented common drug combination used hydroxychloroquine azithromycin case study patients relatively rapid recovery adds body evidence supporting potential use hydroxychloroquine azithromycin empiric treatments covid safety hydroxychloroquine azithromycin likely significant issue given drugs safely utilized decades malaria prophylaxis treat communityacquired pneumonia respectively <NUMBER> summary case report highlights course recovery elderly covid<NUMBER> patient many comorbidities typically associated high rate mortality case supports need study topic appropriate management larger randomized clinical trial assessing efficacy combination treatment hydroxychloroquine azithromycin covid<NUMBER> patients conducted coronavirus disease <NUMBER> covid<NUMBER> started china declared global pandemic world health organization march <NUMBER> <NUMBER> following spread several countries across globe <NUMBER> outbreak china began december <NUMBER> health institutions reported clusters patients reporting pneumonia unknown cause epidemiologically linked seafood wet animal wholesale market wuhan hubei province <NUMBER> <NUMBER> coronaviruses large family viruses caused two pandemics past two decadessevere acute respiratory disease sars <NUMBER> <NUMBER> middle east respiratory syndrome mers <NUMBER> <NUMBER> sars coronavirus sarscov<NUMBER> similar novel coronavirus sarscov<NUMBER> scientists believe sarscov<NUMBER> mainly found bats could cause future disease outbreak aside pneumonia observed clinical symptoms covid<NUMBER> include fever dry cough breathing difficulties dyspnoea disease onset covid<NUMBER> may result progressive respiratory failure owing alveolar damage observed transverse chest computerizedtomography images even death <NUMBER> according covid<NUMBER> spread <NUMBER> countries territories killing <NUMBER> people infecting <NUMBER> million people <NUMBER> recoveries april <NUMBER> <NUMBER> <NUMBER> spread disease forced many countries activate public health surveillance systems intention tracing contacts identified cases quarantine isolating treating active cases reduce spread disease covid<NUMBER> continues rapidly spread efforts made discover vaccines interventions prevent treat infections well flatten infection curve barest minimum college health sciences university kwazulunatal durban south africa soon possible meantime medicines use conditions relied upon treatment active cases based anecdotal reports paper presents pharmacovigilance implications introduction medicines development vaccines remarkable success preventing several infectious diseases ebola virus disease swine flu h<NUMBER>n<NUMBER> infection given mankind hope infectious diseases could controlled even eliminated vaccines typically prevent occurrence infectious diseases uninfected population thus creating opportunity flatten infection curve vaccines work eliciting immune response individual order fight active infection occur future <NUMBER> pandemics media public research institutions pharmaceutical companies stakeholders focus largely design vaccines rather therapies treat patients active disease leaves healthcare professionals predicament deciding best therapeutic agents use order achieve optimal treatment outcomes result selflimiting nature viral infections physicians manage symptoms complications infection patients advised rest maintain good nutrition hydration enhance immune function <NUMBER> <NUMBER> however covid<NUMBER> emerging therapies purported associated good treatment outcomes food drugs administration fda usa instance sanctioned compassionate use chloroquine <NUMBER> <NUMBER>minoquinoline medicine used many years treat rheumatoid arthritis systemic lupus erythematosus porphyria cutanea tarda even though use treatment malaria subsaharan africa banned early <NUMBER>s due incidence adverse reactions resistance <NUMBER> compassionate approval chloroquine well statement made president trump possible benefits chloroquine treatment covid<NUMBER> led many believing chloroquine magical covid<NUMBER> drug aside approval compassionate use chloroquine fda national institutes health nih usa recently published new study found hydroxychloroquine also <NUMBER>aminoquinoline derivative chloroquine effective potent chloroquine covid<NUMBER> vitro <NUMBER> moreover recently conducted randomized controlled study gautret et al france showed <NUMBER> patients received combination hydroxychloroquine azithromycin tested negative virologically cured within <NUMBER> days treatment <NUMBER> consequently large pharmaceutical companies considering repositioning manufacture chloroquine hydroxychloroquine larger volumes seeking establish contacts markets profitability could maximized resulting increase demand chloroquine hydroxychloroquine bayer teva pharmaceutical industries instance donated chloroquine products usa mylan plans restart production chloroquine tablets <NUMBER> currently many countries drafted covid<NUMBER> treatment protocols using medicines varying treatment outcomes corroborate another french study efficacy hydroxychloroquine azithromycin found outthere evidence rapid antiviral clearance clinical benefit <NUMBER> recently conducted systematic review efficacy safety chloroquine treatment covid<NUMBER> observed rationale preclinical evidence effectiveness evidence safety longtime clinical use indications justify clinical research chloroquine patients covid<NUMBER> however authors advised clinical use chloroquine either adhere monitored emergency use unregistered interventions meuri framework ethically approved trial required <NUMBER> compassionate use chloroquine medicines pending approval potent medicines clinical trial data might good news medical professionals covid<NUMBER> patients likely consequences unlicensed indications could people disease well healthcare system include toxicity medicines shortage medicines viral resistance medicines case finally get approved drug regulatory agencies pharmacovigilance issues must addressed ensure safety general population covid<NUMBER> patients crisis period chloroquine hydroxychloroquine associated cardiotoxicity prolonged qt syndrome prolonged use particularly patients hepatic renal dysfunction drugs could also cause immunosuppression aplastic anemia agranulocytosis retinal damage peripheral neuropathy hydroxychloroquine associated lower incidence side effects <NUMBER> <NUMBER> surge demand chloroquine hydroxychloroquine many parts world china complaints people ordering chloroquine online drug stores selfmedicating fatal doses moreover nigeria west africa two cases chloroquine poisoning already reported raised concerns among healthcare professionals <NUMBER> furthermore arizona state usa man died ingesting high dose chloroquine attempt protect covid<NUMBER> wife also ingested drug admitted hospital critical care <NUMBER> rush medicines covid<NUMBER> scare could deny whose conditions require prescriptions patients rheumatoid arthritis systemic lupus erythematosus rely chloroquine hydroxychloroquine part treatment regimen <NUMBER> chloroquine hydroxychloroquine particularly indispensable managing constitutional musculoskeletal skin mild pleuritic symptoms systemic lupus erythematosus autoimmune disease challenging manage shortage medicines could therefore cause poor treatment outcomes current lockdowns enforced many countries across globe reduce movement people toward mitigating spread virus situation could worsened panic buying keep medicines use home first aid pharmaceutical products prevent covid<NUMBER> moreover disruption supply chain due restricted movement humans goods could aggravate situation stocks medicines get depleted recent scoping review conducted phuong et al <NUMBER> revealed medication shortages resulted negative patient clinical economic humanistic outcomes consequently efforts must made curb impending crisis indiscriminate use chloroquine hydroxychloroquine could lead resistance sarscov<NUMBER> medicines event ongoing clinical trials establish medicines must approved fullscale treatment disease resistance plasmodium parasite chloroquine used potent medicine treatment uncomplicated malaria twentieth century resulted indiscriminate counter use repetition could pose challenge covid<NUMBER> treatment even complicate cases efficacies medicines lost misuse given fact drug development long laborious expensive process already existing therapies like chloroquine hydroxychloroquine must preserved way forward assuaging situation intensify public campaign routine counter use chloroquine hydroxychloroquine prevention covid<NUMBER> community pharmacists must adhere strictly recommendation seize opportunity educate patients methods preventing spread disease regular hand washing soap tap water use alcoholbased sanitizers alcohol concentration less <NUMBER> vv eating balanced diet resting well reducing stress <NUMBER> rather selfmedicating chloroquine hydroxychloroquine bid prevent disease doctors must also ensure patients diagnosed covid<NUMBER> given prescriptions medicines require laboratory tools made available health institution facilitate diagnosis continual empirical treatment could lead resistance virus medicines lastly regulation medicines must strengthened enforced subsaharan africa instance drug regulation challenging years unapproved border trade pharmaceuticals drug counterfeiting resulting high demand must vigorously checked collaborative efforts drug regulatory security agencies could save patients taking substandard medicines consuming medicines really need conclusion covid<NUMBER> continues spread efforts made flatten infection curve general population must monitored educated indiscriminate medication use attempt prevent virus infecting human hosts must made aware current medicines served prescription basis hospitals covid<NUMBER> isolation treatment centers covid<NUMBER> prevention rather must educated approved methods preventing spread virus recommended spite global panic quickly resolve covid<NUMBER> pandemic scientists must vigilant ensure rational medicine use repurposing old remedies editorwe read great interest study yao et al <NUMBER> reporting hydroxychloroquine better antiviral activity chloroquine severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> associated high lungtoplasma concentration ratio immunomodulatory effects moreover authors highlighted hydroxychloroquine half maximal effective concentration values tended decrease longer incubation times simulation model lung trough concentrations still target concentration day <NUMBER> <NUMBER>day course hydroxychloroquine besides household contacts sarscov<NUMBER> acquired hospital settings healthcare workers hcws attending invasive procedures respiratory tract ie intubation endotracheal tube aspiration bronchoscopy highest risk accidently infected hcws represent important source infection period asymptomatic presymptomatic transmit virus household contacts patients seeking medical care reasons unrelated sarscov<NUMBER> infection reasons suggest preventive strategies accidentally exposed sarscov<NUMBER> preexposure postexposure prophylaxis avoid viral transmission largely accepted exposed viral agents human immunodeficiency virus hiv <NUMBER> chloroquine hydroxychloroquine able inhibit replication early stages viral infection increasing endosomal ph time viruscell fusion well impairing glycosylation cellular receptors many viruses including coronavirus <NUMBER> contrast similar effect early phases coronavirus infection reported drugs proposed sarscov<NUMBER> treatment able interfere cell infection affecting protease cleavage protease inhibitors viral genome replication remdesivir ribavirin effects chloroquine early phases viral replication permit attenuation vertical transmission animal model zika virus infection significantly reducing brain viral load make cells refractory sarscov infection vitro model <NUMBER> <NUMBER> hydroxychloroquine hiv protease inhibitors particularly lopinavir ribavirin remdesivir promising drugs proposed coronavirus disease <NUMBER> covid<NUMBER> treatment currently drug proposed postexposure preexposure prophylaxis accidently exposed sarscov<NUMBER> <NUMBER> basis investigations believe hydroxychloroquine effective preventing respiratory tract invasion hcws exposed sarscov<NUMBER> hydroxychloroquine administration prophylactic agent could particularly useful hcws attending highrisk procedures respiratory tract covid<NUMBER> patients hydroxychloroquines effectiveness profile ability inhibit lung viral replication <NUMBER>day period <NUMBER>day cycle therapy large amounts knowledge term safety deriving use malaria prophylaxis rheumatologic diseases lead us recommend preexposure postexposure use performing procedures high risk viral diffusion patients covid<NUMBER> pneumonia first cluster cases covid<NUMBER> disease caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> reported world health organization december <NUMBER> st <NUMBER> <NUMBER> march <NUMBER> th <NUMBER> world health organization declared covid<NUMBER> pandemic <NUMBER> time writing greater <NUMBER> million laboratoryconfirmed cases documented globally greater <NUMBER> related deaths <NUMBER> response <NUMBER> interventional trials registered investigate whether existing medications safe effective treatment covid<NUMBER> disease <NUMBER> one class medications demonstrated therapeutic properties vitro antimalarial agents chloroquine hydroxychloroquine <NUMBER> following results early emerging literature including several small clinical trials <NUMBER> <NUMBER> <NUMBER> <NUMBER> uncontrolled case series <NUMBER> open label nonrandomized study france <NUMBER> us food drug administration fda granted emergency use authorization eua hydroxychloroquine hospitalized patients covid<NUMBER> unable participate clinical trials <NUMBER> <NUMBER> <NUMBER> studies heavily referenced media despite inconclusive data trials use prophylaxis treatment ongoing <NUMBER> <NUMBER> recently observational study hydroxychloroquine published showing improvement clinical outcomes patients hospitalized covid <NUMBER> <NUMBER> present time fda infectious disease society america idsa recommend use outside clinical trials <NUMBER> results randomized controlled trials forthcoming medication may still prescribed outside trial lack alternative treatment article protected copyright rights reserved one population critical need effective treatments covid<NUMBER> older adults comorbid conditions including diabetes hypertension cardiac conditions studies suggest older adults susceptible infection covid<NUMBER> higher risk severe complications compared general population <NUMBER> <NUMBER> outbreaks longterm care facilities resulting death emphasized vulnerability population <NUMBER> increasing age higher rates medical conditions observed leading higher prevalence polypharmacy taking multiple medications <NUMBER> many <NUMBER> community dwelling north americans age <NUMBER> taking five regular medications <NUMBER> <NUMBER> polypharmacy harmful given association falls fractures adverse drug events <NUMBER> however encountering another problem taking multiple medications substantial risk drugdrug interactions potential therapies covid <NUMBER> <NUMBER> many interacting medications potentially inappropriate medications pims carry increased risk adverse drug events ades could deprescribed stopped tapered switched safer alternative <NUMBER> <NUMBER> <NUMBER> <NUMBER> hypothesized due polypharmacy clinically significant drugdrug interactions many older adults current drug regimens ineligible covid<NUMBER> therapeutic trials andor treatment medications currently investigation including limited antimalarial hydroxychloroquine despite older adults increased risk complications result covid<NUMBER> representing population likely benefit different therapeutic options postulated many drugdrug interactions due pims could deprescribed proactively light recent fda warning regarding risk qtc prolongation examined hydroxychloroquine <NUMBER> test case estimate prevalence prescribed medications drugdrug interactions cohort hospitalized older adults polypharmacy aimed better characterize burden pims could deprescribed impetus covid<NUMBER> pandemic medsafer pilot study <NUMBER> large controlled deprescribing trial took place september <NUMBER> may <NUMBER> <NUMBER> canadian academic internal medicine clinical teaching units trial designed assess whether computerassisted medication review tool augmented deprescribing pims discharge population hospitalized older adults polypharmacy softwares algorithm identified pims provided deprescribing recommendations individual patient applying rules derived widely available consensus documents safer prescribing older adults <NUMBER> <NUMBER> <NUMBER> details trial described elsewhere <NUMBER> briefly patients identified admission via emergency room one designated units discussion treating team see met broad inclusion criteria <NUMBER>years older taking five medications patient data concerning medical conditions validated medications lab results collected entered medsafer deprescribing electronic decision support software identified pims drugdisease combinations drugdrug interactions avoided used caution older adults medsafer system generated report pim included level harm high risk intermediate risk low risk little added value rationale deprescribing appropriate tapering protocol present study reanalyzed medsafer data representative sample vulnerable older adults polypharmacy first searched literature medications known drugdrug interactions hydroxychloroquine examining product monograph <NUMBER> referring drugdrug interaction websites <NUMBER> <NUMBER> reviewing exclusion criteria currently enrolling fda health canada approved hydroxychloroquine trial covid<NUMBER> nct<NUMBER> <NUMBER> <NUMBER> <NUMBER> medications known interactions hydroxychloroquine grouped according american hospital formulary service ahfs classification <NUMBER> table <NUMBER> divided two categories chronic medications medications typically prescribed short course antibiotics analyzed patients medsafer study consented participate deprescribing trial complete medication reconciliation performed admission theoretically exposed patient cohort treatment hydroxychloroquine minimum <NUMBER>days minimum dose <NUMBER>mg daily nct<NUMBER> identified possible drug interactions well potential harmful outcomes increased toxicity hydroxychloroquine risk qtc prolongation malignant cardiac arrhythmia risk adverse drug events requiring closer monitoring therapy severe hypoglycemia table <NUMBER> interacting medications ran medsafer algorithms determine proportion medications pims could deprescribed also identified triggering condition associated pim eg atrial fibrillation heart failure dementia delirium renal failure require monitoring ongoing use medications likely cannot stopped due risk adverse drug withdrawal event medsafer <NUMBER> cohort contained <NUMBER> patients complete data home medications median age cohort <NUMBER> years approximately <NUMBER> women half hypertension approximately <NUMBER> diabetes close <NUMBER> moderately severely frail defined clinical frailty scale <NUMBER> patients hospitalized tertiary care hospital admitted one four general medical wards one <NUMBER> canadian academic centres montreal ottawa toronto analyzed <NUMBER> participants found <NUMBER> <NUMBER> prescribed one usual home medications could potentially interact hydroxychloroquine commonly prescribed drug classes known interactions antidiabetic medications <NUMBER> <NUMBER> selective serotoninnorepinephrine reuptake inhibitors ssrissnris <NUMBER> <NUMBER> antipsychotics typical atypical <NUMBER> <NUMBER> antiarrhythmics digoxin amiodarone <NUMBER> <NUMBER> table <NUMBER> common classes antidiabetics insulin <NUMBER> <NUMBER> sulfonylureas <NUMBER> <NUMBER> table <NUMBER> serious interaction identified risk qtc prolongation torsade de pointes sudden death common less severe interaction risk hypoglycemia requiring increased monitoring lowering seizure threshold pharmacokinetic interactions leading increased hydroxychloroquine levels uncommon determined many pims identified medsafer tool known interactions hydroxychloroquine presented opportunity proactively deprescribed <NUMBER> <NUMBER> participants prescribed medication could interact hydroxychloroquine <NUMBER> patients respective medication identified pim representing <NUMBER> patients interacting medication common deprescribing opportunities identified included <NUMBER> high dose digoxin patients renal function <NUMBER> antipsychotic use patients known history delirium neurocognitive disorder risk stroke falls confusion <NUMBER> insulin sulfonylureas patients history hypoglycemia andor tight glycemic control hgba<NUMBER>c <NUMBER> table <NUMBER> prepared recommendations management interacting medications patients covid<NUMBER> may want receive treatment hydroxychloroquine found effective examples include holding low doses antipsychotics antidepressants therapy qtc monitoring electrolyte optimization continued use qtc prolonging agents glucose monitoring concurrent diabetes medications also highlight medications amiodarone cannot stopped short notice inclusion clinical trials due prolonged halflife table <NUMBER> reanalyzed data medsafer pilot found <NUMBER> <NUMBER> older adults polypharmacy cohort chronically prescribed medication could potentially interact hydroxychloroquine half pims could deprescribed number medical conditions associated polypharmacy cohort places high risk complications covid<NUMBER> also potentially risk harm treatments identified several common drug classes many also pims would preclude many older adults enrolling trial main finding many older adults taking medications carry known risk prolonging qtc finding caution routine prescribing qtc prolonging covid<NUMBER> treatments outside clinical study real potential harm importantly <NUMBER> interacting drugs identified pim could proactively deprescribed rendering person likely eligible trial increasing generalizability study findings population analysis chose focus specific drug hydroxychloroquine note ongoing debate regarding safety hydroxychloroquine treatment covid<NUMBER> studies efficacy still ongoing risks associated medication hydroxychloroquine likely higher older adults polypharmacy especially given common coadministration qtc prolonging medications prevalence underlying cardiac conditions <NUMBER> many patients cohort also overprescribed oral hypoglycemic agents a<NUMBER>c <NUMBER> history hypoglycemia coprescribed hydroxychloroquine could increase risk hypoglycemia older adults may decreased oral intake result covid<NUMBER> infection subsequent dehydration electrolyte disturbances nausea gi upset also common adverse effects hydroxychloroquine may exacerbate severe cardiac dysrhythmias <NUMBER> identified medications may interact study drugs could deprescribed proactively time treatment eg offlabel low dose quetiapine sleep agitation others stopped abruptly could lead serious adverse drug withdrawal events uncomfortable withdrawal symptoms eg methadone higher doses ssris <NUMBER> finally medications long halflives require weeks months safely discontinue order avoid interactions case may possible stop medication time treatment thus risk interaction reduced eg azithromycin <NUMBER> fluoxetine amiodarone note risk potential interactions medications necessarily mean clinical manifestations currently use antimalarials treatment prevention covid<NUMBER> extremely limited evidence <NUMBER> robust evidence demonstrating efficacy treatment covid<NUMBER> established clinicians might opt continue certain medications cannot stopped abruptly symptoms withdrawal thought significant cases would involve judicious monitoring qtc minimizing risk factors electrolyte abnormalities bradycardia cardiac monitoring generally available hospitalized patients perhaps select nursing homes likely case outpatients finally important take consideration halflife treatment medication know long symptoms monitored safe restart medications hydroxychloroquine range <NUMBER> days mean <NUMBER> days <NUMBER> <NUMBER> <NUMBER> risk qtc prolongation may persist beyond treatment period remain clinically relevant unclear duration note optimal effective hydroxychloroquine known referenced study uses daily dose <NUMBER>mg practice doses variable jurisdictions may prescribe lower doses <NUMBER> mg daily may impact risk drug interactions side effects considerations aside medications pims interactions possible covid<NUMBER> therapies yet another reason evaluate medications safe deprescribing immediately <NUMBER> concern abrupt discontinuation avoided deprescribing advance acute illness <NUMBER> used hydroxychloroquine test case interpreted endorsement medication clinical scenario described herein limited hydroxychloroquine treatments including limited lopinavirritonavir colchicine dapsone also proposed treatments similarly significant evidence support use presently also carry risks serious drugdrug interactions <NUMBER> <NUMBER> clinicians may tempted indeed prescribing medications desperation provide patients form treatment covid<NUMBER> caution rigorous review possible interactions warranted especially older adults polypharmacy notably population often underrepresented clinical trials even proven effective harms may still outweigh benefits therapies individualized approach always taken presently medications shown promise hydroxychloroquine recently remdesivir <NUMBER> medication treatment covid<NUMBER> proven effective would suggest outside clinical trial potential harms offlabel prescribing likely outweigh benefits meantime important reduce number pims patients taking may facilitate treatment options clinical evidence established strengths study include large cohort older adults multisite trial polypharmacy thorough review literature outline potential drug interactions clear instructions medication management setting drug interactions cohort also reflects latest fda recommendation hydroxychloroquine used outside clinical trial hospitalized setting <NUMBER> yet study several limitations hospitalized patients study likely represent likely experience harm result widespread prescribing hydroxychloroquine future work focus finding safe effective treatments longterm care facilities burden polypharmacy high increased risk covid<NUMBER> exposure effective treatments may decrease risk hospitalization chose focus hydroxychloroquine test case order provide realistic examples harm could result widespread prescribing reviewing potential therapies subsequent drugdrug interactions beyond scope paper however similar recommendations could generated potential treatments may complex example interactions lopinavirritonavir extensive outlined hydroxychloroquine additionally clinical significance interactions identified vary cardiac complications sudden death severe whereas absolute risks seizure hypoglycemia less well defined patients cohort least five medications case approximately <NUMBER> older americans <NUMBER> <NUMBER> fewer medications risk drugdrug interactions less hand study looked interactions home medications patients hospitalized may even higher risk interactions receive additional treatments eg concurrent antibiotics prolong qtc antipsychotics management delirium insulin etc finally population patients analyzed canadian problem polypharmacy widely described united states countries across world principles outlined discussion extrapolated jurisdictions polypharmacy many unpredictable consequences well described harms eg falls fractures cognitive impairment <NUMBER> describe emerging concern era covid<NUMBER> patients may eligible covid<NUMBER> trials study effectiveness safety medications investigation others may subject harm result offlabel prescribing due risk drugdrug interactions ever examine medication lists older adults focus medication optimization stopping pims particularly may interact potential covid<NUMBER> therapies wish thank patients enrolled original medsafer study agreed participate research polypharmacy table <NUMBER> potential triggering conditions metformin considered risk causing hypoglycemia purposes analysis pim potentially inappropriate medication cns central nervous system hcqhydroxychloroquine fluoxetine prolonged halflife deprescribing needs take place well advance <NUMBER> weeks combining hydroxychloroquine new coronavirus sarscov<NUMBER> cause serious infection respiratory tract called covid<NUMBER> structures main protease sarscov<NUMBER> pro responsible replication virus solved quickly made available thus allowing design compounds could interact protease thus prevent progression disease avoiding viral peptide cleaved smaller viral proteins released hosts plasma structural data extremely important silico design development compounds well possible quick effectively identify potential inhibitors addressed enzymes structure therefore order identify potential inhibitors pro used virtual screening approaches based structure enzyme two compounds libraries targeted sarscov<NUMBER> containing compounds predicted activity pro way selected docking studies <NUMBER> topranked compounds followed subsequent studies pharmacokinetic toxicity predictions simulations predictions performed obtained <NUMBER> topranked compounds silico analyzed inside pro catalytic site together drugs currently investigated treatment covid<NUMBER> proposing analyzing interaction modes compounds submitted one molecule selected template <NUMBER>d similarity study database containing drugs approved fda found indicated apixaban potential drug future treatment covid<NUMBER> since first reports novel pneumonia wuhan hubei province china considerable discussion origin causative virus sarscov<NUMBER> also referred hcov<NUMBER> emerged <NUMBER> infections sarscov<NUMBER> widespread efforts contain virus ongoing however given many uncertainties regarding pathogen transmissibility virulence effectiveness efforts unknown fraction undocumented infectious cases critical epidemiological characteristic modulates j u r n l p r e p r f general symptoms similar sars mers causing cough difficulty breathing fatigue fever treated properly eventually death <NUMBER> <NUMBER> coronaviruses enveloped structures positive singlestranded large rna viruses infect humans also wide range animals first virus family described <NUMBER> tyrell bynoe cultivated virus obtained patients common colds due morphology spherical grooves central cap superficial projections similar solar corona name coronavirus latin corona crown designated coronavirus four subfamilies alpha beta gammaand deltacoronaviruses alphaand betacoronaviruses apparently originate mammals particular bats gammaand deltaviruses originate pigs birds genome size goes <NUMBER> kb <NUMBER> kb among seven subtypes coronaviruses infect humans betacoronaviruses may cause severe disease fatalities whereas alphacoronaviruses cause asymptomatic mildly symptomatic infections <NUMBER> process infection two proteases essential process maturation infectivity virus case sarscov<NUMBER> sequencing genome revealed papainlike protease pl pro <NUMBER>chymotrypsinlike protease <NUMBER>cl pro also known main proteasem pro <NUMBER> pro one studied therapeutic targets present time possible alternative fight coronavirus proving accessible target development inhibitors <NUMBER> <NUMBER> pro cysteine protease composed three domains ii iii whose main functions maturation viral particles cleavage viral capsid thus releasing viral polypeptides body contributing infection occur active form pro homodimer containing two protomers presents noncanonical cyshys dyad located ii <NUMBER> <NUMBER> pro also structurally conserved among known varieties coronavirus several common characteristics substrate shared among amino acids substrates c n termini numbered p<NUMBER>p<NUMBER>p<NUMBER>p<NUMBER> ↓ p<NUMBER>′p<NUMBER>′p<NUMBER>′ cleavage site located p<NUMBER> p<NUMBER> ′ need almost substrates glycine residue located position p<NUMBER> <NUMBER> <NUMBER> pro active sites highly conserved among different varieties coronavirus usually composed <NUMBER> sites usually referred s<NUMBER> ′ s<NUMBER> s<NUMBER> s<NUMBER> <NUMBER> work considering current pandemic covid<NUMBER> around world propose use drug design lead discovery approaches well including virtual screening admetox predictions molecular docking <NUMBER> design new compounds inhibiting protease pro involved process viral infection sarscov<NUMBER> thus preventing viral peptide cleaved thereby preventing smaller viral charge released hosts plasma <NUMBER> purpose compared repositioned drugs current clinical studies sarscov<NUMBER> proposed novel compounds designed using virtual screening drug databases main steps methodological procedure performed virtual screening shown figure <NUMBER> virtual screening downloaded structure files deposited protein data bank pdb research collaboratory structural bioinformatics related crystallographic structures pro pdb id <NUMBER>lu<NUMBER> resolution <NUMBER>å complex inhibitor called n<NUMBER> gold <NUMBER> software genetic optimization ligand docking performs docking simulations using genetic algorithm generate select conformers flexible compounds bind receptor site protein dna addition able use amino acid rotamer libraries simulations <NUMBER> first order proceed virtual screening experiments validated results redocking calculating root meansquare deviation rmsd crystallographic pose inhibitor docking pose dockingbased virtual screening used following coordinates center sphere x <NUMBER> <NUMBER> z <NUMBER> also radius <NUMBER> å considered two sarscov<NUMBER> targeted libraries available otava chemicals used contain compounds predicted activity pro sarscov<NUMBER> main protease targeted library sarscov<NUMBER>target <NUMBER> compounds ml machine learning sars targeted library sarscov<NUMBER>ml <NUMBER> compounds sequence number <NUMBER> topranked hits obtained reduced using admetox filters calculation pharmacokinetic properties drugs study sarscov<NUMBER> cobicistat darunavir favipiravir hydroxychloroquine lopinavir oseltamivir remdesivir ritonavir well molecules selected two libraries pro inhibitors used sarscov<NUMBER>target sarscov<NUMBER>ml used qikprop software <NUMBER> <NUMBER> selecting following properties particular permeability cns cns logbb psa cell permeability pcaco<NUMBER> pmdck aggregation serum albumin logkhsa oral absorption human oral absorption results obtained software analyzed comparing values obtained investigated molecules average values obtained <NUMBER> drugs made available software databases comparison number stars denotes number violations ranges optimal j u r n l p r e p r f values common drugs used referencestemplates qikprop <NUMBER> <NUMBER> brief following properties well ranges optimal values considered analyzed using qikprop cns <NUMBER> low permeability e <NUMBER> high permeability • logbb bloodbrain barrier <NUMBER> low e <NUMBER> easy permeation • psa van der waals surface area <NUMBER> cross bloodbrain barrier e <NUMBER> cross bloodbrain barrier derek software deductive estimate risk existing knowedge used predict toxicity molecules investigated software expertsystem uses methodology capable making qualitative predictions searches <NUMBER>d similarity shared investigated molecule structures database contain reported toxic moieties predicting comparison associated toxicity <NUMBER> results obtained form alerts fired possible potential toxicity investigated molecule would cause certain toxic effect organism <NUMBER> dereks decisions based knowledgebased expert system method diverse peculiar situations toxicity including skin sensitization hepatotoxicity nephrotoxicity carcinogenicity mutagenicity specific toxicities endpoints <NUMBER> molecular docking simulations selected molecules previous steps biological target pro pdb <NUMBER>lu<NUMBER> performed aid gold <NUMBER> software previously mentioned gold uses genetic algorithm generate select conformers flexible compounds docking used following coordinates center sphere x <NUMBER> <NUMBER> z <NUMBER> radius <NUMBER> å docking grid considered cocrystallized ligand ions water molecules removed crystal structure docking simulations prior calculations hydrogens added compounds respective atomic charges calculated using pm<NUMBER> method better performance accuracy molecular docking j u r n l p r e p r f bindingdb webserver offers possibility calculating structural similarity <NUMBER> using tanimoto coefficient tc <NUMBER> based upon jchem fingerprints resulting numerical value structural similarity know active conformation molecule selected pivot <NUMBER>d similarity provides satisfactory results virtual screening step tc analyzed similarities selected molecules results previous step fda library webserver containing <NUMBER> drugs classified according similarity file classification generated analyzed using discovery studio software <NUMBER> group molecules similar activity equal <NUMBER> extracted <NUMBER> virtual screening computational analogue high throughput screening hts characterized computational screening chemical compounds deposited typically large libraries order find molecules complement biological targets resolved structure selecting potent ones potential <NUMBER> technique low costeffective well high speed generate result giving enormous benefits pharmaceutical research needs urgency sarscov<NUMBER> pandemic different possible protocols virtual screening combined use tools important results could even robust reliable likely validatedconfirmed vitro assays many studies use technique search chemical entities treatment example cancer withdrawal syndrome neuropathic inflammatory pain <NUMBER> <NUMBER> <NUMBER> target structure used screening pro pdb id <NUMBER>lu<NUMBER> belongs family enzymes extensively studied viruses ns<NUMBER> protease dengue virus <NUMBER> protease hiv<NUMBER> <NUMBER> others different viruses proteases known structure well two libraries utilized contain compounds predicted activity pro sarscov<NUMBER>target sarscov<NUMBER>ml first library designed using structurebased virtual screening flexible docking using crystal structure pro second one designed using machine learning artificial neural networks bayesian statistics based compounds known antisars activity library <NUMBER> hits selected highest values affinity score pro thus selected next stages work infection caused covid<NUMBER> related sars affecting pneumocytes macrophages lung target organ also appears related ace<NUMBER> receptor may protect host lung injury well tmprss<NUMBER> protein related facilitating entry virus organism present lung <NUMBER> information presents us peripheral action virus requirement future therapeutic agent initially analyzed pharmacokinetic predictions antiviral drugs well hydroxychloroquine currently available figure <NUMBER> also evaluation biological activity well clinical tests treatment covid<NUMBER> table <NUMBER> order obtain parameters comparison among molecules j u r n l p r e p r f selected using virtual screening whose results presented tables <NUMBER> <NUMBER> molecules investigated showed results median high values oral absorption well median aggregation plasma proteins evaluated drugs showed prediction high cellular permeability results intestinal cells well renal cells pcaco<NUMBER> pmdck exception cobicistat remdesivir drugs evaluated using qikprop software tend permeate cns potential cobicistat darunavir lopiravir remdesivir ritonavir high cellular permeability darunavir favipiravir hydroxychloroquine lopinavir oseltamivir ritonavir prediction median aggregation protein albumin drugs addition prediction low oral absorption cobicistat darunavir favipiravir oseltamivir remdesivir ritonavir hydroxychloroquine although drug indicated treatment rheumatoid arthritis inflammatory diseases used initial satisfactory results treatment covid<NUMBER> pharmacokinetic profile comparison antivirals hydroxychloroquine despite indicating permeation cns high cellular distribution presenting less aggregation serum albumin median aggregation addition high oral absorption similarly lopinavir based pharmacokinetic profile antivirals hydroxychloroquine well knowledge viruss peripheral performance well due main clinical manifestations able evaluate screened molecules regarding evaluation molecules sorted sarscov<NUMBER>target library <NUMBER> molecules best pharmacokinetic profiles predicted shown table <NUMBER> considering number stars results obtained indicate high reliability indicating chemical similarity known drug molecules qikprop software database permeability cns chose work molecules prediction act peripheral level selecting molecules presented results three parameters evaluated cns qplogbb psa prediction crossing bloodbrain barrier since peripheral action sought due clinical characteristics disease seen compared profile antivirals hydroxychloroquine profile obtained molecules sarscov<NUMBER>target library even satisfactory adequate potential cell distribution predicted median high caco<NUMBER> well mdck cells median binding plasma proteins median high hoa prediction pharmacokinetic properties molecules selected sarscov<NUMBER>target library evaluating set predictions made <NUMBER> molecules selected sarscov<NUMBER>ml library containing best pharmacokinetic profiles shown table <NUMBER> considering number stars molecules obtained highly reliable results molecules selected sarscov<NUMBER>ml library showed permeability cns potential showed indicative results high oral absorption whereas none high aggregation plasma proteins predicted permeability cns prediction act peripheral level selected following three parameters evaluated cns logbb psa prediction median high cell distribution intestinal cells well pcaco<NUMBER> pmdck cells comparison predicted profile antivirals hydroxychloroquine noted profile cell distribution pcaco<NUMBER> pmdck logkhsa hoa sarscov<NUMBER>ml molecules also superior prediction pharmacokinetic properties molecules selected sarscov<NUMBER>ml library <NUMBER> reported study result combined use antivirals lopinavir ritonavir pharmacological alternatives initially used treat atypical pneumonia caused covid<NUMBER> unfortunately among group patients evaluated proven efficacy treatment patients clinical evolution acute respiratory failure addition reduction viral charge remained similar untreated patients information indicates urgent need specific effective pharmacological alternative pandemic disease computational tools used predict toxic potential varied molecules significant impact discovery development drugs toxicity one fundamental parameters continuation research drug design development <NUMBER> zhang et al <NUMBER> revealed highresolution structure αketoamide bound protease responsible block viral rna replication report αketoamide prolonged halflife blood plasma addition tested main inhibitory compound mice finding inhalation well tolerated mice adverse effects suggested therefore since human proteases similar cleavage specificity known unlikely class inhibitors toxic results useful structure development drugs combat new coronavirus study derek software used predict toxicological properties drugs study sarscov<NUMBER> cobicistat darunavir favipiravir hydroxychloroquine lopinavir oseltamivir remdesivir ritonavir well molecules selected libraries pro inhibitors software system makes predictions qualitative point view thus alerts fired possible toxic action analyzed chemical compounds able interpret toxicophoric substructures present compounds possible inducers certain types toxicity mutagenicity carcinogenicity skin sensitization irritation reproductive effects neurotoxicity among others correlation rules established software drugs investigated fired alerts described favipiravir antiviral agent selective potently inhibits rnadependent rna polymerase rdrp rna viruses favipiravir discovered hts screening chemical library antiviral activity influenza virus toyama chemical co ltd favipiravir undergoes intracellular phosphoribosylation active form favipiravirrtp favipiravirrtp favipiravir ribofuranosyl<NUMBER>btriphosphate recognized substrate rdrp inhibits activity rna polymerase catalytic domain rdrp conserved among various types rna viruses mechanism action supports broader spectrum broad range antiviral activities favipiravir favipiravir effective wide variety influenza virus types subtypes including strains resistant existing antiinfluenza drugs potentially promising specifically intractable rna viral infections <NUMBER> hand favipiravir presents risk teratogenicity embryotoxicity therefore ministry health labor welfare granted conditional marketing approval strict regulations production clinical use <NUMBER> study furuta et al <NUMBER> found favipiravir potent selective inhibitory activity influenza virus vitro plaque reduction assay favipiravir showed potent inhibitory activity influenza b c viruses <NUMBER> inhibitory concentrations ic <NUMBER> <NUMBER> <NUMBER> gml showing cytotoxicity concentrations <NUMBER> gml mdck cells hydroxychloroquine chloroquine respectively used treatment malaria rheumatoid arthritis systemic lupus erythematosus inflammatory rheumatic diseases considered weak bases drugs interfere lysosomal activity autophagy interact membrane stability alter signaling pathways transcriptional activity result inhibition cytokine production modulation certain costimulatory molecules modes action together chemical properties drug explain clinical efficacy known adverse effects retinopathy cardiac arrythmia drugs <NUMBER> cortegiani et al <NUMBER> systematically reviewed evidence chloroquine hydroxychloroquine treatment covid<NUMBER> found chloroquine appears effective limiting sarscov<NUMBER> replication vitro however present study hydroxychloroquine presented plausible hepatotoxicity probably due quinoline group inhibition herg channels carcinogenicity irritation respiratory tract ethanolamine ocular toxicity derived <NUMBER>aminoquinoline demonstrating high degree toxicity drug reaffirming yam kwok <NUMBER> cite one main side effects hydroxychloroquine ocular toxicity adversely affect cornea ciliary body retina hand recent studies suggest internal retina significantly damaged development human hydroxychloroquine toxicity <NUMBER> toxicity ethanolamine studied toxicology committee <NUMBER> study weeks et al <NUMBER> indicated skin eye irritation addition immediate signs irritability restlessness followed cns depression main adverse effects observed experimental animals anesthetized exposed ethanolamine <NUMBER> ppm <NUMBER> h continuous exposure <NUMBER> j u r n l p r e p r f ppm produced behavioral changes animals <NUMBER> weeks exposure sang et al <NUMBER> chose six approved antihiv<NUMBER> drugs investigate interactions pro well assess potential become clinical drugs new coronavirus pneumonia covid<NUMBER> caused sarscov<NUMBER> infection found darunavir best binding affinity pro among tested inhibitors indicating potential become clinical drug treat covid<NUMBER> however results toxicological properties drug point warnings hepatotoxicity mutagenicity well deserve attention qamar et al <NUMBER> examined database medicinal plants containing <NUMBER> <NUMBER> phytochemicals potential antivirals selected nine promising drugfree nontoxic natural products inhibit pro activity therefore virus replication nine products <NUMBER>tetrahydroxy study singh konwar <NUMBER> performed molecular coupling epigallocatechin gallate egcg analogs virus pro enzyme previous reports indicated egcg pro inhibitor low oral bioavailability thus stimulating molecular optimization according reported data analogues bound enzyme active site improved pharmacological properties estimated comparison egcg predicting admetox analogs study revealed improved pharmacological properties fisher et al <NUMBER> computationally examined library <NUMBER> million compounds binding crystal structure pro evaluated potential toxic effects compounds due interaction <NUMBER> known drugs made final selection <NUMBER> compounds compounds improvement binding free energy contrast cocrystallized inhibitor considered potential toxicity among compounds evaluated authors found natural compound containing lowest value free binding energy taxifoline according jo et al <NUMBER> coronaviruses target flavonoids assumed antiviral activity flavonoids covs directly caused inhibition pro regarding screened molecules <NUMBER> molecules selected sarscov<NUMBER>target library <NUMBER> present human toxicity alert table <NUMBER> <NUMBER> presented one alert <NUMBER> presented two alerts <NUMBER> molecules presented three alerts hand sarscov<NUMBER>ml library <NUMBER> molecules showed warning signs table <NUMBER> <NUMBER> showed one alert <NUMBER> showed two warning signs <NUMBER> molecules presented three alerts molecules selected sarscov<NUMBER> libraries present toxicity alerts according derek software considering analysis pharmacokinetic toxicological properties selected <NUMBER> molecules figure <NUMBER> <NUMBER> sarscov<NUMBER>target library m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> <NUMBER> sarscov<NUMBER>ml library m<NUMBER> supplementary material order analyze intermolecular interactions could occur pro comparison favipiravir presents satisfactory results well hydroxychloroquine since drug presents results literature potential drug treatment covid<NUMBER> <NUMBER> j u r n l p r e p r f evaluating amino acids his<NUMBER> cys<NUMBER> present active site said protease protomer <NUMBER> used purpose comparing docking results addition amino acid residues showed highest number interactions ligands molecules interact amino acid residue cys<NUMBER> exception m<NUMBER> however amino acid residue his<NUMBER> hydroxychloroquine drug screened molecules m<NUMBER> m<NUMBER> m<NUMBER> m<NUMBER> showed interactions molecular docking results indicated lowest number interactions drug favipiravir <NUMBER> interactions <NUMBER> hydrophobic <NUMBER> hydrogen bonds amino acids gly<NUMBER> ser<NUMBER> cys<NUMBER> his<NUMBER> <NUMBER> interactions m<NUMBER> <NUMBER> hydrophobic <NUMBER> hydrogen bonds amino acids gly<NUMBER> ser<NUMBER> cys<NUMBER> met<NUMBER> observed score value <NUMBER> drug favipiravir lowest one observed among molecules investigated <NUMBER> m<NUMBER> hydroxychloroquine m<NUMBER> molecules showed highest number interactions <NUMBER> first <NUMBER> hydrophobic interactions <NUMBER> hydrogen bonds observed amino acid residues his<NUMBER> met<NUMBER> gly<NUMBER> cys<NUMBER> his<NUMBER> met<NUMBER> glu<NUMBER> score value <NUMBER> amino acid residues his<NUMBER> met<NUMBER> cys<NUMBER> met<NUMBER> least two points hydrophobic interaction hydroxychloroquine glu<NUMBER> two points hydrogen bonding gly<NUMBER> presented one hydrogen bonding point his<NUMBER> hydrophobic interaction point inhibitor m<NUMBER> <NUMBER> hydrophobic interactions <NUMBER> hydrogen bonds identified amino acid residues leu<NUMBER> ser<NUMBER> cys<NUMBER> met<NUMBER> glu<NUMBER> arg<NUMBER> gln<NUMBER> thr<NUMBER> obtaining score value <NUMBER> case amino acid residues met<NUMBER> gln<NUMBER> two points hydrophobic interaction sarscov<NUMBER>mlm<NUMBER> ser<NUMBER> cys<NUMBER> two points hydrogen bonding gln<NUMBER> residue addition two hydrophobic interactions also showed hydrogen bond inhibitor finally amino acid residues leu<NUMBER> glu<NUMBER> arg<NUMBER> thr<NUMBER> presented hydrogen bonding point inhibitor one molecules intermediate number interactions m<NUMBER> <NUMBER> m<NUMBER> <NUMBER> m<NUMBER> <NUMBER> m<NUMBER> <NUMBER> m<NUMBER> <NUMBER> satisfactory score values best pose equal <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively m<NUMBER> interact amino acid residues belonging catalytic site unlike m<NUMBER> m<NUMBER> molecules managed interact his<NUMBER> cys<NUMBER> residues molecule highest score value <NUMBER> m<NUMBER> total <NUMBER> interactions observed <NUMBER> hydrophobic interactions <NUMBER> hydrogen bonds case amino acid residues met<NUMBER> cys<NUMBER> glu<NUMBER> leu<NUMBER> presented one point interaction inhibitor interactions hydrophobic met<NUMBER> cys<NUMBER> hydrogen bond glu<NUMBER> leu<NUMBER> amino acid residue pro<NUMBER> one showed multiple interactions m<NUMBER> inhibitor two hydrophobic interactions one hydrogen bond however interaction amino acid residue his<NUMBER> belonging catalytic site pro m<NUMBER> m<NUMBER> molecules stand satisfactory number interactions score value emphasizing first molecule studied showed interaction largest number amino acid residues <NUMBER> m<NUMBER> <NUMBER> interactions observed <NUMBER> hydrophobic <NUMBER> hydrogen bonds amino acids leu<NUMBER> his<NUMBER> gly<NUMBER> cys<NUMBER> met<NUMBER> glu<NUMBER> pro<NUMBER> gln<NUMBER> score value obtained best pose <NUMBER> <NUMBER> m<NUMBER> <NUMBER> interactions identified <NUMBER> hydrophobic <NUMBER> hydrogen bond amino acids his<NUMBER> met<NUMBER> cys<NUMBER> met<NUMBER> glu<NUMBER> pro<NUMBER> gln<NUMBER> score value <NUMBER> important note score values higher obtained drugs studied considering amino acids gly<NUMBER> cys<NUMBER> his<NUMBER> his<NUMBER> glu<NUMBER> gln<NUMBER> tyr<NUMBER> bind crystallographic inhibitor n<NUMBER> m<NUMBER> molecule interacted tyr<NUMBER> residue amino acid gly<NUMBER> interaction favipiravir hydroxychloroquine m<NUMBER> m<NUMBER> molecules amino acid cys<NUMBER> molecules interacted exception m<NUMBER> his<NUMBER> residue interacted j u r n l p r e p r f favipiravir hydroxychloroquine m<NUMBER> m<NUMBER> molecules linker interacted amino acid residue his<NUMBER> amino acid residue glu<NUMBER> showed interaction molecules except favipiravir m<NUMBER> gln<NUMBER> residue hand interacted m<NUMBER> m<NUMBER> m<NUMBER> molecules amino acid residues cys<NUMBER> met<NUMBER> pro<NUMBER> gln<NUMBER> proved capable making multiple chemical interactions different nature inhibitors multiple interactions present cases inhibitors highest number interactions target case inhibitor presented highest score value among twelve selected molecules therefore amino acid residues met<NUMBER> pro<NUMBER> gln<NUMBER> showed relevance multiple interactions different chemical natures inhibitor target addition his<NUMBER> cys<NUMBER> residues already belonging active site pro select m<NUMBER> molecule promising drug candidate treatment covid<NUMBER> figure <NUMBER> j u r n l p r e p r f similar property principle spp states molecules similar overall structure likely similar biological activity <NUMBER> similarity analysis possible select drug apixaban showed <NUMBER> similarity selected molecule m<NUMBER> molecular docking calculations performed target pro figure <NUMBER> obtaining <NUMBER> interactions <NUMBER> catalytic dyad his<NUMBER> cys<NUMBER> <NUMBER> interactions <NUMBER> amino acids met<NUMBER> leu<NUMBER> asn<NUMBER> gly<NUMBER> his<NUMBER> met<NUMBER> pro<NUMBER> arg<NUMBER> score value <NUMBER> apixaban anticoagulant acts selectively inhibiting activated factor xa reversible manner oral bioavailability <NUMBER> administered twice daily dose excreted urine feces apixaban useful atrial fibrillation venous thromboembolism pulmonary embolism bleeding major side effect apixaban <NUMBER> clinical study made tang et al <NUMBER> <NUMBER> patients severe covid<NUMBER> <NUMBER> received heparin mainly low molecular weight heparin lmwh <NUMBER> days longer <NUMBER>day mortality heparin users lower nonusers patients sic score ≥<NUMBER> ddimer <NUMBER> fold upper limit normal concluded anticoagulant therapy mainly lmwh appears associated better prognosis severe covid<NUMBER> patients meeting sepsisinduced coagulopathy sic criteria markedly elevated ddimer injectable anticoagulants heparin prescribed anticoagulation therapy required short duration absence oral form heparin makes impractical longterm use alternative warfarin coumarone derivatives best available oral anticoagulants market <NUMBER> found apixaban superiority warfarin aspirin terms efficacy safety <NUMBER> present study toxicity prediction study using derek software done alerts fired drug apixaban j u r n l p r e p r f work present proposals new potential pro inhibitors sarscov<NUMBER> virus pdb id <NUMBER>lu<NUMBER> alternative treatment covid<NUMBER> compounds designed virtual screening experiments two compound databases one previously built docking compounds pro built compounds known antisars activity virtual screening experiments performed selected <NUMBER> topranked hits base admetox properties calculated compared drugs currently tested covid<NUMBER> attempting reposition function among known antivirals hydroxychloroquine drug used treatment rheumatoid arthritis well others inflammatory diseases compounds designed presented showed pharmacokinetic toxicological properties even satisfactory suitable drugs currently test covid<NUMBER> addition maintain network favorable intermolecular interactions pro new coronavirus according docking studies performed enzyme also inhibitor selected serving template study similarity drug repurposing possible identify apixaban known anticoagulant administered oral route shows promising results future treatment covid<NUMBER> due suitable pharmacotherapeutic profile well low toxicity adverse effects thus estimated potential pro inhibitors sarscov<NUMBER> virus suggest promising compound well apixaban proposals alternative tests covid<NUMBER> future treatment patients affected severe acute respiratory syndrome <NUMBER> coronavirus pandemic covid<NUMBER> led severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> date drugs demonstrated safety efficacy randomized controlled trials patients covid<NUMBER> although association hydroxychloroquine azithromycin efficacy lack solid evidencebase several governments adopted virology confirmed covid<NUMBER> cases even asymptomatic following aim discuss ethical issues associated use treatment association mainly tried discuss following controversial questions ethical treat patient treatment exists used indications covid<NUMBER> it’s proven yet yes randomized controlled trial prove hydroxychloroquine covid<NUMBER> treatment necessary context covid<NUMBER> pandemic government’s right decide hydroxychloroquine treatment covid<NUMBER> patients physicians’ attitudes finally government physicians patient’s rights responsibilities paper conclude since health authorities countries recommended offlabel use treatment physicians challenged requirement veracity providing care patients implications requirementthey facing challenge balancing guideline conviction furthermore fundamental principles beneficence nonmaleficence respect persons underlie reflection process address dilemma addition pandemic context limits government’s practitioner’s patient’s rights obligations clear could significantly endanger universal ethical principles clinical practice could also undermine attempt develop serious clinical trials prove considered offlabel drug ethical issues related hydroxychloroquine treatment prescription covid<NUMBER> la pandémie de coronavirus <NUMBER> covid <NUMBER> conduit au syndrome respiratoire aigu sévère coronavirus <NUMBER> srascov<NUMBER> à ce jour aucun médicament na démontré son innocuité et son efficacité dans des essais contrôlés randomisés pour les patients atteints de covid<NUMBER> bien que lassociation entre lhydroxychloroquine et lazithromycine manque de preuves solides plusieurs gouvernements lont adoptée pour tous les cas de covid<NUMBER> confirmés même pour ceux qui sont asymptomatiques dans ce qui suit nous discutons certains des problèmes éthiques associés à lutilisation de cette association thérapeutique nous avons principalement essayé de discuter les questions controversées suivantes estil éthique de ne pas traiter un patient alors quun traitement existe et est utilisé pour dautres indications que le covid<NUMBER> pour lequel il nest pas encore prouvé si oui un essai contrôlé randomisé pour prouver lhydroxychloroquine pour le traitement covid<NUMBER> estil nécessaire dans le contexte de la pandémie covid<NUMBER> si non le gouvernement atil le droit de décider du traitement à lhydroxychloroquine pour tous les patients de covid<NUMBER> et quelles devraient être les attitudes des médecins enfin quels sont les droits et responsabilités du gouvernement des médecins et des patients le document conclut que puisque <NUMBER> coronavirus pandemic led major morbidity form severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> deaths <NUMBER> date fifth months novel coronavirus pandemic drugs demonstrated safety efficacy randomized controlled trials patients covid<NUMBER> several agents hydroxychloroquine lopinavir ritonavir azithromycin used clinical trial compassionate use protocols based vitro activity sarscov<NUMBER> related viruses limited clinical experience <NUMBER> <NUMBER> although association hydroxychloroquine azithromycin efficacy lack solid evidencebase largely mediatized experts defending efficacy association based previous experiences malaria also based observations made upon covid<NUMBER> patients <NUMBER> refuted allegations effectiveness drug recommended symptomatic treatment monitoring covid<NUMBER> many developed countries china european countries usa still cautious proposed drug waiting many ongoing clinical trials <NUMBER> despite doubt uncertainty drug effectiveness covid<NUMBER> several governments adopted hydroxychloroquine azithromycin association virology confirmed covid<NUMBER> cases even asymptomatic <NUMBER> decision raised many questions ethical issues related hydroxychloroquine treatment prescription might emerge covid<NUMBER> patients management following aim discuss ethical issues associated use treatment association admitted authorized drugs proven case hydroxychloroquine proven covid<NUMBER> yet labeled indication treatment malaria use covid<NUMBER> therefore offlabel use context covid<NUMBER> rising many controversial questions ethical treat patient treatment exists used indications covid<NUMBER> proven yet yes randomized controlled trial prove hydroxychloroquine covid <NUMBER> first randomization best way avoid selection information bias equipoise main justification randomization could overlooked treatment clearly superior case randomization put one group patients disadvantage many historical examples effective treatment based observational studies adequate enough show effectiveness without recourse randomization eg penicillin bacterial infections smallpox vaccination … case hydroxychloroquine covid<NUMBER> may ask sufficient scientific medical evidence prescribe drug treatment recent systematic review efficacy safety chloroquine treatment covid<NUMBER> <NUMBER> concluded sufficient preclinical rationale evidence regarding effectiveness chloroquine treatment covid<NUMBER> well evidence safety longtime use clinical practice indications <NUMBER> justify clinical research topic based conclusion question related prescription drug treatment covid<NUMBER> answered yet however one could argue worldwide emergency rapid spread disease high rates disease mortality mainly beginning pandemic <NUMBER> sufficient reasons prescribing offlabel treatment covid<NUMBER> patients answer yes remain questions main ethical principles applied case evidence based pathway randomized clinical trial support new purposes drug context covid<NUMBER> pandemic characterized high case fatality rate cfr reported <NUMBER> initial period pandemic <NUMBER> healthcare leaders policy makers need estimates mortality case fatality even changing time <NUMBER> cases illness severity <NUMBER> guided forming strategies national level public health perspective including patient care strategy meuri monitored emergency use unregistered interventions framework group stated emergency situation ethically appropriate offer individual patients experimental interventions emergency basis outside clinical trials <NUMBER> even true best available therapeutic option fails patients demand new approach new treatment physicians promote patients interests prescribing products offlabel <NUMBER> also use best available drug supported expert opinion <NUMBER> case hydroxychloroquine however clinical use drugs adhere meuri framework <NUMBER> four principles medical ethics respect autonomy beneficence nonmaleficence justice respected ebola outbreak democratic republic congo good example illustrating reasoning vaccine trials conducted scrutiny meuri method <NUMBER> results trials suggest robust vaccine efficacy within <NUMBER> days good tolerance administered healthy nonpregnant adults <NUMBER> authors deplore none promising treatments used ebola field trials could far convincingly confirmed curative <NUMBER> meuri circumstances substitute properly designed trials said agarwal propose pluralistic evidence instead randomized clinical considering available sources types data including laboratory studies mechanisms action vitro experiments human biopsies vivo animal models quality life data clinical trials offlabel drug use etc <NUMBER> pluralistic evidence approach may feasible acceptable covid<NUMBER> pandemic provide data sufficient quality fill evidence gap efficacy safety offlabel medicine complete causal association minimizing potential biases practitioners confident less reluctant prescription modern societies governments duty provide healthcare established law mean government right decide whether treatment even proven yet prescribed treatment habitual situations authorities monitor offlabel drug uses regularly collect publicize information offlabel uses consider proposals regulate certain offlabel uses well proposed policy measures could decrease risky ineffective offlabel prescribing <NUMBER> <NUMBER> however covid<NUMBER> pandemic government promoting offlabel drug prescription decisionmakers guided available scientific evidence intervention expected benefits harms <NUMBER> specific evidence available decisions based reasoned evidenceinformed substantive arguments analogous situations possible extent <NUMBER> however point emergency context decisions still difficult make especially comes weight given treat patients pandemic context compared important public health priorities <NUMBER> reason include clinicians patients decisionmaking process otherwise decision may considered unacceptably paternalistic many doctors currently facing dilemma choice two options either prescribing yet proven treatment many unanswered questions one hand limited symptomatic treatment recommended may ask might ethical implications government decided treatment prescription doctors may feel forced prescribe treatment regimen necessarily convinced may feel double challenging strictly follow therapeutic protocol dictated government present treatment patients experimental therapeutic physicians duty provide clear clinical information patient accordance universal rules ethics addition standard situation responsible offlabel prescribing requires physicians evaluate whether sufficient evidence justify offlabel use ii press additional information adequate evidence iii inform patients uncertainties potential costs associated offlabel prescribing <NUMBER> however explaining risks benefits detail explaining also although treatment good results indications effectiveness covid <NUMBER> yet proven easy task context addition could argue taking time explain details complexities offlabel drug use emergency context could distract shared clinical goals <NUMBER> <NUMBER> challenge even complicated developing countries considering context multicultural specificity different dialects medical paternalistic decisions often required patients social vulnerability deepened pandemic high level illiteracy low socioeconomic level addition countries <NUMBER> treatment recommended patients even asymptomatic doctors argued treatment given moderate critically ill patients targeting treatment however may viewed public health emergency perspective less effective reducing spread disease contact patients whole population attitude may undermine public health goal individual interests outweigh collective ones first concern comes patients related principle beneficence nonmaleficence address concern need answer two questions first question whether enough evidence benefits hydroxychloroquine reluctancy regarding use drug treatment patients covid<NUMBER> justified absence high level scientific evidence namely randomized controlled clinical trials proving superiority drug indication discussed presence crisis waiting results randomized clinical trials might considered luxury second question extent risks related hydroxychloroquine acceptable justifiable benefits comes much know drug safety tolerance particular case hydroxychloroquine drug known used many years malaria treatment prophylaxis well autoimmune conditions <NUMBER> means used among large patients populations clinicians long experience prescribing monitoring side effects effort trying address concerns would want provide best care patients considering available knowledge time generate valid evidence future offlabel unlicensed use drugs quite common medical practice several reasons explain phenomenon recent paper agarwal discusses pluralistic method ethical efficient evidence generation offlabel medication use realworld situation <NUMBER> allow us wait generating highquality evidence proposing promising drugs recent example recent ebola outbreak democratic republic congo raised similar discussions world health organization advised monitored emergency use unregistered interventions meuri <NUMBER> bhadelia et al also proposed set recommendations choose among available options collect data build evidence <NUMBER> perspectives examples considered translation situation covid<NUMBER> pandemic since beginning pandemic scientists started exploring available options <NUMBER> <NUMBER> date proved vaccine treatment covid<NUMBER> several papers supporting rationale chloroquine use published <NUMBER> articles reported preclinical data <NUMBER> preliminary clinical data <NUMBER> many countries use hydroxychloroquine recommended health authorities case morocco <NUMBER> finally clinical trials ongoing provide evidence <NUMBER> provide supplementary argument ethicists solve question second concern related principle respect persons emphasis patients autonomy healthcare providers transparency veracity offlabel prescription considered legal quite frequent common example prescription many drugs among children drugs tested evaluated among population <NUMBER> another example aspirin prescribed prevent cardiovascular events many years licensed fda indication hand recognized offlabel prescriptions dangerous generally expensive thus important emphasize informed consent shared decisionmaking <NUMBER> case chloroquine cheap drug probability side effects present several arguments requiring consent offlabel use proposed including means respect patients autonomy account potential risk patients related lack scientific evidence another set arguments could discussed requiring consent procedure obtaining approval different uses might considered costeffective pharmaceutical companies use licensed drugs without risks also possible discussing offlabel nature use confuses patient <NUMBER> obtaining valid informed consent requires patients informed proposed treatment licensed indication available rationale data justifying consideration situation appropriate information consideration patients autonomy lead shared decisionmaking achieving informed consent shared decisionmaking application principles patient autonomy veracity paper highlighted ethical issues related prescription offlabel drug pandemic conditions context limits governments practitioners patients rights obligations clear could significantly endanger universal ethical principles clinical practice could also undermine attempt develop serious clinical trials prove considered offlabel drug since health authorities countries recommended offlabel use physicians challenged requirement veracity providing care patients implications requirement furthermore physicians facing challenge balancing guideline conviction fundamental principles beneficence nonmaleficence respect persons underlie reflection process address dilemma hence urgent need guidance encourage proper offlabel use drugs emergency situation step taken considering grounded ethical legal principles important decisions drug prescription taken process transparent inclusive appropriately communicated practitioners well general public <NUMBER> development culturallysensitive communication strategies may achievable relatively modest resources certainty chloroquine andor hydroxychloroquine efficacious severe acute respiratory syndrome caused coronavirus <NUMBER> sarscov<NUMBER> covid<NUMBER>infected patients pneumonia especially immunocompromised patients wish enter ongoing debate whether wellknown drug must given greek covid<NUMBER>infected patients especially pneumonia available data thus far limited originate mainly china inadequate reach safe conclusion generally accepted medication given patient unless causes much good harm times crisis leaders world state regard covid<NUMBER> pandemic rules may apply https wwwbbccomnewsworlduscanada<NUMBER> based italian spanish experience anticipate shortage ventilators intensive care unit beds many severe covid<NUMBER>infected cases greece httpswwwreuterscom articleushealthcoronavirusdraegerwerkventilgermanyitalyrushtobuylifesavingventilatorsasmanufacturerswarnofshortagesiduskbn<NUMBER> may even shortage liquid oxygen due huge demands hospitalized patients seen countries httpswwwexpresscouknews world<NUMBER>coronavirusuknewsitalyupdatelatesthospitalsnhs hence time waste must probably proactive ready take action available therapeutic tools costeffective especially pandemic time waste hydroxychloroquine armoury covid<NUMBER> infected patients countries like greece experienced fiscal crisis years amongst one economical affordable greek health system chloroquine hydroxychloroquine drug belonging <NUMBER>aminoquinoline class efficacy safety profile may desirable may placed top respective list available antiviral agents really need wait international guidelines issued regarding applicability covid<NUMBER> pneumonia may take weeks even months available data still limited large clinical trials still beginning running time may need proactive chinese colleagues far china alone least <NUMBER> clinical trials investigate efficacy safety chloroquine hydroxychloroquine treatment covid<NUMBER>associated pneumonia <NUMBER> studies conducted several hospitals treating thousands covid<NUMBER> infected patients large cities wuhan jingzhou guangzhou beijing shanghai chongqing ningbo <NUMBER> limited data europe france encouraging <NUMBER> clinical trial kind investigating amongst immunogenicity drug also going start soon university hospital larissa central greece hospitals greece anticipated follow based chinese data <NUMBER> chloroquine phosphate superior control treatment promoting virusnegative conversion importantly constraining exacerbation pneumonia improving lung imaging findings limiting disease course duration data definite thousands chinese patients still included final verdict china experts gathered analysed existing data reached decision national health commission peoples republic china issued guidelines chloroquine recommended treatment pneumonia caused covid<NUMBER> per <NUMBER> th <NUMBER> th edition guidelines prevention diagnosis treatment pneumonia caused covid<NUMBER> expert panel national public health authority recently <NUMBER> march <NUMBER> revised therapeutic protocolalgorithm treatment symptomatic covid<NUMBER> patients includes hydroxychloroquine chloroquine harmonized paneuropean protocol issued european health authorities urgently needed china italy lombardy protocol netherlands belgium switzerland france countries issued specific therapeutic protocols based stratification patients however existing recommendations consensus dosage duration patient selection therapeutic intervention country follows recommendations issued respective expert panel health authority task force significant discrepancies exist amongst therapeutic protocols countries recommendations updated regular basis taking account evolving data relevance world health organisation launching solidarity megatrial recruiting thousands patients globe assess efficacy existing antiviral agents used treat covid<NUMBER> patients reported science enrolling subjects solidarity easy person confirmed case covid<NUMBER> deemed eligible physician enter patients data website including underlying condition could alter course disease physician states drugs available hospital website randomize patient one drugs available local standard care covid<NUMBER> httpswwwsciencemag orgnews<NUMBER>wholaunchesglobalmegatrialfourmostpromisingcoronavirustreatments europe several studies started recruiting patients assess efficacy safety drug based clinicaltrialgov repository norwegian coronavirus disease <NUMBER> study nocovid<NUMBER> launched march <NUMBER> nct<NUMBER> twoarm open label pragmatic randomized controlled trial anticipated enrol approximately <NUMBER> patients trial hydroxychloroquine sulphate plaquenil <NUMBER> mg given twice daily seven days primary outcome trial rate decline sarscov<NUMBER> viral load baseline randomization <NUMBER> hours secondary outcomes include change national early warning score admission intensive care unit inhospital mortality duration hospital admission mortality <NUMBER> <NUMBER> days clinical status even start treating covid<NUMBER> pneumonia patients drug several questions remain unanswered going treated must initiate treatment need stratify patients according severity given prophylaxis case malaria appropriate dose ideal duration treatment noted chinese clinical trials conducted far using dosage treatment duration nevertheless according recently issued <NUMBER> th edition formal chinese guidelines chloroquine phosphate suitable treatment covid<NUMBER> pneumonia adults aged <NUMBER> <NUMBER> years old weighing <NUMBER> kg course treatment <NUMBER> mg twice per day <NUMBER> days weighting <NUMBER> kg less course treatment <NUMBER> mg twice day day <NUMBER> day <NUMBER> followed <NUMBER> mg given per day days <NUMBER> <NUMBER> httpwwwgov cnzhengcezhengceku<NUMBER>files ae<NUMBER>f<NUMBER>d<NUMBER>a<NUMBER>d<NUMBER>cbf<NUMBER>a<NUMBER>pdf important issue safety drug proposed doses statements greek media drug extremely toxic must given <NUMBER> <NUMBER> <NUMBER> mediterranean journal rheumatology <NUMBER> <NUMBER> <NUMBER> kill people httpswwwethnosgrellada<NUMBER>exalliiepistimonikikoinotitaafistetihlorokinithasasskotosei helpful chinese guidelines explicit concerning adverse effects precautions contraindications wellknown reported summary product characteristics spc hcq phosphate plaquenil sanofiaventis httpproductssanoficaenplaquenilpdf relate pregnancy allergy <NUMBER>aminoquinolines cardiac arrhythmias heart block chronic heart disease chronic liver kidney diseases reach terminal stages history retinal disease hearing loss deafness history mental illness skin diseases including rash dermatitis psoriasis glucose<NUMBER>phosphate dehydrogenase deficiency concurrent usage following preexisting conditions digoxin derivatives phenylbutazone heparin penicillamine amiodarone bepridil domperidone droperidol haloperidol azithromycin astemizole erythromycin clarithromycin posaconazole methadone procainamide hydrochlorothiazide sparfloxacin levofloxacin moxifloxacin cisapride indapamide chlorpromazine streptomycin penicillamine ammonium chloride ondansetron apomorphine octreotide mao inhibitors triamcinolone httpwww govcnzhengcezhengceku<NUMBER>files ae<NUMBER>f<NUMBER>d<NUMBER>a<NUMBER>d<NUMBER>cbf<NUMBER>a<NUMBER>pdf precautions using chloroquine phosphate treat patients covid<NUMBER> pneumonia also described chinese guidelines electrocardiogram must normal prior medication simultaneous use quinolones macrolide antibiotics drugs may cause qt interval prolongation prohibited patient stable potassium sodium levels normal blood sugar normal liver kidney function special attention must paid potential drug interactions using <NUMBER> antiviral drugs including chloroquine phosphate recommended close monitoring adverse drug reactions discontinuation drug intolerable adverse reaction develops httpwwwgovcnzhengce zhengceku<NUMBER>filesae<NUMBER>f<NUMBER>d<NUMBER>a<NUMBER>d<NUMBER>cbf<NUMBER>a<NUMBER>pdf hydroxychloroquine used decades prevent treat malaria first used world war ii also effective antiinflammatory immunomodulatory agent management various autoimmune rheumatic diseases rheumatoid arthritis sjögrens syndrome systemic lupus erythematosus even sarcoidosis thousands greek patients rheumatic diseases currently treated hydroxychloroquine <NUMBER> mg <NUMBER> mg per day months even years millions people respective rheumatic diseases receiving drug world severe adverse reactions limited minor proportion patients indication take drug discontinue adverse reactions information visit httpswwwncbinlmnihgovbooksnbk<NUMBER> long experience drug safety profile efficacy treatment patients rheumatic diseases coexisting comorbidities currently treating hundreds patients central greece medication said caution must exercised overthecounter use medications american media reported man phoenix area died wife critical condition couple took chloroquine phosphate additive used clean fish tanks httpseditioncnncom<NUMBER>healtharizonacoronaviruschloroquinedeathindexhtml safety profile drug specifically covid<NUMBER> treated patients also topic intense research copcov french observational study recruit <NUMBER> participants address adverse events related treatments used sarscov<NUMBER> including chloroquine uk randomised placebocontrolled prophylaxis study nct<NUMBER> assess prophylactic effect chloroquine chloroquine prevention coronavirus disease healthcare setting study doubleblind randomized placebocontrolled trial conducted health care settings include healthcare workers individuals significant risk followed <NUMBER> months <NUMBER> participants recruited investigators predict average <NUMBER> participants per site <NUMBER> sites loading dose <NUMBER>mgkg body weight given followed <NUMBER> mg daily <NUMBER>mg chloroquine phosphate salt taken <NUMBER> months diagnosed covid<NUMBER> subsequent episodes symptomatic respiratory illness including symptomatic covid<NUMBER> clinical outcomes asymptomatic covid<NUMBER> infection recorded followup period clinical trials kind initiated based urgent need prompt antiviral treatment preliminary vitro vivo data experts think hydroxychloroquine promising start treatment covid<NUMBER>related pneumonia drugs anticoronavirus activity demonstrated <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> hydroxychloroquine appears potent vitro inhibitor chloroquine inhibiting sarscov<NUMBER> infected vero cells <NUMBER> inhibits hcovoc<NUMBER> infected hrt<NUMBER> cells <NUMBER> data also corroborated findings infected mice <NUMBER> still miss data sarscov<NUMBER> also looks like chloroquine also exerts antiviral action increasing endosomal ph required viruscell fusion <NUMBER> <NUMBER> also interferes glycosylation cellular receptors sarscov may least part explain potent efficacy treating patients covid<NUMBER> pneumonia <NUMBER> chloroquine may also antithrombotic effect covid<NUMBER> patients appearing vasculitides thrombotic episodes may also first cases pneumonia due novel betacoronavirus first identified december <NUMBER> wuhan china <NUMBER> later named severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> virus causes coronavirus disease <NUMBER> covid <NUMBER> infected hundreds thousands across <NUMBER> continents <NUMBER> overall casefatality rate covid<NUMBER> remains flux initially reported <NUMBER> mainland china italy reported casefatality rate <NUMBER> <NUMBER> <NUMBER> note casefatality rates reportedly higher patients preexisting cardiovascular disease <NUMBER> transmission sarscov<NUMBER> occurs persontoperson spread respiratory droplets selfinoculation contact virus contaminated surfaces disease incubation period approximately <NUMBER> days <NUMBER> common signs symptoms covid<NUMBER> include fever dry cough shortness breath myalgia however patients present gastrointestinal eg diarrhea nausea vomiting neurological eg headache hypogeusia hyposmia symptoms <NUMBER> <NUMBER> cardiovascular complications myocarditis acute myocardial infarction heart failure reported previously observed acute upper respiratory infections eg influenza <NUMBER> extensive discussion complications relationship covid<NUMBER> described elsewhere <NUMBER> currently established treatment vaccine sarscov<NUMBER> several antiviral immunomodulating therapies used clinical investigation sarscov<NUMBER> infection seems lead severe disease patients elderly comorbidities <NUMBER> review provide overview pharmacology cardiovascular considerations promising therapies investigated use patients covid<NUMBER> particular consideration treatment sarscov<NUMBER> infection may particularly challenging patients risk cardiovascular diseases fig <NUMBER> complete understanding covid<NUMBER> lacking reports china italy describe <NUMBER> phases disease <NUMBER> <NUMBER> initial phase primarily infection characterized predominantly lower respiratory symptoms patients recover however patients progress immunemediated respiratory failure leading acute respiratory distress syndrome ards multiple organ failure associated high mortality rate <NUMBER> early approaches treatment involved antiviral therapies aimed reducing viral replication representing main pathogenetic mechanism least early phase immunomodulatory therapies targeting inflammatory response leads ards also explored important recognize time lowquality data support use therapy covid<NUMBER> field evolving rapidly therefore review considered comprehensive summary current approaches prevention treatment described figure <NUMBER> important consider patients greatest risk covid<NUMBER>related mortality aggressive treatment considered also receiving concomitant cardiovascular therapies therefore drugdrug interactions must considered accounted managing cardiovascular patients covid<NUMBER> table <NUMBER> sarscov<NUMBER> rna betacoronavirus uses glycosylated spike protein gain host cell entry <NUMBER> single region spiked protein receptorbinding domain binds patients covid<NUMBER> increase metabolic demand occurs along progressive decrease cardiac contractility cardiac reserve responsible acute cardiovascular complications decompensation chronic cardiovascular disorders well covid<NUMBER> characterized severe systemic inflammation procoagulant effect may pave way thrombotic events impair immune response leading myocardial injury interestingly individuals history cardiovascular disease hypertension diabetes higher risk develop aggressive potentially lifethreatening disease currently available drugs evaluation may important implications cardiovascular health care providers many agents significant drugdrug interactions cardiovascularrelated side effects acute chronic figure partially created using servier medical art templates licensed creative commons attribution <NUMBER> unported license httpssmart serviercom cv cardiovascular doac direct oral anticoagulants investigational approach covid<NUMBER> management important recognize time approved therapies covid<NUMBER> preventative approaches critical prevent persontoperson spread include social physical distancing proper hygiene patients covid<NUMBER> positive either asymptomatic mild symptoms selfquarantine <NUMBER> weeks receive supportive care home overburden health care system patients severe illness eg worsening shortness breath may receive one several investigational therapies oxygen therapy minority patients require intensive care ventilation may appropriate candidates therapies aimed preventing cytokine storm blunt inflammatory response hostcell receptor host protease cleaves spike allows virus entry host cell humans sarscov<NUMBER> uses angiotensinconverting enzyme ii ace<NUMBER> entry receptor <NUMBER> thus antiviral therapies either interrupt replication sarscov<NUMBER> <NUMBER> eg remdesivir prevent viruscell fusion glycosylation cellular receptors sarscov<NUMBER> necessary binding ace<NUMBER> <NUMBER> eg chloroquine investigated potential treatments antimalarial agents hydroxychloroquine chloroquine commonly used treat autoimmune diseases systemic lupus erythematosus rheumatoid arthritis disrupt immune activation cellular level inhibiting innate adaptive immune responses addition impairing endosomal lysosomal acidification required viruscell binding therapies may exert antiviral activity <NUMBER> vitro studies suggest chloroquine may potent inhibiting sarscov<NUMBER> hydroxychloroquine hydroxychloroquine seems less toxic <NUMBER> hydroxychloroquine administered orally loading dose <NUMBER> mg twice daily followed maintenance dose <NUMBER> mg twice daily <NUMBER> days <NUMBER> electrocardiogram ecg monitoring recommended watch cardiac arrhythmias including qt prolongation torsade de pointe atrioventricular block <NUMBER> reduction dose discontinuation considered qtc <NUMBER> ms increase qtc <NUMBER> ms caution advised used together therapies prolong qtc especially antiarrhythmics antimalarialinduced hypertrophic restrictive cardiomyopathy also occur exceedingly rare occurs prolonged use concern given short duration <NUMBER> days treatment required covid<NUMBER> <NUMBER> chloroquine hydroxychloroquine also inhibit cyp<NUMBER>d<NUMBER> may increase betablocker exposure risk bradycardia pr interval prolongation atrioventricular block potential adverse effects include severe hypoglycemia erythroderma hematological psychiatric disturbances thus routine monitoring include complete blood count comprehensive metabolic panel small pilot study <NUMBER> randomized <NUMBER> patients either intervention hydroxychloroquine <NUMBER> mg daily <NUMBER> days conventional therapy day <NUMBER> patients tested respiratory pharyngeal swab evidence covid<NUMBER> nucleic acid difference number negative swabs hydroxychloroquine n <NUMBER> control n <NUMBER> groups p <NUMBER> favorable trends observed secondary measures including duration hospitalization body temperature regulation radiological progression another small singlearm study effects hydroxychloroquine <NUMBER> mg daily hospitalized patients presence absence virus day <NUMBER> studied <NUMBER> twentysix french subjects received protocol <NUMBER> served controls six stopped hydroxychloroquine therapy early due either transferred intensive care unit n <NUMBER> leaving hospital n <NUMBER> death n <NUMBER> nausea n <NUMBER> day <NUMBER> treatment <NUMBER> hydroxychloroquinetreated patients virologically cured compared <NUMBER> control group p <NUMBER> addition macrolide antibiotic azithromycin hydroxychloroquine significantly effective virus elimination <NUMBER> cure rate suggesting combination may superior hydroxychloroquine alone authors published preprint <NUMBER> larger sample n <NUMBER> patients received combination hydroxychloroquine azithromycin showing clinical improvement <NUMBER> patients authors report <NUMBER> subjects required oxygen therapy <NUMBER> negative nasopharyngeal viral load day <NUMBER> length stay limited average <NUMBER> days despite favorable outcomes reported observational studies proper randomized controlled trial warranted definitive decisions made regarding role therapies treating covid<NUMBER> although mechanism azithromycin would effective patients covid<NUMBER> azithromycin found antiviral antiinflammatory effects vivo vitro studies <NUMBER> <NUMBER> <NUMBER> azithromycin also activity proinflammatory cytokines interleukin il<NUMBER> il<NUMBER> may reduce development cytokine storm warrants study <NUMBER> one potential concern however concomitant antimalarial therapy azithromycin potential qtc prolongation warranting daily ecg monitoring <NUMBER> although macrolides demonstrated similar effects azithromycin minimally inhibits cyp<NUMBER>a<NUMBER> others eg erythromycin clarithromycin strong inhibitors cyp<NUMBER>a<NUMBER> well tolerated azithromycin time data supporting combination hydroxychloroquine azithromycin covid<NUMBER> limited given potential significant toxicity use regimen considered caution also suggested may role hydroxychloroquine chloroquine used prophylaxis highrisk individuals health care workers therefore chloroquine studied potential preventative measure covid<NUMBER> health care workers individuals highrisk environments nct<NUMBER> participants randomized placebo chloroquine loading dose <NUMBER> mgkg followed <NUMBER> mg daily <NUMBER> months primary outcome number covid<NUMBER> cases <NUMBER> days time however little evidence pharmacological measures reduce transmission sarscov<NUMBER> health care workers highrisk individuals remdesivir gilead sciences inc foster city ca nucleotide analog prodrug broad antiviral activity initially used ebola <NUMBER> vivo vitro testing shown inhibit human coronavirus replication including sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> <NUMBER> remdesivir initially available compassionate use received orphan drug status us food drug administration fda march <NUMBER> <NUMBER> recommended dosing initial single dose <NUMBER> mg intravenously followed <NUMBER> mg every <NUMBER> hours duration hospitalization <NUMBER> days <NUMBER> several phase <NUMBER> clinical trials underway united states south korea china europe nct<NUMBER> nct<NUMBER> nct<NUMBER> nct<NUMBER> <NUMBER> two larger ongoing multicenter clinical trials nct<NUMBER> nct<NUMBER> evaluating remdesivir hospitalized patients moderate n <NUMBER> severe n <NUMBER> symptoms yet requiring mechanical ventilation patients studies randomized <NUMBER> <NUMBER> days remdesivir additional standard care arm moderate disease trial focus discharge fever oxygen saturation <NUMBER> days patients severe symptoms requiring mechanical ventilation must pursue individual compassionate use protocols receive access remdesivir importantly trials cardiovascularspecific reasons exclusion overall remdesivir generally well tolerated selflimiting hepatotoxicity observed nephrotoxicity also possible thus use recommended patients estimated glomerular filtration rate <NUMBER> mlmin<NUMBER> <NUMBER> dialysis monitoring recommendations include complete blood count differential comprehensive metabolic panel limited information available time regarding potential drugdrug interactions remdesivir information clinical trial protocol nct<NUMBER> suggests remdesivir prodrug metabolized active form substrate cyp<NUMBER>a<NUMBER> remdesivir substrate cyp<NUMBER>c<NUMBER> cyp<NUMBER>d<NUMBER> cyp<NUMBER>a<NUMBER> vitro yet also states coadministration drugs affect cyp isoforms unlikely significantly affect metabolism remdesivir lopinavir protease inhibitor primarily used treatment hiv combined ritonavir another protease inhibitor also inhibits cyp<NUMBER>a<NUMBER> combined lopinavir enhance potency <NUMBER> cardiovascular perspective lopinavirritonavir induce endothelial dysfunction insulin resistance however cause hypertriglyceridemia <NUMBER> <NUMBER> retrospective singlecenter study suggests ritonavirboosted regimens may worsen cardiovascular outcomes patients hiv heart failure <NUMBER> importantly data sufficient restrict use lopinavirritonavir patients cardiovascular disease heart failure given lifethreatening potential covid<NUMBER> shortterm <NUMBER> weeks duration treatment notable drugdrug interactions lopinavir ritonavir select cardiovascular therapies ritonavir potent inhibitor cyp<NUMBER>a<NUMBER> pglycoprotein mdr<NUMBER> <NUMBER> may result increased concentrations cardiovascular therapies metabolized cyp<NUMBER>a<NUMBER> rivaroxaban apixaban simvastatin lovastatin used combination ritonavir <NUMBER> <NUMBER> likewise ritonavir inhibits bioactivation clopidogrel prasugrel may decrease antiplatelet activity however may affect antiplatelet activity prasugrel making still reasonable option <NUMBER> <NUMBER> ticagrelor used strong inhibitors cyp<NUMBER>a<NUMBER> ritonavir due increased risk bleeding <NUMBER> <NUMBER> use p<NUMBER>y<NUMBER> platelet function assays may appropriate ensure adequate antiplatelet activity gastrointestinal symptoms eg nausea vomiting diarrhea elevations hepatic transaminases also occur routine monitoring includes complete blood count comprehensive metabolic panel baseline ecg recommended used concomitant agents eg antiarrhythmics prolong qt interval recently <NUMBER> hospitalized patients severe covid<NUMBER> disease randomized either fixed dose lopinavirritonavir <NUMBER> <NUMBER> mg respectively twice daily <NUMBER> days standard care <NUMBER> intervention improve time clinical improvement mortality although study underpowered detect mortality benefit gastrointestinal complaints nausea vomiting diarrhea also common <NUMBER> patients discontinued therapy due adverse events additional clinical trials ongoing including one clinical trial comparing lopinavir ritonavir hydroxychloroquine nct<NUMBER> another clinical trial comparing lopinavirritonavir remdesivir <NUMBER> patients covid<NUMBER> note interferonbeta may also used combination lopinavirritonavir shown improve pulmonary function reduce viral loads marmosets mice middle east respiratory syndrome coronavirus yet evaluated humans <NUMBER> <NUMBER> immune modulators patients severe infection may progress severe respiratory failure due ards mediated catastrophic inflammatory cascade <NUMBER> <NUMBER> early observations china italy led widespread use tocilizumab fully humanized monoclonal antibody interleukin<NUMBER> receptor il<NUMBER>r <NUMBER> <NUMBER> although originally fda approved use rheumatoid arthritis tocilizumab routinely used treatment cytokine release syndrome secondary chimeric antigen receptor tcell therapy hematologic malignancies <NUMBER> observational series patients severe respiratory symptoms china showed recovery <NUMBER> <NUMBER> treatment tocilizumab <NUMBER> mgkg iv maximum dose <NUMBER> mg <NUMBER> emerging treatment protocols recommend aggressive doses <NUMBER> mgkg <NUMBER> mg repeated doses <NUMBER> <NUMBER> hours patients showing inadequate responses primary risks tocilizumab relate immunosuppression neutropenia interruption tcellmediated immunity infusion reactions transient transaminase elevations may also occur frequently although tocilizumab significantly increases cholesterol levels blood pressure recent network metaanalysis found cardiovascular risk tocilizumab comparable diseasemodifying antirheumatic drugs <NUMBER> regardless given high mortality rate among patients covid<NUMBER>mediated ards <NUMBER> potential benefits shortterm tocilizumab use seem outweigh risks treatment patients parallels inflammatory pathophysiology chimeric antigen receptor tcell therapymediated cytokine release syndrome covid<NUMBER>mediated ards suggest il<NUMBER> suppression key advancement treatment severe covid<NUMBER> infection sarilumab regeneron pharmaceuticals inc tarrytown ny il<NUMBER> blocker currently market tocilizumab unavailable however limited evidence guide selection dosing agents time urgent public health priority combat covid<NUMBER> future develop safe effective vaccine widespread vaccination could also play role modulating cardiovascular risk similar observed influenza thus importance identifying safe effective vaccine <NUMBER> first phase <NUMBER> clinical trial nct<NUMBER> evaluating vaccine covid<NUMBER> mrna<NUMBER> began march <NUMBER> <NUMBER> sponsored national institutes health openlabel study enroll <NUMBER> healthy adults <NUMBER> <NUMBER> years <NUMBER> weeks although <NUMBER> vaccine candidates pipeline unlikely vaccine available least <NUMBER> increased concern regarding use ace inhibitors angiotensin receptor blockers arbs patients due potential ace inhibitors arbs upregulate ace<NUMBER> receptors found vascular endothelial cells heart kidneys lungs shown host cell entry point sarscov<NUMBER> <NUMBER> thus theoretical increased risk covid<NUMBER> patients taking medications also seems sarscov<NUMBER> consumes ace<NUMBER> increases angiotensin<NUMBER> at<NUMBER> activity activates inflammatory response resulting microvascular constriction ischemic injury <NUMBER> moreover sarscov led downregulation ace<NUMBER> severe lung injury mice could theoretically attenuated administration arb <NUMBER> mice lacking ace<NUMBER> also shown worse outcomes influenza h<NUMBER>n<NUMBER> infection <NUMBER> observational evidence suggests ace inhibitors arbs may reduce risk pneumonia <NUMBER> given limited data available supporting either harm benefit multiple professional organizations released statements provide guidance joint statement heart failure society america american heart association american college cardiology recommends add remove raasrelated treatments beyond actions based standard clinical practice calls research area <NUMBER> likewise council hypertension european society cardiology also released position statement recommending physicians patients continue treatment usual antihypertensive therapy clinical scientific evidence suggest treatment acei arbs discontinued covid<NUMBER> infection <NUMBER> help determine potential role harm ace inhibitors arbs <NUMBER> randomized multicenter clinical trials underway patients presumptive positive test covid<NUMBER> require hospitalization already taking ace inhibitor arb randomized either losartan <NUMBER> mg daily placebo nct<NUMBER> primary outcome study sequential organ failure assessment respiratory score used determine risk mortality respiratory failure similarly designed study nct<NUMBER> compare losartan <NUMBER> mg daily placebo patients test positive covid<NUMBER> require hospitalization primary outcome study hospitalization rates <NUMBER> days addition ace inhibitors arbs ibuprofen purported recent correspondence also increase ace<NUMBER> potentially risk worsening covid<NUMBER> <NUMBER> despite definitive evidence supporting claim promoted french health minister social media <NUMBER> although world health organization originally backed claim later retracted advice recommend nonsteroidal antiinflammatory drug nsaid use <NUMBER> european medicines agency <NUMBER> fda <NUMBER> also confirmed lack evidence support link nsaids worsening covid<NUMBER> regardless nsaids still avoided patients cardiovascular disease especially heart failure renal disease increase bp cause fluid retention well established statins vascular myocardial antiinflammatory effects may exert potential benefit patients acute viral respiratory infections <NUMBER> observational studies reported improvement cardiovascular outcomes even mortality statintreated patients influenza pneumonia however healthy user bias could contributing factor findings <NUMBER> <NUMBER> randomized controlled trial data limited found conflicted results <NUMBER> <NUMBER> importantly reported harm associated statin use patients supports continued use statins patients indication statin therapy established cardiovascular disease diabetes highrisk features particularly true given higher mortality rates observed covid<NUMBER> patients cardiovascular cardiometabolic comorbidities previously discussed however dose reductions therapy substitutions may warranted patients receive lopinavirritonavir treatment statin therapy table <NUMBER> rare instances patients covid<NUMBER> may develop rhabdomyolysis acute liver injury would require prompt statin discontinuation spectrum covid<NUMBER> disease ranges mild severe well described elsewhere <NUMBER> patients risk cardiovascular disease particular high risk severe illness mortality <NUMBER> myocardial injury witnessed elevation troponin levels common patients covid<NUMBER> <NUMBER> <NUMBER> likely reflect demand supply mismatch type ii myocardial infarction septic cardiomyopathy specific therapy recommended attempting optimize oxygen supply delivery demand much possible intervening pulmonary hematologic cardiac vascular systems increased troponin identifies patients severe covid<NUMBER> associated high mortality whether myocardial injury reflects specific pathologic mechanism disease subgroup patients severe disease unclear <NUMBER> anecdotal cases myocarditis reported <NUMBER> <NUMBER> seem rare elevation ddimer levels <NUMBER> suggests activation coagulation cascade patients covid<NUMBER> however increase thrombosis disseminated intravascular coagulation widely reported regardless anticoagulation unfractionated heparin enoxaparin patients markedly elevated ddimer levels considered although precise recommendations challenging given lack evidence recently international society thrombosis haemostasis released pragmatic statement recommending clinicians measure ddimers prothrombin time platelet count patients covid<NUMBER> <NUMBER> furthermore also recommend prophylactic dose low molecular weight heparin patients including critically ill barring contraindications additional study warranted understand anticoagulation needs patients covid<NUMBER> patients covid<NUMBER> experience acute coronary syndrome access emergency coronary angiography become restricted instances fibrinolysis become firstline therapy lower risk stsegment elevation patients preserve personal protective equipment prevent spread infection across different areas hospital hospitals also develop protocols stsegment elevation management patients covid<NUMBER> collaboration infection prevention departments optimize patient management reducing risk patient health care worker transmission patients heart failure reduced ejection fraction careful review medical treatments considered case initiation aforementioned investigational drugs treat covid<NUMBER> possible guidelinedirected medical therapy continued additional monitoring warranted lopinavirritonavir may modestly affect ace inhibitors arbs sacubitrilvalsartan levels increase warranting close monitoring bp lopinavirritonavir increase levels betablockers warranting ecg monitoring potentially dose downtitration hydroxychloroquine chloroquine may reduce levels betablocker require dose uptitration <NUMBER> among mineralocorticoid receptor antagonists spironolactone safely used lopinavirritonavir whereas eplerenone mainly metabolized cyp<NUMBER>a<NUMBER> coadministered reason coadministration ivabradine lopinavirritonavir avoided digoxin levels followed closely patients lopinavirritonavir hydroxychloroquine chloroquine limited contact others minimize spread sarscov<NUMBER> epidemic phase disease advised usually implies rescheduling routine followup visits options include use telehealth conduct brief focused remote visits postponement visits stable patients regardless additional considerations managing patients home blood pressure monitoring devices weight scales heart failure telemonitoring remote equipment offered possible augment telehealth visits equipment may require training patients health care providers also may reveal unequal access resources reinforcing heart healthy lifestyle stress management also important given inherent impact social distancing quarantine pandemic daily routines mental health additional medicationrelated considerations include ensuring patients sufficient refills prescribing longer supply maintenance medications represent potential challenges social isolation pandemic closing sarscov<NUMBER> novel virus spread rapidly throughout world causing potentially lifethreatening disease covid<NUMBER> causing disproportionally high mortality among elder patients concomitant pulmonary cardiovascular diseases although approved therapies currently exist multiple collaborative efforts underway identify effective therapies vaccine prevent future infection cardiovascular clinicians however may accustomed concomitant use antivirals immunomodulators patients thus need understand therapies might impact underlying cardiovascular conditions medications despite significant morbidity mortality associated covid<NUMBER> immense opportunity enhance understanding prevent treat emerging infections well improve understanding relationship infection immune response cardiovascular disease background novel sarscov<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> responsible global coronavirus disease <NUMBER> pandemic small studies shown potential benefit chloroquinehydroxychloroquine±azithromycin treatment coronavirus disease <NUMBER> use medications alone combination lead prolongation qt interval possibly increasing risk torsade de pointes sudden cardiac death methods hospitalized patients treated chloroquinehydroxychloroquine±azithromycin march <NUMBER> <NUMBER> <NUMBER> hospitals within northwell health system included prospective observational study serial assessments qt interval performed primary outcome qt prolongation resulting torsade de pointes secondary outcomes included qt prolongation need prematurely discontinue medications due qt prolongation arrhythmogenic death results two hundred one patients treated coronavirus disease <NUMBER> chloroquinehydroxychloroquine ten patients <NUMBER> received chloroquine <NUMBER> <NUMBER> received hydroxychloroquine <NUMBER> <NUMBER> also received azithromycin primary outcome torsade de pointes observed entire population baseline corrected qt interval intervals differ patients treated chloroquinehydroxychloroquine monotherapy group versus treated combination group chloroquinehydroxychloroquine azithromycin <NUMBER>±<NUMBER> versus <NUMBER>±<NUMBER> ms p<NUMBER> maximum corrected qt interval treatment significantly longer combination group versus monotherapy group <NUMBER>±<NUMBER> ms versus <NUMBER>±<NUMBER> ms p<NUMBER> seven patients <NUMBER> required discontinuation medications due corrected qt interval prolongation arrhythmogenic deaths reported conclusions largest reported cohort coronavirus disease <NUMBER> patients date treated chloroquinehydroxychloroquine±azithromycin instances torsade de pointes arrhythmogenic death reported although use medications resulted qt prolongation clinicians seldomly needed discontinue therapy study need qt interval monitoring needed final recommendations made effect chloroquine hydroxychloroquine azithromycin corrected qt interval patients sarscov<NUMBER> infection rapid spread coronavirus disease <NUMBER> covid<NUMBER> pandemic owing newly identified coronavirus sarscov<NUMBER> originating wuhan china resulted significant morbidity mortality around world early reports shown improved clinical outcome viral clearance use chloroquine hydroxychloroquine <NUMBER> <NUMBER> results recent openlabel nonrandomized clinical trial gautret colleagues <NUMBER> suggest addition azithromycin hydroxychloroquine significantly reduced polymerase chain reaction detection sarscov<NUMBER> nasopharyngeal samples <NUMBER> days <NUMBER> patients compared <NUMBER> patients treated hydroxychloroquine alone <NUMBER> patients baseline prolonged qt intervals excluded study since drugs known prolong qt interval may increase risk torsades de pointes tdp despite drugs qtcprolonging effects several reports suggest risk tdp low either agents used alone combination <NUMBER> <NUMBER> nonetheless risks may higher critically ill hospitalized covid<NUMBER> patients metabolic derangements organ failure medications increasing risk drugdrug interactions combination however proves lifesaving covid<NUMBER> patients managing qt interval allow patients receive combination therapy critical describe algorithm may help manage combination therapy mitigate risk tdp describe possible use intravenous lidocaine permit combination therapy might otherwise possible <NUMBER>yearold woman past medical history rheumatoid arthritis pulmonary fibrosis asthma chronic methotrexate oral inhaled steroids presented combination azithromycin chloroquine hydroxychloroquine shown small number covid<NUMBER> patients effective virucidal potency concerns qt prolongation increased risks torsades de pointes tdp combination raised since agent individually prolong qt interval patients qt prolongation excluded receiving therapy combination therapy azithromycin chloroquine previously found safe treatment resistant malaria without reports syncope tdp addition lidocaine mexiletine may allow type combination therapy even patients prolonged qt interval developed provided flow chart manage risk qt prolongation tdp treating patients hospital combination therapy keywords acquired lqts azithromycin chloroquine covid<NUMBER> drug toxicity flow chart hydroxychloroquine long qt pandemic proarrhythmia torsades de pointes ventricular fibrillation heart rhythm case reports <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> march <NUMBER> <NUMBER> fever cough <NUMBER>week course sinus upper respiratory tract symptoms initially treated doxycycline followed levofloxacin outpatient owing lack improvement presented emergency room found hypoxic computed tomography showed widespread groundglass opacities well honeycombing right lung figure <NUMBER> covid<NUMBER> suspected testing eventually positive within <NUMBER> hours developed profound respiratory failure required intubation also required adrenergic support norepinephrine started intravenous azithromycin march <NUMBER> decision made start hydroxychloroquine march <NUMBER> however stopped <NUMBER> dose owing qtc <NUMBER> ms notched broad wave figure <NUMBER>a ventricular ectopy present serum potassium magnesium <NUMBER> mm <NUMBER> mgdl respectively electrophysiology consultation recommended <NUMBER> mg intravenous lidocaine followed repeat <NUMBER>lead electrocardiogram revealed shortening qtc <NUMBER> ms figure <NUMBER>b recommended restart hydroxychloroquine begin lidocaine infusion patient able complete course hydroxychloroquine without arrhythmic event despite receiving full course hydroxychloroquine remained ventilator dependent died owing progressive metabolic acidosis multiorgan system failure march <NUMBER> time hydroxychloroquine first initiated already intubated <NUMBER> hours severe respiratory failure owing several similar consults covid<NUMBER> patients borderline increased qtc intervals developed flow chart addresses qt interval management order help clinicians taking care covid<NUMBER> patients require chloroquine hydroxychloroquine without azithromycin figure <NUMBER> owing current covid<NUMBER> pandemic great interest using chloroquine hydroxychloroquine combination azithromycin improve virucidal efficacy sarscov<NUMBER> tempered concerns increased risks qt prolongation development tdp may life threatening though generally recommended avoid pharmacological agent prolongs qtc <NUMBER> ms outpatient setting benefitrisk ratio monitored intensive care unit setting may allow shortterm administration lifesaving medications exceed limit although first glance combination chloroquine azithromycin may seem risky pharmacokinetic studies also demonstrated significant interaction <NUMBER> agents <NUMBER> combination used previous outpatient studies treat resistant malaria reports syncope sudden death <NUMBER> similar data available use hydroxychloroquine azithromycin combination observational nonrandomized clinical study <NUMBER> compared risks cardiovascular death patients treated antibacterial drugs azithromycin amoxicillin ciprofloxacin levofloxacin vs antibacterial drug reported increase cardiovascular deaths risk death cause persons treated <NUMBER>day course azithromycin compared persons treated amoxicillin ciprofloxacin drug <NUMBER> study led us food drug administration issue public warning <NUMBER> azithromycin cause abnormal changes electrical activity heart may lead potentially fatal irregular heart rhythm <NUMBER> higher risk included individuals known risk factors existing qtinterval prolongation low blood levels potassium magnesium slowerthannormal heart rate heart failure ischemia use antiarrhythmic drugs deaths reported study however occurred <NUMBER> days therapy cardiovascular death rate different groups <NUMBER> risk would clearly less inpatient cohort telemetry relevant covid<NUMBER> patients treated hospital low risks azithromycin also supported realworld data reveal low incidence sudden death syncope <NUMBER> <NUMBER> risks associated patients age <NUMBER> years concomitant use qtprolonging drugs cardiovascular disease female sex <NUMBER> drugs lead acquired long qt syndrome lqts tdp blocking herg potassium channel <NUMBER> drugs lidocaine mexiletine block nal channel thereby late sodium current shown slightly shorten qt interval suppress tdp acquired lqts <NUMBER> mexiletine successfully used control tdp patients acquired lqts continued tdp despite withdrawal qtprolonging medications electrolyte correction magnesium infusions <NUMBER> treatment mexiletine slightly shortened qt interval approximately <NUMBER> felt property would make lidocaine ideal adjunctive agent intensive care unit allow covid<NUMBER> patients receive shortterm dual therapy azithromycin chloroquinehydroxychloroquine acquired lqts known therapies mitigate tdp maintaining potassium magnesium levels heart rates <NUMBER> beats per minute incorporated flow chart another option may use mexiletine patients able take oral medications unfortunately patient died despite receiving therapy hydroxychloroquine started late course <NUMBER> days presentation <NUMBER> days intubation therefore uncertain whether would survived hydroxychloroquine started earlier previous history rheumatoid arthritis pulmonary fibrosis asthma placed higher risk mortality well conclusion although theoretical risk acquired lqts tdp present chloroquine hydroxychloroquine azithromycin used alone combination previous reports combined treatment malaria patients suggest risk low covid<NUMBER> patients hospitalized however may increased risk qt prolongation tdp owing previous concurrent medications age sex metabolic derangements ph hypoxia electrolyte abnormalities multiorgan system failure well previous cardiovascular disease recent reports suggest direct viralor autoimmuneinduced myocardial injury may also occur covid<NUMBER> patients <NUMBER> <NUMBER> <NUMBER> certainly use combination therapy azithromycin chloroquine hydroxychloroquine patients congenital acquired lqts must carefully weighed risks use late sodium channelblocking drugs like lidocaine mexiletine careful attention serum electrolytes heart rate monitoring qtc intervals may allow administration full course drugs even patients prolonged qt interval data required determine approach safely applied majority covid<NUMBER> patients need therapy qtc flow chart minimize tdp covid<NUMBER> inpatients chloroquineazithromycin figure <NUMBER> flow chart manage effects qtc chloroquine hydroxychloroquine azithromycin bpm <NUMBER> beats per minute dob <NUMBER> dobutamine ecg <NUMBER> electrocardiogram epi <NUMBER> epinephrine iv <NUMBER> intravenous k <NUMBER> serum potassium lqts <NUMBER> long qt syndrome mg <NUMBER> serum magnesium ne <NUMBER> norepinephrine tdp <NUMBER> torsades de pointes middle coronavirus disease <NUMBER> covid<NUMBER> pandemic predicted nearly <NUMBER> million individuals worldwide infected <NUMBER> april <NUMBER> mortality rate country ranges <NUMBER> <NUMBER> <NUMBER> large scale studies conducted multiple countries preliminary results effective therapies least months ahead awaiting results clinical trials providers across globe using offlabel investigational drugs unknown safety profiles emerging data shown cardiovascular comorbidities common patients patients increased risk death <NUMBER> furthermore <NUMBER> hospitalized patients covid<NUMBER> concurrent cardiac injury <NUMBER> <NUMBER> <NUMBER> mechanism may include severe systemic inflammatory responses direct injury severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> hypoxia microthrombi leading microvascular damage <NUMBER> however adverse effects pharmacotherapy cannot entirely excluded addition concomitant cardiac injury sarscov<NUMBER> infection may increase risk adverse events generally safe drugs <NUMBER> instance patients cardiomyopathy andor congestive heart failure reduced repolarization reserve increased risk drugrelated proarrhythmic risk <NUMBER> <NUMBER> specific concerns covid<NUMBER> pandemic may include lack adequate cardiac testing giving shortage healthcare providers ancillary staff well intention minimize risk exposure finally using offlabel medications treat novel disease covid<NUMBER> drugdrug interaction underestimated among investigational drugs antimalarial antirheumatic drugs namely chloroquine hydroxychloroquine respectively gained broad interest vitro study chloroquine <NUMBER> mg twice daily hydroxychloroquine <NUMBER> mg twice day loading followed <NUMBER> mg blocked sarscov<NUMBER> cell entry vitro <NUMBER> addition early study suggested clinical benefit patients covid<NUMBER> showing reduction pneumonia severity length hospitalization viral shedding <NUMBER> despite generally safe profiles chloroquine hydroxychloroquine used low dose drugs significant cardiovascular adverse effects reports longterm users smaller daily dosage found broad prevalence cardiac toxicity form mild severe conduction disorders irreversible cardiomyopathy cumulative dose range <NUMBER> g duration treatment <NUMBER> months <NUMBER> years vary greatly <NUMBER> severe irreversible cardiac damage reported hydroxychloroquine may less toxicity without risk chloroquine hydroxychloroquine proarrhythmic cause significant qt prolongation well increasing risk torsade de pointes tdp even therapeutic doses <NUMBER> generally contraindicated patients congenital long qt syndrome prior history tdp electrocardiographic changes may include twave inversion depression healthy animal models agents especially chloroquine decreased excitability conductivity atrial ventricular myocardium although magnitude much less quinine quinidine related class antiarrhythmic drug <NUMBER> nonetheless chloroquine hydroxychloroquine shown effective acute suppression wide ranges atrial ventricular arrhythmias <NUMBER> study <NUMBER> patients taking <NUMBER> mg daily chloroquine found qt qtc interval lengthened <NUMBER> milliseconds <NUMBER> milliseconds <NUMBER> dose recommended treatment covid<NUMBER> <NUMBER> mg twice day therefore risk qt prolongation expected higher furthermore case reports chloroquine hydroxychloroquine toxicity observed widened qrs complex due excessive na blockage property study <NUMBER> subjects without structural heart disease given acute chloroquine hydroxychloroquine therapy various types atrial ventricular arrhythmias observed one sudden death <NUMBER> dosage used study slightly higher proposed treatment covid<NUMBER> conclusively american heart association listed chloroquine hydroxychloroquine agents cause direct myocardial toxicity exacerbate underlying myocardial dysfunction <NUMBER> current pharmacotherapeutic regimens covid<NUMBER> may include investigational offlabel drugs novel antiviral drug namely remdesivir unknown clinical safety figure <NUMBER> lopinavirritonavir combination remains treatment regimen covid<NUMBER> many countries although clinical benefit observed small study <NUMBER> importantly lopinavirritonavir cause qt prolongation cyp<NUMBER>a<NUMBER> inhibitors <NUMBER> <NUMBER> cannot used major cyp<NUMBER>a<NUMBER> substrates chloroquine prolonged qt interval due favipiravir used treatment covid<NUMBER> regions reported <NUMBER> umifenovir darunavir treatment influenza safe cardiac profile however darunavirritonavir major cyp<NUMBER>a<NUMBER> inhibitor <NUMBER> tocilizumab sarilumab interleukin<NUMBER> il<NUMBER> inhibitors approved treatment rheumatoid arthritis drugs associated heart failure exacerbation proarrhythmia interestingly case series observed shortening qt interval <NUMBER> milliseconds patients rheumatoid arthritis treated tocilizumab <NUMBER> months <NUMBER> <NUMBER> mechanism unclear thought decrease inflammation cardiomyocytes <NUMBER> furthermore tocilizumab used safely among patients autoimmune disease cardiomyopathy <NUMBER> <NUMBER> antibiotics combination chloroquine hydroxychloroquine antiviral drugs antibiotics common practice careful qt interval monitoring performed concomitant macrolide drugs azithromycin moxifloxacin administered <NUMBER> <NUMBER> furthermore piperacillin tazobactam carries risk tdp especially one additional risks tdp presents ie bradycardia hypokalemia hypomagnesemia use concomitant qttdp drugs use drugs cause hypokalemia hypomagnesemia chloroquine hydroxychloroquine metabolized via cyp<NUMBER>c<NUMBER> cyp<NUMBER>a<NUMBER> <NUMBER> therefore caution focused potential drug interactions figure <NUMBER> patients hepatic disease chloroquine substantially excreted kidney risk toxicity may greater patients impaired renal function although specific dosage adjustment may required chloroquine significantly reduces bioavailability ampicillin interval least <NUMBER> hours intake ampicillin chloroquine recommended <NUMBER> hydroxychloroquine remarkably long halflife <NUMBER> days <NUMBER> multiple drugs used treatment covid<NUMBER> cyp<NUMBER>a<NUMBER> inhibitors significantly increase serum chloroquine hydroxychloroquine figure <NUMBER> particular combination chloroquine lopinavirritonavir umifenovirritonavir contraindicated <NUMBER> many cardiovascular drugs ticagrelor rivaroxaban apixaban major substrates cyp<NUMBER>a<NUMBER> coadministration cyp<NUMBER>a inhibitors may require dose adjustment additional monitoring furthermore warfarin concentrations decreased coadministered ritonavir recommended international normalized ratio inr monitored frequently warfarin combined cytochrome p<NUMBER>s generally downregulated infection inflammation stimuli including cytokines il<NUMBER> inhibition il<NUMBER> signaling treated tocilizumab sarilumab may restore cyp<NUMBER> activities higher levels leading increased metabolism drugs cyp<NUMBER> substrates effects may last one week following single dose il<NUMBER> inhibitor clinically relevant cyp<NUMBER> substrates narrow therapeutic index dose individually adjusted warfarin proposed workup monitoring protocol drugs commonly used treatment covid<NUMBER> shown figure <NUMBER> chloroquine hydroxychloroquine figure <NUMBER> respectively algorithms line recently published guidance mayo clinic <NUMBER> american college cardiology magazine focus solely hydroxychloroquine azithromycin <NUMBER> protocol extended statements taking underlying cardiomyopathy consideration well covering drugs currently used treatment pandemic generally drugs potential qt prolongation avoided patients qtc greater <NUMBER> milliseconds <NUMBER> milliseconds intraventricular conduction delay especially setting moderate severe structural heart disease patients highgrade atrioventricular block without pacemaker andor implantable cardioverter defibrillator place <NUMBER> <NUMBER> patients baseline qtc greater <NUMBER> milliseconds normal mild cardiomyopathy benefit may outweigh risk shared decisionmaking discussed checklist shown figure <NUMBER> applied patients includes minimizing concomitant prolonging qt drugs concomitant cyp<NUMBER>a<NUMBER> inhibitors substrates maintaining normal serum electrolyte levels bradycardia precipitate tdp thus conditions medications potential slow heart rate also avoided following criteria prompt dose reduction drug discontinuation subsequent qtc interval greater <NUMBER> milliseconds <NUMBER> milliseconds intraventricular conduction delay baseline qtc less <NUMBER> milliseconds dqtc greater <NUMBER> milliseconds <NUMBER> preliminary report showed maximal change qt interval among patients covid<NUMBER> treated combined hydroxychloroquineazithromycin occurred days <NUMBER> <NUMBER> <NUMBER> thus setting limited resources qtc interval measurement may performed days <NUMBER> chloroquine hydroxychloroquine cause broader spectrum cardiac adverse effects including suppression myocardial function heart block proposed protocol figure <NUMBER> criteria dose adjustment slightly different drugs particular qtc interval measured frequently <NUMBER> subsequent surveillance flexible based underlying cardiac disease function b baseline qtc interval c underlying conduction disorder risk factors tdp addition parameters dqrs greater <NUMBER> high grade atrioventricular block newly developed left bundle branch block prompt dose reduction drug discontinuation <NUMBER>lead electrocardiogram ecg considered gold standard qt measurement limit chance viral transmission healthcare providers using cardiac telemetry wireless device calculating qt interval may applied initial comparison acceptable <NUMBER> <NUMBER> proposed monitoring protocol use chloroquine hydroxychloroquine outpatient setting chloroquine hydroxychloroquine may used early treatment patients mild covid<NUMBER> stable require hospitalization providers ensure patients history without significant underlying cardiomyopathy cardiac symptoms recent <NUMBER>lead ecg available new baseline ecg obtained addition liver function test serum creatinine serum electrolytes may considered patients risk figure <NUMBER> presents proposed monitoring protocol initial checklist patients baseline qtc less <NUMBER> milliseconds consider onetime qtc interval measurement second fourth dose order limit risk exposure mobile wireless device considered purpose multiple pharmacotherapeutic agents including chloroquine hydroxychloroquine antiviral drugs monoclonal antibodies investigated treatment patients sarscov<NUMBER> infection based available data chloroquine hydroxychloroquine cause irreversible cardiomyopathy worsen preexisting myocardial dysfunction known cardiac side effects include highgrade atrioventricular block bundle branch block qt prolongation tdp furthermore favipiravir lopinavirritonavir macrolide agents piperacillintazobactam cause prolonged qt tdp particular concerns patients covid<NUMBER> include underlying structural heart disease cardiac injury renal hepatic dysfunction limited resource cardiac monitoring drugdrug interaction clear administration protocols place every hospital clinic using drugs treatment covid<NUMBER> • multiple investigational offlabel drugs uncertain cardiac safety profiles currently used treatment covid<NUMBER> caused infection <NUMBER> individuals worldwide important topic patients covid<NUMBER> often underlying cardiovascular disease <NUMBER> hospitalized patients cardiac injury • medication list includes antimalaria antirheumatic drugs chloroquine hydroxychloroquine respectively antiviral drugs well monoclonal antibodies addition antimicrobial agents macrolides frequently prescribed • offlabel drug regimens treatment covid<NUMBER> chloroquine hydroxychloroquine favipiravir lopinavirritonavir macrolides cause significant qt prolongation tdp • furthermore chloroquine hydroxychloroquine directly suppress myocardial function cause heart block agents listed direct cause cardiac toxicity american heart association authors declared potential conflicts interest respect research authorship andor publication article authors received financial support research authorship andor publication article middle coronavirus disease <NUMBER> covid<NUMBER> pandemic predicted nearly <NUMBER> million individuals worldwide infected <NUMBER> april <NUMBER> mortality rate country ranges <NUMBER> <NUMBER> <NUMBER> large scale studies conducted multiple countries preliminary results effective therapies least months ahead awaiting results clinical trials providers across globe using offlabel investigational drugs unknown safety profiles emerging data shown cardiovascular comorbidities common patients patients increased risk death <NUMBER> furthermore <NUMBER> hospitalized patients covid<NUMBER> concurrent cardiac injury <NUMBER> <NUMBER> <NUMBER> mechanism may include severe systemic inflammatory responses direct injury severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> hypoxia microthrombi leading microvascular damage <NUMBER> however adverse effects pharmacotherapy cannot entirely excluded addition concomitant cardiac injury sarscov<NUMBER> infection may increase risk adverse events generally safe drugs <NUMBER> instance patients cardiomyopathy andor congestive heart failure reduced repolarization reserve increased risk drugrelated proarrhythmic risk <NUMBER> <NUMBER> specific concerns covid<NUMBER> pandemic may include lack adequate cardiac testing giving shortage healthcare providers ancillary staff well intention minimize risk exposure finally using offlabel medications treat novel disease covid<NUMBER> drugdrug interaction underestimated among investigational drugs antimalarial antirheumatic drugs namely chloroquine hydroxychloroquine respectively gained broad interest vitro study chloroquine <NUMBER> mg twice daily hydroxychloroquine <NUMBER> mg twice day loading followed <NUMBER> mg blocked sarscov<NUMBER> cell entry vitro <NUMBER> addition early study suggested clinical benefit patients covid<NUMBER> showing reduction pneumonia severity length hospitalization viral shedding <NUMBER> despite generally safe profiles chloroquine hydroxychloroquine used low dose drugs significant cardiovascular adverse effects reports longterm users smaller daily dosage found broad prevalence cardiac toxicity form mild severe conduction disorders irreversible cardiomyopathy cumulative dose range <NUMBER> g duration treatment <NUMBER> months <NUMBER> years vary greatly <NUMBER> severe irreversible cardiac damage reported hydroxychloroquine may less toxicity without risk chloroquine hydroxychloroquine proarrhythmic cause significant qt prolongation well increasing risk torsade de pointes tdp even therapeutic doses <NUMBER> generally contraindicated patients congenital long qt syndrome prior history tdp electrocardiographic changes may include twave inversion depression healthy animal models agents especially chloroquine decreased excitability conductivity atrial ventricular myocardium although magnitude much less quinine quinidine related class antiarrhythmic drug <NUMBER> nonetheless chloroquine hydroxychloroquine shown effective acute suppression wide ranges atrial ventricular arrhythmias <NUMBER> study <NUMBER> patients taking <NUMBER> mg daily chloroquine found qt qtc interval lengthened <NUMBER> milliseconds <NUMBER> milliseconds <NUMBER> dose recommended treatment covid<NUMBER> <NUMBER> mg twice day therefore risk qt prolongation expected higher furthermore case reports chloroquine hydroxychloroquine toxicity observed widened qrs complex due excessive na blockage property study <NUMBER> subjects without structural heart disease given acute chloroquine hydroxychloroquine therapy various types atrial ventricular arrhythmias observed one sudden death <NUMBER> dosage used study slightly higher proposed treatment covid<NUMBER> conclusively american heart association listed chloroquine hydroxychloroquine agents cause direct myocardial toxicity exacerbate underlying myocardial dysfunction <NUMBER> current pharmacotherapeutic regimens covid<NUMBER> may include investigational offlabel drugs novel antiviral drug namely remdesivir unknown clinical safety figure <NUMBER> lopinavirritonavir combination remains treatment regimen covid<NUMBER> many countries although clinical benefit observed small study <NUMBER> importantly lopinavirritonavir cause qt prolongation cyp<NUMBER>a<NUMBER> inhibitors <NUMBER> <NUMBER> cannot used major cyp<NUMBER>a<NUMBER> substrates chloroquine prolonged qt interval due favipiravir used treatment covid<NUMBER> regions reported <NUMBER> umifenovir darunavir treatment influenza safe cardiac profile however darunavirritonavir major cyp<NUMBER>a<NUMBER> inhibitor <NUMBER> tocilizumab sarilumab interleukin<NUMBER> il<NUMBER> inhibitors approved treatment rheumatoid arthritis drugs associated heart failure exacerbation proarrhythmia interestingly case series observed shortening qt interval <NUMBER> milliseconds patients rheumatoid arthritis treated tocilizumab <NUMBER> months <NUMBER> <NUMBER> mechanism unclear thought decrease inflammation cardiomyocytes <NUMBER> furthermore tocilizumab used safely among patients autoimmune disease cardiomyopathy <NUMBER> <NUMBER> antibiotics combination chloroquine hydroxychloroquine antiviral drugs antibiotics common practice careful qt interval monitoring performed concomitant macrolide drugs azithromycin moxifloxacin administered <NUMBER> <NUMBER> furthermore piperacillin tazobactam carries risk tdp especially one additional risks tdp presents ie bradycardia hypokalemia hypomagnesemia use concomitant qttdp drugs use drugs cause hypokalemia hypomagnesemia chloroquine hydroxychloroquine metabolized via cyp<NUMBER>c<NUMBER> cyp<NUMBER>a<NUMBER> <NUMBER> therefore caution focused potential drug interactions figure <NUMBER> patients hepatic disease chloroquine substantially excreted kidney risk toxicity may greater patients impaired renal function although specific dosage adjustment may required chloroquine significantly reduces bioavailability ampicillin interval least <NUMBER> hours intake ampicillin chloroquine recommended <NUMBER> hydroxychloroquine remarkably long halflife <NUMBER> days <NUMBER> multiple drugs used treatment covid<NUMBER> cyp<NUMBER>a<NUMBER> inhibitors significantly increase serum chloroquine hydroxychloroquine figure <NUMBER> particular combination chloroquine lopinavirritonavir umifenovirritonavir contraindicated <NUMBER> many cardiovascular drugs ticagrelor rivaroxaban apixaban major substrates cyp<NUMBER>a<NUMBER> coadministration cyp<NUMBER>a inhibitors may require dose adjustment additional monitoring furthermore warfarin concentrations decreased coadministered ritonavir recommended international normalized ratio inr monitored frequently warfarin combined cytochrome p<NUMBER>s generally downregulated infection inflammation stimuli including cytokines il<NUMBER> inhibition il<NUMBER> signaling treated tocilizumab sarilumab may restore cyp<NUMBER> activities higher levels leading increased metabolism drugs cyp<NUMBER> substrates effects may last one week following single dose il<NUMBER> inhibitor clinically relevant cyp<NUMBER> substrates narrow therapeutic index dose individually adjusted warfarin proposed workup monitoring protocol drugs commonly used treatment covid<NUMBER> shown figure <NUMBER> chloroquine hydroxychloroquine figure <NUMBER> respectively algorithms line recently published guidance mayo clinic <NUMBER> american college cardiology magazine focus solely hydroxychloroquine azithromycin <NUMBER> protocol extended statements taking underlying cardiomyopathy consideration well covering drugs currently used treatment pandemic generally drugs potential qt prolongation avoided patients qtc greater <NUMBER> milliseconds <NUMBER> milliseconds intraventricular conduction delay especially setting moderate severe structural heart disease patients highgrade atrioventricular block without pacemaker andor implantable cardioverter defibrillator place <NUMBER> <NUMBER> patients baseline qtc greater <NUMBER> milliseconds normal mild cardiomyopathy benefit may outweigh risk shared decisionmaking discussed checklist shown figure <NUMBER> applied patients includes minimizing concomitant prolonging qt drugs concomitant cyp<NUMBER>a<NUMBER> inhibitors substrates maintaining normal serum electrolyte levels bradycardia precipitate tdp thus conditions medications potential slow heart rate also avoided following criteria prompt dose reduction drug discontinuation subsequent qtc interval greater <NUMBER> milliseconds <NUMBER> milliseconds intraventricular conduction delay baseline qtc less <NUMBER> milliseconds dqtc greater <NUMBER> milliseconds <NUMBER> preliminary report showed maximal change qt interval among patients covid<NUMBER> treated combined hydroxychloroquineazithromycin occurred days <NUMBER> <NUMBER> <NUMBER> thus setting limited resources qtc interval measurement may performed days <NUMBER> chloroquine hydroxychloroquine cause broader spectrum cardiac adverse effects including suppression myocardial function heart block proposed protocol figure <NUMBER> criteria dose adjustment slightly different drugs particular qtc interval measured frequently <NUMBER> subsequent surveillance flexible based underlying cardiac disease function b baseline qtc interval c underlying conduction disorder risk factors tdp addition parameters dqrs greater <NUMBER> high grade atrioventricular block newly developed left bundle branch block prompt dose reduction drug discontinuation <NUMBER>lead electrocardiogram ecg considered gold standard qt measurement limit chance viral transmission healthcare providers using cardiac telemetry wireless device calculating qt interval may applied initial comparison acceptable <NUMBER> <NUMBER> proposed monitoring protocol use chloroquine hydroxychloroquine outpatient setting chloroquine hydroxychloroquine may used early treatment patients mild covid<NUMBER> stable require hospitalization providers ensure patients history without significant underlying cardiomyopathy cardiac symptoms recent <NUMBER>lead ecg available new baseline ecg obtained addition liver function test serum creatinine serum electrolytes may considered patients risk figure <NUMBER> presents proposed monitoring protocol initial checklist patients baseline qtc less <NUMBER> milliseconds consider onetime qtc interval measurement second fourth dose order limit risk exposure mobile wireless device considered purpose multiple pharmacotherapeutic agents including chloroquine hydroxychloroquine antiviral drugs monoclonal antibodies investigated treatment patients sarscov<NUMBER> infection based available data chloroquine hydroxychloroquine cause irreversible cardiomyopathy worsen preexisting myocardial dysfunction known cardiac side effects include highgrade atrioventricular block bundle branch block qt prolongation tdp furthermore favipiravir lopinavirritonavir macrolide agents piperacillintazobactam cause prolonged qt tdp particular concerns patients covid<NUMBER> include underlying structural heart disease cardiac injury renal hepatic dysfunction limited resource cardiac monitoring drugdrug interaction clear administration protocols place every hospital clinic using drugs treatment covid<NUMBER> • multiple investigational offlabel drugs uncertain cardiac safety profiles currently used treatment covid<NUMBER> caused infection <NUMBER> individuals worldwide important topic patients covid<NUMBER> often underlying cardiovascular disease <NUMBER> hospitalized patients cardiac injury • medication list includes antimalaria antirheumatic drugs chloroquine hydroxychloroquine respectively antiviral drugs well monoclonal antibodies addition antimicrobial agents macrolides frequently prescribed • offlabel drug regimens treatment covid<NUMBER> chloroquine hydroxychloroquine favipiravir lopinavirritonavir macrolides cause significant qt prolongation tdp • furthermore chloroquine hydroxychloroquine directly suppress myocardial function cause heart block agents listed direct cause cardiac toxicity american heart association authors declared potential conflicts interest respect research authorship andor publication article december <NUMBER> hospitals wuhan china began report cases pneumonia unknown cause initially identified patients geographically linked local wet seafood wholesale market living slaughtered wild animals sold virus rapidly spread <NUMBER> countries territories resulting <NUMBER> <NUMBER> <NUMBER> confirmed cases <NUMBER> <NUMBER> deaths globally according report released may <NUMBER> <NUMBER> subsequent deep sequencing lower respiratory tract samples identified novel coronavirus distinct strains coronavirus known infect humans subsequently named severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER>a highly contagious virus transmitted person person <NUMBER> designated disease caused sarscov<NUMBER> infection covid<NUMBER> similar diseases caused coronaviruses main transmission route sarscov<NUMBER> via aerosolised droplets possible transmission routes direct contact oralfaecal route mothertochild transmission proposed proof needed regard <NUMBER> retro spective study done beginning pandemic reported incubation period sarscov<NUMBER> approximately <NUMBER> days <NUMBER> however recent report indicates incubation period could long <NUMBER> days <NUMBER> effective cure sarscov<NUMBER> infection common treatment patients covid<NUMBER> support ive care although multiple antiviral drugs including remdesivir lopinavir plus ritonavir used clinical practice <NUMBER> safety efficacy still unclear clinical evaluation immunemediated lung injury acute respiratory distress syndrome ards associated adverse outcomes patients covid<NUMBER> <NUMBER> histological examination lung biopsy tissue patient died covid<NUMBER> showed bilateral diffuse alveolar damage fibroblastic proliferation airspaces laboratory tests indicated hyper activated status circulating cd<NUMBER> cd<NUMBER> lymphocytes <NUMBER> <NUMBER> due hyperactive nature immune system patients severe covid<NUMBER> several diseasemodifying antirheumatic drugs dmards tocilizumab interleukin il<NUMBER> receptor inhibitor baricitinib janus kinase jak inhibitor anakinra il<NUMBER> receptor antagonist antimalarial drug hydroxychloroquine chloroquine proposed potential treatments covid <NUMBER> review discuss immunological aspects sarscov<NUMBER> virus infection potential implication dmards treatment patients covid<NUMBER> coronaviruses group highly diverse enveloped positivesense singlestranded rna viruses belong two subfamilies coronavirinae torovirinae family coronaviridae viruses first discovered <NUMBER>s classified four main genera alphacoronavirus betacoronavirus gammacoronavirus deltacoronavirus basis phylogenetic relationships genomic structures <NUMBER> among four genera alphacoronaviruses betacoronaviruses primarily cause respiratory intestinal infection mammals whereas gammacoronaviruses deltacoronaviruses mainly infect birds currently seven strains coronaviruses known infect humans including recently identified sarscov<NUMBER> human coronavirus <NUMBER>e hcov<NUMBER>e oc<NUMBER> hcovoc<NUMBER> nl<NUMBER> hcovnl<NUMBER> hku<NUMBER> hcovhku<NUMBER> severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> <NUMBER> domestic wild animals could important roles zoonotic reservoirs enable virus transmission humans basis current sequence databases origins sarscov merscov hcovnl<NUMBER> hcov<NUMBER>e sarscov<NUMBER> thought bats whereas hcovoc<NUMBER> hku<NUMBER> probably originated rodents <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> although corona virus infections cause mild respiratory symptoms review infec tion sarscov merscov sarscov<NUMBER> lethal sarscov first appeared southern china quickly spread around world <NUMBER> <NUMBER> virus identified causative agent global pandemic sars <NUMBER> led substantial morbidity mortality decade sars outbreak merscov emerged <NUMBER> <NUMBER> people mers previous contact bats leading identifica tion camels intermediate host <NUMBER> patients sars mers present variety clinical features ranging asymp tomatic mild respiratory illness ful minant severe ards extrapulmonary complications <NUMBER> <NUMBER> sarscov<NUMBER> belongs genus betacoronavirus basis evolutionary analysis similar sarslike coronavirus chinese horseshoe bat nucleic acid homology <NUMBER> <NUMBER> sarscov<NUMBER> also <NUMBER> similarity sarscov <NUMBER> merscov nucleic acid level <NUMBER> <NUMBER> days release sarscov<NUMBER> genome researchers found similar coronavirus fruit bats batcovhku<NUMBER> based evolutionary char acter istics <NUMBER> several later reports suggested snakes mink pangolins could intermediate hosts based codon preference viral infection patterns <NUMBER> <NUMBER> <NUMBER> onset covid<NUMBER> pandemic main symptoms fever <NUMBER> cough <NUMBER> myalgia fatigue <NUMBER> <NUMBER> half patients developed breathing difficulty one week severely ill patients soon developed ards acute cardiac injury secondary infections combination thereof <NUMBER> diagnosis disease mainly depends sarscov<NUMBER> rna detection nasopharyngeal swab realtime polymerase chain reaction epi demiological history clinical manifestations lung imaging invasion pathogenesis sarscov<NUMBER> associated host immune response spike glycoprotein protein viral envelop binds receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> surface human cells <NUMBER> <NUMBER> analysis structure sarscov<NUMBER> protein binding affinity ace<NUMBER> using cryogenic electron microscopy sur face plasmon resonance showed structure sarscov<NUMBER> protein similar sars although minor differences <NUMBER> affinity sarscov<NUMBER> protein binding ace<NUMBER> <NUMBER> <NUMBER> times higher sars protein suggesting sarscov<NUMBER> might transmit readily person person <NUMBER> innate immunity first line defence virus invasion viral infection mammals activates intracellular pattern recognition receptors sense pathogenassociated molecular patterns doublestranded rna uncapped mrna recognition pathogenassociated molecular patterns results subsequent cytolytic immune responses mainly type interferons ifn natural killer cells adaptive immunity also plays important part viral clearance via activated cytotoxic cells destroy virusinfected cells antibodyproducing b cells target virusspecific antigens patients covid<NUMBER> especially severe pneumonia reported substantially lower lymphocyte counts higher plasma concentrations number inflammatory cytokines il<NUMBER> tumor necro sis factor tnf <NUMBER> <NUMBER> <NUMBER> another study <NUMBER> reported cd<NUMBER> cells cd<NUMBER> cells natural killer cells reduced severely ill patients compared mild disease symptoms moreover substantial reduction cd<NUMBER> cell cd<NUMBER> cell counts peripheral blood also observed patient died <NUMBER> ably proinflammatory subsets cells including il<NUMBER>producing ccr<NUMBER> ccr<NUMBER> cd<NUMBER> thelper <NUMBER> th<NUMBER> cells perforin granulysinexpressing cytotoxic cells increased could partly responsible severe immune injury lungs patient <NUMBER> antiviral immune response crucial eliminate invading virus robust persistent antiviral immune response might also cause massive production inflammatory cytokines damage host tissues <NUMBER> overproduction cytokines caused aberrant immune activation known cytokine storm fact late stages coronavirus disease including sars mers covid<NUMBER> cytokine storms major cause disease progression eventual death <NUMBER> <NUMBER> huang colleagues <NUMBER> found increased plasma concentrations th<NUMBER> eg il<NUMBER>β ifnγ th<NUMBER> eg il<NUMBER> cytokines notably patients admitted intensive care unit icu higher plasma concentrations il<NUMBER> il<NUMBER> il<NUMBER> granulocytecolony stimulat ing factor ifnγinduced protein<NUMBER> ip<NUMBER> macro phage chemo attractant protein<NUMBER> macro phage inflam matory pro tein <NUMBER>α tnf compared admitted icu two studies <NUMBER> also showed plasma il<NUMBER> concentrations normal range patients severe symptoms covid<NUMBER> compared healthy individuals milder symptoms mehta colleagues <NUMBER> suggest secondary haemo phagocytic lymphohistio cytosis shlh could associated severe covid<NUMBER> cases hlh disease entity characterised uncon trolled cytokine storm expansion tissue macrophages histiocytes exhibit haemophagocytic activity <NUMBER> hlh result genetic defects cytolytic pathways familial primary hlh diseases infection malignancy rheu matic disease shlh <NUMBER> <NUMBER> farquhar claireaux first described cytokine storm patients hlh <NUMBER> characteristics hlh including hypercyto kinaemia unremitting fever cyto penias hyperferritin aemia multiorgan damage commonly seen seriously ill patients covid<NUMBER> <NUMBER> <NUMBER> suggested alveolar macrophages expressing ace<NUMBER> primary target cells sarscov<NUMBER> infection activated macrophages may play important part hlhlike cytokine storm covid<NUMBER> <NUMBER> thus early identification appropriate treatment hyperinflammatory status important reducing mortality patients covid<NUMBER> <NUMBER> evidence shown asymptomatic covid<NUMBER> carriers transmit disease others virus wider range incubation time initially thought <NUMBER> days <NUMBER> addition virus displays high infectivity virus continues mutate lower pathogenicity high possibility might coexist humans therefore urgent need develop therapies treat sarscov<NUMBER> repurpos ing approved drugs commonly employed fight newly emerged diseases covid<NUMBER> drugs known pharmacokinetic safety profiles due importance immune imbalance pathogenesis sarscov<NUMBER> infection several immunemodulating drugs regulate different aspects inflammation table tested efficacy treatment severe covid<NUMBER> hyperinflamma tion important determinant disease outcome covid<NUMBER> immunosuppression might beneficial reduce mortality patients severe symptoms <NUMBER> therefore early identification patients crucial proposed laboratory tests ferritin lymphocyte leukocyte counts platelet counts erythrocyte counts sedimentation rate could used screen patients high risk hyper inflammation application hscore used evaluation patients shlh recommended mehta colleagues <NUMBER> identify patients covid<NUMBER> high risk hyperinflammation hscore combines laboratory clinical parameters including serum aspartate aminotransferase triglycerides fibrinogen ferritin cytopaenias body temperature organomegaly haemophagocytosis bone marrow aspirate signs immunosuppression <NUMBER> addition evaluation cytokine profiles immune cell subsets important implications selecting appropriate immuno suppressants eg tocilizumab could considered patients high concentrations serum il<NUMBER> given fact antiviral immunity required recover covid<NUMBER> pros cons using immunosuppressant patients carefully considered severity hyperinflam mation viral load replication status needs taken consideration one way avoid suppression antiviral immunity choose selective instead broad immunosuppressive drugs timing treatment also crucial reduce sideeffects immuno suppression unfortunately yet definitive evidence regard appropriate timing admin istration agents studies required determine appropriate timing routes drug administration il<NUMBER> key inflammatory cytokine critical part inflammatory cytokine storm elevated patients covid<NUMBER> <NUMBER> <NUMBER> tocilizumab recombinant humanised monoclonal antibody il<NUMBER> receptor widely used treatment autoimmune diseases rheumatoid arthritis <NUMBER> patients covid<NUMBER> il<NUMBER>producing cd<NUMBER> cd<NUMBER> inflammatory monocytes significantly increased numbers cells increased patients covid<NUMBER> admitted icu <NUMBER> authors study proposed hyperactivated th<NUMBER> cells producing granulocytemacro phage colony stimulating factor gmcsf ifnγ lung promote il<NUMBER>producing monocytes release gmcsf suggesting il<NUMBER> gmcsf might potential therapeutic targets patients covid<NUMBER> <NUMBER> tocilizumab firstline drug treatment cytokine release syndrome rapid massive release cytokines blood immune cells usually caused immunotherapy especially patients comorbidities terms mechanism tocilizumab binds membrane soluble forms il<NUMBER> receptor thereby suppressing jaksignal transducer activator transcription stat signalling pathway production downstream inflam matory molecules <NUMBER> <NUMBER> many ongoing trials assessing efficacy tocilizumab covid<NUMBER> appendix p <NUMBER> however animal studies shown il<NUMBER> required clearance viruses control pulmonary inflammation <NUMBER> therefore clinicians pay close attention possibility blocking il<NUMBER> could interfere viral clearance exacer bate lung inflammation recent observational study <NUMBER> <NUMBER> blockade il<NUMBER> pathway used treatment hyperinflammation conditions il<NUMBER> receptor antag onist anakinra approved rheumatoid arthritis stills disease cryopyrinassociated periodic syndrome phase <NUMBER> randomised controlled trial rct severe sepsis reported treatment anakinra associ ated significantly lower <NUMBER>day mortality patients septic hyperinflammation without increased adverse events <NUMBER> retrospective analysis <NUMBER> <NUMBER> patients shlh treated anakinra indicated treatment anakinra resulted <NUMBER> decrease ferritin con centrations early initiation anakinra associated reduced mortality since il<NUMBER> reported increased patients covid<NUMBER> <NUMBER> blockade il<NUMBER> seems reasonable approach treatment hyperinflammation patients <NUMBER> several trials anakinra currently underway including phase <NUMBER> clinical trial evaluating efficacy safety anakinra emapalumab ifnγ inhibitor reducing hyperinflammation respiratory distress patients covid<NUMBER> nct<NUMBER> appendix p <NUMBER> baricitinib small molecule compound selectively inhibits kinase activity jak<NUMBER> jak<NUMBER> baricitinib used combination one tnf inhibitors approved treatment rheumatoid arthritis <NUMBER> psoriatic arthritis <NUMBER> searching benevolentai database richardson colleagues <NUMBER> pre dicted baricitinib might effectively reduce ability sarscov<NUMBER> virus infect lung cells <NUMBER> noted sarscov<NUMBER> binds ace<NUMBER> receptor host cells enters lung cells receptormediated endocytosis ace<NUMBER> widely expressed several tissues including renal vascular heart lung high concentrations ace<NUMBER> expression pulmonary at<NUMBER> alveolar epi thelial cells makes cells particularly susceptible sarscov<NUMBER> infection <NUMBER> ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> regulates endocytosis via phosphorylation clathrin adaptor protein ap<NUMBER> richardson colleagues identified six highaffinity aak<NUMBER> inhibitors <NUMBER> clini cal candidates benevolentai database baricitinib selected based relatively mild sideeffects feasibility achieve effective concentra tions blood addition baricitinib also bind cyclin grelated kinases also regulate receptormediated endocytosis immu suppressive function baricitinib might also benefit hyperactive immune status severe cases covid<NUMBER> immunemediated lung injury ards might occur ruxolitinib another oral jak<NUMBER> jak<NUMBER> inhibitor approved specifically treatment myelofibrosis used treatment shlh ruxolitinib shown rapidly improve respiratory liver haemodynamic function <NUMBER>yearold boy refractory hlh <NUMBER> substantially improve serum ferritin lactate dehydro genase fibrinogen liver function <NUMBER>yearold female patient refractory epsteinbarr virusrelated shlh <NUMBER> openlabel clinical trial <NUMBER> showed ruxolitinib well tolerated manageable treating shlh symptoms cytopenias improved n<NUMBER> patients within first week ruxolitinib treatment concentrations ferritin soluble il<NUMBER> receptor stat<NUMBER> phosphorylation also reduced administration ruxolitinib <NUMBER> animal studies showed inhibition jak<NUMBER> jak<NUMBER> using ruxolitinib improved weight loss organomegaly anaemia thrombocytopenia hypercytokinaemia tissue inflammation animal models primary hlh shlh reducing stat<NUMBER>dependent cd<NUMBER> tcell expansion <NUMBER> considering similar hyperinflammatory nature shlh severe covid<NUMBER> jak<NUMBER> jak<NUMBER> inhibitors baricitinib ruxolitinib could potential treatments hyperinflammation seen covid<NUMBER> <NUMBER> several registered rcts evaluat ing efficacy ruxolitinib baricitinib treat ment covid<NUMBER> appendix p <NUMBER> chloroquine hydroxychloroquine initially used antimalarial drugs widely used several infectious hiv q fever fungal infections rheumatological systemic lupus erythematosus antiphospholipid antibody syndrome rheumatoid arthritis sjogrens syndrome immunological diseases <NUMBER> mechanism action hydroxychloroquine diverse includes antiinflammatory action immune regula tion antiinfection antitumour metabolic regulation antithrombosis chloroquine shown anticoronavirus effects vitro based immunoregulatory actions drugs chloroquine hydroxychloroquine proposed treatment covid<NUMBER> drugs increase endosomal ph required sarscov<NUMBER> endocytosis cell fusion figure chloroquine also interferes glycosylation ace<NUMBER> required virus attachment host cells <NUMBER> chloroquine first reported <NUMBER> potent inhibitor covid<NUMBER> using vitro sarscov<NUMBER>infected veroe<NUMBER> cell culture model <NUMBER> hydroxychloroquine derivative chloroquine similar pharmacokinetics mechanism action chloroquine substantially fewer sideeffects <NUMBER> compared immunosuppressant drugs methotrexate use hydroxychloroquine chloroquine associated reduced risk infection even chronic use <NUMBER> <NUMBER> therefore hydroxy chloroquine commonly used patients rheumatic diseases conditions hydroxy chloroquine used treat hiv<NUMBER> humans early <NUMBER>s randomised doubleblinded placebocontrolled clini cal trial <NUMBER> asymptomatic patients hiv<NUMBER> <NUMBER> mgd hydroxychloroquine treatment <NUMBER> weeks reduced plasma concentration hiv<NUMBER> rna preserved cd<NUMBER> tcell counts proliferative responses lowered serum il<NUMBER> con cen trations compared placebo group <NUMBER> although takes <NUMBER> months hydroxychloroquine chloro quine fully take effect patients rheumatic disease drugs antiviral effect relatively rapid hydroxy chloroquine treatment short <NUMBER> days shown accelerate virus clearance patients covid<NUMBER> azithromycin reinforced antiviral effect <NUMBER> number ongoing clinical trials testing efficacy hydroxychloroquine chloroquine covid<NUMBER> appendix pp <NUMBER> although recent randomised trial shown chloroquine hydroxychloroquine might improve pneumonia symptoms lab oratory tests decrease progression severe critical condi tions <NUMBER> studies reported either benefits <NUMBER> <NUMBER> <NUMBER> haz ardous effects chloroquine hydroxychloroquine treatment <NUMBER> notably treatment patients covid<NUMBER> might cause cardiotoxicity especially used high dose <NUMBER> <NUMBER> fore results ongoing trials required assess efficacy safety hydroxychloroquine covid<NUMBER> glucocorticoids synthetic analogues widely used rheumatic disease control autoimmune response <NUMBER> due rapid immunosuppressive effect glucocorticoids frequently used hyper inflammatory syndromes ards patients ards glucocorticoid treatment improves oxygen saturation inflammatory markers icu length stay ventilatorfree days although effect mortality consistent trials <NUMBER> <NUMBER> <NUMBER> coronavirus disease inflammationinduced lung injury ards associated adverse outcomes <NUMBER> <NUMBER> histological investigations showed severe lung inflammation diffuse alveolar damage patients coronavirus disease <NUMBER> therefore cortico steroids commonly used severe cases coronavirus disease includ ing sars mers covid<NUMBER> control immunemediated damage lung tissue <NUMBER> <NUMBER> <NUMBER> <NUMBER> however clinical evidence supported beneficial effect glucocorticoids coronavirus illness retrospective study <NUMBER> <NUMBER> critically ill patients mers statistical adjustment timevarying confounders cortico steroid therapy significantly associated improved <NUMBER>day mortality resulted delayed clearance mers coronavirus rna systematic review sars treatments included <NUMBER> studies cortiocosteroid use <NUMBER> studies inconclusive regards effect corticosteroid sars four reported cortico steroids causing possible harm fore highquality rcts needed provide conclusive evidence leflunomide lowmolecular weight synthetic oral antirheumatic drug mechanism action includes inhibition pyrimidine synthesis inhibition protein tyrosine stimulation inhibition nuclear factor kappa beta antitumour effects <NUMBER> <NUMBER> <NUMBER> <NUMBER> leflunomide widely used treatment rheumatoid arthritis <NUMBER> due immunosuppressive function drug also used organ transplantation <NUMBER> another important function leflunomide inhibits virus replication vitro studies shown active metabolite leflunomide a<NUMBER> <NUMBER> protects umbilical cord epithelial cells fibroblasts infection human cytomegalovirus <NUMBER> <NUMBER> electron microscopy revealed morphology virions cytoplasm abnormal assembly virus particles could completed cytomegalovirusinfected cells treated a<NUMBER> <NUMBER> indicating leflunomide interferes assembly virus capsid <NUMBER> study <NUMBER> <NUMBER> patients review cytomegalovirus disease <NUMBER> <NUMBER> patients clinically responded leflunomide therapy <NUMBER> doses <NUMBER> mgday followed <NUMBER> mgdaya dose maintains blood concentrations <NUMBER> ngml viral clearance blood heal ing involved organs therefore leflunomide effective treatment cytomegalovirus disease <NUMBER> antiviral efficacy leflunomide also observed transplant recipients infected bk virus <NUMBER> human papillomavirus hpv <NUMBER> patients polyomavirus type bk nephropathy blood a<NUMBER> <NUMBER> concentrations higher <NUMBER> μgml either cleared virus showed progressive reductions viral load blood urine <NUMBER> another study <NUMBER> leflunomide successfully cleared verrucae vulgaris molluscum lesions four renal transplant patients cutaneous warts usually caused hpv however worth noting leflunomide associated interstitial lung disease <NUMBER> <NUMBER> leflunomideassociated inter stitial lung disease usually occurs within first <NUMBER> weeks leflunomide initiation high mortality patients preexisting interstitial lung disease diffuse alveolar damage ground glass shadowing high resolution ct <NUMBER> exact mechanism remains unclear presence preexisting inter stitial lung disease cigarette smoking low bodyweight use methotrexate risk factors leflunomideinduced interstitial lung disease <NUMBER> remains unclear leflunomide would improve exacerbate pulmonary lesions patients covid<NUMBER> currently one clini cal trial aiming evaluate efficacy safety oral leflunomide tablets pneumonia caused sarscov<NUMBER> appendix p <NUMBER> another dmard thalidomide antiinflammatory antiproliferative activity also used viral infections animal studies shown thalidomide inhibits lung injury mouse models h<NUMBER>n<NUMBER> influenza virus infection improved survival reduced inflammatory cell infiltration reduced con centrations cytokines il<NUMBER> tnf chemokines rantes ip<NUMBER> reduced nuclear factor kappa beta activity <NUMBER> concluded thalidomide could alternative treatment new influenza viruses emerge especially new vaccines developed uk study <NUMBER> indicated thalidomide immuno modulatory immune remodelling effects inhib iting tnf another critical cytokine covid<NUMBER>associated lung injury addition studies shown thalidomide treat pulmonary interstitial fibrosis combat cytokine storm <NUMBER> <NUMBER> studies indicate potential therapeutic value thalidomide viral infection case report <NUMBER> <NUMBER>yearold female patient severe covid<NUMBER> elevated concentrations circulating cytokines including il<NUMBER> il<NUMBER> ifnγ admission treated oral thalidomide <NUMBER> mg day lowdose methylprednisolone <NUMBER> mg intravenously every <NUMBER> h <NUMBER> days <NUMBER> mg intravenously day <NUMBER> days due severity clinical mani festations lack response treatments patients clinical condition including oxygen index fever nausea vomiting resolved within <NUMBER> week thalidomide treatment concentrations il<NUMBER> il<NUMBER> ifnγ returned normal range <NUMBER> days treatment sarscov<NUMBER> tests swab specimens negative <NUMBER> week treatment lung lesions disappeared <NUMBER> days treatment <NUMBER> although single case could provide useful insight clinical invest igation two clinical trials evaluating thera peutic potential thalidomide patients moderate severe covid<NUMBER> appendix p <NUMBER> also many immunemodulating strategies clinical investigation treatment covid<NUMBER> stemcell therapy convalescent plasma treatment mesenchymal stem cells mscs increased importance inflammatory disease due antiinflammatory properties animal experiments showed msc treatment able reduce influenza h<NUMBER>n<NUMBER>induced acute lung injury vivo <NUMBER> stem cells able suppress activities viruses via chaf<NUMBER>amediated sumo<NUMBER>mediated epigenetic regulation termed proviral silencing <NUMBER> several phase <NUMBER> <NUMBER> clinical trials confirmed safety msc therapy patients ards shown beneficial effects <NUMBER> <NUMBER> however several issues limited msc use clinic lack clarity regard optimal dose route msc delivery difficulties largescale production cryopreservation potential substantial variability several ongoing clinical trials testing efficacy msc covid<NUMBER> appendix pp <NUMBER> convalescent plasma patients recovered sarscov<NUMBER> infection also proposed potential treatment covid<NUMBER> convalescent plasma used many severe infections sars mers ebola one therapeutic strategies absence vaccines specific treatments <NUMBER> efficacy therapy especially covid<NUMBER> evaluated ongoing trials appendix p <NUMBER> sarscov<NUMBER> spread rapidly since first emerged december <NUMBER> covid<NUMBER> characterised pandemic new emerging virus approved effective drug vaccine april <NUMBER> <NUMBER> several existing drugs repurposed treatment patients covid<NUMBER> dozens ongoing clinical trials assessing potential efficacy dmards due immunemodu lat ing nature could potential treatment option severe covid<NUMBER> however several issues need taken considera tion first issue hyperinflamma tion versus viral replication although effective antiviral immunity required clearance pathogens hyperactivation immune response causes tissue damage organ failure similarly two sides immunomodulation therapy covid<NUMBER> clinicians determine circumstance use medications second questions timing immunomodulation therapy noted immuno suppressants could affect antiviral immune response timing carefully considered although early intervention considered key factor success immuno modulation therapy infectionassociated hyper inflam mation <NUMBER> direct evidence rcts required determine appropriate timing patients covid<NUMBER> finally pharmacokinetics oral medi cations crucially ill patients merit considera tion physiological altera tions patients sub stantially affect pharmacokinetics drugs need given parenterally due gastrointestinal failure eg chloroquine used parenterally treat severely ill patients malaria although absorbed reliably patients <NUMBER> compared oral route parenteral administration chloroquine results rapid absorption transient high plasma concentrations associated increased risk acute toxicity <NUMBER> addition impaired clearance drugs might problematic patients hepatic dysfunction renal failure therefore smaller frequent doses continuous intravenous infusion choosing less toxic drug eg using hydroxychloroquine instead chloroquine con sidered patients severely ill <NUMBER> <NUMBER> many ongoing trials hopefully provide better understanding potential effects immunomodulation therapy covid<NUMBER>associated hyperinflammation jz jt wrote manuscript input cy ld authors revised manuscript approved final report declare competing interests last months virulence lethality coronavirus breakout presented unprecedented challenge medical community world governments coronavirus disease <NUMBER> covid <NUMBER> first broke december <NUMBER> caused infection severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> previously known novel coronavirus <NUMBER> <NUMBER>ncov <NUMBER> <NUMBER> affected <NUMBER> countries regions <NUMBER> <NUMBER> becoming global pandemic declared world health organization may <NUMBER> <NUMBER> cumulative number confirmed cases covid<NUMBER> infection exceeded <NUMBER> million worldwide <NUMBER> recorded deaths fatality rate <NUMBER> approximately according realtime data released johns hopkins university <NUMBER> prospect effective vaccines months away developed launched scientists physicians alike turned existing drugs known toxicity human pharmacokinetic data deal global healthcare crisis numerous treatment regimens covid <NUMBER> proposed tested clinical trials varying degrees controls sizes subject enrollment limited access compounds live virus testing research institutions around world also resorted tools like virtual screening modeling compile lists potential drugs may efficacious covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> many evaluated sarscov<NUMBER> vitro include medications commonly used decades chloroquine <NUMBER> <NUMBER> <NUMBER> arbidol <NUMBER> ribavirin <NUMBER> <NUMBER> <NUMBER> lopinavir etc <NUMBER> <NUMBER> <NUMBER> list also contains drugs development instance remdesivir <NUMBER> <NUMBER> previously studied drug candidate treating ebola infection <NUMBER> <NUMBER> among notable also controversial repurposed drugs chloroquine cq hydroxychloroquine hcq shown figure <NUMBER>a several initial promising results especially combined azithromycin zinc supplement reported <NUMBER> followed contradicting reports lack efficacy presence severe side effects especially among higher dosed patients based preclinical results cq hcq displayed inhibition viral replication <NUMBER> <NUMBER> <NUMBER> <NUMBER>yearold cq first used clinical practice antimalarial drug indications extended treat systemic lupus erythematosus rheumatoid arthritis several infections <NUMBER> originally developed safer alternative cq treating malaria analogous compound hydroxychloroquine sulfate <NUMBER> become popular drug treating autoimmune diseases including rheumatoid arthritis ra system lupus emphysema sle <NUMBER> <NUMBER> fact <NUMBER> nd prescribed medicine rheumatoid arthritis united states nearly half billion tablets dispensed <NUMBER> drugs long history inexpensive wellreceived treatment options malaria autoimmune well infectious diseases even women patients pregnancy <NUMBER> although us fda granted emergency use authorization eua cq hcq treating covid<NUMBER> march <NUMBER> <NUMBER> believe verdict still ultimate safety efficacy last account currently <NUMBER> <NUMBER> ongoing planned clinical trials clinicaltrialsgov covid<NUMBER> involving use cq hcq respectively remdesivir another repurposed antiviral also generated enormous excitement global communities also approved fda eua treating covid<NUMBER> emerging standard care demonstrated efficacy far ideal development less expensive safer effective accessible treatment options still urgent unmet medical need noticed certain caveats cq hcq worthy taken accounts stakeholders first cq hcq use decades millions patients diverse health conditions since approval mid<NUMBER>s hence wealth information adverse events available <NUMBER> <NUMBER> <NUMBER> secondly unlike iv administered drugs including remdesivir cq hcq taken conveniently oral tablets thirdly cq hcq among least expensive drugs considered covid<NUMBER> excellent prospect accessibility global population safety efficacy proven definitive randomized controlled clinical trials appropriate tailoring according patient conditions time intervention dosing regimen last least preclinical clinical trials cq hcq covid<NUMBER> thus far carried using common cq hcq formulations <NUMBER> ie phosphoric sulfuric acid salt racemic mixture cq hcq respectively commercial chloroquine hydroxychloroquine drug products administrated respective racemates <NUMBER> mixture two enantiomers sand risomers rand sisomers enantiomeric relationship meaning two compounds chemical compositions mirror image relationship spatial arrangement shown figure <NUMBER>b compounds cannot superimpose mirror images defined chiral compounds life biological system chiral nature proteins composed amino acids predominately lconfiguration sugars mostly dconfigurations predisposes different enantiomers chiral drug interact proteins differently hence different pharmacological effects would expected chiral drugs two enantiomers cq hcq might exhibit distinct efficacy safety profiles patients differences big small translate performance variances could potentially influence decision process whether either enantiomer cq hcq ultimately become viable therapeutic agent covid<NUMBER> testing including clinical trials clinical trials covid<NUMBER> conducted far using racemic mixture either cq hcq hence observations actually collective manifestation two different albeit similar optical isomers drugs although cq racemic mixtures exhibited antiviral activity sarscov<NUMBER> vitro ec<NUMBER> <NUMBER> µm vero e<NUMBER> cells hcq also active less toxicity <NUMBER> <NUMBER> <NUMBER> <NUMBER> efficacy possible toxicity individual isomer sarscov<NUMBER> reported preclinical clinical studies yet paper wish present preliminary results difference exhibited enantiomers cq hcq respectively subjected vitro test sarscov<NUMBER> african green monkey kidney vero e<NUMBER> cell line obtained american type culture collection atcc cat <NUMBER> maintained dulbeccos modified eagles medium dmem gibco supplemented <NUMBER> fetal bovine serum fbs <NUMBER> °c incubator <NUMBER> co<NUMBER> clinical isolate sarscov<NUMBER> virus genebank accession mt<NUMBER> propagated vero e<NUMBER> cells viral titer determined plaque assay infection experiments performed biosafety level <NUMBER> bls <NUMBER> laboratory racemic chloroquine diphosphate cas <NUMBER> hydroxychloroquine sulfate cas <NUMBER> purchased bidepharm converted free racemic chloroquine hydroxychloroquine respectively basic conditions enantiomers racemic mixtures separated preparative chiral chromatography freebases shimadzu lc<NUMBER>ad hplc equipment chloroquine hydroxychloroquine dissolved isocratic nhexaneisopropanoldiethylamine ratio <NUMBER> vvv loading needed cq hcq <NUMBER> mgml <NUMBER> mgml respectively resulting solution loaded onto chiralpak ayh ayh<NUMBER>cevc<NUMBER> chiral column eluted solvent system preparation conditions follows flow rate <NUMBER> mlmin detection wavelength uv <NUMBER> nm temperature <NUMBER> ℃ fractions enantiomer collected combined pure optical isomer obtained removing solvent reduced pressure rotary evaporator ee value enantiomer chloroquine hydroxychloroquine higher <NUMBER> spectral data identical reported literature <NUMBER> <NUMBER> freebase enantiomers converted enantiomerically pure diphosphate salt sulfate salt respectively described experimental section antiviral assays sarscov<NUMBER> vitro performed biosafety level<NUMBER> laboratory bsl<NUMBER> state key laboratory respiratory disease guangzhou medical university guangzhou customs district technology center log phase vero e<NUMBER> cells plated overnight <NUMBER>well cell culture plate greiner cat no<NUMBER> pretreated indicated concentration compounds <NUMBER> h concentration three replicates sarscov<NUMBER> multiplicity infection moi <NUMBER> subsequently added <NUMBER> h medium replaced fresh drugcontaining one <NUMBER> hours later cells fixed <NUMBER> paraformaldehyde permeabilized <NUMBER> triton x <NUMBER> blocking <NUMBER> bovine serum albumin bsa room temperature <NUMBER> h rabbit polyclonal antibody sars coronavirus nucleoprotein np <NUMBER> primary antibody used incubate cells alexa <NUMBER> labeled secondary antibody donkey antirabbit igg<NUMBER> jackson added nuclei stained dapi sigma plate scanned using celigo image cytometer fluorescence microscopy images taken inhibition rate calculated using mean intensity green channel versus dapi channel ic<NUMBER> value compound calculated using graphpad prism software version <NUMBER> using nonlinear regression equation chiral hplc separation racemic chloroquine first eluting compound <NUMBER> minutes found dextrorotary thus assigned scq second compound <NUMBER> minutes rcq specific rotation <NUMBER> <NUMBER> respectively depicted figure <NUMBER>d f case hydroxychloroquine figure <NUMBER>a c first eluting compound <NUMBER> minutes determined shcq second compound <NUMBER> minutes rhcq specific rotation <NUMBER> <NUMBER> respectively enantiomeric excess value enantiomer hcq cq found higher <NUMBER> shown figure <NUMBER>b c e f cases baseline separation achieved material recovery <NUMBER> g loaded <NUMBER> g hcq case <NUMBER> g loaded <NUMBER> g cq results vitro antiviral activity sarscov<NUMBER> vero e<NUMBER> cells showed cq hcq enantiomers exhibited respectable antiviral effect concentrationdependent manner ic<NUMBER> values racemic chloroquine diphosphate raccq r enantiomer sarscov<NUMBER> vitro <NUMBER> μm <NUMBER> μm <NUMBER> μm respectively displayed figure <NUMBER>a shown figure <NUMBER>b ic<NUMBER> values racemic hydroxychloroquine sulfate rachcq r enantiomer <NUMBER> μm <NUMBER> μm <NUMBER> μm respectively addition tested antiviral activity azithromycin used combination drug hcq treating covid<NUMBER> patients singledose azithromycin afforded ic<NUMBER> value <NUMBER> μm shown figure <NUMBER>c results immunofluorescence microscopy sarscov<NUMBER> infection displayed visually better antiviral effect senantiomers cq hcq <NUMBER> <NUMBER> improvement compared renantiomer starting dose <NUMBER> μm respectively data showed antiviral activity scq relatively similar racemic cq figure <NUMBER>a whereas efficacy shcq much better racemates figure <NUMBER>b hand azithromycin alone started exhibit antiviral effect relatively high concentration <NUMBER> μm figure <NUMBER>c figure <NUMBER> <NUMBER> h pi infected cells fixed incubated primary antibody rabbit polyclonal antibody sars coronavirus nucleoprotein followed alexa <NUMBER> labeled secondary antibody nuclei stained dapi bars <NUMBER> μm rand senantiomers different substances definition expected biological effect living system inherently chiral enantiomers often different pharmacodynamics pharmacokinetics behaviors hence different therapeutic efficacy safety profiles however significance principle drug development fully appreciated time cq hcq developed <NUMBER> years ago one notorious examples drug chirality thalidomide chiral drug first marketed racemic form <NUMBER> europe antiemetic treating morning sickness ailments drug withdrawn market <NUMBER> amid emergence birth defects among newborn children woman patients later determined two enantiomers caused distinctly different effects one another sisomer attributed culprit teratogenic properties <NUMBER> since enantiomers thalidomide interconverts vivo efforts develop stable singleenantiomer thalidomide thwarted eventually racemic form repurposed launched oncology applications brand thalomid strictly contraindicated pregnancy thalidomide tragedy brought lot attention concerns importance chirality drug development process eventually culminated specific guidance regulations regarding chiral drug development fda <NUMBER>s cq hcq would unlikely approved submitted current regulatory authority likely demand delineation enantiomers properties demonstration noninferiority racemate context safety efficacy allowed marketing approval unlike thalidomide cq hcq stereochemically stable interconversion two enantiomers observed vivo unlikely mechanistic point view separation rand senantiomers cq hcq reported early <NUMBER>s <NUMBER> <NUMBER> part metabolite profiling studies hcq <NUMBER> enantiodiscriminating analytical methods available cq hcq respective metabolites several studies demonstrated varying degrees differences pharmacological properties two enantiomers cq hcq cq hcq extremely long halflives approximating <NUMBER> days predominantly due huge volume distribution <NUMBER> low metabolic rate drugs accumulate excessively tissues time especially eyes skin brain heart liver long term higher doses recommended maximal dose chloroquine hydroxychloroquine <NUMBER> mgkg <NUMBER> mgkg respectively according fda put patients risk adverse effects irreversible retinopathy neuropathic cardiac toxicities <NUMBER> <NUMBER> <NUMBER> <NUMBER> one major adverse effects associated clinical applications cq hcq ocular toxicity manifested pigmentary retinopathy especially higher doses mechanism remains unelucidated pharmacokinetics differences two enantiomers cq hcq documented animals human <NUMBER> <NUMBER> <NUMBER> <NUMBER> study hydroxychloroquine distribution rabbits found renantiomer stereoselectively accumulated ocular tissue rshcq ratio <NUMBER> administration racemates however opposite ratio <NUMBER> total plasma concentration implying possibility significant contribution risomer ocular toxicity <NUMBER> results consistent data clinical pk study humans whole blood concentration renantiomer much higher antipode whereas ratio rs concentrations chiral metabolites less <NUMBER> besides renal clearance senantiomer twice greater renantiomer shorter elimination halflife observed senantiomer <NUMBER> <NUMBER> <NUMBER> <NUMBER> vitro assays using human plasma indicated rand shcq enantiomers <NUMBER> <NUMBER> proteinbound respectively implying rhcq would higher volume distribution shcq results indicated faster renal excretion andor accentuated liver metabolism lower volume distribution senantiomer compared renantiomer <NUMBER> thus stereoselective elimination sisomer stereoselective protein risomer considered attribution differences disposition distribution tissues ocular compartment pharmacological effects also proven different two enantiomers cq hcq various applications difference antimalarial activities reported <NUMBER> <NUMBER> noted scientists sterling winthrop inc shcq approximately <NUMBER> active rhcq rat pleurisy macrophage model <NUMBER> later sand rhcq found suppress hiv<NUMBER> replication similar extent dose proportionally toxic racemic hcq <NUMBER> since hcqs antimalarial antiviral effects purported originate ability increase endosomal ph authors demonstrated enantiomers hcq increased endosomal ph similar levels dose proportionally manner unlike muchexplored pharmacokinetics pharmacological effects racemates limited toxicity information shown schloroquine seems less toxic rchloroquine <NUMBER> animal studies clinical evidence presented pharmacological activities enantiomer studies malaria autoimmune diseases efficacy safety cq andor hcq treating covd<NUMBER> need validated larger definitive clinical trials complicated effects ages doses <NUMBER> disease states prior treatments underlying physiological conditions enrolled patients taking consideration cause bias trial outcomes however running trials racemic drug represents one significant variances ie drug substance <NUMBER> potency preferred isomer unnecessarily complicate delineation clinical outcomes contributed enantiomer fortunately racemic hcq readily available worldwide production volume exceeding <NUMBER> metric tons growing separation racemic mixture pure enantiomer forms industrially feasible asymmetric synthesis also promising longterm solutions seems excuse continue running trial using racemic cq hcq ready availability backdrop separated racemic mixtures cq hcq chiral hplc tested antiviral effects rand scq hcq well racemic cq hcq azithromycin parallel result illustrated figure <NUMBER> <NUMBER> significant finding study scq shcq exhibited pronounced activities respective renantiomer assay sarscov<NUMBER> vitro specifically result shcq demonstrated significant enantioselectivity <NUMBER> efficiency rhcq ic<NUMBER> senantiomer cq hcq <NUMBER> µm <NUMBER> µm respectively compared renantiomers respective ic<NUMBER> value <NUMBER> µm <NUMBER> µm ic<NUMBER> value racemic mixtures cq hcq <NUMBER> µm <NUMBER> µm respectively fell two enantiomers expected ic<NUMBER> racemic mixture cq hcq indicated testing conditions sisomers major contributors antiviral activities implying risomers either coming ride minor contributors antiviral activities providing hitherto unknown benefits cytokine storm management contributing untoward side effects preliminary data antiviral potency sarscov<NUMBER> vitro enantiomers racemates differentiated presented condition suggested covid<NUMBER> may treated effective safer senantiomer substantially free renantiomer might introduce adverse effects dilute therapeutic efficacy single senantiomer possibly administrated lower dose weight racemate improved therapeutic efficacy fewer side effects potentially superior treatment covid<NUMBER> broader therapeutic index since mechanism hcqs antiviral effect remains elucidated remain cautious explaining synergies antiviral antiinflammatory activities without enantioselectivity data latter data clearly indicated rand senantiomer cq hcq exhibited significantly different properties sarscov<NUMBER> first time enantioselective antiviral activities cq hcq sarscov<NUMBER> demonstrated vitro senantiomers cq hcq proved <NUMBER> <NUMBER> active corresponding renantiomers since demonstrated vitro antiviral activities mainly derived sisomer reasonable expect drug dose decreased half even less racemates similar antiviral effect eliminating untoward side effects brought upon risomer moreover data showed significant difference antiviral activity two enantiomers hcq compared cq taken together previous studies malaria hiv human pharmacokinetic data implicating greater ocular accumulation risomers opine clear preference development shcq enantiomerically pure drug treating covid<NUMBER> within compound class summary demonstrated unequivocally pronounced difference antiviral activities enantiomers cq hcq racemate cq hcq would less preferred covid<NUMBER> applications unless shown pharmacological testing prospect reducing eliminating adverse effects attributed presence rhcq strongly recommend studies especially human clinical trials conducted pure shcq constituting expedient highly probable way double therapeutic index hcq purchased chloroquine diphosphate <NUMBER> g <NUMBER> mmol dissolved water <NUMBER> ml followed addition <NUMBER> naoh solution <NUMBER> ml dropwise <NUMBER> ℃ stirring <NUMBER> h etoac <NUMBER> ml added mixture kept stirring another <NUMBER> h rt reaction mixture extracted etoac <NUMBER> x <NUMBER> ml organic phase combined washed brine dried anhydrous na<NUMBER>so<NUMBER> organic solvent removed rotary evaporator reduced pressure obtain yellow residue free chloroquine <NUMBER> g <NUMBER> mmol <NUMBER> yield spectral data identical literature <NUMBER> <NUMBER> purchased hydroxychloroquine sulfate <NUMBER> g <NUMBER> mmol dissolved water <NUMBER> ml followed addition <NUMBER> naoh solution <NUMBER> ml dropwise <NUMBER> ℃ stirring <NUMBER> h etoac <NUMBER> ml added mixture kept stirring another <NUMBER> h rt reaction mixture extracted etoac <NUMBER> x <NUMBER> ml organic phase combined washed brine dried anhydrous na<NUMBER>so<NUMBER> organic solvent removed rotary evaporator reduced pressure obtain yellow residue free hydroxychloroquine <NUMBER> g <NUMBER> mmol <NUMBER> yield spectral data identical literature <NUMBER> chiral highpressure liquid chromatography hplc method used separate enantiomers racemic mixture freebases shimadzu lc<NUMBER>ad hplc equipment chloroquine hydroxychloroquine dissolved isocratic nhexaneisopropanoldiethylamine ratio <NUMBER> vvv loading needed cq hcq <NUMBER> mgml <NUMBER> mgml respectively resulting solution loaded onto chiralpak ayh ayh<NUMBER>cevc<NUMBER> chiral column eluted solvent system preparation conditions follows flow rate <NUMBER> mlmin detection wavelength uv <NUMBER>nm temperature <NUMBER> ℃ fractions enantiomer collected combined pure optical isomer obtained removing solvent reduced pressure rotary evaporator ee enantiomer chloroquine hydroxychloroquine higher <NUMBER> spectral data identical literature <NUMBER> <NUMBER> general conversion enantiomerically pure chloroquine freebase corresponding salt rchloroquine schloroquine <NUMBER> mg <NUMBER> mmol dissolved etoh <NUMBER> ml heated reflux followed addition <NUMBER> phosphoric acid <NUMBER> ml <NUMBER> h large amount white solid precipitated reaction mixture cooled rt filtered resulting solid washed etoh <NUMBER> x <NUMBER> ml obtain product rchloroquine diphosphate schloroquine diphosphate <NUMBER>r<NUMBER>n<NUMBER>chloroquinolin<NUMBER>yl<NUMBER>n<NUMBER>ndiethylpentane<NUMBER> compound obtained white solid <NUMBER> mg <NUMBER> rhydroxychloroquine shydroxychloroquine <NUMBER> mg <NUMBER> mmol dissolved etoh <NUMBER> ml heated <NUMBER> ℃ followed addition <NUMBER> phosphoric acid <NUMBER> mg <NUMBER> h reaction mixture cooled <NUMBER> ℃ large amount white solid precipitated solid filtered resulting solid washed cold etoh <NUMBER> x <NUMBER> ml obtain product rhydroxychloroquine sulfate shydroxychloroquine sulfate compound obtained white solid <NUMBER> mg <NUMBER> compound obtained white solid <NUMBER> mg <NUMBER> myron cohen md severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> virus causes coronavirus disease <NUMBER> covid<NUMBER> generated worldwide pandemic interruption spread depends combination pharmacologic nonpharmacologic interventions initial sarscov<NUMBER> prevention includes social distancing use face masks environmental hygiene hand washing <NUMBER> although important pharmacologic interventions prevent sarscov<NUMBER> infection likely vaccines repurposing established drugs shortterm prophylaxis another immediate option researchers promoted chloroquine hydroxychloroquine treatment prevention illness variety microorganisms including sarscov <NUMBER> hydroxychloroquine inhibit replication sarscov<NUMBER> vitro <NUMBER> observational studies suggested benefits hydroxychloroquine treatment covid<NUMBER> whereas treatment reports described mixed results <NUMBER> boulware et al report journal results randomized trial testing hydroxychloroquine postexposure prophylaxis covid<NUMBER> <NUMBER> described investigators pragmatic trial participants recruited social media almost data reported participants adults described highrisk moderaterisk exposure someone covid<NUMBER> household occupational setting provided hydroxychloroquine placebo mail within <NUMBER> days reported exposure symptoms would expected develop authors enrolled <NUMBER> participants illness considered consistent covid<NUMBER> developed <NUMBER> participants <NUMBER> confirmed polymerasechainreaction assay less <NUMBER> participants incidence new illness compatible covid<NUMBER> differ significantly participants receiving hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> receiving placebo <NUMBER> <NUMBER> <NUMBER> although participantreported side effects significantly common receiving hydroxychloroquine <NUMBER> receiving placebo <NUMBER> serious adverse reactions reported trial many limitations acknowledged investigators trial methods allow consistent proof exposure sarscov<NUMBER> consistent laboratory confirmation symptom complex reported represented sarscov<NUMBER> infection indeed specificity participantreported covid<NUMBER> symptoms low <NUMBER> hard certain many participants trial actually covid<NUMBER> adherence interventions could monitored participants reported lessthanperfect adherence notably group receiving hydroxychloroquine addition enrolled trial younger median age <NUMBER> years fewer coexisting conditions persons severe covid<NUMBER> likely develop <NUMBER> enrollment higherrisk participants might yielded different result trial design raises questions expected prevention benefits hydroxychloroquine studies postexposure prophylaxis intended provide intervention shortest possible time prevent infection smallanimal model sarscov<NUMBER> infection <NUMBER> prevention infection severe disease observed experimental antiviral agent given shortly exposure current trial long delay perceived exposure sarscov<NUMBER> initiation hydroxychloroquine ≥<NUMBER> days participants suggests assessed prevention symptoms progression covid<NUMBER> rather prevention sarscov<NUMBER> infection drugs prevention infections must excellent safety profile hydroxychloroquine initially promoted possible solution sarscov<NUMBER> infection safety drug emphasized <NUMBER> closer scrutiny however potential cardiac toxic effects overall adverse outcomes emphasized especially persons underlying coexisting conditions increase risk severe covid<NUMBER> <NUMBER> boulware et al report frequent mild side effects hydroxychloroquine cardiac toxic effects could assessed results trial advocacy widespread use hydroxychloroquine seem reflect reasonable fear sarscov<NUMBER> infection however would appear extent media social forces rather medical evidence driving clinical decisions global covid<NUMBER> research agenda <NUMBER> editorial published june <NUMBER> <NUMBER> nejmorg since december <NUMBER> pandemic caused coronavirus disease <NUMBER> covid<NUMBER> raises real public health problem <NUMBER> covid<NUMBER> appeared wuhan hubei province china covid<NUMBER> sarscov <NUMBER> coronavirus nearly <NUMBER> common nucleotide sarscov <NUMBER> <NUMBER> manifested fever dry cough rhinitis asthenia headache dyspnea often acute respiratory distress syndrome lead death <NUMBER> <NUMBER> <NUMBER> mortality risk factors appear mainly diabetes high blood pressure coronary heart disease chronic obstructive lung disease chronic kidney disease <NUMBER> although hypotheses made pathogenesis covid<NUMBER> clearly elucidated choices treatment therefore empirical based previous experience sarscov<NUMBER> milddle east respiratory syndrome merscov <NUMBER> <NUMBER> <NUMBER> antiretrovirals lopinavirritonavir remdesivir ribavirin tried treating patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> addition drugs used rheumatology decades seem effective infection part studied <NUMBER> <NUMBER> <NUMBER> <NUMBER> rational use antirheumatic drugs based cytokinic storm hyperproduction il<NUMBER> il<NUMBER> tnf α body covid<NUMBER> severe form <NUMBER> <NUMBER> <NUMBER> <NUMBER> rheumatologists experience administration drugs could help improve use <NUMBER> covid<NUMBER> therefore raises two major concerns rheumatologists chronic inflammatory rheumatic diseases immunosuppressive treatment cause risk admission intensive care units high mortality infected patient antirheumatic drugs used treat covid<NUMBER> infectious part coronaviruses covs viruses subfamily orthocoronavirinae family coronaviridae name coronavirus latin meaning virus crown due appearance virions electron microscope fringe large bulbous projections resemble solar corona <NUMBER> coronaviruses viral envelope positive rna genome kilobase capsid shell incredibly large rna virus classified nidovirals since viruses order produce nested set subgenomic mrna infection peak envelope membrane capsid proteins contribute overall structure coronaviruses rna viruses singlestranded singlestranded positive baltimore classification group iv mutate recombine cytokine dysregulation particular interest patients covid<NUMBER> infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> host immune response one side essential resolution covid<NUMBER> infection also crucial pathogenesis major clinical manifestations disease angiotensinconverting enzyme <NUMBER> ace<NUMBER> identified host cellsurface receptor sarscov<NUMBER> envelope spike glycoprotein <NUMBER> ace<NUMBER> type membrane protein expressed cells kidney heart gastrointestinal tract blood vessels importantly lung at<NUMBER> alveolar epithelial cells particularly prone viral infection <NUMBER> sarscov<NUMBER> infection leads downregulation ace<NUMBER> expression thus resulting excessive production angiotensin ii related enzyme ace suggested stimulation type <NUMBER>a angiotensin ii receptor agtr<NUMBER>a increases pulmonary vascular permeability thus potentially explaining increased lung damage expression ace<NUMBER> decreased <NUMBER> sarziputtini et al hypothesized decrease infɣ covid<NUMBER> may suppress th<NUMBER> favor th<NUMBER> <NUMBER> cytokines seem upregulated especially patients severe disease cell depletion huang et al found il<NUMBER> il<NUMBER> il<NUMBER> gcsf ip<NUMBER> mcp<NUMBER> mip<NUMBER>a tnfα levels correlated disease severity <NUMBER> diao et al found disease severity correlated tnfα il<NUMBER> il<NUMBER> levels <NUMBER> thus documenting tnfα hyperproduction serum covid<NUMBER> patients regulation cytokine storm remains challenge treatment covi<NUMBER> infection explains use chloroquine derivatives anticytokines antiil<NUMBER> antiil<NUMBER> antitnf antijak corona virus disease <NUMBER> covid<NUMBER> pandemic responsible high mortality patients risk factors age <NUMBER> years diabetes cardiovascular history chronic respiratory disease chronic renal failure dialysis cancers treatment immune deficiency cirrhosis obesity pregnant women <NUMBER> inflammatory rheumatism appear associated admission intensive care patient chronic inflammatory rheumatism receiving immunosuppressive treatments risk severe form vidoc<NUMBER> infection date little data available chronic inflammatory rheumatic diseases covid<NUMBER> <NUMBER> rheumatoid arthritis ra associated increased risk infection compared general population without ra <NUMBER> increased risk infection correlated presence risk factors identical reported covid<NUMBER> <NUMBER> <NUMBER> hand corticosteroids nonsteroidal antiinflammatory drugs inhibiting inflammatory response increase risk infections especially bacterial mycotic infections <NUMBER> <NUMBER> methotrexate treatment appear associated increased risk infection combination corticosteroids <NUMBER> contrast methotrexate biological diseasemodifying antirheumatic drugs responsible increased risk infection correlated advanced age female sex treatment prednisone dose <NUMBER> mgday high number hospital stays <NUMBER> particularity pandemic covid<NUMBER> requires specific data infection monti et al studied clinical course covid<NUMBER> series patients chronic arthritis treated immunosuppressive targeted therapies <NUMBER> authors collected information <NUMBER> patients female <NUMBER> mean age <NUMBER> ± <NUMBER> years treated bdmards tsdmards <NUMBER> rheumatoid arthritis <NUMBER> spondyloarthritis <NUMBER> treated tumor necrosis factor inhibitors <NUMBER> bdmards <NUMBER> tsdmards thirteen confirmed andor suspected covid<NUMBER> patients diagnosed one patient required hospitalization <NUMBER> years age deaths observed <NUMBER> despite small sample size study limited data covid<NUMBER> inflammatory rheumatism seems lower risk severity death group patients apart usual risk factors diabetes mellitus hypertension obesity… study also reported reference center management patients covid<NUMBER> <NUMBER> patients severe patient biological diseasemodifying antirheumatic drugs <NUMBER> studies clarify absence higher risk patients chronic inflammatory rheumatism increased monitoring patients necessary application barrier gestures useful chloroquine chloroquine chloroquinine antimalarial drug <NUMBER>aminoquinoline family widely marketed form salts sulphate phosphate medicine used long preventive curative treatment malaria several decades chloroquine used rheumatology immunomodulating effect particularly systemic lupus erythematosus rheumatoid arthritis studies also shown antiviral activity chloroquine vitro h<NUMBER>n<NUMBER> avian influenza <NUMBER> chikungunya <NUMBER> zika <NUMBER> ebola <NUMBER> sarscoronavirus <NUMBER> <NUMBER> chloroquine acts increasing endosomal ph required viralhost cell fusion demonstrated studies sarscov may also interfere glycosylation ace<NUMBER> receptors may inhibit viral entry target cell <NUMBER> systematic review efficacy safety chloroquine treatment covid<NUMBER> involving six articles <NUMBER> ongoing clinical trials china concluded chloroquine effective limiting replication sarscov<NUMBER> vitro <NUMBER> basing action chloroquine covid<NUMBER> vitro efficacy first results open studies carried beijing hospitals hunan province central southern china guangdong province prof raoults team proposes used treatment covid<NUMBER> <NUMBER> however therapeutic efficacy safety chloroquine still discussed <NUMBER> <NUMBER> franck touret xavier de lamballerie inserm <NUMBER> marseille caution must exercised view previous antiviral failures chloroquine vivo deleterious effect acute viral infections <NUMBER> however chloroquine appears effective covidrelated acute respiratory distress syndrome improves pulmonary radiological lesions accelerates seronegativity virus shortens duration disease <NUMBER> chinese experts recommend patients diagnosed mild moderate severe cases covid<NUMBER> pneumonia without contraindications chloroquine treated <NUMBER> mg chloroquine twice day <NUMBER> days <NUMBER> since chloroquine incorporated treatment protocols covid<NUMBER> infection asia <NUMBER> many countries hydroxychloroquine derivative chloroquine differs chloroquine hydroxyl oh group end chain replaced chloroquine many years treatment systemic lupus erythematosus rheumatoid arthritis pharmacological activity chloroquine hydroxychloroquine tested using sarscov<NUMBER>infected vero cells physiologically based pharmacokinetic models pbpk implemented drugs separately integrating vitro data using pbpk models hydroxychloroquine concentrations lung fluid simulated <NUMBER> different dosing regimens explore effective regimen considering drugs safety profile hydroxychloroquine ec<NUMBER> <NUMBER> μm found potent chloroquine ec<NUMBER> <NUMBER> μm vitro based pbpk models results loading dose <NUMBER> mg twice daily hydroxychloroquine sulfate given orally followed maintenance dose <NUMBER> mg given twice daily <NUMBER> days recommended sarscov<NUMBER> infection reached three times potency chloroquine phosphate given <NUMBER> mg twice daily <NUMBER> days advance hydroxychloroquine found potent chloroquine inhibit sarscov<NUMBER> vitro <NUMBER> study confirmed authors suggest addition antiviral immunomodulatory effect hydroxychloroquine antiinflammatory effect may mitigate cytokine storm observed covid<NUMBER> infection <NUMBER> zhou et al propose hydroxychloroquine hcq exhibits antiviral effect highly similar cq could serve better therapeutic approach hcq likely attenuate severe progression covid<NUMBER> inhibiting cytokine storm suppressing cell activation herein strongly urge clinical trials performed assess preventive effects hcq disease infection progression <NUMBER> vein gautret p et al professor raoults team open label nonrandomized study <NUMBER> patients infected covid<NUMBER> showed significant reduction viral load day <NUMBER> inclusion compared controls lower mean duration viral carriage untreated patients literature azithromycin added hydroxychloroquine significantly efficient virus elimination patients gautret el al study proposed oral hydroxychloroquine sulfate <NUMBER> mg three times per days <NUMBER> days <NUMBER> among hydroxychloroquinetreated patients six received azithromycin <NUMBER> mg day <NUMBER> followed <NUMBER> mg per day next <NUMBER> days experience hydroxychloroquine use treating systemic lupus erythematosus forms rheumatoid arthritis <NUMBER> patients included average cumulative dose hydroxychloroquine <NUMBER> g <NUMBER> extremes <NUMBER> g <NUMBER> g average duration treatment hydroxychloroquine <NUMBER> years <NUMBER> years extremes <NUMBER> years <NUMBER> years maculopathy extremely rare <NUMBER> <NUMBER> using corticosteroids covid<NUMBER> infection highly controversial chen et al reported <NUMBER> <NUMBER> patients treated corticosteroids <NUMBER> days methylprednisolone <NUMBER> mgkg per day recommend patients acute respiratory distress syndrome treatment shortest possible duration <NUMBER> zhang et al adverse effects largely dominate benefit corticosteroids <NUMBER> wang et al reported <NUMBER> <NUMBER> patients received corticosteroid therapy without improvement <NUMBER> russel et al reported clinical evidence support corticosteroid treatment covid<NUMBER> lung injury <NUMBER> studies supported others report benefit corticosteroid therapy covd<NUMBER> infection <NUMBER> <NUMBER> ling et al duration viral rna detection oropharyngeal swabs fecal samples glucocorticoid treatment group longer nonglucocorticoid treatment group <NUMBER> days vs <NUMBER> days respectively <NUMBER> p <NUMBER> duration viral rna detection fecal samples glucocorticoid treatment group longer nonglucocorticoid treatment group <NUMBER> days vs <NUMBER> days respectively <NUMBER> p <NUMBER> authors recommended glucocorticoids treating covid<NUMBER> especially mild disease <NUMBER> zheng et al severe covid<NUMBER> patients early shortterm use low dose methylprednisolone beneficial delay sarscov<NUMBER> rna clearance influence igg antibody production <NUMBER> due lack evidences interium guideline support routinely give systemic corticosteroids treatment viral pneumonia outside clinical trials <NUMBER> new randomized controlled trial rct recently registered zhou et al compare methylprednisolone via intravenous injection dose <NUMBER> mgkgday <NUMBER> days versus control group using glucocorticoid clinicaltrialsgov chictr<NUMBER> help answer questions near future tocilizumab tcz recombinant human il<NUMBER> monoclonal antibody specifically binds soluble membranebound il<NUMBER> receptors il<NUMBER>r thus blocking il<NUMBER> signaling mediated inflammatory response totally <NUMBER> patients covid<NUMBER> included luo et al study <NUMBER> two moderately ill <NUMBER> seriously ill <NUMBER> critically ill tcz used combination methylprednisolone mp <NUMBER> patients five patients received tcz administration twice although tcz treatment ameliorated increased crp patients rapidly <NUMBER> critically ill patients received single dose tcz <NUMBER> still dead crp level rest <NUMBER> patient failed return normal range clinical outcome disease aggravation serum il<NUMBER> level tended spiked firstly decreased tcz therapy <NUMBER> patients persistent dramatic increase il<NUMBER> observed <NUMBER> patients failed treatment till several clinical trials registered safety efficacy tocilizumab treatment severe covid<NUMBER> pneumonia adult inpatients including multicenter randomized controlled trial efficacy safety tocilizumab treatment novel coronary pneumonia ncp chictr<NUMBER> single arm open multicenter study tocilizumab chictr<NUMBER> combination tocilizumab drugs chictr<NUMBER> chictr<NUMBER> one known regulators endocytosis ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> aak<NUMBER> inhibitors interrupt passage virus cells helpful preventing virus infections jak inhibitor well aak<NUMBER> inhibitor suggested possible candidate treatment covid<NUMBER> considering relative safety high affinity recently wu et al reviewed th<NUMBER> responses patients sarscov<NUMBER> proposed fda approved jak<NUMBER> inhibitor fedratinib reducing mortality patients th<NUMBER> type immune profiles <NUMBER> another author proposed baricitinib candidat treat covid<NUMBER> <NUMBER> date registered clinical trials jak inhibitor study safety efficacy jakotinib hydrochloride tablets treatment severe acute exacerbation patients novel coronavirus pneumonia covid<NUMBER> chictr<NUMBER> severe novel coronavirus pneumonia covid<NUMBER> patients treated ruxolitinib combination mesenchymal stem cells prospective single blind randomized controlled clinical trial chictr<NUMBER> colchicine used safely variety cardiovascular clinical conditions among potential mechanisms action nonselective inhibition nlrp<NUMBER> inflammasome thought major pathophysiologic component clinical course patients covid<NUMBER> grecco<NUMBER> trial aims identify whether colchicine may positively intervene clinical course covid<NUMBER> <NUMBER> prospective cluster randomized openlabeled controlled study patients laboratory confirmed sarscov<NUMBER> infection rt pcr clinical picture involves temperature <NUMBER>°c least two sustained coughing ii sustained throat pain iii anosmia andor ageusia iv fatiguetiredness v pao<NUMBER> <NUMBER> mmhg included study submitted clinicaltrialsgov march <NUMBER> <NUMBER> hypothesis antitnf use covid<NUMBER> infection based pathophysiology disease <NUMBER> study evaluating adalimumab covid<NUMBER> infection recently registered chinese clinical trial registry chictr<NUMBER> chronic inflammatory rheumatism seem risk factor severity covid<NUMBER> despite presence immunosuppressive therapy however studies allow definitive conclusions drawn subject hydroxychloroquine biological diseasemodifying antirheumatic drugs antiil<NUMBER> antitnf antiil<NUMBER> serious candidates treatment covid<NUMBER> efficacy confirmed ongoing rct studies next challenge rheumatologists infectious diseases specialists intensive care physicians would determine window opportunity considered best intervention best timeframe increase better progression disease disclosures none coronavirus disease <NUMBER> covid<NUMBER> pandemic impacted medical systems societies economies worldwide first case covid<NUMBER> caused severe acute respiratory syndrome <NUMBER> virus sarscov<NUMBER> <NUMBER> reported china december <NUMBER> <NUMBER> virus spread globally rapid pace resulting <NUMBER> million confirmed cases april <NUMBER> <NUMBER> <NUMBER> recent weeks new york city emerged epicenter pandemic <NUMBER> confirmed cases <NUMBER> deaths due confirmed probable covid<NUMBER> death april <NUMBER> <NUMBER> <NUMBER> studies clinical characteristics epidemiologic characteristics covid<NUMBER> conducted countries experiencing outbreaks earlier usa <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> largescale observational data clinical characteristics outcomes covid<NUMBER> population usa scarce study describe clinical characteristics covid<NUMBER> ambulatory inpatient settings identify risk factors associated mortality hospitalized patients multicenter retrospective cohort study patients covid<NUMBER> patients conducted using medical records mount sinai health system large urban health system <NUMBER> hospitals four hundred ambulatory practices new york city metropolitan area patients positive sarscov<NUMBER> test result encounter healthcare provider covid<NUMBER> march <NUMBER> april <NUMBER> <NUMBER> included study confirmed case covid<NUMBER> defined positive result reversetranscriptasepolymerasechainreaction rtpcr assay nasopharyngeal swab specimens study population dichotomized ambulatory hospitalized groups former included patients whose encounter office visit electronic supplementary material online version article httpsdoiorg<NUMBER>s<NUMBER>z contains supplementary material available authorized users emergency department ed visit telehealthtelemedicine inpatients ambulatory patients subsequently admitted hospital included hospitalized group groups subdivided survivors nonsurvivors ambulatory nonsurvivors patients expired prior presentation ed expired ed prior admission hospital units office telemedicine encounter later found deceased ambulatory survivors included ambulatory patients hospitalized nonsurvivors patients expired april <NUMBER> <NUMBER> hospitalized survivors patients discharged home facilities april <NUMBER> <NUMBER> icahn school medicine mount sinai waived informed consent institutional review board approval study used deidentified database following covariates extracted database patients age sex ethnicity race smoking status vital signs including temperature peripheral oxygen saturation spo <NUMBER> heart rate respiratory rate rr blood pressure bp body mass index bmi laboratory results including white blood cell count wbc ddimer interleukin<NUMBER> il<NUMBER> hemoglobin estimated glomerular filtration rate egfr alanine aminotransferase alt aspartate aminotransferase ast creactive protein crp procalcitonin ferritin lactate dehydrogenase ldh fibrinogen fbg interleukin<NUMBER> il<NUMBER> comorbidities treatments continuous variables reported median interquartile range categorical variables expressed proportions temporary changes vital signs laboratory values survivors nonsurvivors first <NUMBER> days admission assessed illustrate risk associated changes continuous variables including vital signs laboratory values multivariate generalized additive models used calculate odds ratio mortality median value set reference ie <NUMBER> hazard ratio hr variable mortality risk assessed using univariate cox proportional hazard regression model account missing data values laboratory results introduced multiple imputation procedure used replace missing values plausible values creating multiple fillingin patterns avert bias caused missing data using dataset imputed values univariate multivariate cox model fit calculate hr multivariate cox model adjusted following variables assessed univariate cox model patients age sex race cigarette use history past medical history asthma hypertension diabetes cancer systolic bp rr spo <NUMBER> bmi initial laboratory values lymphocyte proportion ddimer il<NUMBER> hydroxychloroquine use cox regression analysis excluded variables univariable analysis betweengroup differences significant number events small calculate hazard ratios collinearity significant values hospital considered clustering term cox proportional hazard model analysis clustering effect associated hospitals accounted robust sandwich estimator preliminary confirmation predictability cox proportional hazard model demonstrated area curve auc <NUMBER> <NUMBER> ci <NUMBER> supplementary figure <NUMBER> investigate effect hydroxychloroquine addressing imbalance among treatment groups introduced inverse probability weighting iptw based propensity scoring control observed differences baseline characteristics treatment group control group iptw calculated based variables used cox regression models except hydroxychloroquine use fitted iptwadjusted cox doubly robust methods survival curves stratification hydroxychloroquine constructed using kaplanmeier method statistical analyses performed using version <NUMBER> r programming language r project statistical computing r foundation median age <NUMBER> years old ambulatory group iqr <NUMBER> <NUMBER> <NUMBER> years old hospitalized group iqr <NUMBER> <NUMBER> <NUMBER> patients died <NUMBER> <NUMBER> patients ambulatory group <NUMBER> <NUMBER> patients hospitalized group <NUMBER> among ambulatory patients <NUMBER> emergency room encounters without hospital admission <NUMBER> officebased encounters <NUMBER> telemedicine encounters compared ambulatory patients higher proportion hospitalized patients older male history cigarette use hospitalized patients likely clinical characteristics <NUMBER> survivors <NUMBER> nonsurvivors hospitalized group shown table <NUMBER> supplementary table <NUMBER> ambulatory group median number days discharge survivors <NUMBER> days iqr <NUMBER> <NUMBER> days median number days death nonsurvivors also <NUMBER> days iqr <NUMBER> <NUMBER> days compared survivors nonsurvivors older higher proportion male nonsurvivors likely history cigarette use coexisting medical conditions including copd hypertension dm ckd temporal changes vital signs laboratory values survivors nonsurvivors hospitalization shown figure <NUMBER> throughout hospitalization nonsurvivors higher heart rate respiratory rate lower oxygen saturation compared survivors initial laboratory findings nonsurvivors demonstrated higher wbc count higher levels ddimer il<NUMBER> ast crp procalcitonin ferritin ldh fibrinogen troponin throughout hospitalization nonsurvivors higher wbc count neutrophil proportion ldh ferritin levels lower egfr lymphocyte proportion nonsurvivors also higher levels crp ddimer il<NUMBER> first week hospitalization nonsurvivors showed marked increase ldh crp ddimer ast alt procalcitonin day <NUMBER> admission groups trend decreasing hemoglobin levels increasing platelet counts hospitalization however pronounced decrease hemoglobin levels seen nonsurvivors increase platelet counts greater survivors generalized additive models demonstrated correlations laboratory values increased odds inhospital mortality similar difference observed hospitalized survivors nonsurvivors supplementary figure <NUMBER> majority hospitalized patients received hydroxychloroquine <NUMBER> survivors <NUMBER> nonsurvivors azithromycin <NUMBER> survivors <NUMBER> nonsurvivors fewer hospitalized patients received medications remdesivir anakinra tocilizumab sarilumab table <NUMBER> majority ambulatory patients receive hydroxychloroquine azithromycin kaplanmeier estimate showed lower mortality hospitalized patients received hydroxychloroquine log rank p value <NUMBER> supplementary figure <NUMBER> results multivariate cox proportional hazard regression models shown table <NUMBER> univariate models shown supplementary table <NUMBER> <NUMBER> hospitalized patients <NUMBER> patients remained hospitalized april <NUMBER> included analysis multivariate analysis factors associated higher risk inhospital mortality included age <NUMBER> systolic blood pressure less <NUMBER> mmhg respiratory rate greater <NUMBER> per min spo <NUMBER> less <NUMBER> egfr less <NUMBER> mlmin<NUMBER>m <NUMBER> il<NUMBER> greater <NUMBER> pg continued next page ml <NUMBER> times upper limit normal uln ddimer greater <NUMBER> mcgml <NUMBER> times uln troponin greater <NUMBER> ngml factors associated lower risk inhospital mortality included female sex african american race hydroxychloroquine use adjustment iptw lead significant change hr hydroxychloroquine without iptw hr <NUMBER> ci <NUMBER> iptw hr <NUMBER> ci <NUMBER> report large retrospective cohort study ambulatory hospitalized patients covid<NUMBER> across new york city metropolitan area clinical characteristics described represent first large retrospective cohort study us population city epicenter pandemic early reports showed covid<NUMBER> mortality rate among confirmed cases <NUMBER> <NUMBER> significantly lower compared <NUMBER> mers <NUMBER> <NUMBER> sars <NUMBER> mortality rate hospitalized patients reported previously ranged <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mortality rate <NUMBER> among hospitalized patients study may explained severe disease total cohort different reporting method geographic variation identified several risk factors associated mortality hospitalized patients covid<NUMBER> previously reported including older age male sex report additional risk factors associated inhospital mortality including low sbp tachypnea low spo <NUMBER> low egfr higher levels il<NUMBER> ddimer troponin levels severity coronavirus infection humans previously described increase viral clearance suggesting pathogenicity arising host immune response <NUMBER> study confirmed older patients covid<NUMBER> hospitalization significantly higher risk mortality observe independent association inhospital mortality common coexisting medical conditions including hypertension diabetes cancer however using calculated gfr surrogate ckd observed decreased renal function risk factor inhospital mortality finding consistent previous studies <NUMBER> il<NUMBER> proinflammatory cytokines production felt due immune dysregulation rather normal <NUMBER> <NUMBER> findings consistent theory observed elevated il<NUMBER> independent prognostic risk factor higher levels nonsurvivors hospitalized patients saw fluctuating il<NUMBER> levels significant increase seen day <NUMBER> admission increasing level trend pronounced nonsurvivors thrombocytosis associated disease activity sars thought secondary direct effect virus effect inflammatory cytokines <NUMBER> observed greater thrombocytosis hospitalization survivors nonsurvivors previous study il<NUMBER> primates revealed dosedependent response thrombocytosis induced il<NUMBER> <NUMBER> discrepancy high il<NUMBER> levels lack thrombocytosis nonsurvivors could explained endothelial damage subsequent platelet consumption viral infection impaired platelet release megakaryocytes lung direct impairment hematopoiesis <NUMBER> may suggest absence reactive thrombocytosis may portend poor response sarscov<NUMBER> infection elevated ddimer covid<NUMBER> patients described previously <NUMBER> <NUMBER> report study independent association increased risk inhospital mortality abnormal ddimer alone nonspecific however higher elevation nonsurvivors suggests coagulopathy particularly disseminated intravascular coagulation dic may contribute mortality covid<NUMBER> one functional receptors pathogenic human coronavirus sarscov angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> receptors expressed heart tissues <NUMBER> suggests sarscov<NUMBER> virus could directly affect heart similar previous finding showed association cardiac injury higher risk inhospital mortality <NUMBER> observed elevated troponin levels hospitalized patients risk factor increased mortality hydroxychloroquine analog chloroquine widely used antimalarial immunomodulatory effects <NUMBER> vitro studies shown hydroxychloroquine activity sarscov<NUMBER> <NUMBER> sarscov<NUMBER> hydroxychloroquine use <NUMBER> attempted adjust known confounders groups receive hydroxychloroquine using multivariate regression analyses iptw method revealed hydroxychloroquine use associated decreased risk inhospital mortality due inherent limitations retrospective study design conclusive determination efficacy hydroxychloroquine patients covid<NUMBER> robust studies randomized clinical trials needed study several limitations first longterm follow data ambulatory discharged patients hence clinical outcome observed may reflective true eventual outcome particularly ambulatory group second patients remained hospitalized time analyses outcomes discharge mortality excluded comparison survivors nonsurvivors third due limitations local testing policy study duration unknown number patients diagnosed covid<NUMBER> lack severe symptoms andor hospitalization fourth able adjust unknown confounders may affect true treatment effect limitations prevent definitive conclusions efficacy treatment retrospective study <NUMBER> ambulatory hospitalized patients covid<NUMBER> new york city metropolitan area age male sex tachypnea low systolic blood pressure low peripheral oxygen saturation impaired renal function elevated il<NUMBER> elevated ddimer elevated troponin found risk factors mortality hydroxychloroquine use associated decreased mortality severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> cause coronavirus <NUMBER> disease <NUMBER> emerged china late <NUMBER> zoonotic source <NUMBER> majority <NUMBER> covid<NUMBER> infections either asymptomatic result mild disease however <NUMBER> substantial proportion infected individuals develop respiratory illness requiring hospital <NUMBER> care <NUMBER> progress critical illness hypoxemic respiratory failure requiring <NUMBER> prolonged ventilatory support <NUMBER> amongst covid<NUMBER> patients admitted uk hospitals case <NUMBER> recorded occurrence new major cardiac arrhythmia addition routine health <NUMBER> care registry data obtained including information vital status date cause <NUMBER> death discharge hospital respiratory renal support therapy <NUMBER> outcomes assessed <NUMBER> days randomization analyses specified <NUMBER> <NUMBER> months primary outcome allcause mortality secondary outcomes time <NUMBER> discharge hospital among patients invasive mechanical ventilation <NUMBER> randomization invasive mechanical ventilation including extracorporal membrane <NUMBER> oxygenation death subsidiary clinical outcomes included causespecific mortality use <NUMBER> hemodialysis hemofiltration major cardiac arrhythmia recorded subset receipt <NUMBER> duration ventilation <NUMBER> primary outcome <NUMBER>day mortality logrank observed minus expected statistic <NUMBER> variance used test null hypothesis equal survival curves <NUMBER> calculate onestep estimate average mortality rate ratio comparing patients <NUMBER> allocated hydroxychloroquine patients allocated usual care patients <NUMBER> <NUMBER> followed <NUMBER> days time data cut <NUMBER> june <NUMBER> either <NUMBER> censored <NUMBER> june <NUMBER> already discharged alive rightcensored <NUMBER> mortality day <NUMBER> absence information contrary <NUMBER> assumed survived <NUMBER> days kaplanmeier survival curves constructed display <NUMBER> cumulative mortality <NUMBER>day period methods used analyze time <NUMBER> hospital discharge patients died hospital rightcensored day <NUMBER> median time <NUMBER> discharge derived kaplanmeier estimates prespecified composite <NUMBER> secondary outcome invasive mechanical ventilation death within <NUMBER> days among <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> receiving invasive mechanical ventilation randomization precise date starting invasive <NUMBER> mechanical ventilation available risk ratio estimated instead estimates <NUMBER> absolute risk differences patients allocated hydroxychloroquine patients <NUMBER> allocated usual care also calculated <NUMBER> prespecified analyses primary outcome performed five subgroups defined <NUMBER> characteristics randomization age sex level respiratory support days since symptom <NUMBER> onset predicted <NUMBER>day mortality risk see supplementary appendix one pre<NUMBER> specified subgroup analysis ethnicity conducted data collection completed <NUMBER> observed effects within subgroup categories compared using chisquare test trend <NUMBER> equivalent test heterogeneity subgroups two levels <NUMBER> estimates rate risk ratios hereon denoted rr shown <NUMBER> confidence <NUMBER> intervals pvalues <NUMBER>sided shown without adjustment multiple testing <NUMBER> analyses done according intentiontotreat principle full database held <NUMBER> study team collected data study sites performed analyses nuffield <NUMBER> department population health university oxford <NUMBER> stated protocol appropriate sample sizes could estimated trial <NUMBER> planned start covid<NUMBER> pandemic trial progressed trial steering <NUMBER> committee blinded results study treatment comparisons formed view <NUMBER> <NUMBER>day mortality <NUMBER> comparison least <NUMBER> patients allocated active drug <NUMBER> <NUMBER> usual care alone would yield least <NUMBER> power twosided p<NUMBER> detect <NUMBER> proportional reduction onefifth clinically relevant absolute difference <NUMBER> percentage <NUMBER> points two arms <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> independent data monitoring committee reviewed unblinded analyses study data <NUMBER> information considered relevant intervals around <NUMBER> weeks committee <NUMBER> charged determining view randomized comparisons study <NUMBER> provided evidence mortality strong enough range uncertainty around <NUMBER> results narrow enough affect national global treatment strategies <NUMBER> circumstance committee would inform trial steering committee would make <NUMBER> results available public amend trial arms accordingly unless happened <NUMBER> trial steering committee investigators others involved trial would remain blind <NUMBER> interim results <NUMBER> days last patient randomized particular <NUMBER> intervention arm <NUMBER> <NUMBER> june response request mhra independent data monitoring <NUMBER> committee conducted review data recommended chief investigators review <NUMBER> unblinded data hydroxychloroquine arm trial chief investigators trial <NUMBER> steering committee concluded data showed beneficial effect hydroxychloroquine <NUMBER> patients hospitalized covid<NUMBER> therefore enrolment participants <NUMBER> hydroxychloroquine arm closed <NUMBER> june preliminary result primary <NUMBER> outcome made public investigators advised patients currently taking <NUMBER> hydroxychloroquine part study discontinue treatment june <NUMBER> <NUMBER> <NUMBER> eligible randomized hydroxychloroquine <NUMBER> hydroxychloroquine available hospital time attending clinician <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> <NUMBER> opinion patient known indication contraindication <NUMBER> hydroxychloroquine figure <NUMBER> table s<NUMBER> <NUMBER> randomized <NUMBER> hydroxychloroquine <NUMBER> randomized usual care remainder <NUMBER> randomized one treatment arms mean age study participants <NUMBER> comparison <NUMBER> sd <NUMBER> years table <NUMBER> <NUMBER> patients female children <NUMBER> enrolled hydroxychloroquine comparison history diabetes present <NUMBER> <NUMBER> patients heart disease <NUMBER> chronic lung disease <NUMBER> <NUMBER> least <NUMBER> one major comorbidity recorded analysis <NUMBER> patients laboratory confirmed <NUMBER> sarscov<NUMBER> infection result currently awaited <NUMBER> randomization <NUMBER> <NUMBER> receiving invasive mechanical ventilation extracorporeal membrane oxygenation <NUMBER> <NUMBER> receiving oxygen without noninvasive ventilation <NUMBER> receiving neither <NUMBER> followup information complete <NUMBER> <NUMBER> randomized patients among <NUMBER> completed followup form <NUMBER> <NUMBER> patients allocated hydroxychloroquine received <NUMBER> least <NUMBER> dose table s<NUMBER> median number days treatment <NUMBER> days iqr <NUMBER> <NUMBER> <NUMBER> days <NUMBER> <NUMBER> usual care arm received hydroxychloroquine use azithromycin <NUMBER> macrolide drug followup period similar arms <NUMBER> vs <NUMBER> <NUMBER> use dexamethasone <NUMBER> vs <NUMBER> <NUMBER> significant difference proportion patients met primary outcome <NUMBER> <NUMBER>day mortality two randomized arms <NUMBER> figure <NUMBER> similar results seen across <NUMBER> five prespecified subgroups figure <NUMBER> post hoc exploratory analyses restricted <NUMBER> <NUMBER> <NUMBER> patients positive sarscov<NUMBER> test result result similar rate ratio <NUMBER> <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint allocation hydroxychloroquine associated longer time discharge alive <NUMBER> hospital usual care median <NUMBER> days vs <NUMBER> days lower probability discharge alive <NUMBER> within <NUMBER> days rate ratio <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> table <NUMBER> among invasive <NUMBER> mechanical ventilation baseline number patients progressing prespecified <NUMBER> composite secondary outcome invasive mechanical ventilation death higher among <NUMBER> allocated hydroxychloroquine risk ratio <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> information occurrence new major cardiac arrhythmia collected <NUMBER> <NUMBER> <NUMBER> patients hydroxychloroquine arm <NUMBER> <NUMBER> usual care arm since <NUMBER> fields added followup form <NUMBER> may <NUMBER> among patients <NUMBER> significant differences frequency supraventricular tachycardia <NUMBER> vs <NUMBER> <NUMBER> ventricular tachycardia fibrillation <NUMBER> vs <NUMBER> atrioventricular block requiring <NUMBER> intervention <NUMBER> vs <NUMBER> table s<NUMBER> analyses causespecific mortality receipt renal <NUMBER> dialysis hemofiltration duration ventilation presented relevant <NUMBER> information including certified cause death available one report serious <NUMBER> adverse reaction believed related hydroxychloroquine case torsades de pointes <NUMBER> patient recovered without need intervention <NUMBER> although preliminary results indicate hydroxychloroquine effective treatment <NUMBER> patients hospitalized covid<NUMBER> lower bound confidence limit primary <NUMBER> outcome rules reasonable possibility meaningful mortality benefit addition <NUMBER> allocation hydroxychloroquine associated increase duration <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint hospitalization increased risk requiring invasive mechanical ventilation dying <NUMBER> invasive mechanical ventilation baseline results consistent across <NUMBER> subgroups age sex time since illness onset level respiratory support baseline<NUMBER> recovery large pragmatic randomized controlled platform trial designed provide <NUMBER> rapid robust assessment impact readily available potential treatments covid<NUMBER> <NUMBER> <NUMBER>day mortality around <NUMBER> patients hospitalized covid<NUMBER> uk <NUMBER> study period enrolled trial fatality rate usual care arm consistent <NUMBER> hospitalized case fatality rate uk elsewhere <NUMBER> <NUMBER> <NUMBER> essential data <NUMBER> collected hospital sites additional information including longterm mortality ascertained <NUMBER> linkage routine data sources collect information physiological <NUMBER> electrocardiographic laboratory virologic parameters <NUMBER> hydroxychloroquine proposed treatment covid<NUMBER> based largely <NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> <NUMBER> primary concern shortterm high dose <NUMBER>aminoquinoline regimens cardiovascular <NUMBER> toxicity hydroxychloroquine causes predictable prolongation electrocardiograph qt <NUMBER> interval exacerbated coadministration azithromycin widely prescribed <NUMBER> covid<NUMBER> treatment <NUMBER> <NUMBER> <NUMBER> although torsade de pointes described serious <NUMBER> cardiovascular toxicity reported rarely despite high prevalence <NUMBER> cardiovascular disease hospitalized patients common occurrence myocarditis <NUMBER> covid<NUMBER> extensive use hydroxychloroquine azithromycin together <NUMBER> exception brazilian study stopped early cardiotoxicity however <NUMBER> study chloroquine <NUMBER> mg base given twice daily ten days substantially higher <NUMBER> total dose used trials including recovery <NUMBER> <NUMBER> pharmacokinetic modelling <NUMBER> combination blood concentration mortality data case series <NUMBER> chloroquine <NUMBER> overdose patients predicts base equivalent chloroquine regimen recovery <NUMBER> hydroxychloroquine regimen safe <NUMBER> hydroxychloroquine considered safer <NUMBER> chloroquine <NUMBER> observe excess mortality first <NUMBER> days treatment <NUMBER> hydroxychloroquine time early effects dosedependent toxicity might expected <NUMBER> furthermore preliminary data presented show excess ventricular <NUMBER> tachycardia including torsade de pointes ventricular fibrillation hydroxychloroquine <NUMBER> findings indicate hydroxychloroquine effective treatment hospitalized <NUMBER> patients covid<NUMBER> address use prophylaxis patients less severe <NUMBER> sarscov<NUMBER> infection managed community treatment covid<NUMBER> chloroquine <NUMBER> hydroxychloroquine recommended many treatment guidelines including brazil <NUMBER> china france italy netherlands south korea united states <NUMBER> retrospective <NUMBER> cohort study united states <NUMBER> <NUMBER> covid<NUMBER> patients received <NUMBER> hydroxychloroquine <NUMBER> since preliminary results first made public <NUMBER> june <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint us food drugs administration revoked emergency use authorization <NUMBER> allowed hydroxychloroquine chloroquine used hospitalized patients covid<NUMBER> ceased trials use setting grounds lack benefit recently <NUMBER> released preliminary results solidarity trial effectiveness <NUMBER> hydroxychloroquine hospitalized covid<NUMBER> patients consistent results <NUMBER> recovery trial <NUMBER> <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> views expressed publication authors necessarily <NUMBER> nhs national institute health research department health social <NUMBER> care dhcs <NUMBER> authors conflict interest financial relationships relevant submitted work <NUMBER> disclose form payment given anyone produce manuscript authors <NUMBER> completed submitted icmje form disclosure potential conflicts interest <NUMBER> nuffield department population health university oxford staff policy <NUMBER> accepting honoraria consultancy fees directly indirectly industry see <NUMBER> httpswwwndphoxacukfilesaboutndphindependenceofresearchpolicyjun<NUMBER>pdf <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> <NUMBER> <NUMBER> httpswwwwhointnewsroomdetail<NUMBER>whodiscontinueshydroxychloroquine<NUMBER> andlopinavirritonavirtreatmentarmsforcovid<NUMBER> <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> <NUMBER> results count mean ± standard deviation median interquartile range children <NUMBER> aged <NUMBER> years enrolled †includes <NUMBER> pregnant women † † sarscov<NUMBER> test results <NUMBER> captured followup form currently unknown tests difference <NUMBER> baseline characteristics treatment arms give p<NUMBER> oxygen group includes <NUMBER> noninvasive ventilation severe liver disease defined requiring ongoing specialist care <NUMBER> severe kidney impairment defined estimated glomerular filtration rate <NUMBER> mlmin<NUMBER>m <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients allocated hydroxychloroquine <NUMBER> <NUMBER> patients allocated usual care <NUMBER> alone missing data days since symptom onset <NUMBER> <NUMBER> table <NUMBER> effect allocation hydroxychloroquine main study outcomes <NUMBER> rrrate ratio outcomes <NUMBER>day mortality hospital discharge risk ratio <NUMBER> outcome receipt invasive mechanical ventilation death ciconfidence interval <NUMBER> analyses exclude invasive mechanical ventilation randomization pre<NUMBER> specified composite secondary endpoint receipt invasive mechanical ventilation death <NUMBER> absolute risk difference <NUMBER> percentage points <NUMBER> ci <NUMBER> <NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> randomized convalescent plasma vs control <NUMBER> <NUMBER> patient allocated hydroxychloroquine <NUMBER> arm vs <NUMBER> <NUMBER> patients allocated usual care accordance protocol version <NUMBER> <NUMBER> among <NUMBER> sites randomized least <NUMBER> patient hydroxychloroquine comparison <NUMBER> median number randomized <NUMBER> patients interquartile range <NUMBER> <NUMBER> includes patients receiving noninvasive ventilation method used calculating baseline<NUMBER> predicted risk described supplementary appendix one prespecified subgroup <NUMBER> analysis ethnicity conducted data collection completed <NUMBER> <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted july <NUMBER> <NUMBER> total recruited n<NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted july <NUMBER> <NUMBER> figure <NUMBER> effect allocation hydroxychloroquine <NUMBER>−day mortality ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted july <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted july <NUMBER> <NUMBER> httpsdoiorg<NUMBER> <NUMBER> interventions patients randomized <NUMBER> receive oncedaily oral hydroxychloroquine <NUMBER>mg two months hc group placebo p group addition protective measures appropriate level exposure established hospital serological evaluation carried every <NUMBER> days pcr case seroconversion symptoms risk exposure primary outcome percentage subjects presenting infection seroconversion andor pcr sarscov<NUMBER> virus observation period additionally percentage subjects group presenting pneumonia severity criteria curb <NUMBER> ≥<NUMBER> subjects requiring admission icu determined discussion awaiting vaccine hygiene measures social distancing personal protective equipment primary prophylaxis measures sarscov<NUMBER> sufficient protect healthcare professionals evidence vitro efficacy hydroxychloroquine virus known along clinical data would support study drug chemoprophylaxis infection however still data controlled clinical trials regard hypothesis confirmed hydroxychloroquine help professionals fight infection guarantees participants singlecenter study carried marqués de valdecilla university hospital <NUMBER> health professionals working hospital universitario marqués de valdecilla areas high exposure high risk transmission sars cov<NUMBER> covid hospital areas intensive care unit emergency anesthesia performing aerosolgenerating procedures included inclusion criteria <NUMBER> health professionals aged <NUMBER> <NUMBER> years inclusive time first screening visit <NUMBER> must provide signed written informed consent agree comply study protocol <NUMBER> active work high exposure areas last two weeks following weeks exclusion criteria <NUMBER> previous infection sars cov<NUMBER> positive coronavirus pcr positive serology sars cov<NUMBER> negative pcr absence symptoms <NUMBER> current treatment hydroxychloroquine chloroquine <NUMBER> hypersensitivity allergy contraindication taking hydroxychloroquine technical sheet <NUMBER> previous current treatment tamoxifen raloxifene <NUMBER> previous eye disease especially maculopathy <NUMBER> known heart failure grade iii iv new york heart association classification prolonged qtc <NUMBER> type cancer except basal cell last <NUMBER> years <NUMBER> refusal give informed consent <NUMBER> evidence unstable clinically significant untreated immune endocrine hematological gastrointestinal neurological neoplastic psychiatric illness <NUMBER> antibodies positive human immunodeficiency virus <NUMBER> significant kidney liver disease <NUMBER> pregnancy lactation intervention comparator two groups analyzed <NUMBER> <NUMBER> randomization rate <NUMBER> intervention n <NUMBER> one <NUMBER> mg hydroxychloroquine sulfate coated tablet daily two months <NUMBER> comparator control group n <NUMBER> one hydroxychloroquine placebo tablet identical drug daily two months main outcomes primary outcome study evaluate number percentage healthcare personnel presenting symptomatic asymptomatic infection see diagnosis sars cov<NUMBER> infection sarscov<NUMBER> virus study observation period <NUMBER> weeks treatment arms number percentage healthcare personnel group presenting pneumonia severity criteria curb <NUMBER> ≥<NUMBER> number percentage healthcare personnel requiring admission intensive care unit icu treatment arms diagnosis sars cov<NUMBER> infection determination iga igm igg type antibodies sarscov<NUMBER> using antisarscov<NUMBER> elisa kit euroimmun medizinische labordiagnostika ag germany every two weeks cases seroconversion sarscov<NUMBER> pcr performed rule confirm active infection rtpcr one step rt performed mastermix takara idt probes following protocol published validated cdc evaluation covid<NUMBER> case sarscov<NUMBER> infection continued next page coronavirus disease <NUMBER> covid<NUMBER> generally mild sometimes severe potentially even lifethreatening infection caused severe acute respiratory syndrome coronavirus type <NUMBER> sarscov<NUMBER> previously known <NUMBER> novel coronavirus <NUMBER>ncov since late december <NUMBER> sarscov<NUMBER> quickly spread first epicenter city wuhan hubei province peoples republic china <NUMBER> shortly become pandemic <NUMBER> epidemiological data mainly available countries j u r n l p r e p r f hardly hit covid<NUMBER> peoples republic china <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> italy <NUMBER> usa <NUMBER> <NUMBER> <NUMBER> limited information available countries like israel hand surveys mainly deal clinical characteristics covid<NUMBER> patients terms related risk factors underlying comorbidities whereas unsatisfactory information provided regarding therapeutic interventions adopted furthermore studies mostly clinical reports caseseries designed specific cohort studies targeting specific populations conducted level entire communities example exploiting computerized clinical records similar realworld data <NUMBER> notable exception represented report published chinese center disease control prevention analyzed characteristics <NUMBER> covid<NUMBER> patients even though <NUMBER> entire sample consisted confirmed cases <NUMBER> thus currently available data enable address crucial research questions especially terms therapeutics <NUMBER> <NUMBER> currently effective vaccines specific drugs exist used prevent counteractmitigate burden covid<NUMBER> far countries adopted behavioral nonpharmacological intervention npibased strategies enforcing social distancing selfisolation quarantine even lockdown entire territories communities since npis resourceconsuming unfeasible unsustainable long periods western countries given discovery new vaccine candidates new chemicalmolecular entities ncesnmes design implementation randomized controlled trials rcts timeconsuming procedures scholars attempting repurpose already existing compounds hydroxychloroquine antimalarial drug utilized also treatment rheumatoid colchicine utilized treatment management patients gout behçets disease prevention pericarditis familial mediterranean fever fmf preferred possible therapeutic options nonsteroidal antiinflammatory drugs nsaids steroids <NUMBER> contrasting findings reported existing scholarly literature concerning potential antiviral effects compounds study investigated whether chronic baseline use antiinflammatory medications namely hydroxychloroquine colchicine could provide potentially beneficial effect preventing least partially mitigating burden sarscov<NUMBER> infection therefore purpose utilized large israeli healthcare database israel first covid<NUMBER> case confirmed february <NUMBER> st <NUMBER> since epidemic rise using mhs database identified covid<NUMBER> confirmed cases hypertension <NUMBER> versus <NUMBER> p<NUMBER> found statistically significant higher among covid<NUMBER> positive patients ischemic heart disease ihd instead reported similar percentages cases controls <NUMBER> versus <NUMBER> respectively p<NUMBER> note cases controls <NUMBER> versus <NUMBER> pvalue <NUMBER> lived households low ses concerning baseline treatment hydroxychloroquine colchicine prescribed subjects sarscov<NUMBER> infection compared without rate <NUMBER> versus <NUMBER> p<NUMBER> <NUMBER> versus <NUMBER> p<NUMBER> populations respectively table <NUMBER> present study utilized realworld data explore associations subjects positive sarscov<NUMBER> different underlying comorbidities medications administered antiviral treatment purposes demonstrated underlying comorbidities dm hypertension ckd ihd high bmi male gender associated higher susceptibility contracting sarscov<NUMBER> infection results line recently published comprehensive metaanalysis pooling together <NUMBER> studies <NUMBER> mainland china one australia overall sample consisted confirmed patients according procedure rtpcr testing <NUMBER> half <NUMBER> patients males major underlying comorbidities hypertension <NUMBER> cardiovascular disease <NUMBER> dm <NUMBER> populationbased study evaluating clinical characteristics <NUMBER> patients hospitalized covid<NUMBER> usa <NUMBER> majority patients males <NUMBER> similar pattern underlying comorbidities commonly hypertension <NUMBER> followed obesity <NUMBER> dm <NUMBER> cardiovascular disease <NUMBER> <NUMBER> patients older <NUMBER> years j u r n l p r e p r f another crosssectional study pattern comorbiditieshypertension <NUMBER> p<NUMBER> cardiovascular disease <NUMBER> p<NUMBER> dm <NUMBER> p<NUMBER>and male gender predominance <NUMBER> p<NUMBER> observed population average age <NUMBER> years <NUMBER> thus noticeable underlying comorbidities gender similar among different populations mean age discrepancy exists cohort average age <NUMBER> years mentioned studies discrepancy might due relative high percentage young population israel median age <NUMBER> <NUMBER> years ten years younger populations usa mainland china <NUMBER> even noticeable particular settings covid<NUMBER> endemic cities population especially ultraorthodox jewish populations high number children per family even younger respect country furthermore subjects positive covid<NUMBER> infection lower ses status compared controls <NUMBER> versus <NUMBER> subjects negative sarscov<NUMBER> higher ses compared positive subject <NUMBER> versus <NUMBER> surprising given wellknown association low ses increased risk infections <NUMBER> usa minorities like african americans hispanics higher rates mortality compared caucasian population largely due ses disparities <NUMBER> <NUMBER> concerning alleged antiviral activities hydroxychloroquine <NUMBER> potential protective role infections <NUMBER> existing scholarly literature reports contrasting findings even though date rct shown unequivocal advantage preventing improving major outcomes covid<NUMBER> patients <NUMBER> <NUMBER> regarding antiinflammatory properties colchicine results experimental models found nlrp<NUMBER> inflammasome activated triggered different sarscov<NUMBER> proteins subsequently take part development severe adult respiratory distress syndrome ards complication covid<NUMBER> infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> major inhibitor nlrp<NUMBER> inflammasome <NUMBER> colchicine could utilized treatment covid<NUMBER> currently three clinical trials ongoing <NUMBER> <NUMBER> <NUMBER> however investigation failed detect j u r n l p r e p r f journal preproof potential benefit hydroxychloroquine colchicine even though drugs administered antiviral treatment purposes able identify main reason administration hand assume patients receiving drugs suffer inflammatory diseases ra sle case hydroxychloroquine <NUMBER> fmf gout case colchicine <NUMBER> <NUMBER> despite use large healthcare database study several limitations properly acknowledged first relatively small number patients documented priori treated secondly basic methodology study based computerized database might incomplete instance duration reason treatment previously mentioned lacking however study considered preliminary pilot investigation providing first glance characteristics patients sarscov<NUMBER> infection israel showing <NUMBER> median age infected individuals younger counterparts around world warrants research <NUMBER> hydroxychloroquine colchicine apparently provided protection sarscov<NUMBER> infection severe acute respiratory syndromecoronavirus <NUMBER> sarscov<NUMBER> novel coronavirus responsible causing coronavirus disease <NUMBER> covid<NUMBER> quickly became pandemic beginning <NUMBER> originating wuhan china virus rapidly spread countries world <NUMBER> january <NUMBER> <NUMBER> world health organization declared sarscov<NUMBER> public health emergency international concern pheic <NUMBER> medications quickly tested assess suitable treatment regimen novel virus following systematic statistical review assesses current evidence regarding human controlled covid<NUMBER> treatment trials electronic search compiled human controlled studies analyzing treatments covid<NUMBER> medical therapies investigated included lopinavirritonavir arbidol hydroxychloroquine remdesivir favipiravir heparin glucocorticoids interferon ivermectin convalescent plasma inclusion criteria included needing control whether standard therapy placebo another medication testing among human subjects covid<NUMBER> vitro animal studies plus without controls included review databases included google scholar pubmed key words included covid<NUMBER> sarscov<NUMBER> randomized controlled human retrospective prospective trial chloroquine hydroxychloroquine lopinavir ritonavir arbidol umifenovir tocilizumab favipiravir steroids dexamethasone glucocorticoids interferon ivermectin remdesivir azithromycin heparin lowmolecular weight heparin abstracts titles reviewed relevancy studies human subjects control arm included study otherwise excluded duplicated studies removed studies organized based study medication studies presented one study medication included one group statistical analysis performed two studies showing information regarding positivetonegative conversion rates number days varied based reported similarities among chosen studies common endpoints among trials collected metaanalysis would performed endpoints related viral clearance statistical analyses used review manager version <NUMBER> cochrane collaboration copenhagen denmark software program forest plot created using program dersimonian laird fixedeffects model reduce heterogeneity mean difference confidence interval ci <NUMBER> reported inverse variance method due using scale value marking significance via confidence interval zero i<NUMBER> greater <NUMBER> suggests significant heterogeneity significant heterogeneity randomeffects model would used instead total <NUMBER> articles found keywords selected total <NUMBER> studies included initially based title abstract review total <NUMBER> studies included systematic review four studies elaborated lopinavirritonavir four studies studied arbidol six hydroxychloroquine one remdesivir six tocilizumab two favipiravir two heparin one dexamethasone statistical analyses regarding positivetonegative conversion rates possible lopinavirritonavir arbidol hydroxychloroquine human controlled trials found glucocorticoids interferons ivermectin convalescent plasma statistical analysis regarding positivetonegative conversion rates possible lopinavirritonavir two studies arbidol two studies hydroxychloroquine four studies fig <NUMBER> four controlled trials exist regarding treatment covid<NUMBER> table <NUMBER> two studies randomized controlled trials two retrospective controlled studies <NUMBER>–<NUMBER> recognized randomized controlled openlabel trial cao et al <NUMBER> study showed significant difference terms <NUMBER>day mortality time positivetonegative reverse transcriptasepolymerase chain reaction rtpcr conversion lopinavirritonavir reduce time clinical improvement <NUMBER> day considered marginally nonstatistically significant study many limitations study organized open label lack placebo <NUMBER> trial recipients could complete full <NUMBER>day treatment course due adverse medication effects including nausea vomiting diarrhea however incidence respiratory failure acute kidney injury secondary infection higher standardcare group positivetonegative rtpcr conversion significant lopinavirritonavir fig <NUMBER> <NUMBER> <NUMBER> significant difference study control group <NUMBER> days <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> retrospective studies suggest earlier clearance lopinavirritonavir report results <NUMBER> days <NUMBER> <NUMBER> furthermore two studies suggest clearance retrospective studies two randomized controlled trials significant lopinavirritonavir side effects include loss appetite nausea vomiting diarrhea <NUMBER> <NUMBER> diarrhea possibly become severe <NUMBER> apart elevated transaminase levels laboratory markers significantly differ control group <NUMBER> <NUMBER> currently four controlled trials discussing use arbidol treatment covid<NUMBER> patients table <NUMBER> <NUMBER> <NUMBER>–<NUMBER> two trials randomized two retrospective studies li et al includes comparison arbidol standard supportive therapy <NUMBER> two retrospective studies include comparison lopinavirritonavir <NUMBER> <NUMBER> chen et al compare arbidol favipiravir <NUMBER> arbidol commonly compared lopinavirritonavir <NUMBER> <NUMBER> difference positivetonegative conversion rates two medications seventh <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> <NUMBER>th day <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> figs <NUMBER> <NUMBER> note <NUMBER>day comparison fixed effect model would show arbidol viral clearance compared lopinavirritonavir <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> however significant heterogeneity two studies i<NUMBER> <NUMBER> random effects model therefore employed counter heterogeneity resulting nonsignificant difference two medications adding arbidol lopinavirritonavir show significant conversion rates ct scan improvements compared lopinavirritonavir <NUMBER> favipiravir show difference compared arbidol regarding <NUMBER>day recovery rate show faster recovery fever cough difference regarding oxygen noninvasive positive pressure ventilation use arbidol favipiravir <NUMBER> arbidol side effects include nausea diarrhea <NUMBER> arbidol demonstrated less hyperuricemia compared favipiravir p <NUMBER> favipiravir arbidol show significant difference abnormal liver function tests psychiatric symptom reaction digestive tract reactions <NUMBER> six controlled trials exist comparing hydroxychloroquine versus standard therapy table <NUMBER> <NUMBER>–<NUMBER> three studies randomized one prospective two retrospective studies data regarding hydroxychloroquine remains equivocal three randomized controlled trials present conflicting information regarding significance clinical improvement positivetonegative conversion <NUMBER> <NUMBER> <NUMBER> chen z et al observed conversion based ct scan results ct scans high negative predictive value covid<NUMBER> pandemic <NUMBER>–<NUMBER> prospective trial gautret et al showed earlier conversion hydroxychloroquine <NUMBER> included patients took azithromycin hydroxychloroquine study included analysis yet present clinical status changes study retrospective controlled study among veterans showed increased mortality hydroxychloroquine use mechanical ventilation rates similar among two study arms <NUMBER> another retrospective review showed difference inhospital mortality <NUMBER> positivetonegative conversion analysis fig <NUMBER> performed <NUMBER>–<NUMBER> days include studies rtpcr ct scans used monitor time covid<NUMBER> resolution hydroxychloroquine show significant effects positivetonegative conversion time compared standard therapy <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> significant heterogeneity i<NUMBER> <NUMBER> randomeffects model used analyzing three randomized controlled trials showed significant difference hydroxychloroquine standard therapy <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> fig <NUMBER> <NUMBER> <NUMBER> <NUMBER> nonsignificant heterogeneity i<NUMBER> <NUMBER> therefore fixedeffects model kept cardiac complications including cardiac arrest common hydroxychloroquine use especially combined azithromycin <NUMBER> gastrointestinal symptoms including diarrhea elevated transaminase levels mentioned hydroxychloroquine statistically significant compared control groups <NUMBER> <NUMBER> <NUMBER> currently one published controlled trial remdesivir table <NUMBER> <NUMBER> randomized doubleblind placebocontrolled trial showed difference time clinical improvement compared control arm hazard ratio <NUMBER> <NUMBER> ci <NUMBER>–<NUMBER> <NUMBER> limitation study however patients groups permitted concomitant use lopinavirritonavir interferons andor corticosteroids <NUMBER> received remdesivir reported adverse side effect common side effects constipation hypoalbuminemia hypokalemia anemia thrombocytopenia increased bilirubin <NUMBER> six studies assessed benefits tocilizumab table <NUMBER> tocilizumab presents mixed results half studies report significant benefit compared standard therapy <NUMBER>–<NUMBER> half report improvement severe cases improved hospital stay survival freedom ventilation <NUMBER>–<NUMBER> studies assessed duration positivetonegative sarscov<NUMBER> conversion following studies report associated side effects tocilizumab compared standard therapy two controlled trials regarding use favipiravir table <NUMBER> <NUMBER> <NUMBER> first randomized controlled trial comparing favipiravir arbidol covid<NUMBER> patients <NUMBER> arbidol effects similar standard therapy <NUMBER> openlabel nonrandomized prospective trial comparing favipiravir versus lopinavirritonavir <NUMBER> lopinavirritonavir also similar standard therapy <NUMBER> <NUMBER> table <NUMBER> chen et al showed significant <NUMBER>day recovery rate favipiravir compared arbidol secondary endpoints fever cough relief resolve significantly sooner favipiravir compared arbidol fever resolving patients day <NUMBER> versus days <NUMBER>–<NUMBER> cough improving day <NUMBER> versus day <NUMBER> difference regarding oxygen noninvasive positive pressure ventilation use <NUMBER> cai et al showed faster ct scan improvement viral clearance favipiravir compared lopinavirritonavir day <NUMBER> <NUMBER> <NUMBER> favipiravir subjects improved chest ct scans compared <NUMBER> <NUMBER> lopinavirritonavir patients p <NUMBER> viral clearance sooner <NUMBER> days favipiravir compared <NUMBER> days lopinavirritonavir p <NUMBER> <NUMBER> favipiravir shows similar sideeffect profile lopinavirritonavir including nausea vomiting diarrhea rash elevated transaminase levels <NUMBER> <NUMBER> compared arbidol increases uric acid levels side effect profile similar lopinavirritonavir frequency adverse effects less favipiravir <NUMBER> two retrospective controlled studies included data regarding heparin use table <NUMBER> <NUMBER> <NUMBER> studies involved deep vein thrombosis prophylaxis dosing unfractionated <NUMBER> iuday lowmolecular weight <NUMBER>–<NUMBER> mgday heparin table <NUMBER> tang et al showed difference <NUMBER>day mortality rates patients received lowmolecular weight heparin note significant improvement heparin users among severe sepsisinduced intravascular coagulopathy determined scoring system utilizing platelet count prothrombin time sequential organ failure assessment sofa scoring <NUMBER> shi et al showed difference outcomes including clinical improvement positivetonegative conversion rate patients study improved <NUMBER> studies included review report adverse effects however heparin medications welldocumented sideeffects including hemorrhage osteoporosis renal tubular acidosis type <NUMBER> hyperkalemia heparininduced thrombocytopenia <NUMBER>–<NUMBER> adverse effects lowmolecular weight heparin common patients kidney injury <NUMBER> deep vein thrombosis prophylaxis presents lower rate sideeffects <NUMBER> one large randomized controlled trial recovery trial found overall benefit assessing covid<NUMBER> cases together table <NUMBER> <NUMBER> benefit without oxygen needs dexamethasone reduced mortality onefifth patients requiring noninvasive oxygen therapy onethird requiring mechanical ventilation dexamethasone also reduced hospital length stay progression needing invasive mechanical ventilation recovery trial report adverse reactions compared standard therapy glucocorticoids multiple sideeffects adverse reactions acute use include altered mental status hyperglycemia increased risk infection hypertension arrhythmias myopathy <NUMBER> <NUMBER> metaanalysis portion study limitations first limitation small number patients trials therefore overall analysis another limitation use surrogate endpoints complete metaanalysis regarding use ct scan resolution viral clearance hydroxychloroquine analysis chest ct scans significant negative predictive value directly comparable rtpcr <NUMBER>–<NUMBER> endpoints wellestablished among reviewed medications making difficult compare studies regarding systematic review publication bias influences information presented favipiravir trials covid<NUMBER> involve compared medications placebo supportive therapy control arm heparin dexamethasone studies mainly involved level severity covid<NUMBER> rather infection current investigated medications hasten viral clearance time clinical improvement equivocal lopinavirritonavir arbidol hydroxychloroquine remdesivir favipiravir shows faster viral clearance clinical improvement compared lopinavirritonavir arbidol heparin shows benefit patients severe covid<NUMBER> infections coronavirus disease <NUMBER> sarscov<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> horrific pandemic outbreak covid<NUMBER> coronavirus disease <NUMBER> around world caught health care systems every country storm caught guard without proper defense mechanisms cope control pandemic covid<NUMBER> caused new novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> recently identified characterized <NUMBER>•• coronaviruses named crownlike spikes surface four main subgroupings coronaviruses known alpha beta gamma delta <NUMBER> <NUMBER> sarscov<NUMBER> belongs beta subgrouping one seventh coronavirus date infecting humans <NUMBER>•• coronaviruses <NUMBER>e alpha coronavirus <NUMBER> oc<NUMBER> beta coronavirus <NUMBER> nl<NUMBER> alpha coronavirus <NUMBER> hku<NUMBER> beta coronavirus <NUMBER> associated mild clinical symptoms whereas sarscov beta coronavirus <NUMBER> middle east respiratory syndrome coronavirus merscov beta coronavirus <NUMBER> sarscov<NUMBER> caused severe diseases <NUMBER> sarscov<NUMBER> positivesense singlestranded rna virus <NUMBER> bases <NUMBER> identical wholegenome level bat coronavirus shares <NUMBER> sequence identity sarscov <NUMBER>•• sarscov<NUMBER> encodes spike protein containing receptor binding domain rbd binds human angiotensinconverting enzyme <NUMBER> ace<NUMBER> promotes membrane fusion uptakes virus human cells lung endocytosis <NUMBER> <NUMBER> <NUMBER> <NUMBER> upon entering human cells sarscov<NUMBER> like coronaviruses takeover hijack human cells protein synthesis machinery synthesize viral proteins assemble proteins subsequent viral replication <NUMBER>• inside human body viruses general trigger series good versus bad host responses including autophagy apoptosis stress response innate immunity <NUMBER> fortunately majority <NUMBER> sarscov<NUMBER>infected individuals asymptomatic mild symptoms likely due activation good response good responders would likely activate bodys innate immune system activating bodys antiviral defense mechanisms including natural killer cells antiviral cells induction interferon ifn <NUMBER> <NUMBER> <NUMBER> <NUMBER> unfortunately <NUMBER> sarscov<NUMBER>infected individuals including immune compromised elderly patients underlying health conditions cardiovascular pulmonary problems diabetics hypertension obesity chronic obstructive pulmonary disease copd emphysema pulmonary fibrosis asthma interstitial lung disease <NUMBER> <NUMBER> would encounter severe disease characterized significant respiratory symptoms leading acute respiratory distress syndrome ards even death important consideration note ards occurs later disease progression preceded acute lung injury ali <NUMBER> distinction may inform treatment strategy terms drugs directed towards cytokine storm thrombosis described manuscript study sarscov merscov found two coronaviruses appear evolved mechanisms attenuate delay ifn production resulting enhanced inflammatory host responses severe lung injury <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> aberrant host immune response production powerful inflammatory cytokines known cytokine storm found sarscovand merscovinfected patients would correlate disease severity poor prognosis <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> severe covid<NUMBER> patients exhibit profound inflammatory response <NUMBER> <NUMBER> transcriptomic rnaseq analysis covid<NUMBER> patients revealed several immune pathways proinflammatory cytokines cxcl ccl<NUMBER> cxcl<NUMBER> ccl<NUMBER> il<NUMBER> ccl<NUMBER>l<NUMBER> bronchoalveolar lavage fluid balf tnfsf<NUMBER> cxcl<NUMBER> il<NUMBER> timp<NUMBER> c<NUMBER> il<NUMBER> areg nrg<NUMBER> peripheral blood mononuclear cells pbmc induced sarscov<NUMBER> infection suggesting sustained inflammation cytokine storm <NUMBER> importantly sarscov<NUMBER> infectioninduced excessive cytokine release correlates lung tissue injury covid<NUMBER> pathogenesis <NUMBER> estimated <NUMBER> patients developing severe disease sarscov<NUMBER> infection likely due genetics epigenetics factors dampened innate immune response fight virus coupled enhanced viral load leading cytokine storm severe inflammatoryoxidative stress response severe lung injury secondary ards clear understanding respiratory system dramatically impacted covid<NUMBER> patients evidence suggests organ systems also affected emerging data show sarscov<NUMBER> may lead damage organs including heart brain nearly <NUMBER> hospitalized patients covid<NUMBER> indication cardiac damage <NUMBER> furthermore neurologic symptoms reported patients infection sarscov<NUMBER> found brainstem humans experimental animals <NUMBER> <NUMBER> currently vaccine andor specific therapeutic drugs targeting sarscov<NUMBER> hence remains major challenge decide potential therapeutic regimens prevent treat severely sick covid<NUMBER> patients effective vaccines essential combat extremely contagious sarscov<NUMBER> present lot research efforts invested develop vaccines around world specific vaccines therapeutic drugs targeting sarscov<NUMBER> repurposed drugs approved fda usa indications used treat covid<NUMBER> patients review summarize current pharmacotherapeutics prescribed treatment severe cases covid<NUMBER> patients include antiviral therapy antibiotics systemic corticosteroids antiinflammatory drugs including antiarthritis drugs neuraminidase inhibitors rna synthesis inhibitors convalescent plasma traditional herbal medicines absence definitive specific treatment regimens strategies including early diagnosis timely reporting isolation supportive treatments important line actions covid<NUMBER> infections current social practices including timely release epidemic information maintenance social orders personal practices improving personal hygiene wearing facial coverings masks adequate rest keeping rooms well ventilated remain first line actions covid<NUMBER> pandemic present treatments patients sarscov<NUMBER> infection mainly repurposing available therapeutic drugs based symptomatic conditions considering ards followed secondary infections antibiotics antiviral therapy systemic corticosteroids antiinflammatory drugs including antiarthritis drugs often used treatment regimens addition antiviral interferers antibiotics neuraminidase inhibitors rna synthesis inhibitors convalescent plasma traditional herbal medicines also utilized treatment covid<NUMBER> <NUMBER> nevertheless efficacy treatment regimens remains verified appropriately designed clinical trials remdesivir potential drug treatment covid<NUMBER> phosphoramidate prodrug adenosine cnucleoside broadspectrum antiviral agent synthesized developed gilead sciences <NUMBER> treatment ebola virus infection <NUMBER> remdesivir metabolized active form gs<NUMBER> obscures viral rna polymerase evades proofreading viral exonuclease causing decrease viral rna production antiviral mechanism remdesivir delayed chain cessation nascent viral rna animal experiments indicate remdesivir effectively reduce viral load lung tissue mice infected merscov improve lung function alleviate pathological damage lung tissue <NUMBER> wang <NUMBER> order evaluate efficacy safety drug patients covid<NUMBER> randomized placebocontrolled doubleblind multicenter phase iii clinical trial launched february <NUMBER> <NUMBER> china patients experimental group received initial dose <NUMBER> mg remdesivir subsequent dose <NUMBER> mg <NUMBER> consecutive days via intravenous infusion addition routine treatment patients control group received dose placebo treatment trial expected conclude end april <NUMBER> number cases planned enrolled <NUMBER> <NUMBER> respectively <NUMBER> <NUMBER> current recommendation remdesivir includes <NUMBER>day regimen remdesivir treatment <NUMBER> mg loading dose day <NUMBER> followed <NUMBER> mg oncedaily maintenance doses <NUMBER> days studies regimen remdesivir therapy similar former randomized clinical trial ebola virus <NUMBER> <NUMBER> summary subjects receiving remdesivir via compassionate use usa nearly <NUMBER> patients improvement terms oxygen requirements many patients mechanically ventilated extubated report include control group therefore extrapolating results difficult early conclude direct antiviral effect remdesivir enhanced clearing viral loads respiratory tract indeed suggests promising therapeutic effect remdesivir <NUMBER> chloroquine hydroxychloroquine drugs long history clinical use similar chemical structures often used treatment lupus erythematosus rheumatoid arthritis malaria <NUMBER> compared chloroquine hydroxychloroquine hydroxyl group makes less toxic maintaining similar activity one mechanism action chloroquine hydroxychloroquine targeting lysosome may useful control graftversushost disease humans <NUMBER> accumulation chloroquine lysosomes ph lysosomes significantly changed activity proteases lysosomes directly affected thus affecting degradation proteins glycosaminoglycan <NUMBER> <NUMBER> chloroquine inhibit entry sarscov<NUMBER> prevent viruscell fusion interfering glycosylation ace<NUMBER> receptor binding spike protein suggesting chloroquine treatment might effective early stage infection covid<NUMBER> reduces ace<NUMBER> expression activity <NUMBER> <NUMBER> <NUMBER> hydroxychloroquine possesses antiinflammatory effect th<NUMBER>related cytokines il<NUMBER> il<NUMBER> il<NUMBER> healthy individuals systemic lupus erythematosus sle rheumatoid arthritis ra patients <NUMBER> evidence chloroquine hydroxychloroquine reduce cytokine storm according one analysis main cause death covid<NUMBER> patients related triggering cytokine storm contributed acute respiratory distress <NUMBER> reported hydroxychloroquine effective inhibiting sarscov<NUMBER> infection vitro <NUMBER> <NUMBER> <NUMBER> zinc inhibits sarscovand retrovirus rna polymerase activity vitro zinc ionophores block replication viruses cell culture <NUMBER> also evidence zinc enhances chloroquine intracellular uptake <NUMBER> combining zinc chloroquine hydroxychloroquine intriguing currently investigation overall clinical trials underway evaluate safety efficacy hydroxychloroquine prophylactic treatment covid<NUMBER> us fda issued emergency authorization use chloroquine hydroxychloroquine treatment covid<NUMBER> recent study tang et al reported hydroxychloroquine lead higher negative conversion rates reduced clinical symptoms antiinflammatory properties recovery lymphopenia <NUMBER>• also reported high doses chloroquine <NUMBER> mg twice daily <NUMBER> days total dose <NUMBER> g may associated significant cardiac risks recommended treating covid<NUMBER> <NUMBER>• still lack evidence regarding safety effectiveness agents treating covid<NUMBER> regard clinicians patients made aware risk versus benefit profile medications <NUMBER> lopinavir protease inhibitor high specificity hiv<NUMBER> protease lopinavir marketed administered exclusively combination ritonavir combination first marketed abbott brand name kaletra <NUMBER> <NUMBER> due lopinavirs poor oral bioavailability extensive biotransformation coformulated ritonavir enhance exposure ritonavir potent inhibitor enzymes responsible lopinavir metabolism coadministration boosts lopinavir exposure improves antiviral activity <NUMBER> lopinavir peptidomimetic molecule containing hydroxyethylene scaffold mimics peptide linkage typically targeted hiv<NUMBER> protease enzyme cannot cleaved thus preventing activity hiv<NUMBER> protease <NUMBER> lopinavirritonavir investigated openlabel individually randomized controlled trial patients covid<NUMBER> received either lopinavirritonavir <NUMBER> mg <NUMBER> mg orally twice daily plus standard care standard care alone benefit observed lopinavirritonavir treatment beyond standard care diarrhea nausea asthenia frequently reported adverse effects patients receiving lopinavirritonavirbased regimen <NUMBER> interestingly report korea lopinavirritonavir administration significantly decreased coronavirus titers little coronavirus titers observed followup study however analysis included single patient initial phase outbreak korea <NUMBER> umifenovir branded arbidol derivative indole carboxylic acids first developed <NUMBER> russia since approved russia china treating prophylaxis infections associated influenza b arbovirus <NUMBER> later umifenovir demonstrated vitro antiviral efficacy widely spreading virus strains ebola virus human herpesvirus <NUMBER> hhv<NUMBER> hepatitis c virus hcv tacaribe arenavirus <NUMBER> major mechanism action block viruscell membrane fusion well virusendosome fusion incorporation cell membranes interference hydrogen bonding network phospholipids <NUMBER> influenza virus shown directly interact virus particles stabilize hemagglutinin ha reducing likelihood reaching low ph threshold required conformational transition functional fusogenic ha <NUMBER> blaising et al reported vitro activity umifenovir sarscov<NUMBER> sarscov<NUMBER> <NUMBER> <NUMBER> retrospective cohort study reported compared lopinavirritonavir lpvrtv group combination umifenovir lpvrtv shown increased negative conversion rate sarscov<NUMBER> improved chest ct scan results <NUMBER> however another prospective study chictr<NUMBER> shown compared favipiravir umifenovir inferior outcome clinical recovery rate relief fever cough <NUMBER> two randomized openlabel trials ongoing china investigating efficacy safety umifenovir covid<NUMBER> effect umifenovir plus standard treatment versus lpvrtv plus standard treatment evaluated nct<NUMBER> effect umifenovir plus standard treatment versus standard treatment tested nct<NUMBER> favipiravir branded avigan developed fujifilm toyama chemical <NUMBER> japan treatment avian influenza novel influenza resistant neuraminid e n h b r g u n n e n l g u e w h pyrazinecarboxamide structure antiviral activity decreased presence purine nucleosides due competition <NUMBER> prodrug favipiravir first enters infected cells endocytosis transformed active f v p r v r r b f u r n l p h p h e h r u g h phosphoribosylation phosphorylation <NUMBER> <NUMBER> antiviral activity exhibited selectively targeting conservative catalytic domain rnadependent rna polymerase rdrp interrupting nucleotide incorporation process viral rna replication <NUMBER> dysregulation viral rna replication results increased number frequency transition mutations including replacement guanine g adenine cytosine c thymine c uracil u induces destructive mutagenesis rna viruses <NUMBER> favipiravir used treatment infectious diseases caused rna viruses influenza ebola norovirus <NUMBER> recent vitro human studies repurposed favipiravir experimental agent enveloped positivesense singlestrand rna virus sarscov<NUMBER> vitro research investigated seven potential antisarscov<NUMBER> medicines including ribavirin penciclovir favipiravir nafamostat nitazoxanide remdesivir chloroquine showing remdesivir chloroquine favorable selectivity index <NUMBER> addition study showed favipiravir exerted efficacy vero e<NUMBER> cells infected sarscov<NUMBER> halfmaximal effective concentration ec<NUMBER> <NUMBER> μm halfcytotoxic concentration cc<NUMBER> <NUMBER> μm implying high concentration needed safe effective treatment <NUMBER> clinical trials testing favipiravir covid<NUMBER> carried vigorously various countries including china japan randomized control trial chictr<NUMBER> shown covid<NUMBER> patients treated favipiravir superior recovery rate <NUMBER> treated umifenovir <NUMBER> duration fever cough relief time significantly shorter favipiravir group umifenovir group <NUMBER> midapril <NUMBER> eight undergoing clinical trials china two japan examining antisarscov<NUMBER> potential favipiravir trials include nonrandomized randomized controlled trials evaluating h e e f f c c n f e f f v p r v r l n e chictr<NUMBER> jprnjrcts<NUMBER> jprnjrcts<NUMBER> conjunction interferonα c h c r <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> b l x v r r b x l chictr<NUMBER> chictr<NUMBER> tocilizumab chictr<NUMBER> nct<NUMBER> chloroquine phosphate chictr<NUMBER> nct<NUMBER> oseltamivirbranded tamiflu drug approved treatment influenza b oseltamivir targets neuraminidase distributed surface influenza virus inhibit spread influenza virus human body <NUMBER> <NUMBER> study wuhan reported positive outcomes observed receiving antiviral treatment oseltamivir <NUMBER> several clinical trials still evaluating effectiveness oseltamivir treating sarscov<NUMBER> infection oseltamivir also used clinical trials several combinations chloroquine favipiravir <NUMBER> absence vaccine specific antiviral drugs proven sarscov<NUMBER> many adjunctive therapies used supportive care covid<NUMBER> patients adjunctive therapies including azithromycin ascorbic acid corticosteroids epoprostenol sirolimus tocilizumab sarilumab anakinra highlighted several therapies ie tocilizumab interleukindirected therapies administered effort blunt cytokine storm often seen progressing disease optimal timing administration yet identified conceptually blocking cytokine production progresses exaggerated level would seem mechanistically idea elevated serum concentration il<NUMBER> associated worse outcome covid<NUMBER> blocking activity proinflammatory mediator directed therapies may key target <NUMBER> adjuncts directed viral replication viral entry alternative mechanisms azithromycin antibiotic used fight many different types infections caused susceptible bacteria respiratory infections skin infections sexually transmitted diseases <NUMBER> moreover proven active vitro zika ebola viruses prevent severe respiratory tract infections treated patients suffering viral infection <NUMBER> <NUMBER> <NUMBER> mechanism action azithromycin prevents bacteria growing interfering protein synthesis binds <NUMBER>s subunit bacterial ribosome thus inhibiting translation mrna <NUMBER> previously azithromycin used adjunctive therapy provide antibacterial coverage potential immunomodulatory antiinflammatory effects treatment viral respiratory tract infections eg influenza <NUMBER> <NUMBER> currently many trials testing effect azithromycin conjunction hydroxychloroquine course disease people sarscov<NUMBER> example pfizer announced positive data use z h r c n z h r x r u g l n g w h hydroxychloroquine covid<NUMBER> clinical trial performed france brief clinical trial conducted assess hydroxychloroquine <NUMBER> patients <NUMBER> coadministered azithromycin compared <NUMBER> controls <NUMBER> hydroxychloroquine alone group <NUMBER> patients treated hydroxychloroquine azithromycin presented highest virologic cure rate following <NUMBER>day treatment <NUMBER> three clinical studies used azithromycin <NUMBER> mg day <NUMBER> <NUMBER> mg daily days <NUMBER> cotreated <NUMBER>day regimen hydroxychloroquine <NUMBER> mg daily openlabel nonrandomized study france <NUMBER> pts <NUMBER> openlabel uncontrolled study france <NUMBER> pts <NUMBER> uncontrolled observational study france <NUMBER> pts <NUMBER> specifically gautret et al reported <NUMBER> viral clearance nasopharyngeal swabs <NUMBER> patients cotreated hydroxychloroquine azithromycin <NUMBER> findings reported molina et al stand contrast reported gautret molina et al repeated experiments thought rapid full viral clearance quite unexpected found <NUMBER> <NUMBER> patients significant comorbidities <NUMBER> based results data presented date insufficient evaluate possible clinical benefits azithromycin patients covid<NUMBER> <NUMBER> furthermore one must consider additive cardiac toxicity hydroxychloroquine azithromycin agents known prolong qt interval may potentiate risk cardiac events population known cardiacrelated comorbidities vitamin c essential nutrient plays significant roles within human body neutralize free radicals assist prevent reverse cellular damage potent antioxidant agent also involved biological processes many associated immune health <NUMBER> moreover vitamin c appears effective antiviral agent especially influenza viruses <NUMBER> many studies showed vitamin c positively affects development maturation lymphocytes nk natural killer cells involved immune response viral agents also contributes inhibition reactive oxygen species ros production remodulation cytokine network typical systemic inflammatory syndrome <NUMBER> given background phase ii clinical trial nct<NUMBER> initiated china evaluate highdose iv vitamin c icu patients severe covid<NUMBER>associated pneumonia <NUMBER> hospitals reported giving infected patients <NUMBER> mg vitamin c supportive treatment highdose iv vitamin c given treatment <NUMBER> moderate severe covid<NUMBER> patients china <NUMBER> doses varied <NUMBER> <NUMBER> g per day given period <NUMBER>h iv infusion oxygenation index improved real time patients eventually recovered discharged <NUMBER> moreover highdose <NUMBER> mgkg body weight vitamin c used several decades clinically nih panel also documented clearly dose regimen safe major side effects <NUMBER> <NUMBER> potent antiinflammatory antifibrotic drug low doses methylprednisolone depomedrol solumedrol potential prevent extended cytokine response may accelerate resolution pulmonary systemic inflammation pneumonia <NUMBER> <NUMBER> recently many medical researchers believe corticosteroids especially methylprednisolone may improve dysregulated immune response caused sepsis possible complication infection covid<NUMBER> increase blood pressure low <NUMBER> specifically retrospective cohort study <NUMBER> patients confirmed covid<NUMBER> developed ards treated methylprednisolone <NUMBER> mgkg daily iv <NUMBER> days results showed treatment methylprednisolone may beneficial patients develop ards reduction risk death briefly patients ards received methylprednisolone treatment <NUMBER> <NUMBER> <NUMBER> patients died receive methylprednisolone <NUMBER> <NUMBER> <NUMBER> died <NUMBER> another study <NUMBER> patients severe covid<NUMBER> progressed acute respiratory failure use methylprednisolone associated improvement clinical symptoms ie fever hypoxia shortened disease course patients received drug compared <NUMBER> moreover according expert consensus statement chinese thoracic society dosage regimen methylprednisolone low moderate ie ≤ <NUMBER> <NUMBER> mgkg daily equivalent <NUMBER> common regimens methylprednisolone applied china typically <NUMBER> mg iv daily course <NUMBER> days <NUMBER> appropriate dosage low dose versus high dose place therapy early versus late role corticosteroids cytokine storm comorbidity management require additional clarity concern use corticosteroids may deleterious effects ie inhibition immune response pathogen clearance patients covid<NUMBER> <NUMBER> one study reported effect mortality decreased viral clearance use corticosteroids <NUMBER> furthermore infectious diseases society american recommends routine use corticosteroids covid<NUMBER> however recommend use corticosteroids setting ards context clinical trial <NUMBER> similarly surviving sepsis campaign recommends corticosteroids mechanically ventilated patients acute lung injury absence ards <NUMBER> however provide recommendation use corticosteroids patients ards acknowledging weak level evidence dexamethasone demonstrated utility ards decreasing ventilator days mortality severe ards patients without covid<NUMBER> <NUMBER> whether use corticosteroids provides similar benefit patients covid<NUMBER> ards remains seen ultimately clinical utilization corticosteroids still needs established considered case case basis since patients preexisting pulmonary conditions higher risk covid<NUMBER> closely monitored cared pulmonary vasodilator agents used patients hypoxemia refractory conventional treatments study performed specifically covid<NUMBER> patients surviving sepsis campaign suggested trial inhaled pulmonary vasodilator method rescue therapy mechanically ventilated adults covid<NUMBER> severe ards hypoxemia despite optimized ventilation rescue strategies inhaled nitric oxide ino inhaled epoprostenol iepo naturally occurring prostaglandin two common pulmonary vasodilators widely studied <NUMBER> <NUMBER> <NUMBER> experience patients ards indicates ino substantially reduce mean pulmonary artery pressure improve oxygenation patients furthermore vitro evidence direct antiviral activity sarscov studied genetic similarity sarscov sarscov<NUMBER> suggests potential effectiveness sarscov<NUMBER> <NUMBER> iepo dosages <NUMBER> ngkg per minute used <NUMBER> <NUMBER> <NUMBER> <NUMBER> previous studies reported provide clinically important increase pao<NUMBER> reduction pulmonary artery pressure effective safe dosage appears <NUMBER> ngkg per minute adults <NUMBER> ngkg per minute pediatric patients <NUMBER> ino therapy given ≥ <NUMBER> days <NUMBER> ppm day <NUMBER> followed <NUMBER> <NUMBER> ppm days <NUMBER> <NUMBER> respectively weaned day <NUMBER> pilot study sarscov <NUMBER> additionally clinical trials evaluating ino treatment prevention covid<NUMBER> planned underway nct<NUMBER> nct<NUMBER> nct<NUMBER> <NUMBER> <NUMBER> march <NUMBER> <NUMBER> fda granted emergency expanded access allowing ino delivery system inopulse® immediately used treatment covid<NUMBER> finally additional studies needed evaluate potential role iepo ino treatment covid<NUMBER> patients sirolimus also known rapamycin immunosuppressant used prevent organ transplant rejection treat lymphangioleiomyomatosis lam inhibiting mammalian target rapamycin mtor kinase originally isolated bacterium streptomyces hygroscopicus found easter island rapa nui <NUMBER> commercially available rapamune pfizer mtor specifically protein complex mtorc<NUMBER> formed mtor plays key role viral replication vitro experiment sirolimus shown affect pi<NUMBER>kaktmtor pathway inhibited merscov activity <NUMBER> new randomized doubleblind placebocontrolled clinical trial scope university cincinnati planned conducted april september <NUMBER> test effect sirolimus progression patients hospitalized covid<NUMBER> advanced respiratory support <NUMBER> studies patients hospitalized influenza shed light antiviral effect sirolimus randomized clinical trial conducted <NUMBER> patients confirmed h<NUMBER>n<NUMBER> pneumonia mechanical ventilator support group treated corticosteroids <NUMBER> mgday sirolimus <NUMBER> days n <NUMBER> showed significantly better clinical outcomes compared group treated corticosteroids including shorter median duration ventilator used <NUMBER> delayed oseltamivir plus sirolimus treatment ph<NUMBER>n<NUMBER>infected mouse model suggested significant association sirolimus treatment improved outcomes <NUMBER> additionally new trial chinese university hong kong planned begin august <NUMBER> investigate effect sirolimus oseltamivir normalization respiratory status changes biomarkers viral rna concentration <NUMBER> cytokines chemokines proinflammatory mediators several clinical endpoints influenza patients <NUMBER> least one silico study identified sirolimus one <NUMBER> potential candidates treating covid<NUMBER> patients based data human coronavirus infections using networkbased drug repurposing model <NUMBER> tocilizumab branded actemra humanized mab developed roche chugai pharmaceutical treating ra systemic juvenile idiopathic arthritis patients time publishing article clinicaltrialsgov listed <NUMBER> planned studies included tocilizumab treatment arm recruiting stage earlier study published april <NUMBER> reported <NUMBER> severe critical covid<NUMBER> patients china treated compound <NUMBER> recovered time publication <NUMBER> way recovery still icu encouraged results larger multicenter clinical trial launched chictr<NUMBER> <NUMBER> patients treated tocilizumab already enrolled <NUMBER> <NUMBER> sarilumab branded kefraza humanized mab developed regeneron pharmaceuticals sanofi treatment rheumatoid arthritis ra phase <NUMBER> randomized doubleblind placebocontrolled clinical trial planned regeneron pharmaceuticals sanofi partnership northwell healths feinstein institutes medical research march <NUMBER> targeting enroll <NUMBER> covid<NUMBER> patients measuring percent change cprotein phase <NUMBER> time improvement <NUMBER>point scale based death type hospitalization patients serum il<NUMBER> level threshold primary endpoints time publication results study made public <NUMBER> anakinra branded kineret swedish orphan biovitrum modified human il<NUMBER> receptor antagonist il<NUMBER>ra approved <NUMBER> usa <NUMBER> europe use ra patients il<NUMBER> family receptors triggers innate immune response associated damaging inflammation <NUMBER> <NUMBER> approved clinical trials involving anakinra treatment <NUMBER> also tocilizumab comparison one multicenter openlabel nonrandomized trial greece estimated enrollment <NUMBER> patients <NUMBER> another multicenter randomized openlabel trial belgium estimated <NUMBER> patients enrolled date <NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor regarded important target pathogenesis covid<NUMBER> studies reveal frequently observed comorbidities including hypertension diabetes patients infected sarscov<NUMBER> medication angiotensinconverting enzyme ace inhibitors angiotensin receptor blocker arb <NUMBER> <NUMBER> <NUMBER> <NUMBER> result overexpression ace<NUMBER> speculated sarscovand sarscov<NUMBER> bind human cells via interaction ace<NUMBER> receptors <NUMBER> <NUMBER> opposing physiological actions ace ace<NUMBER> reninangiotensin system reviewed determine therapeutic efficacy ace<NUMBER> inhibitors arbs <NUMBER> <NUMBER> hypertensive patients chronic treatment angiotensin ii type <NUMBER> receptor at<NUMBER>r antagonists like losartan lisinopril olmesartan facilitates cardiac renal ace<NUMBER> overexpression according vivo studies <NUMBER> <NUMBER> contrast sar viral rna following entry respiratory epithelial cells downregulates activity ace<NUMBER> thereby increasing levels angiotensin <NUMBER> may potentially cause severe lung damage <NUMBER> <NUMBER> continued treatment drugs may essential survival attenuate cardiac stress advancing covid<NUMBER> infection limit vasoconstriction profibrotic effects angiotensin <NUMBER> alveolar capillaries antiinflammatory drugs ibuprofen nonsteroidal antiinflammatory drug nsaid activators ace<NUMBER> receptors ace inhibitors arbs usage lead increased risk contracting covid<NUMBER> <NUMBER> since fatal lung failure induced sarscov infections may controlled blocking reninangiotensin pathway <NUMBER> ibuprofen may harmful however strong evidence suggesting link intake nsaid worsening symptoms due infection caused sarscov<NUMBER> fda considers ibuprofen likes potentially promising therapeutic agent covid<NUMBER> <NUMBER> studies demonstrated thiazolidinedione derivatives type <NUMBER> diabetes mellitus drugs show efficacious effect pulmonary disease induced respiratory syncytial virus rsv h<NUMBER>n<NUMBER> influenza infection <NUMBER> <NUMBER> role therapeutic drug coronavirus yet explored interestingly known thiazolidinediones may potential upregulate ace<NUMBER> receptor identified binding target sarscov<NUMBER> host cells <NUMBER> however lack clinical evidence makes uncertain determine therapeutic efficacy coronavirus infections amici et al demonstrated indomethacin wellknown nsaid potential cyclooxygenase cox inhibitor exhibits antiviral activity sarscov canine coronavirus ccov vitro studies suggest indomethacin exhibits dosedependent response canine a<NUMBER> cell monolayers infected ccov ic<NUMBER> <NUMBER> um <NUMBER> h exposure also remarkable inhibition sarscovinfected vero cells <NUMBER> concentrations nontoxic uninfected cells also observed addition indomethacin significantly blocks viral rna synthesis dogs infected ccov following oral administration drug <NUMBER> mgkg <NUMBER> suggests probable efficacy indomethacin sarscov<NUMBER> <NUMBER> colchicine antiinflammatory drug commonly used gout management variety conditions sharing similar pathophysiology mechanisms action related interfering migration neutrophils sites inflammation blocking inflammasome complex neutrophils monocytes thus reducing il<NUMBER>beta activation <NUMBER> colchicine also inhibitory effects macrophages via inhibition nachtlrrpydcontaining protein <NUMBER> nalp<NUMBER> inflammasome pore formation activated purinergic receptors p<NUMBER>x<NUMBER> p<NUMBER>x<NUMBER> may also beneficial effects endothelial function due colchicines antifibrotic activities patients covid<NUMBER> present myopathies colchicine shown reduce inflammation cardiac myocytes <NUMBER> several ongoing studies investigating colchicine cytokine storm nct<NUMBER> nct<NUMBER> nct<NUMBER> niclosamide anthelmintic drug shown effective sarscov virus replication inhibitor dose concentration <NUMBER> um higher vero e<NUMBER> cells without interfering binding corona virus onto cells <NUMBER> another study reveals efficacy niclosamide inhibiting merscov replication verob<NUMBER> cells via reduction skp<NUMBER> regulated becn<NUMBER> ubiquitination enhancement autophagic flux ic<NUMBER> value determined <NUMBER> um <NUMBER> thus possibility niclosamide inhibit sarscov<NUMBER> cannot neglected ivermectin potent anthelmintic drug first discovered inhibit interaction integrase molecule human immunodeficiency virus hiv<NUMBER> nuclear transport receptor importin αβ <NUMBER> studies exhibit potential prevent viral replication broad spectrum viruses including dengue virus flavivirus influenza <NUMBER> <NUMBER> <NUMBER> recently ivermectin shown inhibition sarscov<NUMBER> <NUMBER>fold <NUMBER> h vitro inhibition impαβ<NUMBER>mediated nuclear import viral proteins suggested probable cause antiviral activity <NUMBER> interesting know inhibition effect sarscov<NUMBER> vivo nitazoxanide metabolite tizoxanide shown inhibitory effects merscov llcmk<NUMBER> cells besides inhibition corona virus strains including murine corona virus mouse hepatitis virus strain a<NUMBER> mhva<NUMBER> bovine corona virus strain l<NUMBER> bcovl<NUMBER> human enteric corona virus <NUMBER> hecov<NUMBER> nitazoxanide reported via suppression viral n protein <NUMBER> nitazoxanide found suppress proinflammatory cytokines peripheral blood mononuclear cells pbmcs il<NUMBER> vivo however relevance information currently unknown <NUMBER> treatment option refers transfusion plasma loaded antibodies individuals resolution specific pathogen technique used decades <NUMBER> transfusion offer shortterm immediate immunity individuals convalescent plasma used prophylactically already infected patients attenuate clinical severity <NUMBER> <NUMBER> mechanism action binding transfused antibodies pathogen resulting cellular cytotoxicity phagocytosis direct neutralization pathogen <NUMBER> <NUMBER> previously convalescent plasma used two coronaviruses sarscov mers <NUMBER> one large study hong kong involving <NUMBER> patients sarscov supported early administration antibodies optimal clinical effect compared later administration <NUMBER> limited data taiwan south korea showed clinical benefits severe cases sarscov mers <NUMBER> <NUMBER> reported dosage varied widely terms amount plasma transfused antibody titer <NUMBER> limited data covid<NUMBER> patients china illustrated clinical benefits <NUMBER> <NUMBER> pilot study reported clinical improvement terms fever cough tightness breath chest pain serious side effects reported <NUMBER> considerable attention placed role hypercoagulable state leading microand macrovascular thrombosis covid<NUMBER> disseminated intravascular coagulation elevated ddimer level identified predictors worse outcomes cohort study patients covid<NUMBER> <NUMBER> patients receiving anticoagulants decreased mortality <NUMBER> heparin antiinflammatory properties may also inhibit viral attachment via conformational changes sarscov<NUMBER> surface receptor spike s<NUMBER> <NUMBER> low molecular weight heparin patients hospitalized covid<NUMBER> associated lower serum il<NUMBER> concentrations suggesting may added mechanism besides preventiontreatment thrombosis <NUMBER> based available evidence reasonable administer venous thromboembolism prophylaxis either low molecular weight unfractionated heparin hospitalized patients patients rapidly progressing respiratory deterioration clinical judgment suggests thrombosis treatment doses anticoagulants may considered historically traditional herbal medicines used past control treat epidemic outbreaks <NUMBER> including past epidemic outbreaks sars h<NUMBER>n<NUMBER> influenza <NUMBER> <NUMBER> date china south korea issued traditional medicinal treatment guidelines prevention treatment covid<NUMBER> <NUMBER> reported greater <NUMBER> sarscov<NUMBER>infected patients china received forms traditional chinese medicine tcm treatments <NUMBER> similar sarscov sarscov<NUMBER> uses host receptor ace<NUMBER> cellular entrance appears traditional medicines may capacity target ace<NUMBER> show promises prevent infection sarscov<NUMBER> <NUMBER> <NUMBER> due high similarity epidemiologic genomics pathogenesis sarscov<NUMBER> sarscov herbal medicinal products used treatment patients infection sarscov<NUMBER> china korea <NUMBER> <NUMBER> top <NUMBER> commonly used tcm herbal medicinal products china treat covid<NUMBER> patients include astragalus membranaceus glycyrrhiza uralensis saposhnikoviae divaricata rhizoma atractylodis macrocephalae lonicerae japonicae flos fructus forsythia atractylodis rhizoma radix platycodonis agastache rugosa cyrtomium fortunei j sm <NUMBER> addition tcm herbal products shen fu injection du ning injection could manifest potential immunosuppressive effects thereby decrease level tnfα il<NUMBER>β il<NUMBER> il<NUMBER> il<NUMBER> cytokines resulting inhibition lung inflammation acute lung injury <NUMBER> <NUMBER> <NUMBER> <NUMBER> discussed cytokine storminflammatory responses may contribute deaths many covid<NUMBER> patients thus antiinflammatory agents presumably could reduce severity mortality rate <NUMBER> <NUMBER> <NUMBER> reported qingfei paidu decoction could inhibit alleviate excessive immune response eliminate inflammation regulating immunerelated pathway cytokine actionrelated pathway herbal formula qingfei paidu decoction recommended chinese korean guidelines according recent publication herbal formula increases immunity reduces inflammation targeting lung spleen covid<NUMBER> patients <NUMBER> li et al reported lianhuaqingwen lh tcm formula significantly inhibited sarscov<NUMBER> replication vero e<NUMBER> cells markedly reduced proinflammatory cytokine tnfα il<NUMBER> ccl<NUMBER>mcp<NUMBER> cxcl<NUMBER>ip<NUMBER> production mrna levels <NUMBER> sangju yin yinqiao san commonly used clinical treatment clear lung heat expel phlegm relieve cough regulate patients lungs restore normal lung function <NUMBER> similarly yinqiao san may antibacterial antiviral functions <NUMBER> several clinical studies showed tcm may bring new hope prevention control covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> general appears tcm products commonly used covid<NUMBER> patients mild symptoms severe symptoms could prevent block diseases progression although precise molecular mechanisms currently unknown potential role antiinflammatoryantioxidative stress improving hypoxemiahypoxia antiviral activities among others could major drivers investigations future needed uncover molecular mechanisms conclusion covid<NUMBER> pandemic represents greatest global public health crisis past <NUMBER> years hopefully vaccines specific therapeutic drugs targeting sarscov<NUMBER> made available next months years speed volume basic clinical covid<NUMBER> sarscov<NUMBER> research develop potential drugs therapies disease hope horizon struggling understand human catastrophe coronavirus disease<NUMBER> covid <NUMBER> epidemic <NUMBER> cases documented covid<NUMBER> infection united states <NUMBER> deaths <NUMBER> economy except limited sectors come complete halt practice physical distancing try mitigate effects pandemic <NUMBER> weeks since covid<NUMBER> began accelerate flurry information corners expected unexpected help us understanding rapid publication peerreviewed data defined possible risk factors covid<NUMBER> clinical course possible epidemiology unusual time public health emergency numerous nonpeerreviewed manuscripts uploaded preprint servers unreviewed data conclusions must evaluated spirit nevertheless data published preprint form point tantalizing hypothesis covid<NUMBER> infection severity explained concentration glycosylated severe acute respiratory syndromecoronavirus <NUMBER> sarscov<NUMBER> viral particles lung epithereceptor <NUMBER> ace<NUMBER> lung epithelium degree control pulmonary immune response sarscov<NUMBER> spike protein approximately day <NUMBER> <NUMBER> symptom onset may related ace<NUMBER> appears primary receptor entry sarscov<NUMBER> various epithelial tissues envelope anchored spike protein allows entry coronaviruses host cells binding host receptor fusing viral host membranes <NUMBER> analysis sarscov betacoronavirus similar sarscov<NUMBER> responsible severe acute respiratory syndrome sars <NUMBER> defined receptorbinding domain rbd sarscov spike protein specifically recognized ace<NUMBER> <NUMBER> susceptibility sars appears primarily dependent affinity spike rbd bind host ace<NUMBER> target tissues initial viral attachment step differences affinity rbd ace<NUMBER> may determine zoonotic host epidemiology spread <NUMBER> protein crystal structure analysis sarscov rbd complexed ace<NUMBER> demonstrated differential binding affinity resides critical receptorbinding motif spike receptor protein particular composition amino acids <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> determine affinity human ace<NUMBER> opposed hosts <NUMBER> predicted protein structural analysis critical five residues sarscov<NUMBER> analogous sarscov suggested increased binding affinity human ace<NUMBER> sarscov<NUMBER> <NUMBER> synthetic sarscov<NUMBER> rbd found vitro bind enter cells transfected human ace<NUMBER> receptor known coronavirus targets dpp<NUMBER> target merscov <NUMBER> therefore rational assume like sarscov sarscov<NUMBER> uses ace<NUMBER> receptor target tissues primary mechanism entry recent work cryo electron microscopy ace<NUMBER> bound spike protein fragment sarscov<NUMBER> <NUMBER> suggests viral spike protein trimer one trimer rbd sites exposed bind ace<NUMBER> additional structurefunction studies <NUMBER> also appear indicate viral spike protein sarscov<NUMBER> highly glycosylated protein cleaved proteases two subunits s<NUMBER> s<NUMBER> s<NUMBER> subunit divided sa sb domains sb domain predicted bind human ace<NUMBER> s<NUMBER> subunit responsible fusion virusace<NUMBER> complex cell membrane highly glycosylated evolutionarily conserved sites <NUMBER> tempting speculate alterations glycosylation spike protein well ace<NUMBER> modulate viral binding also tempting speculate alterations highly glycosylated evolutionarily conserved viral fusion subunit could modulate proteinace<NUMBER> complex fusion cell membrane potentially attenuate human human transmission importance ace<NUMBER> binding sarscov<NUMBER> covid<NUMBER> underscored observation anosmia dysgeusia recently observed patients covid<NUMBER> <NUMBER> ace<NUMBER> expression recently found high oropharynx tongue <NUMBER> binding ace<NUMBER> sarscov<NUMBER> covid<NUMBER> also suggests prolonged uncontrolled hyperglycemia history diabetes mellitus may important pathogenesis disease known history diabetes dm ambient hyperglycemia found independent risk factors morbidity mortality sars <NUMBER> followup analysis <NUMBER> patients high fasting plasma glucose fpg independent predictor sars mortality <NUMBER> diabetes found <NUMBER> cohort hospitalized covid<NUMBER> patients appeared risk factor severity disease <NUMBER> history diabetes associated <NUMBER> covid<NUMBER> intensive care unit icu admissions vs <NUMBER> nonicu admissions one case series <NUMBER> another recent icu case series reported <NUMBER> <NUMBER> <NUMBER> history diabetes <NUMBER> mortality covid<NUMBER> patients diabetes found <NUMBER> vs <NUMBER> patients comorbidities <NUMBER> possible explanation link hyperglycemia ace<NUMBER> levels severity covid<NUMBER> disease could explained several clinical observations sars preclinical observations nod diabetic mouse noted potential changes glycosylation ace<NUMBER> well glycosylation viral spike protein possibly induced uncontrolled hyperglycemia may alter binding viral spike protein ace<NUMBER> degree immune response virus subset <NUMBER> patients prior diabetes received steroid treatment hospitalization survived sars fpg levels hospitalization found decrease discharge <NUMBER> twenty <NUMBER> <NUMBER> patients diabetes hospitalization <NUMBER> suggested could cause harm <NUMBER> interesting note article going press another group expressed similar hypothesis <NUMBER> potentially high aberrantly glycosylated ace<NUMBER> lung nasal airways tongue oropharynx uncontrolled hyperglycemia could also serve increased sarscov<NUMBER> viral binding sites thus leading higher propensity covid<NUMBER> infection higher disease severity interestingly high ace<NUMBER> protective effect various organs <NUMBER> ace<NUMBER> gene expression increased estrogen mouse model <NUMBER> potential protective factor sarscov<NUMBER> infection pathogenicity men likely women acquire covid<NUMBER> severe disease recent survey studies found ace<NUMBER> gene expression higher tissues women younger adults inverse correlation disease severity <NUMBER> possible explanation discrepancy gene expression experiments cannot measure posttranslational modifications protein glycosylation nod diabetic mouse model ace<NUMBER> activity lung rise fall insulin administration amount ace<NUMBER> protein apparently <NUMBER> consistent rise glycosylated ace<NUMBER> opposed total ace<NUMBER> since antibody binding proteins measured western blot analysis could affected glycosylation <NUMBER> therefore likely amount glycosylated ace<NUMBER> receptor simply amount ace<NUMBER> alone responsible virus binding fusion true argues better glycemic control patients prediabetes diabetes potential mechanism slow covid<NUMBER> spread reduce severity symptoms additionally since <NUMBER> american population without history diabetes prediabetes hemoglobin a<NUMBER>c <NUMBER> random sampling <NUMBER> appears coincident peak viral load measured nasopharyngeal swabs day <NUMBER> symptom onset sars <NUMBER> timing ards sars also corresponded timing immunoglobulin g igg seroconversion <NUMBER> additionally neutralizing antibody nab response sarscov spike protein patients died sars occurred earlier course disease <NUMBER> days symptom onset vs survived <NUMBER> days nab antibody titer higher died sars survived <NUMBER> notably viral load covid<NUMBER> severe cases appears remain high <NUMBER> days symptom onset <NUMBER> tempting hypothesize similar mechanism applies sarscov<NUMBER> acute onset lung inflammation sars resulting ards appears tightly associated monocytemacrophage polarization function <NUMBER> acute infection macrophages display classically activated inflammatory m<NUMBER> phenotype express cytokines interleukin<NUMBER> il<NUMBER> high il<NUMBER> levels associated brufsky <NUMBER> increased mortality series <NUMBER> hospitalized patients tempting consider mechanism acts covid<NUMBER> sars overactive macrophage m<NUMBER> inflammatory response neutralizing antibodies sarscov<NUMBER> spike protein form day <NUMBER> <NUMBER> results ards susceptible patients also allows consideration agents may interfere overly brisk macrophage inflammatory response perhaps influence course disease particular blunt completely abrogate m<NUMBER> m<NUMBER> balance macrophage polarization well viral load sars appears temporally related onset ards interest mouse model asthma macrophage m<NUMBER> polarization increased estrogen <NUMBER> additionally estrogen also accelerates acquisition m<NUMBER> phenotype monocyte cell culture model <NUMBER> vitro concentrations achievable human lung tissue <NUMBER> chloroquine related compound inhibits sarscov replication spread cell culture possibly reducing glycosylation ace<NUMBER> receptor <NUMBER> interestingly computer simulations suggest hydroxychloroquine chloroquine predicted bind active site enzyme udpnacetylglucosamine <NUMBER>epimerase catalyzes rate determining step sialic acid biosynthesis pathway <NUMBER> thus rational basis assume hydroxychloroquine interfere terminal glycosylation proteins golgi apparatus small unrandomized clinical cohort <NUMBER> patients combination hydroxychloroquine azithromycin shown rapidly reduce viral load covid<NUMBER> patients ameliorate clinical symptoms majority patients <NUMBER> another small randomized hydroxychloroquine also act oral hypoglycemic agent patients diabetes taking hydroxychloroquine rheumatologic diseases significant reduction hemoglobin a<NUMBER>c compared methotrexate <NUMBER> thus serve reduce hyperglycemia possible covid<NUMBER> risk factor disease severity studies mixed topic balance m<NUMBER> m<NUMBER> macrophage polarization may differ depending local microenvironment hydroxychloroquine shown least one study block polarization macrophages m<NUMBER> inflammatory subtype <NUMBER> await larger randomized studies analysis patient subtypes determine anyone benefit hydroxychloroquine context theoretical framework covid<NUMBER> infection results date supportive although much caution used interpretation early small clinical trials regardless results larger clinical trials hydroxychloroquine covid<NUMBER> hoped analysis provide testable theoretical framework allow advances understanding control deadly viral epidemic sarscov<NUMBER> enveloped positive stranded rna coronavirus genetically related sarscov responsible sars outbreak <NUMBER> receptorbinding domain s<NUMBER> subunit high affinity angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor <NUMBER> ace<NUMBER> protein primarily expressed epithelia human lung small intestine also expressed heart kidneys brain <NUMBER> sarscov<NUMBER> enters host cell endocytosis <NUMBER> sarscov sarscov<NUMBER> implicated hijack endocytic pathway gain entry host cells <NUMBER> receptor binding endocytosis virus acidic environment endocytic vesicle proteolytic cleavage allows virus fuse membrane endosome dumping viral nucleocapsid cytosol cell <NUMBER> <NUMBER> taken together targeting endocyticlysosomal pathway could beneficial prevention sarscov<NUMBER> entry host cell chloroquine wellknown drug used prevention treatment malaria treatment rheumatoid arthritis lupus addition drug known antiviral properties viruses hiv <NUMBER> sarscov <NUMBER> mechanism chloroquine wellknown inhibits acidification endosome thus inhibiting entry virus cytosol also reported chloroquine inhibit glycosylation s<NUMBER> protein preventing entry host cell <NUMBER> interferon alpha<NUMBER>b ifn <NUMBER>b antiviral cytokine produced leukocytes cells infected virus currently used treat viral hepatitis c hepatitis b antiviral mechanisms ifn <NUMBER>b incompletely known ifn  inhibits viral replication prevention protein translation <NUMBER> since chloroquine ifn  two different mechanisms action predict two therapies would additive effects prophylaxis covid<NUMBER> vitro chloroquine reported antiviral activity many types rna viruses reviewed devaux <NUMBER> chloroquine studied vitro using cell lines found effective preventing entry virus cells <NUMBER> prophylactic properties ifn <NUMBER>b tested variety viruses including coronavirus <NUMBER> human study involving cold caused coronavirus volunteers used nasal spray ifn <NUMBER>b placebo inoculation coronavirus <NUMBER>e nasal spray ifn  reduced cold symptoms significantly compared placebo although rate viral infection <NUMBER> given effectiveness prophylactic chloroquine vitro demonstrated ability ifn <NUMBER>b reduce symptoms coronavirus human proposing use chloroquine together ifn <NUMBER>b prophylactic measure human likely first line hospital workers highrisk patients hospital nursing home efficacy method tested randomized controlled study clinically high risk group patients individuals prophylaxis compared individuals without prophylaxis ideally would three experimental groups placebo hydroxychloroquine alone hydroxychloroquine ifn <NUMBER>b rate infection severity symptoms compared three groups due low side effect profile chloroquine ifn <NUMBER>b benefit risk ratio using chloroquine ifn <NUMBER>b prevent spread sarscov<NUMBER> covid<NUMBER> could enormous chloroquine long halflife <NUMBER> hours <NUMBER> reason prevention malaria patient asked take drug week period traveling malariainfected region chloroquine large volume distribution penetrate almost tissues including liver spleen brain kidney lungs spleen <NUMBER> due long halflife large volume distribution chloroquine chloroquine potentially prevent sarscov<NUMBER> entry host cell different organs perhaps appealing aspect using chloroquine prophylactic treatment low side effect profile reports severe side effect longterm use chloroquine reports cardiomyopathy severe adverse effect caused chloroquine <NUMBER> bernstein analyzed published cases food drug administration reports retinopathy induced hydroxychloroquine concluded evidence permanent visualfield scotomas occurring daily dose exceed <NUMBER> mgkg body weight maintenance therapy <NUMBER> dosage proposing <NUMBER> <NUMBER> dosage used long term treatment thus rate side effects significantly lower especially short period use intranasal ifn  given prophylaxis intranasally also mild side effect profile side effects mainly nose bleeds <NUMBER> propose test <NUMBER> mg chloroquine daily prophylaxis covid<NUMBER> lower concentration side effect chloroquine minimized general public use period time covid<NUMBER> control concentration plasma would expected <NUMBER> µm well threshold side effects <NUMBER> µm whole blood concentrations chloroquine <NUMBER> times higher plasma <NUMBER> tissue concentrations <NUMBER> times higher plasma <NUMBER> thus dose <NUMBER> mg daily concentrations chloroquine tissue high enough prophylactic effect according concentrations chloroquine used vitro without minimal risk adverse events <NUMBER> several forms chloroquine approved use clinic hydroxychloroquine analog chloroquine less drugdrug interactions found potent <NUMBER> thus hydroxychloroquine may appropriate form chloroquine give prophylaxis study involving prophylaxis cold caused coronavirus healthy individuals dose <NUMBER> x <NUMBER> <NUMBER> iu twice day intranasal ifn <NUMBER>b decreased symptoms cold caused coronavirus <NUMBER> since hypothesize prophylactic effects ifn <NUMBER>b chloroquine would additive recommend using low intranasal dose <NUMBER> x <NUMBER> <NUMBER> iu twice day minimize adverse effects ifn <NUMBER>b treatment note submission manuscript dr jinping xu dr youcheng liu wayne state university school medicine decided collaborate authors initiate clinical trial test hypothesis separate treatment outcomes data reported million existence paper provides encouragement two ways first paper demonstrates teamwork thirtyseven coauthors combined efforts document care outcomes <NUMBER> patients nigerian igbo proverb states takes village raise child similarly large team required mount huge clinical research response try save patients covid<NUMBER> addition tmaid publishing team worked rapidly paper includes data april <NUMBER> reviewed six different peerreviewers extensively revised accepted published may <NUMBER> speed effectiveness rigorous review publication process attest value teamwork second paper exemplifies value scientific process fully separate celebrity opinions political viewpoints authors proposed studied hypothesis rigorous observational study presented data carefully responded effectively peerreview process make data available public review interpretation hydroxychloroquineazithromycin treatment mortality effectively limited <NUMBER> among sarscov<NUMBER>infected adults even though hospitalbased study though limited hospitalized patients mortality wasnt much higher <NUMBER> death rate infected worldwide much lower <NUMBER> inpatient case fatality rate large british study <NUMBER> seeming safety effectiveness hydroxychloroquineazithromycin contradiction data study published week earlier showed dangerously increased death rates hydroxychloroquine chloroquine macrolidetreated patients<NUMBER> multination registry <NUMBER> hospitalized sarscov<NUMBER> patients <NUMBER> centers six continents included <NUMBER> treated chloroquine hydroxychloroquine without macrolide<NUMBER> confounding factors considered patients receiving remdesivir excluded study mortality rates <NUMBER> control nonhydroxychloroquinechloroquine group <NUMBER> received hydroxychloroquine <NUMBER> received hydroxychloroquine macrolide <NUMBER> received chloroquine <NUMBER> received chloroquine macrolide <NUMBER> specific features millions study impact interpretation findings first study subjects included based positive viral testing regardless presence absence symptoms thus patients would probably become seriously ill whether ever diagnosed treated contrast british study <NUMBER> case fatality rate<NUMBER> aforementionedmultinational registry study <NUMBER> included sick enough hospitalized second total <NUMBER> potential study subjects excluded millions study cardiac findings screening use medications might add increased cardiac risk appropriate research methods patient safety might removed patients consideration would unfavorable outcomes thus increased mortality rates toward levels comparable studies third control group millions study france possible helpful yet undocumented features care france unrelated medications contributed seemingly favorable outcomes widespread use incompletely tested medications could potentially dangerous side effects millions group wisely include patients identified risk arrhythmia study screened patients carefully preliminary ecg among included patients though found obvious sign medication toxicity important finding contrast multinational study mehra et al reported new ventricular arrhythmias approximately four times common treated hydroxychloroquine chloroquine controls <NUMBER> study approximately <NUMBER> control treated patients preexisting arrhythmia entry study <NUMBER> discrepancy screening may extent explain different outcomes thus larger multinational observational study <NUMBER> found hydroxychloroquine associated increased risk death increased risk ventricular arrhythmias question arises whether increase mortality new ventricular arrhythmias study caused inappropriate prescription medication without considering known side effects hydroxychloroquine hydroxycloroquine use usa approved fda <NUMBER> <NUMBER> hydroxychloroquine chloroquine included world health organization model list essential medicines <NUMBER> arrhythmogenic side effects hydroxychloroquine well known millions team limited use accordance knowledge readers encouraged enough results millions study something giving hydroxychloroquineazithromycin combined treatment covid<NUMBER> patients others opt await proof safety efficacy randomized blinded controlled clinical trials indeed trial started world health organization solidarity trial <NUMBER> assessing antiviral remdesivir hiv drug combination lopinavirritonavir multiple sclerosis treatment interferon beta<NUMBER>a antimalarial drugs chloroquine hydroxychloroquine study already enrolled approximately <NUMBER> patients <NUMBER> countries recruitment continues <NUMBER> hospitals total <NUMBER> countries<NUMBER> however temporarily paused enrolment hydroxychloroquine arm study dangerous preliminary findings rather data new multinational study <NUMBER> perhaps relevant data still emerge alreadycompleted parts nowpaused hydroxychloroquine treatment arm solidarity trial observational study million colleagues validate legitimacy considering hydroxychloroquineazithromycin treating hospitalized patients covid<NUMBER> however data studies raise cry caution especially considering giving treatment individuals might underlying arrhythmia time soon know whether hydroxychloroquineazithromycin use covid<NUMBER> warranted dangerous pandemic novel coronavirus called sarscov<NUMBER> causing coronavirus disease<NUMBER> covid<NUMBER> emerged spread china date affecting <NUMBER> countries territories around world since december <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> infection transmits human human droplets contact infected surfaces efforts discover potential treatments covid<NUMBER> accelerating focus repositioning previously tested vitro compounds hydroxychloroquine chloroquine antimalarial agents immunomodulatory antiinflammatory activities proposed possible treatments covid<NUMBER> disease <NUMBER> also interest use prophylaxis people highj u r n l p r e p r f risk exposure covid<NUMBER> yet become infected although currently data support use medications preventive therapy <NUMBER> <NUMBER>yearold female medical history mitral valve repair cardiomyopathy ejection fraction <NUMBER> rheumatoid arthritis oral hydroxychloroquine <NUMBER> mg per day developed new onset fever well mild sore throat rhinorrhea following exposure coworker tested positive sarscov<NUMBER> day following onset symptoms received rtpcr test resulted positive sent home continued fever developed symptoms mild productive cough exertional shortness breathing generalized body pain diffuse headache myalgia fatigue nausea diarrhea one week onset symptoms admitted hospital management cascade added developed additional fevers symptoms resolved point determined mild disease deemed appropriate discharge continue selfquarantine home chloroquine hydroxychloroquine agents generated significant interest treatment persons covid<NUMBER> infection appear antiviral effect mediated increasing endosomal ph thereby impeding virus cell fusion well interfering glycosylation cellular receptors sarscov<NUMBER> <NUMBER> <NUMBER> drugs known long elimination halflife least one month high accumulation rate cells <NUMBER> rationale use antimalarial compounds emerged experiments vero e<NUMBER> cells recent letter published wang colleagues vitro activity chloroquine sarscov<NUMBER> showed effective concentration ec<NUMBER> <NUMBER> hours <NUMBER> μm indicating potency <NUMBER> similar studies chloroquine previously done sarscov merscov showing ec<NUMBER> comparable range <NUMBER> recently published comparison study vitro activity demonstrated higher potency hydroxychloroquine chloroquine ec<NUMBER> values similar prior data <NUMBER> authors utilized physiologicallybased pharmacokinetic modeling simulation techniques provided rationale optimal dosing regimen hydroxychloroquine <NUMBER> mg twice day <NUMBER> followed <NUMBER> mg twice daily based silico experiment terms vivo data least <NUMBER> clinical trials conducted chloroquine hydroxychloroquine china <NUMBER> results yet formally published however preliminary report released letter gao colleagues one hundred patients demonstrated chloroquine superior standard care treatment preventing exacerbation pneumonia improving lung imaging findings promoting virusnegative conversion shortening disease course <NUMBER> several proposed dosages chloroquine hydroxychloroquine treatment options covid<NUMBER> one study referring korean guidelines recommended <NUMBER> mg chloroquine twice daily <NUMBER> mg hydroxychloroquine daily <NUMBER> panel china recommended chloroquine dose <NUMBER> mg twice day <NUMBER> days patients severity pneumonia <NUMBER> suggested rheumatoid arthritis <NUMBER> <NUMBER> mg daily single oral daily dose <NUMBER> divided doses <NUMBER> people exposed sarscov<NUMBER> high risk developing covid<NUMBER> health care workers particularly elevated risk forefront public health crisis significant interest finding effective prophylaxis hydroxychloroquine chloroquine considered <NUMBER> preprint nonpeer reviewed retrospective cohort veterans received hydroxychloroquine treatment covid<NUMBER> either without azithromycin reduction risk mechanical ventilation <NUMBER> fact patient developed disease context raises questions effectiveness hydroxychloroquine therapeutic well prophylactic agent <NUMBER> <NUMBER> hydroxychloroquine effective prophylaxis one might expect mild asymptomatic infection requiring hospitalization critical need exists investigation hydroxychloroquine chloroquine derivatives treatment covid<NUMBER> disease also preventive therapy effects potential confounding factors like age comorbidities underlying autoimmune disease clinical stage covid<NUMBER> disease yet determined data larger randomized clinical trials necessary order elucidate questions novel coronavirus <NUMBER> covid<NUMBER> also known severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> enveloped nonsegmented positivesense rna virus belonging betacoronaviridae family <NUMBER> covid<NUMBER> found cause severe pneumonia acute respiratory distress syndrome ards significantly high mortality rate <NUMBER> according world health organization <NUMBER> confirmed cases <NUMBER> deaths covid<NUMBER> march <NUMBER> <NUMBER> rapidly increasing <NUMBER> originating bats like virulent coronavirus cov strains severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov covid<NUMBER> become focus medical world pandemic <NUMBER> <NUMBER> <NUMBER> present case elderly female presenting fever cough shortness breath found positive covid<NUMBER> started highdose iv ascorbic acid antiinterleukin<NUMBER> hydroxychloroquine remdesivir requiring high ventilator settings eventually requiring vasopressors continuous venovenous hemodialysis cvvhd editor maya saranathan authors conflicts interests disclose manuscript unique submission considered publication source medium manuscript published part full form patients next kin provided consent manuscript published data sharing applicable article datasets generated analyzed current study <NUMBER>yearold middleeastern female medical history hypertension hyperlipidemia presented emergency department ed day care facility apartment <NUMBER> people facility tested positive covid<NUMBER> direct contact individuals <NUMBER> days admission patient developed fever temperature <NUMBER>°f home went primary medical doctor sent ed ed found bilateral opacities chest xray continued intermittent fevers generalized weakness cough lethargy dyspnea sent testing covid<NUMBER> transferred facility management facility temperature <NUMBER>°f blood pressure <NUMBER> mm hg heart rate <NUMBER> beats per minute respiratory rate <NUMBER> per minute oxygen saturation <NUMBER> room air physical exam significant dry cough bilateral rales auscultation lung fields bilaterally unremarkable otherwise chest xray fig <NUMBER> performed showing bilateral opacities throughout lung fields predominance lower lung lobes admitted possible pneumonia isolation precautions suspected covid<NUMBER> started oxygen via nasal cannula <NUMBER>gram ceftazidime intravenously every <NUMBER> hours <NUMBER> mg azithromycin orally daily ct scan chest fig <NUMBER> performed showing bilateral ground glass appearance throughout lung predominance peripheral lower lobes respiratory viral panel sent including repeat covid<NUMBER> test table <NUMBER> results came back negative however patients condition deteriorated <NUMBER> days admission facility became hypoxic <NUMBER> oxygen saturation nasal cannula remained spiking fevers <NUMBER>°f intubated transferred intensive care unit icu management switched ceftriaxone <NUMBER> g intravenously daily azithromycin <NUMBER> mg via orogastric tube daily started hydroxychloroquine <NUMBER> mg loading dose followed <NUMBER> mg twice daily <NUMBER>day course required <NUMBER> fraction inspired oxygen fio<NUMBER> positive endexpiratory pressure peep <NUMBER> maintain oxygen saturation <NUMBER> <NUMBER> hours later covid<NUMBER> test initial facility returned positive results day <NUMBER> hospitalization started <NUMBER> g iv ascorbic acid twice daily given one dose <NUMBER> mg per kg <NUMBER> mg tocilizumab antiinterleukin<NUMBER> monoclonal antibody due shortage vitamin c hospital dose decreased <NUMBER> g iv daily <NUMBER>th day hospitalization given another dose tocilizumab day <NUMBER> peep increased <NUMBER> <NUMBER> due worsening oxygen saturation increased requirement despite <NUMBER> fio<NUMBER> due severe ards decision made prone patient <NUMBER> hours day completed course antibiotics hydroxychloroquine remained vitamin c zinc approval remdesivir obtained gilead sciences inc given loading dose <NUMBER> mg day <NUMBER> due worsening oxygen saturation peep increased <NUMBER> day <NUMBER> patient unable tolerate prone due significant desaturation <NUMBER> pulse oximetry remained supine eventually required levophed maintenance hemodynamic stability creatinine increased baseline <NUMBER> since admission day <NUMBER> <NUMBER> day <NUMBER> reason remdesivir discontinued nephrology consulted recommended cvvhd day <NUMBER> day <NUMBER> peep requirement increased <NUMBER> <NUMBER> fio<NUMBER> maintain oxygen saturation <NUMBER> condition remained critical aggressively managed icu ultimately patients family decision pursue comfort measures patient passed away covid<NUMBER> cause severe viral pneumonia rapidly leading ards case series <NUMBER> patients wan et al reported <NUMBER> patients presented fever <NUMBER> cough <NUMBER> fatigue myalgias <NUMBER> headache <NUMBER> dyspnea <NUMBER> less commonly reported <NUMBER> symptoms also found presentation patient covid<NUMBER> tests pending ct scan chest provided valuable information met trend findings infected patients wan et al obtained ct scans patients study found bilateral involvement multiple patchy ground glass appearance primary finding <NUMBER> huang et al found similar findings <NUMBER> ct scans obtained bilateral involvement multilobular consolidations <NUMBER> findings ct scans unusual viral pneumonia influenza h<NUMBER>n<NUMBER> first found cause pandemic <NUMBER> retrospective review <NUMBER> patients çörtük et al found <NUMBER> patients h<NUMBER>n<NUMBER> bilateral patchy pneumonic infiltrates douedi miskoff medicine <NUMBER> <NUMBER> wwwmdjournalcom <NUMBER> bilateral ground glass opacities <NUMBER> lack rapid testing covid<NUMBER> caused delay diagnosis perhaps use ct scans could provide increased suspicion covid<NUMBER> infection leading earlier treatment management patient presented case received treatment vitamin c zinc known improve human immune system aid shortening duration improving outcomes respiratory infections including pneumonia <NUMBER> <NUMBER> addition vitamin mineral supplements hydroxychloroquine azithromycin obtained large amount attention treatment covid<NUMBER> hydroxychloroquine wellknown antimalarial autoimmune medication relatively inexpensive extensively studied treatment covid<NUMBER> studies suggested hydroxychloroquine interfere glycosylation coronavirus receptors increase endosomal ph thus inhibiting viral fusion decreasing viral load <NUMBER> <NUMBER> gautret et al reported synergistic effect using hydroxychloroquine azithromycin viral elimination decreasing viral load <NUMBER> despite evidence use hydroxychloroquine viral infections questioned roques et al reported study using chloroquine chikungunya virus reporting cytokines reduced causing adaptive immune response delayed exacerbating fever unchanged suppression viral load <NUMBER> studies need provide concrete evidence use hydroxychloroquine clinical trials china already shown promising results covid<NUMBER> several countries around world begun using medications tocilizumab recombinant humanized antiinterleukin<NUMBER> receptor monoclonal antibody extensively used autoimmune conditions rheumatoid arthritis <NUMBER> monoclonal antibody interleukin<NUMBER> function blocked hence differentiation helper cells b cells immunoglobulinsecreting cells inhibited <NUMBER> cytokine storm observed patients covid<NUMBER> difficult control manage leading increased mortality tocilizumab therefore helps decrease immune response resulting damage caused cytokines <NUMBER> <NUMBER> still approved united states tocilizumab thus far shown promising results clinical trials <NUMBER> treatments covid<NUMBER> also emerged thus far shown promising results ongoing clinical trials remdesivir gs<NUMBER> favipiravir t<NUMBER> become center attention remdesivir adenosine analog incorporates viral rna causing premature termination <NUMBER> <NUMBER> found effective inhibiting viral replication ebola sarscov merscov infections <NUMBER> <NUMBER> <NUMBER> favipiravir rnadependent rna polymerase inhibitor already obtained approval treatment covid<NUMBER> china february <NUMBER>th <NUMBER> <NUMBER> studies shown favipiravir inhibited rna polymerase activity thus prevented replication rna viruses like covid<NUMBER> minimal side effects <NUMBER> remdesivir gs<NUMBER> gilead sciences inc currently several clinical trials side effects yet defined patient within <NUMBER> days starting remdesivir patient worsening renal function eventually requiring cvvhd vasopressors thus preventing treatment medication patient critically ill icu known medication cause decompensation due kidney injury studies clinical trials required fully understand role remdesivir medications covid<NUMBER> infected patients covid<NUMBER> serious infection led thousands cases severe pneumonia ards even deaths across globe approved treatments viral pandemic several medications shown effective clinical trials studies needed establish dosing treatment course side effects medications number cases deaths continue increase world race develop faster testing modalities rapidly diagnose manage patients earlier continues focus global healthcare system paper published <NUMBER> years ago journal us described potentially therapeutic benefits quinoline antimalarial chloroquine viral diseases hiv<NUMBER>aids severe acute respiratory syndrome sars <NUMBER> chloroquinehydroxychloroquine since adopted treat hiv<NUMBER>infected patients clinical trials new insights antiviral activity obtained invitro studies hivaids front chloroquine <NUMBER> mg twice daily administered hiv<NUMBER>infected patients baseline viral loads <NUMBER> <NUMBER> copies per ml combination lamivudine <NUMBER> mg twice daily hydroxyurea <NUMBER> mg twice daily ongoing clinical trial india <NUMBER> ten <NUMBER> volunteers undetectable viral load week <NUMBER> <NUMBER> median drop viral load <NUMBER>·<NUMBER> log <NUMBER> median <NUMBER>·<NUMBER> log drop seen nucleoside reverse transcriptase inhibitor nrti hydroxyurea alone <NUMBER> results different another trial singapore using didanosine <NUMBER> mg twice daily hydroxyurea <NUMBER> mg twice daily hydroxychloroquine <NUMBER> mg twice daily corresponding <NUMBER> mg chloroquine <NUMBER> median drop viral load <NUMBER>·<NUMBER> log similar induced nrti plus hydroxyurea followup patients week <NUMBER> suggests value hydroxychloroquine may lie maintenance effects didanosine hydroxyurea <NUMBER> discrepancy two studies besides differences design patients enrolled probably reflects different dosages chloroquinehydroxychloroquine drops viral load reported occur using daily doses <NUMBER> mg hydroxychloroquine <NUMBER> corresponding <NUMBER> mg chloroquine used indian study using <NUMBER> mg chloroquine daily <NUMBER> corresponding <NUMBER> mg hydroxychloroquine adopted singapore study chloroquinehydroxychloroquine might thus valuable option tested lowcost antiretroviral combinations correct dosages used considering study new insights antiviral effects chloroquine empirically activity causative filamentous fungi timetested experience <NUMBER> <NUMBER> <NUMBER> newer agents may useful microbiological diagnosis established eg voriconazole aspergillus spp posaconazole zygomycetes although studies required lastly van damme hartman refer noma chancrum oris devastating necrotising destructive process face typically affecting young malnourished children africa condition presented recent excellent review barattimayer colleagues <NUMBER> thank van damme hartman interest paper comments allowed us elaborate upon important topic rapidly progressive sstis participants regularly monitored prevent retinopathy prospective randomised doubleblind placebo studies also needed assess contribution chloroquinehydroxychloroquine part antiretroviral regimen according new invitro results antiretroviral effects chloroquine attributable inhibition viral particle glycosylation <NUMBER> effects appeared specific since chloroquine concentrations effective vitro neither affected step hiv<NUMBER> replication cytotoxic <NUMBER> hypothesis chloroquine might inhibit replication sars coronavirus <NUMBER> confirmed two independent invitro studies <NUMBER> <NUMBER> researchers belgian catholic university leuven found chloroquine inhibited sars coronavirus replication <NUMBER> effective concentration <NUMBER>·<NUMBER> se <NUMBER>·<NUMBER> moll within range blood concentrations achievable antimalarial treatment <NUMBER> dose inducing <NUMBER> cytostatic activity much higher <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> moll timeofaddition experiments indicated chloroquine affected early stage sars coronavirus replication <NUMBER> researchers centers disease control prevention atlanta ga usa reported potent antisars coronavirus effects chloroquine vitro attributable deficit glycosylation sars coronavirus receptor ace<NUMBER> <NUMBER> antiviral drug concentrations cytotoxic animal models confirm results chloroquine might represent valuable therapeutic option sars reemerges broad spectrum antiviral effects chloroquine deserve particular attention time world threatened possibility new influenza computerassisted simulation ligandprotein docking use program gold <NUMBER> indicates chloroquine red fits active site udpnacetylglucosamine <NUMBER>epimerase grey evidence suggests chloroquine could inhibit enzyme catalyses ratedetermining step sialic acid biosynthetic pathway pandemic availability effective drugs would fundamental evaluation effective vaccine effect chloroquine replication orthomyxoviridae long known <NUMBER> inhibitory effects chloroquine type b influenza viruses described <NUMBER> <NUMBER> currently investigating inhibitory effect chloroquine h<NUMBER>n<NUMBER>achickenitaly<NUMBER> avian influenza virus recently isolated poultry italy <NUMBER> depending viral challenging doses methods adopted detect antiviral effects inhibitory concentrations fell within <NUMBER>·<NUMBER> moll rangeie clinically achievable plasma malaria treatment ldt id rc ac unpublished data effects confirmed chloroquine would deserve tested h<NUMBER>n<NUMBER> type avian influenza virus currently matter serious concern public health discussed glycosylation inhibition might represent major mechanism antiviral effects chloroquine suggesting specific interactions chloroquine sugarmodifying enzymes glycosyltransferases may occur within human cells figure chloroquine recently shown inhibit quinone reductase <NUMBER> <NUMBER> structural neighbour udpnacetylglucosamine <NUMBER>epimerases <NUMBER> involved sialic acid biosynthesis chloroquine indeed inhibit biosynthesis sialic acid effect could explain effects chloroquine hiv sars coronavirus sialic acid moieties present hiv<NUMBER> glycoproteins sars coronavirus receptor ace<NUMBER> also invitro effects orthomyxoviruses use sialic acid moieties receptors <NUMBER> effects deserve investigation may lead new strategies controlling replication several viruses started infectious diseases fellowship programme <NUMBER> years ago first trainee andrew kambugu completed training last september recruited faculty member idi three others currently programme primarily used american model includes emphasis developing clinical investigational expertise currently mainly focused hivaids trainees completed training internal medicine paediatrics mentored members alliance director also made experiences available north america training microbiology manitoba canada western clinical infectious diseases salt lake city ut usa one current trainees paediatric infectious diseases rotation baylor houston tx usa another tuberculosis epidemiology rotation atlanta ga usa objective programme train african infectious diseases academic leaders tomorrow part commitment build human resources  fact versus science fiction fighting coronavirus disease <NUMBER> requires wisdom know difference ince december <NUMBER> countries quickly shifted spectators victims severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> outbreak coronavirus disease <NUMBER> covid<NUMBER> pandemic overwhelmed healthcare systems crippled economies around world including united states unlike china many countries time prepare epidemics march <NUMBER> remain early stages time allowed scientific community bear arms mount expedited research efforts unforeseen fashion collaboration academic institutions government agencies unprecedented inspiring countless hours sleepless nights academics around world resulted united front mitigate morbidity mortality covid<NUMBER> despite concerted efforts another pandemic right threatens destroy meticulously built scientific juggernaut surrounding covid<NUMBER> alternative facts commentary uses recent study hydroxychloroquine demonstrate dire need randomized clinical trials importantly explore potential consequences misinformation fear fuels impact offer guidance maintain scientific integrity without relinquishing hope chloroquine less toxic metabolite hydroxychloroquine chemotherapeutic agents used treat malaria <NUMBER> chloroquinehydroxychloroquine also inhibits certain inflammatory pathways resulting treatment multiple rheumatological disorders <NUMBER> sarscov outbreak <NUMBER> led yet another therapeutic potential chloroquine found inhibit sarscov attachment altering binding protein receptor required entry <NUMBER> despite vitro studies identifying potential role killing infected cells <NUMBER> <NUMBER> vivo trials yet confirm findings <NUMBER> fact preclinical trials chloroquine viruses dengue fever chikungunya demonstrated enough promise warrant clinical trials however preclinical effects translate humans <NUMBER> <NUMBER> march <NUMBER> remains randomized control trial humans evidence chloroquine hydroxychloroquine beneficial sarscov sarscov<NUMBER> date randomized control trial published data found benefit viral clearance <NUMBER> patients treated chloroquine compared <NUMBER> patients treated placebo c jun unpublished observations <NUMBER> although abstract published online february <NUMBER> <NUMBER> touts efficacy chloroquine <NUMBER> patients remains publication data <NUMBER> however recent nonrandomized observational study gautret et al <NUMBER> found decreased viral load patients treated hydroxychloroquine compared control group chosen another hospital findings noteworthy many reasons specifically reasons commonly noted lack randomization adjustment study gautret et al <NUMBER> introduces selection confounding bias respectively alone temper interpretation subtle discretion regarding six excluded patients treatment hydroxychloroquine group warrants equivalent amount skepticism patients one died three clinically deteriorated requiring intensive care admission one withdrew secondary drugrelated complication another lost followup excluding patients drastically biases results toward benefit fact included number needed harm hydroxychloroquine six hydroxychloroquine <NUMBER> vs control <NUMBER> harm arguably greater clinical significance compared decreasing unadjusted viral load furthermore mechanistic primary outcome implausible sample size calculation presumed <NUMBER> efficacy creates enough methodological concerns prevent anything beyond hypothesisgenerating conclusions study limitations stated groundbreaking likely appreciated regular seasoned academic readership unfortunately readership article academic literature broadened immensely past <NUMBER> months world understandably grasping discovery scientific community operates worldwide microscope desperate need critical appraisal filter despite methodological limitations lack clinical relevance article gautret et al <NUMBER> continues trend social media days publication article repercussions reinforce adage lie travel halfway around world truth still putting shoes since publication prescriptions chloroquine hydroxychloroquine dramatically increased standard operating procedures incorporated hydroxychloroquine standard care lethal overdoses occurred rising concerns shortages may affect availability us food drug administrationapproved uses medications premature acceptance efficacy new swine flu vaccination <NUMBER> recombinant human activated protein c <NUMBER> prior experiences influence current standards require high quality often multiple randomized control trials change practice high bar contributes estimated <NUMBER> years take best practices translated medical practice <NUMBER> glacial yet safe meticulous pace unacceptable current crisis lowering bar maintaining scientific rigor possible scientific community harmoniously pivots toward single target remarkably succeeded movement coming together international community unfortunately unless maintain narrative scientific surge bar meticulously repositioned may fall quickly floor inaccurate facts stem two levels ability identify suppress misinformation disinformation crucial maintaining scientific process misinformation incorrect misleading information <NUMBER> whereas devious counterpart disinformation false information deliberately often covertly spread obscure truth <NUMBER> example represents misinformation safely assume differing interpretations occurred unintentionally hope provide guidance future situations await results randomized clinical trials misinformation occurs greater degree disasters <NUMBER> natural human tendency crisis find resolution even exist <NUMBER> fear fuels efforts dissipate uncertainty limitations study gautret et al <NUMBER> lost seasoned academic researchers however despite warnings healthcare leaders public health agencies continues premature adoption hydroxychloroquine treatment based limited preclinical data misinformed interpretation nonrandomized study importantly compassionate wellintentioned healthcare workers immune tendencies arguably healthcare workers vulnerable misinformation current climate careful curious lens previously used critically appraise literature blurred intrinsic passion something intentions aside misinformation current public health emergency left unchecked preventable patient morbidity mortality occur simultaneously dismantling remarkable ongoing efforts defeat covid<NUMBER> may risk integrity hydroxychloroquine trials also investigational drug trials currently ongoing widespread use misconception hydroxychloroquine cure may result reduced enrollment hydroxychloroquine trials hesitation enroll drug trials hydroxychloroquine potential ripple effects misinformation pose greatest threat ongoing fight covid<NUMBER> merchant asch <NUMBER> layout countermeasures combat misinformation first essential leverage position social media advocate transparency table <NUMBER> accomplishing undoubtedly require unified effort medical community given majority social media influence resides outside healthcare fortunately turn science provide insight recent article scientific reports analyzed social media mechanisms associated social bursts significant worldly events although motivation propagate liking retweeting topic commonly influenced users fondness topic significant events influence shifted amplified based degree trust source information <NUMBER> live world entertainer politician idols endorsement echoed millions contrast worldrenown scientist medical provider reaches people magnitude thousands creates vacuum credible medical information world looks medical community underutilized mechanisms voice barely whisper currently ethical responsibility leaders field prominent speak misinformation deliver facts condensing timeline research must streamline professional opinions realtime social media engagement similarly imperative journals expedite responses misinformation solicit commentary controversial topics deliver unified message collaboration authors resultantly scientific community controls narrative preserving veracity crucial left unchecked narrative appears increasingly malleable virus fear spread spotlight currently academic community ever owe research coordinators investigational drug service pharmacists couriers project managers statisticians trainees performing chart reviews mentors mentees ensure unrelenting ongoing efforts vain equally important owe family friends community beacon hope preserving scientific integrity ts eliot quote <NUMBER> recently reframed reflect duty scientific community aim arrive startedat bedside critically ill injured patientcaring ways yesterday unimagined today unknown become tomorrow standard <NUMBER> dr tignanelli principal investigator two randomized control trials investigating angiotensinreceptor blockers treatment coronavirus disease <NUMBER> among inpatient outpatients coinvestigators include dr ingraham dr ingraham received funding national institutes health national heart lung blood institute t<NUMBER>hl<NUMBER> information regarding article email ingra<NUMBER>umnedu j u r n l p r e p r f <NUMBER> severe acute respiratory syndrome sars epidemic started <NUMBER> ended numbering <NUMBER> infected people <NUMBER> dead contributing global costs <NUMBER> billion comparison middle east respiratory syndrome mers characterized fewer infections stronger nosocomial outbreaks slightly higher mortality rate approximately <NUMBER> eliminated date <NUMBER> <NUMBER> confirmed cases <NUMBER> deaths <NUMBER> current severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> pandemic reached new dimension estimated death around <NUMBER> percent <NUMBER> times higher seasonal influenza <NUMBER> <NUMBER> infection due virus also known coronavirus disease<NUMBER> covid <NUMBER> covid<NUMBER> declared public health emergency world health organization <NUMBER> according report <NUMBER> june <NUMBER> cases covid<NUMBER> recorded worldwide <NUMBER> confirmed <NUMBER> deaths <NUMBER> currently medicines vaccines claimed useful prevention treatment covid<NUMBER> <NUMBER> <NUMBER> due absence effective treatment public health emergency covid<NUMBER> pandemic alarming entire globe international health care authorities efforts provide quarantine quick diagnosis covid<NUMBER> patients along research find effective treatment control prevent present dangerous consequences disease drug repositioning repurposing investigation existing drugs new therapeutic purposes line scientific research aims develop safe effective treatments covid<NUMBER> <NUMBER> several existing antiviral drugs previously developed used treatments sars mers hiv malaria investigated covid<NUMBER> treatments used clinical trials <NUMBER> <NUMBER> perspective review discussed various potential drugs used anticovid<NUMBER> therapy chloroquine wide spectrum antiviral activity gained primary attention repurposing medicine treatment covid<NUMBER> chloroquine previously used malaria obtained quinine present barks cinchona plants native peru <NUMBER> chloroquine behaves like potent bioactive agent rna viruses invitro studies <NUMBER> case coronaviruses potential therapeutic benefits chloroquine particularly reported sarscov<NUMBER> chloroquine examined covid<NUMBER> due versatile antiviral activity coronaviruses specially sarscov<NUMBER> <NUMBER> absence available useful treatment new study revealed chloroquine inhibited covid<NUMBER> invitro medicine assessed covid<NUMBER> patients <NUMBER> experts china suggested individuals found mild moderate severe cases covid<NUMBER> pneumonia without chloroquine contraindications treated <NUMBER> mg chloroquine therapy twice daily consecutive ten days <NUMBER> <NUMBER> china national center biotechnology development recently reported chloroquine among three available medicines potential activity covid<NUMBER> initial information chinese authorities revealed almost <NUMBER> infected individuals treated chloroquine experienced faster decline fever improved lung computed tomography ct images required shorter recovery time compared control groups potential side effects also recommended addition chloroquine covid<NUMBER> treatment guidelines <NUMBER> <NUMBER> result chloroquine likely firstline treatment china countries treat fatal covid<NUMBER> although prolonged usage chloroquine malarial treatment demonstrates safety acute chloroquine administration humans moreover cant neglect low risk j u r n l p r e p r f <NUMBER> macular retinopathy relies cumulative dose presence cardiomyopathy serious side effect induced chloroquine <NUMBER> currently chloroquine medicine choice among available drugs knock severity covid<NUMBER> till least <NUMBER> clinical studies carried investigate chloroquine anti covid<NUMBER> treatment <NUMBER> <NUMBER> however survey adverse effects patients infected covid<NUMBER> still needed better therapeutic decision hydroxychloroquine chloroquine analog antimalarial antiinflammatory activities used treatment malaria arthritis rheumatoid porphyria cutanea tarda systemic lupus erythematosus dengue somewhat higher potency covid<NUMBER> <NUMBER> safety profile hydroxychloroquine better chloroquine longterm usage allows higher daily dose fewer concerns drugdrug interactions <NUMBER> <NUMBER> based limited anecdotal invitro data hydroxychloroquine presently suggested therapy covid<NUMBER> patients many nations hydroxychloroquine wellknown safety history major concern cardiotoxic prolonged qt syndrome prolonged use individuals renal hepatic malfunction immune suppression however reportedly well tolerated covid<NUMBER> patients <NUMBER> hydroxychloroquine given hospital admitted covid<NUMBER> patients several countries wider availability high invitro activity covid<NUMBER> currently hydroxychloroquine studied clinical trials covid<NUMBER> therapy mild moderate severe cases <NUMBER> according recent trial hydroxychloroquine useful removing viral nasopharyngeal carriage covid<NUMBER> days less week <NUMBER> presently reports randomized clinical trials rcts available update clinical guidance usage dose duration hydroxychloroquine therapy prophylaxis covid<NUMBER> normal dose duration hydroxychloroquine covid<NUMBER> therapy unknown however us clinicians described anecdotal variations hydroxychloroquine dosing <NUMBER> mg bid day one daily <NUMBER> days <NUMBER> mg bid day one <NUMBER> mg bid <NUMBER> days <NUMBER> mg bid day one <NUMBER> mg daily days <NUMBER> <NUMBER> hand china international exchange promotive association medical health care cpam issued novel guidelines <NUMBER> covid<NUMBER> recommended use hydroxychloroquine orally <NUMBER> mg daily chloroquine available <NUMBER> synergistic effect combination azithromycin hydroxychloroquine also demonstrated recent study <NUMBER> azithromycin active vitro ebola <NUMBER> zika <NUMBER> viruses control severe respiratory infections patients viral infection <NUMBER> study revealed hydroxychloroquine alone combination azithromycin reduced covid<NUMBER> rna detection upper respiratory tract specimens compared noncontrol group <NUMBER> azithromycin hydroxychloroquine linked prolong qt caution required using medicines individuals chronic renal failure hepatic patients patients using medicines interact produce arrhythmias <NUMBER> studies combination required combination act antiviral treatment covid<NUMBER> control bacterial superinfections <NUMBER> concerns raised respect veracity data analyses conducted multinational observational realworld study patients covid<NUMBER> regimen containing hydroxychloroquine chloroquine without macrolide although several multicentre randomised controlled trials underway urgent need provide accurate clinical guidance regarding regimen <NUMBER> lopinavir type <NUMBER> aspartate protease inhibitor human immunodeficiency virus hiv used <NUMBER> sarscov due invitro inhibitory activity <NUMBER> combination ritonavir lopinavir increases plasma halflife inhibiting cytochrome p<NUMBER> lopinavir activity merscov vitro <NUMBER> animal model <NUMBER> case study indicates combination lopinavirritonavir ribavirin interferon alfa caused virologic removal <NUMBER> chinese guidelines recommended use lopinavirritonavir tablets <NUMBER> mg<NUMBER> mg orally twice daily critically ill elderly covid<NUMBER> patients <NUMBER> however considerable data efficacy approach human beings lopinavirritonavir shown guarantee therapy covid<NUMBER> hospitalized patients pneumonia recently organized randomized controlled openlabel clinical trial china <NUMBER> remdesivir intravenous investigational drug strong antiviral activity activity covid<NUMBER> related betacoronaviruses drug effective ebola laboratory study remdesivir prevent human cells infected covid<NUMBER> furthermore findings identified remdesivir highly effective controlling covid<NUMBER> infection vitro <NUMBER> according cdc investigational agent remdesivir currently used covid<NUMBER> patients us <NUMBER> fda grant emergency approval usage remdesivir covid<NUMBER> <NUMBER> however remdesivir associated statistically significant clinical benefits adult hospitalized covid<NUMBER> patients <NUMBER> confirmatory large multinational studies needed evaluate efficacy safety covid<NUMBER> patients <NUMBER> <NUMBER> favipiravir fpv antiviral agent selectively strongly inhibits rnadependent rna polymerase rdrp viruses favipiravir antiviral activity influenza virus welldemonstrated actions three influenza b c <NUMBER> according recent experimental study china fpv shown substantially improved therapeutic effects covid<NUMBER> terms infection progression viral removal furthermore research also indicates duration treatment fpv extended required due less adverse reactions <NUMBER> according guardian news report official chinese ministry science technology reported favipiravir recorded promising results clinical trials shenzhen wuhan involving <NUMBER> patients <NUMBER> turkey also begun fpv covid <NUMBER> patients according turkish ministry health fpv resulted improvement intensive care patients decreasing time care <NUMBER> days <NUMBER> days <NUMBER> according randomized clinical trial favipiravir vs arbidol covid<NUMBER> patients fpv considered preferable therapy due higher sevenday clinical recovery rate reduction incidence fever cough except antiviralassociated adverse effects <NUMBER> favipiravir also considered teratogenic thus pregnancy confirmed suspected favipiravir administration avoided women <NUMBER> however approval use fpv course entail clinical testing followed approval widespread use relevant regulatory body medical care country oseltamivir antiviral drug used treat prevent influenza patients aged <NUMBER> year older <NUMBER> oseltamivir recommended people high risk infection pandemic influenza exposure <NUMBER> oseltamivir also used clinical trials various combinations chloroquine favipiravir <NUMBER> clinical trials broad randomized controlled trials needed confirm effective role oseltamivir covid<NUMBER> patients ribavirin strong antiviral activity used treatment hepatitis c respiratory syncytial virus rsv infection certain viral hemorrhagic fever <NUMBER> according chinese <NUMBER>th edition guidelines <NUMBER> review human case reports china <NUMBER> recommended combination ribavirin lopinavirritonavir pegylated interferon reported effective viral clearance covid<NUMBER> patients sofosbuvir also approved fda drug acts nucleotide polymerase inhibitor used treatment hepatitis c virus hcv <NUMBER> drug previously used treatment zika virus <NUMBER> used combination interferon ribavirin <NUMBER> sofosbuvirbased regimens used treating chronic hcv infection considered safe minimal adverse effects respiratory system recent research indicates sofosbuvirs efficacy potent drug newly developed covid<NUMBER> <NUMBER> however covid<NUMBER> greater multicenter studies needed evaluation ivermectin broadspectrum antiparasitic agent approved fda antiviral activity wide variety viruses <NUMBER> demonstrated limit infection rna viruses also effective dna pseudorabies virus prv according recent report ivermectin may useful antiviral reduce covid<NUMBER> <NUMBER> ivermectin safety profile established human use previous analysis shows highdose ivermectin comparable safety standard lowdose treatment although enough evidence conclude safety profile pregnancy <NUMBER> critical next step assessment potential benefit covid<NUMBER> patients examination multiple additional dosing regimen mimics current approved human use ivermectin however known safety profile shows ivermectin worthy consideration possible covid<NUMBER> therapy <NUMBER> interferons ifns essential components innate immune response first line protection virus infection proteins nature derive name word interfere interfere viruses prevent multiplying <NUMBER> ifns used treat hepatitis c virus hcv infection numerous malignancies multiple sclerosis hiv aids <NUMBER> antiviral drug interferon alfa<NUMBER>b produced china confirmed effective treatment hiv human papillomavirus hepatitis b c according studies medicine useful treatment viruses characteristics identical novel coronavirus united kingdom biotech company synairgen approved fasttrack trial ifnalfa<NUMBER>b covid<NUMBER> patients hoped administration ifnalfa<NUMBER>b enhance bodys ability fight virus described drug phase <NUMBER> trials inhaled means patients administer small nebulizer powered battery <NUMBER> however effectiveness interferon therapy covid <NUMBER> yet scientifically proved receptor mainly used treatment systemic juvenile idiopathic arthritis sjia polyarticular juvenile idiopathic arthritis pjia rheumatoid arthritis <NUMBER> recently fda approved study evaluate use tocilizumab covid<NUMBER> patients <NUMBER> details prior use mechanism action adverse effects repurposed drugs may treat covid<NUMBER> discussed table anticoagulants main treatment used prevent treat thrombosis unfractionated heparin ufh low molecular weight heparin lmwh favored anticoagulants acute thrombosis due rapid antithrombotic activity <NUMBER> severe covid<NUMBER> coagulopathy usually problematic associated high mortality <NUMBER> risk venous thromboembolism vte severe covid<NUMBER> patients also increased due evidence viral infection respiratory dysfunction longterm bed rest severe covid<NUMBER> patients treatment anticoagulants heparin help reducing pulmonary coagulopathy venous thromboembolism <NUMBER> documented lmwh improves coagulation dysfunction covid<NUMBER> patients exerts antiinflammatory effects reducing interleukin <NUMBER> il<NUMBER> increase percentage lymphocytes would also seem lmwh may used possible therapeutic drug covid<NUMBER> <NUMBER> however studies required confirm validate efficacy safety profile <NUMBER> ibuprofen painkiller common alternative people headaches fevers two novel coronavirus symptoms however amid growing covid<NUMBER> pandemic situation french health minister olivier véran called social media warn patients take antiinflammatory drugs ibuprofen cortisone may worsen disease rely paracetamol <NUMBER> additionally according recently published letter medical journal hypostasized ibuprofen may increase levels enzyme called angiotensinconverting enzyme <NUMBER> ace<NUMBER> ultimately increases severity covid<NUMBER> ace<NUMBER> enzyme increased people diabetes also received hypertension therapy <NUMBER> however presently scientific proofs establish connection ibuprofen worsening covid<NUMBER> later <NUMBER> march <NUMBER> states suggest use ibuprofen <NUMBER> evidence therefore needed explore issue paracetamol also known acetaminophen used treatment fever pain typically used mild moderate relief pain health care professionals suggest firstline use paracetamol ibuprofen <NUMBER> oppose use nonsteroidal antiinflammatory drugs nsaids ibuprofen symptoms <NUMBER> fda describes presently evidence covid<NUMBER> symptoms worsen nsaids <NUMBER> angiotensinconverting enzyme inhibitors ace inhibitor angiotensin ii receptor blockers arbs used mainly treatment high blood pressure heart failure scientists hoping drugs may beneficial patients covid<NUMBER> university minnesota performed two clinical trials using inexpensive generic losartan drug trials assess explain whether losartan prevent multiorgan failure control prolonged hospitalization covid<NUMBER> patients pneumonia <NUMBER> losartan works blocking receptor gateway cells used chemical called angiotensin ii penetrate cells raise blood pressure covid<NUMBER> binds receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> may assumed losartan block receptors prevent virus infecting cells recently published study raised complicating issues mentioned possibility specific hypertension drugs ace inhibitors arbs specifically losartan may cause body generate ace<NUMBER> thus increase ability virus infiltrate cells <NUMBER> furthermore recent analysis <NUMBER> covid<NUMBER> patients italy found hypertension existed threequarters patients died suggested one reasons increased sensitivity <NUMBER> although theoretical questions ace inhibitors arbs ibuprofen raised convincing evidence either ace inhibitors arbs ibuprofen facilitate worsen covid<NUMBER> infection type patient <NUMBER> corticosteroid medication used suppress immune system reduce inflammation recommended covid<NUMBER> disease complicated <NUMBER> ozone considered natural killer viruses widely used people disinfection sterilization deodorization detoxification bleaching <NUMBER> years ozone kills viruses disseminating protein coat nucleic acid core causing viral rna damage higher concentrations ozone destroys capsid outer protein layer damages either microorganisms dna rna virusbacteria structure <NUMBER> ozone three main attributes full coverage reach every corner environment high detergency toxic residues convenience produced simple equipment ozone adopted weapon global fight covid<NUMBER> due abovementioned features <NUMBER> plants essential food also medicinal products knowing pathways secondary metabolite synthesis also essential production plant drug products <NUMBER> still unclear drug successfully fight disease studies underway different countries try different combinations treat patients early sure safe treatments studies appear indicate troubling side effects currently complete data available large rcts provide clinical advice use dosing duration validate effective role safety profile adverse effects abovementioned drugs prophylaxis treatment covid<NUMBER> desperate need new drugs treat covid<NUMBER> meanwhile scientists working hard develop effective treatments however lot work needs done achieve better treatment outcome take time establish complete safety efficacy trial drugs therefore clinical studies large randomized control studies needed better treatment option safety covid<NUMBER> patients collaborative efforts around world needed achieve goal applicable article based previously conducted studies contain studies human participants animals performed authors applicable data available inside manuscript conflict interest competing interest funding sponsorship received study publication article authors contributed equally work applicable malaria influenza <NUMBER> sars <NUMBER> human coronavirus oc<NUMBER> <NUMBER> transcription translation significantly restricts dna rna synthesis parasite <NUMBER> <NUMBER> macular retinopathy cardiomyopathy <NUMBER> hydroxychloroquine malaria rheumatoid arthritis dengue virus covid<NUMBER> <NUMBER> <NUMBER> bind modify dna cause viral inhibition <NUMBER> arrhythmias <NUMBER> lopinavirritonavir hiv <NUMBER> sars <NUMBER> mers <NUMBER> <NUMBER> viral replication <NUMBER> <NUMBER> <NUMBER> gastrointestinal adverse effects hyperlipidemia glucose intolerance <NUMBER> <NUMBER> remdesivir ebola covid<NUMBER> sars mers <NUMBER> inhibits viral rna polymerases <NUMBER> multiple organdysfunction syndrome septic shock acute kidney injury hypotension <NUMBER> <NUMBER> favipiravir influenza b c <NUMBER> covid<NUMBER> <NUMBER> rnadependent rna polymerase viruses <NUMBER> teratogenic <NUMBER> oseltamivir influenza <NUMBER> covid<NUMBER> <NUMBER> inhibits neuraminidase enzyme viral replication <NUMBER> neuropsychiatric adverse events <NUMBER> <NUMBER> ribavirin respiratory syncytial virus rsv rsv pneumonia <NUMBER> covid<NUMBER> <NUMBER> <NUMBER> viral replication stopping rna synthesis mrna capping <NUMBER> <NUMBER> hemolytic anemia teratogenic <NUMBER> sofosbuvir covid<NUMBER> <NUMBER> hepatitis c virus <NUMBER> zika virus <NUMBER> viral replication inhibiting rna synthesis <NUMBER> pulmonary arterial hypertension <NUMBER> <NUMBER> ivermectin rna viruses <NUMBER> pseudorabies virus viral replication <NUMBER> <NUMBER> neurological adverse events <NUMBER> importance administration hydroxychloroquine without azithromycin treatment coronavirus disease <NUMBER> covid<NUMBER>associated pneumonia carries increased risk corrected qt qtc prolongation cardiac arrhythmias objective characterize risk degree qt prolongation patients covid<NUMBER> association use hydroxychloroquine without concomitant azithromycin design setting participants cohort study performed academic tertiary care center boston massachusetts patients hospitalized least <NUMBER> positive covid<NUMBER> nasopharyngeal polymerase chain reaction test result clinical findings consistent pneumonia received least <NUMBER> day hydroxychloroquine march <NUMBER> <NUMBER> april <NUMBER> <NUMBER> main outcomes measures change qt interval receiving hydroxychloroquine without azithromycin occurrence potential adverse drug events results among <NUMBER> patients given hydroxychloroquine <NUMBER> received concomitant azithromycin <NUMBER> <NUMBER> female mean sd body mass index <NUMBER> <NUMBER> hypertension <NUMBER> patients <NUMBER> diabetes mellitus <NUMBER> patients <NUMBER> common comorbid conditions overall median interquartile range baseline qtc <NUMBER> <NUMBER> milliseconds hydroxychloroquine <NUMBER> <NUMBER> milliseconds vs hydroxychloroquine azithromycin <NUMBER> <NUMBER> milliseconds p <NUMBER> receiving concomitant azithromycin greater median interquartile range change qt interval <NUMBER> <NUMBER> milliseconds compared receiving hydroxychloroquine alone <NUMBER> <NUMBER> <NUMBER> milliseconds p <NUMBER> seven patients <NUMBER> received hydroxychloroquine monotherapy developed prolonged qtc <NUMBER> milliseconds <NUMBER> patients <NUMBER> change qtc <NUMBER> milliseconds received concomitant azithromycin <NUMBER> <NUMBER> <NUMBER> prolonged qtc <NUMBER> milliseconds <NUMBER> <NUMBER> <NUMBER> change qtc <NUMBER> milliseconds likelihood prolonged qtc greater received concomitant loop diuretics adjusted odds ratio <NUMBER> <NUMBER> ci <NUMBER> baseline qtc <NUMBER> milliseconds adjusted odds ratio <NUMBER> <NUMBER> ci <NUMBER> ten patients hydroxychloroquine discontinued early potential adverse drug events including intractable nausea hypoglycemia <NUMBER> case torsades de pointes conclusions relevance cohort study patients received hydroxychloroquine treatment pneumonia associated covid<NUMBER> high risk qtc prolongation concurrent treatment azithromycin associated greater changes qtc clinicians carefully weigh risks benefits considering hydroxychloroquine azithromycin close monitoring qtc concomitant medication usage risk qt interval prolongation associated use hydroxychloroquine without concomitant azithromycin among hospitalized patients testing positive coronavirus disease <NUMBER> covid<NUMBER> importance administration hydroxychloroquine without azithromycin treatment coronavirus disease <NUMBER> covid<NUMBER>associated pneumonia carries increased risk corrected qt qtc prolongation cardiac arrhythmias objective characterize risk degree qt prolongation patients covid<NUMBER> association use hydroxychloroquine without concomitant azithromycin design setting participants cohort study performed academic tertiary care center boston massachusetts patients hospitalized least <NUMBER> positive covid<NUMBER> nasopharyngeal polymerase chain reaction test result clinical findings consistent pneumonia received least <NUMBER> day hydroxychloroquine march <NUMBER> <NUMBER> april <NUMBER> <NUMBER> main outcomes measures change qt interval receiving hydroxychloroquine without azithromycin occurrence potential adverse drug events results among <NUMBER> patients given hydroxychloroquine <NUMBER> received concomitant azithromycin <NUMBER> <NUMBER> female mean sd body mass index <NUMBER> <NUMBER> hypertension <NUMBER> patients <NUMBER> diabetes mellitus <NUMBER> patients <NUMBER> common comorbid conditions overall median interquartile range baseline qtc <NUMBER> <NUMBER> milliseconds hydroxychloroquine <NUMBER> <NUMBER> milliseconds vs hydroxychloroquine azithromycin <NUMBER> <NUMBER> milliseconds p <NUMBER> receiving concomitant azithromycin greater median interquartile range change qt interval <NUMBER> <NUMBER> milliseconds compared receiving hydroxychloroquine alone <NUMBER> <NUMBER> <NUMBER> milliseconds p <NUMBER> seven patients <NUMBER> received hydroxychloroquine monotherapy developed prolonged qtc <NUMBER> milliseconds <NUMBER> patients <NUMBER> change qtc <NUMBER> milliseconds received concomitant azithromycin <NUMBER> <NUMBER> <NUMBER> prolonged qtc <NUMBER> milliseconds <NUMBER> <NUMBER> <NUMBER> change qtc <NUMBER> milliseconds likelihood prolonged qtc greater received concomitant loop diuretics adjusted odds ratio <NUMBER> <NUMBER> ci <NUMBER> baseline qtc <NUMBER> milliseconds adjusted odds ratio <NUMBER> <NUMBER> ci <NUMBER> ten patients hydroxychloroquine discontinued early potential adverse drug events including intractable nausea hypoglycemia <NUMBER> case torsades de pointes conclusions relevance cohort study patients received hydroxychloroquine treatment pneumonia associated covid<NUMBER> high risk qtc prolongation concurrent treatment azithromycin associated greater changes qtc clinicians carefully weigh risks benefits considering hydroxychloroquine azithromycin close monitoring qtc concomitant medication usage risk qt interval prolongation associated use hydroxychloroquine without concomitant azithromycin among hospitalized patients testing positive coronavirus disease <NUMBER> covid<NUMBER> novel coronavirus covid<NUMBER> taken world storm causing widespread quarantines lockdowns entire nations actions seen century since <NUMBER> spanish influenza natural defense infectious pathogen avoid contracting pathogen altogether quarantine practice employed since antiquity <NUMBER> world leaders allude promise vaccines brief time period development novel agents treatment perhaps examine whether already existing therapeutics effective treating people affected covid<NUMBER> researchers china nation first affected covid<NUMBER> expeditiously assessed potential use already existing compounds treating covid<NUMBER> hydroxychloroquine chloroquine nonhydroxylated compound demonstrated effective control infection covid<NUMBER> vitro <NUMBER> hydroxychloroquine demonstrated comparable efficacy chloroquine used treatment sarscov<NUMBER> infection vitro vero cells superior chloroquine used pretreatment prophylaxis <NUMBER> impressive vitro results conducted published rapid timeframes sparked interest use compounds fight covid<NUMBER> infection igniting wave international clinical trials leading adoption hydroxychloroquine chloroquine national guidelines several countries including china korea poland treatment covid<NUMBER> <NUMBER> potential use chloroquine hydroxychloroquine antiviral novel concept chloroquine demonstrated efficacy sarscov vitro avian influenza h<NUMBER>n<NUMBER> mice human coronavirus oc<NUMBER> newborn mice <NUMBER> demonstrated long emergence novel sarscov<NUMBER> although hydroxychloroquine chloroquine demonstrated therapeutic antiviral potential models efficacy compounds antivirals large controlled clinical studies humans yet demonstrated clinical evidence mounting evidenced recent clinical study february <NUMBER> gao colleagues published interim report clinical trials describing chloroquine demonstrated superior efficacy treatment covid<NUMBER> infection seen multiple disease parameters humans leading recommendation widespread use <NUMBER> report noted significant improvements chloroquine improving disease parameters including time seronegative conversion shortening disease though magnitude effects yet published clinical trial recently published marseille found hydroxychloroquine superior standard care eradication virus <NUMBER> study limitations including small size lack reporting clinical assessments openlabel enrollment <NUMBER> results remain promising consistent previous research studies complemented recent additional reports encouraging results hydroxychloroquine chloroquine news outlets given hydroxychloroquine chloroquine among widely prescribed medications world generally confident safety course therapeutic agent always risks adverse effects thus risks benefits treatment always need determined individual basis risks treatment hydroxychloroquine include retinal damage associated long term use qt prolongation hydroxychloroquine contraindicated people history hypersensitivity <NUMBER>aminoquinoline compounds used caution people glucose<NUMBER>phosphate dehydrogenase deficiency <NUMBER> recommended dosing regimens recent literature national guidelines individual hospital guidelines covid<NUMBER> similar currently used malaria <NUMBER> <NUMBER> given hydroxychloroquine demonstrated superior efficacy vitro prevention infection considered firstline agent covid<NUMBER> infection chloroquine hydroxychloroquine utilized given low risks associated treatment explored therapeutic agent dose <NUMBER> mg orally per day addition larger clinical studies evaluate therapeutic efficacy setting active infection particular interest would studies examining utility hydroxychloroquine prophylaxis covid<NUMBER> weekly dose <NUMBER> mg orally given long halflife <NUMBER> days previous utility prophylactic agent malaria infections promising vitro results <NUMBER> <NUMBER> despite limited clinical data hydroxychloroquine taken <NUMBER> mg orally per day active infection may offer avenue infection control treatment affected individuals time rapid need therapeutic options perhaps answer lifetime pandemic found dependable agent used treatment malaria several decades found readily throughout world vp completed work manuscript syndromerelated coronavirus<NUMBER> sarscov<NUMBER> <NUMBER> virus first recognized wuhan china december <NUMBER> quickly spread globally leading pandemic <NUMBER> currently standard care jurisdictions mild moderate covid<NUMBER> includes selfobservation selfquarantine <NUMBER> days <NUMBER> <NUMBER> small studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> methodologic limitations suggested certain therapies may promise time publication proven effective therapies exist major national international guidelines yet incorporate pharmacologic therapies covid<NUMBER> due lack high grade evidence <NUMBER> <NUMBER> effective postexposure prophylaxis preemptive therapeutic intervention would provide significant benefit individuals well public health given high rate sarscov<NUMBER> transmission overburdened healthcare systems onset symptoms covid<NUMBER> generally develops average <NUMBER> days exposure sarscov<NUMBER> <NUMBER> incubation period ranges <NUMBER> days <NUMBER> majority <NUMBER> people covid<NUMBER> exhibit mild symptoms recover spontaneously <NUMBER> however <NUMBER> patients develop hypoxemia requiring hospitalization admission intensive care unit icu andor invasive ventilation <NUMBER> hospitalized north america approximately <NUMBER> individuals develop respiratory failure shock andor multiple organ system dysfunction requiring admission critical care unit <NUMBER> sarscov<NUMBER> demonstrated rapid spread population basic reproductive value r <NUMBER> value <NUMBER> <NUMBER> <NUMBER> <NUMBER> secondary attack rate among household contacts estimated <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> estimates largely based monitoring travelassociated covid<NUMBER> cases context community transmission secondary attack rate may much higher <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> absence appropriate distancing strategies secondary attack rates may significantly higher since <NUMBER> patients secondary infections require hospitalization risk poor outcomes including death protective therapeutic strategy urgently needed following exposure covid<NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint pharmacologic agents shown vitro suppression viral replication coronaviruses <NUMBER> one agent chloroquine shown effective reducing laboratory established infection spread adjacent cells sarscov <NUMBER> recently related drug hydroxychloroquine found prevent sarscov<NUMBER> viral replication infection vero cell lines <NUMBER> exact antiviral mechanism hydroxychloroquine sarscov<NUMBER> incompletely understood may relate impaired angiotensin converting enzyme<NUMBER> ace<NUMBER> receptor binding resultant cell entry well suppression cytokine storm <NUMBER> recent news outlet reports chloroquine poisoning raised concerns regarding safety hydroxychloroquine scientific details lacking recent trial hospitalized covid<NUMBER> patients brazil stopped early n<NUMBER> due safety concerns patients receiving high dose chloroquine <NUMBER> grams <NUMBER> days prolonged qtc <NUMBER> msec <NUMBER> including <NUMBER> deaths secondary ventricular tachycardia <NUMBER> dose orders magnitude higher malaria prophylaxis <NUMBER> mg weekly malaria treatment <NUMBER> grams total wellestablished safety profiles <NUMBER> hydroxychloroquine much less toxic hydroxychloroquine <NUMBER> decades established safety data treatment malaria autoimmune conditions <NUMBER> preliminary data covid<NUMBER> trials demonstrated increased gi upset significant differences serious adverse events <NUMBER> early translational clinical studies demonstrated hydroxychloroquine might effective pharmacologic treatment prevent viral establishment used early exposure established infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> delaying treatment time hospitalization occurs average <NUMBER> days symptom onset <NUMBER> may associated lack benefit due established viral infection <NUMBER> <NUMBER> however current evidence base limited due small underpowered sample sizes large observational studies without proper controls <NUMBER> global political forces continue emphasize notyetproven role hydroxychloroquine paradigm covid<NUMBER> treatment urgent clinical trials therefore needed establish whether hydroxychloroquine may effective therapy covid<NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> determine hydroxychloroquine compared placebo effective <NUMBER> preventing covid<NUMBER> disease exposure known case ie postexposure prophylaxis <NUMBER> preventing severe complications disease started early course illness ie preemptive therapy trial doubleblind placebocontrolled multicenter international randomizedcontrolled trial designed evaluate superiority hydroxychloroquine versus placebo participants enrolled two nested trials randomized separately separate endpoints use workflow study team documents infrastructure postexposure prophylaxis pep trial include asymptomatic healthcare workers household contacts exposed covid<NUMBER> positive cases within <NUMBER> days preemptive therapy pet trial include outpatients covid<NUMBER> symptoms <NUMBER> fewer days duration trial planned recruit total <NUMBER> patients within trial participants randomized <NUMBER> parallel groups receive hydroxychloroquine placebo clinical trial registered ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> participants nonhospitalized adults recruited community via advertisements using traditional methods social media twitter instagram facebook recruitment take place throughout united states least initially within three provinces canada quebec manitoba alberta approval sought additional provinces order limit spread disease inperson visits study personnel performed recruitment followup participants home self isolation quarantine screening informed consent randomization data collection occur online research electronic data capture redcap secure webbased platform study medications delivered directly participants place residence via courier services respect safety protocols home deliveries patients covid<NUMBER> participants contact local study teams region via email phone questions concerns timely responses day business hours following day <NUMBER>pm websites created provide live enrollment updates responses frequently asked questions trial information participants wwwcovidpepumnedu wwwcovid<NUMBER>researchca • adults ≥ <NUMBER> years old • able read comprehend french english ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint enrollment pep trial limited asymptomatic individuals exposed covid<NUMBER> confirmed case within <NUMBER> days mean incubation period sarscov<NUMBER> <NUMBER> days <NUMBER> household contacts defined residing domicile risk exposures healthcare setting defined greater <NUMBER> minutes spent within <NUMBER> meters covid<NUMBER> confirmed case insufficient use personal protective equipment per institutional guidelines healthcare workers selfidentified physicians nurses respiratory therapists workers providing direct patient contact select highrisk group developing clinical infection within time period intervention could prevent ameliorate disease efforts made deliver study medicines prior <NUMBER> th day following exposure however delays may lead symptom onset randomization prior starting intervention events tracked online surveys administered upon receipt intervention due community testing limitations covid<NUMBER> participants included pet group long symptoms compatible covid<NUMBER> exposure person confirmed covid<NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> participants randomized <NUMBER> receive hydroxychloroquine placebo hydroxychloroquine sulfate administered <NUMBER> mg tablets total dose <NUMBER> mg <NUMBER> tablets <NUMBER> consecutive days dosing regimens consist loading dose subsequent maintenance dose follows <NUMBER> day <NUMBER> upon receipt study medicine hydroxychloroquine <NUMBER> mg orally <NUMBER> tablets followed <NUMBER> <NUMBER> hours later <NUMBER> mg orally <NUMBER> tablets <NUMBER> days <NUMBER> <NUMBER> hydroxychloroquine <NUMBER> mg orally daily <NUMBER> tablets per day ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint placebo tablets administered using dosing schedule number tablets interventional arm rational study dose adapted modified malaria dosing schedule hydroxychloroquine <NUMBER> considerations made maximal viral inhibition balancing potential toxicity drug supply anticipated shortages loading dose used similar malaria treatment strategy achieve antiviral activity quickly possible monte carlo simulations conducted proposed dose achieving steadystate serum concentrations ec<NUMBER> <NUMBER> <NUMBER> viral inhibition would occur common anticipated side effect hydroxychloroquine gastrointestinal upset <NUMBER> participants instructed spread doses throughout day eg <NUMBER> tabs breakfast <NUMBER> tab lunch increase tolerability required participants may voluntarily stop taking study medicine time adherence collected selfreport chronic medications taken usual must taken <NUMBER> hours taking study medicine concomitant covid<NUMBER> therapy trial medicines permitted duration trial event hospitalization unblinding group assignment occur request treating physician participants may receive medications therapies including experimental treatments trials primary outcome pep <NUMBER> incidence proven covid<NUMBER> disease onset <NUMBER> days absence sarscov<NUMBER> testing covid<NUMBER> diagnosis made using clinical criteria labelled possible case confirmed cases outcome may limitations related access testing use priori clinical definition using symptoms commonly reported pcr proven patients world health organization <NUMBER> primary outcome pet ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> analysis primary secondary outcomes listed performed separately trials assessment outcome measures selfreport via online questionnaires wherever possible covid<NUMBER> disease status verified public health records medical records death certificates patients positive molecular testing ie rtpcr nasopharyngeal swab sarscov<NUMBER> considered confirmed cases <NUMBER> molecular testing performed per local institution standard procedures patients covid<NUMBER> disease require hospitalization outcome data collected day <NUMBER> participants complete additional online surveys throughout hospitalization assess adverse events related study medicine covid<NUMBER> related outcomes participants complete virtual assessments days <NUMBER> <NUMBER> <NUMBER> figure <NUMBER> symptomatic disease develops participants required complete additional virtual assessments day <NUMBER> <NUMBER> participants pregnant become pregnant participating trial followed postpartum period assess maternal fetal outcomes event participant respond day <NUMBER> survey contact ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint telephone registered mail still available participants given <NUMBER> rd party telephone contact verify vital status recruitment follow exclusively internetbased prospective participants visit trial website read provided study information click link enroll trial website advertised communication strategies media channels internetbased advertisements social media regions covid<NUMBER> positive cases reported public health positive patients notified contact tracing initiated jurisdictions public health officials provide information accessing trial website health care workers notified trial website email communications offices occupational health promotion senior hospital administration online screening questionnaires assess interested participants eligibility criteria eligible participants provide informed consent submitting online form linked trial website contact information provided participants ask questions email andor phone participants randomized via computergenerated permuted block randomization stratified pep trial asymptomatic participants pet trial symptomatic participants randomization sequence prespecified randomization recorded electronic log accessed research pharmacy packaging study medication unblinded statisticians study investigators trial participants care providers outcome assessors data analysts blinded allocation sequence study medication prepared onsite pharmacies packages shipped directly participants via courier participants provided masked study medicine notified whether taking hydroxychloroquine placebo instructions taking medicine identical groups due variety sources hydroxychloroquine used different jurisdictions placebo identically matched hydroxychloroquine tablet ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint however placebo hydroxychloroquine similar rounded oval shapes color indistinct markings making unblinding trial arm unlikely patients asked believe received intervention control upon trial closure event medical emergency oncall investigator available code breaking required code breaking event reported research pharmacy principal investigator data collection including baseline demographics clinical epidemiological characteristics study medicine tolerability adherence outcomes recorded online selfreport captured internetbased questionnaires administered redcap participant submitted data stored maintained secure server data united states us stored secure servers university minnesota data canada stored secure servers research institute mcgill university health centre us canadian databases stored managed respective countries interim data safety monitoring board purposes also upon completion recruitment confidential deidentified data shared facilitate analysis institutional data sharing agreements paper documents retained stored enrollment progress reports generated trial <NUMBER> <NUMBER> <NUMBER> enrollment highlight number participants enrolled study completed lost follow cumulative incidence covid<NUMBER> arms pooled cumulative hospitalizations arms pooled reported according existing research attack rate transmission household contacts approximately <NUMBER> <NUMBER> used fishers exact test twosided α <NUMBER> test power β <NUMBER> detect <NUMBER> relative risk reduction disease incidence using <NUMBER> randomization calculated required sample size n<NUMBER> per arm accounting predicted <NUMBER> dropout rate internet selfstudy design sample size inflated n<NUMBER> per arm therefore aimed recruit total <NUMBER> patients pep trial symptomatic patients proportion patients progress require hospitalization approximately <NUMBER> <NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint trial assumed without treatment <NUMBER> control arm would hospitalized <NUMBER> would hospitalized without icu stay death <NUMBER> would hospitalized icu stay death <NUMBER> randomization <NUMBER> total participants pet trial <NUMBER> power detect log odds ratio <NUMBER> number sample size approximations made accounting differences baseline rates relative effect sizes found appendix <NUMBER> <NUMBER> primary secondary outcomes analyzed separately pep pet trials intentiontotreat primary outcome pep incidence covid<NUMBER> disease day <NUMBER> assessed intervention vs control arm fishers exact test primary outcome pet ordinal scale disease severity outpatient hospitalized without icu hospitalized icu death day <NUMBER> assessed intervention vs control arms proportional odds model pep group subset patients develop symptoms covid<NUMBER> taking least one dose study medicine analyze change symptom severity intervention vs control group use approach primary outcome pet group participants randomized pep group develop symptoms taking one dose study medicine described analyzed separately subgroup analysis secondary outcomes incidence reported fishers exact tests continuous valued secondary outcomes reported mean standard deviation median interquartile ranges depending normality analysis conducted parametric ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint nonparametric tests appropriate symptom severity scores recorded days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> using <NUMBER>centimeter continuous visual analogue scale participants electronically control slider indicating symptom severity <NUMBER> symptoms <NUMBER> severe symptoms measurements recorded nearest <NUMBER>centimeter severity symptoms day <NUMBER> compared first categorical analysis symptoms present yes via fishers exact chi square subsequently via independent twosample test symptom severity among symptomatic data nonnormally distributed analyze data via mannwhitney u test <NUMBER> participants contact sarscov<NUMBER> confirmed positive molecular test <NUMBER> participant sarscov<NUMBER> confirmed positive molecular test <NUMBER> exposure healthcare worker versus household contact <NUMBER> number days exposure <NUMBER> decile age <NUMBER> sex biological variable <NUMBER> censored subjects pep trial become symptomatic taking one dose study medicine data safety monitoring board dsmb formed independent sponsor without competing interests trial pep pet interim analysis presented dsmb <NUMBER> day follow achieved <NUMBER> <NUMBER> <NUMBER> trial enrollment interim analyses pool us canadian deidentified data arrive generalizable conclusion early possible dsmb unblinded statisticians provided unblinded interim analysis results investigators access pooled results landemets spending function analog obrienfleming boundaries primary outcome group provided dsmb stopping boundaries truncated α <NUMBER> z <NUMBER> analysis data reviewed safetyefficacy achieving stopping rules stopping rules primary outcome met dsmb review secondary outcomes consistency clear answer achieved ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint event early termination efficacy trial immediately convert openlabel observational cohort study second dsmb review sample size reestimation occur based disease transmission rate control group priori assumption <NUMBER> transmission risk close contacts based limited data jurisdictions new sample size estimation take account updated transmission rate trial powered detect <NUMBER> relative reduction primary outcome starting second dsmb review dsmb given conditional power trial design parameters current data conditional power less <NUMBER> trial discontinuation may considered shortterm use hydroxychloroquine welltolerated safe track record use approved indications since <NUMBER> commonly reported side effects include gastrointestinal upset nausea vomiting diarrhea headache skin rash itching <NUMBER> gastrointestinal side effects minimized taken meals dosages separated throughout day participants instructed use optional strategies increase tolerance recent study showed risk harm high doses chloroquine <NUMBER> hydroxychloroquine much less toxic <NUMBER> doses used trial <NUMBER> grams total similar malaria treatment doses <NUMBER> grams total significantly less treatment coxiella infection autoimmune conditions <NUMBER> mg daily indefinitely demonstrating long history safety <NUMBER> recent trial covid<NUMBER> using significantly higher doses <NUMBER> grams daily x <NUMBER> days <NUMBER> mg daily <NUMBER> weeks demonstrated significant differences serious adverse advents though gastrointestinal side effects higher dose <NUMBER> safety taking hydroxychloroquine enhanced excluding preexisting retinopathy allergic reactions cardiac conditions certain medications adverse reactions documented via selfreport virtual visits participants provided contact information guided manage adverse effects predefined ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> plans posttrial care standard care offered center participants provided updated public health information covid<NUMBER> pandemic instructions proceed event medical emergency regulatory agencies institutional sponsors rebs authorized conduct trial audits throughout interactions trial participants internetbased redcap electronic case report forms conforming required privacy server security standards participant identifying information disclosed publication activities arising trial anonymized data pooled international collaborators subject interinstitutional agreements information concerning trial released unauthorized third parties without prior written approval participants except monitoring rebs public health authorities immediate study personnel authorized access database protocol amendments reviewed reb updated trial registry websites trial enrollment results available updated wwwclinicaltrialsgov publicly available trial websites wwwcovidpepumnedu wwwcovid<NUMBER>researchca due nature pandemic pooled anonymized trial results published immediately available open access websites submitted urgently accelerated peer reviewed publication full deidentified data made available qualified researchers upon request ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> hydroxychloroquine garnered unprecedented attention potential therapeutic option global covid<NUMBER> pandemic <NUMBER> several vitro vivo studies shown data may support possible efficacy clinical data limited small clinical trials uncontrolled case series cohorts <NUMBER> urgent need rigorous evaluation hydroxychloroquine therapeutic option innovative trial adequately powered rapidly answer urgent questions regarding effectiveness hydroxychloroquine ability prevent reduce severity covid<NUMBER> novel webbased design trial setting highly contagious global pandemic ensured interactions participants including enrollment informed consent done remotely using courier services medicine delivery internetbased followup allow compliance strict social distancing strategies reduce risks infectious spread study personnel others design encourages large scale enrollment rapid achievement enrollment target trial results importantly design finalized regulatory reb approvals obtained large geographic jurisdictions brought online unprecedently short duration within weeks global pandemic goal obtain maximal information minimal amount time recently several public figures promoted widespread use hydroxychloroquine absence robust scientific data <NUMBER> <NUMBER> trial help address large scale dissemination hydroxychloroquine appropriate certain populations importantly study shows positive effect support new therapeutic option mitigate global spread impact covid<NUMBER> null negative effect shown reduce risk harm future patients reduce health care expenditures ineffective medications protect drug supply patients previously established indications hydroxychloroquine results trial instrumental determining hydroxychloroquine may play important role mitigating global impact covid<NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> ccbynd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint since breakout infection novel severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> end <NUMBER> wuhan china <NUMBER> recently plasma convalescent patients used wuhan manage refractory patients successfully scope treatment greatly constrained due limited supply effective plasma chloroquine hydroxychloroquine two classic drugs <NUMBER> originally used treat malaria recent years repurpose existing drugs chloroquine class drugs diseases received increasingly growing attention <NUMBER> <NUMBER> chloroquine hydroxychloroquine used treat rheumatological immunological diseases rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity key reduce mortality covid<NUMBER> however cure critically ill patients study demonstrates hydroxychloroquine application less toxic derivative chloroquine significantly associated decreased mortality critically ill patients covid<NUMBER> attenuating inflammatory cytokine storm investigation retrospective study involving critically ill patients patients medical history imaging characteristics covid<NUMBER> confirmed sarscov<NUMBER> infection laboratory tests rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint addition patients confirmed chest computed tomography ct sarscov<NUMBER> pathogenic test inclusion critically ill patients meet one following criteria <NUMBER> patients respiratory failure needed mechanical ventilation <NUMBER> patients septic shock hospitalization <NUMBER> patients organ failures required monitoring treatment intensive care unit study included critically ill patients hospitalization epidemic period february <NUMBER> <NUMBER> april <NUMBER> <NUMBER> health care data covid<NUMBER> patients including medical history chest ct laboratory tests inhospital therapies clinical deposits death cured discharge extracted data coordinators electronic medical records laboratory test results included inflammatory cytokines counts white blood cells peripheral blood continuous values expressed medians interquartile range q<NUMBER>q<NUMBER> categorical variables counts percentages comparisons continuous values groups performed wilcoxon ranksum tests paired continuous variables paired sample wilcoxon rank test used categorical variables compared using chisquare test survival curves described kaplanmeier method compared logrank test cox regression performed determine hazard ratios hrs <NUMBER> confidence intervals cis mulitivariable model adjusted age sex history hypertension diabetes mellitus coronary heart disease copd oxygen saturation well baseline treatment drugs comparisons twotailed p <NUMBER> considered statistically significant statistical analyses performed r packages version <NUMBER> vienna austria rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint february <NUMBER> <NUMBER> april <NUMBER> <NUMBER> total <NUMBER> critically ill covid<NUMBER> patients admitted tongji hospital <NUMBER> males <NUMBER> females median ages <NUMBER> years old <NUMBER> patients received hydroxychloroquine treatments hcq oral <NUMBER> mg twice per day <NUMBER> days remaining <NUMBER> receiving basic treatments nonhydroxychloroquine treatments nhqc two groups baseline characteristics including age genders original comorbidities well severity disease different table <NUMBER> total <NUMBER> patients <NUMBER> patients died mortality <NUMBER> order eliminate influence confounding factors performed cox rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity laboratory tests showed hcq group il<NUMBER> level plasma <NUMBER> figure <NUMBER> furthermore analyzed change il<NUMBER> level hospitalization period found il<NUMBER> level lowered hcq application kept lower level stable therapy period however interestingly hydroxychloroquine treatment stopped inflammatory mediator il<NUMBER> level went control level figure <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity retrospective study found hydroxychloroquine application significantly associated decreased mortality critically ill patients covid<NUMBER> lower level il<NUMBER> one inflammatory cytokines also found length hospital stay hydroxychloroquinetreated nonsurvivors longer nonhydroxychloroquinetreated nonsurvivors suggesting hydroxychloroquine could prolong lifetime critically ill patients even lives eventually lost supports hydroxychloroquine therapeutic effects critically ill patients covid<NUMBER> importantly found role hydroxychloroquine application associated decreased plasma il<NUMBER> level highly consistent duration administration drug stops plasma il<NUMBER> level rises control level noted hydroxychloroquine vitro antiviral effects several viruses including sars sarscov<NUMBER> <NUMBER> may contribute directly therapeutic effect covid<NUMBER> patients however antisarscov<NUMBER> action chloroquine seems account significant efficiency critically ill patients cohort covid<NUMBER> patients displayed obvious immunity disorders showing marked reduction lymphocyte numbers peripheral blood lymphatic tissues huge amount lymphocyte infiltration lungs well critical organs heart many patients showed symptoms cytokine storm markedlyelevated levels proinflammatory cytokine il<NUMBER> suggesting overactivated immune responses <NUMBER> antiil<NUMBER> antibody tocilizumab shown effective treatment option covid<NUMBER> patients risk cytokine storms <NUMBER> study demonstrate hydroxychloroquine mimic effect antiil<NUMBER> antibody observing decreased levels il<NUMBER> critically ill covid<NUMBER> patients rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity <NUMBER> <NUMBER> inhibit proinflammatory cytokines inhibition lysosomalautophagy pathways <NUMBER> additionally decreased plasma il<NUMBER> level hydroxychloroquine use highly consistent application period stopped role disappear il<NUMBER> level increases level nonhydroxychloroquine patients finding indicates need adjust treatment regimen keep use hydroxychloroquine patients completely cured summary retrospective study demonstrates hydroxychloroquine application associated decreased risk death critically ill covid<NUMBER> patients without obvious toxicity mechanisms action probably mediated inhibition inflammatory cytokine storm top ability inhibiting viral replication therefore hydroxychloroquine considered primary option apply treat critically ill covid<NUMBER> patients could save lives current covid<NUMBER> pandemic despite randomizeddouble blind control study needed provide rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint stronger evidence although retrospective study performed critically ill covid<NUMBER> patients hydroxychloroquine also option early stage patients safety records long history use treating malaria infections rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> percentage represented frequency divided total cohort size n<NUMBER> mechanical ventilation contained noninvasive ventilation invasive ventilation data presented medians interquartile range q<NUMBER>q<NUMBER> hcq hydroxychloroquine treatment nhcq nonhydroxychloroquine treatment rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> data presented medians interquartile range q<NUMBER>q<NUMBER> hcq hydroxychloroquine treatment nhcq nonhydroxychloroquine treatment rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint chloroquine hydroxyanalog hydroxychloroquine first proposed <NUMBER> treatment severe acute respiratory syndrome sars <NUMBER> due promising invitro effects <NUMBER> repurposed drug treatment covid<NUMBER> clinical trials covid<NUMBER> far produced mixed results study interaction drug virushost dynamics vivo necessary order provide insight optimal timing administration association interventions however many decades clinical use hydroxychloroquine part pharmacokinetics still unknown number studies still rely drug plasma concentrations <NUMBER> optimal indicator biodistribution drug weak base becomes readily entrapped intracellular acidic organelles due hendersonhasselbach law <NUMBER> recent advancement likely shed light interplay sarscov<NUMBER> antiviral drugs availability mathematical model able simulate virushost interplay matching clinical observations <NUMBER> similar models developed authors study proven able simulate viral dynamics hivaids providing important therapeutic hints <NUMBER> <NUMBER> present paper use model simulate possible scenarios response hydroxychloroquine covid<NUMBER> patients present paper used system differential equations built gonçalves et al <NUMBER> follows ordinary differential equations describing viral dynamics model target cell population eclipse phase accounting antiviral effectiveness chloroquine viral reproduction target cell populations represents target cells assumed <NUMBER>×<NUMBER> <NUMBER> <NUMBER> based assumption <NUMBER> ml nasopharyngeal volume <NUMBER> maintain cellular concentration <NUMBER> × <NUMBER> <NUMBER> cellsml <NUMBER> become infected constant parameter β changes according constant parameter <NUMBER>ε ε reflects antiviral effectiveness chloroquine simulated <NUMBER> <NUMBER> <NUMBER> based assumption reduction viral basic reproductive number r <NUMBER> antiviral <NUMBER> i<NUMBER> represents infected cells eclipse phase i<NUMBER> represents productively infected cells starts productivity phase average time <NUMBER>k k values considered <NUMBER> <NUMBER> allow prediction intervention timing effect viral propagation releasing virions controlled constant parameter p changes according constant parameter <NUMBER>ε assumed default <NUMBER> <NUMBER> infected cells later cleared constant parameter rate c assumed <NUMBER> <NUMBER> following previous models viral infection <NUMBER> infected cells i<NUMBER> cleared later circulation constant rate δ assumed default <NUMBER> <NUMBER> v reflects viral population modelled changing v <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> copiesml mathematical modelling implemented using python programming language v <NUMBER> httpwwwpythonorg odeint function scipy package used solving ordinary differential equations <NUMBER> numerical solutions applied numpy package <NUMBER> simulations plotted within <NUMBER> days time frame using matplotlib package <NUMBER> ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> <NUMBER> р <NUMBER> advanced stages covid<NUMBER> simulation δ <NUMBER> starting viral load <NUMBER> <NUMBER> copiesml provided considered unrealistic using system differential equations developed gonçalves et al <NUMBER> showed hydroxychloroquine may impact amplitude viral load peak effect viral clearance evident simulations mild viral loads less pronounced viral loads <NUMBER> <NUMBER> viral rna copiesml ie viral load commonly found throat swabs symptomatic disease <NUMBER> using parameters adopted authors model shows early peak viral replication followed gradual slow abatement viral load accompanying consumption target cells figure <NUMBER> supplemental figures s<NUMBER> s<NUMBER> first row treatment simulations gonçalves et al <NUMBER> concluded hydroxychloroquine sufficient effect viral load dynamics pharmacokinetic parameter used conduct simulations plasma drug concentration mentioned unlikely reflect biodistribution drug light plasma concentrations invivo drug efficacy calculated <NUMBER> second row figure <NUMBER> supplemental figures s<NUMBER> s<NUMBER> shows simulations conditions used whole blood concentration including drug compartment entrapped lysosomes <NUMBER> calculated drug efficacy <NUMBER> based concentrationresponse curves published yao et al <NUMBER> case pronounced decrease viral peak observable figure <NUMBER> supplemental figures s<NUMBER> s<NUMBER> third row another aspect needs attention double mechanism antiviral effects hydroxychloroquine derived studies huge number viruses lysosomal entrapment hydroxychloroquine highly likely affect viral entry simulated gonçalves et al <NUMBER> postentry stages cellular organelles viral budding viral particle glycosylation <NUMBER> <NUMBER> considered aforementioned study according data wang et al <NUMBER> chloroquine displayed approximately half antiviral activity added virus adsorption onto cells confirming part activity occurs postentry level therefore also wanted estimate impact hydroxychloroquineinduced impairment viral production times beyond <NUMBER> h period considered estimate hydroxychloroquine efficacy vitro <NUMBER> decreased viral production rate <NUMBER> ie half value calculated basis drug efficacy whole viral replicative cycle obtained decrease viral load peak steadystate figure <NUMBER> fourth row data used estimate response sarscov<NUMBER> hydroxychloroquine based trough blood concentrations provided morita et al <NUMBER> based drug regimen <NUMBER> mgday gautret et al <NUMBER> recently published trough serum concentrations hydroxychloroquine obtained patients covid<NUMBER> treated higher dosage ie <NUMBER> mgday hydroxychloroquine unfortunately blood concentrations reported gautret et al could proportionally derived ratios provided morita et al <NUMBER> maintaining similar plasmablood concentration ratio calculation led prediction drug levels whole blood <NUMBER> μm plotting value doseresponse curves published yao et al <NUMBER> extrapolated efficacy <NUMBER> adjusted viral infection production accordingly obtained decrease viral load peak figure <NUMBER> supplemental figures s<NUMBER> s<NUMBER> fifth row simulation may also account hydroxychloroquine administered <NUMBER> mgday combination another antiviral agent moderate potency among immunemodulating effects hydroxychloroquine capacity induce antigen crosspresentation increase immune cytotoxic response <NUMBER> <NUMBER> enhanced cytotoxic responses result increased death infected cells increasing death rate productively infected cells effect cytotoxic immunity <NUMBER> fold data derived accapezzato et al <NUMBER> could observe decrease peak amplitude shorter time viral load exhaustion figure <NUMBER> supplemental figures s<NUMBER> s<NUMBER> sixth row simulations provide confirm current hypotheses virologic response hydroxychloroquine covid<NUMBER> patients pharmacokinetic basis drug dosages acceptable toxicity profile narrow window overlap antiviral effective concentrations results line previous analyses hiv clinical trials showing dosages adopted safely clinic lowest range therapeutic window significant though yet partial effects observable highest doses administered <NUMBER> observations line clinical data reported far small trial france suggested hydroxychloroquine helps treat covid<NUMBER> <NUMBER> small study china <NUMBER> reported opposite results studies limitations limited statistical power due fact prepared emergency discrepancy results obtained may reside according results present study dosage hydroxychloroquine adopted french study reporting positive results using <NUMBER> mgday hydroxychloroquine chinese study unable show efficacy following adoption lower dosage <NUMBER> mgday furthermore reported response hydroxychloroquine french study incomplete authors add another experimental drug repositioned antiviral azithromycin order increase efficacy considerations line results obtained randomized clinical trials using chloroquine hydroxychloroquine equivalent dosage superior reported two aforementioned studies <NUMBER> <NUMBER> <NUMBER> safety margin chloroquinehydroxychloroquine narrow <NUMBER> administration higher dosages unfortunately hampered toxicity shown borba et al <NUMBER> although recent data show toxicity observed borba et al could fact ascribed concomitant administration azithromycin <NUMBER> results agree part simulations conducted arnold buckner <NUMBER> showing <NUMBER> mgday regimen might significant impact viral replication according parameters adopted garciacremades et al <NUMBER> showing dosage higher equal <NUMBER> mgday necessary obtain sustained remission approach followed conservative adopted arnold buckner <NUMBER> used whole blood concentrations measure prediction tissue accumulation rather predicted accumulation lung according model adopted arnold buckner <NUMBER> drug lung concentrations hundreds times higher plasma predicted reach concentration able inhibit <NUMBER> percent sarscov<NUMBER> replication decided follow prediction <NUMBER> tissue accumulation hydroxychloroquine lung mainly driven tissue macrophages main target virus <NUMBER> according data published yao et al <NUMBER> <NUMBER> per cent inhibition coronavirus replication reachable experimentally using hydroxychloroquine also smit et al reached similar conclusions based pharmacokinetic considerations <NUMBER> based simulations suggest chloroquine may silver bullet eradicating covid<NUMBER> infection side might display beneficial effects vivo simulations go beyond models published indicating earlier virologic negativization expected hydroxychloroquine administered dosages <NUMBER> mgday dosages <NUMBER> mgday iewithin narrow therapeutic window instead believe theoretical capacity hydroxychloroquine decrease viral load peak viral replication active deserves attention investigation results simulations line recent meta analysis far available clinical data showing hydroxychloroquine may decrease disease severity viral clearance administered symptomatic covid<NUMBER> patients <NUMBER> one limitation present study resides fact modeled viral dynamics effects molecule immune mediated mechanisms cytokine storm <NUMBER> may impact immune hyperactivation case inferred estimated potential drug decrease viral load peak amplitude associated deleterious immune hyperactivation coronavirus infections <NUMBER> hypothesis line ability sarscov<NUMBER> infect cd<NUMBER> tcells <NUMBER> target cells hiv characterized immune hyperactivation well <NUMBER> finally show effect chloroquinehydroxychloroquine antigen crosspresentation considered crosspresentation phenomenon dendritic cell presents antigen cd<NUMBER> tcells improving priming activation cd<NUMBER> tcells priming antigen recognition induce selective killing infected cells <NUMBER> taking account parameter possible predict hydroxychloroquine may accelerate viral clearance administered early accordingly model scenario increased cellmediated responses viral loads higher immune dysregulation case likely taken place enhanced cellmediated responses may induce selective killing infected cells also enhance immunity better longterm control infection hydroxychloroquine currently investigated also prophylactic agent <NUMBER> given great interest strategy far evoked context covid<NUMBER> <NUMBER> <NUMBER> future vaccines disease considered coadministration chloroquinehydroxychloroquine case chloroquinehydroxychloroquine prove ineffective protecting sarscov<NUMBER> acquisition plausible may mitigate disease severity attenuating viral replication ccbyncnd <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted april <NUMBER> <NUMBER> collaborative institutional training initiative citi legal counsel pfizer united states food drug administration uptodate receives royalties authorship editorship <NUMBER> textbooks coinventor patents inflammatory markers cardiovascular disease held brigham womens hospital investment management relationship westbacon group within suntrust investment services discretionary investment authority common preferred stock pharmaceutical medical device company thus us accounts <NUMBER> cases <NUMBER> deaths comprising <NUMBER> worlds population alarm healthcare providers patients present even without widespread rapid testing us already reported <NUMBER> times number cases country world even adjusting population sizes <NUMBER> times number deaths south korea whose first case reported day us <NUMBER> also likely widespread lay media reports well statements highestranking us government officials also contributing factor april <NUMBER> <NUMBER> president united states publicly stated lose take really think take next <NUMBER> hours prescriptions drugs healthcare providers skyrocketed <NUMBER> fold usual patterns <NUMBER> continued widespread prescriptions healthcare providers drugs covid<NUMBER> turn leading nationwide shortages thus patients systemic lupus erythematosus sle rheumatoid arthritis hydroxychloroquine approved indication decades unable refill prescriptions <NUMBER> commentary review totality available evidence conclude urgent need moratorium prescription drugs treatment prevention covid<NUMBER> totality evidence incomplete appropriate health care providers remain uncertain <NUMBER> nonetheless regulatory authorities sometimes china one showed significant difference viral clearance <NUMBER> days second difference viral clearance <NUMBER> days third improvements fever cough chest computed tomography findings <NUMBER> <NUMBER> <NUMBER> chief concern side effects prolongation qtc interval <NUMBER> lead electrocardiogram long known qtc prolongations <NUMBER> milliseconds msec lesser increases baseline values <NUMBER> msec associated fatal arrhythmias regards prescription hydroxychloroquine without azithromycin covid<NUMBER> case series qtc interval increased <NUMBER> milliseconds msec <NUMBER> baseline qtc intervals <NUMBER> msec <NUMBER> <NUMBER> respectively us fda adverse event reporting system reported similar findings lack comparison group formulate test hypotheses addition azithromycin little evidence benefit added hydroxychloroquine also independently prolongs qtc interval <NUMBER> summary recommend healthcare provider restrict prescriptions hydroxychloroquine chloroquine compassionate use patients covid<NUMBER> results randomized trials provide sufficient evidence regards risks healthcare providers aware reassuring safety profile hydroxychloroquine derives decades prescriptions autoimmune diseases greater prevalence younger middle age women whose risks fatal outcomes due prolongations qtc reassuringly low contrast risks covid<NUMBER> much higher mortality rates highest older patients comorbidities predominantly men conclusion healthcare providers always prioritize compassion evolving science safety data context recommend moratorium use chloroquine hydroxychloroquine without azithromycin treat prevent covid<NUMBER> exceptions obtaining necessary evidence randomized trials well compassionate use drugs need prescribed patients covid<NUMBER> baseline evaluations serial monitoring absolute necessity <NUMBER> urge competent compassionate healthcare providers adhere first words hippocratic oath primum non nocere backgroundaims efficacies lopinavirritonavir hydroxychloroquine remain determined patients coronavirus disease <NUMBER> covid<NUMBER> compare virological clinical responses lopinavirritonavir hydroxychloroquine treatment covid<NUMBER> patients methods retrospective cohort study included patients covid<NUMBER> treated lopinavirritonavir hydroxychloroquine single center korea february <NUMBER> march <NUMBER> <NUMBER> patients treated lopinavirritonavir hydroxychloroquine concurrently treated lopinavirritonavir hydroxychloroquine less <NUMBER> days excluded time negative conversion viral rna time clinical improvement safety outcomes assessed <NUMBER> weeks followup results <NUMBER> patients mean age <NUMBER> years <NUMBER> men <NUMBER> <NUMBER> treated lopinavirritonavir <NUMBER> treated hydroxychloroquine median duration symptoms treatment <NUMBER> days <NUMBER> patients <NUMBER> required oxygen support baseline patients treated lopinavirritonavir significantly shorter time negative conversion viral rna treated hydroxychloroquine median <NUMBER> days vs <NUMBER> days treatment lopinavirritonavir adjusted hazard ratio ahr <NUMBER> <NUMBER> confidence interval ci <NUMBER> <NUMBER> younger age ahr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> associated negative conversion viral rna significant difference time clinical improvement lopinavirritonavir hydroxychloroquinetreated patients median <NUMBER> days vs <NUMBER> days lymphopenia hyperbilirubinemia frequent lopinavirritonavirtreated patients compared hydroxychloroquinetreated patients conclusions lopinavirritonavir associated rapid viral clearance hydroxychloroquine mild moderate covid<NUMBER> despite comparable clinical responses findings confirmed randomized controlled trials lopinavirritonavir versus hydroxychloroquine viral clearance clinical improvement patients mild moderate coronavirus disease <NUMBER> backgroundaims efficacies lopinavirritonavir hydroxychloroquine remain determined patients coronavirus disease <NUMBER> covid<NUMBER> compare virological clinical responses lopinavirritonavir hydroxychloroquine treatment covid<NUMBER> patients methods retrospective cohort study included patients covid<NUMBER> treated lopinavirritonavir hydroxychloroquine single center korea february <NUMBER> march <NUMBER> <NUMBER> patients treated lopinavirritonavir hydroxychloroquine concurrently treated lopinavirritonavir hydroxychloroquine less <NUMBER> days excluded time negative conversion viral rna time clinical improvement safety outcomes assessed <NUMBER> weeks followup results <NUMBER> patients mean age <NUMBER> years <NUMBER> men <NUMBER> <NUMBER> treated lopinavirritonavir <NUMBER> treated hydroxychloroquine median duration symptoms treatment <NUMBER> days <NUMBER> patients <NUMBER> required oxygen support baseline patients treated lopinavirritonavir significantly shorter time negative conversion viral rna treated hydroxychloroquine median <NUMBER> days vs <NUMBER> days treatment lopinavirritonavir adjusted hazard ratio ahr <NUMBER> <NUMBER> confidence interval ci <NUMBER> <NUMBER> younger age ahr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> associated negative conversion viral rna significant difference time clinical improvement lopinavirritonavir hydroxychloroquinetreated patients median <NUMBER> days vs <NUMBER> days lymphopenia hyperbilirubinemia frequent lopinavirritonavirtreated patients compared hydroxychloroquinetreated patients conclusions lopinavirritonavir associated rapid viral clearance hydroxychloroquine mild moderate covid<NUMBER> despite comparable clinical responses findings confirmed randomized controlled trials lopinavirritonavir versus hydroxychloroquine viral clearance clinical improvement patients mild moderate coronavirus disease <NUMBER> author information event serious based ich definition patient outcome death lifethreatening hospitalisation disability congenital anomaly medically important event observational comparative study <NUMBER> patients coronavirus disease <NUMBER> covid<NUMBER> pneumonia require oxygen admitted four french tertiary care centres <NUMBER> march <NUMBER> <NUMBER> march <NUMBER> three patients ages sexes stated described developed corrected qt interval prolongation first degree atrioventricular block left bundle branch block offlabel treatment hydroxychloroquine covid<NUMBER> pneumonia patients severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> pneumonia required oxygen intensive care initiated offlabel therapy oral hydroxychloroquine <NUMBER> mgday subsequently one patient developed corrected qt interval prolongation <NUMBER>ms observed ecg second patient developed first degree atrioventricular block <NUMBER> days hydroxychloroquine treatment third patient started receiving hydroxychloroquine <NUMBER> days admission transferred intensive care <NUMBER> days later prescribed offlabel therapy ritonavir lopinavir severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> pneumonia patient developed left bundle branch block due hydroxychloroquine hospital day <NUMBER> durations treatments reactions onsets stated hydroxychloroquine stopped <NUMBER> patients due respective adr outcomes stated asia <NUMBER> <NUMBER> <NUMBER> australia <NUMBER> <NUMBER> <NUMBER> total <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> icu los <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> total los <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> table s<NUMBER> tipping point analysis completed assess effects unmeasured confounder findings significance hydroxychloroquine chloroquine unmeasured confounder size g created using lower bound <NUMBER> confidence interval chloroquine <NUMBER> hydroxychloroquine <NUMBER> combination therapy chloroquine secondgeneration macrolide <NUMBER> hydroxychloroquine secondgeneration macrolide <NUMBER> threshold prevalence unmeasured confounder determined medication follows figure shows sensitivity threshold unmeasured confounders various effect sizes function lower bound <NUMBER> confidence interval due similarity groups single tipping point analysis completed chloroquine hydroxychloroquine chloroquine secondgeneration macrolide using chloroquine reference lower <NUMBER> ci <NUMBER> hydroxychloroquine secondgeneration macrolide considered separately lower <NUMBER> ci <NUMBER> chloroquine hydroxychloroquine chloroquine secondgeneration macrolide highlighted green hypothetical unobserved binary confounder prevalence <NUMBER> exposed population would need hazard ratio <NUMBER> tip analysis nonsignificance <NUMBER> level comparison observed confounders study congestive heart failure hr <NUMBER> would need prevalence <NUMBER> population lead confounding analysis adjusted cox proportional hazards model hydroxychloroquine secondgeneration macrolide highlighted yellow hypothetical unobserved binary confounder prevalence <NUMBER> exposed population would need hazard ratio <NUMBER> tip analysis nonsignificance <NUMBER> level comparison observed absence effective treatment severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> infection led clinicians redirect drugs known effective medical conditions treatment covid <NUMBER> key among repurposed therapeutic agents antimalarial drug chloroquine analogue hydroxychloroquine used treat ment autoimmune diseases systemic lupus erythematosus rheumatoid arthritis <NUMBER> drugs shown laboratory conditions antiviral properties well immunomodulatory effects <NUMBER> <NUMBER> however use class drugs covid<NUMBER> based small number anecdotal experiences shown variable responses uncontrolled observational analyses small openlabel randomised trials largely inconclusive <NUMBER> <NUMBER> combination hydroxychloroquine secondgeneration macrolide azithromycin clarithromycin also advocated despite limited evidence effectiveness <NUMBER> previous studies shown treatment chloroquine hydroxychloroquine either drug combined macrolide cardiovascular adverse effect prolongation qt interval could mechanism predisposes ventricular arrhythmias <NUMBER> <NUMBER> although several multicentre randomised controlled trials underway pressing need provide accurate clinical guidance use chloroquine hydroxychloroquine along macrolides widespread often little regard potential risk countries stockpiled drugs resulting shortage medications need approved clinical indications <NUMBER> purpose study evaluate use chloroquine hydroxychloroquine alone combination macrolide treatment covid<NUMBER> using large multi national registry assess realworld application principally sought analyse association treatment regimens inhospital death secondarily aimed evaluate occurrence denovo clinically significant ventricular arrhythmias multinational registry analysis use hydroxychloroquine chloroquine without macrolide treatment covid<NUMBER> registry comprised <NUMBER> hospitals located six continents appendix p <NUMBER> surgical outcomes collaborative surgisphere corporation chicago il usa consists deidentified data obtained automated data extraction inpatient outpatient electronic health records sup ply chain databases financial records registry uses cloudbased healthcare data analytics platform includes specific modules data acquisition data warehousing data analytics data reporting manual data entry process used quality assurance validation ensure key missing values kept minimum surgical outcomes collaborative hereafter referred collaborative ensures compliance us food drug administration fda guidance realworld evidence realworld data collected automated data transfers capture <NUMBER> data healthcare entity regular predetermined intervals thus reducing impact selection bias missing values ensuring data current reliable relevant verifiable source documentation elements include electronic inpatient outpatient medical records accordance fda guidance relevance realworld data data acquisition performed use standardised health level sevencompliant data dictionary data collected evidence study searched medline via pubmed articles published april <NUMBER> <NUMBER> using key words novel coronavirus <NUMBER>ncov covid<NUMBER> sarscov<NUMBER> therapy hydroxychloroquine chloroquine macrolide moreover screened preprint servers medrxiv relevant articles consulted web pages organisations us national institutes health hydroxychloroquine chloroquine used without macrolide widely advocated treatment covid<NUMBER> based invitro evidence antiviral effect severe acute respiratory syndrome coronavirus <NUMBER> use based small uncontrolled studies absence evidence randomised controlled trials concerns raised drugs combination macrolides could result electrical instability predispose patients ventricular arrhythmias whether drugs improve outcomes associated harm covid<NUMBER> remains unknown absence reported randomised trials urgent need evaluate realworld evidence related outcomes use hydroxychloroquine chloroquine used without macrolides covid<NUMBER> using international observational registry across six continents assessed <NUMBER> <NUMBER> patients covid<NUMBER> <NUMBER> <NUMBER> treated hydroxychloroquine chloroquine combination macrolide controlling age sex race ethnicity underlying comorbidities disease severity baseline use four regimens associated increased hazard denovo ventricular arrythmia death hospital study provides realworld evidence use therapeutic regimens including large number patients across world thus knowledge findings provide comprehensive evidence use hydroxychloroquine chloroquine without macrolide treatment covid<NUMBER> found evidence benefit hydroxychloroquine chloroquine used either alone macrolide previous evidence derived either small anecdotal studies inconclusive small randomised trials study included large number patients across multiple geographic regions provides robust realworld evidence date usefulness treatment regimens although observational studies cannot fully account unmeasured confounding factors findings suggest absence therapeutic benefit also potential harm use hydroxychloroquine chloroquine drug regimens without macrolide hospitalised patients covid<NUMBER> see online appendix prospective ongoing basis validation procedure registry refers standard operating procedures place four iso <NUMBER> iso <NUMBER> certified features registry data acquisition data warehousing data analytics data reporting standardised health level sevencompliant data dictionary used collaborative serves focal point data acquisition warehousing data dictionary harmonised electronic health record data data acquisition completed using automated interfaces expedite data transfer improve data integrity collection <NUMBER> sample healthcare entity validated financial records external databases minimise selection bias reduce risk inadvertent protected health information disclosures information stripped storage cloudbased data warehouse collaborative intended minimise effects information bias selection bias capturing allcomer data consecutive patient enrolment capturing <NUMBER> data within electronic systems ensuring results remain generalisable larger population collaborative compliant us agency healthcare research quality guidelines registries onset covid<NUMBER> crisis registry used collect data hospitals usa selected match epidemiological characteristics us population internationally achieve representation diverse populations across six continents data collected variety urban rural hospitals academic community hospitals forprofit nonprofit hospitals data collection analyses deemed exempt ethics review included patients hospitalised dec <NUMBER> <NUMBER> april <NUMBER> <NUMBER> hospitals participating registry pcrconfirmed covid<NUMBER> infection clinical outcome either hospital discharge death hospitalisation recorded positive laboratory finding sarscov<NUMBER> defined positive result highthroughput sequencing reverse transcriptionquantitative pcr assay nasal pharyngeal swab specimens finding used classifying patient positive covid<NUMBER> covid<NUMBER> diagnosed site basis guidance <NUMBER> patients record testing database negative test included study one positive test necessary patient included analysis patients received either hydroxychloroquine chloroquine analoguebased treatment without secondgeneration macrolide included treatment group patients received treatment regimens starting <NUMBER> h covid<NUMBER> diagnosis excluded also excluded data patients treatment initiated mechanical ventilation receiving therapy antiviral remdesivir specific exclusion criteria established avoid enrolment patients treatment might started nonuniform times course covid<NUMBER> illness exclude individuals drug regimen might used critical phase illness could skew interpretation results thus defined four distinct treatment groups patients started therapy within <NUMBER> h established covid<NUMBER> diagnosis chloroquine alone chloroquine macrolide hydroxychloroquine alone hydroxychloroquine macrolide included patients served control population patient demographics including age bodymass index bmi sex race ethnicity continent origin obtained underlying comorbidities based international classification diseases tenth revision clinical modification codes present either inpatient outpatient electronic health record collected included cardiovascular disease including coronary artery disease congestive heart failure history cardiac arrhythmia current previous history smoking history hypertension diabetes hyperlip idaemia chronic obstructive pulmonary disease copd presence immu nosuppressed condition steroid use preexisting immunological condition current chemotherapy individuals cancer collected data use medications baseline including cardiac inhibitors angiotensin receptor blockers statins use antiviral therapy drug regimens evaluated initiation hydroxychloroquine chloroquine hospital admission recorded including time initiation use secondgeneration macrolides specifically azithromycin clarithromycin similarly recorded quick sepsisrelated organ failure assessment qsofa calculated start therapy including scored calculation mental status respiratory rate systolic blood pressure oxygen saturation spo <NUMBER> room air recorded measures disease severity primary outcome interest association use treatment regimen containing chloroquine hydroxychloroquine without secondgeneration macrolide initiated early covid<NUMBER> diagnosis endpoint inhospital mortality secondary outcome interest association treatment regimens occurrence clinically significant ventricular arrhythmias defined first occurrence nonsustained least <NUMBER> sec sustained ventricular tachycardia ventricular fibril lation hospitalisation also analysed rates progression mechanical ventilation use total intensive care unit lengths stay days patients group primary analysis inhospital mortality controlled confounding factors including demographic variables comorbidities disease severity presentation med ication use cardiac medications antiviral therapies categorical variables shown frequencies percentages continuous variables means sds comparison continuous data groups done using unpaired ttest categorical data compared using fishers exact test p value less <NUMBER>·<NUMBER> considered significant multiple imputation missing values possible disease drug variables codes indicate data missing patients electronic health record include information clinical characteristic assumed characteristic present cox proportional hazards regression analysis done evaluate effect age sex race ethnicity using white race reference group comorbidities bmi presence coronary artery disease presence congestive heart failure history cardiac arrhythmia diabetes copd current smoker history hypertension immunocompromised state history hyperlipidaemia medications cardiac medications antivirals treatment regimens interest severity illness scores qsofa <NUMBER> spo <NUMBER> <NUMBER> risk clinically significant ventricular arrhythmia using time admission first occurrence event occur time discharge mortality using time admission inpatient mortality discharge age bmi treated continuous variables data treated categorical variables model model hazard ratios hrs <NUMBER> cis estimated included variables determine effect risk inhospital mortality primary endpoint subsequent mechanical ventilation death composite endpoint independence survival times time first arrhythmia ventricular arrhythmia analysis confirmed proportionality predictors hazard validated evaluation schoenfeld residuals found p<NUMBER>·<NUMBER> thus confirmed proportionality minimise effect confounding factors propensity score matching analysis done individually four treatment groups compared control group received form therapy treatment group separate matched control identified using exact propensityscore matched criteria calliper <NUMBER>·<NUMBER> method used provide close approximation demographics comorbidities disease severity baseline medications patients propensity score based following variables age bmi gender race ethnicity comorbidities use ace inhibitors use statins use angiotensin receptor blockers treatment antivirals qsofa score less <NUMBER> spo <NUMBER> less <NUMBER> room air patients well matched standardised mean difference estimates less <NUMBER> matched parameters additional analyses done examine robustness estimates initially obtained individual analyses continent origin sexadjusted analyses using cox proportional hazards models performed tippingpoint analysis analysis shows effect size prevalence unmeasured confounder could shift upper boundary ci towards null also done statistical analyses done r version <NUMBER> spss version <NUMBER> funder study role study design data collection data analysis data interpretation writing report corresponding author coauthor anp full access data study final responsibility decision submit publication combination therapy one antiviral regimens used <NUMBER> <NUMBER>·<NUMBER> patients treatment groups included <NUMBER> patients given chloroquine alone <NUMBER> given hydroxychloroquine alone <NUMBER> given chloroquine macrolide <NUMBER> given hydroxychloroquine macrolide median time hospitalisation diagnosis covid<NUMBER> <NUMBER> days iqr <NUMBER> mean daily dose duration various drug regimens follows chloroquine alone <NUMBER> mg sd <NUMBER> <NUMBER>·<NUMBER> days <NUMBER>·<NUMBER> hydroxychloroquine alone <NUMBER> mg <NUMBER> <NUMBER>·<NUMBER> days <NUMBER>·<NUMBER> chloroquine macrolide <NUMBER> mg <NUMBER> <NUMBER>·<NUMBER> days <NUMBER>·<NUMBER> hydroxychloroquine macrolide <NUMBER> mg <NUMBER> <NUMBER>·<NUMBER> days <NUMBER>·<NUMBER> additional details study cohort provided appendix pp <NUMBER> <NUMBER> demographic variables comorbidities compared among survivors nonsurvivors table <NUMBER> nonsurvivors older likely obese likely men likely black hispanic diabetes hyperlipidaemia coronary artery disease congestive heart failure history arrhythmias nonsurvivors also likely copd reported current smoking distribution demographics comorbidities outcomes four treatment groups shown table <NUMBER> significant betweengroup differences found among baseline characteristics comorbidities ventricular arrhythmias common <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> decreased risk death increased risk death treatment groups compared control population mortality higher treatment groups compared control population p<NUMBER>·<NUMBER> appendix pp <NUMBER> <NUMBER> <NUMBER> <NUMBER> independent predictors inhospital mortality shown figure <NUMBER> age bmi black race hispanic ethnicity versus white race coronary artery disease congestive heart failure history arrhythmia diabetes hypertension hyperlipidaemia copd current smoker immunosuppressed condition associated higher risk inhospital death female sex ethnicity asian origin use ace inhibitors angiotensin receptor blockers use statins associated reduced inhospital mortality risk compared control group <NUMBER>·<NUMBER> hydroxychloroquine alone <NUMBER>·<NUMBER> hr <NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> hydroxychloroquine macrolide <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> chloroquine alone <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> chloroquine macrolide <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> independently associated increased risk inhospital mortality multivariable cox regression analyses continent shown appendix pp <NUMBER> well data sexadjusted multivariable logistic regression analyses pp <NUMBER> separate cox regression analysis combined endpoint mechanical ventilation mortality p <NUMBER> independent predictors ventricular arrythmia shown figure <NUMBER> coronary artery disease congestive heart failure history cardiac arrhythmia copd independently associated increased risk denovo ventricular arrhythmias hospitalisation compared control group <NUMBER>·<NUMBER> hydroxychloroquine alone <NUMBER>·<NUMBER> hr <NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> hydroxy chloroquine macrolide <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> chloroquine alone <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> chloroquine macrolide <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> <NUMBER>·<NUMBER>·<NUMBER> inde pendently associated increased risk denovo ventricular arrhythmia hospitalisation analyses using propensity score matching treatment group shown appendix pp <NUMBER> <NUMBER> <NUMBER> <NUMBER> results indicated associations drug regimens mortality need mechanical ventilation length stay occurrence denovo ventricular arrhythmias consistent primary analysis tipping point analysis done assess effects unmeasured confounder findings significance hydroxychloroquine chloroquine appendix pp <NUMBER> <NUMBER> chloroquine hydroxychlor oquine chloroquine macrolide hypothetical unobserved binary confounder prevalence <NUMBER> exposed population would need hr <NUMBER>·<NUMBER> tip analysis nonsignificance <NUMBER> level comparison observed confounders study congestive heart failure hr <NUMBER>·<NUMBER> left model would need prevalence approximately <NUMBER> population lead confounding analysis similarly hydroxychloroquine macrolide hypothetical unobserved binary confounder prevalence <NUMBER> exposed population would need hr <NUMBER>·<NUMBER> tip analysis nonsignificance <NUMBER> level congestive heart failure hr <NUMBER>·<NUMBER> would need prevalence approximately <NUMBER> population lead confounding analysis adjusted cox proportional hazards model large multinational realworld analysis observe benefit hydroxychloroquine chloroquine used alone combination macrolide inhospital outcomes initiated early diagnosis covid<NUMBER> drug regimens chloroquine hydroxychloroquine alone combination macrolide associated increased hazard clinically significant occurrence ventricular arrhythmias increased risk inhospital death covid<NUMBER> use hydroxychloroquine chloroquine covid<NUMBER> based widespread publicity small <NUMBER>·<NUMBER> <NUMBER>·<NUMBER> decreased risk ventricular arrhythmia increased risk ventricular arrhythmia uncontrolled studies suggested combination hydroxychloroquine macrolide azithromycin successful clearing viral replication <NUMBER> march <NUMBER> <NUMBER> fda issued emergency use authorisation drugs patients clinical trial access unavailable <NUMBER> countries china issued guidelines allowing use chloroquine covid<NUMBER> <NUMBER> several countries stockpiling drugs shortages approved indications autoimmune disease rheumatoid arthritis encountered <NUMBER> retrospective observational review <NUMBER> men covid<NUMBER> treated us veterans affairs hospitals raised concerns use hydroxychloroquine associated greater hazard death however baseline characteristics among groups analysed dissimilar possibility bias cannot ruled <NUMBER> another observational study <NUMBER> patients france reported use hydroxychloroquine dose <NUMBER> mg per day associated measurable clinical benefit patients covid<NUMBER> pneumonia <NUMBER> largescale international realworld analysis supports absence clinical benefit chloroquine hydroxychloroquine points potential harm hospitalised patients covid<NUMBER> chloroquine hydroxychloroquine associated concerns cardiovascular toxicity particularly known relationship electrical instability characterised qt interval prolongation time taken ventricular depolarisation repolarisation mechanism relates blockade herg potassium channel <NUMBER> lengthens ventricular repolarisation duration ventricular action potentials specific conditions early afterdepolarisations trigger ventricular arrhythmias <NUMBER> propensity arrhythmia provocation often seen individuals structural cardiovascular disease cardiac injury reported occur high frequency covid<NUMBER> illness <NUMBER> <NUMBER> furthermore individuals cardiovascular disease represent vulnerable population experience worse outcomes covid<NUMBER> <NUMBER> <NUMBER> pathological studies pointed derangements vascular endothelium diffuse endotheliitis noted across multiple organs covid<NUMBER> <NUMBER> whether patients underlying cardiovascular disease experience denovo cardiovascular injury greater predilection ventricular arrhythmias chloroquine analogues remains uncertain plausible covid<NUMBER> exemplified initial viral replication followed enhanced systemic inflammation <NUMBER> use chloroquine hydroxy chloroquine combination macrolide designed use antimicrobial properties synergistic manner <NUMBER> macrolides azithromycin clarithromycin antibiotics immunomodulatory antiinflammatory effects <NUMBER> however drugs prolong qt interval increase risk sudden cardiac death <NUMBER> <NUMBER> preliminary analysis borba colleagues <NUMBER> reported doubleblind randomised trial <NUMBER> adult patients hospitalised severe covid<NUMBER> tertiary care facility brazil study suggested higher dose chloroquine represented safety hazard especially taken concurrently azithromycin oseltamivir another cohort study <NUMBER> patients covid<NUMBER> pneumonia mercuro colleagues <NUMBER> found concomitant use macrolide associated greater change corrected qt interval study examine qt interval instead directly analysed risk clinically significant ventricular arrythmias showed independent association use either hydroxychloroquine chloroquine occurrence denovo ventricular arrhythmias also note hazard denovo ventricular arrhythmias increased drugs used combination macrolide analysis dominated patients north america noted higher bmi emerged risk marker worse inhospital survival obesity known risk factor cardiac arrhythmias sudden cardiac death <NUMBER> <NUMBER> commonly reported arrhythmias atrial fibrillation ventricular tachycardia although age race bmi predictive increased risk death covid<NUMBER> analysis found associated increased risk ventricular arrhythmias multivariable regression analysis variables found independently predictive ventricular arrhythmias four treatment regimens along underlying cardiovascular disease copd thus presence cardiovascular comorbidity study population could partially explain observed risk increased cardiovascular toxicity use chloroquine hydroxychloroquine especially used combination macrolides investigation consistent previous findings smaller cohort <NUMBER> patients <NUMBER> found women patients treated ace inhibitors angiotensin receptor blockers statins lower mortality covid<NUMBER> findings imply drugs stabilise cardiovascular function improve endothelial cell dysfunction might improve prognosis independent use cardiotoxic drug combinations <NUMBER> study several limitations association decreased survival hydroxychloroquine chloroquine treatment regimens interpreted cautiously due observational study design cannot exclude possibility unmeasured confounding factors although reassuringly noted consistency primary analysis propensity score matched analyses nevertheless causeandeffect relationship drug therapy survival inferred data apply use treatment regimen used ambulatory outofhospital setting randomised clinical trials required conclusion reached regarding benefit harm agents covid<NUMBER> patients also note although evaluated relationship drug treatment regimens occurrence ventricular arrhythmias measure qt intervals stratify arrhythmia pattern torsade de pointes also establish association increased risk inhospital death use drug regimens linked directly cardiovascular risk conduct drug doseresponse analysis observed risks even limitations suggest conservative interpretation findings believe absence observed benefit could still represent reasonable explanation summary multinational observational realworld study patients covid<NUMBER> requiring hospitalisation found use regimen containing hydroxychloroquine chloroquine without macrolide associated evidence benefit instead associated increase risk ventricular arrhythmias greater hazard inhospital death covid<NUMBER> findings suggest drug regimens used outside clinical trials urgent confirmation randomised clinical trials needed study conceived designed mrm anp acquisition data statistical analysis data supervised performed ssd mrm drafted manuscript authors participated critical revision manuscript important intellectual content mrm anp supervised study authors approved final manuscript responsible decision submit publication mrm reports personal fees abbott medtronic janssen mesoblast portola bayer baim institute clinical research nupulsecv fineheart leviticus roivant triple gene ssd founder surgisphere corporation fr paid time spent committee member clinical trials advisory boards forms consulting lectures presentations payments made directly university zurich personal payments received relation trials activities anp declares competing interests regulated oncogeneα groα increase recruitment neutrophils monocytes also stimulates production il<NUMBER> response extracellular microorganisms also granulocytecolony stimulating factor gcsf granulocytemacrophage gmcsf turn stimulate expansion myeloid lineages production mediators il<NUMBER> tnfα prostaglandin e<NUMBER> pge<NUMBER> <NUMBER> recently shown peripheral mononuclear blood cells patients severe covid<NUMBER> infection presented strikingly high numbers circulating th<NUMBER> cells parallel increased levels cytokines including il<NUMBER>β il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> gcsf interferon γinduced protein <NUMBER> ip<NUMBER> mcp<NUMBER> macrophage inflammatory proteins mips tnfα due role il<NUMBER>a tissue inflammation putative protective function il<NUMBER>a considered new therapeutic target treatment andor management covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> furthermore face typical cytokine storm suggested drug fedratinib janus kinase <NUMBER> jak<NUMBER> small molecule inhibitor could potential therapeutic agent used covid<NUMBER> patients increased th<NUMBER> profile <NUMBER> therefore one treatment strategies covid<NUMBER> includes anticytokine therapies immunomodulators target overactive cytokine response <NUMBER> besides ifn type <NUMBER> ifn type <NUMBER> third type interferon family termed lambda ifn identified fact family consists four members humans ifn<NUMBER>il<NUMBER> ifn<NUMBER>il<NUMBER>a ifn<NUMBER>il<NUMBER>b ifn<NUMBER> share low homology type ifns il<NUMBER> exhibit potent antiviral activity <NUMBER> ifnact binding heterodimeric ifnλ receptor ifnlr complex activating stat phosphorylationdependent signaling cascade thereby inducing several genes modulate immunity complex forward feedback loops <NUMBER> shown ifnare induced lower viral burden influenza virus infections type ifns considered mechanism limit initial infection inducing viral resistance cells helping deal virus load <NUMBER> also ifnseems lack strong proinflammatory effects type ifns rather tissueprotective antiinflammatory therefore proposed potential strategy treatment covid<NUMBER> patients help two main clinical problems persistent virus presence lung induction cytokine storm <NUMBER> cytokine storm also result activation coagulation pathways immune response infection leads unbalance pro anticoagulant factors results micro thrombosis disseminated intra vascular coagulation multiorgan failure evident covid<NUMBER> pneumonia <NUMBER> thus prophylactic dose heparin recommended hospitalized patients <NUMBER> considering current knowledge acquired research data coronavirus infections middle east respiratory syndrome mers acute respiratory syndrome sars associated clinical features observed patients infected sarscov<NUMBER> possible identify basically three stages phases natural history covid<NUMBER> regarding disease severity first phase related onset disease generally characterized development influenzalike symptoms mild moderate <NUMBER> <NUMBER> phase virus detected molecular analysis via reverse transcriptasepolymerase chain reaction rtpcr patients initial phase may asymptomatic even transmit disease people however depending yet unknown factors may progress second stage known pulmonary phase phase possible detect pneumonialike symptoms evidenced lung opacities seen chest radiography glass opacities computed tomography ct <NUMBER> <NUMBER> covid<NUMBER> pneumonia presents particularly distinctive features severe hypoxemia often associated near normal respiratory system compliance variable degrees severity <NUMBER> depending severity phase <NUMBER> patients improve worsen necessity intubation ventilation patients typical examples phase <NUMBER> characterized hyperinflammation sepsis lungs patient often requires intensive care unit icu unfortunately overcome infection fig<NUMBER> preliminary observations based j u r n l p r e p r f medical experiences since outbreak covid<NUMBER> driving search novel repurposed drugs treat disease proteins involved sarscov<NUMBER> entry replication mechanism host cell main targets drug testing development mentioned coronaviruses composed nonstructural proteins ns structural proteins fact sarscov<NUMBER> rna genome consists eleven open reading frames orfs disposed following order orf<NUMBER>ab orf<NUMBER> spike protein orf<NUMBER>a orf<NUMBER> envelope protein orf<NUMBER> membrane protein orf<NUMBER> orf<NUMBER>a orf<NUMBER>b orf<NUMBER> orf<NUMBER> nucleocapsid protein orf<NUMBER> <NUMBER> <NUMBER> direction orf<NUMBER>ab codes polyprotein pp<NUMBER>a pp<NUMBER>ab comprises <NUMBER> nonstructural proteins nsps <NUMBER> nsp<NUMBER> known leader protein binds <NUMBER>s ribosome host cell inactivate host mrna translation degradation keeps viral rna intact <NUMBER> nsp<NUMBER> conserved protein sarscov<NUMBER> shown bind two host proteins prohibitin <NUMBER> prohibitin <NUMBER> phb<NUMBER> phb<NUMBER> involved cell cycle progression cell migration cellular differentiation apoptosis mitochondrial biogenesis <NUMBER> nsp<NUMBER> large papainlike proteinase approximately <NUMBER>kda size whose sequence contains several conserved domains including ssrna binding adpr binding gquadruplex binding protease papainlike protease nsp<NUMBER> binding domains besides transmembrane domain <NUMBER> papain like protease domain responsible release nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> nterminal region polyproteins <NUMBER>a <NUMBER>ab coronaviruses therefore considered important target antiviral agents <NUMBER> nsp<NUMBER> protein interacts nsp<NUMBER> essential viral replication contains transmembrane domain possibly interacts host proteins function membrane rearrangement sarscov<NUMBER> <NUMBER> nsp<NUMBER> <NUMBER>clike proteinase <NUMBER>clpro homology middle east respiratory syndrome mers coronavirus protease protease able cleave eleven different sites yield mature intermediate nonstructural proteins <NUMBER> nsp<NUMBER> thought involved generation autophagosomes endoplasmic reticulum based studies avian coronavirus nsp<NUMBER> facilitate assembly replicase proteins avoid degradation viral components <NUMBER> nsp<NUMBER> form complex nsp<NUMBER> nsp<NUMBER> proteins produce active rna polymerase <NUMBER> based studies porcine reproductive respiratory syndrome virus prrsv nsp<NUMBER> shown interact deadbox rna helicase <NUMBER> ddx<NUMBER> cellular protein important association viral replication <NUMBER> nsp<NUMBER> interacts nsp<NUMBER> resulting stimulation activity latter protein function sadenosylmethionine samdependent guaninen<NUMBER> methyl transferase n<NUMBER>mtase <NUMBER> nsp<NUMBER> also interacts nsp<NUMBER> <NUMBER>′omethyltransferase whose activity stimulated result interaction <NUMBER> nsp<NUMBER> small protein <NUMBER> amino acids unknown function first nine amino acids identical first nine amino acids nsp<NUMBER> protein latter protein rnadependent rna polymerase rdrp makes copies viral rna nsp<NUMBER> forms complex nsp<NUMBER>nsp<NUMBER> essential activity <NUMBER> nsp<NUMBER> works helicase seems interact nsp<NUMBER> <NUMBER>′triphosphatase activity well activity important introduce <NUMBER>′terminal cap viral mrna processing <NUMBER> together nsp<NUMBER> <NUMBER>′<NUMBER>′ exoribonuclease activity n<NUMBER>methyltransferase activity <NUMBER> nsp<NUMBER> characterized endoribonuclease cleaves rna specific regions <NUMBER> nsp<NUMBER> proteins prevent host immune sensing system detecting virus degrading viral polyuridine sequences <NUMBER> nsp<NUMBER> <NUMBER>′oribosemethyltransferase methylates <NUMBER>′hydroxy group adenines viral rna processing using sadenosylmethionine methyl source <NUMBER> spike glycoprotein main target strategies using neutralizing antibodies since sarscov<NUMBER> uses protein bind receptor mediate membrane fusion virus entry protein trimeric structure monomer consisting two subunits named s<NUMBER> s<NUMBER> together account molecular weight approximately <NUMBER> kda <NUMBER> shown sarscov<NUMBER> protein less stable sarscov<NUMBER> another coronavirus responsible j u r n l p r e p r f sars antibodies antisarscov<NUMBER> s<NUMBER> protein able inhibit sarscov<NUMBER> entry sarscov<NUMBER> also sera recovered sars covid<NUMBER> patients showed limited crossneutralization suggesting possible recovery one infection may protect <NUMBER> interestingly protein sarscov<NUMBER> shown furin cleavage site lacking protein sarscov<NUMBER> <NUMBER> could one explanations difference pathogenicity two viruses <NUMBER> besides spike protein nucleocapsid n envelope e membrane proteins well <NUMBER>cl protease <NUMBER>cl pro papain like protease rnadependent rna polymerase complex rdrp proteins include helicase protein suggested antiviral targets <NUMBER> recently gordon et al <NUMBER> reported interesting approach try find new druggable targets treatment covid<NUMBER> authors cloned tagged expressed <NUMBER> <NUMBER> sarscov<NUMBER> proteins human cells using affinitypurification mass spectrometry identified human proteins physically associated one sixty six <NUMBER> human proteins identified shown targeted <NUMBER> compounds fdaapproved clinical preclinical trials similar approach based virtual screening used identify potential drugs bind specifically sarscov<NUMBER> <NUMBER>c like protease <NUMBER>cl pro essential virus replication threedimensional model protease using crystal structure high similar protease ortholog sarscov prepared revealed <NUMBER> candidates evaluation including two repurposed drugs velpatasvir ledispavir <NUMBER> one approaches used find potential effective drug sarscov<NUMBER> testing repurposed drugs among drugs antiviral agents antiinflammatory agents pharmacological drugs aiming modulate immune response inhibit overproduction cytokines another alternative use strategies adopted virus epidemic convalescent plasma therapy structure target repurposed drugs evaluated treatment covid<NUMBER> shown table <NUMBER> updated results current knowledge regarding use drugs therapeutic approaches presented discussed macrocyclic lactone antibiotic azithromycin shown vitro activity zika ebola viruses <NUMBER> <NUMBER> azithromycin also shown exhibit antiinflammatory activity <NUMBER> <NUMBER> additionally shown induce interferon type ifn ifn type iii ifn cells chronic obstructive pulmonary disease patients decrease rhinovirus<NUMBER> viral load bronchial epithelial cells <NUMBER> cytokines induced azithromycin related viral infection response turn induce resistance viral replication target cells <NUMBER> <NUMBER> vitro concentration ec<NUMBER> <NUMBER> effective concentration azithromycin sarscov<NUMBER> determined <NUMBER> m following <NUMBER> hours incubation period post infection <NUMBER> several studies covid<NUMBER> patients showing limitations considering focused mainly viral load end point detailed clinical outcomes generally lacking nevertheless collectively present preliminary evidence inclusion azithromycin various treatment regimens influence course viral infection potentially influence clinical outcomes <NUMBER> <NUMBER> yet still controversies regarding efficacy azithromycin combination hydroxychloroquine covid<NUMBER> french study shown <NUMBER> reduction viral load six patients treated azithromycin hydroxychloroquine contrast <NUMBER> patients treated hydroxychloroquine another study showed efficacy case series eleven patients treated combination <NUMBER> <NUMBER> thus confirmation validation still needed conclusion efficacy azithromycin reached contradictory results reported far one reasons suggesting additional randomized controlled trials essential confirm preliminary data help j u r n l p r e p r f understand benefits role azithromycin treatment combinations used treat covid<NUMBER> infection clinical trials currently ongoing fill gaps chloroquine drug used worldwide antimalarial well treatment immune disorders rheumatoid arthritis lupus <NUMBER> <NUMBER> first indication potential effect chloroquine sarscov<NUMBER> infection came report china outbreak study results <NUMBER> patients demonstrated chloroquine inhibited exacerbation pneumonia improved lung imaging findings promoted virus negative conversion shortening disease course <NUMBER> covid<NUMBER> outbreak previous studies chloroquine shown ability inhibit vitro viral replication another coronavirus sarscov responsible severe acute respiratory syndrome <NUMBER> <NUMBER> hydroxychloroquine less toxic derivative chloroquine shown lower half maximal inhibitory concentration ic<NUMBER> compared chloroquine inhibiting sarscov<NUMBER> vitro <NUMBER> additional studies confirmed finding <NUMBER> <NUMBER> <NUMBER> <NUMBER> small study openlabel nonrandomized clinical trial <NUMBER> confirmed covid<NUMBER> patients conducted france end point presence absence virus six days inclusion protocol results showed significant association hydroxychloroquine treatment viral load reductiondisappearance effect reinforced azithromycin <NUMBER> important note study clinical severity patients ranged asymptomatic pneumonia ie none critically ill also results study questioned international society antimicrobial chemotherapy isac declared due lack clear explanation inclusion criteria triage patients ensure patient safety meet expected standard organization nonetheless analysis data reported gautret work using pharmacokinetic model claim confirm cotreatment covid<NUMBER> hydroxychloroquine azithromycin increases probability negativepcr patients analysis also showed clinical status affects treatment outcome since analysis based limited published data results need interpreted caution <NUMBER> basically three mechanisms proposed antiviral activity hydroxychloroquinechloroquine first drugs interfere terminal glycosylation cellular receptor ace<NUMBER> thus preventing virusreceptor binding secondly drugs increase ph acidic cellular organelles hampering endocytosis intermediate stages negative effects virion transport potentially altering posttranslational modification newly synthesized viral proteins third drugs may disturb process virion assembly viral protein synthesis <NUMBER> <NUMBER> despite lack strong reliable evidence efficacy due pressure covid<NUMBER> imposed worldwide many health authorities implemented official guidelines use hydroxychloroquine chloroquine treatment patients covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> regarding side effects hydroxychloroquine chloroquine clinical use several years thus safety profile well established <NUMBER> gastrointestinal upset reported hydroxychloroquine retinal toxicity described long term use drugs <NUMBER> <NUMBER> <NUMBER> retinal toxicity may also related overdosage <NUMBER> additionally cardiomyopathy heart arrhythmia reported <NUMBER> <NUMBER> address effect chloroquine hydroxychloroquine combination azithromycin qt interval measure delayed ventricular repolarization prospective observational study performed hospitalized patients sarscov<NUMBER> primary outcome evaluated study qt prolongation resulting torsade de pointes tdp cardiac death results showed two hundred one patients treated covid<NUMBER> chloroquinehydroxychloroquine baseline qt intervals differ j u r n l p r e p r f patients treated chloroquinehydroxychloroquine patients treated drugs azithromycin however treatment maximum qt significantly longer combination group compared monotherapy group seven patients required discontinuation medications arrhythmogenic deaths reported authors concluded although clinicians seldomly needed discontinue therapy studies needed final recommendations made <NUMBER> multinational registry evaluation use chloroquine hydroxychloroquine without macrolide treatment covid<NUMBER> using data <NUMBER> hospitals six continents recently published <NUMBER> study included patients hospitalized dec <NUMBER> <NUMBER> april <NUMBER> <NUMBER> positive laboratory finding sarscov<NUMBER> patients included one four treatments chloroquine alone chloroquine macrolide hydroxychloroquine alone hydroxychloroquine macrolide patients received none treatments formed control group total <NUMBER> patients analyzed <NUMBER> patients treatment groups <NUMBER> received chloroquine <NUMBER> received chloroquine macrolide <NUMBER> received hydroxychloroquine <NUMBER> received hydroxychloroquine macrolide <NUMBER> patients control group study concluded controlling multiple confounding factors age sex race ethnicity bodymass index underlying cardiovascular disease risk factors diabetes underlying lung disease smoking immunosuppressed condition baseline disease severity possible confirm benefit hydroxychloroquine chloroquine used alone macrolide inhospital outcomes covid<NUMBER> drug regimens associated decreased inhospital survival increased frequency ventricular arrhythmias used treatment covid<NUMBER> <NUMBER> note study performed hospitalized patients associated comorbidities regrettably study recently withdrawn suspect flawed data ethical concerns methodology used analysis announcement clinical trials designed address safety efficacy chloroquine hydroxychloroquine alone combination azithromycin suspended temporarily world health organization authorities based published results however stepped back authorized continuation ongoing clinical trials therefore great debate persists whether individuals confirmed covid<NUMBER> mild symptoms asymptomatic could benefit treatment drugs ivermectin best known antiparasitic agent sold commercial name stromectol® also demonstrated antiviral activities toward human immunodeficiency virus hiv dengue virus <NUMBER> ivermectin targets host nuclear transport importin <NUMBER> heterodimer virus relies replication assembly new virions <NUMBER> drug shown inhibit sarscov<NUMBER> vitro replication <NUMBER> h concentration <NUMBER> m <NUMBER> inhibition concentration ic<NUMBER> determined <NUMBER> m much higher maximum plasma concentration <NUMBER> study performed aiming predict total bound unbound unbound plasma concentrationtime profiles administration fda approved dose <NUMBER> mgkg <NUMBER> mgkg <NUMBER> mgkg results study showed plasma concentrations reach ic<NUMBER> even doses higher approved furthermore authors concluded oral administration approved dose unlikely ivermectin reaches ic<NUMBER> lungs therefore likelihood successful clinical trial would low despite results combination therapy agents may beneficial suggested <NUMBER> moreover studies animal models shown <NUMBER>fold higher levels pulmonary tissue plasma one week oral dosing demonstrating need research better evaluate effectivity ivermectin treatment respiratory viruses sarscov<NUMBER> <NUMBER> j u r n l p r e p r f lopinavir aspartate protease inhibitor demonstrated high specificity human immunodeficiency virus hiv type <NUMBER> lopinavir developed pharmaceutical company abbot sold brand name kaletra® drug generally administered combination ritonavir due poor oral bioavailability rapid biotransformation increase halflife inhibition cytochrome p<NUMBER> <NUMBER> hiv<NUMBER> infection context lopinavir hydroxy ethylene bond mimics normal peptide cleaved virus hiv<NUMBER> protease <NUMBER> severe acute respiratory syndrome sars epidemic <NUMBER> lopinavir tested vitro showed inhibitory activity sarscov <NUMBER> <NUMBER> <NUMBER> multicenter retrospective study matched cohort study performed chan et al <NUMBER> investigate possible benefits adverse effects addition lopinavirritonavir standard treatment protocol treatment sars showed initial treatment protocol used associated significant reduction overall death rate intubation rate compared matched cohort received standard treatment another study reported <NUMBER> suggested addition lopinavirritonavir compared control group received antiviral ribavirin reduced risk adverse clinical outcomes viral load among patients sars <NUMBER> one study reported case single patient initial phase sarscov<NUMBER> outbreak korea identified index patient caused secondary tertiary transmission administration lopinavirritonavir patient significantly decreased viral load little coronavirus titers observed followup <NUMBER> nevertheless another study reporting randomized controlled openlabel trial involving <NUMBER> hospitalized adult patients confirmed sarscov<NUMBER> infection use lopinavirritonavir showed benefit beyond standard care study time clinical improvement primary end point <NUMBER> nitazoxanide belongs class drugs known thiazolides broad spectrum antiparasitic also shown broad spectrum antiviral activity nitazoxanide previously shown exhibit vitro activity merscov coronaviruses <NUMBER> haffizulla et al showed nitazoxanide given regimen <NUMBER> mg twice daily <NUMBER> days reduced duration symptoms patients acute uncomplicated influenza minor adverse effects <NUMBER> several recommendations made suggesting potential use nitazoxanide treat sarscov<NUMBER> infection often ignored <NUMBER> recent review evaluated nine nitazoxanide research clinical trials assess safety cost potential use drug covid<NUMBER> <NUMBER> authors concluded drug demonstrate good safety profile approved doses although evidence required regarding hepatorenal cardiovascular effects well teratogenicity efficacy nitazoxanide clinically proven covid<NUMBER> may represent affordable safe treatment date <NUMBER> th june <NUMBER> twelve nitazoxanide clinical trials undergoing worldwide registered clinicaltrialgov website five recruiting volunteers table <NUMBER> remdesivir phosphoramidate nucleoside analogue prodrug broadspectrum antiviral agent commercialized pharmaceutical company gilead <NUMBER> demonstrated vitro vivo activity animal models coronaviruses causing mers sars structurally similar sarscov<NUMBER> <NUMBER> remdesivir demonstrated potent block sarscov<NUMBER> infection low concentrations halfmaximal effective concentration ec<NUMBER> <NUMBER> m <NUMBER> report single case patient described clinical improvement use remdesivir j u r n l p r e p r f intravenously treat first united states case covid<NUMBER> <NUMBER> another study reported compassionate use remdesivir hospitalized patients confirmed sarscov<NUMBER> infection oxygen saturation <NUMBER> less receiving oxygen support <NUMBER> authors observed clinical improvement <NUMBER> <NUMBER> patients <NUMBER> treated remdesivir consisting loading dose <NUMBER> mg intravenously day <NUMBER> plus <NUMBER> mg daily following <NUMBER> days however authors suggested efficacy require ongoing randomized placebo controlled trials notwithstanding results randomized doubleblind placebocontrolled study <NUMBER> patients enrolled showed use remdesivir associated statistically significant clinical benefits patients receiving redemsivir numerical reduction time clinical improvement compared placebo although theses results statistically significant <NUMBER> study terminated early due adverse events observed patients favipiravir commercially sold avigan pyrazinecarboxamide derivative guanine analogue shown selectively inhibit rnadependent rna polymerase rdrp rna viruses interfering assembly viable virus <NUMBER> <NUMBER> drug shown activity many rna viruses influenza virus alphavirus filovirus arena norovirus well ebola virus <NUMBER> study designed evaluate potential antiviral activity sarscov<NUMBER> included favipiravir panel drugs tested favipiravir showed efficacy vitro infected vero e<NUMBER> cells demonstrating halfmaximal effective concentration ec<NUMBER> <NUMBER> m half cytotoxic concentration <NUMBER> m <NUMBER> contrast choy et al showed concentrations lower <NUMBER> m effect sarscov<NUMBER> vitro <NUMBER> hand shown covid<NUMBER> patients treated favipiravir show superior recovery rate <NUMBER> patients treated umifenovir <NUMBER> <NUMBER> open label nonrandomized controlled study mg<NUMBER> mg twice daily plus <NUMBER> ku twice daily ifn control group favipiravir treatment associated faster viral clearance significantly higher improvement rate chest imaging fewer adverse effects compared lopinavirritonavir arm <NUMBER> nonrandomized randomized controlled clinical trials aiming investigate efficacy safety favipiravir alone combination tocilizumab chloroquine phosphate currently ongoing umifenovir indole carboxylic acid derivative used treating prophylaxis infections associated h<NUMBER>n<NUMBER>a b arbovirus <NUMBER> also known arbidol umifenovir acts blocking viruscell membrane fusion virusendosome fusion incorporation cell membranes interference phospholipids network organization <NUMBER> drug showed vitro activity sarscov<NUMBER> virus speculated activity sarscov<NUMBER> <NUMBER> combination umifenovir lopinavirritonavir showed increased negative conversion rate sarscov<NUMBER> improved chest ct scans results retrospective cohort study <NUMBER> however shown patients treated umifenovir demonstrated inferior outcome clinical recovery rate less improvement symptoms like fever cough compared favipiravir <NUMBER> contrast another study evaluated antiviral effects safety lopinavirritonavir arbidol fifty patients laboratoryconfirmed covid<NUMBER> divided two groups lopinavirritonavir group consisting <NUMBER> cases arbidol group consisting <NUMBER> cases first group received <NUMBER> mg<NUMBER>mg lopinavirritonavir twice day week second group given <NUMBER> g arbidol three times j u r n l p r e p r f day rtpcr assay used detect sarscov<NUMBER> virus antiviral therapy patients arbidol group shorter duration positive rna test compared lopinavirritonavir group suggesting arbidol monotherapy may superior lopinavirritonavir treating covid<NUMBER> <NUMBER> clinical trials aiming investigate efficacy safety umifenovir alone combination currently ongoing methylprednisolone one classical immunosuppressive drugs used stop delay progress pneumonia proved effective treatment acute respiratory distress syndrome ards patients covid<NUMBER> pneumonia severe cases develop rapidly acute respiratory failure <NUMBER> therefore surprise methylprednisolone became drug choice use severe cases retrospective cohort study <NUMBER> patients covid<NUMBER> developed ard administration <NUMBER>mgkgdaily iv <NUMBER>days apparently reduced risk death although <NUMBER> patients received drug died compared <NUMBER> received drug <NUMBER> early lowdose short application methylprednisolone associated improvement clinical symptoms shortened disease course another study <NUMBER> patients severe covid<NUMBER> <NUMBER> limited study <NUMBER> patients control group corroborated benefits low dose corticosteroids treatment subset critically ill covid<NUMBER> pneumonia patients <NUMBER> another steroid used treatment acute respiratory syndromes fluorinated steroid dexamethasone synthetic member class glucocorticoids closing review june <NUMBER> th results randomized clinical trial established examine potential benefit treatment dexamethasone covid<NUMBER> patients announced university oxford study part proposal called recovery randomized evaluation covid<NUMBER> therapy consisted <NUMBER> patients randomized receive <NUMBER> mg per day dexamethasone either orally intravenous injection ten days <NUMBER> patients randomized receive standard care mentioned patients severe covid<NUMBER> infection requires ventilation oxygen support unfortunately among patients high mortality rate dexamethasone reduced deaths onethird among ventilated patients one fifth among receiving oxygen benefit observed patients require respiratory support announced yet unpublished study encouraging give support hypothesis corticosteroids useful treatment severe covid<NUMBER> patients reducing mortality <NUMBER> studies reporting severe covid<NUMBER> patients present coagulopathy complications <NUMBER> <NUMBER> <NUMBER> disseminated intravascular coagulation frequently observed deaths caused sarscov<NUMBER> <NUMBER> observation led active application anticoagulants heparin patients severe covid<NUMBER> china notwithstanding lack efficacy validation <NUMBER> nevertheless tang et al <NUMBER> performed retrospective study compared <NUMBER>day mortality group severe covid<NUMBER> patients received heparin group receive anticoagulant statistically difference <NUMBER>day mortality observed groups <NUMBER> vs <NUMBER> p<NUMBER> however group patients presenting sepsisinduced coagulopathy score greater <NUMBER> received heparin showed lower <NUMBER>day mortality receive heparin <NUMBER> vs <NUMBER> p <NUMBER> hand negri et al <NUMBER> reported yet peerreviewed study series <NUMBER> consecutive covid<NUMBER> patients admitted hospital são paulobrazil treated heparin therapeutic doses used clinical severity treatment heparin improved ratio arterial oxygen partial pressure fractional inspired oxygen pao<NUMBER>fio<NUMBER> mean time discharge <NUMBER> theses patients <NUMBER> days <NUMBER> cardiac arrhytmias often immediate j u r n l p r e p r f cause death severe patients <NUMBER> therefore suggested use heparin covid<NUMBER> severe patients would useful due anticoagulant activity also antiarrhythmic property <NUMBER> <NUMBER> <NUMBER> beyond virus another factor considered important primary cause mortality patients infected sarscov<NUMBER> proinflammatory response promote cytokine storm secondary bacterial infection therefore drugs acting antiinflammatory thought help decrease severity covid<NUMBER> patients interleukins <NUMBER> il<NUMBER> il<NUMBER> cytokines associated innate immunity damaging inflammation <NUMBER> il<NUMBER> shown reach peak levels time disease onset study ards assessing serial bronchoalveolar lavage fluids cytokine content <NUMBER> anakinra sold brand name kineret recombinant il<NUMBER> receptor antagonist used treat autoinflammatory disorders <NUMBER> retrospective cohort study conducted italy patients covid<NUMBER> moderatetosevere ards hyperinflammation demonstrated highdose intravenous anakinra safe associated clinical improvement <NUMBER> patients <NUMBER> despite recognized limitations study results promising randomized phase two clinical trial nct<NUMBER> ongoing meanwhile cohort prospective study performed france participants admitted groupe hospitalier paris saintjoseph severe covid<NUMBER>related bilateral pneumonia chest xray lung ct scan march <NUMBER> april <NUMBER> <NUMBER> anakinra group consisted <NUMBER> consecutive patients received subcutaneous anakinra <NUMBER> mg twice day <NUMBER> h <NUMBER> mg daily <NUMBER> days well standard treatments institution time control group consisted <NUMBER> patients received standard treatments supportive care intensive care unit icu admission death occurred <NUMBER> <NUMBER> patients anakinra group compared <NUMBER> <NUMBER> patients control group <NUMBER> results suggest need clinical trials confirm efficacy anakinra treat patients severe covid<NUMBER> infection baricitinib janus kinase jak inhibitor licensed primarily treatment rheumatoid arthritis good efficacy safety records <NUMBER> interestingly antiinflammatory drug considered option treatment covid<NUMBER> antiviral effect believed related affinity ap<NUMBER> associated protein aak<NUMBER> reducing sarscov<NUMBER> endocytosis <NUMBER> cantini et al <NUMBER> reported pilot study evaluate safety clinical impact covid<NUMBER> baricitinib given <NUMBER> patients moderate covid<NUMBER> dose <NUMBER> mgdayorally adverse events recorded two weeks clinical respiratory parameters significantly improved two weeks patients required admission icu <NUMBER> caveats study proper control group included interleukin <NUMBER> il<NUMBER> tumor necrosis factor tnf interferon gama ifn targetable cytokines play important role pathogenesis lung seen covid<NUMBER> excessive il<NUMBER> signaling induces several biological pathways including janus kinase jnk contribute organ damage <NUMBER> tocilizumab recombinant humanized monoclonal antiil<NUMBER> antibody binds soluble membrane bound il<NUMBER> receptor <NUMBER> chinese study aiming assess efficacy tocilizumab <NUMBER> patients covid<NUMBER> showed preliminary results demonstrating drug improved clinical outcome immediately severe critical patients effective treatment reduce mortality <NUMBER> patients study discharged average <NUMBER>d giving tocilizumab <NUMBER> interferons ifns first line immune defense viral infections antiviral activity occurs blocking viral replication eliminating virusinfected cells <NUMBER> several cellular proteins located different rlrs cyclic ampgmp synthase cgasstimulator ifn genes sting act sensors specific viral components <NUMBER> <NUMBER> <NUMBER> upon virus infection transcription factors interferon regulatory factors irfs <NUMBER> interferonβ<NUMBER>b treatment shown improve outcome merscov infection nonhuman primate model common marmoset <NUMBER> ifn ifn tested vitro sarscov<NUMBER> shown potent antiviral activity infected vero cells treated ifnα ifnβ concentration <NUMBER> international units iu per milliliter reduced viral titers <NUMBER> log <NUMBER> log respectively demonstrating potential therapeutic use biologicals covid<NUMBER> infections <NUMBER> addition ifn<NUMBER>β treatment covid<NUMBER> patients receiving antivirals lopinavirritonavir shown better treatment two antivirals alone demonstrated open label randomized phase ii clinical trial patients triple combination treatment group significantly shorter median time start study treatment negative nasopharyngeal swab <NUMBER> days compared lopinavirritonavir control group <NUMBER> days <NUMBER> mentioned angiotensinconverting enzyme <NUMBER> ace<NUMBER> identified functional receptor sarscov infection <NUMBER> structural functional analysis sarscov<NUMBER> binding receptor showed spike glycoprotein virus also binds ace<NUMBER> receptor <NUMBER> <NUMBER> <NUMBER> observed patients comorbidities hypertension diabetes frequently medication angiotensinconverting enzyme ace inhibitors angiotensin receptor blockers arb could result overexpression ace<NUMBER> potentially increase availability target molecules sarscov<NUMBER> entry <NUMBER> <NUMBER> <NUMBER> <NUMBER> ace inhibitors arbs used treat patients high blood pressure heart kidney problems conditions believed disbalance ace<NUMBER> caused ace inhibitors nonsteroidal antiinflammatory drug nsaid ibuprofen activator ace<NUMBER> receptors expression may predispose severe disease <NUMBER> hand reports showing association drugs severe covid<NUMBER> <NUMBER> however reninangiotensinaldosterone system complex suggested complexity needs taken consideration treating covid<NUMBER> pneumonia patients comorbidities due opposing physiological actions ace ace<NUMBER> receptors <NUMBER> ace cleaves angiotensin generate angiotensin ii peptide binds activates angiotensin receptor <NUMBER> at<NUMBER>r constrict blood vessels thereby elevating blood pressure contrast ace<NUMBER> inactivates angiotensin ii generating angiotensin <NUMBER> heptapeptide potent vasodilator function via activation mas receptor <NUMBER> context proposed at<NUMBER>r blockers losartan olmesartan could reduce aggressiveness mortality sarscov<NUMBER> virus infections rationale appointed proposal sarscov<NUMBER> binds ace<NUMBER> receptor causes downregulation ace<NUMBER> activity turn results excessive production angiotensinii related enzyme ace less ace<NUMBER> capable converting vasodilator heptapeptide angiotensin <NUMBER> contributes lung injury due increased pulmonary vascular permeability <NUMBER> furthermore observational studies use ace inhibitors arbs covid<NUMBER> pandemic acute respiratory syndromes support hypothesis drugs increase risk infection sarscov<NUMBER> negative impact clinical outcomes covid<NUMBER> patients demonstrate opposite initially raised concerns <NUMBER> <NUMBER> although preclinical animal model treatment losartan shown upregulate ace<NUMBER> mrna expression activity human studies showed significant difference ace<NUMBER> plasma levels patients treated arbs ace inhibitors although local tissue ace<NUMBER> levels measured <NUMBER> <NUMBER> <NUMBER> <NUMBER> ace inhibitors arbs could j u r n l p r e p r f mitigate deleterious effects at<NUMBER>r pathway activation turn decreases inflammation lung injury <NUMBER> however real impact ace inhibitors angiotensin receptor blockers severe acute respiratory illness due sars cov<NUMBER> well established contradictory results published literature far controlled randomized trials able definitively answer question whether ace inhibitors arbs pose harm patients covid<NUMBER> could even beneficial despite controversies suggested use ace inhibitors arbs continued patients stable condition risk infection evaluated infection covid<NUMBER> <NUMBER> convalescent plasma type therapy plasma collected individuals following resolution infection development antibodies transfusion convalescent plasma may prevent infection decrease clinical severity individuals recent exposure virus <NUMBER> type therapy use century <NUMBER> human plasma recovered covid<NUMBER> patients considered safe potentially effective alternative treatment postexposure prophylaxis <NUMBER> <NUMBER> study <NUMBER> sarscov<NUMBER> infected patients detected presence antibodies serial plasma samples demonstrated seroconversion rates antibody ab igm igg <NUMBER> <NUMBER> <NUMBER> respectively presence antibodies <NUMBER> among patients within <NUMBER>week since onset rapidly increased <NUMBER> ab <NUMBER> igm <NUMBER> igg since day<NUMBER> onset demonstrating strong empirical support routine application serological testing diagnosis management covid<NUMBER> patients <NUMBER> still data use convalescent plasma therapy covid<NUMBER> however reports china shown preliminary clinical benefits regarding improvement symptoms like fever cough chest pain serious side effect <NUMBER> <NUMBER> need randomized clinical trials urgent determine true clinical effect treatment whether patients might recovered without therapy according clinicaltrialsgov database currently <NUMBER> studies evaluating therapy covid<NUMBER> vitamin c ascorbic acid essential vitamin known antioxidant properties important boost immune system <NUMBER> studies shown various highdose intravenous vitamin c infusions eg <NUMBER> mgkg body weightday divided <NUMBER> doses shortened intensive care unit icu stay <NUMBER> <NUMBER> accompanied significant reduction mortality rate treatment severe sepsis septic shock <NUMBER> moreover vitamin c also demonstrated antiviral activity recently reviewed <NUMBER> coronaviruses increase oxidative stress promotes cellular malfunction ultimately results organ failure <NUMBER> believed high intravenous dose vitamin c could particularly effective inhibiting production cytokines storm due covid<NUMBER> many physicians china identified promising results using approach covid<NUMBER> <NUMBER> <NUMBER> reported highdose intravenous vitamin c successfully used treatment <NUMBER> moderate severe covid<NUMBER> patients china doses used varied <NUMBER> g <NUMBER> g per day given period <NUMBER> h oxygenation index improving real time patients eventually cured discharged <NUMBER> recently new clinical trial test highdose vitamin c patients covid<NUMBER> identifier nct<NUMBER> begun wuhan china trial investigators treat <NUMBER> patients placebo control intravenous vitamin c dose <NUMBER> gday <NUMBER> days assess requirements mechanical ventilation vasopressor drugs organ failure scores icu length stay <NUMBER>day mortality <NUMBER> j u r n l p r e p r f known vitamin stimulate innate immunity modulate acquired immunity <NUMBER> however although several contradictory results reported literature regarding effect vitamin acute respiratory infections considering pneumonia sepsis respiratory failure acute respiratory distress frequently found sarscov<NUMBER> infected patients suggested vitamin could beneficial patients covid <NUMBER> metaanalysis study shown evidence vitamin supplementation could protected acute respiratory infections <NUMBER> benefit observed individuals received frequent eg daily doses vitamin received bolus doses effect evident individuals vitamin deficiency shown zinc inhibits coronavirus retrovirus rna polymerase activity zinc ionophores exhibit potential block virus replication vitro <NUMBER> moreover zinc also shown play role antiinflammatory agent pneumonia animal models thus limiting tissue damage systemic effects <NUMBER> <NUMBER> furthermore previous work performed covid<NUMBER> pandemic demonstrated chloroquine zinc ionophore increasing zn <NUMBER> flux cell <NUMBER> therefore zinc considered supportive treatment therapy covid<NUMBER> infection recently reported series four patient cases one <NUMBER> years old man three women <NUMBER> <NUMBER> <NUMBER> years old clinical symptoms andor laboratory confirmed covid<NUMBER> used high dose zinc salt oral lozenges alleviate symptoms disease treatment resulted significant improvement objective symptomatic disease measures fever pao<NUMBER> one day high dose therapy <NUMBER> currently standard dosage zinc supplementation established treatment covid<NUMBER> however several clinical trials underway evaluate effects supplementation zinc alone combination supplements drugs vitamin c chloroquine hydroxychloroquine azithromycin covid<NUMBER> table <NUMBER> hydroxychloroquineazithromycin combination therapy shown promising results covid<NUMBER> treatment although clear mechanism action established nevertheless shown molecular dynamics drugs act synergy prevent contact virus plasma membrane cells <NUMBER> azithromycin display similarity sugar moiety ganglioside gm<NUMBER> lipid act important host attachment cofactor antibiotic interacts gangliosidebinding domain sarscov<NUMBER> spike protein thereby prevents virus attachment host cell receptor hand hydroxychloroquine saturates sites vicinity primary coronavirus receptor ace<NUMBER> <NUMBER> results open label randomized phase ii clinical trial designed assess efficacy safety triple combination interferon beta<NUMBER>b lopinavirritonavir ribavirin treating patients covid<NUMBER> recently published study comprised <NUMBER> patients <NUMBER> randomly assigned combination group j u r n l p r e p r f <NUMBER>day combination lopinavir <NUMBER> mg ritonavir <NUMBER> mg every <NUMBER> h ribavirin <NUMBER> mg every <NUMBER> h three doses <NUMBER> million international units interferon beta<NUMBER>b alternate days <NUMBER>patients assigned control group <NUMBER> days lopinavir <NUMBER> mg ritonavir <NUMBER> mg every <NUMBER> h primary endpoint time providing nasopharyngeal swab negative sarscov<NUMBER> rtpcr combination group significantly shorter median time start study treatment negative nasopharyngeal swab <NUMBER> days control group <NUMBER> days p<NUMBER>·<NUMBER> authors concluded early triple antiviral therapy safe superior lopinavirritonavir alone alleviating symptoms shortening duration viral shedding hospital stay patients mild moderate covid<NUMBER> <NUMBER> several treatment combinations protocols drugs mentioned earlier tested ongoing clinical trials clinicaltrialsgov <NUMBER> summary status clinical trials accessed june <NUMBER>th clinicaltrialsgov databank shown table <NUMBER> vaccine named chadox<NUMBER> ncov<NUMBER> first vaccine enter phase clinical trial aiming assess whether health people protected covid<NUMBER> investigational vaccine developed university oxford jenner institute protected six rhesus macaques pneumonia caused sarscov<NUMBER> <NUMBER> started recruit volunteers oxford april <NUMBER> rd <NUMBER> around <NUMBER> people expected take part trial half receiving vaccine half control group vaccine based adenovirus vaccine vector sarscov<NUMBER> spike protein produced oxford <NUMBER> zhu et al <NUMBER> reported may <NUMBER> nd results clinical trial nct<NUMBER> tested safety tolerability immunogenicity recombinant adenovirus type<NUMBER> vectored covid<NUMBER> vaccine healthy adults aged <NUMBER> <NUMBER> years sequentially enrolled allocated one three dose groups <NUMBER> × <NUMBER>¹⁰ <NUMBER> × <NUMBER>¹¹ <NUMBER>·<NUMBER> × <NUMBER>¹¹ viral particles receive intramuscular injection vaccine <NUMBER> participants <NUMBER> male <NUMBER> female mean age <NUMBER>·<NUMBER> years recruited received low dose n<NUMBER> middle dose n<NUMBER> high dose n<NUMBER> vaccine elisa antibodies neutralizing antibodies increased significantly day <NUMBER> peaked <NUMBER> days postvaccination specific tcell response peaked day <NUMBER> postvaccination authors concluded vaccine tolerable immunogenic warrants investigation <NUMBER> notwithstanding preliminary results encouraging shed hope effective treatment near future besides vaccines <NUMBER> clinical trials registered clinicaltrialsgov databank despite great efforts worldwide try find effective drug sarscov<NUMBER> yet consensus definite therapy covid<NUMBER> use repurposed medications shown good alternative j u r n l p r e p r f promising results effective vaccine still available review incorporated key drugs treatments tested demonstrated potential use sarscov<NUMBER> virus june <NUMBER> th <NUMBER> however results obtained far use repurposed drugs must faced caution unfortunately pressure imposed increasingly death toll great attention media politics pandemic stimulated publication small incomplete studies humans questionable empirical clinical data many without desirable scientific rigor fact subject broad debate result misinformation confusion occurred hindering important actions combat covid<NUMBER> advance leading needless discredit science fact published research papers recognized medical journals withdrawn recently several concerns raised respect veracity data analyses conducted authors revealing use dubious methods analysis ethical problems <NUMBER> fact direct impact ongoing clinical trials causing temporary suspension compromising longawaited results hand stated zhang et al <NUMBER> sound science effectively communicated policy makers constitute prime foundation decisionmaking amid pandemic furthermore well designed rigorous randomized controlled trial provide reliable generalized data safety effective use drugs treat infected patients <NUMBER> despite great challenge posed covid<NUMBER> pandemic surfaced ethical issues ongoing efforts fight virus excellence hardworking many research groups across world offer hope near future win battle conflict interest funding research receive specific grant funding agencies public commercial notforprofit sectors fig <NUMBER> preventive measures avoid spread sarscov<NUMBER> virus spread mainly persontoperson people close contact one another respiratory droplets produced infected person cough sneezes talk best way prevent avoid exposed virus life cycle sarscov<NUMBER> potential drug targets <NUMBER> sarscov<NUMBER> enters target cells via two ways either via endosomes plasma membrane fusion ways spike proteins s<NUMBER> e s<NUMBER> mediate attachment cell membrane binding ace<NUMBER> receptor <NUMBER> endosomal via spike proteins activated cathepsin l alternatively transmembrane protease serine <NUMBER> tmprss<NUMBER> close proximity ace<NUMBER> receptor initiates fusion viral membrane plasma membrane <NUMBER> viral rna released part translated produce polyproteins pp<NUMBER>a ppab cleaved proteases pi pro <NUMBER>cl pro yield <NUMBER> nonstructural proteins form rna replicasetranscriptase complex <NUMBER> complex drives production negativesense rnas replication transcription subset around <NUMBER> subgenomic rnas including encoding structural proteins sspike mmembrane nnucleocapsid eenvelope translated <NUMBER> viral nucleocapsids assembled genomic rna n protein cytoplasm followed budding lumen endoplasmic reticulum ergolgi complex <NUMBER> virions released exocytosis potential sarscov<NUMBER> targets drugs shown red drugs treatment strategies investigated aim inhibit viral entryreplication human cells avoid cytokine storm decrease hyperinflammation lung injury ace angiotensinconverting enzyme arb angiotensin receptor blocker cq chloroquine hq hydroxychloroquine tmprss<NUMBER>transmembrane serine protease <NUMBER> ilinterleukin jakjanus kinase j u r n l p r e p r f fig <NUMBER> schematic representation natural history covid<NUMBER> onset recovery death basically three stages phases natural history covid<NUMBER> regarding disease severity first phase related onset disease generally characterized development influenzalike symptoms mild moderate individuals recover progress second phase phase possible detect pneumonialike symptoms evidenced lung opacities seen chest radiography glass opacities computed tomography ct depending severity phase <NUMBER> patients improve worsen necessity intubation ventilation patients typical examples phase <NUMBER> characterized hyperinflammation sepsis lungs patient often requires intensive care unit icu unfortunately overcome infection eventually die table <NUMBER> chemical structure repurposed drugs discussed present review tested potential use treatment covid<NUMBER> structure action reference anakinra recombinant il<NUMBER> receptor antagonist block cytokine storm <NUMBER> azithromycin antiviral antiinflammatory <NUMBER> increases endosomal ph alters glycosylation ace<NUMBER> interfering virusreceptor interaction <NUMBER> dexamethasone steroid antiinflammatory suppression cytokine storm <NUMBER> <NUMBER> reverse hypercoagulation severe cases covid<NUMBER> <NUMBER> increases endosomal ph alters glycosylation ace<NUMBER> interfering virusreceptor interaction <NUMBER> inhibits viral rna transcription protein translation post translational modification <NUMBER> <NUMBER> ivermectin antiviral inhibits viral replication assembly new virions <NUMBER> <NUMBER> lopinavir inhibits <NUMBER>cl protease activity blockage protein processing angiotensin receptor blocker interferes reninangiotensin system blood vessels constrictionvasodilation <NUMBER> antiinflammatory suppress cytokinerelated lung injury block cytokine storm <NUMBER> nitazoxanide antiviral interferes <NUMBER>cl protease activity <NUMBER> remdesivir inhibits rdrp polymerase inhibiting rna synthesis <NUMBER> <NUMBER> ritonavir inhibits <NUMBER>cl protease activity blockage protein processing <NUMBER> late december <NUMBER> outbreak sarslike pneumonia caused novel coronavirus occurred chinese city wuhan officially named covid<NUMBER> coronavirus diseases <NUMBER> world health organization later novel coronavirus designated sarscov<NUMBER> spreading nationwide across world march <NUMBER>th <NUMBER> assessed covid<NUMBER> could considered pandemic far quantity covid<NUMBER> diagnosed worldwide <NUMBER> death toll <NUMBER> march <NUMBER>th <NUMBER> <NUMBER> majority patients infected sarscov<NUMBER> showed nonspecific symptoms fever dry cough fatigue along pneumonia demonstrated chest ct scan imaging mild condition case fatality rate cfr around <NUMBER> <NUMBER> however among elderly patients patients chronic underlying diseases hypertension diabetes higher rate transmission intensive care unit icu mortality <NUMBER> given sarscov<NUMBER> novel strain causing global pandemic effective targeted therapies urgently needed however proven effective antiviral immunomodulatory therapies exist treatment covid<NUMBER> <NUMBER> patients received numerous potentially targeted therapies described far based medication experience severe acute respiratory syndrome sars middle east respiratory syndrome mers mostly belong existing antiviral agents approved development treating infections caused human immunodeficiency virus hiv hepatitis b virus hbv hepatitis c virus hcv influenza section patients participated ongoing uncontrolled clinical trials review summarize current therapeutic medicines used real world according possible mechanisms based chinese clinical experience hoping provide implications clinical medication remdesivir nucleoside analog effective variety viruses including merscov sarscov vitro animal models <NUMBER> <NUMBER> phase iii clinical trial inhibiting ebola virus ongoing <NUMBER> research revealed vitro remdesivir ability inhibit sarscov<NUMBER> recently <NUMBER> first covid<NUMBER> case us improved condition declined viral load treated remdesivir illness day <NUMBER> suggesting remdesivir potential treat covid<NUMBER> recently results trial remdesivir treatment patients severe covid<NUMBER> sympathetic medication published data shown <NUMBER> severe patients relieved symptoms using remdesivir mortality patients <NUMBER> noteworthy though findings need confirmed ongoing randomized placebocontrolled trials remdesivir therapy covid<NUMBER> <NUMBER> remdesivir investigational agent commercially available safety efficacy established covid<NUMBER> patients available part several ongoing clinical trials adult nonpregnant patients individual compassionate use requests limited pregnant women pediatric patients <NUMBER> years age confirmed covid<NUMBER> severe disease although clear contraindications population included clinical trials nct<NUMBER> nct<NUMBER> nct<NUMBER> people creatinine clearance <NUMBER> ml per minute serum levels alanine aminotransferase alt aspartate aminotransferase ast five times upper limit normal range excluded therefore patients liver kidney function impairment used caution chloroquine drug widely used treatment malaria autoimmune diseases <NUMBER> reported broadspectrum antiviral potential in<NUMBER> <NUMBER> recent study <NUMBER> chloroquine found inhibit sarscov<NUMBER> lowmicromolar ec<NUMBER> μm vero e<NUMBER> cells clinically achievable based experience rheumatoid arthritis <NUMBER> addition timeofaddition assay <NUMBER> demonstrated chloroquine functioned entry postentry stages <NUMBER>ncov infection vero e<NUMBER> cells antiviral activity chloroquine may due following three ways figure <NUMBER> <NUMBER> reduce ace<NUMBER> receptor terminal glycosylation surface cells thus interfere binding sarscov<NUMBER> ace<NUMBER> receptor <NUMBER> <NUMBER> increase ph endosomes lysosomes prevent fusion process virus host cells subsequent virus replication <NUMBER> <NUMBER> <NUMBER> impede proinflammatory signaling activation production cytokines eg il<NUMBER> il<NUMBER> tnf inhibiting lysosomal activity antigenpresenting cells apcs interrupting binding tolllike receptors tlr<NUMBER> tlr<NUMBER> rnadna ligands interfering interaction cytosolic dna nucleic acid sensor cyclic gmpamp synthase cgas press released state council china indicated chloroquine phosphate demonstrated marked efficacy preventing deterioration covid<NUMBER> related pneumonia multicenter clinical trials conducted china february <NUMBER> <NUMBER> <NUMBER> latest guideline <NUMBER> recommended adults <NUMBER> years old <NUMBER> mg time <NUMBER> timesday lasts <NUMBER>days patients weigh <NUMBER>kg <NUMBER> mg time <NUMBER> timesday lasts <NUMBER> days <NUMBER> mg time <NUMBER> timeday lasts <NUMBER> days patients weigh less <NUMBER>kg banned people underlying heart disease due cardiotoxicity currently <NUMBER> clinical trials chloroquine registered china clinical trial registry hydroxychloroquine analogue chloroquine similar therapeutic effects significantly reduced toxic side effects <NUMBER> besides vitro hydroxychloroquine exhibited better antisarscov<NUMBER> activity chloroquine <NUMBER> comprehensive treatment management coronavirus disease <NUMBER> expert consensus statement shanghai <NUMBER> recommended hydroxychloroquine attempt antiviral treatment however dosage recommendations made peking university third hospital established physiologybased pharmacokinetic pbpk model based data hydroxychloroquine chloroquine vitro simulate distribution concentration drug lung whole blood plasma different dosing regimens according results pbpk model recommended oral loading dose hydroxychloroquine <NUMBER>mg bid first day maintenance dose <NUMBER>mg bid continue treated four days fifth day lung titer reach three times oral chloroquine phosphate <NUMBER>mg twice daily <NUMBER> dose subsequently confirmed first randomized controlled clinical trial chictr<NUMBER> hydroxychloroquine covid<NUMBER> enroll <NUMBER> patients covid<NUMBER> <NUMBER> received hcq <NUMBER> mgd <NUMBER>mg bid another <NUMBER> entered control group found <NUMBER> days clinical recovery time hydroxychloroquine group significantly shortened symptoms fever cough relieved faster p <NUMBER> <NUMBER> patients hydroxychloroquine group significantly improved pneumonia compared <NUMBER> control group p <NUMBER> patients progressed critical illness control group study affirmed therapeutic effect hydroxychloroquine <NUMBER> recently clinical trial <NUMBER> involving <NUMBER> patients covid<NUMBER> shown combination hydroxychloroquine azithromycin full rapid viral clearance effects better hydroxychloroquine alone mechanism azithromycin enhances efficacy covid<NUMBER> unclear azithromycin previously shown prevent severe respiratory infections patients infected virus <NUMBER> however jean etal <NUMBER> observed similar results <NUMBER> covid<NUMBER> patients received combination therapy hydroxychloroquine azithromycin given trial rct number cases small control group clinical centers expanded clinical trial good quality control needed confirm addition simultaneous use hydroxychloroquine azithromycin lead prolonged qt interval increase risk tip torsion arrhythmia careful evaluation required due cardiac retinal toxicity acute lethal risk chloroquine hydroxychloroquine chloroquine hydroxychloroquine used electrocardiogram monitoring performed attention paid changes patients vision neurological symptoms favipiravir t<NUMBER> belongs nucleoside analogs like ribavirin approved treatment novel reemerging pandemic influenza china japan effectively multiple viruses like influenza ebola yellow fever chikungunya norovirus enterovirus <NUMBER> favipiravir teratogenic strictly prohibited pregnancy lactation <NUMBER> <NUMBER> wang etal reported activity <NUMBER>ncov ec<NUMBER>μm vero e<NUMBER> cells <NUMBER> subsequently <NUMBER> clinical trials favipiravir treatment covid<NUMBER> registered preliminary results one clinical trials chictr<NUMBER> showed group treated favipiravir <NUMBER> cases shorter median time virus clearance <NUMBER> days vs <NUMBER> days high improvement rates chest image <NUMBER> vs <NUMBER> control group treated lopinavir ritonavir <NUMBER> cases significant differences two groups adverse reactions lower control group zhongnan hospital wuhan university initiated multicenter randomized open positive parallelcontrolled clinical study favipiravir treatment covid<NUMBER> chictr<NUMBER> <NUMBER> patients enrolled clinical treatment observations completed results showed experimental group treated favipilavir <NUMBER> cases significantly better control group treated arbidol <NUMBER> cases treatment covid<NUMBER> terms secondary indicators clinical recovery rate day <NUMBER> significantly better experimental group control group <NUMBER> <NUMBER> respectively terms secondary indicators time randomization fever reduction <NUMBER> days vs <NUMBER> days cough relief <NUMBER> days vs <NUMBER> days rate auxiliary oxygen therapy noninvasive mechanical ventilation <NUMBER> vs <NUMBER> trial experimental group significantly better control group view good safety favipiravir drugs available experts formally recommended included guideline soon possible <NUMBER> arbidol licensed russia china upper respiratory tract infections caused influenza b viruses contraindicated patients allergic product antiviral mechanism arbidol inhibiting hemagglutininase protease surface influenza virus binds sialic acid receptors human cells enters cells endocytosis prevent influenza virus infecting human cells besides abidol induce interferon production exert broadspectrum antiviral effect <NUMBER> recent study revealed arbidol inhibit sarscov<NUMBER> infection concentration <NUMBER> µm effectively vitro<NUMBER> deng etal <NUMBER> found patients taking arbidol lpvr n<NUMBER> increased sarscov<NUMBER> negative rate <NUMBER>days <NUMBER>days improved chest ct scan compared oral lpvr n<NUMBER> however effects lpvr arbidol found improve symptoms shorten clearance time nucleic acid respiratory specimens gastrointestinal adverse reactions comparing placebo control group clinical trial shanghai public health clinical center <NUMBER> contradictory results may due small sizes inconsistent timing medications missing best therapeutic window part patients clinical study arbidol using postexposure prophylaxis sarscov<NUMBER> highrisk population including medical staff progress chictr<NUMBER> may providing us whether effects arbidol prevention early treatment latest guide recommends course treatment arbidol exceed <NUMBER> days <NUMBER>mgeach time <NUMBER> timesday lopinavir approved food drug administration fda treat hiv infection protease inhibitor ritonavir booster inhibiting cytochrome p<NUMBER> increase blood concentrations <NUMBER> lopinavirritonavir lpvr contraindicated allergy product severe liver dysfunction drugs highly dependent cyp<NUMBER>a clearance elevated plasma concentrations associated acute lifethreatening reactions nonrandomized clinical trial showed sars patients treated ribavirin combined lpvr lower risk ards death ribavirin monotherapy <NUMBER> korean covid<NUMBER> patient found reduced viral loads improved clinical symptoms treated lopinavirritonavir <NUMBER> clear whether effect antiviral drug natural course lpvr recommended treatment covid<NUMBER> latest guideline <NUMBER> mg<NUMBER> mgeach time <NUMBER> timesday based experience sarscov merscov nausea vomiting fat metabolism disorders elevated blood sugar common adverse reactions lpvr elderly patients chronic diseases type <NUMBER> diabetes hyperlipidemia need close monitoring blood glucose blood lipids however increase number clinical applications clinicians believe effective gastrointestinal adverse reactions also occur frequently <NUMBER> nejm published article march <NUMBER> <NUMBER> reporting randomized controlled openlabel clinical trial involving <NUMBER> patients severe covid<NUMBER> chinajapan friendship hospital chictr<NUMBER> proves lpvr significant effect treatment covid<NUMBER> <NUMBER> might confirm antiviral drugs challenging reverse lung injury caused cytokine storm ribavirin nucleoside analog may multiple mechanisms action including lethal mutagenesis specific nonspecific chain termination inhibition nucleotide biosynthesis eliminate rna viruses <NUMBER> approved treatment respiratory syncytial virus rsv fda <NUMBER> contraindicated autoimmune hepatitis hemoglobin disease impaired kidney function creatinine clearance <NUMBER> ml per minute pregnant females males pregnant partners allergies <NUMBER> due broadspectrum antiviral effect widely used early stages sars epidemic however role ribavirin play controversial one hand severe side effects hypoxia anemia decreased hemoglobin levels related use highdose ribavirin <NUMBER> hand contradictory results clinical observation experiments <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> cell culture ribavirin inhibitory effect saracov<NUMBER> requires higher concentrations ribavirin recommended antiviral treatment diagnosis treatment protocol novel coronavirus disease military medical team supporting wuhan trial version <NUMBER> included guidelines prevention diagnosis treatment novel coronavirusinduced pneumonia trial version <NUMBER> recommend lowdose ribavirin <NUMBER> mg time <NUMBER> <NUMBER> timesday combined lopinavirritonavir interferon instead monotherapy trial comparing effectiveness safety ribavirin plus interferonalpha lopinavirritonavir plus interferonalpha ribavirin plus lopinavirritonavir plus interferonalpha patients mild moderate novel coronavirus pneumonia progress chictr<NUMBER> antiviral effect ribavirin combination multiple drugs clear clinical trials need confirmed antiviral interferon system plays critical role innate immune defense human beings ifns cytokines produced cells meeting viruses <NUMBER> present ifns approved indications hepatitis b hepatitis c various malignancies fda patients infected sarscov merscov ifns production suppressed <NUMBER> <NUMBER> confirmed responsible activating proinflammatory monocyte macrophages cytokines lungs sars mouse model <NUMBER> effect ifn monotherapy combined ribavirin observed vitro animal models given early disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> however clinical trials combination therapy ifn show good curative effect prognosis <NUMBER> <NUMBER> <NUMBER> <NUMBER> might occur due medication delay multiple organ damage caused subcutaneous medications <NUMBER> guidelines <NUMBER> prevention diagnosis treatment novel coronavirusinduced pneumonia trial version <NUMBER> recommend interferon inhalation early possible ensuring higher levels drug lung tissue longer drug circulation time subcutaneous injection noted nebulized interferon contraindicated patients spontaneous pneumothorax pulmonary bullae present corticosteroid use controversial covid<NUMBER> one hand corticosteroids suppress lung inflammation cytokine storms essential covid<NUMBER> patients especially severe critical patients hand increased secondary infection rate delayed virus clearance found sars influenza pneumonia patients using corticosteroids <NUMBER> <NUMBER> <NUMBER> small observational study patients covid<NUMBER> showed potential benefits lowdose corticosteroid treatment critically ill patients despite significant improvement overall survival <NUMBER> ni etal <NUMBER> retrospectively analyzed clinical data <NUMBER> patients covid<NUMBER> found statistically significant difference time viral nucleic acid negation lung image recovery lowmedium dose glucocorticoids methylprednisolone <NUMBER> mgkgd treatment group nonglucocorticoid control group glucocorticoid immunosuppressive therapy prolong virus clearance time patients covid<NUMBER> suggesting hormone therapy may helpful severe patients study reviewed clinical data <NUMBER> cases wuhan red cross hospital treatment low dose methylprednisolone mild common cases became severe critical found optimal window period low dose methylprednisolone treatment covid<NUMBER> within <NUMBER> hours switching mild condition severe critical early administration low dose methylprednisolone within window period patients could significantly reduce critical illness rate mortality rate <NUMBER> expert consensus statement china <NUMBER> recommends lowtomoderate corticosteroid ≤<NUMBER> mgkg per day methylprednisolone equivalent used carefully critically ill patients covid<NUMBER> duration short ≤<NUMBER> days tocilizumab recombinant humanized antibody specifically binds interleukin<NUMBER> il<NUMBER> receptor inhibit activity il<NUMBER> licensed adult rheumatoid arthritis cytokine release syndrome <NUMBER> il<NUMBER> long considered one key cytokines induce cytokine storms among patients covid<NUMBER> il<NUMBER> significantly higher severe dead patients mild discharged patients <NUMBER> <NUMBER> reasons first affiliated hospital university science technology china initiated multicenter randomized controlled trial efficacy safety tocilizumab treatment covid<NUMBER> chictr<NUMBER> first phase clinical study <NUMBER> patients covid<NUMBER> pneumonia maximum age <NUMBER> years <NUMBER> severe <NUMBER> critically ill diffuse lesions lungs treatment <NUMBER> persistent fever treatment new treatment regimen tocilizumab combined conventional therapy temperature <NUMBER> patients fever fell normal within <NUMBER> hours <NUMBER> j u r n l p r e p r f patients better absorption ct lesions lungs xu etal <NUMBER> also found similar results observational studies therefore patients severe conditions caused cytokine storm tocilizumab drug worthy clinical research five clinical trials addition mentioned trastuzumab progress patients extensive infiltrating lesions lungs severe patients elevated il<NUMBER> tocilizumab treatment tried recommended dose <NUMBER> mg cumulative dose <NUMBER> times medical staff pay attention allergic reactions exclude active infections tuberculosis <NUMBER> absence particularly effective medicines western medicine chinese medicine played unique advantage improving immunity improving symptoms china <NUMBER> people use traditional chinese medicine treatment <NUMBER> chinese medicine physicians summarized law experience traditional chinese medicine treatment viral infectious diseases deeply explored ancient classic recipes combined clinical practice thus selecting group prescription drugs represented three drugs three prescriptions obvious curative effects jinhua qinggan granules lianhua qingwen capsules xuebijing injection qingfeipaidu decoction huashibaidufang xuanfeibaidufang jinhua qinggan granule lianhua qingwen capsule used confirmed suspected cases former mainly used patients headache main symptom mild fever symptoms latter used patients severe fever dry stool qingfei paidu decoction general prescription mild severe critical covid<NUMBER> patients <NUMBER> treatment severe critically ill patients xuebijing injection may important therapeutic drug xuebijing injection curative effect inflammatory storm coagulation dysfunction early clinical studies proved xuebijing certain effect severe pneumonia <NUMBER> observational studies <NUMBER> <NUMBER> <NUMBER> suggested traditional chinese medicine improve patients symptoms inflammation promote absorption lung infections however lack reliable rct researches covid<NUMBER> based currently reported retrospective studies covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> found people received two antiviral therapy combination depends patients liver kidney function whether complications adverse reactions various combinations common combinations following interferon ifn lpvr ifn arbidol oseltamivir arbiodol ifn lpvr arbidol multicenter prospective study <NUMBER> patients showed triple combination antiviral therapy ifn lpvr arbidol showed shorter viral shedding time hospitalization time compared dual combination antiviral therapy ifn arbidol earlier time initiate triple antiviral treatment shorter time virus shedding <NUMBER> addition studies suggested troponin elevated severe critically ill patients <NUMBER> <NUMBER> likely cause myocardial damage caused inflammatory storms cardioprotective drugs coenzyme q<NUMBER> trimetazidine hydrochloride creatine phosphate vitamin c could used severe critical patients improve cardiac energy metabolism <NUMBER> elderly patients hematopoietic function liver kidney heart bone marrow declines age underlying complications drug treatments necessary pay attention interaction antiviral drugs treatment drugs basic diseases close monitoring individualized treatment required conclusion antiviral drugs proven effective currently antiviral drugs used carefully reduce viral replication early stages disease based dynamic results clinical trials recommended use antiviral drugs prevention covid<NUMBER> since antiviral effects lpvr arbidol apparent gastrointestinal adverse reactions frequently occur therapeutic effect two drugs covid<NUMBER> still needs evaluation based current clinical trial results clinical medication experience recommend favipiravir interferon patients mild moderate conditions given good results clinical trial remdesivir focused severe patients currently recommend severe patients chloroquine another antiviral drug potential effect severe patients due immunosuppressive effect addition antiviral effect critically ill patients lowtomoderate corticosteroid tocilizumab used combat cytokine storms reduce mortality caution chloroquine developed subsequent bark extract quinine treatment prophylaxis malaria <NUMBER> due potential toxicity drug resistance chloroquine quinine longer frequent use <NUMBER> chloroquine hydroxychloroquine currently investigation possible treatments patients infected severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> causes disease covid<NUMBER> several mechanisms suggested explain chloroquine hydroxychloroquine may therapeutic covid<NUMBER> <NUMBER> <NUMBER> including inhibition viral binding host cell ace<NUMBER> receptor mechanism viral entry host cells inhibition viral replication enzymes via raising host cell organelle ph deescalation monocyte cytokine production decreasing immunemediated host tissue damage mechanisms could serve inhibit virus entry neurons glia slow replication virus brain tissues deescalate neuroinflammatory response delirium risk chloroquine hydroxychloroquine shown inhibit sarscov<NUMBER> vitro <NUMBER> <NUMBER> chinese commentary reported early favorable results placebocontrolled trials chloroquine treatment covid<NUMBER> <NUMBER> based early data department science technology guangdong province health commission guangdong province published chloroquine dosing recommendations covid<NUMBER> <NUMBER> others published recommendations consider hydroxychloroquine instead chloroquine covid<NUMBER> treatment citing superior side effect profile <NUMBER> higher mortality shown covid<NUMBER> treatment higher dose chloroquine <NUMBER> mg twice daily relative lower dose <NUMBER> mg twice daily phase ii doubleblinded randomized clinical trial <NUMBER> one large registry found increased mortality chloroquine treatment well increased risk ventricular arrhythmia <NUMBER> likely due appeal hydroxychloroquines superior side effect profile relative chloroquine research currently published hydroxychloroquine treatment covid<NUMBER> one placebocontrolled randomized trial <NUMBER> patients showed faster covid<NUMBER> recovery time hydroxychloroquine placebo <NUMBER> large retrospective study suggested hydroxychloroquine benefits minimal adverse effects <NUMBER> contrast many observational studies detected mortality benefit hydroxychloroquine treatment covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies even suggest net adverse outcomes hydroxychloroquine treatment covid<NUMBER> cardiac gastrointestinal <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> adjustment renal insufficiency reduce risk toxicity <NUMBER> chloroquine hydroxychloroquine demonstrate dosedependent inhibition platelet aggregation <NUMBER> <NUMBER> one study showed possible synergism cardiovascular thromboprophylaxis five years concomitant administration aspirin hydroxychloroquine <NUMBER> unable find studies evaluating thrombotic impact coadministering chloroquine hydroxychloroquine concomitantly psychiatric medications known inhibit platelet aggregation table <NUMBER> b ssri selective serotonin reuptake inhibitor snri serotonin norepinephrine reuptake inhibitor tca tricyclic amine chloroquine hydroxychloroquine suspected prolong qt interval however clinical significance unclear studies demonstrate qt prolongation others <NUMBER> <NUMBER> systematic review published prospective trials chloroquine demonstrate increased risk sudden deaths attributed cardiac arrhythmias <NUMBER> nevertheless several case reports describe episodes torsades de pointes tdp patients chloroquine <NUMBER> hydroxychloroquine <NUMBER> <NUMBER> setting increased cardiac vulnerability frequent exposure qtcprolonging agents ex azithromycin hospitalization covid<NUMBER> fda released drug safety communication warning addition hydroxychloroquine chloroquine may increase risk negative cardiac outcomes <NUMBER> reasonable psychiatrists anticipate risk tdp may increased combination medications known prolong qt interval antipsychotics tricyclic amines hydroxyzine see funk <NUMBER> comprehensive review qt interval prolongation psychiatric medications <NUMBER> increased risk tdp overdose chloroquine hydroxychloroquine suicidal patients certainly another relevant consideration psychiatrists common central nervous cns system side effects chloroquine headache <NUMBER> dizziness <NUMBER> insomnia <NUMBER> <NUMBER> dosedependent retinopathy occur chloroquine lessfrequent hydroxychloroquine requires monitoring careful attention need dose adjustment <NUMBER> general side effects hydroxychloroquine similar chloroquine less common <NUMBER> infrequent case reports also reported dystonia generalized tonicclonic seizures chloroquine administration <NUMBER> <NUMBER> <NUMBER> <NUMBER> early symptoms cns toxicity include nausea vomiting dizziness headache followed delirium seizures <NUMBER> chloroquine narrow therapeutic window rapid onset toxicity symptoms <NUMBER> <NUMBER> risk mortality overdose <NUMBER> another factor psychiatrists consider patients risk overdose cns toxicity neuropsychiatric effects may occur therapeutic doses <NUMBER> <NUMBER> <NUMBER> hydroxychloroquine overdose less data also fatal <NUMBER> several mechanisms chloroquine proposed contributors chloroquine neuropsychiatric side effects inhibition neuronal calcium currents <NUMBER> dopamine excess <NUMBER> prostaglandin e antagonism <NUMBER> spermidine excess <NUMBER> acetylcholine dysfunction <NUMBER> cns levels chloroquine elevated <NUMBER> times serum levels <NUMBER> possibly influenced interference pglycoprotein function bloodbrain barrier <NUMBER> hydroxychloroquine proposed many similar properties chloroquine often hydroxychloroquine mechanisms action assumed based chloroquine studies <NUMBER> <NUMBER> neuropsychiatric events depression mania psychosis catatonia present less <NUMBER> patients chloroquine <NUMBER> <NUMBER> <NUMBER> events also seem present less hydroxychloroquine exposure chloroquine exposure research regarding phenomena largely composed case series case reports described sections follow although overall incidence unknown cases psychosis following chloroquine described since <NUMBER> <NUMBER> retrospective study biswas colleagues describes <NUMBER> cases diagnosed psychosis following chloroquine course <NUMBER> years extracted records <NUMBER> psychiatric units areas india malaria hyperendemic <NUMBER> inclusion criteria study reasonable included diagnostic criteria substanceinduced mood disorder hallucinations delusions absence delirium minimum <NUMBER> week psychiatric symptoms psychosis onset within <NUMBER> weeks chloroquine initiation least one <NUMBER> mg tablet exposure resolution within <NUMBER> weeks discontinuing chloroquine levels drawn unclear proportion cases featured toxic levels study demonstrated psychosis presentations commonly featured combined psychotic affective symptoms <NUMBER> cases prevalent affective presentation irritability mixed mood episode consistent case series prior study <NUMBER> <NUMBER> psychotic episodes demonstrated prolonged mean duration resolution <NUMBER> days discontinuation chloroquine <NUMBER> psychosis following chloroquine often described feature derealization depersonalization <NUMBER> <NUMBER> <NUMBER> biswass study found present following significant stressors <NUMBER> common positive symptoms study visual hallucinations cases feature negative symptoms <NUMBER> additionally psychosis typically related premorbid psychiatric history patients reported preserved insight psychosis following chloroquine <NUMBER> doseresponse relationship chloroquine dose risk psychotic symptoms demonstrated <NUMBER> chloroquines prolonged halflife high cns penetration mechanisms proposed explain prolonged psychotic symptoms course chloroquine discontinuation <NUMBER> <NUMBER> studies found regarding incidence hydroxychloroquineinduced psychotic symptoms six case reports describe psychosis suspected associated hydroxychloroquine diverse circumstances temporally related hydroxychloroquine prescription preceding onset psychosis resolving hydroxychloroquine discontinuation hydroxychloroquine prescribed lupus presentations three cases <NUMBER> one report patient suspected cns toxicity due pharmacy error resulting tenday exposure excessive hydroxychloroquine dose <NUMBER> another case featured patient borderline personality disorder developed auditory kinesthetic hallucinations well suicidal ideation two hydroxychloroquine exposures five years apart <NUMBER> clearly documented cases lupus cerebritis ruled psychosis etiology one author utilized naranjo probability scale evidence hydroxychloroquine induced psychosis etiology <NUMBER> three cases describe diverse psychotic presentations setting hydroxychloroquine treatment rheumatoid arthritis <NUMBER> q fever <NUMBER> erosive plantar lichen planus <NUMBER> patient rheumatoid arthritis developed disorganized psychosis neurovegetative features <NUMBER> another patient treated q fever demonstrated array hallucinations auditory visual well formication without disorientation fluctuation alertness <NUMBER> final case notable concomitant methylprednisolone exposure well atypical psychotic presentation early nightmares followed depersonalization cenesthetic hallucinations false perception viscera movement <NUMBER> mood episodes without psychotic symptoms associated chloroquine hydroxychloroquine exposure may occur <NUMBER> case series drew <NUMBER> <NUMBER> patients treated chloroquine rheumatoid arthritis developed mild severe depression one severe enough warrant electroconvulsive therapy <NUMBER> presence rheumatic diseases could confounder depression etiology small case series larger sample malaria chemoprophylaxis studies demonstrate association chloroquine exposure high incidence depressive symptoms although feasible higher doses chloroquine used treatment rheumatological conditions could present increased risk incident depression lower doses used malaria chemoprophylaxis <NUMBER> study evaluating database <NUMBER> persons antimalarial chemoprophylaxis chloroquine <NUMBER> mg weekly depression documented <NUMBER> persons <NUMBER> note chloroquine dosing study less dosing used covid<NUMBER> treatment <NUMBER> four arm randomized doubleblind placebocontrolled study mood profiles malaria chemoprophylaxis study arm <NUMBER> patients treated chloroquine demonstrate increased depression symptoms compared controls <NUMBER> note chloroquine dose study <NUMBER> mg per day less used covid<NUMBER> studys placebo group took placebo first <NUMBER> week <NUMBER>week trial transitioned drug exposure <NUMBER> week decreasing validity placebo comparison finally <NUMBER> nested casecontrol analysis <NUMBER> years data united kingdom general practice research database demonstrated <NUMBER> cases incident depression chloroquine chemoprophylaxis reflect significant difference depression risk compared controls <NUMBER> problematic feature study incident case depression would linked chloroquine exposure within <NUMBER> days prior general practitioner diagnosis depression seems like inappropriately long duration ascribe association despite apparent low frequency chloroquineassociated depression malaria chemoprophylaxis studies several case reports describe patients developed severe depressive episodes often suicidal ideation psychotic features within days chloroquine exposure <NUMBER> common feature cases resolution depressive symptoms within several days discontinuing chloroquine completed suicide via overdose chloroquine previously reported fatal overdoses possible times therapeutic dose often <NUMBER> <NUMBER> gram overdose <NUMBER> evoke caution prescription chloroquine patients experiencing active suicidal ideations several case reports describe manic episodes chloroquine exposure <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> although systematic studies published reports onset manic presentations approximately one week initiation chloroquine exposure resolution <NUMBER> weeks discontinuation chloroquine classic manic symptoms present described cases notable grandiosity frequent religiouslythemed delusions patients treated haloperidol chlorpromazine well electroconvulsive therapy one patient developed catatonia mood episodes associated hydroxychloroquine received less research attention <NUMBER> naturalistic study patients receiving treatment rheumatoid arthritis n <NUMBER> <NUMBER> subjects hydroxychloroquine demonstrate elevated risk depression compared treatment groups <NUMBER> however patients hydroxychloroquine scored significantly higher severity suicidal ideation beck scale suicidal ideation mean <NUMBER> ± <NUMBER> patients methotrexate leflunomide severity suicidal ideation patients taking hydroxychloroquine still much lower exposure biologic therapies ex rituximab mean <NUMBER> ± <NUMBER> given naturalistic study clinical features prompted decision one treatment another could represent confounders group comparison clearly controlled study unclear whether data meaningfully generalized context persons taking hydroxychloroquine covid<NUMBER> prophylaxis treatment <NUMBER> review mascolo colleagues evaluated reports hydroxychloroquine psychiatric side effects entered eudravigilance pharmacovigilance database european medicine agency <NUMBER> <NUMBER> <NUMBER> <NUMBER> cases depression reported well <NUMBER> cases completed suicide causation outcomes hydroxychloroquine certainly clear pharmacovigilance data however data raise questions warrant formal study anxiety received much attention psychiatric side effect chloroquine although several case reports described panic episodes attributed chloroquine exposure <NUMBER> <NUMBER> cases anxiety symptoms resolved within days chloroquine discontinuation <NUMBER> case series drew patients described increased claustrophobia nightmares chloroquine exposure <NUMBER> european medicine agency pharmacovigilance database <NUMBER> <NUMBER> <NUMBER> cases anxiety disorders reported setting hydroxychloroquine exposure well <NUMBER> cases insomnia <NUMBER> previously referenced <NUMBER> study pinho de oliveira ribeiro patients hydroxychloroquine treatment rheumatoid arthritis found screen positive anxiety subscale hospital anxiety depression scale hadsa mean <NUMBER> sd <NUMBER> <NUMBER> anxiety scores group significantly higher scores patients methotrexate leflunomide similar affective data rheumatoid arthritis treatment study data may generalize well context persons taking hydroxychloroquine covid<NUMBER> prophylaxis treatment attention directed consideration hydroxychloroquine intervention neurodegenerative disorders based impact lysosomal ph immune system activation <NUMBER> retrospective study large sample patients connective tissue disorders demonstrate significant change risk developing alzheimers dementia patients exposed chloroquine hydroxychloroquine <NUMBER> <NUMBER> doubleblinded randomized controlled trial <NUMBER> subjects early alzheimers disease group <NUMBER> months treatment hydroxychloroquine demonstrate significant difference compared placebo regarding dementia progression cognitive performance behavior changes <NUMBER> although thorough studies neuropsychiatric symptoms covid<NUMBER> published time article written psychiatric presentations expected common hospitalized patients covid<NUMBER> due etiologies chloroquine hydroxychloroquineinduced neuropsychiatric side effects delirium anecdotally frequent patients requiring intensive care critically ill patients frequently become delirious may present confusion aggression mood changes hallucinations delusional thinking neuropsychiatric symptoms <NUMBER> additionally survival acute respiratory distress syndrome ards complicated delirium associated increased incidence posttraumatic stress symptoms <NUMBER> study mao et al <NUMBER> nervoussystem related clinical findings present <NUMBER> <NUMBER> hospitalized covid<NUMBER> cases common findings stroke ataxia seizure depressed level consciousness prevalence neurological symptoms increased <NUMBER> severe covid<NUMBER> cases additionally study <NUMBER> patients covid<NUMBER> ards showed <NUMBER> patients agitation <NUMBER> confused neuromuscular blockade discontinued <NUMBER> within discharged subgroup study <NUMBER> demonstrated executive dysfunction addition physiological impact covid<NUMBER> treatment exposures ie sedatives prolonged mechanical ventilation several authors noted isolation introduces barriers nonpharmacological measures decrease risk delirium <NUMBER> although detailed consideration pathophysiology treatment delirium covid<NUMBER> beyond scope article comprehensive articles published elsewhere <NUMBER> <NUMBER> <NUMBER> additionally case reports published regarding covid<NUMBER> infection complicated steroidresponsive encephalitis <NUMBER> psychosis nondelirious patients <NUMBER> acute hemorrhagic necrotizing encephalopathy <NUMBER> increased depression anxiety memory deficits insomnia posttraumatic stress disorder ptsd symptoms demonstrated survivors sarscov<NUMBER> middle east respiratory syndrome coronavirus infections may symptoms present covid<NUMBER> survivors well <NUMBER> survey one year h<NUMBER>n<NUMBER> influenzaassociated ards survivors reported high anxiety depression posttraumatic stress disorder ptsd <NUMBER> patients hospitalized pandemicrelated infections experience delirium may also experience adjustment disorder depressive andor anxious symptoms well ptsd <NUMBER> survivors hospitalization pandemicrelated infections may also express pessimistic views anger due perception rejection society survivor grief <NUMBER> although covid<NUMBER> pandemic suicidology studies published time writing authors predict increased suicidality based previously demonstrated correlations increased unemployment <NUMBER> based increased suicide rates <NUMBER> sarscov<NUMBER> epidemic <NUMBER> given high expected incidence psychiatric presentations covid<NUMBER> hospitalization infrequent neuropsychiatric side effects chloroquine hydroxychloroquine may difficult clinically isolate population though may clear isolate setting prophylactic use anticipation potential neuropsychiatric sequela chloroquine hydroxychloroquine treatment covid<NUMBER> requires extrapolation chloroquine hydroxychloroquine research treatment rheumatological disease chemoprophylaxis malaria neuropsychiatric side effects uncommon patients chloroquine hydroxychloroquine although better described chloroquine exposure hydroxychloroquine exposure psychiatric symptom presentation hospitalization covid<NUMBER> infection much likely due delirium adjustment disorder neuropsychiatric side effects chloroquine hydroxychloroquine studied neuropsychiatric phenomenon medications psychosis following chloroquine may prolonged resolution conversely psychosis induced hydroxychloroquine described case reports expected quite rare weak evidence suggests potential increased anxiety symptoms suicidal ideation hydroxychloroquine exposure although evidence based limited research unclear generalization given pandemic stressors neuropsychiatric sequelae covid<NUMBER> could possibly synergize possible increased suicide risk attributable hydroxychloroquine best practice may include screening suicidal ideation performance suicide risk assessment patients hydroxychloroquine covid<NUMBER> prophylaxis treatment appropriate clinical practice better clarified future research studying association hydroxychloroquine suicidal ideation suicide attempts particularly setting covid<NUMBER> prophylaxis treatment psychiatric considerations include chloroquine hydroxychloroquines mild cyp<NUMBER>d<NUMBER> inhibition potential psychiatric medications impact chloroquine hydroxychloroquine levels toxicity potential increased risk tdp chloroquine hydroxychloroquine combined psychiatric medications prolong qt interval neuropsychiatric effects chloroquine hydroxychloroquine used treatment covid<NUMBER> previously studied future research regarding incidence phenomenon neuropsychiatric side effects clinical context may helpful guide future risk stratification would like thank arwen mitchell feedback regarding manuscripts grammar flow virus circulates human bird animal causing seasonal epidemic occasional pandemic outbreaks past century world faced five pandemic respiratory diseases caused different subtypes influenza virus pigs serve major reservoirs influenza viruses <NUMBER> h<NUMBER>n<NUMBER> spanish flu originated spanish killed around <NUMBER> million people worldwide <NUMBER> h<NUMBER>n<NUMBER> asian flu originated china killed around <NUMBER> million people worldwide <NUMBER> h<NUMBER>n<NUMBER> hong kong flu killed <NUMBER> million people worldwide <NUMBER> h<NUMBER>n<NUMBER> bird flu affected birds humans <NUMBER> h<NUMBER>n<NUMBER> swine flu caused <NUMBER> human deaths encircled <NUMBER> countries infect humans pigs birds another pandemic born family coronavirus two regional epidemics severe acute respiratory syndrome sars middle east respiratory syndrome mers coronavirus family virus cause illness common cold severe acute respiratory syndrome sars middle east respiratory syndrome mers amanat krammer <NUMBER> <NUMBER> new virus identified china namely novel coronavirus disease <NUMBER> johns hopkins university coronavirus covid<NUMBER> global cases center systems science engineering <NUMBER> particular <NUMBER> peoples united states infected resulting <NUMBER> deaths till <NUMBER> april <NUMBER> far existing drugs could alleviated disease disease symptoms fever cough sore throat runny nose difficulty breathing china international exchange promotive association medical health care cpam recommend using antisars properties lopinavir ritonavir capsule older age covid<NUMBER> patients underlying condition serious symptoms capsules used emergency cases chu et al <NUMBER> huang et al <NUMBER> h jin et al <NUMBER> used covid<NUMBER> instead sarscov<NUMBER> following text human long infected coronavirus one responsible common cold contagious viral infection spread inhalation ingestion viral droplets result coughing sneezing touching infected surface primary sources infection coronavirus genome comprised <NUMBER> nucleotides encodes four structural proteins nucleocapsid n protein membrane protein spike protein envelop e protein several nonstructural proteins nsp figure <NUMBER> capsid protein shell inside capsid nuclear capsid nprotein bound virus single positive strand rna allows virus hijack human cells turn virus factories n protein coats viral rna genome plays vital role replication transcription nterminal n protein binding genomic subgenomic rnas mhv ibv virions process viral replication transcription one important open research problems developing effective drug targeting prevent contacts nterminal nprotein single positive rna strand stop viral replication transcription sarma et al <NUMBER> reported two important class compounds theophylline pyrimidone drugs possible inhibitors rna binding n terminal domain n protein coronavirus thus opening new avenues vitro validations mprotein abundant viral surface believed central organizer coronavirus assembly sprotein integrated surface virus mediates attachment virus host cell surface receptors fusion viral host cell membranes facilitate viral entry host cell kirchdoerfer et al <NUMBER> eprotein small membrane protein composed <NUMBER> <NUMBER> aminoacid minor component virus particle plays important role virus assembly membrane permeability host cell virushost cell interaction gupta et al <NUMBER> lipid envelop encapsulates genetic material hemagglutininesterase dimer located surface viral protein may involved virus entry required replication appears important infection natural hostcell lissenberg et al <NUMBER> stateoftheart cryoem experiments revealed full structure spike protein close pdb id <NUMBER>vxx walls et al <NUMBER> open prefusion states pdb id <NUMBER>vyb wrapp et al <NUMBER> glycoprotein made three identical chains <NUMBER> amino acid composed two welldefined protein domain regions s<NUMBER> s<NUMBER> subunits associated cell recognition fusion viral cellular membranes respectively latter process occurs different protein conformational changes remain still uncharacterized mechanism viral entry replication rna packing human cell mapped figure <NUMBER> coronavirus spike protein attaches angiotensin converting enzyme <NUMBER> ace<NUMBER> receptors found surface many human cells including lungs allowing virus entry coronavirus protein subjected proteolytic cleavages host proteases ie trypsin furin two sites located boundary s<NUMBER> s<NUMBER> subunits s<NUMBER>s<NUMBER> site later stage happens cleavage s<NUMBER> domain s<NUMBER> <NUMBER> site order release fusion peptide event trigger activation membrane fusion mechanism searching antibodies find support molecular targeting utilize structural information aa sequence binding region found angiotensinconverting enzyme <NUMBER> receptor way protocol could device treatment block viral entry typically human cell ingests virus process called endocytosis entered cytoplasm suggested likely covid<NUMBER> employs unique threestep method membrane fusion involving receptorbinding induced conformational changes spike glycoprotein followed cathepsin l proteolysis intracellular proteases activation membrane fusion mechanism within endosomes simmons et al <NUMBER> endosome opens release virus cytoplasm uncoating viral nucleocapsid n started via proteasomes typically hydrolyse endogenous proteins also capable degrading exogenous proteins sars nucleocapsid protein q wang et al <NUMBER> different twostep mechanism suggested li <NUMBER> case virion binds receptor target host cell surface s<NUMBER> subunit spike cleaved host proteases hasan et al <NUMBER> expected fusion low ph viral host target membranes via s<NUMBER> subunit finally viral genetic material single stranded rna fully released cytoplasm takes place replication transcription processes mediated socalled replication transcription complex rtc complex encoded viral genome made nonstructural proteins nsp rtc believed induced doublemembrane structures cytoplasm infected cell van hemert et al <NUMBER> following positive rna genome translated generate replicase proteins open reading frame <NUMBER>ab orf <NUMBER>ab see figure <NUMBER> proteins use genome template generated fulllength negative sense rnas subsequently serve templates generating addition fulllength genomes structural viral proteins e synthesized cytoplasm inserted endoplasmic reticulum er figure <NUMBER> transfer endoplasmic reticulumgolgi intermediate compartment ergic masters <NUMBER> song et al <NUMBER> also cytoplasm nucleocapsids formed encapsidation replicated genomes n protein result coalesce within ergic membrane order selfassembly new virions finally novel virions exported infected cells transport cell membrane smoothwalled vesicles secreted via process called exocytosis infect cells meantime stress viral production endoplasmic reticulum eventually leads cell death however mechanism action novel covid<NUMBER> still unknown masters <NUMBER> covid<NUMBER> replicase gene encoded two polyproteins pp<NUMBER>a pp<NUMBER>ab molecular weight <NUMBER> <NUMBER> kd respectively polyproteins required viral replication transcription zhou et al <NUMBER> proteolytic process functional polypeptides spike membrane envelop nucleoprotein replicase polymerase released polyproteins process carried chymotrypsinfold proteinase namely main protease pro pro vital role polyprotein processing virus maturation hence considered attractive target antiviral drug design approach toward covid<NUMBER> treatment pillaiyar et al <NUMBER> yang et al <NUMBER> chinese scientists first published genome overseas collaboration obtained crystal structure threedimensional novel covid<NUMBER> main protease pro deposited protein data bank z jin et al <NUMBER> crystal structure covid<NUMBER> pro <NUMBER> amino acids three regions first region represented blue contains <NUMBER> residues second region green <NUMBER> residues third region orange <NUMBER> residues first third regions antiparallel bsheet structure third region five alpha helices arranged cluster third region connected second region long loop region contains <NUMBER> residues mass spectroscopy determined weight covid<NUMBER> pro <NUMBER> da singlestranded rna genomes covid<NUMBER> encode two large genes orf<NUMBER>a orf<NUMBER>b genes encode <NUMBER> nonstructural proteins nsp<NUMBER>nsp<NUMBER> structural genes encode structural proteins spike envelope e membrane nucleocapsid n accessory genes denoted shades green structure protein shown beneath genome organization protein consisting s<NUMBER> s<NUMBER> subunits s<NUMBER>s<NUMBER> cleavage sites highlighted dotted lines sprotein cytoplasm domain cp fusion peptide fp heptad repeat hr receptorbinding domain rbd signal peptide sp transmembrane domain tm shown b viral surface proteins spike envelope membrane embedded lipid bilayer singlestranded positivesense viral rna associated nucleocapsid protein theoretical studies confirmed weight <NUMBER> da z jin et al <NUMBER> furthermore literature several crystal structure covid<NUMBER> pro see figure <NUMBER> complex different inhibitor deposited protein data bank httpspdbjorgfeaturedcovid<NUMBER> using xray diffraction technique resolution <NUMBER> å <NUMBER> å covid<NUMBER> featured content <NUMBER> hand hiv<NUMBER> protease inhibitors tipranavir saquinavir ritonavir nelfinavir lopinavir indinavir darunavir atazanavir amprenavir widely reported able deactivate pro yang et al <NUMBER> covid<NUMBER> eprotein short integral membrane protein contains <NUMBER> amino acids size ranging <NUMBER> <NUMBER> kda consist <NUMBER> ahelices <NUMBER> loops protein short hydrophilic amino terminus consisting <NUMBER> amino acids followed large hydrophobic transmembrane domain <NUMBER> amino acids long hydrophilic cterminal domain shown box hydrophobic region generate oligomerization form ionconductive pore membranes plays significant role assembly viral genome protein involved several aspects virus life cycle assembly budding envelope formation pathogenesis schoeman fielding <NUMBER> e proteins ion channel activity found transmembrane region protein verdi ab aguena et al <NUMBER> wilson et al <NUMBER> membrane potential regulated eprotein controlling ion flow intracellular extracellular environment ion conductivity triggered eprotein via manipulation covid<NUMBER> genome seems novel route involved virus pathogenesis although eprotein interacted coronavirus proteins well host cell proteins eproteins ion channel activity alteration coronavirus cell ion balance eprotein necessary process virus production effect eprotein ion channel activity virus pathogenesis remains elusive efforts found mutation eprotein extracellular membrane could disrupt ionconductivity normal viral assembly torres et al <NUMBER> verdi ab aguena et al <NUMBER> hence control e protein dynamics promising target preventing pathogenesis associated covid<NUMBER> pervushin et al <NUMBER> example nietotorres et al <NUMBER> demonstrated mice infected covid<NUMBER> viruses exhibited eprotein ion channel activity wildtype eprotein sequence restored ion transport resulting mice death loss weight contrast mice infected mutant eprotein showed lack ion channel activity result recovered disease survived evidence confirmed ion channel activity correlated well virus growth strong eprotein ion channel activity generated higher chance mortality mice observed hence inhibitor target eprotein process help prevent virus production respect wilson et al showed hexamethylene amiloride inhibitor shown block eprotein ion channel conductance cell membrane inhibits replication parent coronavirus cultured cells wilson et al <NUMBER> recently gupta et al <NUMBER> identified medicinal properties belachinal macaflavanone e vibsanol b inhibitors successfully passed admet test lipinskis rule <NUMBER> compounds reduced random motion human covid<NUMBER> e protein terms inhibiting function human covid<NUMBER> e protein far understanding mechanism eprotein ion channel activity viral assembly ongoing debate one important research topics investigated deals eprotein ion channel activity viral production reduce mortality rate diseased human deletion eprotein inhibitor yang et al z jin et al <NUMBER> f wang et al <NUMBER> yang et al <NUMBER> designed michael acceptor n<NUMBER> inhibitors found optimal pharmaceutical activity viral protease mechanismbased irreversible inhibition also evaluated series widespectrum inhibitors targeting pro proteases multiple coronaviruses including sars mers ren et al <NUMBER> f wang et al <NUMBER> xue et al <NUMBER> yang et al <NUMBER> also exhibited antiviral activity infectious bronchitis virus animal model fights porcine epidemic diarrhea virus causes high mortality pigs well covid<NUMBER> f wang et al <NUMBER> recently jin et al <NUMBER> constructed homology model covid<NUMBER> pro used molecular docking monitor whether n<NUMBER> binds docking showed n<NUMBER> binds covid<NUMBER> pro shown right side figure <NUMBER> subsequently crystal structure covid<NUMBER> pro complex n<NUMBER> inhibitor determined <NUMBER> å resolution deposited protein data bank pdb id <NUMBER>lu<NUMBER> n<NUMBER> inhibitor binds residues <NUMBER> long strand <NUMBER> residues residues <NUMBER> loop connecting second third region form several hydrogen bonds main chain residues substratebinding pocket contact n<NUMBER> covid<NUMBER> pro locked inhibitor inside substrate binding pocket several xray studies covid<NUMBER> featured content <NUMBER> demonstrated small antiviral compound including lopinar locked position n<NUMBER> substratebinding pocket shown left side figure <NUMBER> figure s<NUMBER> table s<NUMBER> second region covid<NUMBER> pro favorable position inhibitors binding yang et al <NUMBER> zhao et al <NUMBER> literature number small bioactive compounds reported reached <NUMBER> million bostr€ om et al <NUMBER> regard researchers device strategies identify anticovid<NUMBER> pro properties candidate based structurebased virtual screening computational approach nowadays drug repurposing used identify potential drugs coronavirus enormous efforts paid ability reuse fda approvedpreclinical trial drugs disease literature find several promised drugs candidate targeted multiple virus protein graham et al <NUMBER> khan et al <NUMBER> yang et al <NUMBER> provided permission doctors scientist carry trial test combination different fdaapproved drugs covid<NUMBER> treatment view urgency current need reduce cost time risks drug development process scientists involved reusing already approved drug candidates test covid<NUMBER> patients short time response scientific community involve enormous efforts develop novel therapy treatment example chloroquine hydroxychloroquine old drugs used treat malarial rheumatoid arthritis lupus sun allergies sixty years activity hydroxychloroquine viruses probably chloroquine since mechanism action two molecules identical chloroquine antimalarial autoimmune disease drugs shown synergistically enhancing effect antiviral drugs vivo studies savarino et al <NUMBER> yan et al <NUMBER> interferes terminal glycosylation cellular receptor angiotensinconverting enzyme <NUMBER> may negatively influencereceptor binding abrogate infection ramifications elevation vesicular ph resulting spread sarscov cell culture prevented vincent et al <NUMBER> hydroxychloroquine shown potent efficacy treating patients covid<NUMBER> pneumonia hundred patients showed superiority chloroquine compared treatment standard care terms reduction exacerbation pneumonia viral load symptoms chinese clinical trial registry nd gao et al <NUMBER> colson group suggested chloroquine hydroxychloroquine available weapons fight covid<NUMBER> <NUMBER> ivermectin antiviral drug used phase <NUMBER> treatment dengue infection daily oral dose significantly reduced serum level viral ns<NUMBER> protein caly et al <NUMBER> demonstrated ivermectintreatment reduce <NUMBER>fold viral rna load compared control sample cell cultural <NUMBER> h reduction observed <NUMBER> h mulangu et al <NUMBER> conducted trial four investigational therapies ebola virus diseased patients total <NUMBER> patients registered november <NUMBER> <NUMBER> august <NUMBER> <NUMBER> patients assigned <NUMBER> ratio receive zmapp triple monoclonal antibody agent remdesivir nucleotide analogue rna polymerase inhibitor mab<NUMBER> single human monoclonal antibody derived ebola survivor regneb<NUMBER> coformulated mixture three human igg<NUMBER> monoclonal antibodies mab<NUMBER> regneb<NUMBER> groups superior zmap remdesivir group reducing mortality ebola patients primary groups faster rate viral clearance later groups remdesivir promised antiviral drug rna viruses including sarsmers cultured cell mice nonhuman primate model sheahan et al <NUMBER> clinical development ebola virus treatment typically distributed entire human body including lung oral administration sheahan et al <NUMBER> tested remdesivir inhibitor shown activity ebola virus potential agent used combat coronaviruses unfortunately could help ebola patients <NUMBER> outbreak democratic republic congo coronavirus research university iowa suggested remdesivir antiviral acting much potential patient takes early patients mild symptoms kai kupferschmidt cohen <NUMBER> importantly wang et al <NUMBER> study reported remdesivir chloroquine highly effective control covid<NUMBER> infection vitro experiments first covid<NUMBER> patient <NUMBER>yearold washington admitted hospital <NUMBER> january <NUMBER> united states dry cough twoday history nausea vomiting holshue et al <NUMBER> reported shortness breath chest pain important signs fever cough rhinorrhea fatigue nausea vomit diarrhea abdominal discomport normal condition high fever <NUMBER> c cough eleventh day hospitalized evening day clinical began treatment intravenous remdesivir next day clinical condition improved january <NUMBER> still hospitalized symptoms resolved exception cough decreased severity conducted trial test using lopinavirritonavir antiviral drugs covid<NUMBER> patients total <NUMBER> patients enrolled test <NUMBER> patients assigned lopinavirritonavir group remaining <NUMBER> patients treated standard care group resulting mortality rate similar lopinavirritonavir group standard care group found lopinavirritonavir treatment failed significantly accelerate clinical improvement reduce mortality diminish throat viral rna detectability patients serious covid<NUMBER> case severe covid<NUMBER> adult patients benefit observed lopinavirritonavir treatment comparison standard care group study found lopinavirritonavir seem effective covid<NUMBER> patients combinations produced side effects summary antiviral drugs alone combination tested human body showed evidence effectiveness sars mers seem effective covid<NUMBER> baden rubin <NUMBER> azithromycin displayed antiviral property zika ebola virus vitro bosseboeuf et al <NUMBER> madrid et al <NUMBER> retallack et al <NUMBER> prevent severe respiratory tract infection case viral infected patients bacharier et al <NUMBER> gautret group treated successfully chronic disease patients longterm hydroxychloroquine medicines <NUMBER> mg per day <NUMBER> <NUMBER> months <NUMBER> march <NUMBER> paper reported gautret et al <NUMBER> monitored viral load covid<NUMBER> patients without receiving drugs six days examined total <NUMBER> patients <NUMBER> hydroxychloroquinetreated patients <NUMBER> control patients among hydroxychloroquinetreated patients six patients received azithromycin <NUMBER> mg day <NUMBER> followed <NUMBER> mg per day next four days day <NUMBER> <NUMBER> patients treated hydroxychloroquine azithromycin combination cured comparing <NUMBER> patients treated hydroxychloroquine <NUMBER> control group finally found hydroxychloroquine azithromycin combination cured covid<NUMBER> patients drawback study used small size survey z jin et al <NUMBER> screened library <NUMBER> compounds consisting approval drugs clinical trial drugs natural products used combined structuralbased abinitio drug design highthroughput screening identified two drugs compound ebselen thiadiazolidinone<NUMBER> tdzd<NUMBER> quantitative realtime rtpcr demonstrated comparison treatment absence inhibitor treatment ebselen reduced amount covid<NUMBER> <NUMBER>fold tdzd<NUMBER> n<NUMBER> n<NUMBER> inhibitor designed z jin et al <NUMBER> inhibit multiple coronavirus pro including covid<NUMBER> merscov showed <NUMBER>fold <NUMBER>fold reduction covid<NUMBER> growth respectively data suggested ebselen potential antiviral inhibitor covid<NUMBER> treatment doctors team reported large doses flu drug oseltamivir combined hiv drugs lopinavir ritonavir could improve conditions several covid<NUMBER> patients rajavithi hospital bangkok httpswwwthescientist comnewsopinionfluandantihivdrugsshowefficacyagain stcoronavirus<NUMBER> based report gromica et al muralidharan et al <NUMBER> utilized computational docking approach analysed effect synergism drugs covid<NUMBER> main protease found combination three drugs lopinavir oseltamivir ritonavir showed better binding energy individual drug reported protein complexed three drugs stable simulations cpam china international exchange promotive association medical health care recommends take lopinavir <NUMBER> mg ritonavir <NUMBER> mg two tablets mouth twice daily chloroquine <NUMBER> mg tablet mouth twice daily older patients patients underlying conditions serious symptoms case chloroquine unavailable consider use hydroxychloroquine <NUMBER> mg mouth daily cannot recommended take ribavirin interferon drug high risk side effects drugs may considered treatment lopinavir ritonavir chloroquine hydroxychloroquine ineffective chu et important research plasma therapy ongoing several convalescent patients donating plasma covid<NUMBER> based positive results another coronavirus koenig <NUMBER> mairjenkins et al <NUMBER> surprisingly preliminarily obtained favourable results severe covid<NUMBER> patients hand recombinant human monoclonal antibody straightforward path neutralize viral load covid<NUMBER> cr<NUMBER> coronavirusspecific human monoclonal antibody bind receptorbinding domain covid<NUMBER> potential developed candidate therapeutics covid<NUMBER> disease monoclonal m<NUMBER> cr<NUMBER> antibodies neutralizing covid<NUMBER> may alternative treatment severe cases effective antiviralcovid<NUMBER> candidates essential reducing disease severity viral load transmission thus helping prevent coronavirus outbreaks several drugs sarscov merscov tested animals infected viral cell lab proteins vaccines graham et al <NUMBER> investigations progress requires months years develop vaccines covid<NUMBER> far infected virus patients population growing rapidly organized effort computational community becoming essential infer structural characteristics virion without interaction drug molecules may help experimentalclinical scientist identify effective inhibitor using vitro studies computational experimental outcomes terms novel drugs recommended new drug test vivo experiments may suitable disease patient following fundamental knowledge research required using computer simulations <NUMBER> elucidate role eprotein ion channel activity virus pathogenesis study eprotein ion conductivity manipulation covid<NUMBER> genome <NUMBER> identify inhibitor block eprotein ion channel activity well inhibits covid<NUMBER> rna polymerase <NUMBER> study energetic binding affinity covid<NUMBER> pro inhibitor ritonavir lopinavir azithromycin hydroxychloroquine n<NUMBER> ribavirin new inhibitors based free energy calculations <NUMBER> investigate structural properties flexibility conformational changes covid<NUMBER> pro study interaction pattern virus membrane virus inhibitor <NUMBER> monitor thermodynamics viruswater interaction properties covid<NUMBER> pro presenceabsence antiviral inhibitor <NUMBER> develop effective drug targeting inhibit contacts nprotein single positive rna strand order stop viral replication transcription <NUMBER> characterize mechanical profile energetic affinities spike protein angiotensin converting enzyme <NUMBER> ace<NUMBER> order device novel targeted molecular treatment aid vaccine developments coronavirinae family made four genera based genetic material including alpha beta gamma delta coronavirus genus coronavirus family positivestranded rna virus mainly causes respiratory central nervous system disease perlman netland <NUMBER> human coronaviruses namely hcovoc<NUMBER> hcov<NUMBER>e hcovnl<NUMBER> hcovhku<NUMBER> responsible mild respiratory diseases owusu et al <NUMBER> sarscov outbreak <NUMBER> demonstrated coronaviruses would cross barrier species emerge highly pathogenic viruses perlman <NUMBER> disease caused sarscov<NUMBER> called covid<NUMBER> coronavirus named sarscov<NUMBER> gorbalenya et al <NUMBER> rna genome <NUMBER> identical sars coronavirus sarscov viruses belong genus betacoronavirus wu et al <NUMBER> novel covid<NUMBER> first reported wuhan china december <NUMBER> outbreak rapidly spread world <NUMBER> countries affected covid<NUMBER> world health organization announced <NUMBER> th march <NUMBER> covid<NUMBER> pandemic disease currently <NUMBER> number <NUMBER> th may <NUMBER> people infected covid<NUMBER> increasing approximately <NUMBER>þ cases per day <NUMBER> people died unfortunately date medication vaccine approved world health organization centers disease control prevention cdc fda effective treatment covid<NUMBER> cdc <NUMBER> <NUMBER> many drugs tried recently treatment covid<NUMBER> due situation publichealth emergency includes antimalarial drugs chloroquine derivative hydroxychloroquine gao et al <NUMBER> wang et al <NUMBER> antiviral drugs hiv protease inhibitors ie lopinavir ritonavir chu et al <NUMBER> investigational nucleoside analogue remdesivir gs<NUMBER> agostini et al <NUMBER> wang et al <NUMBER> investigational rnadependent rna polymerase inhibitor favipiravir beijing chao yang hospital <NUMBER> peking university first hospital <NUMBER> wang et al <NUMBER> adjunctive therapeutic drugs also used treatment covid<NUMBER> includes macrolide antibacterial drug azithromycin amsden <NUMBER> beigelman et al <NUMBER> gautret et al <NUMBER> interleukin<NUMBER> il<NUMBER> receptorinhibiting monoclonal antibody tocilizumab sarilumab assistance publique hopitaux de paris <NUMBER> xu et al <NUMBER> investigational humanized monoclonal antibody chemokine receptor ccr<NUMBER> leronlimab cytodyn <NUMBER> detailed outcomes clinical trials still awaited however among reported drugs chloroquine hydroxychloroquine usedbeing used widely treatment covid<NUMBER> many research institutes well pharmaceutical companies working identify potential candidate sarscov<NUMBER> worldwide researcher reported chloroquine potential treat covid<NUMBER> clinical study well silico study adeoye et al <NUMBER> boopathi et al <NUMBER> gao et al <NUMBER> department pathology vanderbilt university medical center usa reported antiviral remdesivir gs<NUMBER> treat sarscov<NUMBER> agostini et al <NUMBER> investigation covid<NUMBER> plasma therapy clinical trials conducted evaluate use covid<NUMBER> treat patients severe immediately lifethreatening covid<NUMBER> infections duan et al <NUMBER> hasan et al reviewed ongoing challenges future prospects development potential drugs promote targeting specific activities cov hasan et al <NUMBER> research groups also working field computational approach find solution covid<NUMBER> khan et al worked systematic drug repurposing approach identify promising inhibitors <NUMBER>clike proteinase <NUMBER> <NUMBER> oribose methyltransferase proposed raltegravir paritaprevir bictegravir dolutegravir excellent lead candidates crucial proteins could become potential therapeutic drugs sarscov<NUMBER> <NUMBER> dihydropyrimidone class molecule identified drug candidate <NUMBER>ncov nprotein n terminal domain sarma et al <NUMBER> enayatkhani et al worked reverse vaccinology approach design novel multiepitope vaccine candidate covid<NUMBER> conclude nomtlr<NUMBER> nomhlaa<NUMBER> docked model enayatkhani et al <NUMBER> elfiky et al suggested guanosine derivatives guanosine triphosphate gtp uridine triphosphate utp idx<NUMBER> gtp derivative sofosbuvir utp derivative ribavirin wide acting antiviral drug potential candidate covid<NUMBER> elfiky azzam <NUMBER> zhou et al joshi et al reported networkbased methodologies rapid identification candidate repurposable drugs potential drug combinations targeting <NUMBER>ncovsarscov<NUMBER> joshi et al <NUMBER> zhang et al institute biochemistry center structural cell biology medicine university l€ ubeck germany designed improved aketoamide inhibitors inhibition sarscov<NUMBER> yogi vemana university india government medical college anantapur india icarnational rice research institute india collaboratively worked insilico approaches detect inhibitors human severe acute respiratory syndrome coronavirus envelope protein ion channel gupta et al <NUMBER> silico research also done considering fda approved drugs concludes lopinavir pant et al <NUMBER> setrobuvir elfiky <NUMBER>a saquinavir alkhafaji et al <NUMBER> remdesivir saquinavir darunavir disulfiram lobogalo et al <NUMBER> better interactions sars cov<NUMBER> compounds like crocin digitoxigenin beudesmol aanouz et al <NUMBER> andrographolide enmozhi et al <NUMBER> phytoestrogens diadiazin genistein formontein biochanin elfiky <NUMBER>b phytochemicals hypericin cyanidin <NUMBER>glucoside baicalin glabridin aketoamide<NUMBER>r islam et al <NUMBER> resveratrol wahedi et al <NUMBER> rutin das et al <NUMBER> ammoides verticillata abdelli et al <NUMBER> alkaloids <NUMBER>hydroxyusambarensine cryptoquindoline terpenoids <NUMBER>oxoisoiguesterin <NUMBER>hydroxyhopan<NUMBER>one gyebi et al <NUMBER> also reported better candidate covid<NUMBER> umesh et al worked indian spices study structure based interaction covid<NUMBER> conclude three compounds carnosol arjunglucosidei rosmanol umesh et al <NUMBER> sinha et al evaluated different saikosaponins potency sarscov<NUMBER> using nsp<NUMBER> fusion spike glycoprotein targets sinha et al <NUMBER> hydroxychloroquine derivative chloroquine shows better inhibition comparison chloroquine sars cov<NUMBER> pastick et al <NUMBER> current study emphasized derivatives chloroquine covid<NUMBER> set <NUMBER> molecules based chloroquine scaffold scheme <NUMBER> designed optimized computationally using schrodinger software molecules designed substituting different groups like methyl ch<NUMBER> hydroxyl group oh no<NUMBER> amino group nh<NUMBER> halogens f cl br ring aromatic benzene phenol position r<NUMBER> r<NUMBER> scheme <NUMBER> groups considered due potential interact amino acids like hydroxyl group methyl amine interact amino acid hbond halogens cl br f interact halogen bonding no<NUMBER> show hbond well salt bridges ring aromatic compounds show pipi pication interactions addition pipi pication interactions phenol also show hbonding due oh group rawel et al <NUMBER> zavodszky kuhn <NUMBER> generated pharmacophore model efficiently explain essential structural features present molecules potency interact target protein molecular docking mmgbsa study adme property md simulation analysis employed study identify candidate better interactions binding affinity sarscov<NUMBER> molecular simulation studies performed using maestro <NUMBER> module schrodinger release <NUMBER> <NUMBER> <NUMBER> designed molecules including chloroquine hydroxychloroquine protein <NUMBER>lu<NUMBER> jin et al <NUMBER> muralidharan et al <NUMBER> elmezayen et al <NUMBER> optimized followed methodology pharmacophore hypothesis molecular docking mmgbsa study adme property analysis molecular dynamics md simulations per previous reports beura chetti <NUMBER> ganjoo et al <NUMBER> detailed methodologies given supporting information detailed working methodology flowchart shown scheme <NUMBER> validation theoretical results set different pdbids ie <NUMBER>reb fearon et al <NUMBER> <NUMBER>w<NUMBER> michalska et al <NUMBER> downloaded protein data bank redocking self ligand protein performed using ligand docking module extra precision xp mode rmse values calculated crystal redock pose using superimpose module rmsd value generated redocking native ligands active site respective protein <NUMBER> å <NUMBER> å rmsd values less xray resolution corresponding protein <NUMBER> å <NUMBER> å indicates generated model good correlation experimental xray crystal structures figure <NUMBER> total <NUMBER> pharmacophore hypothesis models table <NUMBER> generated using phase module hypotheses consisted active match molecules <NUMBER> types different models generated like dhhhrr model <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> dhhrr model <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> models dhhhrr<NUMBER> considered best model six featured models shows best phasehyposcore <NUMBER> survival score <NUMBER> good bedroc score <NUMBER> pharmacophore hypothesis model dhhhrr<NUMBER> consists one hbond donor blue color three hydrophobic sites green color two aromatic rings orange color shown figure <NUMBER> also shown position features concerning figure <NUMBER> dhhhrr<NUMBER> model shows proper fit designed ligands example hydroxychloroquine cqd<NUMBER> shows proper fit best pharmacophore model dhhhrr<NUMBER> figure <NUMBER>b indicates optimized chloroquine derivatives nearly similar orientations pharmacophore models generated study maximum number structural features present designed molecules ligandreceptor interactions depends upon structural features present ligand like hbond acceptor red color ball hbond donor blue color ball aromatic rings r orange color ring hydrophobic region h green color ball figure <NUMBER> selected molecules cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> shows <NUMBER> <NUMBER> <NUMBER> number structural features whereas chloroquine hydroxychloroquine shows <NUMBER> <NUMBER> number structural features indicates selected molecules cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> potential interact enzyme figure <NUMBER> figure s<NUMBER> phe<NUMBER> phe<NUMBER> val<NUMBER> val<NUMBER> ile<NUMBER> residue ensure excavation best candidates molecular interaction study performed ligand docking active site sarscov<NUMBER> designed <NUMBER> molecules visually inspected based docking score ligandreceptor interactions hbonding hydrophobic potential electrostatic rewards rewards ligand low molecular weight deep study concludes <NUMBER> best molecules ie cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> showing docking scores <NUMBER> à<NUMBER> <NUMBER> respectively table <NUMBER> cqd<NUMBER> shows three hbonds two polar amino acids thr<NUMBER> gln<NUMBER> one charged amino acid asp<NUMBER> two hbonds due hbond donor group one due hbond acceptor site present ligand additionally cqd<NUMBER> shows one pipi interaction hydrophobic amino acid phe<NUMBER> figure <NUMBER> cqd<NUMBER> shows <NUMBER> h bond interactions due two hbond donor groups present ligand along one pipi interaction hbond interactions take place one polar amino acid thr<NUMBER> one charged amino acid gln<NUMBER> present active site figure <NUMBER> cqd<NUMBER> shows similar interactions like cqd<NUMBER> additionally shows one pipi interaction hydrophobic phe<NUMBER> amino acid figure <NUMBER> <NUMBER> new ligands showing good range solvent exposures figure <NUMBER> docked pose shows best fit ligand active site cavity enzyme figure <NUMBER> comparative analysis selected molecules cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> chloroquine hydroxychloroquine studied chloroquine hydroxychloroquine showing docking score <NUMBER> <NUMBER> respectively table <NUMBER> chloroquine shows one pipi stacking hydrophobic region phe<NUMBER> along good range solvent exposure hydroxychloroquine shows two hbond interactions one due hbond acceptor another due hbond donor group present active site sarscov<NUMBER> selected molecules cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> showing better docking scores <NUMBER> à<NUMBER> <NUMBER> respectively well better ligandreceptor interactions comparison chloroquine hydroxychloroquine figure <NUMBER> designed ligands also docked coronavirus sars spike glycoprotein human ace<NUMBER> complex pdb id <NUMBER>cs<NUMBER> kirchdoerfer et al <NUMBER> study impact ligands sars spike glycoprotein human ace<NUMBER> complex docking study ligand sars spike glycoprotein human ace<NUMBER> complex shows similar result like ligand covid<NUMBER> main protease ligands cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> showing docking score <NUMBER> à<NUMBER> <NUMBER> respectably choloroquine hydroxychloroquine shows <NUMBER> <NUMBER> respectively table <NUMBER> detailed interaction diagrams shown figure s<NUMBER>a s<NUMBER>e docking study also performed sarscov<NUMBER> main protease pdb id <NUMBER>buy validate ligandmain protease interactions study also concludes ligands cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> shows better docking score ligandreceptor interactions comparison chloroquine hydroxychloroquine follows trend ligand<NUMBER>lu<NUMBER> docking study detailed interactions docking score shown figure s<NUMBER>a s<NUMBER>e table s<NUMBER> respectively <NUMBER> molecules subjected ligandreceptor binding energy mmgbsa analysis mmgbsa analysis computed binding free energy docked ligandreceptor complex confirms stability ligand binding active site enzyme generated mmgbsadgbind energy using mmgbsa module shows energy difference prime energy optimized ligandreceptor complex combined energy optimized free ligand optimized free receptor mmgbsadgbind energies <NUMBER> compounds shown table <NUMBER> mmgbsa study concludes molecules except cqd<NUMBER> cqd<NUMBER> shows better binding energy comparison choloroquine hydroxychloroquine druglikeness properties molecules studied using wellknown adme analysis ie absorption table <NUMBER> whereas remaining <NUMBER> molecules following standard parameters molecules show percentage oral absorption <NUMBER> adme property analysis concludes molecules except cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> show druglikeness properties md simulations performed study physical movements atoms molecules dynamic evolution best complex <NUMBER>lu<NUMBER>cqd<NUMBER> rmsd quantitative parameter estimate stability protein system figure <NUMBER> protein rmsd trajectory sarscov<NUMBER> <NUMBER>lu<NUMBER> shows fluctuation <NUMBER> ns simulation time gradually tends equilibrium figure <NUMBER> rmsd average value sarscov<NUMBER> <NUMBER>lu<NUMBER> reaching equilibrium <NUMBER> å figure <NUMBER> small globular protein deviation within <NUMBER> å acceptable based stability <NUMBER>lu<NUMBER>cqd<NUMBER> considered study like proteinligand contact study histograms graph ligand property study includes ligand rmsd radius gyration proteinligand contacts stable ligandreceptor complex cqd<NUMBER>lu<NUMBER> studied using proteinligand contact histograms figure <NUMBER> dariya nagaraju <NUMBER> proteinligand interactions contacts categorized four types hydrogen honds hydrophobic ionic water bridge hydrogen bonds play significant role ligand binding consideration hydrogenbonding properties drug design important strong influence drug specificity metabolization adsorption hydrogen bonds protein ligand broken four subtypes backbone acceptor backbone donor sidechain acceptor sidechain donor geometric criteria proteinligand hydrogen bond <NUMBER> å donor acceptor atoms dháááa donor angle <NUMBER> donorhydrogenacceptor atoms dháááa acceptor angle <NUMBER> hydrogenacceptorbondedatom háááax histogram shows active site amino acids mainly gln<NUMBER> gln<NUMBER> thr<NUMBER> asn<NUMBER> asp<NUMBER> tyr<NUMBER> asp<NUMBER> interacting hydrogen bonding figure <NUMBER> hydrophobic contacts fall three subtypes like pcation pp nonspecific interactions types interactions involve hydrophobic amino acid aromatic aliphatic group ligand hydrophobic amino acids like val<NUMBER> ile<NUMBER> tyr<NUMBER> ile<NUMBER> showing hydrophobic interactions ligand figure <NUMBER> ionicinteractions polar interactions two oppositely charged atoms within <NUMBER> å involve hydrogen bond ionic interactions broken two subtypes mediated protein backbone side chains asp<NUMBER> asp<NUMBER> showing minimal ionic interaction ligand figure <NUMBER> water bridges hydrogenbonded proteinligand interactions mediated water molecule hydrogenbond geometry slightly relaxed standard hydrogen bond definition current geometric criteria proteinwater waterligand hydrogen bonds distance <NUMBER> å donor acceptor atoms dháááa donor angle <NUMBER> donorhydrogenacceptor atoms dháááa acceptor angle <NUMBER> hydrogenacceptorbondedatom háááax almost major interacting amino acids showing water bridges figure <NUMBER> proteinligand contact histograms amino acids showing highly effective interactions like asp<NUMBER> phe<NUMBER> <NUMBER> <NUMBER> time interactions <NUMBER>lu<NUMBER>cqd<NUMBER> complex <NUMBER> ns simulation timeline representation interactions contacts hydrogen bonds hydrophobic ionic water bridges summarized ligandreceptor interaction histogram study analysed following two panels figure <NUMBER>a b top panel shows total number specific contacts protein makes ligand every trajectory frame number contact varies zero nine course trajectory figure <NUMBER>a contribution amino acids trajectory frame <NUMBER> ns md simulation studied ligandprotein interaction bottom panel figure <NUMBER>b bottom panel shows amino acid residues interact ligand trajectory frame residues make one specific contact ligand particular trajectory frame represented darker shade orange according scale bellow plot <NUMBER>lu<NUMBER>cqd<NUMBER> receptorligand complex shows two deep bands phe<NUMBER> asp<NUMBER> row explains amino acid interactions ligands almost possible orientations geometry exactly similar histogram results series computational approaches used identify effective drug candidate sarscov<NUMBER> pharmacophore modelling molecular docking mmgbsa study adme property analysis combinedly concluded <NUMBER> ligands cqd<NUMBER> cqd<NUMBER> cqd<NUMBER> good docking score ligandreceptor interactions pharmacophorebased structural features drug likeness property comparison chloroquine hydroxychloroquine ligandreceptor md simulation study validates molecular docking study exploring protein stability rmsd various ligand property proteinligand contacts vitro analysis followed vivo testing may help proving cqd<NUMBER> ligand better inhibitor sarscov<NUMBER> whole study concludes derivatives chloroquine may play prominent role treatment covid<NUMBER> july <NUMBER> johann hans andersag synthesized chloroquine replacing acridine ring atabrine quinoline ring <NUMBER> developed drug salt base using <NUMBER>dihydroxybenzoic acid naming resochin resorcinate <NUMBER>aminochinolin initial clinical test <NUMBER> psychiatric patients bayer <NUMBER> found toxic practical use humans <NUMBER> took ten years chloroquine back clinical arena context malaria trial sponsored us government today world health organizations list essential medicines ie considered belong safest effective medicines needed health care system chloroquine hydroxychloroquine used prevent treat malaria rheumatoid arthritis lupus erythematosus morbus boeck <NUMBER>aminoquinolines recently gained lot attention dozens clinical trials chloroquine hydroxychloroquine sometimes combination drugs like remdesivir currently way animated controversy potential benefits risks treating covid<NUMBER> patients aggravated methodological flaws <NUMBER> high impact publications <NUMBER> underlying rational use fact found block covid<NUMBER> infection lowmicromolar concentration <NUMBER> especially hydroxychloroquine assumed attenuate progression covid<NUMBER> inhibiting cytokine storm reducing cd<NUMBER> expression cells <NUMBER> april <NUMBER> united states food drug administration granted coronavirus disease <NUMBER> covid<NUMBER> emergency use authorizations medical devices including extracorporeal blood purification devices none devices known whether decrease concentration chloroquine hydroxychloroquine one devices seraph ® <NUMBER> microbind ® affinity blood filter produced exthera medical martinez ca usa first licensed european economic area <NUMBER> <NUMBER> aim study investigate invitro adsorption chloroquine hydroxychloroquine human plasma life size approach using equipment also used bedside blood plasma obtained five voluntary donors regular therapeutic plasma exchange tpe treatments due various indications patients received neither chloroquine hydroxychloroquine written informed consent given every patient removed plasma single tpe treatment stored <NUMBER>°c used within <NUMBER> hours <NUMBER> mg chloroquinephosphate <NUMBER> mg hydroxychloroquinesulfate diluted <NUMBER> ml normal saline injected <NUMBER> ml blood plasma placed empty bag luerlock connectors bag served patient dummy nominal concentrations <NUMBER> µgml chloroquine <NUMBER> µgml hydroxychloroquine fluid mixed well <NUMBER> min anticoagulation <NUMBER> iu unfractionated heparin added primed standard hemoperfusion blood tubing system fresenius medical care germany well seraph ® <NUMBER> microbind ® affinity blood filter exthera medical ca usa total filling volume <NUMBER> ml plasma connected dummy patients plasma bag luerlock tubing hemoperfusion circuit multifiltrate fresenius medical care gmbh germany used pump plasma adsorber described previously <NUMBER> brief using standard tubing set multifiltrate roller pump propelled plasma one port plasmabag seraph back second port plasma bag rate <NUMBER> mlmin plasma bag continuously shaken procedure ensure mixture plasma experiment repeated five times different plasma bags different donors visual controls performed plasma bag well drawn samples detect possible drug precipitations article protected copyright rights reserved plasma sample whole plasma c <NUMBER> obtained mixing chloroquine hydroxychloroquine plasma start hemoperfusion pre c pre seraph ® plasma levels obtained <NUMBER> c <NUMBER> <NUMBER> c <NUMBER> <NUMBER> c <NUMBER> <NUMBER> c <NUMBER> <NUMBER> c <NUMBER> <NUMBER> c <NUMBER> minutes procedure two timepoints <NUMBER> min <NUMBER> min post c post seraph ® plasma levels determined used calculate plasma clearance one aliquot whole plasma sample stored room temperature without passing seraph ® determine drug stability plasma levels control samples determined intervals described written informed consent obtained voluntary plasma donors study performed accordance declaration helsinki german federal guidelines plasma concentrations chloroquine hydroxychloroquine measured validated hplc method applying uvdetection plasma samples <NUMBER> µl prepared analysis addition <NUMBER> µl <NUMBER> trifluoroacetic acid <NUMBER> µl <NUMBER> perchloric acid plasma protein precipitation <NUMBER> min centrifugation <NUMBER> × g <NUMBER> µl clear supernatant injected hplc system chloroquine hydroxychloroquine separated gradient elution agilent zorbax sbc<NUMBER> <NUMBER> µm <NUMBER>×<NUMBER> mm column gradient started <NUMBER> <NUMBER> trifluoroacetic acid <NUMBER> methanol evolved <NUMBER> min <NUMBER> methanol returned starting conditions <NUMBER> min applying constant flow rate article protected copyright rights reserved accepted article <NUMBER> mlmin analytes detected wavelength <NUMBER> nm conditions chloroquine hydroxychloroquine specifically separated endogenous plasma constituents precisions accuracies method <NUMBER> <NUMBER> chloroquine <NUMBER> <NUMBER> hydroxychloroquine respectively seraph ® plasma clearance cl drugs assessed <NUMBER> <NUMBER> minutes procedure calculated based plasma flow q e extraction ratio using equation cl drug q e c pre c post c pre calculations performed using graphpad prism <NUMBER> san diego ca usa article protected copyright rights reserved five vitro runs using hydroxychloroquine chloroquine spiked plasma could carried planned <NUMBER> min found significant drug plasma clearance <NUMBER> min procedure median iqr plasma clearance seraph hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> mlmin figure chloroquine median plasma clearance seraph <NUMBER> <NUMBER> <NUMBER> mlmin figure slight decrease plasma levels drugs connecting dummy patient plasma bag <NUMBER> ml spiked plasma start procedure first drug level procedure <NUMBER> minutes decrease <NUMBER> investigated substances due fact dummy patient connected plasma filled tubing system including seraph ® <NUMBER> ml contained neither hydroxychloroquine chloroquine words first drop plasma concentration dilution additional decrease drug plasma levels observed experiment either drugs visual control neither plasma bag drawn samples showed signs drug precipitations article protected copyright rights reserved april <NUMBER> th <NUMBER> us fda issued emergency use authorization seraph® <NUMBER> microbind® affinity blood filter patients covid<NUMBER> admitted icu confirmed imminent respiratory failure removal drugs used treat covid<NUMBER> patients reported devices authorized emergency use knowledge first vitro measurement hydroxychloroquine chloroquine elimination characteristics seraph® using life size adsorber human plasma using plasma flow rate compatible clinical setting extracorporeal procedures remove therapeutic substances making dose adjustments necessary <NUMBER> neither chloroquine molecular weight <NUMBER> da volume distribution <NUMBER> lkg proteinbinding <NUMBER> hydroxychloroquine molecular weight <NUMBER> da volume distribution <NUMBER> lkg proteinbinding <NUMBER> considered dialysable <NUMBER> yet case charcoal hemoperfusion removal could shown vitro <NUMBER> lack drug removal seraph ® explained distinct structure ie ultrahigh molecular weight polyethylene beads endpointattached heparin bacteria viruses fungi toxins shown bind interestingly data available medical devices received emergency use clearance fda treatment covid<NUMBER> thus unknown whether chloroquine hydroxychloroquine adapted dose due removal wish point important limitation vitro study investigated drugs medium human plasma rather whole blood therefore interactions cellular blood components seraph ® chloroquine hydroxychloroquine could investigated study however hydroxychloroquine significantly bound red blood cells white blood cells make <NUMBER> blood volume <NUMBER> time course hydroxycholoroquine chloroquine plasma concentrations hemoperfusion using seraph ® <NUMBER> microbind ® affinity blood filter left upper lower graph n<NUMBER> horizontal bar graphs depicting control sample pumped seraph® right upper lower graph depict calculated plasma clearance seraph ® hydroxycholoroquine chloroquine n<NUMBER> human coronaviruses sarscov<NUMBER> appeared end <NUMBER> led pandemic <NUMBER> high morbidity mortality currently effective drugs targeting virus <NUMBER> drug repurposing represents shortterm strategy treat millions infected patients low <NUMBER> costs hydroxychloroquine showed antiviral effect vitro since end <NUMBER> world encountered pandemic conditions attributable novel <NUMBER> coronavirus sarscov <NUMBER> <NUMBER> <NUMBER> th coronavirus identified infect human <NUMBER> population <NUMBER> first one pandemic potential nonimmune populations <NUMBER> <NUMBER> st century <NUMBER> finding therapeutics thus crucial proposed <NUMBER> repurposing existing drugs <NUMBER> strategy presents advantages safety profiles <NUMBER> drugs known could easily produced relatively low cost thus <NUMBER> quicker deploy new drugs vaccine chloroquine decadesold antimalarial agent <NUMBER> analog quinine known inhibit acidification intracellular compartments <NUMBER> <NUMBER> shown vitro vivo mice models activity different subtypes <NUMBER> antibacterial components also tested teicoplanin glycopeptide <NUMBER> azithromycin azithromycin dihydrate macrolide nmethyl<NUMBER>aza<NUMBER>deoxo<NUMBER> dihydroerythromycin shown antiviral activity zika <NUMBER> azithromycin <NUMBER> wellknown safe drug widely prescribed us example <NUMBER> million <NUMBER> treatment courses children <NUMBER> years age alone <NUMBER> recent study identified <NUMBER> two compounds azithromycin hydroxychloroquine among <NUMBER> total potentially <NUMBER> active agents possible treatments disease <NUMBER> <NUMBER> preliminary clinical study hydroxychloroquine even greater potency <NUMBER> combination hydroxychloroquine azithromycin found effective reducing <NUMBER> sarscov<NUMBER> viral load covid<NUMBER> patients <NUMBER> since beginning epidemic <NUMBER> marseille region isolated numerous strains tested one sarscov<NUMBER> <NUMBER> ihumi<NUMBER> using different concentrations hydroxychloroquine azithromycin <NUMBER> combination vero e<NUMBER> cells <NUMBER> <NUMBER>well plate determined tcid<NUMBER> strain <NUMBER> <NUMBER> infectious particles per ml <NUMBER> µm <NUMBER> <NUMBER> <NUMBER> µm hydroxychloroquine associated <NUMBER> <NUMBER> µm <NUMBER> azithromycin test done least triplicate repeated two times except <NUMBER> conditions <NUMBER> µm hydroxychloroquine associated <NUMBER> <NUMBER> µm azithromycin <NUMBER> repeated third time kruskalwallis test used compare combinations positive controls using <NUMBER> ∆ct h<NUMBER> h<NUMBER> dunns test used correct multiple comparison <NUMBER> test used p<NUMBER> parameter bilateral twosides significant pvalue <NUMBER> indicated figure <NUMBER> others conditions significant <NUMBER> cytotoxicity associated drugs combination <NUMBER> control wells <NUMBER> without viruses detected rna viral production <NUMBER> <NUMBER> cyclethresholds ct <NUMBER> inversely correlated rna copy numbers positive control associated cell lyses cases cell lyses <NUMBER> hours correlated viral production <NUMBER> compared control figure <NUMBER> combination azithromycin hydroxychloroquine led <NUMBER> significant inhibition viral replication wells containing hydroxychloroquine <NUMBER> µm <NUMBER> combination azithromycin <NUMBER> <NUMBER> µm pvalues <NUMBER> a<NUMBER>h<NUMBER> <NUMBER> <NUMBER> a<NUMBER>h<NUMBER> figure <NUMBER>a highlights • sarscov <NUMBER> emergence spreading need found urgently therapeutics • drug repurposing best strategy quick therapeutic response • azithromycin hydroxychloroquine shows synergistic effect replication • concentrations drugs compatible vivo concentrations intervention comparator patients randomly assigned two groups one given hydroxychloroquine given placebo two months treatment two groups treated either hydroxychloroquine amin® pharmaceutical company isfahan iran placebo identical terms shape colour smell single <NUMBER> mg tablet every day patients monitored covid<NUMBER> symptoms followup period signs symptoms occur fever cough shortness breath examined investigated highresolution computed tomography ct scan lungs covid<NUMBER> specific igm igg antibody assay nucleic acid amplification test nat sarscov<NUMBER> virus main outcomes primary end point study investigate incidence covid<NUMBER> patients treated cancer <NUMBER>month period randomisation randomisation performed using randomly permuted blocks using online website wwwrandomizationcom randomization sequence produced quadruple blocks allocation ratio intervention control groups <NUMBER> blinding masking participants caregivers know whether patient intervention control group outcome assessor data analyst also blinded group assignment numbers randomised sample size calculated total sample size <NUMBER> patients <NUMBER> patients group trial status trial began april <NUMBER> <NUMBER> recruitment ongoing recruitment anticipated completed june <NUMBER> <NUMBER> change study protocol since approval protocol version <NUMBER> approved april <NUMBER> <NUMBER> trial registration trial registered title effect hydroxychloroquine novel coronavirus disease covid<NUMBER> prevention cancer patients treatment iranian registry clinical trials irct code irct<NUMBER>n<NUMBER> httpswwwirctirtrial<NUMBER> registration date april <NUMBER> <NUMBER> full protocol full protocol attached additional file accessible trials website additional file <NUMBER> interest expediting dissemination material familiar formatting eliminated letter serves summary key elements full protocol keywords covid<NUMBER> randomised controlled trial protocol hydroxychloroquine acute lymphoid leukemia acute myeloid leukemia breast cancer colon cancer prophylaxis supplementary information accompanies paper httpsdoiorg<NUMBER> <NUMBER>s<NUMBER>x additional file <NUMBER> importance children ages appear susceptible severe acute respiratory syndrome coronavirus <NUMBER> infection support pediatric clinical studies investigational treatments coronavirus disease <NUMBER> covid<NUMBER> pediatricspecific dosing required objective define pediatricspecific dosing regimens hydroxychloroquine remdesivir covid<NUMBER> treatment design setting participants pharmacokinetic modeling simulation used extrapolate investigated adult dosages toward children march <NUMBER>april <NUMBER> physiologically based pharmacokinetic modeling used inform pediatric dosing hydroxychloroquine remdesivir pediatric dosages derived using allometricscaling agedependent exponents dosing simulations conducted using simulated pediatric adult participants based demographics white us population interventions simulated drug exposures following <NUMBER>day course hydroxychloroquine <NUMBER> mg every <NUMBER> hours × <NUMBER> doses followed <NUMBER> mg every <NUMBER> hours × <NUMBER> doses single <NUMBER>mg intravenous dose remdesivir computed simulated adult participants simulationbased doseranging study conducted simulated children exploring different absolute weightnormalized dosing strategies main outcomes measures primary outcome hydroxychloroquine average unbound plasma concentrations <NUMBER> treatment days additionally unbound interstitial lung concentrations simulated remdesivir primary outcome plasma exposure area curve <NUMBER> infinity following singledose administration results hydroxychloroquine physiologically based pharmacokinetic model analysis included <NUMBER> <NUMBER> simulated white adult pediatric participants respectively supported weightnormalized dosing children weighing less <NUMBER> kg geometric meansimulated average unbound plasma concentration values among children within different developmental age groups <NUMBER> ngml congruent adults <NUMBER> ngml simulated unbound hydroxychloroquine concentrations lung interstitial fluid mirrored unbound plasma notably lower vitro concentrations needed mediate antiviral activity remdesivir analysis included <NUMBER> <NUMBER> simulated adult pediatric participants respectively proposed pediatric dosing strategy supported weightnormalized dosing participants weighing less <NUMBER> kg geometric meansimulated plasma area time curve <NUMBER> infinity values among children within different developmental agegroups <NUMBER> ng × hml similar adults <NUMBER> ng × hml conclusions relevance analysis provides pediatricspecific dosing suggestions hydroxychloroquine remdesivir raises concerns regarding hydroxychloroquine use covid<NUMBER> treatment concentrations less needed mediate antiviral effect simulated assessment pharmacokinetically guided dosing investigational treatments pediatric patients coronavirus disease <NUMBER> importance children ages appear susceptible severe acute respiratory syndrome coronavirus <NUMBER> infection support pediatric clinical studies investigational treatments coronavirus disease <NUMBER> covid<NUMBER> pediatricspecific dosing required objective define pediatricspecific dosing regimens hydroxychloroquine remdesivir covid<NUMBER> treatment design setting participants pharmacokinetic modeling simulation used extrapolate investigated adult dosages toward children march <NUMBER>april <NUMBER> physiologically based pharmacokinetic modeling used inform pediatric dosing hydroxychloroquine remdesivir pediatric dosages derived using allometricscaling agedependent exponents dosing simulations conducted using simulated pediatric adult participants based demographics white us population interventions simulated drug exposures following <NUMBER>day course hydroxychloroquine <NUMBER> mg every <NUMBER> hours × <NUMBER> doses followed <NUMBER> mg every <NUMBER> hours × <NUMBER> doses single <NUMBER>mg intravenous dose remdesivir computed simulated adult participants simulationbased doseranging study conducted simulated children exploring different absolute weightnormalized dosing strategies main outcomes measures primary outcome hydroxychloroquine average unbound plasma concentrations <NUMBER> treatment days additionally unbound interstitial lung concentrations simulated remdesivir primary outcome plasma exposure area curve <NUMBER> infinity following singledose administration results hydroxychloroquine physiologically based pharmacokinetic model analysis included <NUMBER> <NUMBER> simulated white adult pediatric participants respectively supported weightnormalized dosing children weighing less <NUMBER> kg geometric meansimulated average unbound plasma concentration values among children within different developmental age groups <NUMBER> ngml congruent adults <NUMBER> ngml simulated unbound hydroxychloroquine concentrations lung interstitial fluid mirrored unbound plasma notably lower vitro concentrations needed mediate antiviral activity remdesivir analysis included <NUMBER> <NUMBER> simulated adult pediatric participants respectively proposed pediatric dosing strategy supported weightnormalized dosing participants weighing less <NUMBER> kg geometric meansimulated plasma area time curve <NUMBER> infinity values among children within different developmental agegroups <NUMBER> ng × hml similar adults <NUMBER> ng × hml conclusions relevance analysis provides pediatricspecific dosing suggestions hydroxychloroquine remdesivir raises concerns regarding hydroxychloroquine use covid<NUMBER> treatment concentrations less needed mediate antiviral effect simulated assessment pharmacokinetically guided dosing investigational treatments pediatric patients coronavirus disease <NUMBER> importance children ages appear susceptible severe acute respiratory syndrome coronavirus <NUMBER> infection support pediatric clinical studies investigational treatments coronavirus disease <NUMBER> covid<NUMBER> pediatricspecific dosing required objective define pediatricspecific dosing regimens hydroxychloroquine remdesivir covid<NUMBER> treatment design setting participants pharmacokinetic modeling simulation used extrapolate investigated adult dosages toward children march <NUMBER>april <NUMBER> physiologically based pharmacokinetic modeling used inform pediatric dosing hydroxychloroquine remdesivir pediatric dosages derived using allometricscaling agedependent exponents dosing simulations conducted using simulated pediatric adult participants based demographics white us population interventions simulated drug exposures following <NUMBER>day course hydroxychloroquine <NUMBER> mg every <NUMBER> hours × <NUMBER> doses followed <NUMBER> mg every <NUMBER> hours × <NUMBER> doses single <NUMBER>mg intravenous dose remdesivir computed simulated adult participants simulationbased doseranging study conducted simulated children exploring different absolute weightnormalized dosing strategies main outcomes measures primary outcome hydroxychloroquine average unbound plasma concentrations <NUMBER> treatment days additionally unbound interstitial lung concentrations simulated remdesivir primary outcome plasma exposure area curve <NUMBER> infinity following singledose administration results hydroxychloroquine physiologically based pharmacokinetic model analysis included <NUMBER> <NUMBER> simulated white adult pediatric participants respectively supported weightnormalized dosing children weighing less <NUMBER> kg geometric meansimulated average unbound plasma concentration values among children within different developmental age groups <NUMBER> ngml congruent adults <NUMBER> ngml simulated unbound hydroxychloroquine concentrations lung interstitial fluid mirrored unbound plasma notably lower vitro concentrations needed mediate antiviral activity remdesivir analysis included <NUMBER> <NUMBER> simulated adult pediatric participants respectively proposed pediatric dosing strategy supported weightnormalized dosing participants weighing less <NUMBER> kg geometric meansimulated plasma area time curve <NUMBER> infinity values among children within different developmental agegroups <NUMBER> ng × hml similar adults <NUMBER> ng × hml conclusions relevance analysis provides pediatricspecific dosing suggestions hydroxychloroquine remdesivir raises concerns regarding hydroxychloroquine use covid<NUMBER> treatment concentrations less needed mediate antiviral effect simulated assessment pharmacokinetically guided dosing investigational treatments pediatric patients coronavirus disease <NUMBER> rapid spread novel severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> critical care physicians seeing increasing numbers patients acute respiratory failure secondary coronavirus disease <NUMBER> covid<NUMBER> reporting mortality rates <NUMBER> requiring mechanical ventilation <NUMBER> strikingly higher mortality rates reported typical acute respiratory distress syndrome associated diseases <NUMBER> focus therapeutic intervention therefore reverse hypoxaemia provide adequate organ support also decrease viral load thus limit disease severity addition several antiviral agents antimalarial drugs proposed treatments could reduce transmission virus invitro studies shown chloroquine hydroxychloroquine inhibit sarscov<NUMBER> transmission <NUMBER> alkalinisation intracellular phagolysosome prevents virion fusion uncoating therefore viral spread early results clinical studies conducted china suggest chloroquine use might associated reduced fever increased resolution lung lesions ct delayed disease progression <NUMBER> results two french studies suggested hydroxychloroquine could reduce viral load patients covid<NUMBER>in particular combined azithromycin <NUMBER> table basis preliminary findings chloroquine hydroxychloroquine prescribed patients reduce length hospital stay improve evolution covid<NUMBER>related pneumonia nevertheless recently published surviving sepsis campaign guidelines management critically ill patients covid<NUMBER> concluded insufficient evidence offer recommendation routine use drugs patients admitted intensive care unit icu <NUMBER> explain discrepancies antimalarial drugs used clinical management patients icu severe covid<NUMBER> first hydroxychloroquine expensive readily available seems safe however clinical observations effects drug patients covid<NUMBER> included critically ill patients receiving several medications organ failure hepatic renal dysfunction might influence drug metabolism potentially increase risk adverse events second clinical data hydroxychloroquine far convincing first study reported philippe gautret colleagues <NUMBER> indicated hydroxychloroquine might effective several limitations small cohort patients <NUMBER> participants received hydroxychloroquine six received azithromycin <NUMBER> controls included final analysis short observation period <NUMBER> days absence randomisation raising concerns selection bias imbalance baseline characteristics intervention control groups report effects clinical evolution <NUMBER> <NUMBER> patients asymptomatic <NUMBER> <NUMBER> pneumonia second french study although larger control arm <NUMBER> moreover inclusion exclusion criteria poorly described patients <NUMBER> <NUMBER> <NUMBER> low national early warning score overall clinical outcome similar reported untreated patients covid<NUMBER> <NUMBER> combination hydroxychloroquine azithromycin associated reduced viral load <NUMBER> <NUMBER> tested negative days <NUMBER> <NUMBER> respectively clinically relevant outcomes reported trial <NUMBER> patients covid<NUMBER> jun chen colleagues found significant difference nasopharyngeal viral carriage day <NUMBER> hydroxychloroquine compared local standard care however concomitant antivirals given might served confounders interpreting results study <NUMBER> second chinese trial <NUMBER> patients zhaowei chen colleagues showed hydroxychloroquine treatment associated shorter time clinical recovery temperature cough placebo <NUMBER> participants mild disease sao <NUMBER> spo <NUMBER> <NUMBER> pao <NUMBER> fio <NUMBER> <NUMBER> possible extrapolate results critically ill patients study <NUMBER> patients covid<NUMBER> reported persistence sarscov<NUMBER> nasopharyngeal swab <NUMBER> <NUMBER> patients receiving hydroxychloroquine <NUMBER> third whether viral load important critically ill covid<NUMBER> patients whether progressive lung involvement related overwhelming inflammatory response unrelated virus remains clarified observational study found high viral load associated disease severity <NUMBER> however influence antiviral strategies advanced forms disease remains unproven fourth search effective new drugs requires appropriate valid trialsie prospective randomised placebocontrolled clinical studies although many drugs invitro activity virus proposal drugs might provide benefit harm inappropriate face clinical evidence supporting efficacy safety patients covid<NUMBER> international multicentre studies discovery study nct<NUMBER> solidarity study eudract number <NUMBER> randomise patients covid<NUMBER> receive different antiviral drugs including hydroxychloroquine adaptive study design initiatives provide important data guide management patients covid<NUMBER> help improve understanding effects antiviral therapies critically ill patients whether antimalarial drugs could effective changing disease course patients severe covid<NUMBER>in particular cases requiring icu admissionremains unknown moreover patients receiving antimalarial drugs require icu admission known whether drug continued considered clinically ineffective stopped assessing viral load either nasopharyngeal swab bronchoalveolar lavage fluid might use understanding whether targeting viral replication rather injurious lung pathways reasonable therapeutic strategy future studies aim clarify precise role chloroquine hydroxychloroquine critically ill patients covid<NUMBER> declare competing interests according centres disease control prevention cdc usa epidemic refers rapid increase cases disease normally expected occurrence particular community geographic area significant population proportions affected area <NUMBER> epidemic escalate pandemic disease spreads wider geographical zones across countries continents affects higher number people world <NUMBER> recent months world health organization cdc declared coronavirus infectious disease coronavirus disease <NUMBER> termed covid<NUMBER> <NUMBER> pandemic caused newly discovered coronavirus strain named severe acute respiratory syndrome coronavirus <NUMBER> sars cov<NUMBER> colloquially referred covid<NUMBER> <NUMBER> <NUMBER> coronavirus covid <NUMBER> belong family rnaviruses take humans mammals formal hosts live replicate <NUMBER> covid<NUMBER> reported extraordinarily contagious virus <NUMBER> people get infected virus experience mild moderate httpsdoiorg<NUMBER>jsapharm<NUMBER> received <NUMBER> april <NUMBER> accepted <NUMBER> april <NUMBER> respiratory distress including fever dry cough shortness breath <NUMBER> <NUMBER> <NUMBER> according recent study huang et al manifests clusters severe respiratory symptoms similar severe acute respiratory syndrome outbreaks caused coronaviruses viruses reported within last two decades <NUMBER> viruses termed severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov resulted <NUMBER> cumulative cases high fatality rates cases <NUMBER> end <NUMBER> novel covid<NUMBER> disseminated rapidly starting china spreading many countries around world short space time clear treatment vaccine sight yet <NUMBER> <NUMBER> <NUMBER> april <NUMBER> <NUMBER> reported covid<NUMBER> outbreak resulted <NUMBER> confirmed cases world <NUMBER> cases confirmed deaths <NUMBER> countries disease <NUMBER> pharmacists part health care system role critical completing management cycle coronavirus outbreak <NUMBER> march <NUMBER> <NUMBER> international pharmaceutical federation fip released guideline clarify required coronavirus information pharmacists pharmacy workforce <NUMBER> addition guideline stipulated responsibilityrole community hospital pharmacists control outbreak <NUMBER> pharmacists need engaged coordinated efforts pandemics readily adaptive changes required pharmacy practice fip advocated community pharmacies outbreakaffected unaffected countries often first point contact health system healthrelated concerns simply need information reliable advice <NUMBER> hence important explore pharmacists around world managing customary newly emerging roles covid<NUMBER> outbreak macau china home outbreak documented perspective authors pharmacists roles ensuring stable supply key medicines providing information coronavirus infection performing early detection cases appropriate referral implementing government arrangement guaranteed mask supply scheme <NUMBER> another study china acknowledged community pharmacy management teams shall support different services providing adequate supply covid<NUMBER> related medications preventative products addition providing sufficient staff trainings <NUMBER> colombia community pharmacists proposed contribute early detection appropriate referral possible cases virus reported designated telephone lines addition providing patient education <NUMBER> united arab emirates uae stated pharmacists also play role promoting empathy culture help preventing stigmatization infected individuals based ethnicity population nationality broadcasting facts communities via various media <NUMBER> expected pharmacists around world finding ways contribute collaborative forces combating spread virus pharmacists assume role humanitarian health emergency settings application realworld data <NUMBER> addition provision tailored training programs taking consideration aspects including psychological impact roles vital <NUMBER> <NUMBER> published research far provide reference pharmacists providing patient care services improve patients outcomes make contribution control pandemic previous study looked pharmacists perspective role management coronavirus pandemic awareness important facts needed able deliver roles successfully source facts aim study investigate pharmacists pharmacy students preparedness take part management epidemics pandemics specifically investigate participants awareness important facts regarding current coronavirus pandemic source information well perspective pharmaceutical professional roles emergent situation study objectives addressed descriptive crosssectional online survey study conducted jordan coronavirus outbreak <NUMBER> <NUMBER> march <NUMBER> eligible participants licensed pharmacists practicing community hospital pharmacies jordan academics pharmacy students ethics approval study obtained faculty pharmacy applied science private university participation study pose risk participants voluntary potential participants completed survey considered given informed consent participation study following extensive review literature <NUMBER> <NUMBER> <NUMBER> <NUMBER> leading research team developed first draft questionnaire questionnaire administered english since english official language education pharmacists jordan several sources used generate pool questions considered relevant study objectives questions tabled reviewed research team order combine concepts remove duplicates ensure face validity first draft questionnaire evaluated six independent academics previous experience pharmacy practice education informed research team items questionnaire clear difficult comprehend comments feedback provided considered research team incorporated appropriate develop final version questionnaire finally research team revised items necessary make concise fit online administration final version questionnaire organized three main sections addressing different topics interest first section included items collect demographics data second section included items aimed assessing potential participants current epidemicspandemics covid<NUMBER> awareness potential participating pharmacists asked much know coronavirus including symptoms b modes transmission c prevent transmission spread virus awareness access latest coronavirus updates regarding treatment sections several detailed items eg participants asked example probed modes coronavirus transmission virus transmitted respiratory droplets person person among close contacts touching surfaces contaminated virus <NUMBER> questions investigated participants awareness regarding highest risk patients addition symptoms associated coronavirus fever dry cough shortness breath muscle aches gastrointestinal symptoms <NUMBER> latest coronavirus updates treatment questioned example hydroxychloroquine alone combination azithromycin used preventive therapy coronavirus infection oseltamivir used management coronavirus infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> another question assessed awareness concerning use nonsteroidal antiinflammatory drugs ibuprofen infection <NUMBER> <NUMBER> questions treatment section whether use drugs glucocorticoids autoimmune disease medications increase susceptibility contract coronavirus infection <NUMBER> <NUMBER> participants awareness prevent transmission spread virus assessed depth well washing hands soap water <NUMBER> would enough clean hands also least distance kept counseling patients <NUMBER> m<NUMBER> feet <NUMBER> <NUMBER> <NUMBER> two questions exercise first one asked exercise causes antibodies white blood cells circulate rapidly body therefore detecting combating infections early stage second question asked brief rise body temperature exercise prevents bacterial growth thus increases bodys ability fight infection <NUMBER> <NUMBER> rest questions immune system ways boost combat viral infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> example participants asked proteincalorie malnutrition increases opportunistic infection <NUMBER> <NUMBER> role garlic mushrooms vitamin c also questioned smoking importance decreasing stress boost immunity also questioned <NUMBER> <NUMBER> <NUMBER> finally effect sunlight activating thelper cells order boost immunity questioned <NUMBER> participants asked provide email receive answers awareness questions study completed wished receive information potential participants also given choice view correct answers via facebook page designed study items section required truefalsenot sure response third section concentrated potential participants perspective role pharmacist epidemics pandemics new coronavirus pandemic included <NUMBER> closedended questions participants responses sections used likert scale answer ie strongly agree agree neutral disagree strongly disagree study participants recruited social media facebook whatsapp willing consider participation could open link initially view ethics committee approved information study proceeding survey end data collection phase <NUMBER> days correct answers awareness part survey made available participants informed information section improve awareness coronavirus prevention symptoms proposed treatment based number licensed pharmacists amman <NUMBER> sample size calculation using margin error <NUMBER> confidence level <NUMBER> response distribution <NUMBER> minimum sample size <NUMBER> pharmacies needed pharmacy students sample size calculation performed using following formula n p × <NUMBER> p × z <NUMBER> <NUMBER> p anticipated prevalence prevalence awareness desired precision z appropriate value normal distribution desired confidence using <NUMBER> confidence level <NUMBER> precision level <NUMBER> anticipated prevalence inappropriate awareness conservative prevalence value results highest possible sample size used study previous studies area found indicate prevalence inappropriate awareness sample size <NUMBER> considered representative sampling frame data analyzed using statistical package social science spss version <NUMBER> spss inc chicago il usa descriptive analysis undertaken using mean standard deviations continuous variables percentage qualitative variables checking data normality carried using shapirowilk test pvalue ≥<NUMBER> indicating normally distributed continuous variable group differences students pharmacists explored using chisquared analysis screening factors affecting participants awareness score coronavirus pandemic carried using linear regression multiple linear regression analysis using entry method variable entry criterion set <NUMBER> ie variables found significant single predictor level p <NUMBER> entered multiple linear regression analysis explore variables significantly independently associated participants awareness score variables selected checking independence tolerance values <NUMBER> variance inflation factor vif values <NUMBER> selected indicate absence multicollinearity independent variables regression analysis homoscedasticity assumption multiple linear regression checked using breuschpagan test p ≥ <NUMBER> indicating absence heteroscedasticity sample size required study reached n <NUMBER> mean age <NUMBER> years table <NUMBER> majority participants females <NUMBER> marriedsingle <NUMBER> participants came <NUMBER> participants believed got enough education previously epidemicspandemics <NUMBER> reported currently followed latest coronavirus updates treatments quite closely fig <NUMBER> regards sources information coronavirus treatment study participants reported obtain information mostly general media followed reports published research papers facebook fig <NUMBER> assessing awareness coronavirus pandemic responses demonstrated half participants knew appropriate answers items except two items first item need keep distance least <NUMBER> <NUMBER> feet counseling patients pandemic appropriate answer jordanian context would <NUMBER> <NUMBER> feet sufficient second item highest population risk category people contracting coronavirus elderly <NUMBER> immunecompromised people children age <NUMBER> children age <NUMBER> amongst highest risk people contracting coronavirus table <NUMBER> yet <NUMBER> participants chose statement true rest awareness items pharmacist <NUMBER> student participants <NUMBER> knew nonsteroidal antiinflammatory drugs ibuprofen may theoretically increase risk complications used viral infections p <NUMBER> muscle aches gi symptoms nauseavomitingdiarrhea could associated coronavirus infections p <NUMBER> case items stating steroids may increase susceptibility coronavirus infection cases hydroxychloroquine trialed preventative therapy coronavirus infection azithromycin trialed along hydroxychloroquine treatment coronavirus infection oseltamivir used management coronavirus infection p <NUMBER> hence overall awareness score <NUMBER> higher score higher awareness pharmacists significantly higher p <NUMBER> students fig <NUMBER> multiple linear regression analysis factors affecting awarenesss cores among study participants highlighted older age study group pharmacist versus student graduating public university versus private university attending educational workshops yearly basis significantly affected awareness level participants table <NUMBER> <NUMBER> strongly agreedagreed expressed believed major role management pandemics epidemics pharmacies role ensure availability key medications fig <NUMBER> <NUMBER> believed role counsel people coronavirus infection reduce transmission spread disease ensure personal safety avoiding close contact patients <NUMBER> said suspected someone may coronavirus knew seek immediate medical attention pharmacies allowed send medications patients home coronavirus pandemic needed <NUMBER> reported would provide hydroxychloroquine patients need even dont prescription <NUMBER> believed allowed sell medications coronavirus management via drivethrough service available chain pharmacies although <NUMBER> participants provided email addresses majority participants <NUMBER> chose view correct answers <NUMBER> awareness questions study completed via study facebook page rest <NUMBER> chose receive answers via email sent email address research team pharmacists play important role active members healthcare team <NUMBER> internationally pharmacists integrated pandemic planning response <NUMBER> effective role clinical settings <NUMBER> community settings play important role community making pharmaceutical products available enhancing health awareness among public <NUMBER> <NUMBER> along lines participants present study believed could play effective role covid<NUMBER> pandemic infection control counseling individuals regarding hygiene practices needed reduce infection spread <NUMBER> participants knew act seeking immediate medical attention suspected someone may coronavirus infection study supports notion pharmacists willing play important role infection control public safety <NUMBER> assuring public health wellbeing majority participants indicated able act suspected patient covid<NUMBER> one important aspects pharmacy practice context pharmaceutical care able triage patients appropriate health care <NUMBER> furthermore majority participants willing deliver medicines patients homes required jordanian drug pharmacy laws fact pharmacists allowed adopt courier home delivery service <NUMBER> hence covid<NUMBER> pandemic registered pharmacists allowed deliver medications would effective service especially elderly patients risk infection complication increased although course delivery personnel probably pharmacy stafftrainee pharmacists freeup pharmacy capacity pandemic situation <NUMBER> participants indicated willing dispense hydroxychloroquine directly patients quite surprising hydroxychloroquine regulated jordan food drug administration allowed sold community pharmacy without valid prescription furthermore efficacy hydroxychloroquine thoroughly established covid<NUMBER> using simple linear regression using multiple linear regression significant <NUMBER> significance level medication risk benefit profile requires clinical supervision used participants willingness dispense without prescription may influenced media proposing hydroxychloroquine treatment covid<NUMBER> <NUMBER> participants study reported currently follow latest coronavirus updates treatments obtaining information mostly <NUMBER> media highlighting reliable sources fip released guideline march year could benefit providing accurate information pharmacists globally clarifying required coronavirus information pharmacists pharmacy workforce presenting evidencebased information <NUMBER> many pharmacists sure role hydroxychloroquine <NUMBER> <NUMBER> thought used preventative therapy coronavirus infection may posed jordanian pharmacists need made aware current preliminary recommendations symptomatic management mild covid<NUMBER> cases iefluids antipyretics rest specialist hospital unit physicians course trialed may using treatments chloroquine hydroxychloroquine well course ventilatory support patients severe respiratory distress symptoms <NUMBER> participants <NUMBER> knew azithromycin trialed along hydroxychloroquine treatment coronavirus infection <NUMBER> knew antivirals oseltamivir used management critical cases infection <NUMBER> sure <NUMBER> ibuprofen nonsteroidal antiinflammatory medicine nsaid sold number brand names including advil® nurofen® addition treating pain often used manage fever associated various viral bacterial infections time designing study said nsaids ibuprofen increase risk complications used viral infections including coronavirus infection however declared march <NUMBER> <NUMBER> post titled antiinflammatory drug subject conflicting reports theres evidence suggest using ibuprofen manage symptoms covid<NUMBER> worsen condition earlier reports said spokesperson cautioned using ibuprofen manage symptoms illness caused coronavirus experts could investigate case provides good example confusing information provided healthcare professionals including pharmacists via media regarding covid<NUMBER> pandemic <NUMBER> use corticosteroids covid<NUMBER> patients also confusing issue many pharmacists corticosteroids widely used previous outbreaks similar types infection middle east respiratory syndrome merscov <NUMBER> however although appeared evidence corticosteroids may beneficial used early acute phase infections conflicting evidence surrounding corticosteroid use certain viral infections means evidence conclusive <NUMBER> current reports indicate unique reason exists expect patients covid<NUMBER> infection benefit corticosteroids might likely harmed treatment <NUMBER> hence considering current availability literature caution exercised evidence emerges surrounding use corticosteroids covid<NUMBER> patients <NUMBER> pharmacists pharmacy students showed acceptable awareness covid<NUMBER> pandemic half knew correct answers awareness related items except items probing appropriate distance need maintain patients majority <NUMBER> believed least <NUMBER> <NUMBER> feet needed distance counseling patients pandemic appropriate answer per jordanian guidelines <NUMBER> <NUMBER> feet <NUMBER> sure important raise awareness fact participants received correct answers upon completion study anecdotal comments pharmacists indicated allow customers come anywhere near negatively affected counseling process majority <NUMBER> aware highest risk population group terms contracting coronavirus infection believed children age <NUMBER> highest risk along extent elderly <NUMBER> immunecompromised patients <NUMBER> sure interesting note generally significantly pharmacists answered awareness items survey correctly pharmacy student may indicate experience boosts clinical awareness reasoning skills pharmacists study results indicated practicing pharmacist versus pharmacy student associated better awareness older age public university alumnus versus private university alumnus attending educational workshops yearly basis also significantly associated better level awareness none course surprising except course difference graduating different type educational institution public vs private noteworthy recognize finding could due fact half graduates private educational institutions jordan international students travel back countries graduate international students remain jordan able practice pharmacists representing frontline professional component essential health care accessible healthcare providers pharmacists role expanding along advancement different configurations pharmacy services provided customers drivethrough pharmacy service one example numerous newly emerging community pharmacy services jordan model initiated nineties united states america usa pharmacy research social administrative pharmacy xxx xxxx xxxxxx chains initial adopters though well espoused model acrossthe usa <NUMBER> jordan drivethrough pharmacy services recently introduced representing new trend community pharmacy services positive customer awareness perceptions towards service <NUMBER> although course model limits sitdown counseling deemed higher order role pharmacists jordan service appeared well received particularly certain subset customers concerns regarding proper counseling represented main disadvantage service <NUMBER> <NUMBER> participants study believed allowed sell medications coronavirus management via drivethrough service available chain pharmacies jordan although benefits may found approach dispensing covid<NUMBER> era suboptimal counseling raises concern discussion falls unto policymakers make clear announcement whether allow encourage prohibit pharmacists dispensing coronavirus patients medications via drivethrough service public health emergencies clinical pharmacists enact professional expertise analyzing current situation rationally working professionally cohesive efficient manner provide innovative pharmacy services around medication safety rational use medicines <NUMBER> acknowledge scope community pharmacy practice varies considerably across countries hence important examine ways profession assist public health response covid<NUMBER> donenot maintaining continuity healthcare services achieving optimal use possible services <NUMBER> limitation study conducted via online questionnaire due pandemic world going public quarantine currently imposed jordan research methods possible course issues representativeness profile participants majority participants amman capital availability cpd workshops higher areas country ask pharmacy students study year could played role results obtained fourth fifth year students example expected wider awareness clinical field compared students earlier years study survey also course validated although items put together realtime based literature reviewed team clinical pharmacy experts half pharmacists pharmacy students believed got enough education previously epidemicspandemics majority follow latest coronavirus updates treatments mostly media followed reports majority believed major role management epidemics pandemics pharmacies certain gaps awareness covid<NUMBER> identified highlighting areas improvement generally pharmacists showed significantly higher awareness score students way satisfactory expected finding higher age participants graduating public university versus private university attending educational workshops yearly basis also significantly affected awareness level study funded deanship academic research applied science private university amman jordan authors involved parts study manuscript preparation including literature search study design analysis data manuscript preparation review manuscript severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> lead coronavirus disease <NUMBER> covid<NUMBER> spreading rapidly world time writing article july <NUMBER> <NUMBER> infected <NUMBER> million people caused <NUMBER> deaths globally httpswwwwhointdocsdefaultsourcecoronavirusesituationreports<NUMBER>covid<NUMBER>sitrep<NUMBER>pdfsfvrsn<NUMBER>e<NUMBER>e<NUMBER>df<NUMBER> disease declared “pandemic” world health organization march <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> singlestrand rna virus coronaviridae family affect various organs including limited respiratory system kidneys gastrointestinal system cardiovascular system <NUMBER> data published wuhan china indicate patients underlying cardiovascular disease cvd increased risk mortality morbidity covid<NUMBER> <NUMBER> infectious disease affect cardiovascular system directly indirectly <NUMBER> increased susceptibly patients cvd covid<NUMBER> outbreak notwithstanding fact population already treatment various classes medication places higher risk adverse drug events possible drug–drug interactions although current understanding covid<NUMBER> pathology would suggest increased number cardiovascular complications pandemic total number cardiovascularrelated admissions paradoxically declined <NUMBER> united states <NUMBER> however may largely attributable fear contracting covid<NUMBER> medical centers thus indicative true reduction cardiovascular diseases prudent therefore pay sufficient heed cardiovascular problems patients even still number one killer globally even covid<NUMBER> era approved therapy patients covid<NUMBER> yet emerge however medications used treatment sarscov<NUMBER> infection globally include hydroxychloroquinechloroquine immunomodulatory effects inhibit viral fusion lopinavirritonavir antiretroviral agent block virus replication dexamethasone antiinflammatory agent remdesivir inhibitor rna synthesis lastly passive immunotherapeutic agents tocilizumab sarilumab canakinumab anakinra <NUMBER> although yet approved regulatory agencies remdesivir shown evidence shortened time recovery among patients covid<NUMBER> <NUMBER> according recent recovery trial dexamethasone showed beneficial effects patients <NUMBER> days treatment initiation dose <NUMBER> mgday <NUMBER> days reduced <NUMBER>day mortality patients mechanical ventilation one third one fifth patients supplemental oxygen <NUMBER> finally convalescent plasma showed positive effects improving rate nasopharyngeal viral rna clearance <NUMBER> h patients severe lifethreatening covid<NUMBER> however increase overall rate clinical improvement patients lifethreatening covid<NUMBER> infection <NUMBER> article seeks review uptotheminute evidence view explaining possible pharmacotherapies cardiovascular complications covid<NUMBER> including acute coronary syndrome acs heart failure myocarditis arrhythmias coagulopathy well possible interactions medications currently administered evaluation treatment covid<NUMBER> similar coronaviruses sarscov<NUMBER> uses angiotensinconverting enzyme <NUMBER> ace<NUMBER> cell entry <NUMBER> ace<NUMBER> membrane protein highly expressed lung enterocytes heart responsible converting angiotensin ii angiotensin<NUMBER>–<NUMBER> vasodilator peptide potential role lung protection <NUMBER> based animal studies sarscov<NUMBER> downregulate ace<NUMBER> expression facilitate neutrophil infiltration subsequently accelerate lung myocardial damage <NUMBER> damage speculated profound patients cardiovascular disorders may likely upregulated ace<NUMBER> expression due pharmacological inhibitors renin–angiotensin–aldosterone system raas underlying conditions <NUMBER> <NUMBER> sarscov<NUMBER> infections also directly lead viral myocarditis elevated levels myocardial injury markers troponin creatine kinase <NUMBER> severe cases sarscov<NUMBER> disease progresses ace<NUMBER>dependent alveolar damage hypoxia systemic inflammatory response syndrome acute respiratory distress syndrome ards exaggerated cytokine release result may myocardial supplyanddemand imbalance plaque rupture thrombosis procoagulant states fig <NUMBER> hypotheses may explain patients cvd prone higher rates sarscov<NUMBER> infections mortality also patients chronic stable states even otherwise healthy individuals might sustain acute cardiovascular problems covid<NUMBER> pandemic effective antiplatelet regimen matter utmost importance acs management optimal antiplatelet regimen hinges treatment strategy covid<NUMBER> status current guidelines stipulate fibrinolytic agents used patients receiving active therapy covid<NUMBER> p<NUMBER>y<NUMBER> inhibitor choice clopidogrel <NUMBER> although ticagrelor also considered according treat trial <NUMBER> patients undergoing primary percutaneous interventions prasugrel ticagrelor recommended whatever case may decisionmaking regard patients covid<NUMBER> light drug–drug drug–disease interactions aspirin low dose administered acs minimal antiinflammatory effects concerns regarding potentially detrimental effects nonsteroidal antiinflammatory drugs clinical course covid<NUMBER> applicable aspirin <NUMBER> loading maintenance doses aspirin patients covid<NUMBER> administered normal population patient coagulopathy clopidogrel p<NUMBER>y<NUMBER> inhibitor choice poses lowest bleeding risk <NUMBER> another concern prescription antiplatelets interaction p<NUMBER>y<NUMBER> inhibitors protease inhibitors lopinavirritonavir potential antiviral agent covid<NUMBER> strong inhibition cyp<NUMBER>a<NUMBER> pathway increase risk bleeding ticagrelor consequently ticagrelor contraindicated patients receiving lopinavirritonavir lopinavirritonavir could also diminish antiplatelet activity clopidogrel platelet function test suggested adjust clopidogrel dose accordingly individuals without coagulopathy bleeding risk prasugrel may good option lopinavirritonavir administered table <NUMBER> <NUMBER> respect glycoprotein iibiiia inhibitors given high bleeding risk propensity acute kidney injury patients covid<NUMBER> use ideally avoided tirofiban eptifibatide may considered needed abciximab recommended due high risk thrombocytopenia <NUMBER> large cohort study patients covid<NUMBER> haung et al <NUMBER> recorded <NUMBER> thrombocytopenia platelet count <NUMBER>l entire population higher prevalence among patients icu <NUMBER> low molecular weight heparin lmwh may advantages unfractionated heparin ufh patients coagulopathy <NUMBER> may regarded agent choice still patient considered high bleeding risk severe kidney injury ufh may preferable protamine available reversal bleeding occurs patients receiving fibrinolytic therapy lmwh used agent choice cardiologist defers angiography <NUMBER> nonetheless centers angiography routinely done within <NUMBER> h fibrinolytic therapy ufh still constitutes best option table <NUMBER> complete revascularization achieved per typical management patients absence risk factors vein thrombosis anticoagulants discontinued <NUMBER> noted interactions parenteral antithrombotic agents currently available covid<NUMBER> medications <NUMBER> reperfusion therapy thrombolytics attractive option stable patients without contraindications tenecteplase fibrinspecific agent prudent choice patients covid<NUMBER> strength high success rate low bleeding risk singledose administration strategy <NUMBER> tenecteplase also associated least fibrin depletion fibrinolytics statins beneficial vascular myocardial effects attributed antiinflammatory effects may explain continued use class medication patients cardiovascular cardiometabolic indication may positive effects presence acute viral respiratory infections <NUMBER> irrespective covid<NUMBER> highintensity statin atorvastatin rosuvastatin administered every patient acs <NUMBER> cohort studies china demonstrated prevalent elevated levels hepatic transaminase creatine kinase afflicted covid<NUMBER> <NUMBER>–<NUMBER> advisable therefore monitor liver function creatine kinase levels baseline periodically thereafter case severe rhabdomyolysis increased liver enzymes recommended statins temporarily withheld <NUMBER> another concern potential drug interaction atorvastatin rosuvastatin lopinavirritonavir respective daily dose atorvastatin rosuvastatin exceed <NUMBER> mg <NUMBER> mg concomitant use lopinavirritonavir table <NUMBER> <NUMBER> interleukin<NUMBER> il<NUMBER> receptor antibodies tocilizumab may also lower statin concentrations reversing cytochrome p<NUMBER> cyp<NUMBER> suppression however clinical significance effect may minimized shortterm use antiil<NUMBER> receptor treatments <NUMBER> according guidelines acs beta<NUMBER> selective betablockers may preferred nonselective agents <NUMBER> among beta<NUMBER> selective betablockers whereas metoprolol metabolized cyp<NUMBER>d<NUMBER> bisoprolol partially metabolized cyp<NUMBER>a<NUMBER> cyp<NUMBER>d<NUMBER> atenolol metabolized cyp<NUMBER> table <NUMBER> <NUMBER> bradycardia hydroxychloroquine also reported may potentiated betablockers patients receiving betablocker diligent monitoring heart rate blood pressure warranted patients hemodynamic instability receive betablockers unless clear improvements blood pressure heart rate conflicting evidence pros cons use aceis arbs patients covid<NUMBER> fang et al <NUMBER> demonstrated ace<NUMBER> upregulated patients chronically receiving raas blockers might place patients increased risk infection sarscov<NUMBER> conversely animal models indicated potentially protective effect losartan administration lungs <NUMBER> present three major studies aceis arbs patients covid<NUMBER> reported harm use raas blockers patients covid<NUMBER> <NUMBER>–<NUMBER> given conflicting reports issue almost international societies <NUMBER> <NUMBER> recommended discontinuation aceis arbs due covid<NUMBER> hence patients acs acei arb started first <NUMBER> h admission case normal population <NUMBER> important issue potential drug interaction lopinavirritonavir arbs administered concomitantly ritonavir losartan irbesartan may less ability transform respective active moiety lose efficiency <NUMBER> hand concentration valsartan may increase inhibition organic aniontransporting polypeptide <NUMBER>b<NUMBER> oatp<NUMBER>b hepatic efflux transporter multidrug resistanceassociated protein <NUMBER> mrp<NUMBER> <NUMBER> ultimately patients covid<NUMBER> receiving aceis arbs close monitoring blood pressure serum creatinine potassium recommended <NUMBER> exclusion patients hemodynamic instability lung edema patients heart failure reduced ejection fraction receive betablocker similar patients acs beta<NUMBER> selective betablockers ie metoprolol succinate bisoprolol may preferred patients respiratory infections among betablockers used heart failure carvedilol metabolized glucuronidation ugt<NUMBER>a<NUMBER> cyp<NUMBER> primarily <NUMBER>d<NUMBER> <NUMBER>c<NUMBER> metoprolol chiefly metabolized cyp<NUMBER>d<NUMBER> bisoprolol partially metabolized cyp<NUMBER>a<NUMBER> cyp<NUMBER>d<NUMBER> table <NUMBER> <NUMBER> ritonavir consequently affect metabolism agents watchful monitoring heart rate blood pressure patients receiving lopinavirritonavir highly recommended similar acs scenario regardless covid<NUMBER> infection patients heart failure reduced ejection fraction receive acei arb close surveillance <NUMBER> concentration sacubitril rises tandem administration ritonavir hence importance thorough monitoring blood pressure serum creatinine potassium patients sacubitrilvalsartan table <NUMBER> specific interaction loop diuretics anticovid medications drugs safely initiated continued patients covid<NUMBER> given high rate acute kidney injury among group patients diuretic therapy closely monitored terms vital signs serum electrolytes creatinine mineralocorticoid antagonists administered close surveillance also continued patients covid<NUMBER> concerning patients receiving protease inhibitors area curve auc eplerenone increase fourfold may favor use spironolactone patients lopinavirritonavir table <NUMBER> specific interaction known thiazides lopinavirritonavir indapamide exception concentration indapamide may increase administered lopinavirritonavir necessitating extreme caution also essential take heed risk qt prolongation associated chloroquinehydroxychloroquine patients electrolyte disturbances greater risk receiving diuretics monitored potassium magnesium levels <NUMBER> patients digoxin hospitalized covid<NUMBER> monitored meticulously possibility instability acute infection may necessitate measurement serum concentration patients covid<NUMBER> continue receive digoxin furthermore ritonavir increase auc digoxin <NUMBER> halflife <NUMBER> hydroxychloroquine also increase concentration digoxin unknown mechanism <NUMBER> narrow therapeutic index drug–drug interactions potential unpredictable serum concentrations digoxin may require physicians reconsider continued use digoxin patients covid<NUMBER> table <NUMBER> protease inhibitors reduce formation nitric oxide isosorbide dinitrate compromise efficacy protease inhibitors also significantly interact hydralazine dose adjustments based patient’s response considered <NUMBER> ivabradine channel blocker used symptomatic management patients ejection fractions <NUMBER> lower sinus rhythms minimum resting heart rates <NUMBER> beats per minute despite maximum tolerable dose betablockers appears ivabradine continued safely hemodynamically stable patients covid<NUMBER> coadministration potent cyp<NUMBER> inhibitors increase auc ivabradine <NUMBER>fold ivabradine discontinued patients receiving lopinavirritonavir covid<NUMBER> <NUMBER> viral infections common etiology myocarditis selflimiting without sequelae cases <NUMBER> pathophysiology covid<NUMBER> myocarditis detected several days fever initiation <NUMBER> underlying mechanism myocardial injury patients covid<NUMBER> related upregulation ace<NUMBER> cardiovascular system <NUMBER> <NUMBER> rise cardiac markers may related solely myocarditis elevated levels troponin brain natriuretic peptide correlated worse outcomes <NUMBER> <NUMBER> appears similar instances viral myocarditis covid<NUMBER>–related myocarditis exist without clinical symptoms nevertheless fulminant viral myocarditis cardiac enlargement acute heart failure also reported <NUMBER> also case report italy showed endomyocardial localization virus patient fulminant myocarditis cardiogenic shock <NUMBER> based data extracted cases myocarditis consequence viral infections treatment covid<NUMBER>–related myocarditis mostly supportive <NUMBER> antiviral therapy immunomodulators also help treatment newonset heart failure balanced use vasopressors inotropes diuretics vasodilators fluid therapy may lifesaving based latest guideline management critically ill adults covid<NUMBER> norepinephrine vasopressor choice vasopressin added target mean arterial pressure achieved norepinephrine use dopamine discouraged increased risk arrhythmias mortality patients covid<NUMBER> suffer cardiogenic shock dobutamine inotrope choice milrinone added refractory cases <NUMBER> critically ill patients covid<NUMBER> routine use corticosteroids intravenous immunoglobulins recommended absence ards <NUMBER> <NUMBER> corticosteroids may beneficial patients lymphocytic myocarditis <NUMBER> also true patients covid<NUMBER> systemic corticosteroids suggested mechanically ventilated patients ards <NUMBER> significant information use immunomodulators among patients covid<NUMBER> myocarditis comes case report coronavirus fulminant acute myocarditis treated methylprednisolone suppress inflammation <NUMBER> mgday <NUMBER> days immunoglobulin regulate immune status <NUMBER> gday <NUMBER> days <NUMBER> another case report young male patient covid<NUMBER>–related myocarditis recovered without specific treatment supportive heartfailure–related medications <NUMBER> setting heart failure secondary ischemia corticosteroids avoided may increase potential mechanical complications infarction sarscov<NUMBER> place patient danger pericardial inflammation due cytotoxic effects immunemediated pathways reported dabbagh et al <NUMBER> furthermore colchicine known beneficial agent treatment pericarditis showed improvement time clinical deterioration covid<NUMBER> patients grecco<NUMBER> trail <NUMBER> cardiac arrhythmias tachyarrhythmias bradyarrhythmias cardiovascular complications occur frequently patients covid<NUMBER> <NUMBER> <NUMBER> study china prevalence cardiac arrhythmias higher icu patients nonicu patients <NUMBER> vs <NUMBER> <NUMBER> cardiac arrhythmias may attributed direct myocardial injury secondary systemic alterations due acute viremia eg metabolic derangement hypoxia neurohormonal changes inflammatory stress patients covid<NUMBER> hyperinflammatory state hypercytokinemia arrhythmogenic potential cytokine storm increasing levels il<NUMBER> il<NUMBER> il<NUMBER>β il<NUMBER> monocyte chemoattractant protein tumor necrosis factoralpha tnfα associated fatal arrhythmias <NUMBER> cytokines particularly il<NUMBER> prolong qtc via direct effect ion channels cardiomyocytes indirect effect bioavailability qtcprolonging medications inhibiting cyp<NUMBER>a<NUMBER> hyperactivating cardiac sympathetic system <NUMBER> several covid<NUMBER> pharmacotherapies including chloroquinehydroxychloroquine without azithromycin lopinavirritonavir prolong qtc interval increase risk druginduced torsade de pointes ditdp druginduced sudden cardiac death discd risk discd augmented drugs used combination ie chloroquinehydroxychloroquine plus azithromycin without lopinavirritonavir <NUMBER> <NUMBER> largest multinational registry analysis regard date reported use hydroxychloroquinechloroquine alone macrolide associated increased risk de novo ventricular arrhythmias mortality patients covid<NUMBER> <NUMBER> may manuscript subsequently retracted casting doubt reliability data decisionmaking another important adverse effect risk atrioventricular block associated lopinavirritonavir chloroquinehydroxychloroquine altered cardiac functions secondary use chloroquinehydroxychloroquine include bundle branch block ventricular tachycardia ventricular fibrillation <NUMBER> several risk factors identified increase risk ditdp discd risk factors include advanced age female sex structural heart disease congenital longqt syndromes electrolyte disturbances eg hypokalemia hypomagnesemia hypocalcemia concomitant use loop diuretics hepaticrenal failure baseline qtc prolongation concomitant qtcprolonging medications fever sepsis inflammatory state <NUMBER> <NUMBER>–<NUMBER> irrespective efficacy hydroxychloroquine alone combination azithromycin concerns regarding ditdp discd underscore need meticulous surveillance optimization risk factors <NUMBER> <NUMBER> end several risk scores tisdale score proqt score utilized prediction drugassociated qtc prolongation <NUMBER> <NUMBER> significance detection risk factors treatment initiation necessitates baseline periodic <NUMBER>lead ecgs also considerable importance baseline periodic monitoring hepaticrenal function serum potassium serum magnesium unnecessary qtcprolonging medications discontinued switched alternatives less qtc liability <NUMBER> <NUMBER> <NUMBER> recent study posited baseline qtc greater <NUMBER> ms <NUMBER>–<NUMBER> ms qrs <NUMBER> ms minimum tisdale risk score <NUMBER> failure monitor serial ecgs inpatients regarded contraindication use hydroxychloroquine moreover baseline qtc greater <NUMBER> ms <NUMBER>–<NUMBER> ms qrs <NUMBER> ms minimum tisdale risk score <NUMBER> outpatients absolute relative contraindication combined use hydroxychloroquine azithromycin decision made treat patient minimum baseline qtc <NUMBER> ms qtcprolonging medications may reasonable start hydroxychloroquine monotherapy <NUMBER> <NUMBER> discontinuation azithromycin andor reduction dose hydroxychloroquine considered patients increase qtc greater <NUMBER> <NUMBER> ms treatment initiation ecg monitoring conducted <NUMBER> <NUMBER> h first dose <NUMBER> <NUMBER> h thereafter patients baseline qtc greater <NUMBER> ms patients baseline qtc less <NUMBER> ms need acquire ecg first dose daily ecgs considered inpatients receiving qtcprolonging agents <NUMBER> <NUMBER> <NUMBER> <NUMBER> however measurement qtc alone cannot prevent chloroquine hydroxychloroquineinduced arrhythmias since agents may affect conduction velocity calcium hemostasis changes cannot assessed qtc assessment <NUMBER> another alteration ecg patients covid<NUMBER> brugadalike ecg morphology <NUMBER> necessary differentiate brugada syndrome brugadalike ecg morphology since fever patients brugada syndrome associated lifethreatening arrhythmic events patients take precautionary measures eg social distancing use aggressive antipyretic therapy alleviate fever ecg monitoring considered respond antipyretics body temperatures exceeding <NUMBER> °c <NUMBER> <NUMBER> drug interactions antiarrhythmic medications antiviral agents eg hydroxychloroquine lopinavirritonavir another cause concern antiarrhythmic agents increase risk qt prolongation tdp concomitant use chloroquinehydroxychloroquine hence importance ecg monitoring initiation maintenance serum magnesium <NUMBER> mgdl serum potassium <NUMBER> mgdl <NUMBER> <NUMBER> <NUMBER> <NUMBER> another source concern interaction antiarrhythmics protease inhibitors protease inhibitors augment effects amiodarone lidocaine quinidine patients administration mentioned antiarrhythmics necessary caution exercised ecg monitoring dose reduction additionally antiarrhythmics concomitant use amiodarone blood pressure liverthyroid function monitored periodically alternative agents considered coadministration protease inhibitors class <NUMBER>c antiarrhythmics flecainide propafenone recommended <NUMBER> coagulopathy reported predictor poor prognosis patients covid<NUMBER> <NUMBER> primary reports covid<NUMBER> comparing patients survive survived showed former group significantly higher levels ddimer fibrin degradation products well longer prothrombin activated partial thromboplastin times aptt <NUMBER> nonetheless based recent publications coagulopathy patients covid<NUMBER> manifests elevated fibrinogen ddimer levels minimal alterations prothrombin time aptt platelet count early stages disease <NUMBER> tang et al showed disseminated intravascular coagulation dic occurred <NUMBER> nonsurvivors versus <NUMBER> survivors hospitalization study <NUMBER> contrast report klok et al none patients intensive care unit icu whose cases complicated thrombotic events developed dic <NUMBER> interestingly zhang et al described three patients covid<NUMBER> overt coagulopathy positive antiphospholipid antibody tests <NUMBER> bowles et al case series <NUMBER> patients covid<NUMBER> prolonged aptt found positive lupus anticoagulant assays <NUMBER> <NUMBER> patients <NUMBER> thus still unclear whether observed coagulopathy marker severity disease observed septic shock whether virus direct impact coagulation cascade <NUMBER> <NUMBER> several investigations tried implicate coagulopathy indices survival prediction patients covid<NUMBER> posited ddimer level prothrombin time <NUMBER> <NUMBER> thrombocytopenia <NUMBER> potential prognostic factors suggested potential ddimer cutoff points predicting severity disease <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> mgl <NUMBER> consensus regarding role ddimer patients covid<NUMBER> yet single study reported ddimer determinant clinical risk model predicting occurrence critical illness <NUMBER> salient point ddimer generally accepted important factor patients covid<NUMBER> <NUMBER> conversely bleeding complications appear rare group patients <NUMBER> coagulopathy described covid<NUMBER> conjunction severe inflammatory response hypoxia may increase risk thrombotic events patients infection <NUMBER> reports elaborated prevalence different thrombotic complications patients covid<NUMBER> study conducted three hospitals netherlands klok et al observed <NUMBER> incidence rate thrombotic complications majority vte <NUMBER> patients compared arterial thrombotic events <NUMBER> patients <NUMBER> similarly high incidence pulmonary emboli observed poissy et al reported rate <NUMBER> vte infected patients addition rate twice time interval previous year <NUMBER> noted diagnosis vte might challenging patients hospitalized covid<NUMBER> apart fact ddimer deemed inapplicable transfer critically ill patients imaging wards positioning properly means straightforward result diagnostic process considerable numbers patients remains incomplete although definitive diagnostic measures right ventricular enlargementdysfunction echocardiography deep vte lower limbs ultrasound might helpful toward diagnosis vte controversy persists concerning treatment patients without definite diagnosis various experts suggested intermediate fulldose anticoagulation <NUMBER> patients suspected pulmonary embolism low bleeding risk fulldose anticoagulation might acceptable <NUMBER> whereas patients suspected pulmonary embolism high bleeding risk intermediatedose anticoagulation could considered <NUMBER> <NUMBER> halftherapeuticdose regimen adopted intermediatedose anticoagulation many centers <NUMBER> several trials ongoing true value proposed regimens <NUMBER> symptom overlap pulmonary emboli acute respiratory disease covid<NUMBER> <NUMBER> aforementioned challenges diagnosis treatment pulmonary emboli pandemic call appropriate prophylaxis strategy tang et al investigated validity sepsisinduced coagulopathy score ddimer level risk stratification patients covid<NUMBER> regard vte prophylaxis <NUMBER> retrospective analysis <NUMBER> patients hospitalized severe covid<NUMBER> <NUMBER>day mortality benefit among heparin lmwh ufh users however patients minimum sepsisinduced coagulopathy score <NUMBER> ddimer level greater <NUMBER> μgml heparin prophylaxis significantly improved <NUMBER>day mortality hence tang colleagues recommended prophylaxis implementation based risk stratification <NUMBER> risk stratification tools eg caprini improve also suggested experts <NUMBER> international society thrombosis haemostasis isth offered liberal recommendation suggesting administration lmwh patients hospitalized covid<NUMBER> including critically ill contraindications platelet count ≤<NUMBER> × <NUMBER>l active bleeding <NUMBER> currently dearth data suggesting routine vte prophylaxis case series klok et al confirmed high incidence vte <NUMBER> patients hospitalized covid<NUMBER> may regarded justification liberal approach investigators suggested higherthanroutine ie “escalated” dose vte prophylaxis patients icu especially patients ards <NUMBER> successful experiences previously published <NUMBER> regarding mentioned approach patients h<NUMBER>n<NUMBER> complicated ards accordingly metaanalysis <NUMBER> trials showed minimum <NUMBER> ud lmwh succeeded significantly decreasing <NUMBER>day mortality among patients ards rr <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> elevated level ddimer proposed marker benefit escalating regimen <NUMBER> additionally mechanical prophylaxis suggested patients contraindications pharmacological prophylaxis <NUMBER> notably importance vte prophylaxis recognized since early days current pandemic wang et al short report <NUMBER> patients hospitalized covid<NUMBER> showed <NUMBER> patients obtained minimum padua prediction score <NUMBER> ie high risk vte <NUMBER> received appropriate treatment <NUMBER> patients chronic treatment anticoagulants switch parenteral agents recommended upon admission <NUMBER> druginteraction point view worth mentioning warfarin used covid<NUMBER> medications careful monitoring international normalized ratio inr according european society cardiology esc <NUMBER> guideline rivaroxaban apixaban fewer interactions chloroquinehydroxychloroquine dabigatran edoxaban <NUMBER> still lopinavirritonavir use rivaroxaban contraindicated due increased risk bleeding furthermore edoxaban recommended lack evidence dose apixaban halved dabigatran administered full dose <NUMBER>h gap lopinavirritonavir <NUMBER> <NUMBER> <NUMBER> vital remember cardiovascular complications remain leading cause death pandemic era indeed cardiovascular complications common finding covid<NUMBER> patients underlying cvd susceptible infection pharmacotherapy integral component patient care adjusted patients active coronavirus infection based comorbidities may affect drug choice dosage drug interactions cardiovascular medications antiviral agents hydroxychloroquine lopinavirritonavir constitute another issue deserving special note herein sought suggest appropriate therapies common cardiovascular problems covid<NUMBER> namely acs heart failure myocarditis arrhythmias vte based current literature clearly paucity information complications present studies needed elucidate best pharmacotherapy regimen patients suffering covid<NUMBER> patients pep pet trials participants randomized <NUMBER> receive five days hydroxychloroquine placebo primary pep trial outcome incidence symptomatic covid<NUMBER> primary pet trial outcome ordinal scale disease severity hospitalized hospitalized without intensive care hospitalization intensive care death participant screening informed consent followup exclusively internetbased appropriate regulatory research ethics board approvals canada united states discussion complementary randomizedcontrolled trials innovatively designed adequately powered rapidly answer urgent questions regarding effectiveness hydroxychloroquine reduce virus transmission disease severity covid<NUMBER> pandemic inperson participant followup conducted facilitate social distancing strategies reduce risks exposure study personnel innovative trial approaches needed urgently assess therapeutic options mitigate global impact pandemic trials registration clinicaltrialsgov nct<NUMBER> registered <NUMBER> march <NUMBER> keywords hydroxychloroquine á covid<NUMBER> á clinical trials á coronavirus á sarscov<NUMBER> á postexposure prophylaxis á preemptive therapy á healthcare worker coronavirus disease covid<NUMBER> novel infection caused severe acute respiratory syndromerelated coronavirus<NUMBER> sarscov<NUMBER> <NUMBER> virus first recognized wuhan china december <NUMBER> quickly spread globally leading pandemic <NUMBER> currently standard care jurisdictions mild moderate covid<NUMBER> includes selfobservation selfquarantine seven <NUMBER> days <NUMBER> <NUMBER> small studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> methodologic limitations suggested certain therapies may promise time publication proven effective therapies exist major national international guidelines yet incorporate pharmacologic therapies covid<NUMBER> highgrade evidence lacking <NUMBER> <NUMBER> effective postexposure prophylaxis pep preemptive therapeutic pet intervention would provide significant benefit individuals well public health given high rate sarscov<NUMBER> transmission overburdened healthcare systems coronavirus disease <NUMBER> symptoms generally develop average four five days exposure sarscov<NUMBER> <NUMBER> incubation period ranges one <NUMBER> days <NUMBER> majority <NUMBER> people covid<NUMBER> exhibit mild symptoms recover spontaneously <NUMBER> nevertheless <NUMBER> patients develop hypoxemia requiring hospitalization admission intensive care unit icu andor invasive ventilation <NUMBER> hospitalized north america approximately <NUMBER> individuals develop respiratory failure shock andor multiple organ system dysfunction requiring admission critical care unit <NUMBER> severe acute respiratory syndromerelated coronavirus<NUMBER> spread rapidly population basic reproductive value r <NUMBER> value <NUMBER> <NUMBER> <NUMBER> <NUMBER> secondary attack rate among household contacts estimated <NUMBER> <NUMBER> confidence interval ci <NUMBER> <NUMBER> <NUMBER> estimates largely based monitoring travelassociated covid<NUMBER> cases context community transmission secondary attack rate may high <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> <NUMBER> absence appropriate distancing strategies secondary attack rates may significantly higher since <NUMBER> patients secondary infections require hospitalization risk poor outcomes including death protective therapeutic strategy urgently needed following exposure covid<NUMBER> pharmacologic agents shown vitro suppression viral replication coronaviruses <NUMBER> one agent chloroquine shown effective reducing laboratory established infection spread adjacent cells sarscov <NUMBER> recently related drug hydroxychloroquine found prevent sarscov<NUMBER> viral replication infection vero cell lines <NUMBER> exact antiviral mechanism hydroxychloroquine sarscov<NUMBER> incompletely understood may related impaired angiotensin converting enzyme<NUMBER> receptor binding resultant cell entry well suppressed cytokine storm <NUMBER> recent news outlet reports chloroquine poisoning raised concerns regarding safety hydroxychloroquine scientific details lacking recent trial chloroquine among patients hospitalized covid<NUMBER> brazil stopped early n <NUMBER> safety concerns patients receiving highdose chloroquine <NUMBER> g ten days prolonged qtc <NUMBER> msec <NUMBER> cases including two deaths secondary ventricular tachycardia <NUMBER> dose orders magnitude higher malaria prophylaxis <NUMBER> mg weekly malaria treatment <NUMBER> g total wellestablished safety profiles <NUMBER> hydroxychloroquine much less toxic chloroquine <NUMBER> decades established safety data treatment malaria autoimmune conditions <NUMBER> preliminary data covid<NUMBER> trials shown increased gastrointestinal upset significant differences serious adverse events <NUMBER> early translational clinical studies shown hydroxychloroquine might effective pharmacologic treatment prevent viral establishment used early exposure established infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> delaying treatment time hospitalization occurs average seven eight days symptom onset <NUMBER> may associated lack benefit established viral infection <NUMBER> <NUMBER> nevertheless current evidence base limited small underpowered sample sizes large observational studies without proper controls <NUMBER> global political forces continue emphasize notyetproven role hydroxychloroquine paradigm covid<NUMBER> treatment urgent clinical trials therefore needed establish whether hydroxychloroquine may effective therapy covid<NUMBER> determine hydroxychloroquine compared placebo effective <NUMBER> preventing covid<NUMBER> disease exposure known case ie pep <NUMBER> preventing severe complications disease started early course illness ie pet trial doubleblind placebocontrolled multicentre international randomizedcontrolled trial designed evaluate superiority hydroxychloroquine vs placebo participants enrolled two nested trials randomized separately separate endpoints use workflow study team documents infrastructure pep trial include asymptomatic healthcare workers household contacts exposed covid<NUMBER>positive cases within four days pet trial include outpatients covid<NUMBER> showing symptoms four fewer days trial planned recruit total <NUMBER> patients within trial participants randomized <NUMBER> parallel groups receive hydroxychloroquine placebo clinical trial registered clinical trialsgov nct<NUMBER> <NUMBER> march <NUMBER> approved participants nonhospitalized adults recruited community via advertisements using traditional methods social media twitter instagram facebook recruitment take place throughout united states us least initially within three provinces canada quebec manitoba alberta approval sought additional provinces limit spread disease inperson visits study personnel performed recruitment followup participants home selfisolation quarantine screening informed consent randomization data collection occur online research electronic data capture redcap secure webbased platform study medications delivered directly participants place residence via courier services respect safety protocols home deliveries patients covid<NUMBER> participants contact local study teams region via email phone questions concerns timely responses day business hours following day <NUMBER> pm websites created provide live enrolment updates responses frequently asked questions trial information participants wwwcovidpepumnedu wwwcovid<NUMBER>researchca • adults c <NUMBER> yr old • able read comprehend french english • access internet valid email address enrolment followup surveys postexposure prophylaxis <NUMBER> atrisk exposure covid<NUMBER>positive case within past <NUMBER> days <NUMBER> household contact healthcare worker preemptive therapy <NUMBER> nonhospitalized communitydwelling symptomatic fever cough shortness breath covid<NUMBER> within four days symptom onset <NUMBER> coronavirus disease confirmed reverse transcriptase polymerase chain reaction rtpcr healthcare workers compatible symptoms following exposure person known positive rtpcr result exposure occurring within past <NUMBER> days enrolment pep trial limited asymptomatic individuals exposed covid<NUMBER>confirmed case within b four days mean incubation period sarscov<NUMBER> five days <NUMBER> household contacts defined residing domicile atrisk exposures healthcare setting defined greater ten minutes spent within <NUMBER> covid<NUMBER>confirmed case insufficient use personal protective equipment per institutional guidelines healthcare workers selfidentified physicians nurses respiratory therapists workers providing direct patient contact select highrisk group developing clinical infection within time period intervention could prevent ameliorate disease efforts made deliver study medicines fourth day following exposure however delays may lead symptom onset randomization prior starting intervention events tracked online surveys administered upon receipt intervention community testing covid<NUMBER> limited participants included pet group long symptoms compatible covid<NUMBER> exposure person confirmed covid<NUMBER> qtc interval personal family history structural ischemic heart disease known episode sudden cardiac death <NUMBER> severe diarrhea andor vomiting screening may interfere drug absorption <NUMBER> significant hepatic impairment defined known cirrhosis history hepatic encephalopathy ascites <NUMBER> known pregnancy breastfeeding <NUMBER> current use following medications known drugdrug interactions amiodarone amitriptyline artemether azithromycin ciprofloxacin citalopram clarithromycin dapsone desipramine digoxin dofetilide doxepin droperidol erythromycin escitalopram flecainide fluoxetine haloperidol imipramine itraconazole ketoconazole levofloxacin lithium lumefantrine mefloquine methadone moxifloxacin procainamide propafenone quetiapine sertraline sotalol sumatriptan thioridazine venlafaxine bupropion ziprasidone zolmitriptan <NUMBER> current use antiepileptic exclusion criteria <NUMBER> specific participants canada request health canada exclusion criteria <NUMBER> specific participants us us fda approved inclusion pregnant breastfeeding women citing hydroxychloroquine safety data pregnant patients autoimmune conditions including systemic lupus erythematosus malaria <NUMBER> interventions participants randomized <NUMBER> receive hydroxychloroquine placebo hydroxychloroquine sulfate administered <NUMBER> mg tablets total dose <NUMBER> mg <NUMBER> tablets five consecutive days dosing regimens consist loading dose subsequent maintenance dose follows <NUMBER> day <NUMBER> upon receipt study medicine hydroxychloroquine <NUMBER> mg orally four tablets followed six eight hours later <NUMBER> mg orally three tablets <NUMBER> days <NUMBER> <NUMBER> hydroxychloroquine <NUMBER> mg orally daily three tablets per day placebo tablets administered using dosing schedule number tablets interventional arm rationale study dose adapted modified malaria dosing schedule hydroxychloroquine <NUMBER> considerations made maximal viral inhibition balancing potential toxicity drug supply anticipated shortages loading dose used similar malaria treatment strategy achieve antiviral activity quickly possible monte carlo simulations conducted proposed dose achieving steadystate serum concentrations ec<NUMBER> <NUMBER> <NUMBER> viral inhibition would occur common anticipated side effect hydroxychloroquine gastrointestinal upset <NUMBER> participants instructed spread doses throughout day eg two tablets breakfast one tablet lunch increase tolerability required participants may voluntarily stop taking study medicine time adherence determined selfreport chronic medications taken usual must taken <NUMBER> hours taking study medicine concomitant covid<NUMBER> therapy trial medicines permitted duration trial event hospitalization unblinding group assignment occur request treating physician participants may receive medications therapies including experimental treatments trials absence sarscov<NUMBER> testing covid<NUMBER> diagnosis made using clinical criteria labelled possible case confirmed cases outcome may limitations related access testing use priori clinical definition using symptoms commonly reported pcrproven patients world health organization <NUMBER> primary outcome pet <NUMBER> incidence confirmed sarscov<NUMBER> detection <NUMBER> incidence possible covid<NUMBER> symptoms <NUMBER> incidence allcause study medicine discontinuation <NUMBER> severity symptoms day <NUMBER> <NUMBER> visual analogue scale primary secondary outcomes listed analyzed separately trials outcome measures assessed selfreport via online questionnaires wherever possible covid<NUMBER> disease status verified public health records medical records death certificates patients positive rtpcr results sarscov<NUMBER> nasopharyngeal swab considered confirmed cases <NUMBER> rtpcr performed per local institutions standard procedures patients covid<NUMBER> require hospitalization outcome data collected day <NUMBER> participants complete additional online surveys throughout hospitalization assess adverse events related study medicine covid<NUMBER>related outcomes participants complete virtual assessments days <NUMBER> <NUMBER> <NUMBER> figure symptomatic disease develops participants required complete additional virtual assessments days <NUMBER> <NUMBER> participants pregnant become pregnant participating trial followed postpartum period assess maternal fetal outcomes event participant respond day <NUMBER> survey contact telephone registered mail still available participants given thirdparty telephone contact verify vital status recruitment followup exclusively internetbased prospective participants visit trial website read provided study information click link enrol trial website advertised communication strategies media channels internetbased advertisements social media regions covid<NUMBER>positive cases reported public health officials positive patients notified contact tracing initiated jurisdictions public health officials provide information accessing trial website healthcare workers notified trial website email communications offices occupational health promotion senior hospital administration online screening questionnaires assess interested participants eligibility criteria eligible participants provide informed consent submitting online form linked trial website contact information provided participants ask questions email andor phone randomization sequence generation allocation concealment blinding participants randomized via computergenerated permuted block randomization stratified pep trial asymptomatic participants pet trial symptomatic participants randomization sequence prespecified randomization recorded electronic log accessed research pharmacy packaging study medication unblinded statisticians study investigators trial participants care providers outcome assessors data analysts blinded allocation sequence study medication prepared onsite pharmacies packages shipped directly participants via courier participants provided masked study medicine notified whether taking hydroxychloroquine placebo instructions taking medicine identical groups variety sources hydroxychloroquine used different jurisdictions placebo identically matched hydroxychloroquine tablet however placebo hydroxychloroquine similar rounded oval shapes colour indistinct markings making unblinding trial arm unlikely patients asked believe received intervention control upon trial closure event medical emergency oncall investigator available code breaking required code breaking event reported research pharmacy principal investigator data collection methods data management data collection including baseline demographics clinical epidemiological characteristics study medicine tolerability adherence outcomes recorded online selfreport captured internetbased questionnaires administered redcap participantsubmitted data stored maintained secure server data us stored secure servers university minnesota data canada stored secure servers research institute mcgill university health centre us canadian databases stored managed respective countries interim data safety monitoring board purposes also upon completion recruitment confidential deidentified data shared facilitate analysis institutional data sharing agreements paper documents retained stored enrolment progress reports generated trial <NUMBER> <NUMBER> <NUMBER> enrolment highlight number participants enrolled study completed lost followup cumulative incidence covid<NUMBER> arms pooled cumulative hospitalizations arms pooled reported according existing research attack rate transmission household contacts approximately <NUMBER> <NUMBER> used fishers exact test twosided <NUMBER> test power b <NUMBER> detect <NUMBER> relative risk reduction disease incidence using <NUMBER> randomization calculated required sample size n <NUMBER> per arm accounting predicted <NUMBER> dropout rate internet selfstudy design sample size inflated n <NUMBER> per arm therefore aimed recruit total <NUMBER> patients pep trial symptomatic patients proportion patients progress require hospitalization approximately <NUMBER> <NUMBER> trial assumed without treatment <NUMBER> control arm would hospitalized <NUMBER> would hospitalized without icu stay death <NUMBER> would hospitalized icu stay death <NUMBER> randomization <NUMBER> total participants pet trial <NUMBER> power detect log odds ratio <NUMBER> number sample size approximations made accounting differences baseline rates relative effect sizes found appendices <NUMBER> <NUMBER> primary secondary outcomes analyzed separately pep pet trials intentiontotreat primary outcome pep incidence covid<NUMBER> day <NUMBER> assessed intervention vs control arm fishers exact test primary outcome pet ordinal scale disease severity outpatient hospitalized without icu hospitalized icu death day <NUMBER> assessed intervention vs control arms proportional odds model secondary outcomes pep pet analyzed pep group subset patients develop symptoms covid<NUMBER> taking least one dose study medicine analyze change symptom severity intervention vs control group use approach primary outcome pet group participants randomized pep group develop symptoms taking one dose study medicine described analyzed separately subgroup analysis secondary outcomes incidence reported fishers exact test continuous valued secondary outcomes reported mean standard deviation median interquartile range depending normality analysis conducted parametric nonparametric tests appropriate symptom severity scores recorded days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> using <NUMBER>cm continuous visual analogue scale participants electronically control slider indicating symptom severity <NUMBER> symptoms <NUMBER> severe symptoms measurements recorded nearest <NUMBER> cm severity symptoms day <NUMBER> compared first categorical analysis symptoms present yes via fishers exact chi square subsequently via independent twosample test symptom severity among symptomatic nonnormally distributed data analyzed via mannwhitney u test hydroxychloroquine sarscov<NUMBER> <NUMBER> number days exposure <NUMBER> decile age <NUMBER> sex biological variable <NUMBER> censored subjects pep trial become symptomatic taking one dose study medicine data safety monitoring board dsmb formed independent sponsor without competing interests trial pep pet interim analysis presented dsmb <NUMBER>day followup completed <NUMBER> <NUMBER> <NUMBER> enrolled participants interim analyses pool us canadian deidentified data arrive generalizable conclusion early possible dsmb unblinded statisticians provided unblinded interim analysis results investigators access pooled results landemets spending function analogue obrienfleming boundaries primary outcome group provided dsmb stopping boundaries truncated <NUMBER> z <NUMBER> analysis data reviewed safetyefficacy achieving stopping rules stopping rules primary outcome met dsmb review secondary outcomes consistency clear answer achieved event early termination efficacy trial immediately convert openlabel observational cohort study second dsmb review sample size reestimation occur based disease transmission rate control group priori assumption <NUMBER> transmission risk close contacts based limited data jurisdictions new sample size estimation take account updated transmission rate trial powered detect <NUMBER> relative reduction primary outcome starting second dsmb review dsmb given conditional power trial design parameters current data conditional power less <NUMBER> trial discontinuation may considered shortterm use hydroxychloroquine welltolerated safe track record use approved indications since <NUMBER> commonly reported side effects include gastrointestinal upset nausea vomiting diarrhea headache skin rash itching <NUMBER> gastrointestinal side effects minimized taken meals dosages separated throughout day participants instructed use optional strategies increase tolerance recent study showed risk harm high doses chloroquine <NUMBER> hydroxychloroquine much less toxic <NUMBER> doses used trial <NUMBER> g total similar doses used treat malaria <NUMBER> g total significantly less doses used treat coxiella burnetii infection autoimmune conditions <NUMBER> mg daily indefinitely showing long history safety <NUMBER> recent trial covid<NUMBER> using significantly higher doses <NUMBER> g daily three days <NUMBER> mg daily two three weeks showed significant differences serious adverse advents though gastrointestinal side effects higher dose <NUMBER> safety taking hydroxychloroquine enhanced excluding preexisting retinopathy allergic reactions cardiac conditions certain medications adverse reactions documented via selfreport virtual visits participants provided contact information guided manage adverse effects predefined plans posttrial care standard care offered centre participants provided updated public health information covid<NUMBER> pandemic instructions proceed event medical emergency regulatory agencies institutional sponsors rebs authorized conduct trial audits throughout interactions trial participants internetbased redcap electronic case report forms conforming required privacy server security standards participant identifying information disclosed publication activities arising trial anonymized data pooled international collaborators subject interinstitutional agreements information concerning trial released unauthorized third parties without prior written approval participants except monitoring rebs public health authorities immediate study personnel authorized access database protocol amendments reviewed reb updated trial registry websites trial enrolment results available updated wwwclinicaltrialsgov publicly available trial websites wwwcovidpepumnedu www covid<NUMBER>researchca nature pandemic pooled anonymized trial results published immediately available open access websites submitted urgently accelerated peer reviewed publication full deidentified data made available qualified researchers upon request hydroxychloroquine garnered unprecedented attention potential therapeutic option global covid<NUMBER> pandemic <NUMBER> several vitro vivo studies shown data may support possible efficacy clinical data limited small clinical trials uncontrolled case series cohorts <NUMBER> urgent need rigorous evaluation hydroxychloroquine therapeutic option covid<NUMBER> <NUMBER> innovative trial adequately powered rapidly answer urgent questions regarding effectiveness hydroxychloroquine ability prevent reduce severity covid<NUMBER> novel webbased design trial setting highly contagious global pandemic ensured interactions participants including enrolment informed consent done remotely using courier services deliver medicine using internetbased followup allow compliance strict social distancing strategies reduce risks infectious spread study personnel others design encourages large scale enrolment ensure target number participants enrolled trial results obtained quickly possible importantly design finalized regulatory reb approvals obtained large geographic jurisdictions brought online unprecedently short duration within weeks global pandemic goal obtain maximal information minimal amount time recently several public figures promoted widespread use hydroxychloroquine absence robust scientific data <NUMBER> <NUMBER> trial help address large scale dissemination hydroxychloroquine appropriate certain populations importantly study shows positive effect support new therapeutic option mitigate global spread impact covid<NUMBER> null negative effect shown reduce risk harm future patients reduce healthcare expenditures due ineffective medications protect drug supply patients previously established indications hydroxychloroquine results trial instrumental determining hydroxychloroquine may play important role mitigating global impact covid<NUMBER> coronavirus disease <NUMBER> covid<NUMBER> severe public health emergency worldwide caused severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> <NUMBER> number confirmed cases mortality rate increasing worldwide world health organization acknowledged covid<NUMBER> pandemic march <NUMBER> <NUMBER> <NUMBER> currently many efforts diagnose number patients symptoms close contacts prevent spread community may prevent spreading virus perfectly moreover many confirmed cases occurring diagnosis definite guideline initial therapeutic approach therefore many patients dying covid<NUMBER> symptoms severe patients hospitalized treatment done though established yet currently however treatment provided isolated home shelter among also cases severe lung injury cytokine storm progressed <NUMBER> leading sudden death case fatality rates countries especially italy spain high effective therapeutic measures urgently needed <NUMBER> review discuss important points dedicated management patients covid<NUMBER> help reducing morbidity mortality risk develop acute lung injury followed acute respiratory distress syndrome ards eventually death circumstance called cytokine release syndrome crs cytokine storm <NUMBER> main pathogenesis covid<NUMBER> may similar viruses influenza others however efforts make potential hypothesis covid<NUMBER> could cause higher incidence acute lung injury ards cytokine storm death viruses going make simple hypothetical model inflammatory processes cytokine storm covid<NUMBER> understand pathophysiology covid<NUMBER> associated lung injury ards cytokine storm • first covid<NUMBER> sarscov<NUMBER> first attached angiotensin converting enzyme <NUMBER> ace<NUMBER> receptors nasopharynx respiratory epithelium <NUMBER> • second host immune responses initiated entry covid <NUMBER> cells proinflammatory cytokines induced covid<NUMBER> formed various kinds immune cells cells bcells macrophages others <NUMBER> <NUMBER> • third degree increase proinflammatory cytokines determines degree covid<NUMBER>induced lung injury increase proinflammatory cytokines higher injury lung tissue severe ards could related higher mortality • fourth degree increase proinflammatory cytokines covid<NUMBER> higher induced viruses especially effect pronounced older age comorbid conditions • fifth reason effect less pronounced younger age groups may obscure could due immaturity immune system predominance th<NUMBER> immunity th<NUMBER> groups • sixth reason effect pronounced older age groups comorbid conditions may obscure could due preexisting subclinical subtle inflammations represented increased highsensitive crp hscrp groups • seventh exaggerated increase proinflammatory cytokines covid<NUMBER> could due hyperactivation various kinds immune cells response nprotein covid<NUMBER> called cytokine storm • eighth increase proinflammatory cytokines induced covid<NUMBER> cytokine storm cause acute lung injury ards eventually multiorgan failure • ninth cytokine storm may start early course disease later stage according degree activation host immune response may rapidly progressive time • tenth may clinicopathologic noncorrelations <NUMBER> patient may asymptomatic mild symptoms despite severely progressed conditions delay appropriate treatment early stage pathogenesis covid<NUMBER> summarized fig <NUMBER> regarding immunity <NUMBER> states <NUMBER> immunosuppressive state <NUMBER> normal immune state also classified lower normal normal upper normal <NUMBER> hyperimmune state <NUMBER> normal persons distributed <NUMBER> <NUMBER> scale according degree antiviral immunity mostly represented th<NUMBER> response person immunocompromised heshe minus points scale lower minus number located severe immunosuppressive condition number higher <NUMBER> person get hyperactivated host immune response lung injury ards multiorgan failure person infected usual respiratory viruses rhinovirus influenza heshe fever sore throat caused host immune response however degree increase inflammatory reaction <NUMBER> person number immunity scale <NUMBER> infected viruses number scale increase <NUMBER> however degree increase inflammatory reaction patients current covid<NUMBER> <NUMBER> therefore person number immunity scale <NUMBER> infected covid<NUMBER> number scale increase <NUMBER> means high probability patient progress cytokine storm due hyperactivated immune response might lead death younger age groups immune system may immature may predominance th<NUMBER> immunity th<NUMBER> <NUMBER> might number immunity scale <NUMBER> therefore even though infected covid<NUMBER> number increased <NUMBER> covid<NUMBER> number located <NUMBER> <NUMBER> therefore lower possibility progress severe cytokine storm may explain less mortality group however person older age group multiple comorbidities aging process atherosclerosis hypertension diabetes mellitus metabolic syndrome chronic kidney disease might preexisting subclinical subtle inflammations represented increased hscrp groups <NUMBER> therefore might number immunity scale <NUMBER> therefore infected covid<NUMBER> number <NUMBER> increased covid<NUMBER> number located <NUMBER> <NUMBER> therefore high possibility progress severe cytokine storm may explain high mortality group surely additional factors influence susceptibility severity covid<NUMBER> genetic variant different polymorphisms environmental factors smoking addition basic <NUMBER> increase degree inflammatory reaction patient progressed cytokine storm number rapidly increase <NUMBER> going discuss use steroids later basic increase <NUMBER> various proinflammatory cytokines induced covid<NUMBER> might suppressed shortcourse low dose steroids early stage disease steroids may effective later stage disease ards multiorgan failure suppress cytokine storm <NUMBER> cannot suppressed even though high dose steroids used recently hydroxychloroquine shown effective covid<NUMBER> <NUMBER> drug may reduce increase degree inflammatory reaction however know agent may better decreasing inflammatory reactions much number might decreased steroids hydroxychloroquine addition rate bacterial complications increase accordance progression time covid<NUMBER> think bacterial complication combined cytokine storm severe inflammatory reactions although theory may perfect may helpful understand pathogenesis potential harms covid<NUMBER> guide patients treated evidence based medicine ebm conscientious explicit judicious reasonable use modern best evidence making decisions care individual patients <NUMBER> ebm integrates clinical experience patient values best available research information <NUMBER> many clinicians applying treatment current coronavirus covid<NUMBER> based previous experiences mers sars however exactly evidencebased since covid<NUMBER> different evidencebased largescale randomized placebocontrolled trial covid<NUMBER> urgently conducted however difficult find appropriate drug covid<NUMBER> pandemic state take long time although effort also done concurrently addition even results small rcts meaningful often reversed larger rct performed <NUMBER> moreover although results metaanalysis may considered best evidence interpreted caution metaanalysis results significant even though results individual rcts statistical significance <NUMBER> furthermore claimed published research findings false useful <NUMBER> <NUMBER> though also interpreted caution numerously published metaanalyses also misleading <NUMBER> addition guidelines suggested experts also mistake <NUMBER> context find best strategies protect humans form harms covid<NUMBER> even though apply several therapeutic strategies investigated sars mers interpreted caution cannot apply ebm immediately covid<NUMBER> pandemic also make every effort find wise ways solve problems situation experiencebased approach may also important pandemic era many publications urgently published even though case reports case series covid<NUMBER> causing severe public health emergency word mortality rapidly increasing world would like remind basic principle treatment patients often forget harm <NUMBER> think harms means harms would look like pandemic thought summarized potential harms things regarding covid<NUMBER> summarized table <NUMBER> <NUMBER> continuing smoking significant harm respiratory epitheliums dont recommend cessation smoking time causing significant harm patients <NUMBER> cytokine storm considered significant harm important cause death dont make every effort prevent process early course disease causing significant harm patients <NUMBER> currently asymptomatic patients mild symptoms severe radiologic findings bacterial complications lead sudden death radiologic examinations treatment done patients severe symptoms develop may considered significant harm dont make every effort detect patients treat early course disease causing significant harm patients <NUMBER> currently covid<NUMBER> infected patients divided two groups one person isolated home medications provided person developed severe symptoms time admitted hospital currently many patients covid<NUMBER> recommended home severe symptoms develop due infectivity others think patient group moderate symptoms early treatment done steroids antibiotics progress severe conditions let home significant harm dont provide medications steroids antibiotics time covid<NUMBER> test monitor patient even phone considering practically difficult patient points current potential harms novel covid<NUMBER> disease • smoking cessation recommended pandemic era may significant harm • although cytokine storm considered significant harm important cause death efforts prevent process early course disease • person covid<NUMBER> isolated home receive medications treatment severe symptoms dyspnea develops • although asymptomatic patients covid<NUMBER> mild symptoms severe radiologic findings radiologic examinations given patients severe symptoms develop • although mild patients covid<NUMBER> bacterial complications stage treatment given severe symptoms develop • misinterpretation results various studies including systematic review without considering biases lead false guidance treatment covid<NUMBER> significant harm visit clinic policy changed pandemic era medications given patients liberally usual situations causing significant harm patients hesitating use steroids antibiotics may harm patients covid<NUMBER> <NUMBER> something better nothing currently established guidelines covid<NUMBER> rely previous treatments sars mers influenza expert opinions recently investigators discussing beneficial effect hydroxychloroquine covid<NUMBER> based vitro studies much experience dont interests use elderberry supplements shown effective cold influenza randomized doubleblind placebocontrolled study metaanalysis <NUMBER> <NUMBER> <NUMBER> treatments elderberry supplements betadine mouth nasal spray causing significant harms think something better nothing <NUMBER> misinterpretation various studies including systematic review without considering biases lead false guidance treatment covid<NUMBER> significant harm <NUMBER> role experts evidencebased medicine metaresearch important reduce harm patients pandemic era see table <NUMBER> addition may current harms pandemic era also urgently discussed based pathogenesis covid<NUMBER> infection principles mentioned would like suggest <NUMBER> recommendations covid<NUMBER> urgently considered pandemic era first smoking cessation encouraged always recommended general population also difficult people covid<NUMBER> predominantly damage respiratory epitheliums lungs least recommended recently also hypothesized individuals exposed nicotine prior exposure virus primed higher risk nicotine directly impact putative receptor virus ace<NUMBER> lead deleterious signaling lung epithelial cells <NUMBER> addition several cytokines including il<NUMBER> il<NUMBER> tnfα induced smoking might trigger cytokine storm covid<NUMBER> still know whether short duration smoking cessation could reduce susceptibility severity covid<NUMBER> beneficial something smoking cessation better nothing second povidoneiodine polyvinylpyrrolidoneiodine pvpi betadine mouth nasal spray applied kill covid<NUMBER> viruses reduce number covid<NUMBER> viruses enter cells covid<NUMBER> initiated attachment virus pharynx respiratory epithelium causes sore throat currently however know whether number virus attached pharynx respiratory epithelium influence severity covid<NUMBER> easily speaking inhaled <NUMBER> viruses inhaled <NUMBER> viruses infection risk disease severity different currently cannot proved easily however considering effectiveness mask prevents respiratory infections less exposure likely prevent infection indirect evidence one previous metaanalysis showed physical measures highly effective preventing spread sars wearing masks odds ratio <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> number needed treat nnt <NUMBER> <NUMBER> <NUMBER> vs wearing n<NUMBER> masks <NUMBER> <NUMBER> <NUMBER> nnt <NUMBER> <NUMBER> <NUMBER> <NUMBER> make potential hypothesis <NUMBER> viruses inhaled attached throat may cleared host immunity however <NUMBER> viruses inhaled attached throat go fight virus host immunity viruses cleared host immunity person free virus viruses win may replicate exponentially within relatively short time cause viremia blood situation still know whether degree viremia viral load might correlated degree host hyperimmune response whether reduction viruses throat example using betadine mouth spray gargles could decrease degree viremia blood currently inhibiting angiotensin converting enzyme <NUMBER> ace<NUMBER> blocking angiotensin receptor <NUMBER> ar<NUMBER> considered key target sarscov<NUMBER> vaccination covid<NUMBER> therapy <NUMBER> due finding authors recommend use angiotensin converting enzyme inhibitors acei angiotensin receptor <NUMBER> blockers arbs <NUMBER> currently findings suggestions cant transferred clinical practice easily acei arbs widely used clinical daily practice clinical studies made set covid<NUMBER> outbreak far even basic science due pathophysiological mechanisms eg effectiveness blocking ar<NUMBER> limited <NUMBER> due substantiated benefitrisk evaluation therapy arbs acei cannot recommended addition know many ace<NUMBER> receptors could downregulated blocked antibodies vaccines many entries viruses could inhibited developed however blocking entry virus potential therapeutic target think direct killing virus throat betadine mouth nasal spray might efficacious receptor downregulation several studies showed severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov could inactivated pvpi vitro <NUMBER> <NUMBER> one phase <NUMBER> study shows application pvpi nasal spray nasal mucosa result demonstrable limitation nasal function detectable damage multilayer ciliated epithelium nose <NUMBER> anyone buy betadine mouth nasal spray gargles without prescription overthecounter medicines cause significant harm reason use applied person feels sore throat early course disease although side effects pvpi use rare adverse effect iodine precautions also recognized pvpi cause allergic reactions used patients suffering thyroid diseases <NUMBER> even exist studies pvpi sarscov<NUMBER> either due benefitrisk evaluation pvpi used patients infected sarscov<NUMBER> mild • hydroxychloroquine used secondary drug patients worsening symptoms • policy drug use changed like giving steroids antibiotics patients time diagnostic test drive system reduce harms patients autoimmunity reviews xxx xxxx xxxx symptoms without allergies pvpi thyroid diseases person visiting crowded places airport also applied easily third use elderberry supplements considered early course disease although tested coronavirus elderberry supplements shown effective cold influenza randomized doubleblind placebocontrolled study metaanalysis <NUMBER> <NUMBER> <NUMBER> currently one cleveland clinic news reported emily bamforth use elderberry supplements <NUMBER> although several reports beneficial effect elderberry supplements several viral infections <NUMBER> <NUMBER> <NUMBER> hypotheses potential immunologic mechanisms beneficial effect elderberry supplements focusing covid<NUMBER> well known angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor sarscov <NUMBER> recent study showed sarscov<NUMBER> covid<NUMBER> spike glycoproteins also uses ace<NUMBER> enter cells receptorbinding domains sarscov<NUMBER> sarscov bind similar affinities human ace<NUMBER> correlating efficient spread sarscov<NUMBER> among humans <NUMBER> although less discussed ace<NUMBER> shown cd<NUMBER>l lsign encoded clec<NUMBER>m also receptor sarscov <NUMBER> study cd<NUMBER>l expressed human lung type ii alveolar cells endothelial cells potential targets sarscov large glycoprotein sarscov might use ace<NUMBER> cd<NUMBER>l virus infection pathogenesis <NUMBER> addition chan et al demonstrated individuals homozygous clec<NUMBER>m tandem repeats less susceptible sars infection lsign expressed nonsars sarscovinfected lung <NUMBER> also showed compared cells heterozygous lsign cells homozygous lsign show higher binding capacity sarscov higher proteasomedependent viral degradation lower capacity trans infection suggesting homozygosity lsign plays protective role sars infection <NUMBER> summary first encounter virus host might binding attachment receptors receptors might play important role infection large number enveloped viruses capturing concentrating transmitting infectious virions <NUMBER> virus reaches target cell cascade events generally starting interaction viral envelope glycoproteins specific entry receptors coreceptors necessary order trigger viruscell membrane fusion <NUMBER> although much studied coronavirus capture transmission hiv<NUMBER> ctype lectin lsign inhibited carbohydratebinding agents cbas <NUMBER> study mannoseand nacetylglucosamine glcnacspecific cbas dosedependently prevented virus capture lsignexpressing <NUMBER> trexlsign cells <NUMBER> coronavirus also uses lsign receptor entry one study suggested influenza virus coronavirus infections might also qualify treated cbas <NUMBER> keyaerts et al evaluated effect <NUMBER> plant lectins different specificities coronavirus <NUMBER> showed plant lectins possessed marked antiviral properties coronaviruses ec<NUMBER> values lower microgramml range middle nanomolar range nontoxic cc<NUMBER> <NUMBER> microgml strongest anticoronavirus activity found predominantly among mannosebinding lectins addition number galactose nacetylgalactosamine glucose nacetylglucosaminespecific plant agglutinines exhibited anticoronaviral activity <NUMBER> also found significant correlation rvalue <NUMBER> ec<NUMBER> values <NUMBER> mannosespecific plant lectins effective two coronaviruses little correlation seen activity types lectins <NUMBER> therefore reported two targets possible antiviral intervention identified replication cycle sarscov first target located early replication cycle probably viral attachment second target located end infectious virus cycle <NUMBER> de clercq summarized various compounds reported exhibit vitro activity sarscov though illdefined mode action selectivity indexes <NUMBER> valinomycin glycopeptide antibiotics plant lectins hesperetin glycyrrhizin aurintricarboxylic acid chloroquine niclosamide nelfinavir calpain inhibitors among plant lectins chloroquine discussed potential treatment covid<NUMBER> included <NUMBER> hypothesis tested later merscov epidemic coronaviruses enveloped viruses spike proteins present surface responsible virus entry target cell <NUMBER> merscov also cause high mortality rate <NUMBER> vaccine available therapeutic options merscov infections limited palliative supportive care search specific antiviral treatments urgently needed <NUMBER> millet et al thought lectins attractive anticoronavirus candidates highly glycosylated nature spike protein tested antiviral effect griffithsin grft lectin isolated red marine alga griffithsia sp merscov infection <NUMBER> demonstrated griffithsin potent inhibitor merscov infection without significant cytotoxicity <NUMBER> griffithsin inhibited entry host cells particles pseudotyped merscov spike protein suggesting griffithsin inhibits spike protein function entry binding step <NUMBER> compounds found elderberries phenolic acids flavonoids vitamins lectins aroma compounds etc <NUMBER> similar lectin called sambucus nigra fruit specific agglutinin snaif identified minor protein ripe elderberry fruits <NUMBER> although elderberry supplements tested current covid<NUMBER> pandemic lectin components might inhibit spike protein function entry binding step mentioned unknown effects currently anyone buy elderberry supplements without prescription overthecounter medicines cause significant harm reason use applied early course disease although reports increase cytokines elderberry supplements <NUMBER> elderberry supplements also various kinds effects surely however also weigh benefit risk use elderberry supplements like otcs know even otcs eg tylenol many adverse effects drug information addition also look evidencebased systematic review elderberry elderflower sambucus nigra natural standard research collaboration <NUMBER> could applied current covid<NUMBER> pandemic point able guide use elderberry supplements general population patients covid<NUMBER> elderberry supplements used covid<NUMBER> early course disease understand previous efficacy potential adverse effects fourth use oral steroids actively considered early course disease cause death covid<NUMBER> ards organ failure due cytokine storm hyperactivated host immune response considering suppress prevent process early course disease think increase various proinflammatory cytokines induced covid<NUMBER> may suppressed shortcourse low dose steroids early stage disease may effective later stage disease ards multiorgan failure situation assimilated forest fire first small fire cigarette butts detected hiker early early covid<NUMBER> extinguished small amounts water kronbichler et al autoimmunity reviews xxx xxxx xxxx low dose steroids easily wild forest fires spread persistent high fever dyspnea mountain without early suppression cannot suppressed despite every effort numerous fire trucks longterm use high dose steroids mountains burned destructed lung requiring ecmo one recent systematic review reporting use steroids may harmful patients covid<NUMBER> <NUMBER> however result interpreted caution quality included studies extremely low many biases many studies missing included studies use steroids vs use result generalized patients early course disease mild symptoms one study investigated structural arrangement n protein explaining first steps interaction nucleic acid initial stages virus structure assembly <NUMBER> nucleocapsid n protein covid<NUMBER> nearly <NUMBER> amino acid sequence identity sarscov n protein antibodies sarscov may cross react covid<NUMBER> may provide crossimmunity similar fashion sarscov n protein covid<NUMBER> may play important role suppressing rna interference rnai overcome host defense <NUMBER> rat models nprotein sarscov pathogenicity could induce obvious pulmonary inflammatory reaction acute lung injury related increase imbalance proinflammatory antiinflammatory cytokines <NUMBER> study glucocorticoids could effectively alleviate pulmonary inflammatory reaction induced nprotein sarscov supporting beneficial role steroids inflammatory reactions caused nprotein current covid<NUMBER> <NUMBER> according chinese governments daily report <NUMBER> patients covid<NUMBER> developed severe fatal illness therefore chinas national health commission released fifth trial version diagnosis treatment scheme pneumonitis covid<NUMBER> provided systematic treatment strategy severe cases systematic corticosteroids treatment methylprednisolone <NUMBER> mg per kg body weight <NUMBER> days recommended adjuvant therapy <NUMBER> zou et al recently showed systematic corticosteroids therapy first <NUMBER> days severe patients could enhance oxygen saturation sao<NUMBER> arterial oxygen tension pao<NUMBER>inspiratory oxygen fraction fio<NUMBER> corticosteroids exert intervention survival ncp patients complicated ards shock multiple organ injury <NUMBER> nevertheless concluded corticosteroids phase ards would effectively inhibit furious inflammatory storm gain valuable time controlling infection preventing secondary multiorgan damage shock implies corticosteroids synergistic biological effects combined intensivists treatment severe fatal ncp patients <NUMBER> however mentioned think increase various proinflammatory cytokines induced covid<NUMBER> may suppressed shortcourse low dose steroids early stage disease may effective later stage disease ards multiorgan failure later stage may big fire cannot suppressed easily one another thing short course low dose oral steroids easily prescribed treatment urticaria afraid prescribing use oral steroids acute covid<NUMBER> setting even though many patients progress severe disease patients mild symptoms severe radiologic findings lower percentage progressing cytokine storm early use steroids even though found statistically nonsignificant pvalue <NUMBER> several patients rescued therefore interpret results based pvalue cautiously conversely misinterpretation misunderstanding pvalue cause significant harm patients covid<NUMBER> recently groups showed beneficial effect hydroxychloroquine <NUMBER> reports evidence hydroxychloroquine coronavirus vitro study <NUMBER> <NUMBER> therefore doctor first used drug patient covid<NUMBER> might done treatment nonevidencebased medicine try oral steroids patients covid<NUMBER> early course disease fifth use oral antibiotics actively considered patient feels good secondary bacterial infection might aggravate acute immunological lung injury induced several cytokines eg il<NUMBER> il<NUMBER> tnfα covid<NUMBER> controlled clinical trials evaluating use empiric antimicrobials covid<NUMBER> patients coronavirus driven diseases therefore recommendations based viral diseases like influenza <NUMBER> furthermore another guideline treating covid<NUMBER> patients released guidelines suggest blind inappropriate use antibacterial drugs especially combination broadspectrum antibacterial drugs avoided patients mild symptoms <NUMBER> however guidelines current covid<NUMBER> situation definitely different usual viral infections patients mild symptoms severe radiologic features sudden death furthermore bacterial superinfection hard detect cannot easily diagnosed symptoms covid<NUMBER> bacterial superinfection may overlap data prevalence bacterial superinfection patients covid<NUMBER> limited <NUMBER> influenza pneumonia often associated staphylococcus aureus coinfection especially virulent <NUMBER> initiating empiric antibacterial therapy adults communityacquired pneumonia test positive influenza recommended recent clinical practice guidelines <NUMBER> therefore suggest according clinical manifestations patients accompanying bacterial infection cannot ruled patients take antibacterial drugs communityacquired pneumonia amoxicillin azithromycin fluoroquinolones <NUMBER> empirical antibacterial treatment severe patients cover possible pathogens deescalating therapy pathogenic bacteria clarified <NUMBER> addition current special situation also considered currently patient diagnosed covid<NUMBER> heshe isolated home recommended severe symptoms developed come hospital medications provided however think dangerous situation persons might mild symptoms despite severe progression lung injury patients become feel dyspnea come hospital time might late recovery receive intravenous antibiotics also various kinds multiple drugs speculate many patients became get severe symptoms might bacterial complications reported bacterial coinfection associated approximately <NUMBER> viral respiratory tract infections requiring hospitalization <NUMBER> incidence bacterial complications covid<NUMBER> unknown yet considering patients covid<NUMBER> get severe symptoms observed respiratory viral diseases speculate bacterial complications might combined severe conditions also mild conditions patient usual respiratory viral infections heshe visit clinic prescribed antibiotics however current situation patient covid<NUMBER> cannot visit usual clinic wait recover get dyspnea virus damages throat lungs bacteria oral cavity cause secondary infection cannot exactly evaluated diagnosed laboratory examinations bacteria culture procalcitonin may exact due false negative bacteria cannot examined situation based medical principle harm waiting patient deteriorate severe harm therefore prevent deterioration patient covid<NUMBER> oral antibiotics oral steroids given patient time covid<NUMBER> recommended patient high fever feels bad take antibiotics steroids empirically acceptable pandemic era many patients dying due complications covid<NUMBER> doctor monitor guide patients phone calls better enough medical personnels current situation liberal early use oral antibiotics steroids may harm may different situation usual common cold situation experiences patient feels bad earlier antibiotics steroids used patients condition recover sixth hydroxychloroquine used secondary drug patients worsening symptoms covid<NUMBER> chloroquine metabolite hydroxychloroquine antimalarial agents demonstrated antiviral effects sarscov sarscov<NUMBER> vitro <NUMBER> <NUMBER> chloroquine inhibitory effects multiple rna viruses vitro chloroquine showed antiviral clinical beneficial effects treatment dengue chikungunya virus infections influenza prophylaxis <NUMBER> news briefing suggested use <NUMBER> patients showed superior control inhibiting exacerbation pneumonia improving lung imaging findings promoting virus negative conversion shortening disease course data published yet <NUMBER> recent consensus document recommended chloroquine phosphate <NUMBER> mg twice daily minimum <NUMBER> days <NUMBER> another study found hydroxychloroquine potent chloroquine vitro based data hydroxychloroquine <NUMBER> days <NUMBER> mg twice daily loading dose <NUMBER> mg recommended <NUMBER> recent systematic review found published studies covid<NUMBER> patients <NUMBER> furthermore adding azithromycin hydroxychloroquine <NUMBER> mg daily treatment seemed beneficial outcome small french cohort <NUMBER> however also cautious interpreting results hydroxychloroquine current situation based vitro studies small number case series also adverse effects hydroxychloroquine also considered situation think hydroxychloroquine used routine treatment covid<NUMBER> condition patients worsens despite use steroids antibiotics hydroxychloroquine used secondary drug seventh policy drug use changed reduce mortality patients usual situation patient visit clinic frequently according condition therefore steroids antibiotics given timely based judgement doctors however pattern examination diagnosis treatment cannot done covid<NUMBER> era doctors prescriptions surely important diagnose treat patients however mentioned patients waiting recovery deterioration severe symptoms treatment done meanwhile patient infected occur covid<NUMBER> gets fever visit different clinics treatment standardized among doctors doctor concerns fever nature rapid deterioration covid<NUMBER> may use steroids antibiotics early doctors may make guidelines practical use antibiotics steroids hydroxychloroquine patients use drugs also include benefit adverse effect drug policy proposing give drugs patients freely although range drug also discussed korea diagnosis covid<NUMBER> done drive suggestion make another drive place give drugs patients avoid dissemination infection infected patient go hospital treatment heshe infect patients also good drugs given patient visiting screening clinic example time drive diagnosis explain detail benefit adverse effect drug doctor check result covid<NUMBER> guides patient taking drugs phone calls also patient take drugs hisher judgement concept based <NUMBER> treatment covid<NUMBER> established <NUMBER> even though patient visits doctor treatment patterns different among doctors <NUMBER> steroids frequently used mild diseases urticaria <NUMBER> exactly know presence absence secondary infection patient get fever oral antibiotics <NUMBER> days acceptable treatment routine clinical practice <NUMBER> hydroxychloroquine also given patients recommended patients symptoms worsen despite use steroids antibiotics heshe take hydroxychloroquine recognizing adverse effect drug symptoms worsen patient surely visit hospital well covid<NUMBER> causing severe public health emergency mortality rapidly increasing word era suggested <NUMBER> recommendations rescue patients reduce morbidity mortality due covid<NUMBER> based immunological point view table <NUMBER> may personal opinions believe may beneficial control complications exerted covid<NUMBER> addition conflicting evidences publications regarding opinions however would like remind basic principle treatment patients often forget harm think deeply harm harm addition would like say something better nothing acceptable level clinical practice hope opinions transferred cdc also clinicians researchers many institutions covid<NUMBER> could finished rapidly possible result <NUMBER> sarscov epidemic china created rapidresponse infectious disease reporting system unfortunate delay recognizing early cases december <NUMBER> new sarslike outbreak rapid spread covid<NUMBER> hubei beyond <NUMBER> incubation period covid<NUMBER> ranges <NUMBER> <NUMBER> days <NUMBER> <NUMBER> <NUMBER> covid<NUMBER> cases spread person person symptoms appear thus emphasizing difficulty containing spread importance testing virus well importance control measures reduce spread virus hand washing social distancing use face masks <NUMBER> furthermore people initially asymptomatic may remain asymptomatic serve spread infection throughout community although report china stated majority tested initially found asymptomatic went develop covid<NUMBER> <NUMBER> clinical manifestations represent wide spectrum disease ranging mild severe respiratory syndrome influenzalike illness mainly lower respiratory tract symptoms complicated pneumonia acute respiratory distress syndrome ards high fever headache <NUMBER> many cases loss taste smell severe gastrointestinal symptoms reported cardiac problems latter perhaps secondary cytokine storm seen severely affected patients <NUMBER> <NUMBER> <NUMBER> based data china approximately <NUMBER> people infected covid<NUMBER> present mild moderate disease may include pneumonia <NUMBER> severe disease blood oxygen saturation յ<NUMBER> <NUMBER> critical respiratory failure septic shock andor serious multipleorgan dysfunction failure <NUMBER> elderly persons multiple comorbidities cancer cardiovascular disease diabetes immunosuppressive diseases higher risk acquiring infection developing complications likely succumb infection <NUMBER> <NUMBER> case fatality rate estimated range <NUMBER> <NUMBER> countrytocountry variability likely inaccurate data reported many countries true number infected persons unknown due inadequate testing <NUMBER> <NUMBER> <NUMBER> public health perspective important health care workers public aware resilience virus reported new england journal medicine aerosol form leaves human host sarscov<NUMBER> virus halflife <NUMBER> <NUMBER> h range similar seen sarscov<NUMBER> <NUMBER> however halflife sarscov<NUMBER> metal plastic much longer halflife <NUMBER> h stainless steel less copper cardboard halflife <NUMBER> h plastic thus appropriate care needs taken handling cleaning disinfectant potentially viruscontaminated packages containers <NUMBER> addition potential presence asymptomatic carriers sarscov<NUMBER> community experiences covid<NUMBER> pandemic point clearly need impose social distancing wearing face masks cancellation public events including sports religious gatherings thus limiting slowing spread pandemic article discuss current status treatment prevention covid<NUMBER> lessons far learnt therefore help world prepare future pandemics global pandemic lessons learnt first <NUMBER> months <NUMBER> rapid rise number cases covid<NUMBER> rapid global spread first case officially confirmed wuhan <NUMBER> december <NUMBER> cases reported several countries asia europe north america australia new zealand end january <NUMBER> covid<NUMBER> first reported middle east february <NUMBER> south america africa south pacific countries march <NUMBER> may <NUMBER> <NUMBER> million cases covid<NUMBER> <NUMBER> deaths <NUMBER> million recoveries reported <NUMBER> <NUMBER> <NUMBER> absence vaccine drugs known effectiveness sarscov<NUMBER> coronavirus highly variable response threat covid<NUMBER> china south korea taiwan vietnam offer success stories control spread disease main lesson experiences aggressive early action critically important china rolled ambitious agile aggressive disease containment effort history although experiencing ͼ<NUMBER> cases ͼ<NUMBER> deaths date seems controlled spread covid<NUMBER> although china pursuing equally vigorous regimen prevent second wave infections result citizens returning overseas strategy underpinned containment effort initially national approach promoted universal temperature monitoring masking hand washing <NUMBER> <NUMBER> january <NUMBER> chinese government announced lockdown city wuhan population <NUMBER> million <NUMBER> <NUMBER> point total number known cases china <NUMBER> soon lockdown expanded <NUMBER> cities covering whole hubei province population <NUMBER> million described actions taken china unprecedented public health history taiwan based countrys experience earlier sarscov outbreak established taiwanese national health command center <NUMBER> well prepared contain spread covid<NUMBER> immediately informed covid<NUMBER> outbreak <NUMBER> december <NUMBER> taiwan officials began checking incoming airline passengers wuhan proactive testing appropriate quarantine <NUMBER> <NUMBER> may <NUMBER> taiwan population approximately <NUMBER> million reported ͻ<NUMBER> cases <NUMBER> deaths <NUMBER> <NUMBER> similarly south korea took aggressive action manifested early testing hundreds thousands people tracking isolation infected individuals even using smartphone gps technology <NUMBER> similar approaches considered past united kingdom fluphone date reluctance disinterest respect accepting might considered breach privacy <NUMBER> south korea also introduced drivethrough testing covid<NUMBER> achieved rates testing approximately <NUMBER>day representing approach envied beginning copied rest world result south korea first wave covid<NUMBER> infection receding situation seems control based experiences china south korea argued government action may initially seen excessive unjustified possibly overly invasive individual rights essential thus stringent controls benefits controlling spread pandemic reducing mortality vietnam example country limited resources proactive responding covid<NUMBER> case taiwan ministry health hospitals clinics well prepared country recorded first case january <NUMBER> <NUMBER> authorities vietnam checked passengers airports restricted movement necessary followed possible contacts closed schools <NUMBER> may <NUMBER> administered ͼ<NUMBER> tests virus recorded <NUMBER> cases <NUMBER> <NUMBER> among nonasian countries new zealand stands low number cases <NUMBER> may <NUMBER> stood ͻ<NUMBER> cases <NUMBER> per million capita <NUMBER> deaths <NUMBER> <NUMBER> new zealand also proactive checking incoming airline passengers requiring returning citizens selfquarantine tracing contacts finally locking country interestingly majority covid<NUMBER> cases occurred clusters ϳ<NUMBER> individuals suggesting contact tracing may completely effective many countries covid<NUMBER> spread quickly devastating effects iran one hardest hit covid<NUMBER> infections failure restrict travel early stage outbreak lack availability hospital supplies due usinitiated sanctions may contributing factors <NUMBER> <NUMBER> <NUMBER> march number countries europefirst italy next spain united kingdomsoon rivaled surpassed china epicenters covid<NUMBER> overtaken united states cases skyrocketed end march <NUMBER> italy first case identified lombardy region northern italy early february <NUMBER> infected individual recent visitor china however second case confirmed <NUMBER> february <NUMBER> person prior contact first case recently visited china many cases quickly confirmed indicating covid<NUMBER> already widely spread community availability testing difficulties containing spread virus undoubtedly contributed rapid increase confirmed cases deaths although clear answer high case mortality rate italy ͼ<NUMBER> <NUMBER> may <NUMBER> <NUMBER> <NUMBER> age may one factor citizens italy represent second oldest population world japan approximately <NUMBER> population <NUMBER> higher mortality care homes may also factor problem reported several countries regardless comparison age profiles covid<NUMBER> cases deaths italy versus china distinct differences noted although mortality increases age case mortality rates lower chinese population <NUMBER> china mean age died reported <NUMBER> years suffering least one comorbidity approximately <NUMBER> covid<NUMBER> disease <NUMBER> years old whereas <NUMBER> people <NUMBER> died disease <NUMBER> lesson also learnt community vò northern italy aggressive contact tracing used seek identify asymptomatic infected individuals ϳ<NUMBER> members community tested resulting much better control infections <NUMBER> germany despite identified high number confirmed cases covid<NUMBER> <NUMBER> may <NUMBER> managed keep casefatality rate much lower seen either italy spain ϳ<NUMBER> versus ϳ<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> answer would seem proactive testing program utilizing large network independent laboratories started testing early january <NUMBER> factors including number available hospital beds lower population age italy may also contributed <NUMBER> united kingdom government initially hoped development herd immunity would reduce impact covid<NUMBER> british government also depended upon public cooperation restrict travel <NUMBER> march <NUMBER> late prime minister announced people would allowed homes nonessential reasons police power impose fines offenders similarly united states despite first case recorded washington state <NUMBER> january <NUMBER> initial dismissal federal level severity risks covid<NUMBER> initial problems accuracy cdcs covid<NUMBER> test kit consequence infection rapidly spread least part due us citizens returning primarily europe already infected <NUMBER> number factors might also contribute differences infection fatality statistics thus based genomic analysis <NUMBER> genomes rom genbank two distinct strains sarscov<NUMBER> reported l type prevalent early stages breakout wuhan also aggressive evolutionary older type <NUMBER> however supportive evidence produced indicating strain differences explain differing countrytocountry mortality rates also argued seasonal flu prevalent winter months wanes warmer weather arrives evidence weather would dramatically affect spread covid<NUMBER> example countries singapore spared covid<NUMBER> number cases per million similar rate sweden <NUMBER> <NUMBER> another factor may relate differences vaccination requirements country country particular interest whether mycobacterium bovis bcg bacille calmette guérin vaccine tuberculosis provides protection covid<NUMBER> thus countries without national requirement policy dropped requirement france italy spain netherlands united states comparatively high infection case fatality rates covid<NUMBER> whereas countries china japan policy requiring vaccination newborns report much lower levels <NUMBER> whether causeandeffect relationship different strains sarscov<NUMBER> weather bcg vaccination infection susceptibility covid<NUMBER> requires careful retrospective epidemiological evidence require analysis finally differences reporting covid<NUMBER> deaths may distort statistics evident apparent omission dying care homes well deaths due morbidities may attributed covid<NUMBER> benefit lessons covid<NUMBER> <NUMBER> sarscov epidemic world sensitized necessity fast response contain future zoonotic infections recognition threat china established nationwide webbased automated system reporting responding infections <NUMBER> unfortunately covid<NUMBER> still managed catch world flatfooted lack preparedness many countries rapidly became apparent however better prepare next potentially equally lethal outbreak recommendations include following <NUMBER> establishing rapid reporting system unusual infectious outbreak eg pneumonia unknown origin immediately reported national health organization appropriate investigation action notification high priority <NUMBER> immediately isolating infected persons identifying quarantining individuals contact infected persons crucial <NUMBER> case covid<NUMBER> wuhan spread virus occurred within local community essential initiate rigorous attempt identify persons might contact infected individuals appropriate testing potential quarantine immediate lockdown town area also considered rigorous pursuit contacts extremely important learnt covid<NUMBER> many infected individuals may show symptoms disease could become super spreaders <NUMBER> spread infection longer localized steps taken impose social distancing limit travel limit public gatherings including sporting religious events quarantine impose actions better contain spread pathogen lessons learnt covid<NUMBER> actions require <NUMBER> cooperation public strong endorsement necessary enforcement governments clearly evident countries <NUMBER> case covid<NUMBER> early genomic identification causative pathogen important facilitate determining developing optimal treatment options <NUMBER> vaccine development could enhanced pursuing progress clinical trials made earlier vaccines developed instance sarscov basis vaccines may also benefit patients infected related pathogen coronavirus help facilitate development new vaccines <NUMBER> enhancing drug development programs undertaken would serve identify establish preclinical testing candidate molecules effective coronaviruses potential zoonotic viruses <NUMBER> establishing global network mandate ensure sufficient personal protective equipment hospital equipment available affected countries deal pandemic also performed constrain global spread pandemic discussed asian countries china including hong kong south korea taiwan generally fared better european countries united states respect containing spread covid<NUMBER> attributed part proactive measures taken control proactively test covid<NUMBER> however another significant difference western asian countries wearing face masks practice countries example china south korea japan already common almost ubiquitous even absence known infection contrast west assumed individual wearing face mask infected individual possibly subjected harassment furthermore west argument made absence evidence wearing nonn<NUMBER> surgical mask would provide protection covid<NUMBER> encouraging asymptomatic noninfected people wear face masks would strain personal protective equipment supply train reduce availability health care personnel however stressed priority governments ensure adequate stocks personal protective equipment maintained thus shortages occur interestingly correctly stated feng et al <NUMBER> reference benefits wearing face mask however essential distinction absence evidence evidence absence indeed proof provided wearing surgical mask reduce droplet transmission infected people <NUMBER> course surgical masks routinely worn hospital personnel treating patients assumption made likely reduce infections transmitted patients health care personnel vice versa interestingly many countries reversed recommendations wearing face masks require use undoubtedly appropriate decision reduce infection transmission sarscov<NUMBER> group silent asymptomatic carriers noninfected public treatment <NUMBER> january <NUMBER> sarscov<NUMBER> genome sequenced chinese researchers made available genbank yongzhen zhang shanghai public health clinical center school public health fudan university <NUMBER> sarscov<NUMBER> rna molecule <NUMBER> bases encoding <NUMBER> amino acids containing <NUMBER> genes one gene codes spike glycoprotein located surface viral envelope responsible binding hosts cell via receptor humans angiotensin ang converting enzyme <NUMBER> ace<NUMBER> <NUMBER> <NUMBER> significance <NUMBER> homology sarscov<NUMBER> sars viruses external binding domain virus spike protein <NUMBER> may importance respect assuming drugs proved least potentially successful used treat sars mers patients might effective might entirely ineffective sarscov<NUMBER> <NUMBER> currently specific therapeutic agents preventive vaccines available approved covid<NUMBER> furthermore anticipated despite unprecedented research activity vaccine available <NUMBER> <NUMBER> however number drugs approved diseases tried patients sarscov merscov evaluated treatment covid<NUMBER> drugs include remdesivir baricitinib chloroquine hydroxychloroquine interleukin<NUMBER> il<NUMBER> receptor monoclonal antibody tocilizumab antiinfluenza drugs favipiravir umifenovir <NUMBER> <NUMBER> advantage investigating drugs already extensive knowledge base respect use safety humans however also case vaccines essential despite urgency introduction new therapies rushed expense safety <NUMBER> first among drugs considered use treatment covid<NUMBER> chloroquine first synthesized bayer pharmaceuticals germany <NUMBER> advantage generic inexpensive shows good bioavailability given orally chloroquine first used <NUMBER>s treat malaria also successfully used autoimmune diseases rheumatoid arthritis lupus drugs immunosuppressive effects proinflammatory cytokines tumor necrosis factor alpha tnf␣ il<NUMBER> beneficial examples toxicity chloroquine well known central nervous system cns side effects macular retinopathy serious however chloroquine used acutely covid<NUMBER> treatment risk side effects considerably less hydroxychloroquine also effective malaria lupus rheumatoid arthritis use diseases associated significant cardiovascular side effects hydroxychloroquine also advantage doses higher appropriate chloroquine could used antiviral purposes nonetheless concerns cardiac toxicity ignored particularly use covid<NUMBER> promoted appropriate testing used patients preexisting cardiovascular disease chloroquine hydroxychloroquine direct inhibitory effects cardiac sodium potassium channels albeit high doses potential cardiac toxicity critical evidence emerged sarscov<NUMBER> may directly negatively affect cardiac function perhaps result downregulation ace<NUMBER> andor secondary cytokine storm <NUMBER> hydroxychloroquine good bioavailability long halflife ϳ<NUMBER> <NUMBER> days metabolized via cytochrome p<NUMBER>s cyp<NUMBER> azithromycin macrolide antibiotic used combination hydroxychloroquine several clinical trials azithromycin cyp<NUMBER>inhibitory effects therefore may reduce metabolism hydroxychloroquine also precipitate cardiac arrhythmias via ability prolong qt interval thus combination two drugs may result accumulation hydroxychloroquine toxic levels trigger fatal arrhythmia addition serious concerns hydroxychloroquine also used lupus rheumatoid arthritis diverting use covid<NUMBER> may seriously affect availability drug patients treated autoimmune diseases mechanisms antiviral actions chloroquine hydroxychloroquine fully understood however known vitro studies basic lysosomotropic drugs pk ϳ<NUMBER> become trapped acidic endosomes alkalinizing organelle thereby interfere phdependent entry viruses including coronaviruses endolysosomal pathway <NUMBER> chloroquine may also interfere glycosylation cell membrane receptor coronavirus ace<NUMBER> thus preventing binding cellular entry virus shown vitro sarscov <NUMBER> <NUMBER> number clinical trials way early preliminary data china demonstrated benefits <NUMBER> patients pneumonia treatment chloroquine resulted elimination virus improved recovery time compared standardofcare treatment soc <NUMBER> chloroquine included <NUMBER>th version guidelines prevention diagnosis treatment novel coronavirusinduced pneumonia issued national health commission nhc peoples republic china another clinical trial french researcher didier raoult marseille reported <NUMBER>day treatment hydroxychloroquine plus azithromycin antibiotic azithromycin included reduce complications secondary bacterial infections performed initially <NUMBER> patients later <NUMBER> patients covid<NUMBER> improved recovery reduced viral load <NUMBER> however small nonrandomized unblinded trials confirmative results required larger appropriately randomized controlled studies one randomized trial discovery launched europe compare effectiveness hydroxychloroquine plus standard care versus standard care alone arms study effectiveness remdesivir lopinavir plus ritonavir lopinavir plus ritonavir plus interferon beta <NUMBER> interestingly results multicenter openlabel randomized trial <NUMBER> patients china treated hydroxychloroquine versus soc <NUMBER> days demonstrate relief symptoms hydroxychloroquine group reported significantly higher levels side effects <NUMBER> versus <NUMBER> <NUMBER> treatment hydroxychloroquine however lower creactive protein crp levels thus supporting antiinflammatory action drug collectively based current evidence available positive data insufficient demonstrate treatment hydroxychloroquine would benefit covid<NUMBER> patients despite current lack conclusive positive medical evidence covid<NUMBER> patients treated hydroxychloroquine united states provisions emergency use authorization second baricitinib smallmolecule janus kinase jak inhibitor currently approved treatment rheumatoid arthritis viruses mentioned discussion putative antiviral effects chloroquine infect cells via cell surface receptormediated endocytosis sarscov<NUMBER> receptor ace<NUMBER> endocytosis regulated kinases including ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> baricitinib inhibits aak<NUMBER> <NUMBER> arguably baricitinib disrupt ace<NUMBER>mediated sarscov<NUMBER> endocytosis entry cells within therapeutic plasma concentration range used rheumatoid arthritis therefore baricitinib postulated another candidate clinical trials treat covid<NUMBER> <NUMBER> <NUMBER> third remdesivir developed treat infections due ebola virus use pursued remdesivir prodrug administered via intravenous iv infusion active metabolite adenosine nucleoside analog inhibits action viral rna polymerase thereby preventing viral replication remdesivir shown effective vitro mouse model sarscov appears possess fairly broad anticoronavirus activity <NUMBER> several clinical trials way asia china united states study efficacy safety remdesivir including nihsponsored randomized controlled trial university nebraska medical center omaha one small nonrandomized multicenter trial <NUMBER> patients remdesivir reported clinical improvement <NUMBER> <NUMBER> patients data could analyzed however control group high number side effects serious side effects reported <NUMBER> patients <NUMBER> fourth ritonavir lopinavir two protease inhibitors widely used haart highly active antiretroviral therapy regimens ritonavirboosted protease inhibitor treatment hiv ritonavir protease inhibitor also inhibitor cytochrome p<NUMBER>a<NUMBER> thereby reduces metabolism enhances prolongs action second protease inhibitor case lopinavir protease inhibitors prevent viral replication virtue blocking proteolytic cleavage precursor proteins required virus <NUMBER> ritonavirlopinavir combination previously shown effective vitro animal model middle east respiratory syndrome mers clinical trial way assess effectiveness mers <NUMBER> <NUMBER> furthermore reported case study south korea patient treated ritonavir plus lopinavir displayed reduced viral loads improved clinical symptoms however recognized recovery may simply reflect natural course disease regression norm <NUMBER> randomized controlled openlabel study <NUMBER> covid<NUMBER> patients chinas jin yintan hospital wuhan led conclusion combination ritonavir plus lopinavir provide sufficient benefits standard care including reduction viral rna load <NUMBER> days study <NUMBER> studies needed however therapies directed viral replication may prove effective early stages covid<NUMBER> significant pneumonia symptoms developed fifth antiinfluenza drug favipiravir orally effective prodrug developed japan approved <NUMBER> treatment influenza differs neuraminidase inhibitors oseltamivir zanamivir inhibits viral rnadependent rna polymerase midmarch <NUMBER> china announced favipiravir shown good clinical efficacy covid<NUMBER> <NUMBER> however remains clarified stage infection covid<NUMBER> favipiravir effective another influenza drug repurposed russia china umifenovir often referred brand name arbidol believed prevent virus entry cell inhibiting membrane fusion scientific support antiviral efficacy umifenovir sparse however approved fda treatment influenza another drug interest antiparasitic drug ivermectin vitro data suggest potential benefits however based pharmacokinetic evidence dose required demonstrate vivo efficacy covid<NUMBER> treatment humans would likely prove toxic use <NUMBER> camostat promising drug approved japan pancreatitis reflux esophagitis targets serinethreonine protease tmprss<NUMBER> tmprss<NUMBER> protease utilized sarscov<NUMBER> prime spike protein facilitate binding ace<NUMBER> entry cell camostat reported inhibited sarscov<NUMBER> entry human epithelial cells vitro assay clinical trials initiated <NUMBER> approaches pursued include use cytokine interferon ␤ applied inhalation directly lungs activate immune response medicines healthcare products regulatory agency mhra health research authority hra <NUMBER> approved fasttracked phase<NUMBER> trial interferon ␤ united kingdom one drugs whose use either alone combinations lopinavirritonavir studied treating coronavirus diseases <NUMBER> serum therapy also consideration whereby antibodies plasma recovered covid<NUMBER> patients human convalescentphase serum used combat infection severely infected patients therapy used previously instance <NUMBER> <NUMBER> h<NUMBER>n<NUMBER> influenza virus pandemic <NUMBER> <NUMBER> severely ill covid<NUMBER> patients cytokine storm major contributor high mortality rate tocilizumab humanized monoclonal antibody soluble membranebound forms interleukin<NUMBER> il<NUMBER> receptor used success drugs discussed larger trials required appropriate controls sciencebased recommendations use made <NUMBER> inhibitors reninangiotensinaldosterone system raas used extensively treatment cardiovascular disease beneficial many patients comorbidities hypertension diabetes help protect renal function ace<NUMBER> ubiquitously expressed highest levels detected lungs cardiovascular system kidneys gastrointestinal system ace<NUMBER> serves key receptor cellular entry sarscov<NUMBER> also aminopeptidase cleaves angiotensin ang angiotensin ii ang ii ang<NUMBER> ang<NUMBER> ang<NUMBER> ang<NUMBER> peptides critically ang<NUMBER> signaling via mas receptor cardiovascular protective activity reducing levels ang ii thus loss ace<NUMBER> would expected increase risk patient particularly comorbidities epidemiological evidence covid<NUMBER> indicates elderly comorbidities higher mortality rate many likely already treated drugs target raas underlying cardiovascular diseases controversy however arisen regard whether patients treated specifically angiotensin converting enzyme <NUMBER> inhibitors aceis ang ii receptor <NUMBER> blocker inhibitors arbs protected higher risk covid<NUMBER> ace<NUMBER> downregulated sarscov loss ace<NUMBER> may factor contributing pulmonary dysfunction treatment aceis arbs arguably though without reproducible evidence increase ace<NUMBER> levels result redirecting ang <NUMBER> ang ii ang <NUMBER> ang<NUMBER> respectively thus prove protective covid<NUMBER> conversely increasing ace<NUMBER> activity treatment aceis arbs might enhance sarscov<NUMBER> entry exacerbate covid<NUMBER> lung pathology use recombinant ace<NUMBER> protein proposed potential therapeutic approach treat covid<NUMBER> ace<NUMBER> protein acting decoy receptor sarscov<NUMBER> <NUMBER> arguments use aceis arbs presence covid<NUMBER> reviewed leading conclusion based available evidence given risk reduction benefits continued treatment aceis arbs reason switch treatment patients remain current therapy <NUMBER> <NUMBER> information undoubtedly become available contribution traditional chinese medicine tcm therapeutic management sars evaluated result extensive use sarscov although evidence reduced morbidity mortality possibly linked antiinflammatory effects design studies fact treatment tcm often combined western medicines make difficult arrive definitive conclusions respect individual effectiveness tcms <NUMBER> sarscov<NUMBER> estimated <NUMBER> covid<NUMBER> patients china treated tcms <NUMBER> prospect new drugs specific sarscov<NUMBER> previously noted <NUMBER> homology sarscov<NUMBER> spike protein sars viruses <NUMBER> thus efforts directed identifying lead molecules specifically target sarscov<NUMBER> viruss proteases mpro one target since known human homologues prove specific viruss replication machinery <NUMBER> symptomatic treatment patients covid<NUMBER> present fever many headache drug choice needed antipyretic analgesic actions paracetamol acetaminophen paracetamol true nonsteroidal antiinflammatory drug nsaid lacks antiinflammatory antiplatelet anticoagulant effects nsaids also gastrointestinal sparing gastrosparing therefore avoids potential problems might present patients comorbidities may also present severe gastrointestinal symptoms covid<NUMBER> disease concerns presented french officials respect use nsaids patients severe lung infections seen covid<NUMBER> antiinflammatory actions may suppress patients immune response stated european medicines agency currently scientific evidence support argument <NUMBER> noted use cox<NUMBER> selective drugs coxibs celecoxib nonaspirin nsaids associated increase cardiovascular risk thus use drugs patients cardiovascular disease covid<NUMBER> evaluated basis risk versus benefit <NUMBER> vaccine prospective currently vaccine available prevent infection sarscov<NUMBER> however several lines evidence suggesting development vaccine sarscov<NUMBER> achievable including following <NUMBER> group researchers australia examined immune response <NUMBER>yearold female experiencing mildtomoderate symptoms covid<NUMBER> <NUMBER> showed recruitment immune cell populations activated cd<NUMBER> ϩ cd<NUMBER> ϩ cells together igm igg sarscov<NUMBER>binding antibodies patients blood resolution symptoms data indicate robust multifactorial immune responses elicited response sarscov<NUMBER> infection <NUMBER> <NUMBER> study involving four rhesus macaques found contracting sarscov<NUMBER> protected future reinfections <NUMBER> researchers reinfected two four monkeys virus <NUMBER> days initial infection total <NUMBER> nasopharyngeal anal swabs tested negative reexposure monkeys sarscov<NUMBER> data obtained following euthanasia necropsy one two monkeys confirmed results <NUMBER> data suggest immune response developed <NUMBER> animals protected future exposure sarscov<NUMBER> <NUMBER> hoffmann colleagues <NUMBER> <NUMBER> passive immunization convalescent sera containing antibodies patients recovered covid<NUMBER> could prevent covid<NUMBER> infection evidence supporting benefits using convalescent plasma covid<NUMBER> provided china includes radiological resolution reduction viral loads improved survival <NUMBER> several efforts way devise new vaccines phase <NUMBER> clinical trials ongoing united kingdom united states germany france china first one taking place kaiser permanente washington health research institute seattle wa <NUMBER> trial <NUMBER> healthy volunteers receive vaccine contains segment genetic code copied sarscov<NUMBER> vaccine contain actual sarscov<NUMBER> participants develop covid<NUMBER> stage main purpose trial confirm safety vaccine might take <NUMBER> <NUMBER> months vaccine deployed preventive vaccine covid<NUMBER> <NUMBER> moderna inc cambridge usa developing mrnabased vaccine mrna<NUMBER> codes appropriate coronavirus proteins vaccine injected body immune cells lymph nodes process mrna start immediately making protein recognized marked destruction <NUMBER> another mrnabased vaccine developed curevac biotech company tübingen germany plans enter human clinical trial june <NUMBER> <NUMBER> united kingdom sarah gilbert colleagues oxford university begun human animal trial chadox<NUMBER> vaccine expect available end <NUMBER> <NUMBER> china recombinant vaccine developed cansino biologics collaboration academy military medical sciences clinical trial begun among volunteers <NUMBER> <NUMBER> years age <NUMBER> conclusion still unclear true mortality rate covid<NUMBER> clear elderly comorbidities cardiovascular disease diabetes cancer immunosuppressionrelated diseases greater risk however unknown fact percentage people mild symptoms perhaps attributed flu misdiagnosed therefore omitted tested possibly mortality prove high reflected reports hopefully prove closer <NUMBER> become clearer coming months also apparent overall global response covid<NUMBER> inadequate considerable differences rapidly appropriately different nations responded deficiencies emphasize need greater collaboration well benefits testing disease timely manner contact tracing suspected carriers containing spread limiting movement people within regions valuable lessons learnt considerable cost appropriate quote bill gates <NUMBER> ted talk also published new england journal medicine <NUMBER> perhaps good news tragic ebola epidemic guinea sierra leone liberia may serve wakeup call must prepare future epidemics diseases may spread hopefully <NUMBER> lessons learnt covid<NUMBER> stimulate collaborative global effort greater focus better control future pandemics development new drugs vaccines target potential zoonotic diseases additional relatively rare exclusion criteria included hydroxychloroquine allergy retinal eye disease glucose<NUMBER>phosphate dehydrogenase g<NUMBER>pd deficiency chronic kidney disease stage <NUMBER> <NUMBER> receiving dialysis porphyria weight less <NUMBER> kg receiving chemotherapy concurrently using hydroxychloroquine azithromycin cardiac arrhythmia medications canada additional exclusions consisted pregnancy breastfeeding severe diarrhea vomiting known cirrhosis encephalopathy ascites known prolonged cardiac qt interval ventricular arrhythmia history sudden cardiac death qtprolonging medicines <NUMBER> april <NUMBER> <NUMBER> us food drug administration fda required additional exclusions structural ischemic heart disease personal family history cardiac qt prolongation qtprolonging medications weight less <NUMBER>kg concomitant medication exclusion criteria included current use • hydroxychloroquine chloroquine • cardiac medicines flecainide amiodarone digoxin procainamide sotalol • qt prolonging medicines clinically compatible symptoms one following exposures <NUMBER> days onset symptoms close contact person diagnosed covid<NUMBER> travel residence area sustained ongoing community transmission sarscov<NUMBER> member risk cohort defined public health authorities outbreak close contact person diagnosed covid<NUMBER> whereby close contact defined within <NUMBER> feet period <NUMBER> minutes <NUMBER> minutes depending upon exposure healthcare settings may defined exposures greater minutes data insufficient precisely define duration exposure constitutes prolonged exposure thus close contact enrolled persons reported household occupational contact <NUMBER> feet <NUMBER> minutes levels risk defined high risk eye shield facemask respirator moderate risk eye shield however simple surgical facemask respirator used low risk persons wearing eye shield facemask respirator enrolled trial persons contact <NUMBER> minutes <NUMBER> feet distance enrolled trial priori assumption designing internetbased trial <NUMBER> lost follow responding email surveys coinvestigators emailed texted called participants andor nextofkin attempt assess vital status <NUMBER> isolated symptoms headache n<NUMBER> diarrhea n<NUMBER> nasal congestion n<NUMBER> diffuse pruritic maculopapular rash lasting <NUMBER> days n<NUMBER> nasal congestion rhinorrhea n<NUMBER> one case nasal congestion rhinorrhea lab confirmed pcrpositive <NUMBER> surveys directly query chills rigors free text field symptoms case numbers include assignment free text descriptions similar symptom terminology <NUMBER> us case definition possible cases actually considered probable case due epidemiologic linkage possible classification used distinguish robust symptomcomplex presentation cases pcr epidemiologic linkage four adjudicated possible cases using clinical case definition alone pcr positive ie definitive covid<NUMBER> isolated symptoms fatigue n<NUMBER> myalgia n<NUMBER> anosmia lack taste n<NUMBER> excluding <NUMBER> possible cases one covid<NUMBER> compatible symptom without lab confirmation incidence new covid<NUMBER> differ receiving hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> versus placebo <NUMBER> <NUMBER> <NUMBER> p<NUMBER> <NUMBER> symptoms could possibly occur covid<NUMBER> diarrhea headache also overlap side effect profile hydroxychloroquine particularly symptoms occurred <NUMBER> days study medicine administration stopped day <NUMBER> blinded adjudication process thought isolated symptoms less compatible covid<NUMBER> compatible medication side effects diarrhea occurred persisted <NUMBER> days considered possible adjudications blinded study arm total number symptoms study arm presented manuscript table <NUMBER> inclusion new selfreported possible covid<NUMBER> symptoms ie without adjudication narrows events observed hydroxychloroquine placebo groups <NUMBER> vs <NUMBER> p<NUMBER> events adjudicated probable covid<NUMBER> compatible illness us case definition also consistent world health organization case definition <NUMBER> used us clinical case classification basis adjudication <NUMBER> participants met classification symptoms complex probable <NUMBER> covidrelated symptom possible noncovid symptoms part case definition noncases four infectious diseases physicians discussed ahead time use case definition obtained consensus case definition adjudications adjudications straight forward counting pcr cough dyspnea <NUMBER> nonpulmonary covid symptoms <NUMBER> <NUMBER> events ie confirmed probable covid<NUMBER> per case definition main role adjudication translating freetext descriptions nearest symptom example difficulty breathing counted shortness breath category events adjudicated noncovid case definition isolated symptoms headache n<NUMBER> diarrhea n<NUMBER> receiving study medication nasal congestion n<NUMBER> diffuse pruritic maculopapular rash lasting <NUMBER> days n<NUMBER> nasal congestion rhinorrhea n<NUMBER> nasal congestion rhinorrhea turned pcr positive ie confirmed final diagnosis rash could covid based emerging dermatology case series info conservatively viewed likely drugallergy final adjudications based information provided table s<NUMBER> possible cases defined herein clinical trial also officially meet us clinical case definition probable covid<NUMBER> due epidemiologic linkage pcrpositive index case compatible illness <NUMBER> distinction made within manuscript separate possible probable cases due robust symptom complex probable cases overall <NUMBER> participants reported diarrhea questioning diarrhea detailed frequency selfidentified thus aware defined per strict research definition diarrhea free text descriptions varied loose stool significant <NUMBER> stools per day distribution diarrhea association symptoms follows  <NUMBER> cases also pulmonary symptoms cough n<NUMBER> shortness breath n<NUMBER>  <NUMBER> cases reported diarrhea without pulmonary symptoms <NUMBER> associated <NUMBER> symptoms fever n<NUMBER> headache n<NUMBER> sore throat n<NUMBER> fatigue n<NUMBER> myalgia n<NUMBER> probable cases per clinical case definition without diarrhea informing case adjudication <NUMBER> associated rhinorrhea possible case <NUMBER> prolonged continuing discontinuation study medicine associated abdominal cramping possible case <NUMBER> diarrhea loose stool alone within first <NUMBER> days rated noncases due possible side effects study medicine adjudications blinded study arm relative risk zinc use <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> relative risk vitamin c use <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> observational comparisons may suffer confounding indication deemed highest risk developing infection may likely additionally take either zinc vitamin c regardless suggestion zinc added hydroxychloroquine additional benefit among randomized hydroxychloroquine taking zinc <NUMBER> incidence new covid<NUMBER> versus <NUMBER> incidence new covid<NUMBER> without selfreported zinc use zinc received great deal attention potential adjunctive therapy used hydroxychloroquine <NUMBER> vitro study xue et al used human ovarian carcinoma cell culture examine interaction chloroquine ionic zinc <NUMBER> xue found chloroquine acts zinc ionophore increasing cellular uptake zinc culture media increasing cytotoxic effect chloroquine cause death cancer cells levels <NUMBER>fold higher would achieved plasma trials dosing <NUMBER> <NUMBER> importantly lab experiment designed emulate zinc levels average human body cell culture media started minimal zinc north americans low prevalence inadequate dietary zinc intake <NUMBER> prevalence <NUMBER> based subgroup analysis found evidence supplementary zinc intake effect incidence new covid<NUMBER> compatible illness highrisk exposure exact details zinc formulation dose duration queried conclusive information values n median iqr internet search discover obituaries lost follow unknown vital status nonhealthcare nonhousehold contact occupational exposure number covid<NUMBER> symptoms based april <NUMBER> <NUMBER> us clinical case definition <NUMBER> labconfirmed cases reported pcr confirmation number covid<NUMBER> symptoms limited cough shortness breath fever myalgia fatigue headache sore throat lack smelltaste symptoms chills rigors difficulty breathing directly queried follow surveys difficulty breathing free text descriptions included shortness breath trial commenced march <NUMBER> whereas us case definition released april <NUMBER> <NUMBER> thus limitation directly querying full symptomology eg chills rigors difficulty breathing may result undercount total number symptoms plot includes three participants reported symptoms <NUMBER> days marked asterisk number covid<NUMBER> symptoms based april <NUMBER> <NUMBER> us clinical case definition <NUMBER> adjudications blinded study arm number covid<NUMBER> symptoms limited cough shortness breath fever myalgia headache sore throat fatigue lack smell chills rigors difficulty breathing directly queried assessed freetext descriptions thus may undercount covid<NUMBER> related symptoms per clinical case definition possible cases <NUMBER> possible covid<NUMBER> symptom meeting criteria compatible illness cough shortness breath noncases adjudicated unlikely covid<NUMBER> alternative diagnoses mediation side effect isolated headache upper respiratory tract infection likely excluding <NUMBER> possible covid<NUMBER> cases incidence new covid<NUMBER> differ <NUMBER> <NUMBER> <NUMBER> receiving hydroxychloroquine versus <NUMBER> <NUMBER> <NUMBER> receiving placebo p<NUMBER> similarly comparing anyone complaining new symptom study arm ie without adjudication alter result p<NUMBER> presented manuscripts table <NUMBER> significance research questionpurpose severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> rapidly emerging viral infection causing covid<NUMBER> current strategy uses public health model identifying infected cases isolation quarantine stop transmission exposed observation standardofcare effective therapy currently exists treatment lack effective therapy diminishes persons presenting postexposure selfquarantine effective postexposure prophylaxis even partially effective may additionally create synergy public health strategy case identification isolation safe prophylaxis available people develop covid<NUMBER> disease generally develop signs symptoms including mild respiratory symptoms fever average <NUMBER> days exposure ie mean incubation period range incubation period <NUMBER> <NUMBER> days <NUMBER> people infected covid<NUMBER> virus mild disease recover approximately <NUMBER> laboratoryconfirmed patients mild moderate disease includes nonpneumonia pneumonia cases <NUMBER> severe disease <NUMBER> critically ill respiratory failure shock andor multiple organ dysfunction <NUMBER> chloroquine vitro activity cell lines sarscov sarscov<NUMBER> vero e<NUMBER> cell line halfmaximal effective concentration ec<NUMBER> activity chloroquine <NUMBER> μm sarscov<NUMBER> <NUMBER> hydroxychloroquine functionally equivalent chloroquine another compound treatment trials remdesivir gilead ec<NUMBER> <NUMBER> μm <NUMBER> remdesivir gilead fdaapproved limited quantities hydroxychloroquine fdaapproved globally inexpensive chloroquine longer broadly available usa existing literature several drugs ribavirin interferon lopinavirritonavir corticosteroids used patients sars mers although efficacy poorly understood gold standard randomized clinical trial conducted <NUMBER> cdc investigators reported postinfection chloroquine treatment effective vitro preventing spread sarscov infection vitro cellbased system <NUMBER> vincent et al reported order investigate antiviral properties chloroquine sarscov initiation infection vero e<NUMBER> cells infected virus fresh medium supplemented various concentrations chloroquine added immediately virus adsorption infected cells incubated additional <NUMBER> h presence virus antigens analyzed indirect immunofluorescence analysis chloroquine added initiation infection dramatic dosedependent decrease number virus antigenpositive cells fig <NUMBER>a little <NUMBER> μm chloroquine reduced infection <NUMBER> <NUMBER> inhibition observed <NUMBER> μm concentrations fig <NUMBER>b concentrations chloroquine excess <NUMBER> μm small number individual cells initially infected spread infection adjacent cells eliminated halfmaximal inhibitory effect ec<NUMBER> estimated occur <NUMBER> ± <NUMBER> μm chloroquine fig <NUMBER>c data clearly show addition chloroquine effectively reduce establishment infection spread sarscov drug added immediately following virus adsorption <NUMBER> <NUMBER> vincent et al also reported since observed antiviral effects chloroquine immediately virus adsorption extended analysis adding chloroquine <NUMBER> <NUMBER> h virus adsorption examined presence virus antigens <NUMBER> h found chloroquine still significantly effective even added <NUMBER> h infection fig <NUMBER> however obtain equivalent antiviral effect higher concentration chloroquine required drug added <NUMBER> <NUMBER> h adsorption <NUMBER> experiments demonstrated chloroquine impaired terminal glycosylation angiotensinconverting enzyme<NUMBER> ace<NUMBER> receptor binding site envelope spike glycoprotein sarscov sarcov<NUMBER> <NUMBER> conversely chloroquine activity middle east respiratory syndrome coronavirus merscov may related mers binding cd<NUMBER> receptor protein <NUMBER> march <NUMBER> <NUMBER> publication hydroxychloroquine found greater activity chloroquine <NUMBER> sarscov<NUMBER> ec <NUMBER> values hydroxychloroquine <NUMBER> μm <NUMBER> hours <NUMBER> μm <NUMBER> hours <NUMBER> conversely chloroquine ec<NUMBER> values <NUMBER> μm <NUMBER> hours <NUMBER> μm <NUMBER> hours <NUMBER> inhibition assay performed vero cells using infectious dose <NUMBER> plaque forming units current standard care observation quarantine exposure covid<NUMBER> march <NUMBER> <NUMBER> cdc estimates transmission sarscov<NUMBER> us household close contract <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> <NUMBER> among close contacts sarscov<NUMBER> transmission rate estimated <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> cdc estimates based monitoring travelassociated covid<NUMBER> cases conversely setting community transmission secondary attack rate china <NUMBER> <NUMBER>ci <NUMBER> based <NUMBER> transmissions among <NUMBER> persons <NUMBER> index patients chloroquine hydroxychloroquine may antiviral effects sarscov<NUMBER> may prevent covid<NUMBER> disease early preemptive therapy may ameliorate disease severity trial use modification standard malaria dosing hydroxychloroquine provide postexposure prophylaxis preemptive therapy standard malaria treatment dosing • <NUMBER>mg <NUMBER>mg <NUMBER> hours <NUMBER>mg daily x <NUMBER> days <NUMBER> days total propose dose sarscov<NUMBER> postexposure prophylaxis • <NUMBER>mg <NUMBER>mg <NUMBER> hours <NUMBER>mg daily x <NUMBER> days <NUMBER> days total projected levels achieved approximately <NUMBER> µm half maximal effective concentration ec<NUMBER> <NUMBER> viral inhibition would occur delayed start prophylaxis occurring based intrinsic delay exposure case notification trial enrollment receipt first medication dose thereby higher doses may necessary seen cdc study <NUMBER> thus malaria loading dose sequence used higher daily doses thereafter target reaching ec<NUMBER> incubation period <NUMBER> days mean incubation period <NUMBER> days seek deliver postexposure prophylaxis morning day <NUMBER> latest <NUMBER> days inclusion criteria recognize may turn postexposure prophylaxis preemptive therapy subjects rapidly develop disease trial randomization hydroxychloroquine prevent disease preemptive therapy may ameliorate covid<NUMBER> disease severity attenuated disease may turn associated reduced rates transmission shortterm use hydroxychloroquine welltolerated safe track record since <NUMBER> common reported side effects include • headache dizziness ringing ears • nausea vomiting stomach pain • loss appetite weight loss • mood changes feeling nervous irritable • skin rash itching • hair loss gi side effects minimized taken meal milk antacid medications spaced apart least <NUMBER> hours • potential adverse effects system listed fda package insert ○ eye chloroquine retinopathy rate sideeffect chronic use multiple years use occurred <NUMBER> year continuous use determine postexposure prophylaxis hydroxychloroquine effective prevention covid<NUMBER> disease ameliorating disease severity assessment outcome measures primarily selfreport necessary covid<NUMBER> disease verified public health records medical records death certificates two strata <NUMBER> asymptomatic exposures <NUMBER> symptomatic covid<NUMBER> disease follow occur <NUMBER> days symptomatic covid<NUMBER> disease individually identifiable health information name date birth phone number collected prescribe study medication email addresses collected communication participants hospitalized hospitalization date collected na participants undergo screening via internetbased google forms screening inclusion criteria based selfreport mean incubation period <NUMBER> days thus wish limit enrollment higher risk progression deliver study medicine time period intervene covid<NUMBER> pep rct version <NUMBER> <NUMBER> march <NUMBER> prevent disease ameliorate disease ie start study medicine <NUMBER> days exposure current march <NUMBER> <NUMBER> delays testing makes window particularly tight may need relaxed future via protocol amendment clinical practice tropical medicine chloroquine hydroxychloroquine prescribed without baseline laboratory testing monitoring chronic use hydroxychloroquine <NUMBER> year cause retinopathy cardiomyopathy thus persons baseline conditions excluded study medicine excreted via kidney dose reduction recommended crcl <NUMBER> ccmin stage <NUMBER> kidney disease g<NUMBER>pd deficiency listed caution fda label g<NUMBER>pd testing routinely performed clinical care prior giving hydroxychloroquine prescriptions unlike primaquine medication exclusions possible drugdrug interactions particularly cardiac arrhythmia medicines caution fdapackage insert participants randomized via permuted block randomization randomization recorded electronic log pharmacy study investigators subjects blinded randomization stratified symptomdisease status time entry participants provided masked study medicine shipped courier eg fedex intervention vs placebo identical however participants outcome assessors masked assignment participants may withdraw time point discretion withdraws counted failures secondary endpoint completion study medication study may prematurely terminated sufficient reasonable cause including limited • unexpected significant unacceptable risk subjects • interim analyses dsmb • insufficient compliance protocol requirements • data sufficiently complete andor evaluable • regulatory authorities decide study terminated study prematurely terminated harm current subjects complete follow subjects enrolled study terminated due benefit study immediately convert openlabel prospective cohort collect observational data safety efficacy intervention irb approved recruitment limit fdaapproved formulation hydroxychloroquine purchased study medicines packaged mhealth investigational drug services dispensed medications delivered courier eg fedex study participants hydroxychloroquine sulfate • absorption rapid almost completely • distribution widely distributed body tissues • metabolism partially hepatic main metabolyte desethylchloroquine • excretion urine <NUMBER> unchanged drug acidification urine increases elimination • c max <NUMBER> nmolml <NUMBER> µmoll <NUMBER> µm <NUMBER>mg single dose <NUMBER> <NUMBER> • max <NUMBER> hours • t<NUMBER> <NUMBER> <NUMBER> hours <NUMBER> <NUMBER> days • auc last <NUMBER> <NUMBER> nmolhml • c max therapeutic window sarscov<NUMBER> activity • steady state doses <NUMBER>mg dose <NUMBER> µgl <NUMBER> µm <NUMBER> thus <NUMBER>mg dose generate approximately <NUMBER> µm ec<NUMBER> viral inhibition <NUMBER> µm ec<NUMBER> <NUMBER> inhibition however inhibition better likely ec<NUMBER> reported <NUMBER> µm <NUMBER> although precise measurement view range error present reported ec<NUMBER> point <NUMBER> maximal inhibition drug would better balanced toxicity drug supply percentage persons achieving <NUMBER> hour level ec<NUMBER> follows figure study investigator send prescription ids pharmacy pharmacy randomize subject dispense appropriate study medicine medicine provided research volunteers via fedex courier delivery united states mild side effects participants instructed split <NUMBER> tablet daily dosing multiple times per day event substantial side effects participants may discontinue study medication event development acute kidney injury creatinine clearance <NUMBER> mlmin dose reduced onethird accountability via selfreport day <NUMBER> virtual visit adherence via selfreport day <NUMBER> virtual visit participants may receive concomitant medications therapies asked report regards therapies received event hospitalization • baseline screening eligibility • informed consent selfadministered • performed via webbased form eligibility criteria selfreport • participants randomized computergenerated algorithm using permuted block randomization sequence • randomization stratified symptomatic vs asymptomatic status baseline • investigational pharmacy dispense masked study medicine • study personnel fedex study medicine participant • participant sent email expect medication arrive <NUMBER>am participants develop new worsening symptoms coronavirus directed healthcare provider andor local public health authority follow hospitalized patients <NUMBER> days final outcome subjects provided central email contact faqcovid<NUMBER>gmailcom contact point questions concerns email forward oncall study physician call participant resolve concerns additionally email communications contain url sick visit webform participants note current development symptoms medication side effects follow ecrf sent day <NUMBER> <NUMBER> <NUMBER> completed multiple times clinical evaluations self report laboratory evaluations protocol clinical outcomes selfreport sarscov<NUMBER> positivity selfreport informed consent request permission contact local public health authorities medical provider event lost follow covid<NUMBER> disease incentive dishonest believe healthcare workers particular take responsibilities seriously assessment safety hydroxychloroquine track record safety since fdaapproval <NUMBER> already fdaapproved medicine trial designed pragmatic trial setting public health emergency hydroxychloroquine excellent safety track record first fdaapproved <NUMBER> adverse events captured unless result hospitalization see serious adverse events expected adverse events would include normal events within general population well covid<NUMBER>related disease events may include need hospitalization pneumonia respiratory failure sepsis death applicable hospitalization death protocoldefined endpoints applicable ae suspected adverse reaction considered serious adverse event sae results following outcomes • lifethreatening adverse event • hospitalization • persistent significant incapacity substantial disruption ability conduct normal life functions • congenital anomalybirth defect • important medical events may result death lifethreatening require hospitalizations may considered serious based upon appropriate medical judgment may jeopardize patient subject may require medical surgical intervention prevent one outcomes listed definition examples medical events include allergic bronchospasm requiring intensive treatment emergency room home blood dyscrasias convulsions result inpatient hospitalization development drug dependency drug abuse lifethreatening adverse event ae considered lifethreatening view either site principal investigator sponsor occurrence places patient subject immediate risk death include ae occurred severe form might caused death life threatening aes subjects would recommended expected hospitalized based known safety track record hydroxychloroquine pragmatic protocol focus death lifethreatening aes hospitalizations incapacity permanent disability possibility covid<NUMBER> associated hydroxychloroquine event incapacity subject would expected hospitalized hydroxychloroquine chloroquine known cause teratogenic events viewed safe pregnancy especially short term use trials sample size delineate risk covid<NUMBER> disease may indeed teratogenic women pregnant ask follow end pregnancy thus hospitalization death secondary endpoint capture relevant saes hydroxychloroquine fdaapproved medicine used standard dosing reporting regulatory authorities occur summary format dsmb reports frequency least annually serious unexpected suspected adverse reactions susars expected covid<NUMBER> listed fda package insert reported irb susars deemed independent medical monitor related study medicine reported fda irb chloroquine hydroxychloroquine known teratogenic chloroquine hydroxychloroquine accumulate neonatal eyes conversely risk severe covid<NUMBER> infection unknown likely heightened risk pregnant women cdc states information adverse pregnancy outcomes pregnant women covid<NUMBER> pregnancy loss including miscarriage stillbirth observed cases infection related coronaviruses sarscov merscov pregnancy high fevers first trimester pregnancy increase risk certain birth defects thus riskbenefit would favor enrollment women may pregnant discriminate pregnant women women pregnant ask follow end pregnancy assess outcome pregnancy via brief survey participants hospitalized covid<NUMBER> saes <NUMBER> day follow conducted assess final outcome management per participants local healthcare provider data safety monitoring board dsmb oversee trial quorum include three members biostatistician pi nonvoting observer providing input requested landemets spending function analog obrienfleming boundaries provided dsmb report disease severity outcome thus dependent precise dmsb time period difference necessary trigger early stoppage vary converging toward <NUMBER> relative risk reduction study conclusion provided table assumes four interim analyses final analysis overall alpha<NUMBER> effect size unknown obrienfleming boundaries conservative yet truncated zscore <NUMBER> equating pvalue approx <NUMBER> first dsmb review stopping boundary unlikely crossed purpose early review assess trends safetyefficacy allow dsmb determine frequent reviews appropriate interim analyses desired dmsb landemets spending function recalculated using obrienfleming boundaries provided dsmb report stopping boundary crossed would recommend analysis determine whether findings consistent across secondary endpoints clear answer achieved event early halting due efficacy study immediately convert open label observational cohort hydroxychloroquine prescribed consented participants based public health situation dsmb prerogative alter stopping rules time second dsmb review sample size reestimation occur based disease transmission rate control group apriori assumption based limited data <NUMBER> transmission risk effect size powered remain <NUMBER> relative reduction reestimation account accumulating data intervention arm example incidence covid<NUMBER> disease control arm <NUMBER> sample size increase fourfold <NUMBER> participants per arm conditional power <NUMBER> time second interim analysis approximately <NUMBER> participants enrolled discontinuation considered possible recommendation dsmb sample size reestimation considered well pace enrollment clinical site monitoring conducted ensure rights wellbeing trial subjects protected reported trial data accurate complete verifiable clinical monitoring also ensures conduct trial compliance currently approved protocol amendments ich gcp applicable regulatory requirements sponsor requirements clinical monitoring also verify critical study procedures completed following specific instructions monitoring responsibility university minnesota hydroxychloroquine superior placebo preventing progression covid<NUMBER> disease hydroxychloroquine superior placebo preventing progression among symptomatic mild covid<NUMBER> disease preventing hospitalizationdeath two strata <NUMBER> subjects <NUMBER> asymptomatic exposures <NUMBER> symptomatic covid<NUMBER> disease planned sample size <NUMBER> participants per arm based assumptions • transmission covid<NUMBER> case close contacts <NUMBER> placebo • progression symptomatic illness hospitalization <NUMBER> placebo conservative estimate rate progression based probable enrollment youngerhealthier internet savvy population enrolling • primary analysis intention treat • type <NUMBER> error <NUMBER> <NUMBER>sided power <NUMBER> • n<NUMBER> per arm <NUMBER> power detect <NUMBER> relative risk reduction disease incidence well ordinal scale disease severity • <NUMBER> dropout n<NUMBER> per arm transmission frequency increases sample size dramatically decreases need demonstrate effect figure right instance <NUMBER> control prevalence transmission orange line sample size n<NUMBER> per arm would <NUMBER> power detect <NUMBER>reduction <NUMBER> transmission intervention arm conversely transmission frequency <NUMBER> <NUMBER> power detect effect size <NUMBER> reduction transmission <NUMBER> interim analyses focus statistical testing primary endpoint descriptive reporting secondary endpoints well interim analyses conducted enrollment approximately <NUMBER> <NUMBER> <NUMBER> <NUMBER> participants enrolled interval may modified dsmb interim analyses assess also evidence harm unintended consequences b appropriateness baseline assumptions specifically incidence disease control group c futility particularly time third dsmb onwards symptomatic disease baseline separately analyzed analysis stratified baseline strata <NUMBER> asymptomatic exposure <NUMBER> symptomatic covid<NUMBER> disease incidence new covid<NUMBER> disease assessed via fishers exact test among asymptomatic baseline • primary analysis use pcr confirmed disease • however absence sufficient testing supplies continues outpatients offered sarscov<NUMBER> testing unless sick enough hospitalized thus alternative priori planned analysis define incident covid<NUMBER> disease composite sarscov<NUMBER> pcr confirmed covid<NUMBER> disease symptomatic disease ie possible covid<NUMBER> without testing primary endpoint symptomatic entry assessed ordinal scale estimate proportional odds model primary hypothesis test based whether commons odds ratio prophylaxis equal one • symptomatic illness baseline three score ordinal scale also used illness without hospitalization ii hospitalizationposthospital discharge iii hospitalization icu staydeath outcomes assessed day <NUMBER> sensitivity analysis also performed day <NUMBER> capture delayed hospital outcomes • descriptive analysis report hospitalization hospitalization icu respiratory failure requiring mechanical ventilation andor death however subgroups expected small formally statistically tested analysis modified intention treat limited participants receive least one dose study medicine participants become symptomatic covid<NUMBER> receiving study medicine censored primary analysis incident disease separately described secondary endpoints assessed via fishers exact test proportions study arm among symptoms severity symptoms recorded <NUMBER> visual analog scale compared via mannwhitney u study arm day <NUMBER> <NUMBER> duration pcrpositivity time pcr negative assessed trial arms cumulative incidence function duration hospitalization assessed via independent ttest priori subgroup analyses include assessment • confirmed sarscov<NUMBER> disease disease exposure • healthcare worker vs household contact • days exposure • decile age • sex biological variable • censored subjects became symptomatic receipt first dose study medicine d<NUMBER> separately analyzed reported source documents include internet forms selfcompleted participants directly entered redcap database protocol based selfreport internetbased protocol meant enable large number participants recruited quickly well maintain safety research staff person visits create public health participants asked provide consent obtain medical records healthcare provider public health official need verify outcomes sarscov<NUMBER> test results hospitalizations study medications fdaapproved following good manufacturing practice study conducted according us international standards good clinical practice international conference harmonization guidelines declaration helsinki international ethical guidelines biomedical research involving human subjects applicable us government regulations institutional research policies procedures investigators must received human subject protection gcp training prior human subject involvement prior initiation study protocol informed consent forms participant information materials submitted approved single irb record likewise future amendments study protocol submitted approved irb implementation protocol amendments undergo review approval human subjects board university minnesota dhhs assurance fwa<NUMBER> • written informed consent obtained via englishlanguage internetbased web form potential participants questions may contact faqcovid<NUMBER>gmailcom reach study staff member answer questions research either via email phone call • completion reading form participants assessed comprehension querying ○ concept randomization hydroxychloroquine vitamin placebo ○ whether hydroxychloroquine known effective preventing disease • persons <NUMBER> years age eligible participate covid<NUMBER> <NUMBER> mortality children rate progression symptomatic disease may likely different furthermore pediatric dosing weight based making remote administration complicated • persons <NUMBER> years age eligible participate covid<NUMBER> <NUMBER> mortality children young adults • nonenglish speaking adults eligible webpage consents available english • interaction via internetbased redcap ecrfs conforming required us privacy server security standards • clinical data entered study specific database designated staff regular basis completed electronic case record forms ecrf access database given authorized personnel members immediate study team ecrf trial documents kept secure database • documentation data information generated held strict confidence information concerning study data released unauthorized third party without prior written approval participant except necessary monitoring irb public health authorities • participant identifying information disclosed publication conference activities arising study • specimens collected investigators maintain redcap database study records survey forms selfcompleted study participants • data obtained via internetbased redcap forms • participants asked provide data regarding covid<NUMBER> exposure timing location also asked provide ongoing symptom reports followup period • enrollment progress report generated monthly ○ participants enrolled ○ participants study ○ participants completed study ○ lost follow ○ cumulative covid<NUMBER> pooled arms ○ cumulative hospitalizations pooled arms • data safety monitoring board dsmb review data every <NUMBER> participants complete <NUMBER> days followup • deidentified data shared research team members analysis • paper documents retained stored • digital records kept secure server setting protocol violations reported irb record protocol utilize single institutional review board irb registered office human research protections ohrp issued federal wide assurance fwa research reviewed approved irb subject continuing review <NUMBER> cfr <NUMBER>b signature constitutes approval protocol provides necessary assurances trial conducted according stipulations protocol including statements regarding confidentiality according local legal regulatory requirements applicable us federal regulations ich guidelines x participants develop symptomatic disease followed <NUMBER> days assess final outcome status event hospitalization stratification based symptom status baseline <NUMBER> <NUMBER> asymptomatic healthcare workers household contacts exposed covid<NUMBER> <NUMBER> <NUMBER> symptomatic covid<NUMBER> outpatients significance research questionpurpose severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> rapidly emerging viral infection causing covid<NUMBER> current strategy uses public health model identifying infected cases isolation quarantine stop transmission exposed observation standardofcare effective therapy currently exists treatment lack effective therapy diminishes persons presenting postexposure selfquarantine effective postexposure prophylaxis even partially effective may additionally create synergy public health strategy case identification isolation safe prophylaxis available people develop covid<NUMBER> disease generally develop signs symptoms including mild respiratory symptoms fever average <NUMBER> days exposure ie mean incubation period range incubation period <NUMBER> <NUMBER> days <NUMBER> people infected covid<NUMBER> virus mild disease recover approximately <NUMBER> laboratoryconfirmed patients mild moderate disease includes nonpneumonia pneumonia cases <NUMBER> severe disease <NUMBER> critically ill respiratory failure shock andor multiple organ dysfunction <NUMBER> chloroquine vitro activity cell lines sarscov sarscov<NUMBER> vero e<NUMBER> cell line halfmaximal effective concentration ec<NUMBER> activity chloroquine <NUMBER> μm sarscov<NUMBER> <NUMBER> hydroxychloroquine functionally equivalent chloroquine another compound treatment trials remdesivir gilead ec<NUMBER> <NUMBER> μm <NUMBER> remdesivir gilead fdaapproved limited quantities hydroxychloroquine fdaapproved globally inexpensive chloroquine longer broadly available usa existing literature several drugs ribavirin interferon lopinavirritonavir corticosteroids used patients sars mers although efficacy poorly understood gold standard randomized clinical trial conducted <NUMBER> cdc investigators reported postinfection chloroquine treatment effective vitro preventing spread sarscov infection vitro cellbased system <NUMBER> vincent et al reported order investigate antiviral properties chloroquine sarscov initiation infection vero e<NUMBER> cells infected virus fresh medium supplemented various concentrations chloroquine added immediately virus adsorption infected cells incubated additional <NUMBER> h presence virus antigens analyzed indirect immunofluorescence analysis chloroquine added initiation infection dramatic dosedependent decrease number virus antigenpositive cells fig <NUMBER>a little <NUMBER> μm chloroquine reduced infection <NUMBER> <NUMBER> inhibition observed <NUMBER> μm concentrations fig <NUMBER>b concentrations chloroquine excess <NUMBER> μm small number individual cells initially infected spread infection adjacent cells eliminated halfmaximal inhibitory effect ec<NUMBER> estimated occur <NUMBER> ± <NUMBER> μm chloroquine fig <NUMBER>c data clearly show addition chloroquine effectively reduce establishment infection spread sarscov drug added immediately following virus adsorption <NUMBER> vincent et al also reported since observed antiviral effects chloroquine immediately virus adsorption extended analysis adding chloroquine <NUMBER> <NUMBER> h virus adsorption examined presence virus antigens <NUMBER> h found chloroquine still significantly effective even added <NUMBER> h infection fig <NUMBER> however obtain equivalent antiviral effect higher concentration chloroquine required drug added <NUMBER> <NUMBER> h adsorption <NUMBER> experiments demonstrated chloroquine impaired terminal glycosylation angiotensinconverting enzyme<NUMBER> ace<NUMBER> receptor binding site envelope spike glycoprotein sarscov sarcov<NUMBER> <NUMBER> conversely chloroquine activity middle east respiratory syndrome coronavirus merscov may related mers binding cd<NUMBER> receptor protein <NUMBER> march <NUMBER> <NUMBER> publication hydroxychloroquine found greater activity chloroquine <NUMBER> sarscov<NUMBER> ec <NUMBER> values hydroxychloroquine <NUMBER> μm <NUMBER> hours <NUMBER> μm <NUMBER> hours <NUMBER> conversely chloroquine ec<NUMBER> values <NUMBER> μm <NUMBER> hours <NUMBER> μm <NUMBER> hours <NUMBER> inhibition assay performed vero cells using infectious dose <NUMBER> plaque forming units accumulating clinical data treatment hospitalized patients covid<NUMBER> infection chloroquine hydroxychloroquine data summarized pastick et al april <NUMBER> <NUMBER> <NUMBER> date conclusive evidence clinical benefit hydroxychloroquine treatment hospitalized patients studies early therapy preventative therapy limitations study design treatment regimen location outcomes chen j et al <NUMBER> statistically significant differences conversion rate day <NUMBER> <NUMBER> vs <NUMBER> p<NUMBER> difference clinical outcomes groups full article available chinese peerreviewed gautret et al <NUMBER> unadjusted analyses significantly reduced viral titers hcq arm day <NUMBER> <NUMBER> compared <NUMBER> pcr negative p<NUMBER> six patients receiving hcq azithromycin sarscov<NUMBER> negative day <NUMBER> study design small sample sizeunderpowered lack longterm outcomes gautret et al <NUMBER> reduced nasopharyngeal viral titers day <NUMBER> <NUMBER> negative <NUMBER> <NUMBER> mean length hospitalization <NUMBER> days study design small sample size short followup time peerreviewed gao j et al <NUMBER> cq stated superior standard care treatment preventing exacerbation pneumonia reducing days conversion rate shortening time clinical recovery current standard care observation quarantine exposure covid<NUMBER> march <NUMBER> <NUMBER> cdc estimates transmission sarscov<NUMBER> us household close contract <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> <NUMBER> among close contacts sarscov<NUMBER> transmission rate estimated <NUMBER> <NUMBER>ci <NUMBER> <NUMBER> cdc estimates based monitoring travelassociated covid<NUMBER> cases conversely setting community transmission secondary attack rate china <NUMBER> <NUMBER>ci <NUMBER> based <NUMBER> transmissions among <NUMBER> persons <NUMBER> index patients chloroquine hydroxychloroquine may antiviral effects sarscov<NUMBER> may prevent covid<NUMBER> disease early preemptive therapy may ameliorate disease severity trial use modification standard malaria dosing hydroxychloroquine provide postexposure prophylaxis preemptive therapy standard malaria treatment dosing • <NUMBER>mg <NUMBER>mg <NUMBER> hours <NUMBER>mg daily x <NUMBER> days <NUMBER> days total propose dose sarscov<NUMBER> postexposure prophylaxis • <NUMBER>mg <NUMBER>mg <NUMBER> hours <NUMBER>mg daily x <NUMBER> days <NUMBER> days total projected levels achieved approximately <NUMBER> µm half maximal effective concentration ec<NUMBER> <NUMBER> viral inhibition would occur delayed start prophylaxis occurring based intrinsic delay exposure case notification trial enrollment receipt first medication dose thereby higher doses may necessary seen cdc study <NUMBER> thus malaria loading dose sequence used higher daily doses thereafter target reaching ec<NUMBER> incubation period <NUMBER> days mean incubation period <NUMBER> days seek deliver postexposure prophylaxis morning day <NUMBER> latest <NUMBER> days inclusion criteria recognize may turn postexposure prophylaxis preemptive therapy subjects rapidly develop disease trial randomization hydroxychloroquine prevent disease preemptive therapy may ameliorate covid<NUMBER> disease severity attenuated disease may turn associated reduced rates transmission shortterm use hydroxychloroquine welltolerated safe track record since <NUMBER> common reported side effects include • headache dizziness ringing ears • nausea vomiting stomach pain • loss appetite weight loss • mood changes feeling nervous irritable • skin rash itching • hair loss gi side effects minimized taken meal milk antacid medications spaced apart least <NUMBER> hours potential adverse effects system listed fda package insert ○ eye chloroquine retinopathy rare sideeffect chronic use multiple years use occurred <NUMBER> year continuous use <NUMBER> april <NUMBER> fda issued caution close supervision strongly recommended fda aware reports serious heart rhythm problems patients covid<NUMBER> treated hydroxychloroquine chloroquine often combination azithromycin qt prolonging medicines also aware increased use medicines outpatient prescriptions therefore would like remind health care professionals patients known risks associated hydroxychloroquine chloroquine continue investigate risks associated use hydroxychloroquine chloroquine covid<NUMBER> communicate publicly information hydroxychloroquine chloroquine cause abnormal heart rhythms qt interval prolongation dangerously rapid heart rate called ventricular tachycardia risks may increase medicines combined medicines known prolong qt interval including antibiotic azithromycin also used covid<NUMBER> patients without fda approval condition patients also health issues heart kidney disease likely increased risk heart problems receiving medicines inclusion exclusion criteria exclude cardiac risk factors chronic kidney disease antiarrhythmia medicines <NUMBER> april additional qt prolonging medicines excluded • known benefits humans preemptive treatment • vitro antiviral activity sarscov sarscov<NUMBER> viruses • chloroquine hydroxychloroquine long history safe effective use antimalarial acutely longterm use determine hydroxychloroquine effective prevention covid<NUMBER> disease reducing disease severity asymptomatic cohort • incidence covid<NUMBER> disease within <NUMBER> days among asymptomatic baseline symptomatic cohort • change symptom severity score visual analog scale <NUMBER> <NUMBER> days • incidence hospitalization death • incidence confirmed sarscov<NUMBER> detection • incidence symptoms compatible covid<NUMBER> possible disease • incidence allcause study medicine discontinuation withdrawal • incidence adverse reactions • symptom severity day <NUMBER> <NUMBER> via visual analog scale • ordinal scale covid<NUMBER> disease severity day <NUMBER> among symptomatic trial entry illness without hospitalization hospitalization posthospital discharge hospitalization icu stay death assessment outcome measures primarily selfreport necessary covid<NUMBER> disease verified public health records medical records death certificates primary endpoints different two cohorts asymptomatic known exposure symptomatic trial entry analyses done separately two cohorts primary analysis use pcr confirmed disease however absence sufficient testing supplies continues outpatients offered sarscov<NUMBER> testing unless sick enough hospitalized case alternate priori planned analysis define incident covid<NUMBER> disease composite sarscov<NUMBER> pcr confirmed result symptomatic disease ie possible covid<NUMBER> without testing two strata <NUMBER> asymptomatic healthcare workers household contacts exposed covid<NUMBER> n<NUMBER> <NUMBER> symptomatic covid<NUMBER> disease n<NUMBER> follow occur <NUMBER> days symptomatic covid<NUMBER> disease become hospitalized randomized doubleblind placebocontrolled clinical trial parallel design • intervention arm hydroxychloroquine <NUMBER> mg orally <NUMBER> tablets followed <NUMBER> <NUMBER> hours <NUMBER> mg <NUMBER> tabelts <NUMBER> mg day <NUMBER> consecutive days <NUMBER> days total • control arm vitamin placebo <NUMBER> tablets orally followed <NUMBER> <NUMBER> hours <NUMBER> tablets <NUMBER> tablets day <NUMBER> consecutive days <NUMBER> days total • <NUMBER> days consisting internetbased virtual visits • participants ill covid<NUMBER> disease hospitalized sae observational follow extend <NUMBER> days assess final outcome status sae • pregnant women fetal outcome assessed postpartum exclude teratogenic sae • procedures consist internetbased questionnaires completed selfreport • informed consent provided access medical records verify information necessary • optional blood spot collected approximately day <NUMBER> • optional daily cardiac monitoring remote ekg reads qtc interval name date birth addresses phone number collected prescribe study medication email addresses collected communication participants hospitalized hospitalization date collected additional substudies undergo separate irb approval studies involve separate informed consent consented participants queried wish participate future research <NUMBER> serology coronavirus antibodies new participants offer optional participation selfcollection dried blood spots order measure serologies antibodies participants already consented entered trial approached amendment consent purpose serology testing twofold first verify infection second prevalence antibodies compared among symptomatic asymptomatic persons scientific question many asymptomatic persons seroconvert high risk exposure absence symptomatic illness exact serology methodology conducted determined based availability diagnostic performance blood spot collection materials eg <NUMBER>g lancet filter paper bandaid instructions return envelope <NUMBER> cardiac monitoring handheld ekg check cardiac qtc interval daily first <NUMBER> days safety substudy optional participants undergo screening via internetbased forms screening inclusion criteria based selfreport • exposure covid<NUMBER> case within <NUMBER> calendar days either ○ occupational exposure healthcare worker first responder etc ○ household contact • symptomatic covid<NUMBER> disease ○ confirmed diagnosis pcr sarscov<NUMBER> within <NUMBER> days symptom onset ○ individual compatible symptoms exposure known pcr sarscov<NUMBER> case within <NUMBER> days compatible symptoms fever cough shortness breath available pending testing individual • <NUMBER> years age • provision informed consent • current hospitalization • contraindication allergy hydroxychloroquine • retinal eye disease • concurrent malignancy requiring chemotherapy • known glucose<NUMBER> phosphate dehydrogenase g<NUMBER>pd deficiency • known chronic kidney disease stage <NUMBER> <NUMBER> receiving dialysis • known porphyria • weight <NUMBER> kg • structural ischemic heart disease • personal family history prolonged qt • current use hydroxychloroquine chloroquine cardiac medicines flecainide tambocor amiodarone cordarone pacerone digoxin digox digitek lanoxin procainamide procan procanbid propafenone rythmal sotalol • current use qt prolonging medicines ○ antimicrobials levofloxacin ciprofloxacin moxifloxacin azithromycin clarithromycin erythromycin ketoconazole itraconazole mefloquine ○ antidepressants amitriptyline citalopram desipramine escitalopram imipramine doxepin fluoxetine wellbutrin venlafaxine ○ antipsychotic mood stabilizers haloperidol droperidol lithium quetiapine thioridazine ziprasidone ○ methadone ○ sumatriptan zolmitriptan rationale inclusion exclusion criteria <NUMBER> march <NUMBER> testing limited many us states locales due insufficient supplies thus outpatient testing may available person known exposure confirmed covid<NUMBER> case subsequent compatible symptoms eligible enrollment testing available symptomatic person tests negative sarscov<NUMBER> eligible enrollment mean incubation period <NUMBER> days thus wish limit enrollment higher risk progression deliver study medicine time period intervene prevent disease ameliorate disease ie start study medicine <NUMBER> days exposure current march <NUMBER> <NUMBER> delays testing makes window particularly tight may need relaxed future via protocol amendment clinical practice tropical medicine chloroquine hydroxychloroquine prescribed without baseline laboratory testing monitoring chronic use hydroxychloroquine <NUMBER> year cause retinopathy cardiomyopathy thus persons baseline conditions excluded study medicine excreted via kidney dose reduction recommended crcl <NUMBER> ccmin stage <NUMBER> kidney disease g<NUMBER>pd deficiency listed caution fda label g<NUMBER>pd testing routinely performed clinical care prior giving hydroxychloroquine prescriptions unlike primaquine medication exclusions possible drugdrug interactions particularly cardiac arrhythmia medicines caution fdapackage insert april <NUMBER> <NUMBER> fda mandated exclusion structural ischemic heart disease personal family history prolonged qt april <NUMBER> <NUMBER> fda issued caution qt prolongation persons heart disease chronic kidney disease taking qt prolonging medicines participants randomized via permuted block randomization randomization recorded electronic log pharmacy study investigators subjects blinded separate randomization schedules two cohorts asymptomatic exposure symptomatic participants provided masked study medicine shipped courier eg fedex intervention vs placebo identical however participants outcome assessors masked assignment participants may withdraw time point discretion withdraws counted failures secondary endpoint completion study medication participants discontinue study medication still asked complete follow visit schedule study may prematurely terminated sufficient reasonable cause including limited • unexpected significant unacceptable risk subjects • interim analyses dsmb • insufficient compliance protocol requirements • data sufficiently complete andor evaluable • regulatory authorities decide study terminated study prematurely terminated harm current subjects complete follow subjects enrolled study terminated due benefit study immediately convert openlabel prospective cohort collect observational data safety efficacy intervention irb approved recruitment limit fdaapproved formulation hydroxychloroquine purchased study medicines packaged mhealth investigational drug services dispensed medications delivered courier eg fedex study participants ec<NUMBER> reported <NUMBER> µm <NUMBER> although precise measurement view range error present reported ec<NUMBER> point <NUMBER> maximal inhibition drug would better balanced toxicity drug supply percentage persons achieving <NUMBER> hour level ec<NUMBER> follows figure store room <NUMBER>° c <NUMBER>° f dispense tight lightresistant container drugdevice handling hydroxychloroquine placebo dispensed mhealth investigational drug service ids pharmacy study investigators send prescription ids pharmacy pharmacy randomize subject dispense appropriate study medicine medicine provided research volunteers via fedex courier delivery united states mild side effects participants instructed split <NUMBER> tablet daily dosing multiple times per day event substantial side effects participants may discontinue study medication stay study complete follow accountability via selfreport day <NUMBER> virtual visit adherence via selfreport day <NUMBER> virtual visit participants may receive concomitant medications therapies asked report regards therapies received day <NUMBER> day <NUMBER> event hospitalization • baseline screening eligibility • informed consent selfadministered • performed via webbased form eligibility criteria selfreport • participants randomized computergenerated algorithm using permuted block randomization sequence • randomization stratified symptomatic vs asymptomatic status baseline • investigational pharmacy dispense masked study medicine • study personnel fedex study medicine participant • participant sent email expect medication arrive <NUMBER>am participations sae prior final study visit eg hospitalization final resolution event followed resolution <NUMBER> days hospitalization ecrf sent <NUMBER> days interval assess clinical outcome resolution hospitalization pregnancies followed delivery assess teratogenic sae participants develop new worsening symptoms coronavirus directed healthcare provider andor local public health authority clinical care follow hospitalized patients resolution sae <NUMBER> days assess final outcome participants sent hospitalization ecrf <NUMBER> days hospitalization reported repeats <NUMBER> day intervals participant discharged hospital subjects provided central email contact faqcovid<NUMBER>gmailcom contact point questions concerns email forward oncall study physician call participant resolve concerns clinical evaluations selfreport sarscov<NUMBER> positivity selfreport informed consent asks access medical records follow pcr testing within <NUMBER> days asked followed questionnaires pending test results <NUMBER> days hospitalization queried final results repeat survey sent day <NUMBER> informed consent request permission contact local public health authorities medical provider event lost follow covid<NUMBER> disease incentive dishonest believe healthcare workers particular take responsibilities seriously optional dried blood spot collection offered day <NUMBER> time informed consent participants may opt collection dried blood spots used future serology testing participants opt testing mailed instructions ii whatman filter paper dried blood spot collection iii one time use lancet iv return envelope participants entered trial prior dried blood spot offered <NUMBER> days study entry contact option dried blood spot testing antibody serology assessment safety hydroxychloroquine track record safety since fdaapproval <NUMBER> already fdaapproved medicine trial designed pragmatic trial setting public health emergency hydroxychloroquine excellent safety track record first fdaapproved <NUMBER> adverse events captured unless result hospitalization see serious adverse events expected adverse events would include normal events within general population well covid<NUMBER>related disease events may include need hospitalization pneumonia respiratory failure sepsis death applicable hospitalization death protocoldefined endpoints saes eg hospitalizations followed <NUMBER> days assess final outcome applicable ae suspected adverse reaction considered serious adverse event sae results following outcomes based known safety track record hydroxychloroquine pragmatic protocol focus death lifethreatening aes hospitalizations incapacity permanent disability possibility covid<NUMBER> associated hydroxychloroquine event incapacity subject would expected hospitalized hydroxychloroquine chloroquine known cause teratogenic events viewed safe pregnancy especially short term use trials sample size delineate risk covid<NUMBER> disease may indeed teratogenic women pregnant ask follow end pregnancy sent follow ecrf <NUMBER> month postpartum based reported estimated date delivery provided day <NUMBER> study visit thus hospitalization death secondary endpoint capture relevant saes ongoing hospitalization day <NUMBER> study visit participants queried <NUMBER> day intervals hospital ecrf assess final clinical outcome hydroxychloroquine fdaapproved medicine used standard dosing reporting regulatory authorities occur summary format dsmb reports frequency least annually serious unexpected suspected adverse reactions susars expected covid<NUMBER> listed fda package insert reported irb susars deemed independent medical monitor related study medicine reported fda irb chloroquine hydroxychloroquine known teratogenic chloroquine hydroxychloroquine accumulate neonatal eyes conversely risk severe covid<NUMBER> infection unknown likely heightened risk pregnant women cdc states information adverse pregnancy outcomes pregnant women covid<NUMBER> pregnancy loss including miscarriage stillbirth observed cases infection related coronaviruses sarscov merscov pregnancy high fevers first trimester pregnancy increase risk certain birth defects thus riskbenefit would favor enrollment women may pregnant discriminate pregnant women women pregnant ask follow end pregnancy assess outcome pregnancy via brief survey participants hospitalized covid<NUMBER> saes <NUMBER> day follow conducted assess final outcome management per participants local healthcare provider data safety monitoring board dsmb oversee trial quorum include three members biostatistician pi nonvoting observer providing input requested see dsmb charter details clinical site monitoring conducted ensure rights wellbeing trial subjects protected reported trial data accurate complete verifiable clinical monitoring also ensures conduct trial compliance currently approved protocol amendments ich gcp applicable regulatory requirements sponsor requirements clinical monitoring also verify critical study procedures completed following specific instructions monitoring responsibility university minnesota automated logic redcap database system enable complete records data self report hypothesize hydroxychloroquine superior placebo preventing progression covid<NUMBER> disease among asymptomatic hypothesize hydroxychloroquine superior placebo preventing progression among symptomatic mild covid<NUMBER> disease preventing hospitalizationdeath two cohorts <NUMBER> subjects <NUMBER> asymptomatic persons exposed covid<NUMBER> disease <NUMBER> placebo <NUMBER> intervention <NUMBER> symptomatic outpatient covid<NUMBER> disease <NUMBER> placebo <NUMBER> intervention assuming <NUMBER> power twosided alpha <NUMBER> loss followup <NUMBER> cohort planned sample size <NUMBER> participants per arm based following assumptions • <NUMBER> transmission rate covid<NUMBER> cases close contacts • symptomatic illness proportions day <NUMBER> placebo group <NUMBER> <NUMBER> <NUMBER> respectively illness without hospitalization hospitalization icu stay death hospitalization icu stay death estimated transmission rates uncertain table <NUMBER> asymptomatic cohort exposure shows well powered detect even smaller <NUMBER> relative reduction incidence covid <NUMBER> <NUMBER> power transmission rates least <NUMBER> placebo table <NUMBER> symptomatic group shows well powered detect common odds ratio <NUMBER> assumption control proportions illness without hospitalization hospitalization without icu stay death hospitalization icu stay death <NUMBER> <NUMBER> <NUMBER> respectively landemets spending function analog obrienfleming boundaries provided dsmb report primary outcome cohort obrienfleming boundaries truncated alpha <NUMBER> z <NUMBER> cohort interim analyses separately planned <NUMBER> <NUMBER> <NUMBER> trial enrollment enrollment may brisk timing interim analyses may altered pi discretion based pace enrollment may possible trial fully enrolled time day <NUMBER> outcomes available first <NUMBER> enrolled case analyses would related release interim results first dsmb review stopping boundary unlikely crossed purpose early review assess trends safetyefficacy allow dsmb determine probable timing reviews based pace enrollment stopping boundary crossed would recommend analysis determine whether findings consistent across secondary endpoints clear answer achieved starting <NUMBER> nd dsmb review approximately <NUMBER> enrollment dsmb given conditional power cohorts study design parameters current data conditional power less <NUMBER> trial discontinuation may considered event early halting due efficacy intervention study immediately convert open label observational cohort hydroxychloroquine prescribed consented participants relevant cohort event early halting due futility effect protocol modification made alter intervention based public health situation dsmb prerogative alter stopping rules time <NUMBER> enrollment sample size reestimation occur based disease transmission rate control group priori assumption based limited data <NUMBER> transmission risk new sample size estimation take account updated transmission rate treatment powered detect <NUMBER> relative reduction outcome primary outcome analyses intention treat asymptomatic cohort primary analysis asymptomatic exposure incidence covid <NUMBER> disease day <NUMBER> assessed via fishers exact test symptomatic cohort primary analysis symptomatic disease study entry summary metric change symptom severity <NUMBER> days longitudinal change time repeated measures mixedregression model estimate treatment effect study arm subjects without symptoms coded zero severity persons hospitalized dead coded <NUMBER> severity participants become symptomatic covid<NUMBER> day <NUMBER> receiving study medicine described symptomatic cohort secondary analyses asymptomatic exposure cohort primary analysis intention treat repeated participants received least one dose study medicine • secondary endpoints assessed via fishers exact test median interquartile ranges appropriate • symptomatic disease study entry proportional odds models used assess ordinal scale disease severity day <NUMBER> illness without hospitalization hospitalization without icu stay death hospitalization icu stay death • severity overall symptoms day <NUMBER> <NUMBER> <NUMBER> <NUMBER> recorded <NUMBER> visual analog scale severity symptoms day <NUMBER> compared first categorical analysis symptoms vs symptoms via fishers exact chi square ○ second among symptoms <NUMBER> visual analog scale severity data compared via independent twosample test data nonnormally distributed data compared via mannwhitney u study arm priori subgroup analyses include assessment • confirmed sarscov<NUMBER> disease disease exposure • healthcare worker vs household contact • days exposure • decile age • sex biological variable • censored subjects became symptomatic receipt first dose study medicine d<NUMBER> separately analyzed reported large lost follow study discontinue rate primary endpoint asymptomatic cohort would secondary analysis assess incidence <NUMBER>category analysis disease ii incident disease iii unknown similarly symptomatic cohort would add fourth category unknown participants stop taking study medicine agree followed <NUMBER> days assessed intenttotreat day <NUMBER> ask medications vitamins taken study period persons screened enrolled summarized consort diagrams descriptive summaries covid<NUMBER> related information data deidentified source documents include internet forms selfcompleted participants directly entered redcap database protocol based selfreport internetbased protocol meant enable large number participants recruited quickly well maintain safety research staff person visits create public health participants asked provide consent obtain medical records healthcare provider public health official need verify outcomes sarscov<NUMBER> test results hospitalizations study medications commercially procured us fdaapproved hydroxychloroquine anda <NUMBER> following good manufacturing practice study conducted according us international standards good clinical practice international conference harmonization guidelines declaration helsinki international ethical guidelines biomedical research involving human subjects applicable us government regulations institutional research policies procedures investigators must received human subject protection gcp training prior human subject involvement prior initiation study protocol informed consent forms participant information materials submitted approved single irb record likewise future amendments study protocol submitted approved irb implementation protocol amendments undergo review approval human subjects board university minnesota dhhs assurance fwa<NUMBER> • written informed consent obtained via englishlanguage internetbased web form potential participants questions may contact faqcovid<NUMBER>gmailcom reach study staff member answer questions research either via email phone call • completion reading form participants assessed comprehension querying ○ concept randomization hydroxychloroquine vitamin placebo ○ whether hydroxychloroquine known effective preventing disease ○ duration study <NUMBER> days ○ duration taking study medicine <NUMBER> days ○ follow surveys sent days <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> ○ hydroxychloroquine shared • persons <NUMBER> years age eligible participate covid<NUMBER> negligible mortality children <NUMBER> years rate progression symptomatic disease may likely different furthermore pediatric dosing weight based making remote administration complicated fixed dose <NUMBER>mg tablets • persons <NUMBER> years age eligible participate covid<NUMBER> <NUMBER> mortality children young adults • nonenglish speaking adults eligible webpage consents available english • interaction via internetbased redcap ecrfs conforming required us privacy server security standards • clinical data entered study specific database designated staff regular basis completed electronic case record forms ecrf access database given authorized personnel members immediate study team ecrf trial documents kept secure database • documentation data information generated held strict confidence information concerning study data released unauthorized third party without prior written approval participant except necessary monitoring irb public health authorities • participant identifying information disclosed publication conference activities arising study • specimens stored future research investigators maintain redcap database study records survey forms selfcompleted study participants • data obtained via internetbased redcap forms • participants asked provide data regarding covid<NUMBER> exposure timing location also asked provide ongoing symptom reports followup period • enrollment progress report generated monthly ○ participants enrolled ○ participants study ○ participants completed study ○ lost follow ○ cumulative covid<NUMBER> pooled arms ○ cumulative hospitalizations pooled arms • data safety monitoring board dsmb review data every <NUMBER> participants complete <NUMBER> days followup • deidentified data shared research team members analysis • paper documents retained stored • digital records kept secure server setting protocol violations reported irb record h e ne w e ngl nd jou r na l f e dicine evere acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> global rapidly emerging virus causing coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> current public health strategies mitigate transmission rapid identification cases isolation contact tracing selfquarantine exposed person exposed observation quarantine <NUMBER>day incubation period standard care date medication shown prevent sarscov<NUMBER> transmission chloroquine derivative molecule hydroxychloroquine vitro activity sarscov sarscov<NUMBER> <NUMBER> <NUMBER> hydroxychloroquine thought impair terminal glycosylation angiotensinconvertingenzyme <NUMBER> ace<NUMBER> receptor binding site envelope spike glycoprotein shown inhibit endolysosome function <NUMBER> <NUMBER> addition hydroxychloroquine may greater vitro activity sarscov<NUMBER> chloroquine <NUMBER> majority clinical studies chloroquine hydroxychloroquine covid<NUMBER> focused hospitalized patients <NUMBER> <NUMBER> <NUMBER> <NUMBER> yet alter trajectory epidemic necessary break chain transmission risk secondary household transmission estimated <NUMBER> <NUMBER> <NUMBER> <NUMBER> small nonrandomized noncontrolled cohort studies suggested use hydroxychloroquine might reduce even eliminate risk <NUMBER> whether shortterm highdose hydroxychloroquine prevent disease soon highrisk exposure remains unknown hypothesized hydroxychloroquine could potentially used postexposure prophylaxis prevent symptomatic infection exposure covid<NUMBER> conducted randomized doubleblind placebocontrolled trial evaluate postexposure prophylaxis hydroxychloroquine exposure covid<NUMBER> <NUMBER> randomly assigned participants <NUMBER> ratio receive either hydroxychloroquine placebo participants known exposure participant report person laboratoryconfirmed covid<NUMBER> whether household contact health care worker person occupational exposures trial enrollment began march <NUMBER> <NUMBER> eligibility threshold enroll within <NUMBER> days exposure objective intervene median incubation period <NUMBER> <NUMBER> days limited access prompt testing health care workers could initially enrolled basis presumptive highrisk exposure patients pending tests however march <NUMBER> eligibility changed exposure person positive polymerasechainreaction pcr assay sarscov<NUMBER> eligibility window extended within <NUMBER> days exposure trial approved institutional review board university minnesota conducted food drug administration investigational new drug application canada trial approved health canada ethics approvals obtained research institute mcgill university health centre university manitoba university alberta included participants household occupational exposure person confirmed covid<NUMBER> distance less <NUMBER> ft <NUMBER> minutes wearing neither face mask eye shield highrisk exposure wearing face mask eye shield moderaterisk exposure participants excluded younger <NUMBER> years age hospitalized met exclusion criteria see supplementary appendix available full text article nejmorg persons symptoms covid<NUMBER> pcrproven sarscov<NUMBER> infection excluded prevention trial separately enrolled companion clinical trial treat early infection recruitment performed primarily use social media outreach well traditional media platforms participants enrolled nationwide united states canadian provinces quebec manitoba alberta participants enrolled secure internetbased survey using research electronic data capture redcap system <NUMBER> participants read consent form comprehension contents assessed participants provided digitally captured signature indicate informed consent sent followup email surveys days <NUMBER> <NUMBER> <NUMBER> <NUMBER> survey <NUMBER> hydroxychloroquine prophylaxis <NUMBER> weeks asked followup testing illness hospitalizations participants respond followup surveys received text messages emails telephone calls combination ascertain outcomes methods unsuccessful emergency contact provided enrollee contacted determine participants illness vital status communication methods exhausted internet searches obituaries performed ascertain vital status randomization occurred research pharmacies minneapolis montreal trial statisticians generated permutedblock randomization sequence using variably sized blocks <NUMBER> <NUMBER> <NUMBER> stratification according country research pharmacist sequentially assigned participants assignments concealed investigators participants pharmacies access randomization sequence hydroxychloroquine sulfate placebo dispensed shipped overnight participants commercial courier dosing regimen hydroxychloroquine <NUMBER> mg <NUMBER> tablets <NUMBER> mg <NUMBER> tablets <NUMBER> <NUMBER> hours later <NUMBER> mg <NUMBER> tablets daily <NUMBER> days total course <NUMBER> days <NUMBER> tablets total participants gastrointestinal upset advised divide daily dose two three doses chose hydroxychloroquine dosing regimen basis pharmacokinetic simulations achieve plasma concentrations sarscov<NUMBER> vitro half maximal effective concentration <NUMBER> days <NUMBER> placebo folate tablets similar appearance hydroxychloroquine tablets prescribed identical regimen control group rising pharmaceuticals provided donation hydroxychloroquine hydroxychloroquine purchased primary outcome prespecified symptomatic illness confirmed positive molecular assay testing unavailable covid<NUMBER>related symptoms assumed health care workers would access covid<NUMBER> testing symptomatic however access testing limited throughout trial period covid<NUMBER>related symptoms based us council state territorial epidemiologists criteria confirmed cases positivity sarscov<NUMBER> pcr assay probable cases presence cough shortness breath difficulty breathing presence two symptoms fever chills rigors myalgia headache sore throat new olfactory taste disorders possible cases presence one compatible symptoms could include diarrhea <NUMBER> participants epidemiologic linkage <NUMBER> per trial eligibility criteria four infectious disease physicians unaware trialgroup assignments reviewed symptomatic participants generate consensus respect whether condition met case definition <NUMBER> secondary outcomes included incidence hospitalization covid<NUMBER> death incidence pcrconfirmed sarscov<NUMBER> infection incidence covid<NUMBER> symptoms incidence discontinuation trial intervention owing cause severity symptoms days <NUMBER> <NUMBER> according visual analogue scale scores ranged <NUMBER> symptoms <NUMBER> severe symptoms data adverse events also collected directed questioning common side effects along openended free text outcome data measured within <NUMBER> days trial enrollment outcome data including pcr testing results possible covid<NUMBER>related symptoms adherence trial intervention side effects hospitalizations collected participant report details trial conduct provided protocol statistical analysis plan available nejmorg anticipated illness compatible covid<NUMBER> would develop <NUMBER> close contacts exposed covid<NUMBER> <NUMBER> using fishers exact method <NUMBER> relative effect size reduce new symptomatic infections twosided alpha <NUMBER> <NUMBER> power estimated <NUMBER> persons would need enrolled group pragmatic internetbased selfreferral recruitment strategy planned <NUMBER> incidence attrition increasing sample size <NUMBER> participants per group specified priori participants already symptomatic day <NUMBER> receiving hydroxychloroquine placebo would excluded prophylaxis trial would instead separately enrolled companion symptomatic treatment trial h e ne w e ngl nd jou r na l f e dicine estimates incident symptomatic covid<NUMBER> exposure loss followup relatively unknown early march <NUMBER> <NUMBER> protocol prespecified samplesize reestimation second interim analysis reestimation used incidence new infections placebo group observed percentage participants lost followup aimed maintaining ability detect effect size <NUMBER> relative reduction new symptomatic infections independent data safety monitoring board externally reviewed data <NUMBER> <NUMBER> participants completed <NUMBER> days followup stopping guidelines provided data safety monitoring board use landemets spending function analogue obrienfleming boundaries primary outcome conditional power analysis performed second third interim analysis option early stopping futility second interim analysis april <NUMBER> <NUMBER> sample size reduced <NUMBER> participants could evaluated <NUMBER> power basis higherthanexpected event rate infections control group third interim analysis may <NUMBER> trial halted basis conditional power less <NUMBER> since deemed futile continue assessed incidence covid<NUMBER> disease day <NUMBER> fishers exact test secondary outcomes respect percentage patients also compared fishers exact test among participants incident illness compatible covid<NUMBER> developed summarized symptom severity score day <NUMBER> median interquartile range assessed distributions kruskalwallis test conducted analyses sas software version <NUMBER> sas institute according intentiontotreat principle twosided type error alpha <NUMBER> participants missing outcome data conducted sensitivity analysis outcomes excluded included event subgroups specified priori included type contact household vs health care days exposure enrollment age sex recruited <NUMBER> asymptomatic adult participants randomly assigned hydroxychloroquine group <NUMBER> participants placebo group <NUMBER> participants fig <NUMBER> demographic clinical characteristics participants provided table <NUMBER> figure <NUMBER> shows development covid<NUMBER> time two hospitalizations reported one group arrhythmias deaths occurred meaningful difference effectiveness according time starting postexposure prophylaxis prespecified subgroups fig s<NUMBER> supplementary appendix overall <NUMBER> participants <NUMBER> hydroxychloroquine group <NUMBER> placebo group complete day <NUMBER> survey among participants vital status unknown <NUMBER> hydroxychloroquine group <NUMBER> control group sensitivity analyses exclusion persons denominator inclusion event affect trial conclusions table s<NUMBER> <NUMBER> persons symptomatic illness developed <NUMBER> pcrconfirmed disease <NUMBER> illness compatible probable covid<NUMBER> per us case definition <NUMBER> possible covid<NUMBER> compatible symptoms epidemiologic linkage <NUMBER> adjudicated covid<NUMBER> basis symptom complex table s<NUMBER> four additional participants positive pcr tests asymptomatic <NUMBER>day trial period symptoms eventually developed <NUMBER> participants median number symptoms <NUMBER> interquartile range <NUMBER> <NUMBER> among participants covid<NUMBER> frequent symptoms cough <NUMBER> <NUMBER> participants covid<NUMBER> fever <NUMBER> shortness breath <NUMBER> fatigue <NUMBER> sore throat <NUMBER> myalgia <NUMBER> anosmia <NUMBER> among participants symptomatic day <NUMBER> median symptomseverity score scale <NUMBER> <NUMBER> higher scores indicating greater severity <NUMBER> interquartile range <NUMBER> <NUMBER> receiving hydroxychloroquine <NUMBER> interquartile range <NUMBER> <NUMBER> receiving placebo p <NUMBER> adherence among trial participants moderate full adherence trial intervention differed according trial group <NUMBER> participants hydroxychloroquine group <NUMBER> <NUMBER> <NUMBER> placebo group <NUMBER> <NUMBER> taken <NUMBER> prescribed tablets period <NUMBER> days p <NUMBER> common reason participants stopped taking assigned hydroxychloroquine placebo side effects <NUMBER> participants hydroxychloroquine group <NUMBER> placebo group side effects frequent hydroxychloroquine placebo table <NUMBER> among <NUMBER> participants underwent randomization <NUMBER> complete day <NUMBER> followup survey <NUMBER> formally withdrew trial <NUMBER> group investigators confirmed vital status lack infection <NUMBER> participants <NUMBER> hydroxychloroquine group <NUMBER> control group <NUMBER> completed followup surveys without symptoms lost followup <NUMBER> hydroxychloroquine group <NUMBER> control group total <NUMBER> participants never completed surveys enrollment respond investigators emails text messages telephone calls <NUMBER> hydroxychloroquine group <NUMBER> control group sarscov<NUMBER> denotes severe acute respiratory syndrome coronavirus <NUMBER> day <NUMBER> assessed well masking trial interventions maintained <NUMBER> participants hydroxychloroquine group completed day <NUMBER> survey question <NUMBER> <NUMBER> correctly identified received hydroxychloroquine <NUMBER> <NUMBER> unsure <NUMBER> <NUMBER> believed received placebo <NUMBER> participants control group completed day <NUMBER> survey question <NUMBER> <NUMBER> correctly identified received placebo <NUMBER> <NUMBER> unsure <NUMBER> <NUMBER> believed received hydroxychloroquine participants reported side effect regardless trial group day <NUMBER> <NUMBER> times likely believe received hydroxychloroquine participants report side effects <NUMBER> <NUMBER> participants <NUMBER> reporting side effects <NUMBER> <NUMBER> participants <NUMBER> reporting side effects p<NUMBER> absence side effects blinding well maintained randomized doubleblind placebocontrolled trial investigated efficacy hydroxychloroquine covid<NUMBER> postexposure percentages may total <NUMBER> rounding iqr denotes interquartile range ppe personal protective equipment † total <NUMBER> women <NUMBER> <NUMBER> pregnant <NUMBER> <NUMBER> <NUMBER> breastfeeding time enrollment one woman <NUMBER> reported new pregnancy day <NUMBER> ‡ highrisk exposure defined exposure person confirmed coronavirus disease <NUMBER> covid<NUMBER> distance less <NUMBER> ft <NUMBER> minutes wearing neither face mask eye shield prophylaxis trial high doses hydroxychloroquine prevent illness compatible covid<NUMBER> initiated within <NUMBER> days highrisk moderaterisk exposure used pragmatic approach recruitment followup participants internetbased selfreferral online followup surveys couriered trial interventions directly participants homes approach allowed recruitment across north america minimized risk sarscov<NUMBER> infection researchers lowered burden research participation provided timely answer question whether postexposure prophylaxis effective moreover approach allowed broad geographic participation regardless anyones physical distance academic centers increasing generalizability findings one result approach enrolled participants generally younger healthier risk severe covid<NUMBER> although risk severe covid<NUMBER> related age coexisting conditions <NUMBER> risk acquiring symptomatic infection generally still present among adults regardless age although pcr serologic testing asymptomatic infection would added scientific strength trial possible cannot assess effect mild asymptomatic infections although marginal possible benefit prophylaxis atrisk group cannot ruled potential risks associated hydroxychloroquine may also increased atrisk populations may essentially negate benefits shown large trial involving younger healthier participants acknowledge trial limitations lack availability diagnostic testing united states vast majority participants including health care workers unable access testing thus priori symptomatic case definition used us clinical case definition probable covid<NUMBER> <NUMBER> trial represents realworld implementation exposure context randomized trial design nonsarscov<NUMBER> viral infection eg influenza adenovirus rhinovirus equally distributed trial groups owing internetbased approach used rapidly recruit participants context pandemic data obtained means participant report types frequency symptoms observed similar previous studies involving us health care providers <NUMBER> us case definition probable covid<NUMBER> cases nationally reportable <NUMBER> <NUMBER> however predictive power case definition unknown particularly younger populations studied given small number pcr tests remains theoretically possible hydroxychloroquine therapy limits proven infection reproduction results ongoing trials would confirm findings randomized trial demonstrate significant benefit hydroxychloroquine postexposure prophylaxis covid<NUMBER> whether pre covid<NUMBER> cumulative incidence illness compatible covid<NUMBER> <NUMBER> hydroxychloroquine group <NUMBER> <NUMBER> participants <NUMBER> placebo group <NUMBER> <NUMBER> p <NUMBER> difference equates number needed treat prevent one infection <NUMBER> persons lower boundary <NUMBER> confidence interval number needed treat prevent one infection <NUMBER> persons upper boundary <NUMBER> confidence interval number needed treat harm <NUMBER> person <NUMBER> persons excluded participants lost followup withdrew fully adherent trial intervention results similar excluded <NUMBER> persons possible covid<NUMBER> cases one symptom compatible covid<NUMBER> laboratory confirmation incidence new covid<NUMBER> still differ significantly two groups <NUMBER> hydroxychloroquine group <NUMBER> <NUMBER> participants <NUMBER> placebo group <NUMBER> <NUMBER> p <NUMBER> vertical bars represent <NUMBER> confidence intervals h e ne w e ngl nd jou r na l f e dicine exposure prophylaxis would effective highrisk populations separate question trials ongoing order end pandemic reduction community transmission needed values day <NUMBER> date scheduled completion trial intervention one side effect could occur ongoing side effects reported approximately <NUMBER> participants hydroxychloroquine group days <NUMBER> <NUMBER> less <NUMBER> placebo group association occurrence side effects incidence covid<NUMBER> among participants covid<NUMBER> developed <NUMBER> <NUMBER> <NUMBER> reported side effect compared <NUMBER> <NUMBER> <NUMBER> reporting side effect covid<NUMBER> develop p <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> pandemic rapidly spreading worldwide reported <NUMBER> severe patients mild atypical symptoms initially rapidly progress acute respiratory distress syndrome main cause respiratory failure <NUMBER> studies reported effectiveness convalescent plasma cp transfusion treating critically ill patients covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> clinical symptoms significantly improved within <NUMBER> days viral load undetectable within <NUMBER> days cp transfusion <NUMBER> results encouraging worthy investigation nevertheless zeng et al <NUMBER> reported sarscov<NUMBER> became undetectable cp transfusion could reduce mortality critically ill covid<NUMBER> patients moreover hydroxychloroquine found active sarscov<NUMBER> vitro treatment option clinical practice yao et al <NUMBER> reported hydroxychloroquine potent chloroquine inhibit sarscov<NUMBER> vitro herein administered cp transfusion hydroxychloroquine patient severe covid<NUMBER> analyzed clinical symptoms oxygenation index oi dynamics viral load <NUMBER>yearold chinese man diagnosed laboratoryconfirmed covid<NUMBER> admitted isolation ward <NUMBER> march <NUMBER> week admission flew brazil airport subsequently home isolation <NUMBER> march <NUMBER> presented fever <NUMBER>°c chills myalgia viral rna test throat swab positive cycle threshold ct values open reading frame <NUMBER>ab orf<NUMBER>ab nucleocapsid n genes rtpcr assay <NUMBER> <NUMBER> indicating high viral load computed tomography ct scan showed bilateral pneumonia laboratory findings showed high lactic acid level <NUMBER> mmoll creactive protein crp <NUMBER> mgl low white blood cell count <NUMBER> × <NUMBER> <NUMBER> l indicative severe covid<NUMBER> oxygen atomized inhalation recombinant human interferonɑ<NUMBER>b given admission cp two convalescent patients intravenously given hydroxychloroquine shanghai zhongxi pharmaceuticals shanghai china orally administrated week <NUMBER> g three times day shown fig <NUMBER> day <NUMBER> cp transfusion lactic acid crp levels remained high <NUMBER> mmoll <NUMBER> mgl respectively arterial oxyhemoglobin saturation sao <NUMBER> decreased <NUMBER> oi decreased <NUMBER> mmhg mechanical ventilation administered temperature returned normal oi ascended <NUMBER> day <NUMBER> ventilator withdrawn day <NUMBER> cp transfusion rna test remained positive throat swab ct revealed severe pulmonary lesions fig <NUMBER> addition apparent sideeffects found cp transfusion hydroxychloroquine treatments currently pathogenesis covid<NUMBER> remains unclear specific treatment available cytokine storm excessive inflammation coexist may lead multiple organ failure antiviral therapy treatment systematic response important patients rapid deterioration covid<NUMBER> study small sample size median time onset illness cp transfusion <NUMBER> days disappearance viremia observed <NUMBER> days cp transfusion <NUMBER> results suggested cp therapy could potentially improve clinical outcomes neutralizing viremia severe covid<NUMBER> <NUMBER> another study cp transfusion given median <NUMBER> days first detection sarscov<NUMBER> viral load became negative <NUMBER> days cp transfusion though <NUMBER> <NUMBER> patients died eventually <NUMBER> unexpectedly viral load remained detectable day <NUMBER> combination therapy cp hydroxychloroquine considering time onset illness cp transfusion previous studied <NUMBER> <NUMBER> difficult prove whether viremia cured cp antiviral agent natural course covid<NUMBER> indeed limitation antibodies sarscov<NUMBER> cp two convalescent patients present patient detected based clinical experience sufficient evidence supporting use cp hydroxychloroquine treating covid<NUMBER> lacking findings suggested effectiveness combination therapy cp hydroxychloroquine may nonoptimal specific therapy needs explored march <NUMBER> <NUMBER> world health organization launched solidarity trial soon addon trial european initiative reacting consortium discovery trial announced <NUMBER> <NUMBER> currently approved therapies specific human cov trials based repurposed drugs already approved diseases acceptable safety profiles performed well animal studies two deadly coronaviruses cause sars middle east respiratory syndrome mers solidarity includes research looking four possible therapeutics direct antiviral actions remdesivir chloroquine hydroxychloroquine lopinavir plus ritonavir lopinavir plus ritonavir interferonbeta chloroquine included discovery trial additionally discovery trial include placebo arm standard care solidarity trial blinded patients know received treatment would cause placebo effect stated ana maria henao restrepo medical officer department immunization vaccines biologicals additional information regarding lung imaging blood gases monitored discovery trial besides data hospitalization length requirement oxygen ventilation collected solidarity trial <NUMBER> sarscoronavirus<NUMBER> sarscov<NUMBER> etiologic agent new lung disease covid<NUMBER> <NUMBER> closely related sarscov together merscov three new human coronaviruses emerged last <NUMBER> years <NUMBER> three viruses associated increased risk acute lung injury <NUMBER> april <NUMBER> <NUMBER> <NUMBER> million people infected worldwide <NUMBER> countries resulting death toll surpasses <NUMBER> people ongoing pandemic https wwwworldometersinfocoronavirus sarscov<NUMBER> enveloped positive sense single stranded nonsegmented rna virus betacoronavirus family <NUMBER> copying synthesis novel viral genomes viral mrnas expression viral proteins remdesivir incorporation nascent viral rna rdrp results premature chain termination high conservation core rdrp enzyme among coronaviruses broadspectrum antiviral efficacy multiple genetically distinct coronaviruses including sarscov merscov vitro vivo <NUMBER> furthermore shown prophylactic action infection corona viruses animal models <NUMBER> notably remdesivir potently blocked sarscov<NUMBER> infection lowmicromolar concentration showed high selectivity index vero e<NUMBER> cells monkey epithelial cell line ec <NUMBER> <NUMBER> µm cc <NUMBER> <NUMBER> µm si <NUMBER> <NUMBER> noted remdesivir resistance already documented sarscov coronaviruses lead reduced viral inhibition <NUMBER> outcomes cohort patients hospitalized severe covid<NUMBER> treated remdesivir compassionateuse basis recently reported grein et al <NUMBER> fiftythree patients received <NUMBER>day course remdesivir consisting loading dose <NUMBER> mg intravenously day <NUMBER> plus <NUMBER> mg daily following <NUMBER> days improvement oxygensupport status observed <NUMBER> patients overall mortality <NUMBER> median followup <NUMBER> days although data viral dynamics documented throughout study clinical improvement less frequent among patients receiving invasive ventilation among receiving noninvasive ventilation among patients aged <NUMBER> years older compared patients younger <NUMBER> years chloroquine hydroxychloroquine less toxic derivative represent potential broadspectrum example inhibiting viral cell entry chloroquine weak base becomes entrapped membraneenclosed low ph organelles endosomes lysosomes inhibits acidification low ph endosomes regulates action proteases lead conformational changes virus envelope proteins allowing fusion cellular viral membranes escape viral genome cytosol attachment entry sarscov<NUMBER> host cells requires interaction spike protein subdomain <NUMBER> angiotensin converting enzyme <NUMBER> ace<NUMBER> proteolytic cleavage tmprss<NUMBER> lesser degree acid activated cathepsin bl <NUMBER> although exact mechanism sarscov<NUMBER> entry completely understood new study suggested phdependent fusion viral cellular membranes dispensable viral genome entry host cells chloroquine similarly remdesivir inhibited sarscov<NUMBER> infection lowmicromolar concentration showed high selectivity index vero e<NUMBER> cells ec <NUMBER> <NUMBER> µm cc <NUMBER> <NUMBER> µm si <NUMBER> <NUMBER> chloroquine also used treatment autoimmune diseases sle ra <NUMBER> although precise mechanism action documented inhibition endosome acidification also interferes innate immune response signaling endosomal tlrs tlr <NUMBER> <NUMBER> <NUMBER> <NUMBER> mainly detect nucleic acid pamps damps way reduce inflammatory responses therefore chloroquine hydroxychloroquine may also protect host overt inflammatory responses driven activation immune cells macrophages increased load viral rna cellular nucleic acids released infected cells results clinical trials using chloroquine provided promising results despite limitations studies suggest chloroquine may represent line defense protection medical stuff patients increased risk severe covid<NUMBER> symptoms chen et al <NUMBER> evaluated efficacy hydroxychloroquine hcq treatment <NUMBER> patients mild covid<NUMBER> february <NUMBER> <NUMBER> <NUMBER> renmin hospital wuhan university patients randomized either control group receiving standard treatment hcq group patients received standard treatment plus hcq <NUMBER> mgbid days <NUMBER> <NUMBER> study focused time clinical recovery ttcr clinical characteristics patients pulmonary recovery depicted chest ct results one day day <NUMBER> one day day <NUMBER> beneficial effect hcq treatment covid<NUMBER> pointed despite small number cases specifically body temperature recovery time cough remission time significantly reduced hcq treatment group moreover study chest ct scans revealed larger proportion patients improved pneumonia hcq group <NUMBER> compared control group <NUMBER> gautret et al <NUMBER> france conducted single arm protocol early march march <NUMBER> patients received <NUMBER> mg hydroxychloroquine daily azithromycin added treatment regimen clinical presentation required control group represented untreated patients another center cases refusing protocol patients viral load nasopharyngeal swabs evaluated daily basis virus clearance day<NUMBER> postinclusion primary endpoint virus clearance study period clinical parameters occurrence sideeffects considered secondary outcomes regarding effect hydroxychloroquine viral load study showed greater proportion patients treated group negative pcr results days <NUMBER> postinclusion compared control group interestingly day <NUMBER> postinclusion percentage negative pcr patients treated group <NUMBER> <NUMBER> control group p<NUMBER> addition azithromycin therapeutic regimen enhanced beneficial effect hydroxychloroquine intensely patients treated hydroxychloroquine azithromycin <NUMBER> clear virus day <NUMBER> postinclusion comparing <NUMBER> group treated hydroxychloroquine <NUMBER> control group p<NUMBER> last two arms solidarity discovery trials include kaletra combination two antiviral drugs lopinavir ritonavir normally used treat hiv lopinavir acts viral <NUMBER>cl protease responsible cleavage viral structural proteins polypeptide chain order produce new virions lopinavir modest antiviral activity mers significantly less potent remdesivir <NUMBER> however combination ritonavir antiviral immunomodulator interferon β currently clinical trials treatment mers <NUMBER> efficacy safety oral lopinavirritonavir sarscov<NUMBER> infection tested randomized controlled trial china found benefit beyond standard care <NUMBER> kaletra without interferon β<NUMBER> tested solidarity discovery trials favipiravir brand name avigan type rnadependent rna polymerase rdrp inhibitor acts blocking replication rna viruses potential antiviral agent sarscov<NUMBER> <NUMBER> prospective multicenter openlabel randomized superiority trial examined efficacy favipiravir n<NUMBER> versus arbidol n<NUMBER> treating covid<NUMBER> <NUMBER> difference <NUMBER>day clinical recovery rate primary endpoint favipiravir versus arbidol overall population <NUMBER> versus <NUMBER> p<NUMBER> however difference existed subgroup noncritical patients without hypertension diabetes favipiravir <NUMBER> versus arbidol <NUMBER> p<NUMBER> <NUMBER> three registered clinical trials planned regarding use favipiravir covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> several promising theurapeutic options emerging protease inhibitor specific tmprss<NUMBER> cell protease required virus entry <NUMBER> broad spectrum orally bioavailable βdn<NUMBER>hydroxycytidine nhc eidd<NUMBER> incorporated viral genome rdrp leading accumulation deleterious mutations viral inactivation <NUMBER> four current regimens solidarity discovery focus antiviral drugs rather treating ards symptoms actually cause virus morbidity mortality hyperinflammation coronavirus disease <NUMBER> covid<NUMBER> could driver severity may managed immunomodulatory therapeutic options <NUMBER> <NUMBER> lowdose corticosteroid therapy shockreversal corticosteroid therapy suggested adults covid<NUMBER> refractory shock mechanically ventilated adults covid<NUMBER> respiratory failure without ards routine use systemic corticosteroids suggested however mechanically ventilated adults covid<NUMBER> ards using systemic corticosteroids suggested <NUMBER> <NUMBER> <NUMBER> importantly use hydroxychloroquine without coadministration azithromycin may beneficial treatment critically ill patients admitted icu <NUMBER> recommended <NUMBER> <NUMBER> immunomodulatory drugs tocilizumab actemra antiil<NUMBER> tested pandemic however great caution inhibiting host antiviral responses taken <NUMBER> tocilizumab actemra recombinant humanized antihuman il<NUMBER> receptor monoclonal antibody currently used rheumatoid arthritis <NUMBER> xu et al demonstrated giving tocilizumab addition routine therapy patients diagnosed severe critical covid<NUMBER> effective treatment <NUMBER> covacta newly initiated randomized doubleblind placebocontrolled phase iii study evaluate safety efficacy intravenous actemraroactemra added standard care adult patients hospitalized severe covid<NUMBER> pneumonia compared placebo plus standard care primary secondary endpoints include clinical status mortality mechanical ventilation intensive care unit icu variables <NUMBER> finally use stem cell therapy treat covid<NUMBER> currently considered multiple clinical trials china registered wwwclinicaltrialsgov <NUMBER> recently published clinical trial limited number patients <NUMBER> patients <NUMBER> critically serious <NUMBER> serious <NUMBER> common infected coronavirus received one dose stem cell therapy <NUMBER> patients control group <NUMBER> serious patients stem cell therapy recovered whereas control group one patient died another patient developed ards one patient control group stable <NUMBER> important considerations successful testing use currently available future therapies covid<NUMBER> timing treatment viral load patient markers predictive lung injury antiviral treatment efficient prophylactic measure earlier times infection virus replication peak conversely immunomodulatory antiinflammatory treatments may effective later may combined careful monitoring patient viral loads emergence zoonotic human viruses causing pandemics probably going limited sarscov<NUMBER> represent enormous threats global health pandemic preparedness future broadbased vaccines therapeutics active higher risk virus families prone emergence desperately needed well global efforts minimize emergence das editorinchief journal personal involvement reviewing process influence terms adjudicating final decision article authors declare competing interests abstract world health organization informed december <NUMBER> coronavirus pneumonia outbreak wuhan hubei province china subsequently march <NUMBER> <NUMBER> <NUMBER> cases <NUMBER> deaths reported coronavirus enveloped rna virus genus betacoronavirus distributed birds humans mammals named novel coronavirus disease covid<NUMBER> <NUMBER> clinical trials launched test coronavirus treatment including drug repurposing repositioning covid<NUMBER> hence performed search march <NUMBER> clinicaltrialsgov database eligibility criteria retrieved studies contain clinicaltrialsgov base identifier number describe number participants period study describe participants clinical conditions utilize interventions medicines already studied approved disease patients infected novel coronavirus sarscov<NUMBER> <NUMBER>ncov essential emphasize article captured trials listed clinicaltrialsgov database identified <NUMBER> clinical trials involving <NUMBER> medicines human immunoglobulin interferons chloroquine hydroxychloroquine arbidol remdesivir favipiravir lopinavir ritonavir oseltamivir methylprednisolone bevacizumab traditional chinese medicines tcm although drug repurposing limitations repositioning clinical trials may represent attractive strategy facilitate discovery new classes medicines lower costs take less time reach market existing pharmaceutical supply chains formulation distribution clinical trials drug repositioning covid<NUMBER> treatment ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la covid<NUMBER> ensaios clínicos de reposicionamento de medicamentos para tratamento covid<NUMBER> world health organization informed december <NUMBER> <NUMBER> pneumonia outbreak wuhan hubei province china city <NUMBER> million inhabitants march <NUMBER> <NUMBER> <NUMBER> <NUMBER> cases <NUMBER> <NUMBER> deaths nearly <NUMBER> cases reported novel coronavirus <NUMBER> named <NUMBER>novel coronavirus <NUMBER>ncov later renamed severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> named novel coronavirus disease covid<NUMBER> <NUMBER> <NUMBER> confirmed cases <NUMBER> countries territories outside china including japan united states america italy iran brazil <NUMBER> coronavirus enveloped rna virus genus betacoronavirus distributed birds humans mammals <NUMBER> <NUMBER> new evidence indicates link sarscov<NUMBER> bat coronavirus <NUMBER> six species coronavirus known infectious humans four <NUMBER>e oc<NUMBER> nl<NUMBER> hku<NUMBER> cause common cold symptoms <NUMBER> however authors claimed sarscov<NUMBER> even related coronavirus species responsible severe acute respiratory syndrome sarscov well middle east respiratory syndrome merscov zoonotic origins linked severe significant illness higher mortality <NUMBER> <NUMBER> example july <NUMBER> reported <NUMBER> <NUMBER> sarscov cases especially china hong kong <NUMBER> related deaths <NUMBER> concerning merscov june <NUMBER> april <NUMBER> <NUMBER> <NUMBER> people infected <NUMBER> countries <NUMBER> <NUMBER> cases saudi arabia <NUMBER> deaths <NUMBER> unfortunately vaccines medicines approved novel coronavirus infection <NUMBER> <NUMBER> clinical trials launched test coronavirus treatments including drug repurposing repositioning covid<NUMBER> <NUMBER> drug repositioning neglected diseases essential universal strategy development new drugs due lower costs reduced time reach market clinical trial steps might required especially concerning phases ii b existing pharmaceutical supply chains available formulation distribution c possibility combinations drugs treatments effective monotherapy may facilitate discovery new mechanisms action old drugs new classes medicines <NUMBER> <NUMBER> hand repurposing strategy limitations including patent barriers complexity regulatory pathways absence funding opportunities greater access data industrysponsored clinical trials heterogeneity population new clinical studies <NUMBER> nevertheless drug repurposing still tool discovery entirely new classes medicines <NUMBER> <NUMBER> hence considering scenario felt interest aware drug repositioning clinical tests covid<NUMBER> treatment performed search march <NUMBER> <NUMBER> clinicaltrials gov database descriptor coronavirus simple search field conditions disease search without restrictions languages disease conditions results locations eligibility criteria retrieved studies contain clinicaltrialsgov base identifier number describe number participants study period describe patients clinical conditions interventions utilize medicines already studied approved disease patients covid<NUMBER> clinicaltrialsgov resource us national library medicine contains clinical studies conducted <NUMBER> countries identified <NUMBER> clinical trials table <NUMBER> <NUMBER> studies clinical phases <NUMBER> <NUMBER> <NUMBER> pharmaceutical interventions found covid<NUMBER> treatment include human immunoglobulin interferons chloroquine hydroxychloroquine arbidol remdesivir oseltamivir favipiravir carrimycin methylprednisolone bevacizumab thalidomide vitamin c pirfenidone bromhexine fingolimod danoprevir ritonavir darunavir cobicistat lopinavir xiyanping traditional chinese medicines tcm chloroquine hydroxychloroquine antimalarial drugs antiviral effects human immunodeficiency virus hiv namely inhibiting virus entry host cells another antiviral mechanism related posttranslation alteration newly synthesized proteins via glycosylation inhibition <NUMBER> hydroxychloroquine already used clinical trials acquired immune deficiency syndrome aids treatment <NUMBER> recent trial patients covid<NUMBER> treatment <NUMBER> <NUMBER> patients treated hydroxychloroquine combination macrolide antibiotic azithromycin virologically cured comparing <NUMBER> patients treated hydroxychloroquine alone <NUMBER> control group currently chloroquine hydroxychloroquine tested <NUMBER> <NUMBER> patients pneumonia caused <NUMBER>ncov chloroquine preventative medicine covid<NUMBER> shown table <NUMBER> immunoglobulins useful several diseases idiopathic thrombocytopenia purpura itp guillainbarre syndrome gbs chronic inflammatory demyelinating polyneuropathy cidp kawasaki disease multiple neurological autoimmune disorders refractory standard immunosuppressive treatments <NUMBER> broadly neutralizing antibodies recognize wide variety glycoproteins gps virus surfaces protein shell nonenveloped virus however hiv<NUMBER> dengue virus denv influenza viruses hepatitis c virus hcv ebola virus ebov mutate superficial gps order evade antibody response obstacle development new therapies infections <NUMBER> trial nct<NUMBER> <NUMBER> utilizing human immunoglobulin patients pneumonia caused <NUMBER>ncov table <NUMBER> two clinical studies refer use remdesivir severe <NUMBER> mild <NUMBER> respiratory infections sarscov<NUMBER> remdesivir nucleotide analog inhibitor ebov rnapolymerase rnadependent rdrp dyer et al <NUMBER> <NUMBER> described preliminary findings mortality rate <NUMBER> <NUMBER> patients treated remdesivir ebov disease early infection stages authors noted mortality rate <NUMBER> almost <NUMBER> <NUMBER> people nontreated infected patients epidemic period <NUMBER> wang et al <NUMBER> <NUMBER> presented data showing remdesivir effective <NUMBER>ncov vero e<NUMBER> cells ec <NUMBER> <NUMBER> μm suggested mechanism remdesivir involves host cells postentry stage <NUMBER> arbidol also known umifenovir approved russia china treatment influenza virus infections significant adverse effects patented sars treatment <NUMBER> shown table <NUMBER> four clinical trials conducted covid<NUMBER> treatment one arbidol comparison basic treatment <NUMBER> three studies comparing effects oseltamivir <NUMBER> <NUMBER> lopinavirritonavir <NUMBER> carrimycin <NUMBER> arbidol antiviral mechanism influenza b involves viral fusion inhibition targeted membrane blocks virus entry cell <NUMBER> oseltamivir another drug approved influenza b treatment inhibits viral neuraminidase consequently blocks release viral particles host cells reducing spread respiratory tract <NUMBER> additionally use oseltamivir already reported covid<NUMBER> epidemic china either without antibiotics corticosteroids <NUMBER> oseltamivir also used clinical trial multiple combinations chloroquine favipiravir <NUMBER> nucleoside analog wellknown broadspectrum antiviral drug shown <NUMBER> ec <NUMBER> <NUMBER> µm sarscov<NUMBER> low toxicity cc<NUMBER> <NUMBER> µm lopinavirritonavir combination approved aids treatment several countries drugs hiv protease inhibitors ritonavir also cytochrome p<NUMBER> gp inhibitor fact endorses lopinavir pharmacokinetic pharmacodynamic activities hiv <NUMBER> combination plus b<NUMBER>b interferon phase <NUMBER> mers treatment <NUMBER> several trials involve lopinavirritonavir treatment comparison use drugs covid<NUMBER> <NUMBER> <NUMBER> carrimycin <NUMBER> tcm <NUMBER> <NUMBER> xiyanping <NUMBER> <NUMBER> danoprevirritonavir <NUMBER> interferon inhalation <NUMBER> <NUMBER> nevertheless one previous article argued clinical trial <NUMBER> patients laboratoryconfirmed sarscov<NUMBER> infection lopinavirritonavir combination associated clinical improvement comparing standard care procedures <NUMBER> carrimycin macrolide antibiotic effects grampositive bacteria vitro effects mycobacterium tuberculosis <NUMBER> danoprevir hcv ns<NUMBER> protease inhibitor approved china treatment noncirrhotic genotype <NUMBER>b chronic hepatitis c combination ritonavir peginterferona ribavirin <NUMBER> traditional chinese medicine tcm uses phytotherapeutic formulations teas pills powders tinctures cultural components originated <NUMBER> years ago chinese medicine <NUMBER> tcms already used sarscov infection <NUMBER> coadjuvant therapy enhancement patients symptoms increased oxyhemoglobin arterial saturation proved useful early stages infection <NUMBER> interferons ifns proteins bind cellular surfaces receptors initiate jakstat signaling cascades transcriptional regulation genes controlled interferons effects viruses like hepatitis b virus hcv <NUMBER> xiyanping tcm preparation andrographolide principal component significant antibacterial antiviral effects <NUMBER> darunavir combination cobicistat used trial number nct<NUMBER> <NUMBER> patients covid<NUMBER> pneumonia united states food drug administration fda currently approves combination aids treatment darunavir another hiv protease inhibitor cobicistat like ritonavir booster enhancing pharmacokinetics pharmacodynamics darunavir cytochrome p<NUMBER> cyp<NUMBER>a inhibition <NUMBER> <NUMBER> recombinant human interferon a<NUMBER>b described inhibitory effects merscov sarscov <NUMBER> purpose clinical trials found paper evaluate efficacy safety recombinant human interferon a<NUMBER>b treating patients new coronavirus infection <NUMBER> thalidomide used two trials covid<NUMBER> <NUMBER> <NUMBER> thalidomide antiinflammatory action due ability speed degradation messenger rna blood cells thus reduce tumor necrosis factora tnfa furthermore thalidomide increase secretion interleukins il<NUMBER> activate natural killer cells <NUMBER> corticosteroid methylprednisolone tested covid<NUMBER> <NUMBER> long et al <NUMBER> <NUMBER> reported corticosteroid therapy methylprednisolone dexamethasone hydrocortisone beneficial treating sarscov patients significantly prolongs survival time clinical cases nevertheless authors described use corticosteroids early stages sars infection increasing values viral load <NUMBER> furthermore studies corticosteroids adjuvant therapy merscov infection unable prove efficacy patients died <NUMBER> methylprednisolone already used covid<NUMBER> patients combination antibiotics oseltamivir oxygen therapy <NUMBER> finally vitamin c ascorbic acid pirfenidone bevacizumab fingolimod bromhexine hydrochloride going tested covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> vitamin c antioxidant activity may reduce oxidative stress inflammation <NUMBER> <NUMBER> effects improve vasopressor synthesis enhance immune cell function improve endovascular function provide epigenetic immunologic modifications clinical trials demonstrated promising data mortality improvement sepsis extensive studies necessary validate conclusions <NUMBER> pirfenidone used treatment idiopathic pulmonary fibrosis diseases due antiinflammatory antioxidant effects namely inhibiting il<NUMBER>b il<NUMBER> <NUMBER> trial nct<NUMBER> claimed <NUMBER> antiinflammatory effects may helpful sarscov<NUMBER> infection bevacizumab humanized monoclonal antibody targets vascular endothelial growth factor vegf <NUMBER> <NUMBER> may reduce levels vegf caused hypoxia severe inflammation upregulation infected respiratory tract epithelium might suppress edema patients covid<NUMBER> <NUMBER> fingolimod sphingosine<NUMBER>phosphate receptor regulator fty<NUMBER> effective immunology modulator useful multiple sclerosis <NUMBER> according pathological findings pulmonary edema hyaline membrane formation use immune modulators together ventilator support considered severe patients prevent development acute respiratory distress syndrome ards study nct<NUMBER> aims determine efficacy fingolimod covid<NUMBER> <NUMBER> bromhexine transmembrane protease serine inhibitor protease responsible activation sglycoprotein sarscov merscov viral entry plasma membrane <NUMBER> <NUMBER> one study <NUMBER> evaluate efficacy bromhexine combined standard treatmentstandard treatment patients covid<NUMBER> conclusion declared epidemic pneumonia caused sarscov<NUMBER> <NUMBER> review found <NUMBER> clinical trials already started repositioning <NUMBER> medicines covid<NUMBER> treatment human immunoglobulin interferons chloroquine hydroxychloroquine arbidol remdesivir favipiravir oseltamivir thalidomide methylprednisolone bevacizumab tcm hydroxychloroquineazithromycin combination first drug repurposed excellent results clinical trials sarscov<NUMBER> extended studies higher number patients needed confirm results besides limitations repositioning clinical trials still attractive strategy may facilitate discovery new classes medicines may reduce costs time reach market existing pharmaceutical supply chain formulation distribution possibility combinations drugs treatments effective monotherapy studies found article scheduled end <NUMBER> hope repositioning trials may help find solutions covid<NUMBER> treatment year disclaimer authors hold sole responsibility views expressed manuscript may necessarily reflect opinion policy rpsppajph andor paho coronavirus disease <NUMBER> covid<NUMBER> caused <NUMBER> novel coronavirus <NUMBER>ncov caused significant mortality declared global pandemic world health organization infection mainly presents fever cough breathing difficulty patients develop severe symptoms purpose review analyze impact virus kidney covid<NUMBER> infection causes acute kidney injury aki independent risk factor mortality angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors direct viral damage immunemediated damage play important roles pathogenesis aki covid<NUMBER> infection could synergistic effect virusinduced direct cytotropic effect cytokineinduced systemic inflammatory response aki caused viral infection analyzed available epidemiological studies proportion patients developing aki significantly higher develop severe disease continuous renal replacement therapy crrt used blood purification technique needed impact covid<NUMBER> infection chronic kidney disease ckd renal transplant patients also discussed manuscript vaccine developed <NUMBER>ncov virus date critical aspect management supportive care several investigative drugs studied drugs approved indications used several clinical trials underway across globe recently remdesivir received emergency use authorization food drug administration fda usa use patients hospitalized covid<NUMBER> prevention infection holds key management patients underlying kidney problems renal transplant patients vulnerable developing covid<NUMBER> infection covid<NUMBER> pandemic causing acute kidney injury impact patients chronic kidney disease renal transplantation series pneumonia cases unexplained etiology wuhan china since december <NUMBER> created public health concern resulted identification viral cause initial reports viral infection traced huanan seafood market wuhan china etiological agent identified coronavirus <NUMBER> world health organization named virus <NUMBER> novel coronavirus <NUMBER>ncov january <NUMBER> <NUMBER> declared public health emergency globally january <NUMBER> <NUMBER> <NUMBER> disease caused virus named coronavirus disease <NUMBER> covid<NUMBER> february <NUMBER> <NUMBER> <NUMBER> international committee taxonomy viruses designated etiological coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> number cases multiplying alarming rate globally resulting mortality declared covid<NUMBER> pandemic march <NUMBER> <NUMBER> <NUMBER> may <NUMBER> <NUMBER> <NUMBER> million confirmed cases covid<NUMBER> infection cases globally number reported deaths <NUMBER> <NUMBER> sars middle eastern respiratory syndrome mers covid<NUMBER> third known zoonotic cov infection belong betacov cluster <NUMBER> determination animal species carrying ncov preliminary studies showed ncov closely related adapa et al j clin med res <NUMBER> coronavirus isolated bats postulating theory possible transmission bats humans <NUMBER> genome homology sequence sarsncov sarscov <NUMBER> sarsncov high homology bat cov <NUMBER> studies suggest evidence strongly sarsncov might originated bats intermediate host transmission humans yet ascertained ji et al found snakes wildlife repositories sarsncov <NUMBER> various studies reported epidemiological data sarsncov studies shown elderly patients affected higher male preponderance mortality higher elderly severe comorbid conditions <NUMBER> case fatality rate estimated <NUMBER> depending case series described <NUMBER> <NUMBER> median incubation period <NUMBER> days median time first symptom death less elderly <NUMBER> mode transmission close contact people infection respiratory droplets infected person coughs sneezes another possible mechanism infected surfaces objects epidemiological data revealed severe illness rate covid<NUMBER> infection high <NUMBER> even though lungs main organs affected kidney also one main organs affected severe illness <NUMBER> acute kidney injury aki seen <NUMBER> cases infected sarscov merscov higher mortality rate <NUMBER> per literature <NUMBER> covid<NUMBER> infection causes aki independent risk factor mortality <NUMBER> <NUMBER> also impacts patients chronic kidney disease ckd patients chronic replacement therapies patients kidney transplant mohamed et al <NUMBER> evaluated contributing factors developing aki <NUMBER> intensive care unit icu patients study incidence aki <NUMBER> approximately <NUMBER> patients developed aki history ckd stages <NUMBER> <NUMBER> twentyeight percent patients ckd stages <NUMBER> <NUMBER> aki <NUMBER> sarscov<NUMBER> spike protein attaches angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptors protein cleaved activated transmembrane serine proteases family tmprss allows virus release fusion peptide aids membrane fusion <NUMBER> aki covid<NUMBER> infection could synergistic effect virusinduced direct cytotropic effect cytokineinduced systemic inflammatory response aki pronounced patients severe disease acute respiratory distress syndrome ards needing icu admission possible mechanisms aki could acute tubular necrosis atn due multiorgan failure shock possible prerenal etiology volume depletion secondary decreased oral intake high fever drug toxicity hemodynamic insult contrast exposure also play role workup aki covid<NUMBER> infection similar causes aki mohamed et al <NUMBER> discussed different etiologies aki study include ischemic acute tubular injury toxic acute tubular injury combination acute interstitial nephritis de novo glomerular disease prerenal azotemia unspecified reasons contributing factors different etiologies include hypotension shock rapid atrial fibrillation prolonged volume depletion rhabdomyolysis toxic agents vancomycin iodinated contrast overt proteinuria <NUMBER> prior studies shown positive sarscov ribonucleic acid rna polymerase gene fragments detected immunohistochemistry situ hybridization kidney specimens autopsy patients died sars <NUMBER> merscov infections also shown cause kidney epithelial cell damage apoptosis mediated receptors <NUMBER> studies suggest injury coronavirus direct cytotoxic effect kidney epithelial cells diao et al analyzed kidney tissue six patients autopsy immunohistochemistry demonstrated presence sarscov<NUMBER> nucleocapsid np protein kidney tubule possibly related potential direct tubular injury virus <NUMBER> sarscov<NUMBER> rna detected urine patients quantitative realtime polymerase chain reaction qrtpcr <NUMBER> normal human lung type <NUMBER> type <NUMBER> alveolar epithelial cells express ace<NUMBER> expressed <NUMBER> type <NUMBER> cells men higher expression rate ace<NUMBER> levels compared women similarly asians express higher ace<NUMBER> levels compared white african american populations <NUMBER> analysis xu et al found ace<NUMBER> receptor expression kidney less lung comparative analysis <NUMBER> podocytes proximal convoluted tubule cells significantly coexpress ace<NUMBER> tmprss genes potential targets sarscov<NUMBER> kidney tissue expresses ace<NUMBER> gene higher lung tissue binding affinity sarscov<NUMBER> ace<NUMBER> receptors <NUMBER> <NUMBER> times higher sarscov described wrapp colleagues <NUMBER> proinflammatory cytokine levels elevated covid<NUMBER> infection probable activation tcell response <NUMBER> possible occurrence cytokine storm severe cases evidenced significantly higher cytokine levels cytokine storm immune system damages healthy tissues rather sarscov<NUMBER> <NUMBER> autopsies six kidney tissues light microscopy revealed cluster differentiation <NUMBER> cd<NUMBER> macrophage infiltration tubulointerstitium severe atn tubules showed complement <NUMBER>b<NUMBER> deposition six cases deposition glomeruli capillaries seldom seen cd<NUMBER> lymphocyte cells cd<NUMBER> natural killer cells seen kidney tissue <NUMBER> recently published studies china showed incidence aki patients infected covid<NUMBER> around <NUMBER> <NUMBER> <NUMBER> patients severe covid<NUMBER> infection icu rates aki increased significantly <NUMBER> <NUMBER> <NUMBER> variation reporting incidence aki depends number patients severity infection reporting aki across studies diagnosis aki based kidney disease improving global outcomes kdigo classification summarized table <NUMBER> <NUMBER> cheng colleagues analyzed large cohort <NUMBER> patients kidney disease confirmed covid<NUMBER> admitted tongji hospital january <NUMBER> <NUMBER> february <NUMBER> <NUMBER> <NUMBER> patients <NUMBER> years age patients history renal transplant maintenance dialysis excluded study baseline serum creatinine elevated <NUMBER> patients admission patients elevated serum creatinine group elderly higher percentage males days onset illness hospital admission shorter patients also severe disease comorbidities compared normal baseline serum creatinine patients pronounced aki higher rates mechanical ventilation hospital mortality rate higher patients elevated serum creatinine also leukocytosis lymphopenia thrombocytopenia prolonged activated partial thromboplastin time higher ddimer levels patients elevated baseline serum creatinine higher percentage increased procalcitonin aspartate aminotransferase lactic dehydrogenase levels aki occurred within <NUMBER> days much quicker severe elevated baseline serum creatinine group patients normal baseline creatinine later onset aki recovered quickly elevated blood urea nitrogen bun creatinine highgrade proteinuria hematuria elevated baseline serum creatinine patients along significantly lower estimated glomerular filtration rate egfr significant gap peak baseline creatinine elevated serum creatinine group patients elevated serum creatinine baseline worse outcomes compared patients normal baseline serum creatinine study li et al <NUMBER> analyzed <NUMBER> cases inpatients multiple hospitals around wuhan january <NUMBER> <NUMBER> february <NUMBER> <NUMBER> covid<NUMBER> disease <NUMBER> patients diagnosed severe cases according chinese nation health guidance three patients died severe cases <NUMBER> proteinuria present <NUMBER> patients many detected protein first day admission suggesting presence prior renal impairment bun elevated <NUMBER> patients also higher level bun present two patients died serum creatinine elevated <NUMBER> patients patients died extremely high levels density reduced computed tomography ct images kidney suggestive edema inflammation study wang et al <NUMBER> patients needing icu admission higher bun creatinine levels hospital admission compared nonicu admission patients overall patients general bun creatinine levels continued get worse nonsurvivors death <NUMBER> summarized finding multiple studies including patient characteristics comorbidities incidence aki general well icuseverely ill patients number patients requiring continuous renal replacement therapy crrt extracorporeal membrane oxygenation ecmo mortality table <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients developed aki covid<NUMBER> infection around <NUMBER> required rrt form crrt <NUMBER> <NUMBER> proportion patients needing rrt increased <NUMBER> severe infection <NUMBER> <NUMBER> per international experts severe covid<NUMBER> cases hypoxemic respira tory failure along renal liver dysfunction ecmo without crrt used crrt used blood purification modality clinical practice severe covid<NUMBER> patients sepsis ards hemoperfusionplasma adsorption treatment also selected clear inflammatory mediators <NUMBER> recommendations care hospitalized patients covid<NUMBER> kidney failure needing rrt american society nephrology asn summarized <NUMBER> health care personnel follow centers disease control prevention cdcrecommended personal protective equipment ppe safety guidelines interactions patients health care personnel work team limit exposure infection indications rrt similar patients aki providers significant expertise place dialysis catheters patients cohorted dedicated icus possible preferred dialysis modality crrt slow lowefficiency dialysis sled available intermittent hemodialysis ihd also performed crrt sled available crrt preferred ihd setting isolation ihd needs oneonone nursing support patients needing crrt exceeds machines available prolonged intermittent treatments eg <NUMBER> h instead continuous higher flow rates eg <NUMBER> <NUMBER> mlkgh terminal cleaning used another patient patients cohorted dedicated floor possible patients active suspected covid<NUMBER> needing dialysis treatment transported central acute dialysis unit ihd provided oneonone nursing care patient negative pressure room covid<NUMBER> patients isolated one floor one dialysis nurse may able monitor two three patients ihd video electronic monitoring available nurse enters room patient needs anything troubleshoot machine peritoneal dialysis continued automated peritoneal dialysis apd limit exposure medical staff dialysis equipment cleaned disinfectant removing room hospital infection control policy directs proper disposable rrt machine equipment per hospital protocol crrt filters need changed every <NUMBER> h longer continuous venovenous hemofiltration also known cvvh continuous venovenous hemodiafiltration cvvhdf preferred techniques usa continuous venovenous hemodialysis cvvhd common modality used volume overloaded patients treated using slow continuous ultrafiltration scuf keep fluid balance net negative <NUMBER> temporary dialysis catheters recommended vascular access providers significant expertise place dialysis catheters recommended use doublelayered protection personnel performing procedure filters high ultrafiltration coefficient high molecular weight cutoff membrane <NUMBER> <NUMBER> nm membrane pore size suggested <NUMBER> would help clearing high molecular weight inflammatory mediators however albumin would need replaced removed concurrently essential assess patients bleeding risk choosing anticoagulation patients severe covid<NUMBER> infection high bleeding risk recommended avoid anticoagulation normal hypercoagulable states one use heparin citratebased anticoagulation depending hospital protocols using crrt combination ecmo anticoagulation needed ecmo utilizes systemic heparinization <NUMBER> essential pay close attention hemodynamics volume status patients covid<NUMBER> infection using arterial central venous pressure cvp monitors patients frequent renal panels checks every <NUMBER> <NUMBER> h monitor strict input output maintain net negative fluid balance ards patients patients without ards volume status assessed maintain euvolemic state patients monitored recovery kidney function daily basis rrt discontinued patient nonoliguric euvolemic improved ventilation requirements also supported improved laboratory findings without alarming electrolyte acidbase imbalance aki associated increased inhospital mortality patient meticulously managed providing hemodynamic support avoiding nonsteroidal antiinflammatory drugs nsaids nephrotoxins contrast early institution crrt improve outcomes proteinuria hematuria also associated inhospital mortality close attention paid urine analysis inpatient outpatient settings experience various published studies patients infected covid<NUMBER> infection showed aki associcovid<NUMBER> pandemic kidney injury j clin med res <NUMBER> ated mortality shi et al analyzed <NUMBER> patients died covid<NUMBER> infection showed <NUMBER> aki <NUMBER> patient underlying ckd bun myoglogin levels higher patients died within <NUMBER> days median time hospitalization death <NUMBER> days <NUMBER> cheng analysis showed elevated baseline serum creatinine elevated bun peak serum creatinine <NUMBER> proteinuria hematuria aki stages <NUMBER> <NUMBER> associated mortality adjusting confounding factors <NUMBER> impact covid<NUMBER> infection ckd reported incidence known ckd patients varied <NUMBER> depending upon series described <NUMBER> <NUMBER> increased mortality patients described one study <NUMBER> incidence aki higher patients established ckd <NUMBER> studies analyzed kidney function patients admitted confirmed covid<NUMBER> infection revealed incidence proteinuria hematuria <NUMBER> <NUMBER> significant number patients proteinuria day admission could related cytotropic effects virus podocytes proteinuria may result direct podocyte injury expression ace<NUMBER> <NUMBER> patients recovered covid<NUMBER> infection proteinuria hematuria need followed closely resolution patients sustained aki infection need monitored ckd ongoing outbreak covid<NUMBER> amassed great concern worldwide influence transplant recipients unknown previously experienced coronavirus outbreaks taught us transplant recipients easily affected infections <NUMBER> <NUMBER> said little known risk donor receive transmission disease several factors concerning donor exposure like infectivity incubation period etc play important role although strict guidelines donor restrictions would advisable potential donors hold organ donation suffering respiratory illness american red cross european centre disease prevention control ecdc recommend <NUMBER>day <NUMBER>day period delay respectively potential organ donors history recent travel highrisk areas contact person suspected proven coivd<NUMBER> <NUMBER> <NUMBER> ecdc recommends <NUMBER>day delay recovery confirmed infection michaels colleagues recently well described possible risks associated transplants covid<NUMBER>positive recipients <NUMBER> andrea et al italy described experience institution limiting liver transplantation urgent cases residents epidemic area <NUMBER> liberal allocation policy used patients outside epidemic areas however recipients screened avoid transplantation sarscov<NUMBER>positive subjects internal board consistently reviews updates transplant list every <NUMBER> weeks according new insights covid<NUMBER> continuously train healthcare providers screen nasopharyngeal swabs frequent intervals providing timely information patients caregivers raise awareness time avoid panic confusion important <NUMBER> per review literature best knowledge one case covid<NUMBER> infection described kidney transplant recipients <NUMBER> years <NUMBER> patient successfully managed initially cessation immunosuppression given intravenous stress dose steroids prevent adrenal insufficiency patient improved clinically immunosuppression resumed gradually overall clinical characteristics including symptoms radiological findings lung imaging laboratory findings similar nontransplanted adult patients covid<NUMBER> pneumonia case reported far difficult say possible see atypical findings severe presentations covid<NUMBER> disease transplant recipients healthcare providers aware experimental drugs like remdesivir lopinavirritonavir could cause drugdrug interactions calcineurin inhibitors <NUMBER> therefore recommended use drugs extreme caution regarding treatment kidney transplant recipients covid<NUMBER> infection much information available help guide therapy immunosuppression regimens would recommended use due diligence tailor management treatment options based patients clinical status duration transplant severity illness pandemic progresses expect information available guidance vaccine developed sarscov<NUMBER> virus date critical aspect management supportive care multiple treatments empiric antibiotics antiviral therapy systemic corticosteroids used worldwide several investigative drugs studied drugs approved indications used several clinical trials underway across globe one promising therapies remdesivir inhibits viral replication premature termination rna transcription shown activity beta coronaviruses vitro activity sarscov<NUMBER> <NUMBER> received emergency use authorization food drug administration fda usa use patients hospitalized covid<NUMBER> recommended <NUMBER> days patients mechanical ventilation ecmo recommended <NUMBER> days patients mechanical ventilation ecmo <NUMBER> recommended patients lower gfr gfr <NUMBER> mlmin <NUMBER> others drug gained attention chloro quine hydroxychloroquine either alone combination azithromycin chloroquine hydroxychloroquine vitro activity sarscov<NUMBER> <NUMBER> used several countries treating covid<NUMBER> infection based anecdotal data invitro studies news report china chloroquine increased viral clearance decreased disease progression improved radiological findings <NUMBER> <NUMBER> another clinical trial reported france nonrandomized openlabel trial <NUMBER> patients compared hydroxychloroquine combination hydroxychloroquine azithromycin versus standard care control group combination hydroxychloroquine azithromycin six patients resulted superior viral clearance compared hydroxychloroquine monotherapy <NUMBER> recent study among <NUMBER> veterans found benefit hydroxychloroquine associated risks due side effect profile <NUMBER> medications used caution patients renal hepatic impairment cause qt prolongation electrocardiogram hydroxychloroquine use pre postexposure prophylaxis treatment sarscov<NUMBER> infection currently investigation several clinical trials planned usa test usage hydroxychloroquine treatment prophylaxis covid<NUMBER> clinicians using different doses hydroxychloroquine prophylaxis treatment recent clinical trial china show efficacy lopinavirritonavir treatment pneumonia covid<NUMBER> patients trial underpowered <NUMBER> launched global mega trial called solidarity four promising coronavirus treatments remdesivir chloroquine hydroxychloroquine ritonavirlopinavir ritonavir lopinavir interferon beta <NUMBER> antiretroviral medications coronavirus treatment used like lopinavir ritonavir dose adjustments medications crrt needed <NUMBER> protein bound particular attention paid dosing drugs drugs interferon beta interferon alpha mefloquine favipiravir darunavir ribavirin umifenovir tocilizumab type ii transmembrane serine protease tmspss<NUMBER> inhibitors support therapies using vitamin b c e thymosin alpha <NUMBER> thymopentin selenium zinc pyrithione combination used treatment sarscov<NUMBER> infection <NUMBER> <NUMBER> covid<NUMBER> infection spreading rapidly causing mortality daily worldwide unfortunately knowledge novel virus limited causes significant clinical threat general population healthcare workers several countries imposed strict regulations public limit spread virus many government agencies like cdc fda hospitals public health systems working every day usa contain spread infection studies shown involvement kidneys covid<NUMBER> infection associated high mortality health care providers recognize aspect early appropriate management instituted soon possible patients underlying kidney problems renal transplant patients vulnerable developing covid<NUMBER> infection limited understanding pathogenesis disease virulence virus moment prevention critical aspect management several vaccines promising treatments undergoing clinical trials hope finding cure global crisis soon polyadpribose polymerase <NUMBER> coronaviruses large family positive singlestranded rna viruses ssrna perlman netland <NUMBER> classified four major genera including alphaand betacoronaviruses infect humans gammaand deltacoronaviruses generally infect birds main reason respiratory infections diseases ranging common cold severe ones middle east respiratory syndrome mersand severe acute respiratory syndrome sarsassociated coronavirus belong betacoronavirus genus responsible recent epidemic worldwide recent <NUMBER> years novel coronavirus cov named <NUMBER> novel coronavirus <NUMBER>ncov severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> caused recent pneumonia outbreak named coronavirus disease <NUMBER> covid<NUMBER> since early december <NUMBER> wuhan city hubei province china pandemic worldwide pathophysiology virulence mechanisms coronaviruses related function structural nonstructural proteins proteases one important nonstructural proteins within viral replication cycle utilized produce functional structural proteins papainlike cysteine protease plp<NUMBER> pro chymotrypsinlike cysteine protease <NUMBER>cl pro<NUMBER> also called pro main proteases sarscov mukherjee et al <NUMBER> interestingly papainlike cysteine protease damper antiviral response host cells lindner et al <NUMBER> niemeyer et al <NUMBER> helicase rnadependent rna polymerase crucial nonstructural proteins encoded coronaviruses genome zumla et al <NUMBER> high similarity main proteins sarscov covid<NUMBER> <NUMBER> sequence similarity et al <NUMBER> suggests drug designed proteins sarscov mukherjee et al <NUMBER> could effective covid<NUMBER> main structural proteins coronaviruses include spike glycoprotein membrane envelope nucleocapsid proteins perlman netland <NUMBER> spike glycoproteins viral surface composed two subunits s<NUMBER> s<NUMBER> s<NUMBER> subunit discovers virushost range cellular tropism receptorbinding domain rbd s<NUMBER> subunit mediates virushost cell membrane fusion guo et al <NUMBER> et al <NUMBER> su wu <NUMBER> similar sarscov covid<NUMBER> utilizes host cell angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor enter cells <NUMBER>to <NUMBER>fold higher affinity sarscov et al <NUMBER> su wu <NUMBER> clinical presentation covid<NUMBER> varies asymptomatic paucisymptomatic forms severe conditions need respiratory support sepsis septic shock multiorgan dysfunction syndrome common sign symptoms disease fever <NUMBER> dry cough <NUMBER> myalgia fatigue <NUMBER> dyspnea <NUMBER> less common symptoms sputum production <NUMBER> headache <NUMBER> hemoptysis <NUMBER> diarrhea <NUMBER> chest computerized tomography scans show pneumonia bassetti et al <NUMBER> huang herrmann <NUMBER> laboratory markers include leukopenia <NUMBER> lymphopenia <NUMBER> thrombocytopenia <NUMBER> high lactate dehydrogenase <NUMBER> bassetti et al <NUMBER> clinical features covid<NUMBER> divided severity following forms wu mcgoogan <NUMBER> <NUMBER>a mild disease occurred <NUMBER> cases mild pneumonia <NUMBER>severe disease occurs <NUMBER> cases manifests dyspnea respiratory frequency ≥ <NUMBER>min blood oxygen saturation ≤ <NUMBER> partial pressure oxygenfraction inspired oxygen ratio ratio blood pressure oxygen percentage oxygen supplied <NUMBER> lung infiltrates <NUMBER> within <NUMBER> <NUMBER> h <NUMBER>critical disease occurs <NUMBER> cases respiratory failure septic shock multiple organ dysfunction failure according world health organization centers disease control prevention us food drug administration fda management covid<NUMBER> mainly focused infection prevention case detection monitoring supportive care however specific anticovid<NUMBER> treatments recommended absence evidence beware fraudulent coronavirus tests vaccines treatments <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> information clinicians therapeutic options covid<NUMBER> patients <NUMBER> given urgency <NUMBER>ncov outbreak researchers pay particular attention repositioning existing antiviral agents approved development infections caused human immunodeficiency viruses hiv hepatitis b virus hbv hepatitis c virus hcv influenza li de clercq <NUMBER> besides since coronaviruses especially mers sars covid<NUMBER> similar viral structure similar infection pathway similar structure proteins similar research strategies used covid<NUMBER> yu et al <NUMBER> general treatment strategies include bed rest supportive treatment ensuring sufficient calorie water intake maintaining waterelectrolyte balance homeostasis monitoring vital signs respiratory support circulation support oxygen therapy necessary measuring blood routine urine routine creactive protein blood biochemical indexes including liver kidney function myocardial enzyme spectrum coagulation function according patients conditions blood gas analysis timely reexamination chest imaging performed necessary shen et al <NUMBER> nearly patients accept oxygen therapy recommends extracorporeal membrane oxygenation patients refractory hypoxemia guo et al <NUMBER> nitric oxide inhalation chen et al <NUMBER> epoprostenol inhalation prostacyclin vasodilator properties alessandri et al <NUMBER> searcy et al <NUMBER> recommended options treat acute respiratory distress syndrome vitro study revealed nitric oxide inhibit replication sarscov åkerström et al <NUMBER> time writing article drug fda approved treat covid<NUMBER> old drugs suggested manage covid<NUMBER> used anecdotally based vitro vivo studies however poor clinical data supporting include remdesivir chloroquine hydroxychloroquine combination azithromycin tocilizumab lopinavirritonavir coronavirus disease <NUMBER> covid<NUMBER> epidemiology virology clinical features diagnosis prevention <NUMBER> march <NUMBER> started global mega trial four promising coronavirus treatments <NUMBER> countries called solidarity response covid<NUMBER> pandemic remdesivir chloroquine hydroxychloroquine lopinavirritonavir lopinavir ritonavir combination interferon beta experimental therapy currently researched solidarity trial launches global megatrial four promising coronavirus treatments <NUMBER> group korean specialist physicians treating covid<NUMBER> recommended following antiviral medication treating older patients patients underlying comorbid severe conditions recommended regime lopinavir <NUMBER> mg ritonavir <NUMBER> mg kaletra ® <NUMBER> tablets mouth twice daily chloroquine <NUMBER> mg mouth daily hydroxychloroquine <NUMBER> mg mouth daily <NUMBER> <NUMBER> days depending clinical progress coadministration chloroquine hydroxychloroquine lopinavirritonavir may cause serious arrhythmias drug interaction according advice combined therapy recommended limited cases physicians work treatment guidelines coronavirus <NUMBER> group iranian physicians experts experience treating covid<NUMBER> developed recommendations treatment hospitalized patients covid<NUMBER> based <NUMBER>th edition recommendation proposed antiviral monotherapy chloroquine <NUMBER> mg q<NUMBER>h first day followed <NUMBER> mg q<NUMBER>h orally hydroxychloroquine <NUMBER> mg q<NUMBER>h first day followed <NUMBER> mg q<NUMBER>h orally <NUMBER> <NUMBER> days based clinical progress combination therapy lopinavirritonavir <NUMBER> mg q<NUMBER>h orally administrated chloroquine <NUMBER> mg sd orally hydroxychloroquine <NUMBER> mg sd orally first day followed lopinavirritonavir <NUMBER> mg q<NUMBER>h orally <NUMBER> days combination therapy atazanavirritonavir atazanavirritonavir <NUMBER> mg sd orally plus chloroquine <NUMBER> mg q<NUMBER>h orally hydroxychloroquine <NUMBER> mg q<NUMBER>h orally administrated first day <NUMBER> days suggested atazanavirritonavir lower side effects drug interaction chloroquine hydroxychloroquine arrhythmia gastrointestinal intolerance lopinavirritonavir flowchart diagnosis treatment covid <NUMBER> disease outpatient inpatient levels <NUMBER> two main ways drug discovery including traditional drug development drug repositioning first way usually takes <NUMBER> years needs high investments expensive success rate low second one uses old drugs investigating approving new therapeutic contrast first way efficient economical riskless xue et al <NUMBER> days emergency investigate appropriate drugs covid<NUMBER> seems drug repositioning helpful review mainly trying gather findings old drugscovid<NUMBER> relationship introduce lead suitable therapy however covid<NUMBER> therapy must based expert clinical experience published literature guidelines major health organizations regard recommended dosages proposed drugs currently trialed covid<NUMBER> based latest version <NUMBER>st march <NUMBER> included table <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> interventions limited clinical data introduced article relevant data published since start <NUMBER> included searching google scholar pubmed valid encyclopedias furthermore bibliographies eligible articles examined additional relevant studies keywords used search terms novel coronavirus covid<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> therapy treatment virology clinical future pathology restriction type studies kinds peerreviewed nonpeerreviewed research projects reviews letters comments editorials ebooks published published proof press situation included nonenglish language studies studied using google translate software strong studies proved efficacy chloroquine intracellular microorganism well malaria coxiella burnetii tropheryma whipplei colson et al <NUMBER> chloroquine hydroxychloroquine used autoimmune diseases worth effect coronaviruses colson et al <NUMBER> wang et al <NUMBER>b chloroquine prescription improves pneumonia lung imaging findings infected patients covid<NUMBER> shorts disease course promotes virusnegative stage decreases length hospital stay gao et al <NUMBER> good distribution lungs drug alkalizes endosomal ph interferes virusendosome fusion affects virus entry exit vincent et al <NUMBER> shown sarscov spike glycoprotein mediates viral entry phdependent endocytosis yang et al <NUMBER> chloroquine inhibits glycosylation ace<NUMBER> receptor expression cell surface vincent et al <NUMBER> possesses immunomodulatory antiinflammatory impacts many pathways including inhibition phospholipase a<NUMBER> activity blocking cytokine production release albari <NUMBER> may worth full covid<NUMBER> cytokine storm mentioned activity hydroxychloroquine covid<NUMBER> probably chloroquine colson et al <NUMBER> although hydroxychloroquine seems potent antiviral activity yao et al <NUMBER> since chloroquine inhibits attachment fusion virus host cells could good prophylactic candidate viral diseases studies shown prophylactic effects chloroquine sarascov preand postexposure preexposure prophylaxis <NUMBER> mg daily postexposure prophylaxis <NUMBER> mgkgday <NUMBER> days recommended prophylaxis covid<NUMBER> however certain evidence proves efficacy chloroquine prophylaxis covid<NUMBER> chang <NUMBER> postulated prophylactic use chloroquine may impair innate immune system response infection soraya <NUMBER> qt interval baseline important item evaluation chloroquine toxicity covid<NUMBER> cardiovascular dermatological problems exacerbation porphyria severe hypoglycemia abdominal cramps anorexia diarrhea nausea vomiting endocrine metabolic gastrointestinal problems chloroquine related side effects chloroquine may cause hematological immunological abnormalities may raise liver enzymes induce hypersensitivity reactions nervous system problems neuromuscular skeletal ophthalmic otic difficulties reported side effects furthermore medicine used caution patients preexisting auditory damage g<NUMBER>pd deficiency hepatic impairment porphyria psoriasis seizure disorder since chloroquine substrate cyp<NUMBER>d<NUMBER> major cyp<NUMBER>a<NUMBER> major risk potentially harmful drug interactions must considered combination therapies chloroquine drug information <NUMBER> niclosamide old antihelminthic drug reported impose broadspectrum antiviral properties sarscov merscov zika virus japanese encephalitis virus hcv ebola virus human rhinoviruses chikungunya virus human adenovirus epstein−barr virus xu et al <NUMBER> wu et al <NUMBER> reported niclosamide able inhibit sarscov replication eliminate viral antigen synthesis wu et al <NUMBER> drug stimulates autophagy merscov reduces viral replication gassen et al <NUMBER> nitazoxanide antiparasitic drug fdaapproved treating cryptosporidium giardia studies mentioned broadspectrum antiviral activity rossignol <NUMBER> drug suggested effective therapy coronaviruses cao et al <NUMBER> also candidate new drug treatment mers rossignol <NUMBER> cells infected foreign rna nitazoxanide amplifies host innate immune antiviral responses triggering foreign cytoplasmic rna sensing type <NUMBER> interferon axis jasenosky et al <NUMBER> respect nitazoxanide may potential covid<NUMBER> adnan shereen et al <NUMBER> headache abdominal pain nausea urine discoloration reported <NUMBER> patients receive nitazoxanide nitazoxanide drug information <NUMBER> based previous studies revealed lopinavirritonavir alone combination antivirals reduces incidence mortality acute respiratory distress syndrome related sars mers diseases chu et al <NUMBER> lopinavirritonavir inhibits hiv protease protein cleavage causes noninfectious immature viral particles guo et al <NUMBER> therapy also recommended management covid<NUMBER> pneumonia appears little effect cao et al <NUMBER>a effectiveness hiv protease inhibitors covid<NUMBER> protease enzymes uncertain based two reasons hiv proteases belong aspartic protease family coronavirus proteases belong cysteine protease family c<NUMBER>symmetric pocket catalytic site hiv protease dimer inhibited antiproteases absent coronaviruses proteases li de clercq <NUMBER> skin rash dyslipidemia diarrhea vomiting nausea abdominal pain rise liver enzymes upper respiratory infections reported <NUMBER> patients receive lopinavirritonavir medication also may alter cardiovascular conduction lopinavir undergoes extensive metabolism via hepatic cyp<NUMBER>a isozymes coadministration cyp<NUMBER>a inducers decreases level furthermore ritonavir potent cyp<NUMBER>a inhibitor coadministration drugs metabolized enzyme elevates plasma concentration lopinavir ritonavir drug information <NUMBER> rnadependent rna polymerase important enzyme life cycle rna viruses including coronaviruses hcv zika virus enzyme target antiviral drugs sofosbuvir ribavirin nucleotide derivatives inhibit rnadependent rna polymerase used hcv therapy idx<NUMBER> another rnadependent rna polymerase clinical trials hcv therapy silico study proved efficacy remdesivir covid<NUMBER> rnadependent rna polymerase elfiky <NUMBER> remdesivir novel antiviral prodrug developed ebola virus treatment also prophylaxis postexposure showed broadspectrum antiviral activity vitro filoviruses arenaviruses coronaviruses remdesivir approved licensed time writing article warren et al <NUMBER> remdesivir metabolized adenosine nucleotide analog interferes action virus rna polymerase post entry seems good inhibitory effects covid<NUMBER> cellular level guo et al <NUMBER> case report remdesivir started intravenously day <NUMBER> patient covid<NUMBER> side effects holshue et al <NUMBER> nausea vomiting prolonged prothrombin time raise liver enzymes reported remdesivir consumption remdesivir united states investigational agent refer prescribing access restrictions drug information <NUMBER> favipiravir prodrug metabolized nucleoside analog inhibits viral rnadependent rna polymerase furuta et al <NUMBER> rna viruses influenza ebola yellow fever chikungunya norovirus enterovirus covid<NUMBER> approved drug influenza japan de clercq <NUMBER> february <NUMBER> drug studied chinese randomized trials experimental treatment covid<NUMBER> li de clercq <NUMBER> indinavir atazanavir darunavir fosamprenavir saquinavir abacavir elvitegravir raltegravir enzaplatovir presatovir maribavir tipranavir darunavir jin et al <NUMBER> proposed antiviral drugs threating covid<NUMBER> table <NUMBER> medication therapy influenza including neuraminidase inhibitors oseltamivir peramivir zanamivir drugs like ganciclovir acyclovir ribavirin well methylprednisolone prescribed previously treating covid<NUMBER> valid guo et al <NUMBER> although use antibiotics especially broadspectrum types avoided patients covid<NUMBER> patients bacterial infection use antibacterial agents recommended jin et al <NUMBER> proposed antimicrobial agents communityacquired pneumonia amoxicillin azithromycin fluoroquinolones severe patients possible pathogens covered empirical antibacterial treatment pathogenic bacteria clarified <NUMBER> moxifloxacin best recommendation covering mycoplasma chlamydia zhang et al <NUMBER>b azithromycin macrolide bestproposed antimicrobial added hydroxychloroquine regimen covid<NUMBER> induced synergic effect virus elimination combination therapy azithromycin <NUMBER> mg day <NUMBER> followed <NUMBER> mg per day next <NUMBER> days hydroxychloroquine sulfate <NUMBER> mg three times per day <NUMBER> days reduced number viral carriages viral carrying duration gautret et al <NUMBER> azithromycin antibiotic macrolide group antiinflammatory effects amsden <NUMBER> beigelman et al <NUMBER> ivetić tkalčević et al <NUMBER> furthermore antiviral iannetta et al <NUMBER> menzel et al <NUMBER> schoegler et al <NUMBER> schögler et al <NUMBER> properties may reason adding drug hydroxychloroquine improved clearance covid<NUMBER> regard need test azithromycin firstline therapy covid<NUMBER> considered chloroquinehydroxychloroquine silva et al <NUMBER> azithromycin hancox et al <NUMBER> known prolong qtcinterval combination therapy may increase risk cardiac side effects similar sarscov covid<NUMBER> attaches host cell ace<NUMBER> receptors receptorbinding motif located rbd s<NUMBER> subunit spike glycoprotein human cells expressing ace<NUMBER> susceptible infected covid<NUMBER> guo et al <NUMBER> shanmugaraj et al <NUMBER> specific neutralizing monoclonal antibodies host cell ace<NUMBER> receptors virus receptorbinding domain spike protein interfere virus attachment entry monoclonal antibodies sarscov proposed due similarity covid<NUMBER> could useful virus neutralize s<NUMBER> fragment block interaction s<NUMBER> subunit protein cellular receptor ace<NUMBER> including <NUMBER>r cr<NUMBER> cr<NUMBER> f<NUMBER>g<NUMBER> f<NUMBER>g<NUMBER> m<NUMBER> <NUMBER> <NUMBER>a<NUMBER> monoclonal antibody binds s<NUMBER> fragment antiasthma monoclonal antibody cd<NUMBER> inhibit interaction cd<NUMBER> spike protein sarscov<NUMBER> immunoglobulins human gamma globulin immunoglobulins improving passive immunity modulating immune inflammation cao et al <NUMBER>b zhang et al <NUMBER>b research statement contains neutralizing antibodies suppress viremia acceleration infected cell clearance chen et al <NUMBER> interferons ifn β interferon type <NUMBER> immunomodulatory cytokines lin young <NUMBER> sarscov blocks interaction s<NUMBER> subunit protein cellular receptor s<NUMBER> binds rbd blocks interaction s<NUMBER> subunit protein cellular ace<NUMBER> receptor <NUMBER>d<NUMBER> <NUMBER> proposed neutralizing monoclonal antibodies sarscov shanmugaraj et al <NUMBER> cr<NUMBER> neutralizing antibody binds potently saracov covid<NUMBER> spike protein neutralizing antibodies including m<NUMBER> cr<NUMBER> showed potent inhibitory saracov spike protein bind covid<NUMBER> spike protein probably due differences rbd tow viruses cr<NUMBER> worth potential therapy covid<NUMBER> reported direct interaction cd<NUMBER> spike protein sarscov<NUMBER> mediates role virus infection inhibition receptor meplazumab monoclonal antibody cd<NUMBER> shown promising inhibitory effect sarcov<NUMBER> vitro clinic bian et al <NUMBER> cd<NUMBER> presented epithelial cells activated inflammatory cells induces cytokine secretion leukocyte chemotaxis binding cyclophilin cyclophilin participates cell chemotaxis local inflammation dawar et al <NUMBER>a b convalescent plasma intravenous immunoglobulin ivig proposed strategies improve survival rate patients sars maybe covid<NUMBER> clinical study shanghai shown positive effects convalescent plasma strategy covid<NUMBER> derebail falk <NUMBER> therapy shorted hospital stay decreased mortality viral load related neutralizing antibodies convalescent plasma suppresses viremia possible explanation efficacy convalescent therapy acceleration infected cell clearance chen et al <NUMBER> new decision fda approving use convalescent plasma treat critically ill patients covid<NUMBER> tanne <NUMBER> administration ivig low molecular weight heparin anticoagulant therapy early stages covid<NUMBER> interrupt cytokine storm enhance immunity lin et al <NUMBER> series case studies revealed administration highdose ivig <NUMBER> gkg daily <NUMBER> days early stage covid<NUMBER> could block progression disease lymphocytopenia elevated inflammation markers although three patients antiviral medication outcome ivig therapy improving passive immunity modulating immune inflammation covid<NUMBER> worth full cao et al <NUMBER>b zhang et al <NUMBER>b efficacy immunoglobulin therapy revealed sars ho et al <NUMBER> influenza liu et al <NUMBER> diseases enough clinical trials covid<NUMBER> hypotension hypertension tachycardia decreased heart rate headache fatigue chills pain rigors dizziness injection site pruritus sore throat gastrointestinal problems hematological abnormalities rise liver enzymes neuromuscular skeletal problems common side effects <NUMBER> patients received ivig immune globulin intravenous subcutaneous intramuscular drug information <NUMBER> interferons ifns immunomodulatory cytokines classified types ii iii based receptors cell membrane surface type glycoproteins ifn alpha beta fda approved viral infections lin young <NUMBER> ifn β recommended janus kinase gak inhibitor inhibits clathrinmediated endocytosis cytokine release inflammation richardson et al <NUMBER> monoclonal antibody targeting il<NUMBER> zhang et al <NUMBER>a siltuximab antineoplastic monoclonal antibody targeting il<NUMBER> gritti et al <NUMBER> research statement polyadpribose polymerase <NUMBER> parp<NUMBER> inhibition ge et al <NUMBER> montelukast deoxyrhapontin polydatin chalcone disulfiram carmofur shikonin ebselen tideglusib px<NUMBER> tdzd<NUMBER> cyclosporin cinanserin jin et al <NUMBER> proposed agents covid<NUMBER> included text table ace<NUMBER> angiotensinconverting enzyme <NUMBER> dgtp deoxyguanosine triphosphate based wwwmedscapecom april <NUMBER> wwwuptodatecom march <NUMBER> <NUMBER> mentioned references effective covid<NUMBER> ifn β showed valuable efficacy sarscov replication tissue culture hart et al <NUMBER> nonhuman primate model chan et al <NUMBER> shown ribavirin combination ifn α<NUMBER>a significantly improved survival <NUMBER> days patients infected sarscov omrani et al <NUMBER> published article advised administration ifn α atomization inhalation <NUMBER> million u per time adults sterile injection water twice day jin et al <NUMBER> noticed use nebulized drugs may distribute virus air disturb infection control simonds et al <NUMBER> mentioned previous sections ace<NUMBER> cell surface protein expressed lung at<NUMBER> alveolar epithelial cells main role <NUMBER>ncov endocytosis entry cells ap<NUMBER>associated protein kinase <NUMBER> one main promoters clathrinmediated endocytosis inhibition may disrupt penetration virus cells assembly particles janus kinase jak regulator passage virus lung cells proposed baricitinib <NUMBER> <NUMBER> mg day inhibition kinases may useful covid<NUMBER> acute respiratory disease drug one way blocks virus entry way inhibits cytokine release inflammation inhibiting jak<NUMBER> jakstat signaling richardson et al <NUMBER> tofacitinib baricitinib fedratinib ruxolitinib jakstat signaling nhibitors antiinflammatory effects however baricitinib better fedratinib ruxolitinib due high affinity ap<NUMBER>associated protein kinase <NUMBER> oncedaily dosing acceptable side effects low proteinbinding properties interaction cyp drugmetabolizing enzymes drug transporters cause good potential combining therapy baricitinib covid<NUMBER> richardson et al <NUMBER> upper respiratory tract infection <NUMBER> nausea rise liver enzymes dyslipidemia anemia thrombosis lymphocytopenia increase creatine phosphate serum creatinine reported side effects baricitinib used combination strong immunosuppressants including azathioprine cyclosporine jak inhibitors biological diseasemodifying antirheumatic drugs baricitinib drug information <NUMBER> moribund patients <NUMBER>ncov infection also associated cytokine storm characterized increase plasma concentrations interleukins <NUMBER> <NUMBER> <NUMBER> granulocytecolony stimulating factor interferonγinducible protein <NUMBER> monocyte chemoattractant protein <NUMBER> macrophage inflammatory protein <NUMBER> alpha tumor necrosis factor α survive intensive care aberrant excessive immune responses lead longterm lung damage fibrosis cause functional disability reduce quality life zumla et al <NUMBER> previous studies proved proinflammatory role polyadpribose polymerase <NUMBER> parp<NUMBER> inducing inflammatory disorders especially lung injuries acute respiratory distress syndrome asthma jagtap szabo <NUMBER> parp<NUMBER> activation enhances inflammation activation proinflammatory cytokines inducible nitric oxide synthase intracellular adhesion molecule <NUMBER> cyclooxygenase <NUMBER> nadph oxidase well major histocompatibility complex class ii promotes cytokine storm activation nfkbmediated proinflammatory signals activation ap<NUMBER> il<NUMBER>β il<NUMBER> tnfα downstream cytokines chemokines pathways parp<NUMBER> activation results cellular energy failure necrosis cell death zingarelli et al <NUMBER> parp<NUMBER> inhibitors suppress viral replication inhibit adpribosylation viral core proteins suppress binding nucleocapsid protein viral rna interfere structure packaging viral genome liu et al <NUMBER> furthermore parp<NUMBER> inhibitors reduce energy failure suppress nad atp depletion larmonier et al <NUMBER> according aforementioned data parp<NUMBER> inhibitors including cvl<NUMBER> binds nterminal domain nucleocapsid protein covid<NUMBER> might worthy candidate treating infected people virus ge et al <NUMBER> drugs mitigate effects cytokines released response covid<NUMBER> limit lung damage patients severe disease include siltuximab monoclonal antibody il<NUMBER> approved multicentric castlemans disease gritti et al <NUMBER> diseasemodifying antirheumatic drugs tocilizumab monoclonal antibody targeting il<NUMBER> zhang et al <NUMBER>a sarilumab recombinant humanized monoclonal antibody specific il<NUMBER> singh et al <NUMBER> anakinra recombinant human interleukin<NUMBER> il<NUMBER> receptor antagonist mehta et al <NUMBER> edema pruritus skin rash weight gain hyperuricemia upper respiratory tract infection common complications <NUMBER> patients receive siltuximab hypotension headache dyslipidemia dermatological reactions constipation thrombocytopenia hypersensitivity reactions renal insufficiency reported side effects siltuximab drug information <NUMBER> common side effects <NUMBER> patients treated tocilizumab dyslipidemia rise liver enzymes injection site reaction cardiovascular gastrointestinal renal ophthalmic dermatologic endocrine metabolic problems reported complications drug tocilizumab drug information <NUMBER> rise liver enzymes common <NUMBER> treated sarilumab injection site pruritus hypertriglyceridemia hematological abnormality reported side effects sarilumab drug information <NUMBER> patients receive tocilizumab sarilumab increased risk developing serious infections may lead hospitalization death sarilumab drug information <NUMBER> tocilizumab drug information <NUMBER> headache vomiting antibody development infection injection site reaction arthralgia nasopharyngitis fever reported <NUMBER> patients treated anakinra anakinra drug information <NUMBER> carfilzomib bortezomib jin et al <NUMBER> imatinib ge et al <NUMBER> carrizumab zhang et al <NUMBER>a proposed antineoplastic drugs covid<NUMBER> abl kinases nonreceptor tyrosine kinases expressed cytoplasm nucleus mitochondria shown abl<NUMBER> important entry sarscov cell abl kinase inhibitors prevent syncytia formation protein block coronavirus smediated fusion sisk et al <NUMBER> background imatinib abl fusion kinase inhibitor found attention novel candidate covid<NUMBER> therapy ge et al <NUMBER> carrizumab camrelizumab shr<NUMBER> suggested f r e v e r e n v e l c r n v r u p n e u n w h lymphocytopenia antitumor drug inhibits programmed cell death protein <NUMBER> zhang et al <NUMBER>a programmed cell death protein<NUMBER> inhibitors activate immune system syn et al <NUMBER> carfilzomib bortezomib imatinib considered hazardous agents bortezomib drug information <NUMBER> carfilzomib drug information <NUMBER> imatinib drug information <NUMBER> nausea vomiting fatigue chills headache dyspnea cough fever hypertension peripheral edema hematological abnormalities common reported side effects occurrence <NUMBER> patients receive carfilzomib carfilzomib drug information <NUMBER> peripheral neuropathy fatigue diarrhea nausea thrombocytopenia common complaints <NUMBER> patients treated bortezomib bortezomib drug information <NUMBER> edema fatigue pain headache skin rash dermatitis fluid retention rise lactate dehydrogenase weight gain nausea diarrhea vomiting abdominal pain anorexia hematological disorders rise liver enzymes muscle cramps musculoskeletal pain spasm arthralgia myalgia periorbital edema rise serum creatinine fever reported <NUMBER> patients treated imatinib imatinib drug information <NUMBER> use class drugs severe acute respiratory distress syndrome controversial needs caution especially systemic route shown administration corticosteroids sarsinfected patients decreased degree disease progression dyspnea alleviated clinical symptoms however strategy effect length hospital stay meng et al <NUMBER> corticosteroid therapy used management covid<NUMBER>induced lung injury shock outside clinical trial although corticosteroid treatment could role suppressing lung inflammation associated interruption clearance viral rna respiratory tract secretions positive impact decrease mortality rate critically ill patients russell et al <NUMBER> corticosteroid therapy accompanied neutrophilic leukocytosis eosinopenia decrease peripheral blood lymphocytic count especially cells coutinho chapman <NUMBER> according published articles <NUMBER>s administration corticosteroids induces transient lymphocytopenia peaks <NUMBER> h returns normal level <NUMBER> h duration depends potency dose administrated corticosteroids fauci dale <NUMBER> webel et al <NUMBER> yu et al <NUMBER> recently proven corticosteroid therapy induces immunosuppression predominantly suppression cellmediated immunity minimal inhibitory effect humoral immunity cell subsets cd<NUMBER> susceptible cd<NUMBER> baris et al <NUMBER> viral diseases may get wild immunocompromised state rouse sehrawat <NUMBER> body cannot fight covid<NUMBER> concerns patients treated ace inhibitors eg captopril angiotensin receptor blockers eg losartan shown patients received medications expression ace<NUMBER> receptor high risk infection virus increased fang et al <NUMBER> zheng et al <NUMBER> however enough data approving concern american heart association american college cardiology associations recommend continuing treatment ace inhibitors angiotensin receptor blockers population russell et al <NUMBER> possible antiviral activity indomethacin nonsteroidal antiinflammatory drug sars reported amici et al <NUMBER> concern use pharmacological drugs patients covid<NUMBER> march <NUMBER> use nonsteroidal antiinflammatory drugs ibuprofen antipyretic drug covid<NUMBER> warned acetaminophen recommended report <NUMBER> young patients covid<NUMBER> underlying health problem use ibuprofen worsened covid<NUMBER> symptoms speculated antiinflammatory properties could damp immune system prolong viral shedding day <NUMBER> may reduce inflammation fever patients covid<NUMBER> diminish utility diagnostic signs detecting infections longterm use ibuprofen may cause gastrointestinal bleeding fluid retention renal dysfunction even therapeutic doses toxic doses may result respiratory depression hypotension shock depressed mental status severe metabolic acidosis severe gastrointestinal hemorrhage lifethreatening electrolyte imbalances arrhythmias ershad vearrier <NUMBER> however convincing evidence support association ibuprofen negative outcomes covid<NUMBER> outbreak covid<NUMBER> infection posed significant threats international health economy present specific antiviral therapy approved treatment covid<NUMBER> urgent researchers trying repositioning existing drugs covid<NUMBER> old drugs may effective different pharmacological categories including antimalarials anthelmintics antiprotozoal antihivs antiinfluenza antihepacivirus antineoplastics neutralizing antibodies immunoglobulins interferons focus sarscov<NUMBER> fusionentry process either inhibition s<NUMBER>mediated virus attachment blocking s<NUMBER>mediated viruscell membrane fusion interfere viral replication proposed agents fight virus modulating host immune response neutralizing inflammatory cytokines inducing passive immunity convalescent plasma seems best therapy patients covid<NUMBER> newly introduced fig <NUMBER> schematic represents possible effects proposed drugs severe acute respiratory syndrome coronavirus <NUMBER> aak<NUMBER> ap<NUMBER>associated protein kinase <NUMBER> ab<NUMBER> nonreceptor tyrosine kinase ace<NUMBER> angiotensinconverting enzyme <NUMBER> ifn<NUMBER> interferons type <NUMBER> jak janus kinase mrna messenger ribonucleic acid parp<NUMBER> polyadpribose polymerase <NUMBER> rna ribonucleic acid pp<NUMBER>a <NUMBER>ab protein phosphatase <NUMBER>a <NUMBER>ab activator effect inhibitory effect viral cell cycle agents focus mainly host cell ace<NUMBER> receptors receptors virus table <NUMBER> fig <NUMBER> suggest attention bradykinin neutralizing agents could worth full pathway mentioned recent research projects reninangiotensin kallikreinkinin systems linked ace kallikrein converts kininogen kinins including bradykinin converted inactive peptide via ace blocking ace ace inhibitors antihypertensive drugs restricts inactivation kinins increases level bradykinin alhencgelas et al <NUMBER> bradykinin cause dry cough patients ace inhibitor drugs fox et al <NUMBER> proinflammatory peptide potent endotheliumdependent vasodilator smooth muscle contractor bronchus severe cases may result angioedema joseph kaplan <NUMBER> previously reported bradykinin b<NUMBER> receptor antagonist men<NUMBER> inhibitor tissue kallikrein va<NUMBER> attenuated response parainfluenza<NUMBER> virusinduced inflammation airway hyperactivity broadley et al <NUMBER> seems feature covid<NUMBER> similar activation bradykinin body inhibition pathway suggested therapy patients infected covid<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> cause coronavirus disease <NUMBER> covid<NUMBER> spread across globe resulting pandemic time review covid<NUMBER> diagnosed <NUMBER> <NUMBER> patients associated <NUMBER> deaths centers disease control prevention world health organization behalf society infectious diseases pharmacists herein summarize current evidence march <NUMBER> <NUMBER> provide guidance potential covid<NUMBER> treatment options important caution readers new data emerges daily regarding clinical characteristics treatment options outcomes covid<NUMBER> optimized supportive care remains mainstay therapy clinical efficacy subsequent agents still investigation antimicrobial stewardship programs including infectious diseases pharmacists physicians forefront covid<NUMBER> emergency preparedness encourage readers continue assess clinical data emerges share experience within community wellcontrolled adequately powered fashion coronavirus disease <NUMBER> treatment review early emerging options december <NUMBER> several patients wuhan hubei china diagnosed pneumonia secondary unknown virus response epidemiological alert placed world health organization dated december <NUMBER> <NUMBER> january <NUMBER> <NUMBER> chinese scientists isolated severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> months followed sarscov<NUMBER> cause coronavirus disease <NUMBER> covid <NUMBER> spread across globe resulting current pandemic time review covid<NUMBER> diagnosed <NUMBER> <NUMBER> patients associated <NUMBER> <NUMBER> deaths centers disease control prevention cdc behalf society infectious diseases pharmacists herein summarize current evidence march <NUMBER> <NUMBER> provide guidance potential covid<NUMBER> treatment options important caution readers new data emerges approximately every hour regarding clinical characteristics treatment options outcomes covid<NUMBER> optimized supportive care remains mainstay therapy clinical efficacy subsequent agents still investigation existing preclinical clinical data antiviral therapy derived viruses including sarscov<NUMBER> first reported <NUMBER> middle east respiratory syndrome coronavirus merscov first reported <NUMBER> noncoronaviruses eg ebola virus disease unclear well data extrapolated sarscov<NUMBER> furthermore clinical relevance antiviral vitro activity defined halfmaximal effective concentration ec <NUMBER> values remains unclear given absence pharmacokineticpharmacodynamic clinical data equates achievable exposures relative values treatment effect finally vitro data compared cautiously across studies given potential variability testing methodologies could impact perceived activity antimicrobial stewardship programs including infectious diseases pharmacists physicians forefront covid<NUMBER> emergency preparedness <NUMBER> encourage readers continue assess clinical data emerges share experience within community preferentially evaluating agents context randomized controlled trials gilead sciences inc response ebola outbreak west africa <NUMBER> <NUMBER> active triphosphate nucleoside form remdesivir binds ribonucleic acid rnadependent rna polymerase acts rnachain terminator displays potent vitro activity sarscov<NUMBER> ec <NUMBER> <NUMBER> hours <NUMBER> µm vero e<NUMBER> cells <NUMBER> similar activity demonstrated zoonotic coronaviruses ec <NUMBER> values <NUMBER> µm demonstrated sarscov<NUMBER> merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> remdesivir highly selective viral polymerases therefore expected low propensity cause human toxicity accordingly sheahan et al <NUMBER> demonstrated wide therapeutic index remdesivir human airway epithelial cell model drug also displays high genetic barrier resistance coronaviruses long intracellular halflife allows oncedaily dosing <NUMBER> <NUMBER> dose investigation treatment covid<NUMBER> <NUMBER> mg intravenously iv day <NUMBER> followed <NUMBER> mg iv daily <NUMBER> days infused <NUMBER> minutes table <NUMBER> therapeutic efficacy remdesivir first described animal model ebola among infected rhesus monkeys oncedaily dosing resulted suppression viral replication protection lethal disease <NUMBER> however human study remdesivirtreated patients ebola experienced <NUMBER>day mortality rate <NUMBER> randomized controlled trial <NUMBER> experimental therapies conducted response democratic republic congo outbreak <NUMBER> resulting early termination study arm <NUMBER> worth noting trial active control arm mortality rates experimental treatments <NUMBER> zmapp <NUMBER> <NUMBER> mab<NUMBER> <NUMBER> regneb<NUMBER> merscov sheahan et al <NUMBER> evaluated therapeutic efficacy remdesivir among infected mice found treatment significantly reduced virus lung titers weight loss lung hemorrhage lung injury scores authors proposed importance early therapy initiation diminish virus replication promote pulmonary repair remdesivir demonstrated less clinical benefit hightiter virus inoculum notably authors also noted prophylactic remdesivir diminished merscov replication disease similar findings murine model sarscov<NUMBER> <NUMBER> <NUMBER> first report remdesivirtreated patient covid<NUMBER> united states <NUMBER>yearold male snohomish county washington received treatment hospital day <NUMBER> illness day <NUMBER> due developing pneumonia persistent fevers <NUMBER> patient experienced clinical improvement negativity oropharyngeal swab hospital day <NUMBER> although nasopharyngeal swab remained positive adverse events remdesivir reported patient consistent previous case reports use viruses <NUMBER> <NUMBER> among first <NUMBER> patients confirmed cdc covid<NUMBER> united states <NUMBER> treated remdesivir via compassionate use protocol <NUMBER> patients reported transient gastrointestinal symptoms aminotransferase elevation patients reportedly recovering authors unable assess efficacy safety remdesivir based lack comparator confounding treatments including concomitant use corticosteroids one patient <NUMBER> clinical trials currently enrolling patients united states table <NUMBER> two additional trials recruiting china registered clinicaltrialsgov nct<NUMBER> severe disease nct<NUMBER> mildmoderate disease remdesivir may also obtained compassionate use emergency investigational new drug eind application process time review requests compassionate use must submitted online via httpsrdvcugilead com compassionate use considered hospitalized patients polymerase chain reaction pcrconfirmed sarscov<NUMBER> requiring mechanical ventilation enrollment clinical trial feasible patients excluded compassionate use program meet criteria evidence multiorgan failure receiving vasopressors hypotension liver disease defined alanine aminotransferase alt <NUMBER> × upper limit normal uln renal impairment defined creatinine clearance crcl <NUMBER> mlmin receiving dialysis continuous venovenous hemofiltration inclusion exclusion criteria compassionate use may change applicants encouraged review date criteria potential patients clinicians cognizant typically takes minimum <NUMBER> hours institutions receive emergency institutional review board authorization required protocol consent forms gilead us food drug administration fdaapproval eind eventual drug shipment clinicians coordinate local information technology teams build medication order sentence electronic health record time patients may receive antiviral therapies waiting period must immediately discontinue receive remdesivir compassionate use interesting note adaptive clinical trial protocol originally stated remdesivir prodrug metabolized active form substrate cyp<NUMBER>a<NUMBER> implies existence drugdrug interaction cyp<NUMBER>a<NUMBER> substrate inhibitors ritonavir voriconazole however protocol also stated although remdesivir substrate cyp<NUMBER>c<NUMBER> cyp<NUMBER>d<NUMBER> cyp<NUMBER>a<NUMBER> vitro coadministration inhibitors cyp isoforms unlikely markedly increase remdesivir levels metabolism likely predominantly mediated hydrolase activity unlike former latter statement substantiated well described chemistry molecule national institute allergy infectious diseases contacted discrepancy collaboration gilead corrected reason believe significant drug interactions remdesivir cyp<NUMBER>a<NUMBER> inhibitors inducers likely <NUMBER> emerging clinical evidence available vitro data suggest remdesivir promising agent treatment covid<NUMBER> institutions explore clinical trial enrollment compassionate use remdesivir moderatetosevere patients additional clinical data eagerly anticipated help define role agent covid<NUMBER> chloroquine antimalarial agent antiinflammatory immunomodulatory activities gained significant interest potential therapeutic option management covid<NUMBER> early february wang et al <NUMBER> demonstrated potent vitro activity chloroquine sarscov<NUMBER> ec <NUMBER> <NUMBER> hours <NUMBER> µm vero e<NUMBER> cells data consistent previous data chloroquines inhibitory activity sarscov<NUMBER> merscov various cell lines ec <NUMBER> values <NUMBER> <NUMBER> µm demonstrated respectively <NUMBER> findings supported clinical use chloroquine dose <NUMBER> mg mouth twice daily numerous clinical trials china outbreak although rationale dosing regimen remains unclear peer reviewed data trials currently unavailable announced midfebruary promising early results demonstrated per gao et al <NUMBER> thus far results <NUMBER> patients demonstrated chloroquine phosphate superior control treatment inhibiting exacerbation pneumonia improving lung imaging findings promoting virusnegative conversion shortening disease course according news briefing severe adverse reactions chloroquine phosphate noted aforementioned patients although development encouraging supply issues united states cardiovascular toxicity concerns limit use chloroquine alternative hydroxychloroquine compound differs chloroquine single hydroxyl group garnered interest hydroxychloroquine perceived better tolerability chloroquine led longterm usage rheumatological disorders historically limited data published assessing activity hydroxychloroquine coronaviruses <NUMBER> biot et al <NUMBER> assessed comparative inhibitory activity chloroquine hydroxychloroquine sarscov<NUMBER> vero cells authors demonstrated chloroquine approximately <NUMBER>fold increased potency ec <NUMBER> <NUMBER> ± <NUMBER> µm compared hydroxychloroquine ec <NUMBER> <NUMBER> ± <NUMBER> µm sarscov<NUMBER> yao et al <NUMBER> performed <NUMBER>part study assessing comparative vitro activity chloroquine hydroxychloroquine performed pharmacologybased pharmacokinetic pbpk modeling assess comparative exposure predicted activity <NUMBER> compounds lung vitro analyses vero cells demonstrated potency hydroxychloroquine ec <NUMBER> <NUMBER> µm greater chloroquine ec <NUMBER> <NUMBER> µm sarscov<NUMBER> <NUMBER> inform optimal dosing hydroxychloroquine investigators performed pbpk modeling analysis investigators utilized human population pharmacokinetic rat lung penetration data compound estimate free trough concentrations lung ec <NUMBER> ratios r ltec <NUMBER> <NUMBER> mg chloroquine mouth twice daily reported demonstrate efficacy sarscov<NUMBER> target r ltec hydroxychloroquine regimens set ≥<NUMBER> day <NUMBER> <NUMBER> day <NUMBER> <NUMBER> day <NUMBER> r ltec values predicted efficacious <NUMBER> mg mouth twicedaily dosing chloroquine <NUMBER> various dosing regimens simulated <NUMBER> particularly notable first oral loading dose <NUMBER> mg divided <NUMBER> mg <NUMBER> mg day <NUMBER> followed <NUMBER> mg daily regimen led significantly higher r ltec day <NUMBER> <NUMBER> day <NUMBER> <NUMBER> day <NUMBER> <NUMBER> values demonstrated chloroquine second regimen loading dose <NUMBER> mg <NUMBER> mg × <NUMBER> day <NUMBER> followed <NUMBER> mg twice daily also associated higher r ltec values chloroquine day <NUMBER> <NUMBER> <NUMBER> corresponding <NUMBER> <NUMBER> <NUMBER> respectively <NUMBER> authors concluded data support lower dose regimen r ltec values significantly higher proven efficacious regimen <NUMBER> mg chloroquine mouth twice daily clinicians note chloroquine hydroxychloroquine halflives <NUMBER> days <NUMBER> therefore short durations would likely provide prolonged courses therapy exemplified pbpk modeling r ltec values hydroxychloroquine predicted still targeted efficacy threshold day <NUMBER> even <NUMBER>day course therapy although data encouraging potential role hydroxychloroquine sarscov<NUMBER> caution solely relying data support dosing regimens patients use <NUMBER> mg chloroquine mouth twice daily reference efficacy rational given initial reports china <NUMBER> important note dosing still requires validation improved r ltec values reported largely driven finding hydroxychloroquine <NUMBER> times potent chloroquine vitro although enhanced potency may well prove true data become available report counter relative potency demonstrated structurally similar sarscov<NUMBER> strain <NUMBER> chloroquine approximately <NUMBER> times potent hydroxychloroquine addition recently published study demonstrated ec <NUMBER> value chloroquine <NUMBER> µm <NUMBER> similar value reported hydroxychloroquine analysis yao et al <NUMBER> currently efficacy data available hydroxychloroquine covid<NUMBER> additional consideration given optimal dosing strategy use following example illustrate point one consider <NUMBER> compounds equally potent identical ec <NUMBER> values utilize pbpk data yao et al <NUMBER> <NUMBER> mg load <NUMBER> mg daily regimen hydroxychloroquine would yield r ltec values <NUMBER> <NUMBER> <NUMBER> day <NUMBER> <NUMBER> <NUMBER> respectively r ltec values would slightly lower achieved <NUMBER> mg mouth twice daily chloroquine day <NUMBER> significantly lower day <NUMBER> suggesting potential need higher dose similar activity although <NUMBER> mg daily regimen common regimen currently assessed clinical trials rationale dose currently unclear least <NUMBER> clinical trial china using higher dose <NUMBER> mg mouth daily point gautret et al <NUMBER> recently published initial experience impact <NUMBER> mg hydroxychloroquine mouth every <NUMBER> hours viral eradication patients covid<NUMBER> authors reported <NUMBER> patients <NUMBER> hydroxychloroquine <NUMBER> control covid<NUMBER> positive able nasopharyngeal sampling first <NUMBER> days therapy treated arm investigators demonstrated hydroxychloroquine <NUMBER> <NUMBER> <NUMBER> superior standard care <NUMBER> <NUMBER> <NUMBER> p <NUMBER> eradicating sarscov<NUMBER> nasopharynx interesting note <NUMBER> patients prescribed azithromycin prevent bacterial superinfection investigators found viral eradication numerically superior subgroup <NUMBER> <NUMBER> <NUMBER> compared received hydroxychloroquine alone <NUMBER> <NUMBER> <NUMBER> authors concluded azithromycin reinforced sarscov<NUMBER> viral load achieved hydroxychloroquine although data intriguing certain limitations data set must acknowledged first although viral eradication important endpoint authors report clinical outcomes patients second cohort initially contained <NUMBER> hydroxychloroquine patients <NUMBER> removed analysis due early cessation hydroxychloroquine therapy including <NUMBER> pcrpositive patients transferred intensive care unit icu <NUMBER> pcrnegative patient passed away <NUMBER> pcrpositive patient discontinued hydroxychloroquine due nausea finally hydroxychloroquine monotherapy arm included patients significantly higher viral loads represented lower cycle threshold c values received combination therapy hydroxychloroquine monotherapy patients c values <NUMBER> separated c values ≥<NUMBER> notable discordance viral eradication rates <NUMBER> <NUMBER> <NUMBER> vs <NUMBER> <NUMBER> <NUMBER> latter number approaching <NUMBER> <NUMBER> demonstrated hydroxychloroquine azithromycin combination therapy patients c values ≥<NUMBER> given finding small numbers study lack clinical outcomes presented potential additive toxicity hydroxychloroquine azithromycin desperate need practice good antimicrobial stewardship covid<NUMBER> pandemic would caution clinicians using data support combination therapy despite unknowns initial experience china encouraging potential role chloroquine alternatively hydroxychloroquine management covid<NUMBER> clinicians encouraged closely follow subsequent peerreviewed publications ongoing chloroquine hydroxychloroquine trials others raised concerns regarding apparent vitro andor vivo discordance witnessed chloroquine viral infections <NUMBER> furthermore hydroxychloroquine utilized careful consideration dose selection given accordance aforementioned data well considerations initiate course illness lopinavir human immunodeficiency virus hiv<NUMBER> protease inhibitor administered fixeddose combination ritonavir lpvr potent cyp<NUMBER>a<NUMBER> inhibitor boosts lopinavir concentrations lopinavir seems block main protease sarscov<NUMBER> inhibiting viral replication <NUMBER> <NUMBER> chu et al <NUMBER> evaluated series antivirals vitro activity sarscov<NUMBER> reported lopinavir <NUMBER> µgml ribavirin <NUMBER> µgml inhibited sarscov<NUMBER> <NUMBER> hours incubation agents synergistic used together <NUMBER> de wilde et al <NUMBER> later described antiviral activity lopinavir sarscov<NUMBER> demonstrated ec <NUMBER> <NUMBER> ± <NUMBER> vero e<NUMBER> cells near upper range lpv plasma concentrations previously measured patients hiv <NUMBER> sheahan et al <NUMBER> evaluated vitro efficacy lpvr combination interferon beta infb merscov found addition lpvr significantly enhance antiviral activity infb alone ec <NUMBER> <NUMBER> vs <NUMBER> iuml respectively also described ec <NUMBER> lpvr <NUMBER> µm lpv alone <NUMBER> µm suggesting similar activity described sars cov<NUMBER> despite vitro activity merscov therapeutic doses lpvr infb mice models failed reduce virus titer exacerbated lung disease <NUMBER> notable study remdesivir demonstrated potent vitro activity well vivo efficacy however vivo animal data merscov appears equivocal given nonhuman primate model demonstrated improved clinical pathological features lpvr treatment <NUMBER> randomized controlled trial lpvr recombinant interferonβ<NUMBER>b versus placebo currently enrolling patients merscov might help clarify apparent discrepancy vitro animal models <NUMBER> based vitro findings chu et al <NUMBER> utilized combination therapy lpvr ribavirin corticosteroids newly diagnosed patient sarscov<NUMBER> without acute respiratory distress syndrome ards starting april <NUMBER> patients receiving lpvr combination therapy n <NUMBER> matched historical patients receiving ribavirin plus corticosteroids n <NUMBER> significant reduction development ards death <NUMBER> days observed <NUMBER> vs <NUMBER> p <NUMBER> corroborated expanded casecontrol matched study <NUMBER> lpvrtreated patients center demonstrated significant reduction pulse steroid use <NUMBER> vs <NUMBER> intubation <NUMBER> vs <NUMBER> mortality <NUMBER> vs <NUMBER> among patients received lpvr combination versus lpvr respectively initial therapy <NUMBER> important benefits lpvr demonstrated patients received initial treatment lpvr defined initiation drug time sarscov<NUMBER> diagnosis observed benefit lpvr added rescue salvage therapy death rate <NUMBER> vs <NUMBER> compelling mortality difference sarscov<NUMBER> continued investigation merscov led inclusion lpvr chinese sarscov<NUMBER> guidelines dose <NUMBER> mg<NUMBER> mg <NUMBER> capsulestablets mouth twice day <NUMBER> days even though knowledge vitro data lpvr sarscov<NUMBER> exist <NUMBER> pediatric patients weighing <NUMBER> kg recommended dose united states <NUMBER> mgkg suspension mouth twice daily <NUMBER> ongoing registered clinical trials china korea thailand hong kong evaluating lpvr monotherapy combination antivirals eg ribavirin interferon beta<NUMBER>b traditional chinese medicine treatment covid<NUMBER> realworld data treatment covid<NUMBER> lpvr emerging young et al <NUMBER> reported outcomes first <NUMBER> patients infected sarscov<NUMBER> singapore <NUMBER> received lpvr monotherapy three patients reduction oxygen requirements treatment initiation <NUMBER> deteriorated respiratory failure two <NUMBER> patients <NUMBER> experienced clearance viral shedding treatment <NUMBER> <NUMBER> <NUMBER> experienced adverse events precluded completion planned <NUMBER>day treatment course published case reports case series korea china comprising <NUMBER> total patients describe decreased viral load clinical improvement lpvr initiation data difficult interpret light concomitant drug therapies varied time points therapy initiation heterogeneous severity illness amongst patients lack comparator treatments <NUMBER> <NUMBER> <NUMBER> finally early reports wuhan described patients receiving lpvr addition therapies including corticosteroids clinical outcomes adverse events either described delineated treatment group <NUMBER> <NUMBER> <NUMBER> recently cao <NUMBER> et al reported results openlabel randomized trial comparing lpvr <NUMBER> mg twice daily n <NUMBER> standard care n <NUMBER> treatment covid<NUMBER> pneumonia primary endpoint defined time randomization improvement <NUMBER> points <NUMBER>category ordinal scale discharge hospital secondary outcomes included <NUMBER>day mortality time discharge virologic response repeat oropharyngeal swabs course study median time symptom onset randomization <NUMBER> interquartile range iqr <NUMBER> days differ groups significant difference time clinical improvement <NUMBER> iqr <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> −<NUMBER> <NUMBER> patients receiving lpvr standard care <NUMBER> patients died randomization receiving lpvr removed remained difference mortality <NUMBER> vs <NUMBER> absolute difference −<NUMBER> percentage points <NUMBER> ci −<NUMBER> <NUMBER> important difference treatment arms reduction viral loads time <NUMBER> groups available data difficult assess whether lpvr role treatment covid<NUMBER> either monotherapy combination data sarscov<NUMBER> encouraging must weighed inferior performance mouse models merscov less potent vitro activity compared remdesivir chloroquine sarscov<NUMBER> limited data suggesting advantage standard care sarscov<NUMBER> important warrants comment recent randomized controlled trial covid<NUMBER> pneumonia median time symptom onset initiation therapy <NUMBER> days sarscov<NUMBER> experience therapy appeared effective started early rescue andor salvage used drug interactions must screened gastrointestinal toxicities including diarrhea nausea vomiting hepatotoxicity require close monitoring particularly elevated aspartate transaminase alt may exclude patients covid<NUMBER> clinical trials lpvr tablets taken without regard food crushed decreases systemic exposure solution used patients cannot receive intact tablets <NUMBER> nitazoxanide demonstrated potent vitro activity sars cov<NUMBER> ec <NUMBER> <NUMBER> hours <NUMBER> µm vero e<NUMBER> cells <NUMBER> potent activity consistent ec <NUMBER> values nitazoxanide active metabolite tizoxanide merscov llcmk<NUMBER> cells ec <NUMBER> values <NUMBER> <NUMBER> µm respectively demonstrated <NUMBER> nitazoxanide displays broadspectrum vitro antiviral activity influenza respiratory syncytial virus parainfluenza rotavirus norovirus among others addition coronaviruses <NUMBER> broadspectrum antiviral activity believed due fact mechanism action based interference hostregulated pathways involved viral replication rather virusspecific pathways <NUMBER> due broadspectrum antiviral activity nitazoxanide investigated management influenza acute respiratory infections positive results demonstrated phase <NUMBER>b<NUMBER> study outpatient management influenza dose <NUMBER> mg mouth bid nitazoxanide associated <NUMBER>day improvement time resolution symptoms compared placebo p <NUMBER> <NUMBER> three phase <NUMBER> randomized controlled trials uncomplicated influenza since completed clinicaltrials gov identifier nct<NUMBER> march <NUMBER> nct<NUMBER> april <NUMBER> nct<NUMBER> september <NUMBER> although results unavailable nitazoxanide failed reduce duration hospitalization time symptom alleviation phase <NUMBER> randomized controlled trial patients severe acute respiratory illnesses requiring hospitalization predominantly caused respiratory viruses <NUMBER> although vitro activity nitazoxanide sarscov<NUMBER> encouraging data clearly needed determine role management covid<NUMBER> tocilizumab humanized monoclonal antibody inhibits membranebound soluble interleukin<NUMBER> il<NUMBER> receptors interleukin<NUMBER> secreted monocytes macrophages one main drivers immunologic response symptoms patients cytokinerelease syndrome crs although tocilizumab first approved fda <NUMBER> treatment rheumatoid arthritis gained traction recent years treatment patients crs following chimeric antigen receptor tcell car therapy corticosteroidsparing agent <NUMBER> indeed received fda approval severe lifethreatening car tassociated crs <NUMBER> due efficacy safety profile although criteria grading crs severity varies cancer center proposed administer tocilizumab crs patients following oxygen requirement <NUMBER> hypotension responsive fluids low dose single vasoactive agent grade <NUMBER> organ toxicity defined common terminology criteria adverse events <NUMBER> interleukin<NUMBER> antagonism may make patient susceptible bacterial infection associated neutropenia thrombocytopenia patients receiving chronic therapy tocilizumab giant cell arteritis rheumatoid arthritis case series <NUMBER> adult patients relapsed refractory bcell acute lymphoblastic leukemia grade <NUMBER> crs higher associated increased risk subsequent infection unclear whether tocilizumab corticosteroid use promoted risk <NUMBER> reported adverse events <NUMBER> tocilizumabtreated patients submitted fda crs indication recommends maximum <NUMBER> doses treatment <NUMBER> hyperinflammatory states cytokine storming including elevated il<NUMBER> reported severe covid<NUMBER> associated increased mortality patients china <NUMBER> preprint nonpeer reviewed case series <NUMBER> patients treated tocilizumab february <NUMBER> <NUMBER> <NUMBER> china reported marked success including rapid resolution fever creactive protein decreased oxygen requirements resolution lung opacities computerized tomography imaging <NUMBER> authors state patients routine treatment week tocilizumab described standard care according national treatment guidelines including lopinavir methylprednisolone supportive care patients il<NUMBER> analyzed tocilizumab administration mean value <NUMBER> ± <NUMBER> pgml normal <NUMBER> pgml noted united states il<NUMBER> monitoring sendout laboratory institutions turnaround time <NUMBER> days adverse events described chinese cohort however longterm assessment done immunotherapy tocilizumab listed treatment option severe critical cases covid<NUMBER> elevated il<NUMBER> <NUMBER>th edition national health commission peoples republic china covid<NUMBER> diagnosis treatment guide <NUMBER> recommended dose <NUMBER> mgkg <NUMBER> mg standard dose iv option repeat dose <NUMBER> hours exceed total dose <NUMBER> mg <NUMBER> ongoing trials china evaluating safety efficacy tocilizumab patients covid<NUMBER> pneumonia none registered united states anticipate data regarding tocilizumab use patients covid<NUMBER> emerge imperative clinicians evaluate closely optimal timing tocilizumab administration disease course yet defined known il<NUMBER> threshold progression severe disease imperative continue follow longterm outcomes patients assess risk versus benefit tocilizumab similar severe respiratory tract infections significant interest controversy surrounding role corticosteroids management severe pneumonia due coronaviruses potential benefit agents blunt inflammatory cascade seen severe disease needs carefully weighed concerns secondary infections adverse events complications corticosteroid therapy data assessing role corticosteroids adjunctive care severe coronavirus sarscov<NUMBER> merscov sarscov<NUMBER> pneumonia difficult interpret given retrospective observational nature analyses significant confounding indication difficult control correct addition limited sample sizes patients receive corticosteroids higher severity illness likely require invasive interventions likely receiving intensive care addition significant heterogeneity regard timing corticosteroid initiation significantly impact disease progression likelihood response features lead patients receive steroids increased risk poor outcomes addition great variation agent dosage used impact safety efficacy therefore clinicians making therapeutic decisions based literature corticosteroids need keep considerations mind clinical data use corticosteroids sarscov<NUMBER> infections mixed multiple analyses show impact outcomes <NUMBER> one report demonstrates decreased mortality critically ill patients <NUMBER> others documented worse outcomes patients receiving steroids including increased time viral clearance <NUMBER> increase composite endpoint icu admission death <NUMBER> merscov receipt corticosteroids associated delayed time viral clearance large cohort n <NUMBER> infected patients <NUMBER> however data set showed nonsignificant reduction <NUMBER>day mortality patients receiving corticosteroids adjusted odds ratio <NUMBER> <NUMBER> ci <NUMBER> accounting differences groups regression model accounting timevarying exposures finally recent evidence sarscov<NUMBER> suggested decrease mortality patients ards receipt corticosteroids <NUMBER> <NUMBER> <NUMBER> vs <NUMBER> <NUMBER> <NUMBER> without hazard ratio <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> demonstrated data corticosteroids inconsistent confusing inconclusive although target patients corticosteroids improve outcomes may exist eg cytokinerelated lung injury may develop rapidly progressive pneumonia population remains illdefined <NUMBER> clinicians need carefully weigh risks benefits corticosteroids individual patient level need riskbenefit assessment individual patients careful consideration dose exemplified covid<NUMBER> diagnosis treatment guide national health commission peoples republic china authors state based respiratory distress chest imaging may consider glucocorticoid equivalent methylprednisolone <NUMBER> mgkgday <NUMBER> days less note largedose glucocorticoid suppresses immune system could delay clearance sarscov<NUMBER> <NUMBER> recent consensus statement chinese thoracic society recommends lower dose ≤<NUMBER> mgkg per day methylprednisolone ≤<NUMBER> days select patients careful consideration risks benefits <NUMBER> randomized controlled trial data urgently needed clearly define role corticosteroids covid<NUMBER> ribavirin guanosine analog terminates rna synthesis first approved <NUMBER>s used clinically respiratory syncytial virus viral hemorrhagic fever combination interferon hepatitis c mentioned previously see lpvr section evaluated sarscov<NUMBER> <NUMBER> used clinically combination corticosteroids andor interferon absence treatment options however outcomes either poor illdefined <NUMBER> <NUMBER> doses required antiviral activity sars range <NUMBER> <NUMBER> grams mouth every <NUMBER> hours associated excessive toxicity patients <NUMBER> wang et al <NUMBER> evaluated vitro activity ribavirin sarscov<NUMBER> found ec <NUMBER> <NUMBER> µm <NUMBER> times less potent remdesivir risk hematologic toxicity high doses likely outweighs potential clinical benefit therefore ribavirin considered viable candidate investigation research development plan sarscov<NUMBER> given lack vitro efficacy toxicity profile poor outcomes interferons α β may stimulate innate antiviral responses expected vitro activity sarscov<NUMBER> given previously described activity demonstrated merscov ec <NUMBER> <NUMBER> iuml however toxicities substantial including severe cytopenias hepatotoxicity including fatality neuropsychiatric events risk developing fatal lifethreatening ischemia infection particularly combined ribavirin combination associated improved mortality enhanced viral clearance retrospective analysis patients infected merscov initiated combination therapy within <NUMBER> days icu admission <NUMBER> despite limited poor data chinese guidelines recommend ribavirin <NUMBER> mg iv <NUMBER> times daily combination lpvr inhaled interferonα <NUMBER> million units nebulized twice daily one standard treatment options covid<NUMBER> various combinations ribavirin interferon antiviral agents currently studied several clinical trials based poor vitro activity absence animal human data supporting use significant toxicity profile recommend avoiding use ribavirin patients covid<NUMBER> time although interferons may useful adjunctive care pose significant risk critically ill patients absence supportive data also cannot currently recommended given antiviral activity influenza considerable attention paid oseltamivir lesser degree baloxavir potential treatment options covid<NUMBER> exacerbated initial report huang et al <NUMBER> wuhan patients managed covid<NUMBER> received oseltamivir addition broadspectrum antimicrobials important note use oseltamivir targeted therapy sarscov<NUMBER> rather driven lack knowledge causative pathogen time treatment desire empirically treat influenza authors suggest use oseltamivir covid<NUMBER> publication data suggest vitro activity oseltamivir sarscov<NUMBER> fact data assessing oseltamivir activity coronaviruses demonstrated ineffective inhibiting sarscov<NUMBER> even concentration <NUMBER> <NUMBER> µml <NUMBER> coronaviruses utilize neuraminidase thus enzyme inhibited oseltamivir would hold true zanamivir peramivir neuraminidase inhibitor agents similarly neither defined mechanism vitro data suggested baloxavir would demonstrate activity sarscov<NUMBER> coronaviruses therefore given critical need agents management influenza concern drug shortages oseltamivir agents avoided patients covid<NUMBER> influenza ruled table <NUMBER> lists agents investigated andor theoretically considered management sarscov<NUMBER>infected patients time recommendation made agents general avoided without additional supporting evidence appropriate management strategies patients covid<NUMBER> rapidly evolving therapeutic challenge optimal agents treat infection prevent progression critical illness remain illdefined although certain agents listed review encouraging potential benefit therapy likely outweighs relatively minor risk adverse events shortcourse therapy evidence remains inconclusive changes almost daily patient populations warrant therapy timing initiation therapy need defined given disease progression occur rapidly stable patients viral loads highest early infection course authors review opine rapid initiation therapy highrisk populations patients hospitalized outpatients high risk complications rational considered ideally context wellcontrolled adequately powered trial important however strategy without risk needs weighed potential adverse events remain poorly defined impending drug shortages increases use agents help address concerns careful consideration given duration therapy many clinical trials institutional protocols recommending <NUMBER> days uncomplicated disease duration therapy individualized patient progression disease clinicians must continually monitor adapt new literature becomes available caution applied bulk available clinical data uncontrolled peer reviewed even unpublished given <NUMBER> safety efficacy convalescent plasma transfusion sarscov<NUMBER>infected patients established protocols exist currently united states protocols reportedly developed johns hopkins university hospital darunavircobicistat hiv<NUMBER> protease inhibitor currently evaluated clinical trial nct<NUMBER> vitro human data exist support use time thiuram derivative blocks alcohol oxidation demonstrated ability competitively inhibit papainlike proteases sars however clinical data exist <NUMBER> vitro clinical data exist covid<NUMBER> humanized monoclonal igg antibody binds complement protein c<NUMBER> prevents formation membrane attack complex mac evaluated clinical trial nct<NUMBER> covid<NUMBER> quell immune response data exist time support use favipiravir rnadependent rna polymerase inhibitor broadspectrum antiviral activity however demonstrated high ec <NUMBER> decreased potency sarscov<NUMBER> effective protecting mice ebola virus despite similarly high ec <NUMBER> values <NUMBER> currently evaluated clinical trial nct<NUMBER> patients covid<NUMBER> agent fda approved available united states galidesivir bcx<NUMBER> nucleoside rna polymerase inhibitor reported wide spectrum antiviral activity currently pipeline biocryst pharma previously evaluated ebola hemorrhagic fever virus infections algaederived lectin potent hiv entry inhibitor agent demonstrated vitro activity sarscov<NUMBER> <NUMBER> ivig ivig remains critical national shortage united states benefit patients covid<NUMBER> unclear nelfinavir hiv<NUMBER> protease inhibitor might active sarscov<NUMBER> based preprint publication utilized homology modeling <NUMBER> clinical data exist anthelminthic drug vitro efficacy sarscov<NUMBER> however low absorption oral bioavailability resulting wide range serum concentrations healthy volunteers single dose may limit utility antiviral treatment <NUMBER> human monoclonal antibody discovered regeneron reportedly binds protein merscov currently phase <NUMBER> trial healthy volunteers nct<NUMBER> company reportedly announced recruitment phase <NUMBER> <NUMBER> trials sarscov<NUMBER> however registered clinicaltrialsgov sarilumab il<NUMBER> receptor antagonist fdaapproved rheumatoid arthritis recently announced usbased trial begin enrolling medical centers new york patients severe covid<NUMBER> disease sofosbuvir antiviral used treat hepatitis c vitro activity sarscov<NUMBER> clinical data exist <NUMBER> novel fully human antiil<NUMBER>r tiziana life sciences company recently announced moving forward clinical development patient use patients covid<NUMBER> excessive il<NUMBER> production vitamin c ongoing clinical trial <NUMBER> grams iv bid vitamin c china treatment covid<NUMBER> nct<NUMBER> use agent recommended time chinese herbal medicine extract infusion formulation given <NUMBER> ml iv twice daily suggested may consider treatment severe critical cases national health commission peoples republic china covid<NUMBER> diagnosis treatment guide <NUMBER>th edition previously demonstrated improved mortality patients severe community acquired pneumonia china <NUMBER> limitations critical institutions clinicians report experiences management treatment covid<NUMBER> medical community may modify optimize treatment recommendations pathways background severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> first broke wuhan china subsequently spread worldwide chloroquine sporadically used treating sarscov<NUMBER> infection hydroxychloroquine shares mechanism action chloroquine tolerable safety profile makes preferred drug treat malaria autoimmune conditions propose immunomodulatory effect hydroxychloroquine also may useful controlling cytokine storm occurs latephase critically ill sarscov<NUMBER> infected patients currently evidence support use hydroxychloroquine sarscov<NUMBER> infection methods pharmacological activity chloroquine hydroxychloroquine tested using sarscov<NUMBER> infected vero cells physiologicallybased pharmacokinetic models pbpk implemented drugs separately integrating vitro data using pbpk models hydroxychloroquine concentrations lung fluid simulated <NUMBER> different dosing regimens explore effective regimen whilst considering drugs safety profile results hydroxychloroquine ec<NUMBER> µm found potent chloroquine ec<NUMBER> µm vitro based pbpk models results loading dose <NUMBER> mg twice daily hydroxychloroquine sulfate given orally followed maintenance dose <NUMBER> mg given twice daily <NUMBER> days recommended sarscov<NUMBER> infection reached three times potency chloroquine phosphate given <NUMBER> mg twice daily <NUMBER> days advance conclusions hydroxychloroquine found potent chloroquine inhibit sarscov<NUMBER> vitro vitro antiviral activity projection optimized dosing design hydroxychloroquine treatment severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> background severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> first broke wuhan china subsequently spread worldwide chloroquine sporadically used treating sarscov<NUMBER> infection hydroxychloroquine shares mechanism action chloroquine tolerable safety profile makes preferred drug treat malaria autoimmune conditions propose immunomodulatory effect hydroxychloroquine also may useful controlling cytokine storm occurs latephase critically ill sarscov<NUMBER> infected patients currently evidence support use hydroxychloroquine sarscov<NUMBER> infection methods pharmacological activity chloroquine hydroxychloroquine tested using sarscov<NUMBER> infected vero cells physiologicallybased pharmacokinetic models pbpk implemented drugs separately integrating vitro data using pbpk models hydroxychloroquine concentrations lung fluid simulated <NUMBER> different dosing regimens explore effective regimen whilst considering drugs safety profile results hydroxychloroquine ec<NUMBER> µm found potent chloroquine ec<NUMBER> µm vitro based pbpk models results loading dose <NUMBER> mg twice daily hydroxychloroquine sulfate given orally followed maintenance dose <NUMBER> mg given twice daily <NUMBER> days recommended sarscov<NUMBER> infection reached three times potency chloroquine phosphate given <NUMBER> mg twice daily <NUMBER> days advance conclusions hydroxychloroquine found potent chloroquine inhibit sarscov<NUMBER> vitro vitro antiviral activity projection optimized dosing design hydroxychloroquine treatment severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> coronavirus disease <NUMBER> covid <NUMBER> acute respiratory viral infection related severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> disease outbreak started china late december <NUMBER> quickly spread rest world resulting pandemic affecting <NUMBER> countries territories worldwide far <NUMBER> current mortality rate disease estimated <NUMBER> total number cases <NUMBER> million april <NUMBER> <NUMBER> <NUMBER> incidence new cases increasing devastating proportions united states declared public health emergency <NUMBER> article provides comprehensive review disease epidemiology pathogenesis diagnosis mitigation measures treatment options also provides insights ongoing clinical trials aimed limiting disease progression rna strand nonsegmented positive sense measure <NUMBER> nm diameter <NUMBER> outer surface contains spikes measuring <NUMBER> nm length looks like crown looked microscope <NUMBER> outer surface virus possesses four vital structural proteins spike envelope e membrane nucleocapsid n proteins <NUMBER> <NUMBER> glycoprotein ability attach angiotensinconverting enzyme <NUMBER> receptor ace<NUMBER> helps fusion eventual entry virion particles host cell <NUMBER> <NUMBER> coronaviruses zoonotic viruses spread animals humans two incidents past human infections resulted severe disease first event <NUMBER> sars outbreak humans got infected betacoronavirus named sarscov usually found bats epidemic started china affecting <NUMBER> people resulting many <NUMBER> deaths worldwide <NUMBER> later <NUMBER> another beta group coronavirus merscov bat origin resulted outbreak started saudi arabia affecting nearly <NUMBER> people resulting <NUMBER> deaths mortality rate disease high <NUMBER> <NUMBER> december <NUMBER> novel coronavirus discovered wuhan city china linked group pneumonia cases later virus assumed transmitted wild animals humans cases associated seafood market <NUMBER> december <NUMBER> <NUMBER> world health organization informed chinese health department outbreak <NUMBER> international committee taxonomy viruses ictv named virus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> announced name coronavirus disease <NUMBER> covid<NUMBER> refer disease caused virus <NUMBER> <NUMBER> studies shown virus capable spreading among humans droplets fomites direct contact confirmed epidemiological investigation january <NUMBER> <NUMBER> two patients travel history wuhan detected virus guangdong province china far original outbreak <NUMBER> january <NUMBER> rapid increase number cases coupled global travel resulted spread infection around globe declared outbreak sixth international public health emergency january <NUMBER> <NUMBER> <NUMBER> march <NUMBER> china reported total <NUMBER> cases sarscov<NUMBER> infection mortality rate <NUMBER> resulting <NUMBER> fatalities <NUMBER> middle february <NUMBER> infection spread countries italy iran united kingdom spain france united states <NUMBER> january <NUMBER> <NUMBER> first case reported united states state washington <NUMBER> since infection spread <NUMBER> states march <NUMBER> <NUMBER> <NUMBER> april <NUMBER> <NUMBER> affected <NUMBER> people resulted almost <NUMBER> deaths <NUMBER> disease severe people underlying conditions resulting acute respiratory distress syndrome ards multiorgan dysfunction <NUMBER> april <NUMBER> <NUMBER> disease spread <NUMBER> countries territories worldwide affecting nearly <NUMBER> million people mortality rate estimated <NUMBER> <NUMBER> deaths april <NUMBER> <NUMBER> <NUMBER> initial symptoms covid<NUMBER> consist fever chills dry cough sore throat nausea headache myalgias similar influenza <NUMBER> unique symptom reported sarscov<NUMBER> infection involvement gastrointestinal system vomiting diarrhea found case sars mers <NUMBER> another interesting feature covid<NUMBER> infection presence asymptomatic carriers shed virus <NUMBER> days without clinical signs symptoms patients severe illness present shortness breath sob severe respiratory distress pneumonia also increased reporting newonset anosmia ageusia presenting symptoms cases <NUMBER> average incubation period covid<NUMBER> <NUMBER> days <NUMBER> however studies reported incubation period long <NUMBER> days cases incubation period covid<NUMBER> longer compared mers <NUMBER> days sars <NUMBER> days study wang et al <NUMBER> hospitalized patients reported common symptoms included fever <NUMBER> dry cough <NUMBER> fatigue <NUMBER> also study median time observed first symptoms complications five days dyspnea seven days hospitalization eight days ards <NUMBER> findings helpful clinicians managing atrisk populations comorbidities early identification complications timely treatment helps patient survival chen et al conducted study <NUMBER> hospitalized people reported common symptoms fever <NUMBER> cough <NUMBER> sob <NUMBER> <NUMBER> findings centers disease control prevention cdc report china comprising <NUMBER> case records including confirmed suspected diagnosed asymptomatic cases follows overall fatality rate <NUMBER> <NUMBER> confirmed cases mortality higher elderly <NUMBER> aged <NUMBER> years <NUMBER> aged <NUMBER> years <NUMBER> another interesting finding report half critically ill patients underlying comorbidities diabetes chronic lung disease cardiovascular disease cancer studies shown older patients comorbidities susceptible complications respiratory failure multiorgan dysfunction shock acute cardiac injury acute kidney injury even death severe cases <NUMBER> several diagnostic tests developed detect presence covid<NUMBER> infection realtime polymerase chain reaction pcr reverse transcription polymerase chain rtpcr reverse transcription loopmediated isothermal amplification rtlamp assay enzymelinked immunosorbent assay elisa <NUMBER> recently united states march <NUMBER> <NUMBER> abbott laboratories got fda approval portable pointofcare antibody test kit deliver test results within <NUMBER> minutes <NUMBER> studies shown blood cell profile covid<NUMBER> patients consists decreased white blood cell wbc count lymphopenia thrombocytopenia rnaemia elevated aspartate aminotransferase ast elevated erythrocyte sedimentation rate esr creactive protein crp mildly elevated procalcitonin secondary infection levels <NUMBER> moreover severe cases associated elevated levels lactate dehydrogenase ldh alanine transaminase alt creatinine prothrombin time <NUMBER> radiological findings covid<NUMBER> patients show variety changes groundglass opacities bilateral lung involvement multiple lobular subsegmental areas consolidation mottling pneumothorax <NUMBER> addition histological findings hyaline membrane formation fibromyxoid exudates diffuse alveolar damage desquamation pneumocytes observed critically ill patients <NUMBER> <NUMBER> leading cause mortality critically ill covid<NUMBER> happened due respiratory failure severe bilateral pneumonia <NUMBER> studies shown sarscov<NUMBER> causes cytopathic damage airway epithelial cells result activation severe dysregulated immune responses ultimately leading ards <NUMBER> histological examination patients ards shown hyperactive cytotoxic tcells filled large volumes cytotoxic granules <NUMBER> addition studies shown critically ill patients covid<NUMBER> elevated levels interleukin il <NUMBER> due hyperinflammation process called cytokine storm syndrome <NUMBER> high levels il<NUMBER> responsible shock respiratory failure multiorgan failure patients <NUMBER> addition cellular immune mechanisms also thought responsible grave prognosis severe disease damage lymphocytes resulting lymphopenia increased susceptibility secondary infections also observed critically ill patients <NUMBER> elevation proinflammatory cytokines along suppression antiinflammatory cytokines suggests cellular immune response sarscov<NUMBER> <NUMBER> humoral immune response role pathogenesis covid<NUMBER> decrease levels immunoglobulins covid<NUMBER> indicates effects antibodyproducing b lymphocytes <NUMBER> though antigens sarscov<NUMBER> shown potential stimulating antibody production impact overall lymphopenia may caused depletion immunoglobulins <NUMBER> n proteins surface coronavirus thought elicit immune responses <NUMBER> severely ill covid<NUMBER> patients virusspecific antibodies thought play role pathogenesis hyperinflammation cytokine storm depletion lymphocytes process called antibodydependent enhancement <NUMBER> blood profile hospitalized patients showed elevated neutrophillymphocyte ratio along decrease monocytes basophils eosinophils <NUMBER> addition depletion b lymphocytes natural killer nk cells seen critically ill patients suppression subsets cells helper cells regulatory cells suppressor cells observed cytokine storm severely ill patients results elevation proinflammatory cytokines plasma including interferon gamma ifnγ il<NUMBER> beta tumor necrosis factor alpha tnfα granulocyte colonystimulating factor gcsf il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> <NUMBER> therefore detection il<NUMBER> play significant role estimating severity disease studies shown sarscov<NUMBER> result hyperinflammation lungs fibrosis release il<NUMBER>β mediated attachment virions tolllike receptors tlr <NUMBER> therefore drugs targeting il<NUMBER>β could potentially beneficial severely ill patients prevention mainstay blocking disease spread lowering mortality rate proper handwashing maintaining least <NUMBER> feet social distancing public selfisolation quarantining suspicious disease contraction ways preventing disease transmission several ongoing studies dedicated assessing treatment options covid<NUMBER> drugs investigation include remdesivir chloroquine hydroxychloroquine tocilizumab convalescent serum wang et al conducted vitro studies sarscov<NUMBER> specimen investigated effectiveness antiviral drugs ribavirin penciclovir remdesivir gs<NUMBER> favipiravir t<NUMBER> medications nitazoxanide nafamostat chloroquine treatment covid<NUMBER> <NUMBER> findings study showed remdesivir chloroquine potential inhibiting virus cell cultures remdesivir nucleotide analog exhibits antiviral properties incorporation nascent viral rna chains resulting early termination studies remdesivir mice cell lines nonhuman primate nhp cell lines shown positive results coronaviruses sars merscov ebola virus <NUMBER> results study wang et al showed remdesivir able attain required concentrations inside monkey cell lines infected virus moreover remdesivir able inhibit infection effectively human liver huh<NUMBER> cells second drug chloroquine immunosuppressive antimalarial drug traditionally used rheumatoid arthritis lupus vitro studies shown chloroquine potential inhibit sarscov<NUMBER> mechanisms including raising ph inside endosomes prevents fusion virus infected cell interrupting glycosylation viral receptors <NUMBER> addition antiviral properties immunosuppressive properties chloroquine showed cumulative benefit viral inhibition cell lines <NUMBER> said vivo studies studies patients infected sarscov<NUMBER> necessary assess potential drugs treating covid<NUMBER> minimal side effects france gautret et al conducted openlabel nonrandomized small population study hospitalized patients covid<NUMBER> <NUMBER> study patients given combination chloroquine azithromycin criteria patient selection age <NUMBER> years detection sarscov<NUMBER> antigens nasal swab pcr test admission irrespective clinical status <NUMBER> patients pregnant breastfeeding contraindications chloroquine retinopathy qt prolongation deficiency glucose<NUMBER> phosphate dehydrogenase g<NUMBER>pd enzyme excluded study primary endpoint study negative test result nasopharyngeal swab test six days treatment study enrolled <NUMBER> patients based criteria <NUMBER> people put hydroxychloroquine azithromycin needed remaining <NUMBER> put control group <NUMBER> patients classified three groups based symptoms asymptomatic upper respiratory tract infection urti group symptoms fever body aches rhinitis pharyngitis lower respiratory tract infections lrti group symptoms bronchitis pneumonia <NUMBER> results study follows <NUMBER> patients received drugs showed resolution viral load compared patients receiving hydroxychloroquine alone <NUMBER> control population <NUMBER> <NUMBER> moreover effectiveness treatment significant urti lrti groups compared asymptomatic patients end february <NUMBER> almost seven clinical trials reviewed effectiveness chloroquine hydroxychloroquine covid<NUMBER> people china <NUMBER> liu et al conducted vitro studies evaluating effect drugs sarscov<NUMBER> <NUMBER> study demonstrated similar drug profile chloroquine hydroxychloroquine terms cytotoxicity drug concentration target cells tissue distribution previously several clinical studies shown hospitalized critically ill patients covid<NUMBER> exhibit excessive levels cytokines plasma compared less symptomatic people suggesting role cytokines disease severity <NUMBER> hydroxychloroquine possesses good antiinflammatory properties thought effective patients liu et al concluded results stating hydroxychloroquine potential inhibit sarscov<NUMBER> infection effectively study also highlighted adverse effects drug low safety index <NUMBER> point clinical trials necessary assess effectiveness hydroxychloroquine covid<NUMBER> studies reported hyperactivation humoral immune responses release il<NUMBER> observed critically patients covid<NUMBER> <NUMBER> therefore drugs targeting il<NUMBER> receptors tocilizumab could potential benefit patients tocilizumab biological agent used moderatetosevere rheumatoid arthritis acts binding il<NUMBER> receptors thereby inhibiting effects il<NUMBER> china italy nonrandomized openlabel study conducted <NUMBER> critically ill patients covid<NUMBER> treated tocilizumab <NUMBER> patients put standard therapy consisting lopinavir methylprednisolone addition intravenous tocilizumab <NUMBER> mg patients study reported resolution symptoms fever within <NUMBER> hours start treatment <NUMBER> moreover <NUMBER> patients reported significant decrease oxygen requirement within two five days receiving treatment <NUMBER> patients resolution pneumonia radiologically well <NUMBER> study report side effects treatment however evidence terms positive outcomes large patient groups necessary substantiate results study late april <NUMBER> wang et al published findings randomized casecontrol study effectiveness intravenous remdesivir severely ill covid<NUMBER> patients <NUMBER> study recruited <NUMBER> patients <NUMBER> hospitals wuhan china met following criteria age ≥ <NUMBER> years labconfirmed infection sarscov<NUMBER> onset symptoms enrollment ≤ <NUMBER> days oxygen saturation ≤ <NUMBER> room air chest xray findings positive pneumonia patients pregnant breastfeeding complications liver disease cirrhosis elevated liver enzymes ≥<NUMBER> times normal renal impairment dialysis patients excluded study concurrent therapy medications steroids lopinavirritonavir interferons allowed clinical improvement within <NUMBER> days starting remdesivir primary endpoint study study reported patients remdesivir group achieved clinical improvement faster compared placebo patients symptoms ≤<NUMBER> days hazard ratio <NUMBER>·<NUMBER> <NUMBER> ci <NUMBER>·<NUMBER>·<NUMBER> <NUMBER> however results statistically significant relatively small patient population might one reasons limitations study include remdesivir introduction late stage disease insufficient data patient recovery remdesivir stopped early adverse effects anemia thrombocytopenia elevated bilirubin <NUMBER> apart drug trials notable studies include effectiveness passive immunization use convalescent plasmaantibodies critically ill covid<NUMBER> patients antibody treatment successfully used treatment infectious diseases past metaanalysis effectiveness convalescent plasma acute viral infections sarscov merscov shown positive results terms decrease viral load case fatality rates <NUMBER> study china reported <NUMBER> critically ill people shown positive results treated antibodies recovered people including improved o<NUMBER> saturation decreased viral load <NUMBER> studies postulated antibodies potential neutralize viral particles inhibit infection new cells activate complement phagocytosis however treatment associated adverse effects addition ethical issues careful donor selection antibody treatment associated risk thrombosis <NUMBER> <NUMBER> addition studies ongoing vaccine trials across globe coronavirus finally <NUMBER> including withdrawn clinical trials dedicated management covid<NUMBER> united states <NUMBER> active studies currently conducted clinical trials shown covid<NUMBER> outbreak overwhelming nations terms economy public health aspects curbing disease spread keeping incidence cases lowest level possible furthermore disease management challenging clinicians medical personnel terms treatment options availability personal protective equipment offlabel use drugs hydroxychloroquine emergency use authorization remdesivir hopefully help clinicians treating critically ill patients use convalescent serum also shown interim benefit definitive treatment preventive options uncovered vaccines effective treatment regimens disclosures coronavirus disease <NUMBER> covid<NUMBER> causal pathogen severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> classified world health organization pandemic <NUMBER> <NUMBER> <NUMBER> cases confirmed globally <NUMBER> <NUMBER> majority available united states uspublished reports present populations community spread urban areas <NUMBER> <NUMBER> letter describe characteristics pharmacologic treatment preliminary outcomes <NUMBER> acute care patients covid<NUMBER> within three hospitals sanford health integrated healthcare system upper midwest north dakota south dakota represent rural areas usa median incomes north dakota south dakota <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> respectively april <NUMBER> north dakota civilian labour force <NUMBER> <NUMBER> people unemployment rate <NUMBER> south dakota civilian labour force <NUMBER> <NUMBER> people unemployment rate <NUMBER> <NUMBER> infectious diseases society america covid<NUMBER> treatment guidelines published <NUMBER> april <NUMBER> recommend treatment covid<NUMBER> pharmacological agents context clinical trial however rural health systems may always capabilities resources necessary rapidly join open clinical trials <NUMBER> thus feel important outline rural healthcare system deployed therapeutic options available covid<NUMBER> study patients confirmed sarscov<NUMBER> infection positive nasopharyngeal polymerase chain reaction test seen emergency department admitted one three sanford health hospitals <NUMBER> march <NUMBER> <NUMBER> april <NUMBER> included participants enrolled irbapproved registrybased cohort waiver informed consent data presented collected review secure confidential electronic health records accessed permission irb publicly available total <NUMBER> patients included <NUMBER> male n <NUMBER> median age <NUMBER> years range <NUMBER> month<NUMBER> years <NUMBER> <NUMBER> caucasian demographic clinical characteristics described table <NUMBER> common comorbidities observed cardiovascular cv disease diabetes mellitus fourteen patients never admitted inpatient treatment rather discharged home emergency department encounter abnormal chest radiograph findings observed <NUMBER> patients common admission symptoms included cough shortness breath fever pharmacological treatments prescribed treatment covid<NUMBER> related sequelae summarised table <NUMBER> patients selected receive different pharmacological treatments based physician discretion support internal covid<NUMBER> treatment guidance document continuously updated new peerreviewed literature became available risks benefits treatment explained within document well guidance subsets patients may benefit certain treatments others median length time admission patients received pharmacological treatment less <NUMBER> day least <NUMBER>day course hydroxychloroquine azithromycin prescribed <NUMBER> <NUMBER> covid<NUMBER> patients sixteen patients received convalescent plasma note tocilizumab administered <NUMBER> patients critical illness elevated interleukin<NUMBER> il<NUMBER> levels <NUMBER> pgml andor elevations inflammatory markers five patients received two doses therapies included zinc ascorbic acid lopinavirritonavir nonsteroidal antiinflammatory agents therapeutic anticoagulation corticosteroids critically ill patients appeared refractory therapies supportive care convalescent plasma pursued patient cohort received remdesivir yet available hospitals outside manufacturers compassionate use programme pregnant paediatric patients preliminary outcomes also described table <NUMBER> <NUMBER> june <NUMBER> acute respiratory distress syndrome ards occurred <NUMBER> <NUMBER> patients <NUMBER> <NUMBER> ards patients requiring mechanical ventilation vasopressor support administered <NUMBER> patients acute kidney injury diagnosed <NUMBER> patients total <NUMBER> patients survived hospital emergency department discharge date <NUMBER> patients never admitted inpatient treatment remain alive <NUMBER> june <NUMBER> <NUMBER> patients three received pharmacologic treatment specifically covid<NUMBER> diagnosis form <NUMBER>day course azithromycin followup completed form appointments provider inperson via telephone emergency department discharge four <NUMBER> patients admitted inpatient treatment followup appointments scheduled <NUMBER> june <NUMBER> <NUMBER> patients followup appointments mean followup period <NUMBER> days emergency department visit <NUMBER> june <NUMBER> <NUMBER> patients remain alive hospitalised eight intensive care unit three general ward <NUMBER> patients survive discharge <NUMBER> patients survive discharge seven received hydroxychloroquine azithromycin note one patient transferred higher level care extracorporeal membrane oxygenation average length stay including patients still hospitalised sanford facility <NUMBER> june <NUMBER> cohort approximately <NUMBER> days median length stay <NUMBER> days range <NUMBER> report first describe treatment acute care patients within rural healthcare system usa includes general ward critically ill patients hydroxychloroquine azithromycin appeared common treatment strategy cohort impact disease progression survival unclear <NUMBER> deaths occurred cohort <NUMBER> june <NUMBER> first confirmed covidpositive patient admitted hospital system <NUMBER> march <NUMBER> patients one received tocilizumab il<NUMBER> serum level upper limit normal <NUMBER> pgml patient received tocilizumab without elevated il<NUMBER> serum level elevations inflammatory markers ferritin creactive protein ddimer therapies impact convalescent plasma survival yet clear report potentially signals lower hospital mortality rate current national average however unknown covid<NUMBER> mortality rate dakotas change projected surge covid<NUMBER> approaches <NUMBER> efficacy hydroxychloroquine azithromycin use without tocilizumab yet clarified without risks corrected qt interval qtc prolongation arrhythmias cohort <NUMBER> patients received hydroxychloroquine <NUMBER> <NUMBER> developed arrhythmia <NUMBER> <NUMBER> developed qtc <NUMBER> ms initiation therapy baseline ekgs reveal presence arrhythmias prolonged qtc patients prior initiation hydroxychloroquine azithromycin therapy additionally <NUMBER> <NUMBER> <NUMBER> patients arrhythmia development underlying cv disease <NUMBER> <NUMBER> <NUMBER> patients prolonged qtc <NUMBER> ms underlying cv disease nine patients received hydroxychloroquine without azithromycin none developed arrhythmia qtc <NUMBER> ms therapy initiation incidence arrhythmias initiation hydroxychloroquine azithromycin cohort <NUMBER> appears higher incidence arrhythmias initiation hydroxychloroquine macrolide antibiotic <NUMBER> largest multinational registry analysis <NUMBER> <NUMBER> patients hospitalised covid<NUMBER> patients date although caution exercised interpreting comparison given small size cohort <NUMBER> diarrhoea occurred <NUMBER> <NUMBER> patients constipation developed <NUMBER> <NUMBER> patients nausea andor vomiting occurred <NUMBER> <NUMBER> patients note possible gastrointestinal occurrences could attributed sarscov<NUMBER> virus rather side effects medications furthermore appreciate adverse effects appeared related tocilizumab convalescent plasma administration patient subsets similar recent us reports data limited small important sample use preliminary outcomes however findings may provide insight severity disease across rural acute care cohort agents utilised treatment rapid clinical trial access may feasible recognise unavailability symptom duration prior inpatient admission limitation report may helped better characterise disease progression duration statistical comparisons treatment groups also pursued given nonrandomised patient selection small sample size use medications rural hospitals treat covid<NUMBER> infection yet clarified without risks especially regards combination hydroxychloroquine azithromycin patients cv comorbidities larger trials randomisation methods examining efficacy safety pharmacologic therapies treat covid<NUMBER> needed urgently see table a<NUMBER> onset symptoms fever cough fatigue production sputum shortness breath sore throat headache along reports diarrhoea vomiting began rise group pneumonia cases december <NUMBER> later identified bcoronavirus wuhan hubei province china guan et al <NUMBER> bcoronavirus firstly named <NUMBER>novel coronavirus <NUMBER>ncov <NUMBER> january <NUMBER> formally named disease coronavirus <NUMBER> world emergency disease cause concern globally international committee coronavirus study group csg recommended use name sarscov<NUMBER> published <NUMBER> february <NUMBER> analyzing viral sequence evolutionary analysis bat suspected natural host virus virus might transferred humans intermediate host binding ace<NUMBER> receptor angiotensin converting enzyme<NUMBER> receptor zhou et al <NUMBER> first lethal case reported <NUMBER> january <NUMBER> infection patients healthcare workers first verified <NUMBER> january <NUMBER> reported chinese new year people migrated wuhan various countries world new cases evolved countries especially various patients travel history china notified scientific medical communities local human human transmission seen countries rothe et al <NUMBER> recently total number cases around world recorded <NUMBER> confirmed cases <NUMBER> deaths httpswwwworldometersinfocoronavirus various types treatments proposed mainly antiviral drugs sarscov merscov antibodies used clinicians recent recommended combination therapy hydroxychloroquine azithromycin studied results open labelled non randomized clinical trial published gautret et al <NUMBER> meanwhile food drug administration fda stated chloroquine phosphate hydroxychloroquine sulphate approved treating covid<NUMBER> upon certain vitro clinical data chloroquine phosphate hydroxychloroquine sulphate advised treatment covid<NUMBER> enough randomized trials compounds provided allowed administration drugs used emergency httpswwwfdagovemergencyuseauthorizationcovidtherapeutics hydroxychloroquine may inhibitory mechanism viral processes metabolisms may involved mechanisms inhibition ace<NUMBER> cellular receptor acidification cell membrane preventing entry virus modulation immune response respective cytokine release covid<NUMBER> drug therapyelsevier <NUMBER> march <NUMBER> recent studies shown hydroxychloroquine also cause drug poisoning severe moderate adverse effects individuals already taking treatments diabetic hypersensitive patients patient group found affected severely covid<NUMBER> administration hydroxychloroquine found inhibit proinflammatory cytokines finally leads acute respiratory distress syndrome ards guastalegname vallone <NUMBER> found adverse neuropsychiatric condition seen post treatment hydroxychloroquine hypothesized specifies lysosomal dysfunction leading psychiatric symptoms initiated normal state patient administered drug ali jones et al <NUMBER> lethal adverse effect retinal toxicity seen patient acute renal impairment administered hydroxychloroquine tailor et al <NUMBER> study high doses hydroxychloroquine along atorvastatin diabetic patients showed highest decline blood glucose patients wondafrash et al <NUMBER> antimalarial drug hydroxychloroquine administered patients dermatomyosis nonlife threatening cutaneous reactions seen dermatomyosis patients cutaneous lupus erythrematosus pelle callen <NUMBER> many side effects reported according website httpswww guidetopharmacologyorgcoronavirusjsp many ligands synthetic nature proposed treatment covid<NUMBER> clinical trials process peer review due high adverse effects site target hydroxychloroquine acts viral proteasome spike proteins proteins involved life cycle virus unknown covid<NUMBER> drug therapyelsevier <NUMBER> march <NUMBER> potential natural nonsynthetic drug compound found minimal side effects drugs necessary act targets ace<NUMBER> receptors tmprss<NUMBER> sarscov<NUMBER> cd<NUMBER> httpswww guidetopharmacologyorgcoronavirusjsp process found order decrease prognosis disease life cycle virus silico studies chemically synthetic drugs paritaprevir raltegravir doultegravir bictegravir targets <NUMBER>clpro <NUMBER> <NUMBER> omtase khan jha et al <NUMBER> theophylline pyrimidone derivatives possible inhibitors rna bound n terminal domain sarma et al <NUMBER> remdesivir saquinavir darunavir also two natural compounds flavone coumarine derivatives inhibition <NUMBER>cl pro khan zia et al <NUMBER> published though many targets found treatment covid<NUMBER> main protease pro sarscov<NUMBER> chosen due interest treating infected patients stop multiplication virus within cells pro involved release polypeptides functional extensive proteolysis cleavage enzyme sites genome pp<NUMBER>a ppa<NUMBER>ab plant compounds ideal finding drug components interest economical one produce quickly possible known concept repurposing natural phytomolecules hasten drug discovery process search potent plant compounds found recent study potential plant compounds able inhibit pro process publication khaerunnisa et al <NUMBER> discussing findings paper group siddha ayurvedic doctors advised us examine properties traditional available plant several plant molecules obtained medicinal plants explored outcome andrographis paniculata found antiviral property already reported ancient texts could investigated good bet examined main compound andrographis paniculata found main compound plant andrographolide plant compound evidenced antiinflammatory anticancer antiobesity antidiabetes dai et al <NUMBER> andrographolide found antiviral properties many types viral infections gupta et al <NUMBER> found activity chikungunya wintachai et al <NUMBER> potential inhibitor herpes simplex virus type<NUMBER> seubsasana et al <NUMBER> also outbreak dengue india <NUMBER> aqueous extracts andgrographis paniculata given advice ministry ayush ayurveda unani siddha homeopathy department india led decrease cases infection disease preventive measure even normal people acting immune booster study antidengue activity found published quantification dengue viral inhibition showed antiviral inhibitory effects denv <NUMBER> infected vero cells maximum nontoxic dose krishnasamy et al <NUMBER> due antiviral activities compound andrographolide chosen due interests paper involves silico analysis andrographolide crystal structure sarscov<NUMBER> main protease provided inhibition site pdb id <NUMBER>lu<NUMBER> prediction adme httpswwwswissadmech target prediction httpswww swisstargetpredictionch done using swissbioinformatics online tools prediction toxicity andrographolide seen using pkcsm online web tool httpsbiosigunimelbeduaupkcsm <NUMBER> docking andrographolide sarscov<NUMBER> main protease sarscov<NUMBER> main protease figure <NUMBER>a <NUMBER>b pdb id <NUMBER>lu<NUMBER> used receptor inhibitor selected removed receptor preparation done using dock prep tool ucsfchimera hydrogens added optimized hydrogen bonding network allowed method determine histidine protonation state receptor saved mol<NUMBER> format recchargedmol<NUMBER> using untransformed coordinates sybylstyle hydrogen naming hydrogen present structure removed protein saved pdb format recnohpdb <NUMBER> structure andrographolide figure <NUMBER>a <NUMBER>b pubchem cid<NUMBER> downloaded pubchem httpspubchemncbinlmnihgovcompound andrographolide hydrogen added ligands using addh function structure editing tools ucsfchimera charges added ligands using am<NUMBER>bcc method ligand file saved mol<NUMBER> format ligchargedmol<NUMBER> using untransformed coordinates molecular surface receptor recnohpdb prepared using write dms tool ucsfchimera spheres outside surface generated using sphgen function <NUMBER> angstroms maximum sphere radius <NUMBER> angstroms minimum sphere radius cluster present binding site inhibitor chosen using showsphere function box created around chosen cluster extra margins enclosed <NUMBER> angstroms <NUMBER> directions grid generated using program grid dock<NUMBER> flexible docking parameters employed andrographolide important analyze pharmacodynamics proposed molecule could used drug swissadme website httpswwwswissadmech allows user draw respective ligand drug molecule include smiles data pubchem provides parameters lipophilicity ilogp xlogp<NUMBER> wlogp mlogp silicosit log p <NUMBER> w water solubilitylog esol ali silicosit drug likeness rules lipinski ghose veber egan muegge medicinal chemistry pains brenk leadlikeness synthetic accessibility methods analyzed daina et al <NUMBER> data pubchem consists smiles andrographolide httpspubchemncbinlmnih govcompoundandrographolide entered search bar analyzed molecular target studies important find phenotypical side effects potential cross reactivity caused action small biomolecules keiser et al <NUMBER> gfeller et al <NUMBER> swiss target prediction website httpswwwswisstargetpredictionch logged zinc number andrographolide zinc<NUMBER> entered search bar analyzed toxicology prediction small molecules important predict amount tolerability small molecule ingested human animal models pkcsm online database small molecule drawn virtually analyzed submitting smiles website provide details toxicology effects fields ames toxicity human maximum tolerance dose hergi inhibitor hergii inhibitor ld<NUMBER> loael hepatotoxicity skin toxicity pyriformis toxicity minnow toxicity website logged smiles andrographolide data pubchem searched submitted website toxicity mode selected pires et al <NUMBER> docking analysis compound sarscov<NUMBER> protease generated negative values free energy <NUMBER> kj mol grid box suggesting high affinity binding pocket binding conformations compound active binding pocket involved hbond salt bridge interaction compound bind protease <NUMBER> hydrogen bonds <NUMBER> residues namely gly<NUMBER> cys<NUMBER> glu<NUMBER> shown figure <NUMBER>a <NUMBER>b details atoms involved bonding ligands bond lengths docking energies salt bridges given table <NUMBER> adme prediction done using swissadme database came results following submission small biomolecule andrographolide water solubility properties calculated esol <NUMBER> solubility <NUMBER>e à<NUMBER> mgml soluble class ali <NUMBER> solubility <NUMBER>e à<NUMBER> mgml soluble class silicosit <NUMBER> solubility <NUMBER>e à<NUMBER> mgml soluble class pharmacokinetic data predicted found high gastrointestinal absorption gi blood brain barrier permeant acts pgp substrate inhibit cyp<NUMBER>a<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>d<NUMBER> cyp<NUMBER>a<NUMBER> cytochromes skin permeation kinetics log k p found <NUMBER> cms druglikeness factors found drug like compound obeys lipinskis rules violation also obeys druglikeness score rules ghose veber egan muegge <NUMBER> bioavailability score medicinal chemistry parameters found pains alert violates brenks laws two alerts isolated alkene one michael acceptor lead likeness molecular weight greater <NUMBER> synthetic accessibility <NUMBER> rate target prediction analysis displayed web page following observations top <NUMBER> results given piechart figure <NUMBER> pie chart predicts <NUMBER> kinase <NUMBER> protease <NUMBER> fatty acid binding protein family <NUMBER> transferases <NUMBER> enzymes <NUMBER> ligases <NUMBER> nuclear receptors <NUMBER> electrochemical transporters <NUMBER> secreated protein <NUMBER> family ag protein coupled receptor <NUMBER> unclassified protein <NUMBER> lyase output table consistting target common name uniprot id chemblid target class probability known actives <NUMBER> d<NUMBER>d given supplementary<NUMBER> possible sites target compound may bind mostly targets predicted software probability score less <NUMBER> <NUMBER> makes inference small compound may high target attraction towards specific binding site directed toxicity predicted displayed website results follows andrographolide ames toxicity maximum tolerated dose human <NUMBER> log mgkgday inhibit hergi hergii acute oral rat toxicity ld <NUMBER> found <NUMBER> molkg chronic oral rat toxicity loael found <NUMBER> log mg kgbwday produce hepatotoxicity cause skin sensitivity <NUMBER> log mgl causes pyriformis toxicity <NUMBER> log mm causes minnow toxicity need hour therapy sarscov<NUMBER> virus many small molecules like remdesivir trial provide cure dreadful viral outbreak hydroxychloroquine azithromycin complex advised given affected case emergency though studied increase ph protease published potent inhibitor sarscov<NUMBER> infection spread healdsargent gallagher <NUMBER> vincent et al <NUMBER> hydroxychloroquine azithromycin complex mentioned may potent adverse side effects bring patients alarming shared already drastic side effects need bring equally potent alternatives form plant derived drug essential much safe known side effects interested finding pure potent plant compounds without adding analogs derivatives found plant compound andrographolide intriguing due awesome properties drug compound andrographolide isolated produced easily extracting plant andrographis paniculata compound analyzed silico computational docking tools successfully docked inhibitor region main protease sarscov<NUMBER> virus docking score <NUMBER> kcalmol docking score showed great binding compared synthetic compounds docked pro disulfiram tideglusib shikonin <NUMBER> kcalmol à<NUMBER> kcal mol <NUMBER> kcalmol also shows great binding score compared recently proposed combination three drugs namely lopinavir ostelmivir ritonavir whose binding scores <NUMBER>kcalmol<NUMBER> kcalmol <NUMBER> kcalmol muralidharan et al <NUMBER> even plant molecules studied inhibit main protease sarscov<NUMBER> failed prove binding score compared andrographolide compounds kaempferol <NUMBER> kcalmol quercetin <NUMBER> kcalmol demethoxycurcumin <NUMBER> kcalmol curcumin <NUMBER> kcalmol catechin <NUMBER> kcalmol epichatechin gallate<NUMBER> kcalmol zingerol <NUMBER> kcalmol gingerol <NUMBER> kcalmol respectively khaerunnisa et al <NUMBER> even proposed inhibitor pro prd<NUMBER> docking score <NUMBER> kcalmol bouchentof missoum <NUMBER> proclaims andrographolide better properties proposed inhibitors compound possesses excellent properties druggability well small biomolecule molar refractivity compound confirms drug compound permeable particular membranes remain constant even midst strong weak solutesolvent solventsolvent interactions exemplary tpsa says great transport properties lipophilicity drug compound know compound ideal property oral intestinal absorption able absorbed sublingual well water solubility properties predicted drug free soluble pharmacokinetic data predicted absorption permeability echoes predicted values lipophilicity solubility also predict able release phosphate atp simultaneous binding adp glycoprotein thus compound acts pgp substrate compound andrographolide inhibit liver metabolism inhibiting cyp<NUMBER>a<NUMBER> stop metabolism several therapeutic drugs especially antiulcer antimalarial anticonvulsant anesthetic sedative drugs via inhibiting cyp<NUMBER>c<NUMBER> stop metabolism antihypersensitive drugs b blockers antiarrhythmic drugs antidepressants via inhibition cyp<NUMBER>d<NUMBER> stop metabolism anticlotting agents antiseizure management typeii diabetes antihypertensive nonsteroidal antiinflammatory drugs nsaids via cyp<NUMBER>d<NUMBER> stop oxidation steroids fatty acids xenobiotics well hormone synthesis breakdown cyp<NUMBER>a<NUMBER> druglikeness factor rules obeyed accordingly without violation compound describes compound act drug biological systems medical chemistry parameters exclaims zero panassay interference compounds pains alert compound meaning progressive compound worthy testing biochemical assays toxicity prediction says compound andrographolide safe given drug value tolerance prescribed human consumption predicted website though properties appreciable silico due extensive lockdown work home command government findings continued wet lab studies vitro clinical studies dealing sarscov<NUMBER> considered studies httpsclinicaltrialsgov chloroquine found act antitumour well anticancer agent <NUMBER> indicating chloroquine supplementation conventional treatments glioblastoma patients might improve midterm survival patients another study found chloroquine diminishes intratumoural hypoxia <NUMBER> result making cancer cell sensitive radiotherapy oxygendependent therapies <NUMBER> dominant metastasis documented autophagy promotes many cancers <NUMBER> autophagy occurs cells several conditions degradative process forms auto phagosome retains degraded cell components fuse lysosomes recycled understood autophagy halted chloroquine disrupting energy source autophagy pathway <NUMBER> <NUMBER> despite inhibition autophagic flux cq hcq cancer another study reported drugs affect tolllike receptor <NUMBER> p<NUMBER> cxcr<NUMBER>cxcl<NUMBER> pathway cancer cells addition tumour stroma cq affects tumour vasculature cancerassociated fibroblasts immune system <NUMBER> cq shown wideranging properties bacteria fungal protozoal parasitic viral infections study newman et al <NUMBER> shown chloroquine boosts human macrophages suppress growth yeast limiting availability iron macrophage chloroquine induced human mononuclear phagocytes kills cryptococcus neoformans commonly found immune deficient patients <NUMBER> <NUMBER> besides immune modulation chloroquine combination therapy drug resistant candida albicans chloroquine shown promising effects inhibiting biofilm formation low concentrations <NUMBER> humans threat due outbreak novel coronavirus disease covid<NUMBER> previously known <NUMBER>ncov <NUMBER> first reported wuhan china late december <NUMBER> <NUMBER> consequently virus infection declared pandemic <NUMBER> th april <NUMBER> <NUMBER> <NUMBER> <NUMBER> people reported confirmed cases covid<NUMBER> <NUMBER> <NUMBER> deaths <NUMBER> covid<NUMBER> acute resolved disease deadly immediately properly managed severity disease massively causing alveolar damage respiratory failure consequently death <NUMBER> however pathology reported due barely accessible autopsy biopsy affected patients <NUMBER> every country world exhaustively trying get cure preventative measures virus present treatments symptomatic supportive despite antiinflammatory antiviral treatments employed specific antiviral drugs confirmed effective given development vaccine time dependent physicians scientists trying find quick effective treatments covid<NUMBER> scientific information currently available suggests reports several clinical trials suggesting ageold antimalarial drug cqhcq could potent therapeutic agent covid<NUMBER> infection accumulating scientific reports proposed highlighted possible different modes actions chloroquinehydroxychloroquine particularly viral infections chloroquine known chloroquine phosphate <NUMBER>aminoquinoline introduced <NUMBER> medicine malaria hans andersag coworkers bayer laboratories discovered <NUMBER> weak base drug exists protonated unprotonated forms quinine cinchona tree bark natural antimalarial agent <NUMBER> paul ehrlichs group chemically synthesized cq methylene blue dye kill malaria parasite selectively chemistry work structure activity relationships sars change basic methyl group resulted effective antimalarial agent pamaquine subsequently attachment basic side chain pamaquine several different heterocyclic ring systems resulted synthesis acridine derivative quinacrine extra benzene ring research resulted discovery two chloroquine analogues sontoquine primaquine improved better antimalarial drugs <NUMBER> studies compounds lead discovery resochin world war ii investigations resochin lead synthesis cq hydroxychloroquine hcq sulfate derivative cq first synthesized <NUMBER> introducing hydroxyl group cq demonstrated much less <NUMBER> toxic cq animals <NUMBER> <NUMBER> fig <NUMBER> also believed hcq less blood retinal barrier permeability less toxic retina cq <NUMBER> <NUMBER> pharmacokinetic properties hydroxychloroquine almost similar chloroquine reported hydroxychloroquine less active chloroquine resistant malaria parasite leaving chloroquine ageold drug malaria emergence cqresistant malaria parasite solubility drug andor analogues water absorption occurs almost entirely digestive tract plasma level drug analogues found reach peak <NUMBER>h initial dose halflive chloroquine hydroxychloroquine long ranging <NUMBER> <NUMBER> days chloroquine analogs strong affinities blood constituents highly protein bound particularly thrombocytes granulocytes reduces plasma concentrations addition major fraction chloroquine analogs plasma bound plasma proteins primarily albumin <NUMBER> <NUMBER> <NUMBER> since last decades humans confronted emerging reemerging several viruses like dengue <NUMBER> <NUMBER> <NUMBER> ebola <NUMBER> <NUMBER> avian influenza severe acute respiratory syndrome sars <NUMBER> <NUMBER> middle east respiratory syndrome mers <NUMBER> hepatitis c chikungunya chikv <NUMBER> <NUMBER> human immune deficiency virus hiv <NUMBER> <NUMBER> <NUMBER> <NUMBER> others vitro study revealed cq effective entry post entry stages sarscov<NUMBER> infection vero e<NUMBER> cells <NUMBER> currently sarscov<NUMBER> virus causes covid<NUMBER> specific therapeutic strategies available physicians researchers scientists involved several clinical trials chloroquine andor hydroxychloroquine different stages table <NUMBER> data sourceclinicaltrialorg search treatment curb menace covid<NUMBER> pandemic chloroquine unprotonated form easily diffuse across cell membranes acidic vesicles cytoplasm lysosomes late endosomes transgolgi network tgn vesicles trapped vesicles protonated protonated chloroquine unable diffuse lysosome endosomes cellular compartments restrain hydrolases chloroquine andor analogues diprotic weak base unprotonated form selectively enter lysosomes become protonated manner inversely proportional ph according hendersonhasselbach law <NUMBER> <NUMBER> reason known lysomotropic agents <NUMBER> hydrolases optimal activity maintained lysosomes andor tgn help hatpase activity maintains ph <NUMBER> inside compartments <NUMBER> hatpase lysosome influx h ions atpdependent pumps irreversible drug accumulation rises inside lysosome fig <NUMBER> cytoplasm differences ph drug alters acidic environment lysosomes result cell cannot proceed endocytosis exsosome release phagolysosomal fusion systematically <NUMBER> addition et al <NUMBER> reported cqhcq also hamper interaction cytosolic dna nucleic acid sensor cyclic gmpamp cgamp synthase cgas cytosol <NUMBER> elevation ph lysosomes interference cq hcq obstructs antigen presentation chemotaxis proteolysis cell reduction antigen presentation due elevation ph cqhcq decreases antigenmhc complex auto antigenic peptides low affinity selfmhc reduced amount selfpeptidemhc complex antigen presenting ap cells consequence subordinate activity target cells well release cytokines immune cells like tcells ap cells <NUMBER> moreover cqhcq causes sporadic obligation tolllike receptor tlr <NUMBER> tlr <NUMBER> rnadna ligands due changing ph towards basic cellular endosomal environment suppressed tlr signaling <NUMBER> <NUMBER> <NUMBER> impending sting pathway tlr cgas response interferon genes results attenuation proinflammatory cytokines like tnf il<NUMBER> il<NUMBER> fig <NUMBER> <NUMBER> <NUMBER> hand enveloped viruses trapped within endoplasmic tgn vesicles posttranslational modification envelope glycoproteins process involves proteases glycosyltransferases require low ph environment neutralizing acidic ph cqhcq becomes responsible deactivation several enzymes vesicles like glycosylating enzymes glycosyltransferases turn responsible inhibition glycosylation inhibition glycosylation results host developing adaptive immune response infection <NUMBER> <NUMBER> impair cellular receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> sarscov<NUMBER> blocks fusion host cell <NUMBER> <NUMBER> connection believed sarscov<NUMBER> also employ ace<NUMBER> receptor enter host cell <NUMBER> <NUMBER> <NUMBER> colson et al <NUMBER> reported spike protein sarscov<NUMBER> cleaved autophagosome formed inhibition cathepsins changing ph lysosome result cq accumulation addition several studies showed many human viruses like influenza <NUMBER> corona virus <NUMBER> <NUMBER> affects respiratory tract enter cell help sialic acid linked gangliosides <NUMBER> including sialic acid receptor <NUMBER> angiotensin converting enzyme receptor <NUMBER> ace<NUMBER> <NUMBER> transmembrane serine protease <NUMBER> tmprss<NUMBER> <NUMBER> <NUMBER> extracellular matrix metalloproteinase inducer cd<NUMBER> also known basigin <NUMBER> investigation researcher entry sever acute respiratory syndrome corona viruses human cell fig <NUMBER> biosynthesis inhibiting quinine reductase<NUMBER> viruses use sialic acid moieties receptors <NUMBER> considering higher transmissibility sarscov<NUMBER> fantini et al <NUMBER> observed cell surface attachment factor sialicacidcontaining glycoproteins gangliosides molecular modeling study results support cq hcq bind readily sialic acids high affinity <NUMBER> also bind sialicacid containing gangliosides <NUMBER> <NUMBER> another study gautret et al <NUMBER> reported day <NUMBER> postinclusion <NUMBER> patients cured <NUMBER> mg hydroxychloroquine <NUMBER> mg <NUMBER> times daily <NUMBER> days compared <NUMBER> patients control group p<NUMBER> recently two trials china nct<NUMBER> hcq <NUMBER>mgday <NUMBER> days chictr<NUMBER> hcq <NUMBER>mg bd released findings based context details clinical trial china chictr<NUMBER> <NUMBER> <NUMBER> efficacy chloroquine phosphate five days drugs observed covid<NUMBER> compared <NUMBER> efficacy lopinavir ritonavir combinatorial five days drugs chinese patients pneumonia <NUMBER> huang et al <NUMBER> found clinical study chloroquinetreated patients <NUMBER> mg orally <NUMBER> days twice daily better patients treated lopinavir ritonavir consequently chloroquinetreated patients already released hospital another clinical trial conducted hundred chinese patients covid <NUMBER> infection reported cq phosphate remarkable result terms clinical outcome viral clearance comparing control group <NUMBER> gao et al <NUMBER> also reported drug effective inhibiting exacerbation pneumonia improving lung imaging virusnegative shortening activity covid<NUMBER> infection recommended drug adding guidelines prevention diagnosis treatment pneumonia caused covid<NUMBER> <NUMBER> preliminary nonpeer reviewed scientific reports coming suggest cqhcq may beneficial use covid <NUMBER> another study report brazil warns highdose group patients severe qt prolongation syndrome heart rhythm disorder causes arrhythmias tendency near higher lethality compared low dose time reporting overall fatality rate across arms study <NUMBER> indicating percentage fatality rate overlapping patients taking cq <NUMBER> medical centres total <NUMBER> patients followed study patients groups received hydroxychloroquine alone hcq hcq azithromycin hcqaz treatments addition group received treatment standard supportive management covid<NUMBER> analysis looked two primary outcomes death need mechanical ventilation authors study concluded found evidence efficacy hcq alone combination az found mortality higher patients receiving hcq alone <NUMBER> combination hcqaz <NUMBER> significantly lower group receiving drug treatment <NUMBER> <NUMBER> according authors found association mortality patients treated hcq alone although studies small retrospective highlight important decision making rush widespread recommendation drugs covid<NUMBER> considering global health crisis covid<NUMBER> pandemic option using drugs chloroquine hydroxychloroquine especially hydroxychloroquine drug treatment sarscov<NUMBER> might logical approach follow available scientific information reports point diverse mode actions cq andor hcq puts favorable choice covid<NUMBER> effect pre post viral infections course need put attention doses well negative effect cqhcq human health however new evidence coming need precautionary measure taken rush recommending cqhcq use covid<NUMBER> patients need wait results would come larger prospective randomized dose determining controlled clinical trials making clinical recommendations hcq indicating covid<NUMBER> meantime looking vaccine may preventative indepth expedited responsive discovery clinical research needed include looking traditional medicinesbased research therapies recent outbreak severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> subsequent coronavirus disease <NUMBER> covid <NUMBER> created global health emergency unparalleled worldwide burden <NUMBER> full epidemiological impact virus remains seen understanding approximate denominator important considering clinical characteristics cases percentage cases severe disease resultant mortality <NUMBER> december <NUMBER> first reports covid<NUMBER> included cluster patients hospitalized pneumonia wuhan china common presenting symptoms patients fever <NUMBER> cough <NUMBER> dyspnea <NUMBER> myalgia fatigue <NUMBER> <NUMBER> characteristic laboratory radiologic findings included lymphopenia <NUMBER> rapid development multiple patchy consolidations ground glass opacities bilaterally notable peripheral distribution seen chest computed tomography ct <NUMBER> <NUMBER> patients may present chest ct suggestive covid<NUMBER> even developing positive reverse transcriptionpolymerase chain reaction assay result <NUMBER> epidemiology diagnostics covid<NUMBER> rapidly evolving giving us greater understanding risk elucidating potential pharmacologic targets <NUMBER> sarscov<NUMBER> betacoronavirus subgroup severe acute respiratory syndromecoronavirus sarscov caused sars outbreak <NUMBER> middle east respiratory syndrome coronavirus merscov caused mers outbreak <NUMBER> <NUMBER> rational approach initial therapies target covid<NUMBER> would studied sars mers outbreaks novel therapies repurposing old drugs studied therapeutic strategies covid <NUMBER> treatment strategies identified thus far include medications uncommonly used clinical practice understanding important practical considerations quite limited one study<NUMBER> patients covid<NUMBER> required admission intensive care unit icu patients older <NUMBER> vs <NUMBER> yrs age likely underlying comorbidities <NUMBER> vs <NUMBER> <NUMBER> study wuhan showed <NUMBER> critically ill icu patients infected sarscov<NUMBER> mortality <NUMBER> among icu patients covid<NUMBER> organ dysfunction included acute respiratory distress syndrome ards <NUMBER> acute kidney injury <NUMBER> hepatic dysfunction <NUMBER> <NUMBER> icu level complexity required care patients involves underlying disease states multitudes comorbidities polypharmacy intent review provide health care providers foundational knowledge therapies proposed use covid<NUMBER> review critical key concepts consideration use therapies practice particularly icu setting severe patients managed pharmacologic therapies sarscov<NUMBER> target viral structure genome figure <NUMBER> sarscov<NUMBER> expresses viral proteins outer surface facilitate attachment host cells via angiotensinconverting enzyme <NUMBER> ace<NUMBER> sarscov<NUMBER> singlestranded ribonucleic acid rna beta coronavirus replicates recruiting nonstructural proteins <NUMBER>chymotrypsinlike protease papainlike protease helicase rnadependent rna polymerase <NUMBER> structural components similarities known viruses hepatitis b hepatitis c human immunodeficiency virus hiv prompting repurposing currently approved antiviral therapies targeted viruses nucleoside analogs available hiv respiratory viruses may therapeutic role blocking rna synthesis targeting rnadependent rna polymerase found sarscov<NUMBER> furthermore currently available hiv protease inhibitors displayed vitro activity <NUMBER>chymotryspinlike protease found sars mers <NUMBER> critical aware currently available therapies specifically designed target viral genome certain virus sarscov<NUMBER> physical structure may differ limiting vivo efficacy <NUMBER> nonstructural accessory proteins role potential therapeutic targets development shown figure <NUMBER> opposed directly targeting viral replication therapeutic approaches aimed modulating innate immune system attack virus inhibit cytokines upregulated viral replication dampen physiologic response disease <NUMBER> <NUMBER> practical considerations current therapies available sarscov<NUMBER> summarized tables <NUMBER> <NUMBER> discussed length following sections metabolized cells tissues active nucleoside triphosphate gs<NUMBER> inhibits viral rnadependent rna polymerases early viral infectious cycle <NUMBER> <NUMBER> potential mechanisms adenosine nucleotide analog may involve lethal mutagenesis chain termination <NUMBER> incorporation active nucleoside triphosphate via remdesivir beginning stages replication murine hepatitis virus vitro profound effect <NUMBER> hours preand postinfection decreasing effect greater <NUMBER> hours postinfection suggesting timedependent effect drug activity <NUMBER> nucleotide analogs used viral rna dna polymerase inhibition demonstrated decreased viral replication use resistance mutagens medications vitro resulted exoribonuclease proofreading removal remdesivir shown potential avoid proofreading thus removal via exoribonuclease <NUMBER> vitro studies human airway epithelial cell cultures lung model found activity coronaviruses <NUMBER> studies assessing potency remdesivir efficacious among divergent coronaviruses human airway epithelial cells <NUMBER> based existing evidence remdesivir activity sarscov similar viruses remdesivir investigated use sarscov<NUMBER> united states remdesivir used compassionate purposes duration <NUMBER> days patients remdesivir continued improvement respiratory symptoms <NUMBER> ongoing clinical trials studying remdesivir loading dose <NUMBER> mg intravenously followed <NUMBER> mgday intravenously <NUMBER> <NUMBER> days adult patients <NUMBER> <NUMBER> dosing patients weighing less <NUMBER> kg <NUMBER> mg kg loading dose followed <NUMBER> mgkg day maintenance dose studied treatment ebola <NUMBER> existing remdesivir pharmacokinetic data extrapolated vitro human cell data vivo mouse nonhuman primate data remdesivir converted parent metabolite active metabolite triphosphorylated nucleoside via anabolic intracellular kinase <NUMBER> <NUMBER> mice received remdesivir subcutaneously <NUMBER> mgkg onceday <NUMBER> mgkg twiceday decrease plasma concentrations prodrug steady concentration activated drug lung <NUMBER> murine model twiceday dosing maintained lung concentrations longer duration vitro human lung cell model vivo nonhuman primate model onceday dosing found reach sufficient concentrations remdesivir demonstrating activated nucleoside triphosphate halflife of<NUMBER> hours <NUMBER> <NUMBER> data available date regarding remdesivir dosing patients renal hepatic impairment data clearance remdesivir renal replacement therapy also yet available important pharmacokinetic considerations need elucidated given patients receiving remdesivir likely critically ill endorgan failure <NUMBER> reported adverse effects remdesivir use three patients united states included nausea vomiting gastroparesis rectal bleeding reported symptoms patients also experienced elevated aminotransferase levels occurring <NUMBER> days initiating remdesivir <NUMBER> however unclear whether laboratory change due drug virus third critically ill patients covid<NUMBER> observed liver dysfunction <NUMBER> study using remdesivir ebola virus humans one patient experienced hypotension infusion loading dose necessitating discontinuation patient ultimately died due cardiac arrest <NUMBER> patient experienced neurologic complications receiving remdesivir ebola treatment phase <NUMBER> study however clear due exclusively received remdesivir <NUMBER> currently data remdesivir use humans sparse clear adverse effect profile agent current phase <NUMBER> randomized clinical trials provide conclusive insight adverse effects remdesivir <NUMBER> <NUMBER> <NUMBER> remdesivir manufactured lyophilized powder requires reconstitution administered intravenously <NUMBER> minutes infusion duration also extended longer times obtain higher intracellular concentrations active metabolite <NUMBER> data available regarding compatibility remdesivir intravenous medications date drugdrug drugnutrition interactions reported chloroquine analogs chloroquine phosphate hydroxychloroquine used prevention treatment malaria since early <NUMBER>s <NUMBER> aside antimalarial properties chloroquine analogs possess immunomodulatory effects lending utility treatment autoimmune conditions systemic lupus erythematosus rheumatoid arthritis multimodal properties chloroquine analogs minimal toxicity profile led investigation treatment virusinduced illness pathologic features driven inflammatory response hivassociated immune reconstitution inflammatory syndrome <NUMBER> chloroquine analogs weak bases nonprotonated form penetrate concentrate within acidic intracellular organelles endosomes lysosomes present intracellularly chloroquine analogs become protonated increase intravesicular ph resulting prevention endosomal trafficking dysfunctional cellular enzymes impaired protein synthesis <NUMBER> chloroquinemediated ph alterations proposed result early inhibition viral replication interference endosomemediated viral entry late transport enveloped virus mechanism translated potential role chloroquine analogs treatment covid<NUMBER> also appears interfere terminal glycosylation ace<NUMBER> receptor expression prevents sarscov<NUMBER> receptor binding subsequent spread infection <NUMBER> clinical data supporting use chloroquine analogs treatment coronavirus centered around several vitro studies sarscov outbreak early <NUMBER>s use chloroquine one group tested cytotoxic potential chloroquine sarscov vitro cell culture chloroquine demonstrated potent cytotoxic response <NUMBER> inhibition viral replication day <NUMBER> <NUMBER> vitro models supported cytotoxic response observed application chloroquine viral exposure resulted favorable inhibition viral spread suggesting potential role effective prophylactic intervention <NUMBER> hydroxychloroquine hydroxy derivative chloroquine improved safety profile also studied vitro sarscov<NUMBER> <NUMBER>fold higher cytotoxic potential compared covid<NUMBER> emerging pharmacotherapy barlow et al <NUMBER> chloroquine <NUMBER> one study demonstrated potent antiviral effect entry postentry states plasma concentrations <NUMBER> lm concentration safely achieved humans <NUMBER> clinical data humans thus far limited best available evidence date <NUMBER> patients <NUMBER> different hospitals china current covid<NUMBER> outbreak pooled analysis demonstrated superiority chloroquine compared control inhibiting exacerbations pneumonia improving lung imaging findings promoting viral negative conversion shortening disease course absence adverse effects <NUMBER> dual mechanism antiviral antiinflammatory effects chloroquine proposed account utility preventing covid<NUMBER>related pneumonia ongoing trials hydroxychloroquine actively recruiting hopes delineate role treatment paradigm covid<NUMBER> <NUMBER> chloroquine formulated tablet phosphate salt form oral administration treatment covid<NUMBER> expert consensus recommends chloroquine phosphate tablet dose <NUMBER> mg orally twiceday duration <NUMBER> days <NUMBER> bioavailability oral administration complete <NUMBER> rapid within <NUMBER> minutes chloroquine widely distributed nearly every organ system including eyes heart kidney liver lungs retention prolonged <NUMBER> chloroquine metabolized active metabolite desethyl chloroquine via hepatic enzymes cytochrome p<NUMBER> cyp <NUMBER>c<NUMBER> cyp<NUMBER>a<NUMBER> metabolite accounts small portion pharmacologic activity chloroquine major substrate cyp<NUMBER>d<NUMBER> enzyme accounts for<NUMBER> inactivation inhibitors enzyme avoided due heightened risk accumulation toxicity chloroquine predominantly eliminated urine with<NUMBER> dose recovered unchanged dose adjustments needed creatinine clearance cl cr <NUMBER> mlminute however administration <NUMBER> dose required patients intermittent hemodialysis peritoneal dialysis cl cr <NUMBER> mlminute patients receiving continuous renal replacement therapy crrt receive fulldose chloroquine <NUMBER> hydroxychloroquine sulfate available filmcoated tablet oral administration dosing recommendations covid<NUMBER> welldefined clinical trials vitro data ongoing assist dose optimization current vitro pharmacokinetic models suggest loading dose hydroxychloroquine <NUMBER> mg orally twiceday day <NUMBER> followed <NUMBER> mg orally twiceday <NUMBER> days hydroxychloroquine similar possibly superior cytotoxic effects sarscov<NUMBER> chloroquine <NUMBER> mg twiceday translation cytotoxic effects hydroxychloroquine vivo remains unknown <NUMBER> clinical trial hydroxychloroquine covid<NUMBER> actively recruiting planned intervention <NUMBER> mg mouth onceday total duration <NUMBER> days <NUMBER> major difference dosing strategies utility loading dose given terminal halflife hydroxychloroquine is<NUMBER> days blood remains body <NUMBER> months loading dose reasonable approach clinical outcomes ongoing trials published hydroxychloroquine rapid absorption oral administration wide volume distribution vd prolonged halflife metabolism elimination hydroxychloroquine differ chloroquine reliance cyp enzymes elimination minimal clearance correlated renal function renal hepatic dose adjustments recommended however cautious use severe impairment advised given wide vd <NUMBER> lhr high lipophilicity compound crrt likely minimal impact drug removal chloroquine hydroxychloroquine generally well tolerated common adverse effects gastrointestinal intolerances nausea vomiting abdominal cramping metallic taste acute toxicity setting supratherapeutic dosing may manifest cardiomyopathy neuropathy myopathy retinopathy hallmark toxicity hydroxychloroquine chloroquine predominantly associated high doses longterm administration ie hydroxychloroquine systemic lupus erythematosus rheumatoid arthritis unlikely concern setting covid<NUMBER> treatment although manufacturers labeling chloroquine hydroxychloroquine cautions use patients glucose<NUMBER>phosphate dehydrogenase g<NUMBER>pd deficiency limited data support risk incidence hemolytic anemia seen patients g<NUMBER>pd <NUMBER> years drug exposure <NUMBER> <NUMBER> agents safe pregnancy minimal risk congenital malformations <NUMBER> albeit rare use patients preexisting cardiac disease qtc prolongation avoided due risk torsades de pointes concurrent administration qtc prolonging agents strong <NUMBER>d<NUMBER> inhibitors chloroquine avoided minimize cardiac adverse effects notable dermatologic adverse effects include photosensitivity lichenoid reactions drug eruptions chloroquine acute generalized exanthematous pustulosis hydroxychloroquine <NUMBER> <NUMBER> postmarketing data case reports hypoglycemia progressing loss consciousness occurred agents patients history diabetes concurrent antidiabetic agents <NUMBER> <NUMBER> proposed mechanism hypoglycemia involves inhibited insulin degradation patients required <NUMBER> reduction insulin doses concurrent hydroxychloroquine administration <NUMBER> baseline routine monitoring blood glucose electrocardiogram qtc interval recommended patients chloroquine analog therapy mitigate nausea vomiting recommended administer chloroquine hydroxychloroquine food chloroquine crushed mixed flavored syrups enclosed gelatin capsules mask bitter taste <NUMBER> patients mechanically ventilated chloroquine extemporaneously compounded oral suspension hydroxychloroquine tablets crushed split bedside administration covid<NUMBER> emerging pharmacotherapy barlow et al instead require removal film coating compounded extemporaneously solution administration via enteral tubes neither agent available intravenous administration would unfavorable option patients permitted take anything mouth enteral access administration antacids within <NUMBER> hours chloroquine avoided due potential chelation reduced bioavailability interaction present hydroxychloroquine theoretical drugdrug interaction exists proton pump inhibitors ppis chloroquine analogs blockage h k àatpase ppis lysosomes raise ph reduce drug accumulation could weaken immunomodulatory effects however effects interaction vivo unknown <NUMBER> <NUMBER> lopinavirritonavir lopinavir lpv aspartic acid protease inhibitor developed treatment hiv lopinavir coformulated ritonavir lpv r boost pharmacokinetic activity halflife lpv inhibition cyp<NUMBER> lpvr provides potent sustained viral load reductions patients hiv prompted interest assessing efficacy viruses function similar machinery <NUMBER> proteases essential enzymes production maturation viral genomes primary antiviral effect protease inhibitors prevention viral replication thus limiting spread host cells <NUMBER> therapeutic rationale lpvr arises vitro studies demonstrating inhibition <NUMBER>chymotrypsinlike protease found novel coronaviruses <NUMBER> <NUMBER> however lpv specifically designed match structure c<NUMBER> catalytic site within hiv aspartic acid protease sarscov<NUMBER> protease cysteine protease family structurally dissimilar lacks c<NUMBER> catalytic site <NUMBER> therapeutic value lpvr emerged vitro studies testing utility sars mers vitro testing lpvr performed severe merscov marmosets lopinavirritonavir improved clinical scores weight loss symptom burden improved radiologic clearance decreased viral loads necroscopied lungs <NUMBER> benefit lpvr yet clearly replicated human cell cultures studies showing complete lack vitro activity <NUMBER> clinical vivo studies sars mers outbreaks demonstrated use lpvr <NUMBER> mg mouth twiceday combined ribavirin without corticosteroids initiated early phase viral acquisition reduced rates ards death compared matched cohort received supportive care ribavirin alone <NUMBER> <NUMBER> <NUMBER> however findings remain significant lpvr initiated later disease course reiterating lack pharmacologic effect viral genome integrated host dna <NUMBER> available literature date lpvr treatment covid<NUMBER> stems descriptive case series five patients singapore receiving lpvr <NUMBER> mg twiceday <NUMBER> days three patients reductions ventilation requirements within <NUMBER> days treatment initiation two progressive respiratory failure despite lower dosing regimen compared previous studies four five patients premature treatment discontinuation secondary nausea vomiting diarrhea increased liver function tests deaths occurred study efficacy outcomes difficult interpret based lower dosing strategy compared previous data raise concerns potential tolerability higher dose regimen <NUMBER> another retrospective cohort showed lpvr limited influence duration viral shedding occur median <NUMBER> days initially contracting virus <NUMBER> <NUMBER> recent randomized controlled openlabel trial including hospitalized patients sarscov<NUMBER> infection patients receiving lpvr <NUMBER>à<NUMBER> mg twiceday <NUMBER> days versus standard care found benefit versus standard care treatment <NUMBER> multiple ongoing studies evaluated clinical utility lpvr monotherapy combination therapies ribavirin interferon ifn <NUMBER> <NUMBER> considerable potential drugdrug interactions lpvr requires thorough review concomitant medications ritonavir strong inhibitor cyp<NUMBER>a<NUMBER> major enzyme responsible metabolism elimination many medications addition ritonavir moderate inhibitor pglycoprotein pgp organic anion transporter oatp<NUMBER>b<NUMBER> oatp<NUMBER>b<NUMBER> inducer udpglucuronosyltransferase <NUMBER> patients requiring icu admission covid<NUMBER> often elderly multiple comorbidities polypharmacy potential therapeutic benefit lpvr weighed considerable interactions commonly used medications icu eg midazolam fentanyl antiarrhythmics <NUMBER> treatment lpvr may result intolerable gastrointestinal toxicities although administration food may ameliorate severity symptoms <NUMBER> patients experience diarrhea although usually improves within <NUMBER> weeks <NUMBER> adverse events particularly relevant icu patients include potentially fatal pancreatitis hepatitis hepatic decompensation among preexisting liver disease increased pr intervals especially congenital qtc prolongation <NUMBER> previous studies using lpvr sars demonstrated increased serum amylase liver enzyme elevations compared matched cohort routine monitoring liver function tests critical supportive care antiemetics antimotility agents considered <NUMBER> cardiovascular metabolic toxicities lipid abnormalities commonly observed patients hiv receiving therapies prolonged periods less likely used abbreviated durations covid<NUMBER> lopinavirritonavir tablets chewed crushed patients unable swallow <NUMBER> patients intubated limited oral access oral suspension available delivery via nasogastric tube <NUMBER> note suspension contain <NUMBER> ethanol available data suggest administration enteral nutrition adversely impact drug concentrations <NUMBER> coadministration food contains moderate high fat content enhance lpvr bioavailability <NUMBER> ribavirin purine nucleoside analog elicits antiviral affect inhibition viral rna synthesis ribavirin prodrug undergoes metabolic conversion liver metabolic structure closely mimics purine analog guanosine enhances incorporation rna structural elements prohibit subsequent addition nucleoside analogs effectively halting synthesis rna <NUMBER> ribonucleic acid ubiquitous many viruses ribavirin studied broad range viral diseases including hepatitis b c respiratory syncytial virus <NUMBER> nonselective antiviral properties ribavirin prompted investigators evaluate use sars mers outbreaks initial sars outbreak ribavirin used throughout hong kong oral covid<NUMBER> emerging pharmacotherapy barlow et al intravenous formulations <NUMBER> however distribution intravenous formulation available countries including united states restricted midst epidemic given concern lack vitro susceptibility considerable toxicity <NUMBER> patients treated ribavirin hemolysis anemia occurred <NUMBER> <NUMBER> cases respectively <NUMBER> <NUMBER> vivo data suggest serum concentrations ribavirin needed blunt viral replication effectively higher safely achievable humans <NUMBER> vitro data suggest rapid resistance sars mers used monotherapy potential activity combined antivirals lpvr chloroquine analogs <NUMBER> <NUMBER> outcomes ribavirin use combination interferon ifna<NUMBER>a merscov discussed ifn section ribavirin commercially available oral capsule oral solution inhaled formulation <NUMBER> inhaled formulation studied sars mers covid<NUMBER> intravenous form available united states oral ribavirin dosed <NUMBER>g loading dose followed <NUMBER> g every <NUMBER> hours two small studies sars <NUMBER> <NUMBER> management covid<NUMBER> data limited ongoing studies using dosing strategy <NUMBER> mg mouth twiceday <NUMBER> days part combination regimen ribavirin prolonged halflife of<NUMBER> days loading doses may aid achieving steady state rapidly <NUMBER> ribavirin metabolized active form via extrahepatic enzymes <NUMBER> however use hepatic impairment childpugh class b c recommended given metabolized cyp enzyme pathways ribavirin eliminated primarily renal excretion requiring strict dose reductions renal insufficiency varies based indication <NUMBER> review use ribavirin sars recommended <NUMBER> dose reduction cl cr <NUMBER> <NUMBER> mlminute <NUMBER> reduction cl <NUMBER> mlminute <NUMBER> established safety ribavirin patients receiving renal replacement therapy restricted stable renal function ribavirin carries boxed warning hemolytic anemia <NUMBER> study assessing adverse effects associated use ribavirin use sars common adverse effects hemolytic anemia <NUMBER> hypocalcemia <NUMBER> hypomagnesemia <NUMBER> <NUMBER> onset hemolytic anemia occurs early <NUMBER> days therapy high doses <NUMBER> g used loading doses coronavirus <NUMBER> <NUMBER> risk highest patients elderly poor renal function consideration also taken patients preexisting cardiac disease reduction hemoglobin increases risk decompensation <NUMBER> ribavirin teratogen significant potential embryonic toxicity contraindicated women pregnant male partners women pregnant ribavirin considered women men childbearing potential use systemic barrier contraception must strictly enforced active metabolites ribavirin persist plasma <NUMBER> months contraception required treatment least <NUMBER> months treatment completed <NUMBER> ribavirin drugdrug interactions metabolism elimination rely cypp<NUMBER> system however certain therapies used cautiously ribavirin due potential enhanced toxicities ribavirin combination immunosuppressive therapies particularly azathioprine ifn lead severe pancytopenia <NUMBER> ribavirin administered orally solution capsule absolute bioavailability <NUMBER> compared intravenous aerosol formulation <NUMBER> oral formulations enhanced bioavailability taken highfat meal recommended administer oral formulations food due teratogenic potential ribavirin identified hazardous medication national institute occupational safety health niosh list requires significant safety precautions use capsules opened crushed broken <NUMBER> health care providers handling ribavirin must also follow niosh recommendations wear gloves packaging administering receiving intact capsules handling solution double gloving protective gown eyeface protection required especially administration oral liquid feeding tube pharmacotherapy volume <NUMBER> number <NUMBER> <NUMBER> nitazoxanide nitazoxanide <NUMBER>acetyloxyn<NUMBER>nitro<NUMBER>thiazolyl benzamide approved food drug administration fda indication antiprotozoal activity treat diarrhea caused giardia parvum giardia lamblia <NUMBER> nitazoxanide since found activity cryptosporidium vitro activity anaerobic grampositive gramnegative bacteria <NUMBER> <NUMBER> another studied use nitazoxanide treatment influenza <NUMBER> nitazoxanide studied severe acute respiratory illness benefit seen clinical outcomes specifically length hospital stays <NUMBER> nitazoxanide interferes pyruvate ferredoxin oxidoreductase enzymedependent electron transfer thus impairing anaerobic energy metabolism protozoa <NUMBER> nitazoxanide metabolized active circulating metabolite tizoxanide <NUMBER> tizoxanide selectively blocks posttranslational influenza viral hemagglutinin maturation intracellular movement addition blocking protein implantation plasma membrane <NUMBER> nitazoxanide may potentiate production type <NUMBER> ifns produced host cell fibroblasts may potentiate antiviral activity via hemagglutinin inhibition <NUMBER> nitazoxanide demonstrated vitro activity merscov <NUMBER> anticoronavirus effect observed nitazoxanide vitro screen small molecules recombinant murine coronavirus <NUMBER> vitro studies canine coronavirus found use nitazoxanide inhibited viral replication <NUMBER> based vitro animal data thought nitazoxanide may activity sarscov<NUMBER> human data limited regarding efficacy nitazoxanide human coronavirus <NUMBER>patient doubleblind placebocontrolled trial patients influenzalike illness five participants received nitazoxanide coronavirus positive <NUMBER> subgroup analysis five coronaviruspositive patients found difference primary outcome days hospitalization p<NUMBER> recommended nitazoxanide dosing cryptosporidium parvum g lamblia <NUMBER> mg oral suspension tablet every <NUMBER> hours <NUMBER> days <NUMBER> dosing used acute respiratory illness twiceday <NUMBER> days dose strength based age patients <NUMBER> years age older received two <NUMBER>mg tablets children <NUMBER> years old received <NUMBER> mg suspension toddlers <NUMBER> years old received <NUMBER> mg suspension <NUMBER> recommended nitazoxanide administered food pharmacokinetic studies found increased area curve auc maximum concentration c max tizoxanide <NUMBER> specifically doubling auc <NUMBER> increase c max observed tablet administered food suspension administered food <NUMBER> increase auc <NUMBER> increase c max important consideration oral suspension bioequivalent tablet suspension bioavailability <NUMBER> necessitating dose adjustments transitioning dosage forms <NUMBER> plasma tizoxanide <NUMBER> bound proteins metabolism nitazoxanide tizoxanide occurs via hydrolysis conjugation via glucuronidation nitazoxanide studied patients impaired renal hepatic function dosage adjustment recommendations exist <NUMBER> data geriatric pediatric populations available common adverse effects nitazoxanide gastrointestinal mainly abdominal pain nausea headache patients may also experience discoloration eyes urine diarrhea dizziness gastroesophageal reflux disease skin rash urticaria compared patients receiving standard care placebo patients receiving nitazoxanide additional adverse effects groups patients experienced gastrointestinal respiratory effects <NUMBER> headache diarrhea reported patients receiving placebo versus lowdose nitazoxanide versus highdose nitazoxanide treatment viral respiratory infection significant difference among three groups <NUMBER> nitazoxanide available dosage forms administered enterally including controlledcovid<NUMBER> emerging pharmacotherapy barlow et al release filmcoated tablet oral suspension nitazoxanide tablets crushed mixed food existing data regarding absorption nitazoxanide administered via gastric feeding tubes however gastric feeding tube administration needed oral suspension used drugdrug interactions nitazoxanide attributed cytochrome cyp enzymes vitro metabolism data found significant effect tizoxanide enzyme pathways <NUMBER> notably nitazoxanide may binding site competition highly proteinbound drugs narrow therapeutic index drug would concern case warfarin however pharmacokinetic study patients received nitazoxanide twice day <NUMBER> days onetime warfarin <NUMBER> mg dose compared patients receiving warfarin result pharmacokinetic dynamic changes well tolerated <NUMBER> nelfinavir nelfinavir hiv<NUMBER> protease inhibitor originally developed use combination antivirals target hiv via alternative mechanisms development newer combination antivirals hiv nelfinavir fallen favor indication <NUMBER> nelfinavir binds site hiv<NUMBER> protease activity inhibits cleavage viral gagpol polyprotein precursors functional proteins needed hiv remains nonviable hiv particles longer infectious <NUMBER> sars outbreak nelfinavir identified potential agent activity sarscov based vitro studies <NUMBER> nelfinavir found inhibit replication sarscov vero e<NUMBER> cells originating african green monkey recently nelfinavir identified via homology models based threedimensional sars structures specifically main protease chymotrypsinlike protease <NUMBER> models assessed ability small molecule drugs dock sars structures sarscov used sequence <NUMBER> similar sarscov<NUMBER> <NUMBER> drugs assessed nelfinavir found promising activity sarscov<NUMBER> nelfinavir studied humans efficacy sarscov sarscov<NUMBER> recommended dosing nelfinavir treatment hiv <NUMBER> mg mouth <NUMBER> times day <NUMBER> mg mouth twiceday halflife nelfinavir <NUMBER> hours effective dose treatment covid<NUMBER> unknown nelfinavir dosage adjustments need made renal impairment less <NUMBER> nelfinavir excreted urine <NUMBER> patients hepatic impairment nelfinavir recommended patients childpugh class b c <NUMBER> <NUMBER> <NUMBER> pharmacokinetics patients using nelfinavir chronic liver disease may unpredictable <NUMBER> dosage adjustments recommended use patients childpugh class impairment nelfinavir metabolized cyp<NUMBER>a<NUMBER> cyp<NUMBER>c<NUMBER> could potentially interact medications inhibitors inducers enzymes vitro data found cyp<NUMBER>a enzymes inhibited nelfinavir therapeutic concentrations <NUMBER> major adverse effect nelfinavir gastrointestinal intolerance primarily diarrhea nausea flatulence nonspecific rash may also occur incidence side effects minimal occurring less <NUMBER> time phase <NUMBER> <NUMBER> trials <NUMBER> nelfinavir available tablet dosage form <NUMBER>mg tablets dissolved water readily dissolve patients gastric tube enteral access nelfinavir crushed dissolved water administered via gastric tube dissolving nelfinavir taken administered immediately notably nelfinavir may bitter taste mixed acidic food juice <NUMBER> absorption nelfinavir found result less pharmacokinetic variability higher nelfinavir levels taken food nelfinavir volume distribution <NUMBER> lkg highly protein bound <NUMBER> <NUMBER> pharmacotherapy volume <NUMBER> number <NUMBER> <NUMBER> immunomodulating therapeutics interferona interferons endogenous signaling proteins released host cells response infections inflammation upregulation ifns stimulates immune system blunt viral replication eradicate offending pathogens <NUMBER> two ifns mediate host immune responses b interferona elicits potent hostmediated immune cell response generated interest treatment viral diseases hepatitis b c various cancers melanoma chronic lymphocytic leukemia interferonb primarily used treatment autoimmune condition multiple sclerosis <NUMBER> nonspecific immunomodulatory effects gained attraction investigators viral illnesses including covid<NUMBER> <NUMBER> sars outbreak observed viral inoculation sarscov able effectively evade upregulation ifns human macrophages allowed continued viral replication due suppression innate immune response <NUMBER> two ifn products available b currently unknown whether products would influence coronavirus disease expression interferona studies related use thus far human data use ifna novel coronaviruses sparse sars outbreak pegylated ifna assessed vitro analysis macaque cells different periods sars exposure <NUMBER> used sars inoculation ifna reduced viral replication excretion however results observed postsars exposure <NUMBER> vitro analysis assessing ifna monotherapy mers demonstrated serum concentrations required effectively inhibit viral replication higher safely achieved humans <NUMBER> nevertheless vitro isolates ifna b multimodal regimen ribavirin sars displayed potent synergy virus <NUMBER> <NUMBER> vivo studies yet able replica benefits studies showing influence disease course mers whereas others suggest small improvement survival <NUMBER> days <NUMBER> days used combination ribavirin <NUMBER> <NUMBER> viruses may display different vitro vivo susceptibilities current sarscov<NUMBER> extrapolation current covid<NUMBER> pandemic difficult dampened potential application therapy investigators await results ongoing studies assessing efficacy ifna<NUMBER>b part combination therapy ribavirin covid<NUMBER> elucidate benefit ifn treatment <NUMBER> <NUMBER> dosing pharmacokinetics interferona<NUMBER>b also comes pegylated form prolong halflife <NUMBER> hours <NUMBER> hours permitting lower dosing frequency <NUMBER> due lack established human data ifns covid<NUMBER> therapy considered covid<NUMBER> part clinical trial established dosing regimen ifn treatment covid<NUMBER> vivo data ifna<NUMBER>a treatment mers using dose <NUMBER> µg per week <NUMBER> weeks similar hepatitis b virus <NUMBER> established dosing regimen ifn treatment covid<NUMBER> study currently recruiting time publication using ifnb<NUMBER>b dose <NUMBER> mg <NUMBER> million iu day <NUMBER> <NUMBER> <NUMBER> combination therapies ribavirin lpvr <NUMBER> additional studies evaluating ifna<NUMBER>b evaluating utility inhaled therapy <NUMBER> used part trial key clinical considerations consider safe use drug labeling provides cautionary statement use childpugh class b c <NUMBER> renal elimination accounts <NUMBER> total clearance dose reductions required patients cl cr <NUMBER> mlminute ifna used combination ribavirin hepatitis c <NUMBER> given agents investigation covid<NUMBER> used part combination therapy precaution considered interferon therapies increased risk adverse effects used renal replacement therapy thus caution recommended population <NUMBER> <NUMBER> interferon pose risk drugdrug interactions cyp enzyme pathways concomitant medications enhance myelosuppressive hepatotoxic effects ifn used sparingly <NUMBER> interferons associated significant adverse reactions even used shortterm therapy injection site reactions resulting flulike symptoms fever myalgias headaches occur within first <NUMBER> hours administration rotation injection sites application ice application premedication acetaminophen mitigate reactions additional adverse reactions include leukopenia lymphopenia autoimmune hepatitis thyroid disease patients exposed ifns currently approved indications develop neutralizing antibodies reduce therapeutic efficacy agent development neuropsychiatric adverse effects expected occur shortterm use <NUMBER> safety ifn pregnancy established <NUMBER> interferon available injectable inhaled formulations current study enrolling patients using b<NUMBER>b injected subcutaneously abdomen thigh <NUMBER> baricitinib janus kinase jak inhibitor originally developed treatment rheumatoid arthritis approved fda moderate severe active rheumatoid arthritis patients responded one tumor necrosis factor antagonists baricitinib reversibly selectively inhibits jak<NUMBER> jak<NUMBER> less inhibition jak<NUMBER> tyrosine kinase inhibition jak results inability signal transmission cytokine growth receptors resulting decreased hematopoiesis immune cell function <NUMBER> inhibition signal transmission prevents phosphorylation thus activation signal transducers activators transcription baricitinib high affinity associated protein kinase <NUMBER> aak<NUMBER> binding could prevent intracellular passage viral cells development viral particles <NUMBER> rationale proposed therapy covid<NUMBER> may result secondary hemophagocytic lymphohistiocytosis shlh result viral infection <NUMBER> patients covid<NUMBER> exhibited ferritin inflammatory marker elevations similar shlh including elevated interleukin il<NUMBER> il<NUMBER> granulocyte stimulating factor tumor necrosis factor tnfa evaluation risk factors mortality covid<NUMBER> cases wuhan found ferritin il<NUMBER> levels higher ultimately died versus survivors p<NUMBER> <NUMBER> considering potential increased lung injury corticosteroid use patients covid<NUMBER> reported use tocilizumab covid<NUMBER> jakstat inhibitors theorized effect hyperinflammatory state occurs covid<NUMBER> baricitinib may also prevent endocytosis viral infection inhibiting aak<NUMBER> activity baricitinib studied humans covid<NUMBER> baricitinib typically dosed <NUMBER> mgday mouth rheumatoid arthritis <NUMBER> data exist treatment covid<NUMBER> however proposed <NUMBER>to <NUMBER>day course would needed <NUMBER> dose adjustments recommended patients lymphopenia neutropenia anemia <NUMBER> recommended hold baricitinib patients absolute lymphocyte count less <NUMBER> cellsmm <NUMBER> absolute neutrophil count less <NUMBER> cellsmm <NUMBER> hemoglobin less <NUMBER> gdl patients hepatic impairment baricitinib recommended dose adjustments recommended renal impairment patients estimated glomerular filtration rate egfr less <NUMBER> mlminute <NUMBER> <NUMBER> recommended hold baricitinib patients egfr <NUMBER> mlminute <NUMBER> <NUMBER> recommended decrease dose <NUMBER> mg onceday dosing recommendations patients requiring crrt baricitinib reaches peak concentrations within <NUMBER> hour oral administration steady state achieved <NUMBER> days <NUMBER> baricitinib oral bioavailability <NUMBER> significantly impacted taking without food baricitinib volume distribution <NUMBER> l <NUMBER> bound plasma proteins <NUMBER> bound serum proteins substrate pgp breast cancer resistance protein oat multidrug toxin extrusion protein transporters pharmacotherapy volume <NUMBER> number <NUMBER> <NUMBER> metabolism baricitinib occurs mainly cyp<NUMBER>a<NUMBER> elimination is<NUMBER> renal relevant drugdrug interactions baricitinib include strong oat <NUMBER> inhibitors may increase baricitinib exposure <NUMBER> patients concomitantly taking strong oat <NUMBER> inhibitors recommended dose baricitinib <NUMBER> mg onceday several boxed warnings exist baricitinib including risk infection particularly upper respiratory tract infection malignancy thrombosis <NUMBER> note side effects higher patients receiving <NUMBER>mg dose baricitinib recommended dose due safety concerns patients clinical trials also experienced increased incidence neutropenia platelet elevations aminotransferase elevations lipid elevations creatinine elevations creatine phosphokinase elevations nausea monitoring longterm treatment rheumatoid arthritis recommended baseline complete blood counts including neutrophils liver function tests lipids <NUMBER> monitoring signs symptoms infection treating baricitinib recommended addition skin examinations patients increased risk skin cancer baricitinib available filmcoated immediaterelease tablet enteral administration <NUMBER> given without consideration food data available regarding crushing baricitinib administration via gastric feeding tubes although baricitinib niosh list medications carcinogenic virtue adverse effect profile may treated hazardous drug tocilizumab monoclonal antibody fda approval chimeric antigen receptor cart cellinduced cytokine release syndrome crs giant cell arteritis rheumatoid arthritis polyarticular systemic juvenile idiopathic arthritis <NUMBER> evolving data suggest patients severe covid<NUMBER> experience significant lung injury secondary surge inflammatory cytokines resulting cytokine storm viral replication activates innate immune system secrete various signaling proteins ils results hyperinflammation lung damage interleukin<NUMBER> key inflammatory protein involved pathway <NUMBER> tocilizumab binds il<NUMBER> receptors thereby blunting cell signaling effectively downregulating excess inflammatory response <NUMBER> rationale use tocilizumab covid<NUMBER> stems data discovered sars mers sars patients noted crs result proinflammatory marker release including il<NUMBER> tnfa <NUMBER> patients mers discovered elevations il<NUMBER> il<NUMBER> il<NUMBER>b <NUMBER> data wuhan critically ill patients covid<NUMBER> also found increased levels cytokines including il<NUMBER> granulocytecolony stimulating factor <NUMBER> <NUMBER> lung tissue obtained postmortem patient covid<NUMBER> showed elevated inflammatory factors suggestive cytokine storm <NUMBER> interleukin<NUMBER> may key driver robust inflammatory response within lungs icu patients covid<NUMBER> recently published data wuhan indicate tocilizumab added lopinavir methylprednisolone oxygen therapy <NUMBER> patients severe covid<NUMBER> resulted rapid reductions fever patients improvement oxygenation <NUMBER> facilitated discharged hospital <NUMBER> patients <NUMBER> additional studies underway tocilizumab combined antivirals compared renal replacement therapy management crs associated covid<NUMBER> <NUMBER> <NUMBER> sarilumab another antiil<NUMBER> antibody currently evaluation treatment covid<NUMBER> studied supportive care measures provide enhanced insight utility targeting pathway <NUMBER> tocilizumab indications weight based maximum dose <NUMBER> mg dosing tocilizumab covid<NUMBER> well established used case series patients covid<NUMBER> onetime dose intravenous tocilizumab <NUMBER> mg administered <NUMBER> <NUMBER> crs secondary chimeric covid<NUMBER> emerging pharmacotherapy barlow et al antigen receptor car tcell therapy three additional doses tocilizumab given least <NUMBER> hours dose covid<NUMBER> reports three patients received additional dose tocilizumab <NUMBER> hours later result continued fevers <NUMBER> tocilizumab auc varies based body weight vd intravenous tocilizumab steady state <NUMBER> l <NUMBER> published data regarding use tocilizumab <NUMBER> mg obese patients covid<NUMBER> whether <NUMBER>mg dose adequate halflife tocilizumab concentration dependent <NUMBER> days dosed <NUMBER> mgkg <NUMBER> days dosed <NUMBER> mgkg tocilizumab held absolute neutrophil count <NUMBER> cellsmm <NUMBER> platelet count <NUMBER> cellsmm <NUMBER> liver enzymes <NUMBER> times upper limit normal particularly relevant treatment covid<NUMBER> demonstrated elevate liver enzymes severe cases <NUMBER> tocilizumab elimination influenced renal dysfunction dose adjustments required patients receiving tocilizumab covid<NUMBER> one patient history chronic kidney disease patients reported hepatic impairment <NUMBER> limited efficacy data tocilizumab weighed significant cost potential toxicities secondary interference host immune response infections ranging bacterial viral fungal sources may develop <NUMBER> patients screened active latent tuberculosis infection administering tocilizumab gastrointestinal perforation use tocilizumab reported patients history diverticulitis receiving highdose corticosteroids <NUMBER> infusion reactions causing hypertension headache skin reactions within <NUMBER> hours administration reported administration tocilizumab <NUMBER> tocilizumab recommended administered intravenously <NUMBER> hour <NUMBER> <NUMBER> tocilizumab administered line medications studied compatibility <NUMBER> pertinent drugdrug interactions tocilizumab may occur result increased cyp<NUMBER> enzyme activity vitro studies reported tocilizumab may increase cyp<NUMBER>a<NUMBER> cyp<NUMBER>b<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>d<NUMBER> cyp<NUMBER>a<NUMBER> activity vivo studies reported tocilizumab may interact simvastatin via increased activity cyp<NUMBER>a<NUMBER> resulting decreased simvastatin exposure findings also similar omeprazole tocilizumab combined resulting decreased omeprazole auc increased cyp<NUMBER> activity passive immunity delivered anticoronavirus antibodies convalescent human plasma may offer novel therapeutic approach covid<NUMBER> proposed mechanism benefit convalescent human plasma derived survivors coronavirus transfer passive immunity effort restore immune system critical illness neutralize virus suppress viremia <NUMBER> main driver investigation convalescent human blood products treatment covid<NUMBER> originated use h<NUMBER>n<NUMBER> pandemic patients derived clinically significant mortality benefit improved viral clearance convalescent blood products <NUMBER> retrospective review <NUMBER> patients sars failed treatment methylprednisolone ribavirin <NUMBER> days <NUMBER> <NUMBER> patients received convalescent plasma discharged day <NUMBER> compared <NUMBER> <NUMBER> patients received highdose corticosteroids p<NUMBER> five deaths reported steroid group compared deaths convalescent plasma obtain greatest benefit convalescent plasma treatment used early course disease day <NUMBER> viremia sars shown peak first week treatment followed primary immune response days <NUMBER> <NUMBER> <NUMBER> preliminary data ongoing convalescent plasma therapy data covid<NUMBER> outbreak suggest improvement clinical symptoms signal adverse effects <NUMBER> targeted antisarscov<NUMBER> antibodies allow selective therapy coronavirus development companies begun active recruitment investigation clinical efficacy safety treatment covid<NUMBER> <NUMBER> takeda pharmaceutical announced investigation new plasmaderived therapy coined tak<NUMBER> plasma pharmacotherapy volume <NUMBER> number <NUMBER> <NUMBER> derived therapy involves removing plasma covid<NUMBER> survivors extracting coronavirusspecific antibodies administer infected patients stimulate potent immune response sarscov<NUMBER> convalescent therapy remains experimental phase appears may favorably influence treatment course enrollment patients clinical trial aid defining role therapy given lack efficacy risk delayed viral clearance world health organization consensus document management covid<NUMBER> strongly recommends use corticosteroids unless alternative indications present acute lung injury respiratory distress syndrome secondary systemic inflammation wellcharacterized sequelae sars mers outbreaks pulmonary histology demonstrating evidence inflammation diffuse alveolar damage <NUMBER> corticosteroids proposed benefit suppression lung inflammation mers sars due immunomodulatory properties however clinical data clear patients derive benefit corticosteroids management sars mers covid<NUMBER> instead demonstrated evidence increased risk harm including prolonged mechanical ventilation avascular necrosis delayed viral clearance secondary infections <NUMBER> <NUMBER> retrospective observational study critically ill patients mers received hydrocortisone <NUMBER> mg per day find <NUMBER>day mortality benefit adjusted odds ratio <NUMBER> <NUMBER> confidence interval ci <NUMBER> p<NUMBER> find delayed viral clearance adjusted hr <NUMBER> <NUMBER> ci <NUMBER> p<NUMBER> <NUMBER> lack survival benefit supported systematic review corticosteroids patients sars showed increased risk psychosis avascular necrosis prolonged viremia hyperglycemia corticosteroid treatment <NUMBER> although severe potentially lifethreatening ards occur generalizing evidence corticosteroids covid<NUMBER>associated ards problematic fails account differing pathogenesis viralinduced lung injury <NUMBER> corticosteroids considered required alternative indication ie septic shock bronchoconstriction despite lack benefit defined previous trials clinical trial actively recruiting assess efficacy safety methylprednisolone <NUMBER> mgkgday duration <NUMBER> days noncritically ill patients identify risks benefits therapy <NUMBER> emerging therapies treatment covid<NUMBER> addition drug therapies previously discussed several additional drugs evaluated potential therapies covid<NUMBER> clinical trials arbidol drug used russia china prophylaxis treatment influenza respiratory viral infections works blocking viral fusion target cell membrane demonstrated activity several viruses including sars <NUMBER> arbidol currently evaluated treatment covid<NUMBER> several studies china currently recommended treatment option covid<NUMBER> arbidol available united states favipiravir drug licensed japan treatment influenza another potential agent due activity wide spectrum rna viruses including coronaviruses <NUMBER> several studies underway evaluating favipiravir treatment covid<NUMBER> antiviral agents evaluated china treatment covid<NUMBER> include antiretroviral agents darunavircobicistat emtricitabinetenofovir alafenamide well influenza drug baloxavir finally oseltamivir neuraminidase inhibitor used treatment influenza also studied treatment covid<NUMBER> however oseltamivir unlikely active sarscov<NUMBER> based previous studies sarscov <NUMBER> drugs decrease inflammation associated covid<NUMBER> also evaluated one drugs thalidomide may decrease inflammation antiinflammatory immunomodulatory effects <NUMBER> covid<NUMBER> pandemic presented enormous global health crisis pharmaceutical industry working develop novel treatments targeted sarscov<NUMBER> meantime medical community trialing variety therapies target different antiviral immunomodulating mechanisms combat virus drugs investigational old drugs repurposed new pathogen gain information effectiveness drugs covid<NUMBER> emerging pharmacotherapy barlow et al sarscov<NUMBER> pharmacokinetics especially complex setting critical illness better equipped optimize therapeutic strategies identified cases trigger pneumonia recorded wuhan city health commission hubei province china december <NUMBER> clinical manifestation viral pneumonia chan et al <NUMBER> chen et al <NUMBER> kumar <NUMBER> lu et al <NUMBER> tahir ul qamar et al <NUMBER> umesh et al <NUMBER> initially <NUMBER> patients registered number increased <NUMBER> <NUMBER> january <NUMBER> chan et al <NUMBER> finally world health organization declared corona viruses disease <NUMBER> april <NUMBER> <NUMBER> <NUMBER> laboratory confirmed cases identified worldwide <NUMBER> died fahmi <NUMBER> data compiled worstaffected nations china western pacific <NUMBER> confirmed cases <NUMBER> deaths situation european region worsens <NUMBER> cases spain islam et al <NUMBER> tahir ul qamar et al <NUMBER> wahedi et al <NUMBER> renders <NUMBER> genome equivalent sarscov third virulent disease <NUMBER>st century triggered merscov sarscov significant fatality rate khan zia et al <NUMBER> coronavirus nonsegmented enveloped positivestranded rna virus rna genome ranging <NUMBER> <NUMBER> kb length sinha et al <NUMBER> wu et al <NUMBER> coronae family four main genetic subgroups namely alpha coronavirus genus beta coronavirus genus delta coronavirus genus gamma coronavirus genus several types human coronavirus particularly hcovhku<NUMBER> hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> flow human body induce lenient respiratory infection enayatkhani et al <NUMBER> since epidemic sarscov <NUMBER> merscov <NUMBER> identified extremely pathogenic properties human coronavirus causing extreme respiratory syndrome accumulating <NUMBER> cases last two decades <NUMBER> death rate sarscov <NUMBER> merscov elfiky azzam <NUMBER> sarcov<NUMBER> spread via respiratory tract therefore causes pneumonia thus molecular diagnosis oral swabs provided approval disease may also spread infected intestines via oral fecal route khan jha et al <NUMBER> zhang et al <NUMBER> structure sarscov<NUMBER> consists three major viral proteins namely spike protein causes viral infection binding host receptor membrane protein envelope protein e abdelli et al <NUMBER> boopathi et al <NUMBER> sarma et al <NUMBER> wahedi et al <NUMBER> ace<NUMBER> essential receptor interacts spike protein host cell membrane hasan et al <NUMBER> common signs symptoms coronavirus include fever trouble coughing difficulty breathing pyrexia potentially lethal pneumonia severe types kidney failure fatigue diarrhea rhinorrhea vomiting nausea senior citizens prone infected disease gyebi et al <NUMBER> kumar et al <NUMBER> lobogalo et al <NUMBER> study peptide mass fingerprinting pmf technique conducted sarscov<NUMBER> peptide mass fingerprinting one significant methods used identify peptides especially deployment molecular masses peptides pmf chosen basis simple effective process detection peptides specific masses one key technologies driving growth proteomics henzel et al <NUMBER> technique first protein interest digested small fragments called peptide aid endonucleases typically trypsin owing satisfactory magnificent characteristics matthiesen <NUMBER> second mass spectroscopy analysis performed test precise mass peptides step gives catalog peak inventory identified peptides third number peak list associated abstract number peaks obtained insilico digestion using various databases computer software identifies protein creating leading match one key advantages pmf rely protein sequencing protein identification simple liebler <NUMBER> medicinal plants commonly used treatment bacterial noninfectious diseases disorders emerging infectious diseases present relentless danger human life aanouz et al <NUMBER> shinwari et al <NUMBER> selected medicinal plant drug check activity covid<NUMBER> medicinal plant moringa oleifera extremely nutritional serves antiretroviral lead molecule improve activity immunesystem antipyretic antiulcer antispasmodic antiulcer antibacterial antioxidant antihypertensive cardiac circulatory analeptic properties moringa oleifera often known miracle tree strong immuneboosting antimicrobial characteristics categorize family moringacae busani et al <NUMBER> kini et al <NUMBER> phytochemical screening extraction oleifera shows presence alkaloids saponins tannins glycosides carbohydrates flavonoids resins acidic compounds proteins various parts plant specific seeds leaves fruits flowers barks unripe pods kini et al <NUMBER> shinwari et al <NUMBER> flavonoids often inhibitory effect viruses especially respiratory syncytial virus das et al <NUMBER> many works reveals oleifera derived gist inhibits initiation viral replication cycle shinwari et al <NUMBER> presence phytochemical anthraquinone moringa oleifera extract serves antiviral antifungal agent rehabilitate minor diseases found many plants kasolo et al <NUMBER> compound exhibits antiviral properties towards human cytomegalovirus hcmv strain displays inhibitory effects polioviruses also indicate strong degree antiviral activity towards hiv<NUMBER> barnard et al <NUMBER> schinazi et al <NUMBER> semple et al <NUMBER> moringa oleifera ethanolic aqueous extracts rich flavonoids <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> anthraquinone <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> respectively nkechinyere onyekwere felix <NUMBER> moringa oleifera chosen due essential antiviral components demonstrated significant antiviral activity viral diseases though hydroxychloroquine hcq derivative chloroquine prescribed treatment autoimmune diseases antiinflammatory agents virulent chloroquine hcq also included triallist treat covid<NUMBER> wang et al <NUMBER> theoretical experimental preclinical clinical evidence effectiveness hydroxychloroquine patients affected covid<NUMBER> hydroxychloroquine works suppressing lysosomes reducing various cell functions immune cells thats used rheumatologic conditions antiinflammatory effects many vitro studies confirm hydroxychloroquine potent inhibiting sars cov<NUMBER> schrezenmeier d€ orner <NUMBER> yao et al <NUMBER> computeraided drug designing structural molecular biology key tool molecular docking aims identify major binding modes ligand docking important broader libraries compounds virtual screening barnard et al <NUMBER> elmezayen et al <NUMBER> muralidharan et al <NUMBER> autodock vina effective readily available molecular docking technique recognized successful usage research analysis drug discovery forli et al <NUMBER> considered standardized system uses highly structured method local optimization local optimization mechanism single assessment trott olson <NUMBER> acquires systematize files ligand receptor test offers optimal dock conformities welltested default procedures commonly used various aspects primarily virtual screening forli et al <NUMBER> study using mass fingerprinting technique use moringa oleifera effective inhibitor ncov<NUMBER> extract medicinal plant improve immune system produce antibodies sarscov<NUMBER> figure <NUMBER> whole genome sequence novel coronavirus obtained ncbi httpswwwncbinlmnihgov accession mn<NUMBER> <NUMBER>bp length described severe acute respiratory syndrome coronavirus <NUMBER> originated wuhanhu<NUMBER> <NUMBER> march <NUMBER> kruse <NUMBER> obtained sequence sarscov<NUMBER> translated protein identification peptides translation done embl emboss transeq httpwwwebiacuk translates nucleotide sequence amino acid sequence gives three forward three reverse frames may also result multiple outputs rice et al <NUMBER> protein sequence digested protein prospector baker et al <NUMBER> mass peptide calculated online bioinformatics tool peptidemass httpweb expasyorgpeptidemass purpose peptidemass tool help peptidemapping experiments culminating analysis peptidemass fingerprinting pmf massspectrometry data wilkins et al <NUMBER> trypsin used cut protein sequence order estimate number peptide masses mass charge ratio protein gundry et al <NUMBER> peak list peptides generated mass charge ratio protein protein mass calculations homology modeling identified peak list conducted mascot server tsugita et al <NUMBER> server determines active peptides comparing calculated peak lists already existing masses peptides database resulting active peptides additional information peptides structures predicted pepfold<NUMBER> server de novo approach peptide prediction predicts structure peptides sequence <NUMBER> <NUMBER> amino acids pepfold<NUMBER> quicker gives results minutes lamiable et al <NUMBER> selected active peptides sarscov<NUMBER> docked selected three antiviral activity containing compounds check efficacy sarscov<NUMBER> flavonoids anthraquinone phytochemical extracts moringa oleifera contain antiviral properties shinwari et al <NUMBER> hydroxychloroquine derivative chloroquine used treat autoimmune diseases compounds tested lipinski rule <NUMBER> acdi lab toxicity checked protox server drwal et al <NUMBER> masunov <NUMBER> resultant docked complexes analyzed visualized pymol biovia discovery studio <NUMBER> check compare accurate binding different antiviral compounds provide threedimensional <NUMBER>d platform visualization results technologies developed facilitate study simulation docked complexes drug designing phase gusman shoemake <NUMBER> yuan et al <NUMBER> complete genome sarscov<NUMBER> downloaded <NUMBER> kb size ncbi length sequence enough need split sequence fragments peptide mass fingerprinting nucleotides sequence forwarded analysis sarscov<NUMBER> sequence translated amino acid sequence accomplish targeted goal calculate peptide masses use emboss transeq server translate ncov<NUMBER> genome sequence every possible outcome selected whole amino acid sequence calculate peptide masses protein structure translated amino acid sequence shown figure <NUMBER> silico based peptide mass calculation produced <NUMBER> decimals masses peptides amino acids sequences based enzyme digestion average monoisotopic isotopic mass values also given modifications peptide mass online server used identify peptide masses digested amino acid sequence sarscov<NUMBER> silico trypsin selected online parameters threshold value resultant peptide must greater <NUMBER> daltons peptides threshold may small visualize mass spectrum also allow <NUMBER> missed cleavage generated masses peptides peptide mass also results masses values concerned protein theoretical points protein prospector also used cross validation results <NUMBER> sequence covered estimated masses sars cov<NUMBER> peptides overall silico fragmentation protein sequence shown table <NUMBER> searched mascot database peptides obtained digestion peak list needed peptide mass fingerprint peak list created translating raw file peak list peaking peak detection mascot server used peptide mass fingerprinting important tool use mass spectrometry data peptide identification several programs similar mascot unique since integrates validated searching methods damodaran et al <NUMBER> ncov<NUMBER> viral disease selected whole taxonomy viruses looked mascot cleavage enzyme trypsin missed cleavage <NUMBER> implies allow <NUMBER> mutation related peptides peak list entered peptide mass fingerprinting data file picked swissprot search database nonredundant fairly small helpful statistically meaningful matches bairoch apweiler <NUMBER> homology search results found three substantial matches significant threshold pvalue less <NUMBER> highest score <NUMBER> two match sars coronavirus maier et al <NUMBER> one belongs pseudomonas phage b<NUMBER> brief description shown table <NUMBER> mascot database identifies viruses proteins contain matched peptides sequences along complete annotation screened highest scored matched peptides shown table <NUMBER> predict structures identified peptides <NUMBER>d structure determines function stryer nd predicted peptide structures matched peptide sequence de novo peptide predicting approach pepfold <NUMBER> online server used purpose lamiable et al <NUMBER> <NUMBER>d structures identified peptides given table <NUMBER> peptide sequence missed cleavages identified peptide structures sarscov<NUMBER> peptides bound drug medicinal compound binding important test compounds valid purpose properties compounds checked acdi labs protox server lipinski rules identified acdi labs either less adverse effects gupta et al <NUMBER> hamza et al <NUMBER> consists <NUMBER> properties molecular weight less <NUMBER> da hydrogen bond acceptor hba ¼<NUMBER> hydrogen bond donor <NUMBER> topological polar surface area tpsa <NUMBER> logp <NUMBER> toxicity predicted protox web server includes details chemical molecular targets according globally harmonized system ghs toxicity classified six classes scale class vi nontoxic class v moderate class iv figure <NUMBER> druggability pocket identified selected peptide pockdrug server interacting amino acids peptides arg<NUMBER> phe<NUMBER> val<NUMBER> val<NUMBER> val<NUMBER> gly<NUMBER> ile<NUMBER> glu<NUMBER> molecular docking extensively used study interaction large molecule small ligand drug development drug discovery docking performed determine binding energy bound conformation small molecules protein target pant et al <NUMBER> seeliger de groot <NUMBER> actually different methods available ligand docking autodock <NUMBER> autodock vina effective manual among data organized interpreted methods freely accessible autodock vina due extra default features considered credible quick forli et al <NUMBER> furthermore autodock <NUMBER> limitations autodock vina helps improve limitations specifically limited grid map size rotatable bonds many atom numbers computes consequence binding mode prediction consequently autodock vina satisfactory preferable trott olson <NUMBER> less toxic class iii toxic class ii fatal hamza et al <NUMBER> three selected compounds fulfill lipinski rules lie safe zone toxicity shown table <NUMBER> ability protein bind druglike molecule high affinity considered druggability protein pocket druggability selected peptide predicted pockdrug server providing consistent druggability results several estimation methods hussein et al <NUMBER> selected peptide gvithdvssainrpqigvvrefltr docking chosen pocket peptide shown figure <NUMBER> autodock vina used bind sarscov<NUMBER> peptides chosen antiviral compounds autodock vina opensource free users chang et al <NUMBER> jaghoori et al <NUMBER> yang sharp <NUMBER> autodock vina input requires interacting amino acid residues analysis predicted peptide gvithdvssainrpqigvvrefltr anthraquinone shows ligand fits hydrophobic surface energy <NUMBER> kcalmol b <NUMBER>d interacted structure peptide anthraquinone described druggability pocket contains several amino acids arg<NUMBER> phe<NUMBER> val<NUMBER> val<NUMBER> val<NUMBER> gly<NUMBER> ile<NUMBER> glu<NUMBER> interacting amino acids correlated three selected compounds docking figure <NUMBER> surface exposed selected peptide fulllength protein figure <NUMBER> blue color shows whole protein yellow selected peptide lies sidefront protein molecule easily access peptide pdbqt files ligand receptor outputs poses list ranking dg kcalmol binding energy maximum number poses output nummodes set <NUMBER> energy range <NUMBER> best poses screened using rmsd values ranging <NUMBER> <NUMBER> first prepared peptide gvithdvssainrpqigvvrefltr docking receptor saved macromolecule pdbqt file default grid options xyz dimensions <NUMBER> spacing angstrom ¼ <NUMBER> cover maximum area peptide set second ligand compounds prepared adding torsions ¼ <NUMBER> saved pdbqt file configuration file selected exhaustiveness ¼ <NUMBER> performed simulations docking best poses obtained molecular docking shown figures <NUMBER> along interacting residues peptides position energies obtained autodock vina hydroxychloroquine <NUMBER> kcalmol kaempferol flavonoid à<NUMBER> kcalmol anthraquinone <NUMBER> kcalmol figures <NUMBER> shows visualization drug complex visualized pymol discovery studio drug compounds accurately fit hydrophobic surface peptides ensure optimal attachment drug compounds target peptides figures <NUMBER>d structures drug compounds shows different types bonding receptor molecules produce unfavorable bumps affect nature bonding aforementioned findings confirmed chosen antiviral compounds effective inhibitors severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> help immune system fight covid<NUMBER> figures <NUMBER> <NUMBER> since peptides shorter length could embedded fulllength protein question arises whether ligand compound meet target peptide binding mechanism surface exposed chosen binding easily accessed ligand compound successfully results docked complex selected peptide modeled yellow color figures <NUMBER> <NUMBER> research work viral peptides sarscov<NUMBER> identified peptide mass fingerprinting technique approach involves mass calculation protein translated whole genome sarscov<NUMBER> masses searched databases identification viral peptides fifteen viral peptides identified <NUMBER>d structures predicted study three compounds hydroxychloroquine kaempferol anthraquinone chosen basis antiviral properties could bind target nontoxic molecular docking viral peptides antiviral compounds autodock vina used molecular docking viral peptides antiviral compounds accurate reliable online servers techniques autodock vina conforms ligand rotational conformational shifts results optimum poses compounds chosen compounds provided strongest interaction peptides future suggested compounds considered clinically tested new effective antiviral compounds covid<NUMBER> httporcidorg<NUMBER> 